Poster Sessions

114A

POSTER SESSIONS

HEPATOLOGY, October, 2009

Poster Sessions Poster Session 1 Saturday, October 31 POSTER VIEWING: 2:00 - 8:00 PM Hynes: Exhibit Hall C Presenters in attendance: 5:30 - 7:00 PM Those posters identified as AASLD Presidential Poster of Distinction by a ribbon icon have received review scores that place them within the top 10 percent of all posters. We encourage you to make them a priority as you visit the poster sessions.

Acute Liver Failure #241 HEPATIC STEM/PROGENITOR CELLS IMMORTALIZED WITH HTERT MAINTAIN THE CONJOINT MESO-ENDODERM PHENOTYPE OF PRIMARY FETAL HUMAN LIVER CELLS AND RESCUE ANIMALS WITH ACUTE LIVER FAILURE Kang Cheng, Sriram Bandi, Sanjeev Gupta Medicine, Albert Einstein College of Medicine, Bronx, NY, USA

#242 LIVER TISSUE ENGINEERING USING HGFTRANSDUCED HEPATOCYTES PROVIDES THERAPEUTIC EFFECTS ON LETHAL LIVER FAILURE IN MICE Kazuo Ohashi1, Hiroyuki Kuge2, Ken-ichiro Kosai3, Teruo Okano1 of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University, Shinjyuku, Japan. 2Departmen of Surgery, Nara Medical University, Kashihara, Japan. 3Kagoshima University Faculty of Medicine, Kagoshima, Japan

S AT U R D AY OCTOBER 31

1Institute

#243 INTRACRANIAL PRESSURE MONITORING IN ACUTE LIVER FAILURE USING A LUMBAR SUBARACHNOID CATHETER Oren K. Fix1, Lawrence H. Pitts2, Timothy J. Davern3, John P. Roberts4, William P. Dillon5, Michael W. McDermott2, Nathan M. Bass1 1Medicine, University of California, San Francisco, San Francisco, CA, USA. 2Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA. 3Department of Transplantation, California Pacific Medical Center, San Francisco, CA, USA. 4Surgery, University of California, San Francisco, San Francisco, CA, USA. 5Neuroradiology, University of California, San Francisco, San Francisco, CA, USA

Denotes AASLD Presidential Poster of Distinction

#244 IMPROVEMENTS IN HEPATIC SEROLOGICAL BIOMARKERS CORRELATE WITH CLINICAL BENEFIT OF INTRAVENOUS N-ACETYLCYSTEINE IN EARLY STAGE NON-ACETAMINOPHEN ACUTE LIVER FAILURE Sundeep Singh1, Linda S. Hynan2, William M. Lee1 1Medicine, University of Texas at Southwestern Medical Center, Dallas, TX, USA. 2Clinical Sciences, University of Texas at Southwestern Medical Center, Dallas, TX, USA

#245 AUTOIMMUNE ACUTE LIVER FAILURE (AI-ALF): DIAGNOSIS AND RESPONSE TO CORTICOSTEROIDS (CS) R. Todd Stravitz1, Jay H. Lefkowitch2, M E. Gershwin3, Patrick S. Leung3, Richard K. Sterling1, Gary L. Norman5, William M. Lee4 1Virginia Commonwealth University, Richmond, VA, USA. 2Columbia University, New York, NY, USA. 3University of California-Davis, Davis, CA, USA. 4University of Texas-Southwestern, Dallas, TX, USA. 5INOVA Diagnostics, San Diego, CA, USA

#246 LONG-TERM SURVIVAL IS SIGNIFICANTLY HIGHER IN LIVER TRANSPLANT RECIPIENTS COMPARED TO SPONTANEOUS SURVIVORS WITH ACUTE LIVER FAILURE (ALF) Robert J. Fontana1, Lorenzo Rossaro2, Linda S. Hynan3, R. Todd Stravitz4, William M. Lee3 1Divison of Gastroenterology, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA. 2Division of Gastroenterology & Hepatology, University of California, Davis, Davis, CA, USA. 3Department of Clinical Sciences, Division of Biostatistics, UT Southwestern Medical Center, Dallas, TX, USA. 4Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA

#247 LAMIVUDINE AND ENTECAVIR SIGNIFICANTLY IMPROVED THE PROGNOSIS OF EARLY- AND MID-STAGE HEPATITIS B RELATED ACUTE ON CHRONIC LIVER FAILURE —A PROSPECTIVE, RANDOMIZED, OPEN AND PARALLEL CONTROLLED CLINICAL TRIAL Jinhua Hu, Weiping He, Xiaoyan Liu, Ning Du, Xuezhang Duan, Jing Chen, Jinbiao Ding, Kun Huang, Ke Li, Jumei Chen, Huifen Wang Liver Failure Treatment and Research Center, 302 military hospital, Beijing, China

HEPATOLOGY, VOLUME 50, NUMBER 4 (SUPPL)

POSTER SESSIONS

115A

#248

#252

ALGORITHM TO DETERMINE THE INDICATIONS FOR LIVER TRANSPLANTATION IN PATIENTS WITH ACUTE LIVER FAILURE: DATA MINING ANALYSIS USING DECISION TREES

INTERNATIONAL COLLABORATIVE WORK: A UNIFIED LIST OF DRUGS ASSOCIATED WITH HEPATOTOXICITY AND THE REPORTING FREQUENCY OF LIVER EVENTS IN THE WHO

Nobuaki Nakayama1, Sumiko Nagoshi1, Kenji Fujiwara2, Makoto Oketani3, Hirohito Tsubouchi3, Yoshihiro Kawamura4, Satoshi Mochida1 1Department of Gastroenterology and Hepatology, Saitama Medical University, Moroyama-Machi, Japan. 2Yokohama Rosai Hospital for Labor Welfare Corporation, Yokohama, Japan. 3Department of Digestive and Life-style related Disease, Kagoshima University, Kagoshima, Japan. 4IBM Japan, Tokyo, Japan

Ayako Suzuki1, Raul J. Andrade2,3, Einar Bjornsson4, M. I. Lucena5,3, Nancy A. Yuen6, Christine M. Hunt6, James W. Freston7 1Gastroenterology, Duke University Medical Center, Durham, NC, USA. 2Unidad de Hepatología, Facultad de Medicina, Hospital Universitario Virgen de la Victoria, Málaga, Spain. 3Networkbased biomedical research centre working on liver and digestive diseases (CIBERehd), Málaga, Spain. 4Section of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden. 5Servicio de Farmacología Clínica, Facultad de Medicina, Hospital Universitario Virgen de la Victoria, Málaga, Spain. 6Clinical Safety, GlaxsoSmithKlein, Durham, NC, USA. 7Department of Internal Medicine, University of Connecticut, Farmington, CT, USA

#249 NEUTROPHIL DYSFUNCTION IN ACUTE LIVER FAILURE DEFINES THOSE PATIENTS WHO HAVE A POOR PROGNOSIS AND IS REVERSED FOLLOWING LIVER TRANSPLANTATION Nicholas J. Taylor, Yun Ma, (Robin) Daniel Abeles, Munther J. Hussain, Georg Auzinger, Diego Vergani, William Bernal, Julia Wendon, Debbie L. Shawcross Institute of Liver Studies & Transplantation, King’s College London, London, United Kingdom

#250 CYTOKINES DYNAMIC CHANGE IN PATIENTS WITH ACUTE ON CHRONIC HEPATITIS B LIVER FAILURE (ACHBLF) AND THERAPEUTIC EFFICACY DURING ENTECAVIR TREATMENT Bingliang Lin, Yubo Huang, Xing Zuo, Xiaohong Zhang, Junqiang Xie, Yubao Zheng, Yutian Chong, ZhiLiang Gao Department of Infectious Diseases, The third affiliated hospital of Sun Yat-sen University, Guangzhou, China

#251

Brandy Lu1,2, Song Zhang3, Michael Narkewicz1,2, Steven H. Belle3, Robert H. Squires4, Ronald J. Sokol1,2 1University of Colorado Denver School of Medicine, Aurora, CO, USA. 2The Children’s Hospital, Aurora, CO, USA. 3Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. 4School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

DETECTION OF SERUM CASPASE ACTIVATION PREDICTS THE OUTCOME OF ACUTE LIVER FAILURE Matthias Anstätt, Matthias J. Bahr, Michael P. Manns, Heike Bantel Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

#254 CELLULAR IMMUNE PROFILING IN PERIPHERAL BLOOD, HEPATIC VEIN BLOOD AND IN THE LIVER IN PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE (ACLF) Nirupma T. Pati1,2, Shiv K. Sarin1,2, Vishal Garg2, Arshi Khanam2, Shikha Shrivastava2, Jaswinder S. Maras2, Archana Rastogi1, Puja Sakhuja2 1Research, Institute of Liver and Biliary Sciences, New Delhi, India. 2Department of Gastroenterology, G.B. Pant Hospital, Delhi, India

#255 INCLUDING THE OVERALL CELL DEATH INTO THE MELD-SCORE ENHANCES SENSITIVITY AND SPECIFICITY IN PREDICTING THE OUTCOME OF ACUTE LIVER FAILURE Lars Bechmann, Christoph Jochum, Peri Kocabayoglu, Marco Kassalik, Robert K. Gieseler, Fuat H. Saner, Guido Gerken, Ali Canbay Gastroenterology and Hepatology,, University clinic Essen, Essen, Germany

#256 INCREASED KILLING OF LIVER NK CELLS BY FAS/FASL AND NKG2D/NKG2DL CONTRIBUTES TO HEPATOCYTE NECROSIS IN VIRUS-INDUCED LIVER FAILURE Yong Zou1, Tao Chen1, Meifang Han1, Hongwu Wang1, Weiming Yan1, Ge Song1, Zeguang Wu1, Xiaojing Wang1, Chuanlong Zhu1, Xiaoping Luo2, Qin Ning1 1Department of Infectious Disease, Tongji Hospital,Huazhong Univeristy of Science& Technology, Wuhan, China. 2Department of Padiatric, Tongji Hospital, Huazhong Univeristy of Science& Technology, Wuhan, China


VALIDATION OF A SCORING SYSTEM TO PREDICT SURVIVAL IN 455 PATIENTS WITH PEDIATRIC ACUTE LIVER FAILURE

#253

116A

POSTER SESSIONS

#257

#262

SHORT-TERM PROGNOSIS AND OUTCOME PREDICTORS OF ALCOHOL-RELATED CIRRHOSIS ADMITTED TO THE INTENSIVE CARE UNIT

THE PLASMA OF ACUTE LIVER FAILURE PATIENTS PROMOTES THE SURVIVAL OF MOUSE LIVER STEM/PROGENITOR CELLS THROUGH JNK ACTIVATION

Kara Rye1, Rajesh Krishnamoorthy1, Hannah Skene1, Alastair H. Boyd2,1, Andrew Austin1, Jan Freeman1 1Hepatology, Derby City General Hospital, Derby, United Kingdom. 2Intensive Care Unit, Derby City General Hospital, Derby, United Kingdom

Keisuke Kakisaka, Yasuhiro Takikawa, Mio Onodera, Ting Wang, Kazuyuki Suzuki Gastroenterology and Hepatology, Iwate Medical University, Morioka, Japan

#258

#263

HIGH DENSITY LIPOPROTEIN IN CRITICALLY ILL PATIENTS WITH LIVER FAILURE: RELATION TO OUTCOME AND ADRENAL INSUFFICIENCY

EFFICACY OF A NEW JAPANESE SCORING SYSTEM PREDICTING PROGNOSIS OF PATIENTS WITH ACUTE LIVER FAILURE

Frederique-Estelle Etogo-Asse1, William Bernal1, Carel Le Roux2, Georg Auzinger1, Julia Wendon1 1Liver Intensive Care, Institute of Liver Studies., Kings College Hospital, London, United Kingdom. 2Department of clinical biochemistry, Kings College Hospital, London, United Kingdom

Yoshiyuki Yamagishi, Hidetsugu Saito, Hirotoshi Ebinuma, Keisuke Ojiro, Nobuhiro Nakamoto, Yoshinori Horie, Shinzo Kato, Toshifumi Hibi Division of Gastroenterology & Hepatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan

#259

#264

META-ANALYSIS OF PERFORMANCE OF KINGS’S COLLEGE HOSPITAL CRITERIA IN PREDICTION OF OUTCOME IN NON-ACETAMINOPHEN INDUCED ACUTE LIVER FAILURE

CLINICOPATHOLOGICAL FEATURES OF SEVERE AND FULMINANT FORMS OF AUTOIMMUNE HEPATITIS

1Department

Julia William of Hepatology, Division of Medicine, St Mary’s Hospital, Imperial College London, London, United Kingdom. 2Institute of Liver Studies, Kings College Hospital, London, United Kingdom

Shin Yasui1, Keiichi Fujiwara1, Yutaka Yonemitsu1, Koichiro Okitsu1, Masayuki Nakano2, Osamu Yokosuka1 1Department of Medicine and Clinical Oncology, Chiba University, Chiba, Japan. 2Department of Pathology, Tokyo Women’s Medical University Yachiyo Medical Center, Chiba, Japan

#260

#265

CIRCULATING LEVELS OF THE HEPATOCYTE APOPTOSIS MARKER M-30 ARE PREDICTIVE OF OUTCOME IN NON-ACETAMINOPHEN ACUTE LIVER FAILURE

MOLECULAR BASIS OF SYNERGISM BETWEEN BRAIN AMMONIA AND PROINFLAMMATORY MECHANISMS IN ACUTE LIVER FAILURE

Mark



McPhail1,2,

Wendon2,

Bernal2

Chetan Vedvyas1, Corron Sanders4, Lindsay Yount2, Hui Zheng3, Anne M. Larson4, Anna E. Rutherford2, William M. Lee4, Raymond Chung1 1GI Unit, Massachusetts General Hospital, Boston, MA, USA. 2GI Unit, Brigham and Women’s Hospital, Boston, MA, USA. 3Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. 4UT Southwestern Medical Center at Dallas, Dallas, TX, USA

#261 ASSOCIATIONS WITH NON-COMPLIANCE OR CHRONIC REJECTION IN PATIENTS TRANSPLANTED FOR ACUTE LIVER FAILURE Gail S. Masterton1, Joanna A. Leithead2, Peter C. Hayes2,1, Kenneth Simpson2,1 1Dept of Hepatology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom. 2Department of Hepatology, University Of Edinburgh, Edinburgh, United Kingdom

Wenlei Jiang, Paul Desjardins, Roger F. Butterworth Neuroscience Research Unit, CHUM (Hôpital St-Luc), Montreal, QC, Canada

#266 AGE & PT AS PROGNOSTIC FACTORS OF ACUTE LIVER FAILURE (16 YEARS OF NATIONAL LIVER TRANSPLANT PROGRAM IN SINGAPORE) Vincent Lai1, Aung Myat Oo1, Kum Faut Teoh1, Belinda Mak1, Seng Gee Lim1,2 1Gastroenterology & Hepatology, National University Hospital, Singapore, Singapore. 2Department of Medicine, National University of Singapore, Singapore, Singapore

#267 THE ESTIMATED DISTRIBUTION VOLUME OF REMOVED GLUTAMINE IS A USEFUL INDEX FOR THE EVALUATION OF ARTIFICIAL LIVER SUPPORT Kazuaki Inoue, Makoto Yoshiba Gastroenterology, Showa University Fujigaoka Hospital, Yokohama, Japan



POSTER SESSIONS

117A

#268

#273

ALTERATIONS OF OCCLUDIN AND CLAUDIN-5 IN BRAIN ENDOTHELIAL CELLS IN VITRO AND IN BRAINS OF MICE WITH ACUTE LIVER FAILURE

PREDICTORS OF MORTALITY IN ALCOHOLIC LIVER DISEASE

Chen1,

Eckman2,

Nguyen1

Florence Christopher Justin H. 1Department of Transplantation, Division of Transplant Surgery, Mayo Clinic in Florida, Jacksonville, FL, USA. 2Department of Neuroscience, Mayo Clinic in Florida, Jacksonville, FL, USA

#269 ACUTE VIRAL HEPATITIS EPIDEMIC CAUSED BY HEPATITIS E VIRUS VARIANTS: VIGILANT SAMPLING AND APT TEST INFLUENCE DIAGNOSIS Anis Khan1, Yasuhito Tanaka1, Zaigham Abbas2, Zahid Azam2, Fuat Kurbanov1, Abeer Elkady1, Kazuaki Takahashi3, James W. Shih4, Ningshao Xia4, Saeed Hamid2, Syed M. Jafri2, Shunji Mishiro3, Masashi Mizokami1,5 1Nagoya City University, Nagoya, Aichi, Japan. 2Aga Khan University, karachi, Pakistan. 3Toshiba General Hospital, Tokyo, Japan. 4NIDVD, Xiamen University, Xiamen, Fujian, China. 5International Medical Center of Japan Kounodai Hospital, Kounodai, Ichikawa, Japan

#270 OUTCOMES FOLLOWING LIVER TRANSPLANT FOR ACUTE LIVER FAILURE SECONDARY TO ACETAMINOPHEN OVERDOSE IS SIMILAR TO THOSE OF OTHER CAUSES Gail S. Masterton1, Joanna A. Leithead2, Peter C. Hayes2,1, Kenneth Simpson2,1 1Dept of Hepatology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom. 2Department of Hepatology, University of Edinburgh, Edinburgh, United Kingdom

#271

Praveen Srungaram1, Andreas Reimold4,3, Benny Dahl2, Jody A. Balko1, Corron Sanders1, William M. Lee1 1Gastroenterology and Liver Diseases, UT Southwestern Medical Center, Dallas, TX, USA. 2Department of Orthopedic Surgery, Rigshospitalet, National University Hospital of Denmark, Copenhagen, Denmark. 3Department of Rheumatology, UT Southwestern Medical Center, Dallas, TX, USA. 4Section of Rheumatology, Dallas VA Medical Center, Dallas, TX, USA

#272 ROLE OF ALCOHOL IN ACETAMINOPHEN RELATED ACUTE LIVER FAILURE LuLu Iles-Shih1, Atif Zaman1, Anne M. Larson2, William M. Lee2, Jonathan M. Schwartz1 1Medicine, Oregon Health and Sciences University, Portland, OR, USA. 2Medicine, UT Southwestern Medical School, Dallas, TX, USA

#274 LONGITUDINAL ASSESSMENT OF BRAIN VOLUMES DURING TREATMENT OF CHRONIC HEPATIC ENCEPHALOPATHY WITH L-ORTHININEL-ASPARTATE Mark McPhail1, Vijay P. Grover1, Fitzpatrick Julie2, Bill Saxby3, Howard Thomas1, Simon D. Taylor-Robinson1 1Department of Hepatology, Division of Medicine, St Mary’s Hospital, Imperial College London, London, United Kingdom. 2Robert Steiner MRI Unit, Hammersmith Hospital, Imperial College London, London, United Kingdom. 3Cognitive Drug Research, CDR House, Goring-on-Sea, United Kingdom

Complications of Cirrhosis-Clinical Partial Hypertensive and Varices #275 A RANDOMIZED, CONTROLLED TRIAL OF LIGATION PLUS NADOLOL VS. NADOLOL ALONE IN THE PROPHYLAXIS OF FIRST VARICEAL BLEEDING IN CIRRHOSIS Gin-HO Lo1, Wen-Chi Chen2,1, Huay-Min Wang2 Center, E-DA Hospital, Kaohsiung County, Taiwan. 2Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan 1Digestive

#276 RANDOMIZED TRIAL OF EMERGENCY ENDOSCOPIC SCLEROTHERAPY VERSUS EMERGENCY PORTACAVAL SHUNT FOR ACUTELY BLEEDING ESOPHAGEAL VARICES IN CIRRHOSIS Marshall J. Orloff, Jon I. Isenberg, Henry O. Wheeler, Kevin S. Haynes, Horacio B. Jinich, Roderick Rapier, Florin Vaida, Robert J. Hye Surgery, University of California,San Diego, San Diego, CA, USA

#277 SEDATION WITH PROPOFOL BUT NOT MIDAZOLAM FOR UPPER ENDOSCOPY DOES NOT AGGRAVATE SUB CLINICAL HEPATIC ENCEPHALOPATHY IN PATIENTS WITH COMPENSATED CIRRHOSIS Olga Alexandrov1,2, Iad. Kamayse3,4, Vladimire. Mysh3, Kamal. Dabbah3, Agness. Djibre1, Nimer Assy1,4 1Liver Unit, Ziv Medical Centre, Safed, Israel. 2Anesthesia, Ziv Medical Centre, Safed, Israel. 3Gastroenterology, Ziv Medical Centre, Safed, Israel. 4Faculty of Medicine, Technion, Haifa, Israel


PLASMA OSTEOPONTIN LEVELS IN ACUTE LIVER FAILURE (ALF)

Sajid Hussain1, Sufian Ali2, Denish Moorthy1, Amir A. Shah2 University, Boston, MA, USA. 2Crosshouse Hospital, Kilamrnock, United Kingdom

1Tufts

118A

POSTER SESSIONS

#278

#282

COMPARATIVE STUDY OF TRANS-NASAL SMALLCALIBER WITH PER-ORAL CONVENTIONAL ESOPHAGOGASTRODUODENOSCOPY FOR VARICEAL EVALUATION IN CIRRHOTIC PATIENTS WITHOUT SEDATION

A LIVER STIFFNESS MEASUREMENT-BASED, NONINVASIVE PREDICTION MODEL FOR HIGHRISK ESOPHAGEAL VARICES IN B-VIRAL LIVER CIRRHOSIS

Soon-Young Ko, So Young Kwon, Byung Kook Kim, Won Hyeok Choe, Dong Choon Seol, Jung Hyeon Lee, Chang Hong Lee, JaeDong Lee Konkuk Univ Hospital, Seoul, Korea, South

#279 RENAL DYSFUNCTION IS THE MAIN MODIFIABLE DETERMINANT OF EARLY SURVIVAL IN CIRRHOTIC PATIENTS WITH ACUTE VARICEAL BLEEDING TREATED WITH STANDARD OF CARE THERAPY Salvador Augustin, Laura Muntaner, Antonio González, Rafael Esteban, Jaime Guardia, Joan Genescà Internal Medicine - Liver Unit, Hospital Universitari Vall d’Hebron, Barcelona, Spain

#280 PREDICTORS OF EARLY MORTALITY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS (TIPS) Renumathy Dhanasekaran1, Patrick C. Gonzales1, Jonathan West1, Ram Subramanian2, Samir Parekh2, James R. Spivey2, Preeti Reshamwala2, Louis G. Martin1, Hyun S. Kim2 1Department of Radiology, Division of Interventional Radiology and Image Guided Medicine, Emory University Hospital, Atlanta, GA, USA. 2Department Of Medicine, Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA, USA

#281



THE IMPACT OF SUSTAINED VIROLOGIC RESPONSE AND HEPATOCELLULAR CARCINOMA OCCURRENCE ON THE DE-NOVO DEVELOPMENT OF ESOPHAGEAL VARICES IN COMPENSATED, HCV-INDUCED CIRRHOSIS. A LONG TERM PROSPECTIVE STUDY Savino Bruno1, Andrea Crosignani2, Corinna Facciotto1, Sonia Rossi1, Luigi Roffi3, Alessandro Redaelli3, Piero L. Almasio4, Roberto De Franchis5, Patrick Maisonneuve6 1Department of Internal Medicine, A.O. Fatebenefratelli e Oftalmico, Milan, Italy. 2Department of Internal Medicine, A.O. S. Paolo, University of Milan, Milan, Italy. 3Department of Internal Medicine, A.O.S. Gerardo, Monza, and Bicocca University of Milan, Milan, Italy. 4Gastroenterology and Hepatology Unit, University of Palermo, Palermo, Italy. 5Department of Medical Sciences, University of Milan, Milan, Italy. 6Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy

Beom Kyung Kim1, Kwang-Hyub Han1, Jun Yong Park1, Sang Hoon Ahn1, Ja Kyung Kim1, YongHan Paik1, Kwan Sik Lee1, Byung Soo Moon1, Chae Yoon Chon1, Young Myoung Moon2, Do Young Kim1 1Internal medicine, Yonsei University College of Medicine, Seoul, Korea, South. 2Internal medicine, Kwan Dong University College of Medicine, Goyang, Korea, South

#283 TRANSIENT ELASTOGRAPHY AND HVPG MEASUREMENTS IN THE STAGING OF RESECTABLE HEPATOCELLULAR CARCINOMA IN PATIENTS WITH COMPENSATED CIRRHOSIS Elba Llop, Annalisa Berzigotti, Maria Elisa Reig, Eva Erice, Juan G Abraldes, Jordi Bruix, Jaime Bosch, Juan Carlos Garcia-Pagán Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, Barcelona, Spain

#284 SYSTEMIC ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION: RELATIONSHIP WITH CARDIOVASCULAR RISK FACTORS, SYSTEMIC AND HEPATIC HEMODYNAMICS AND WITH THE HVPG RESPONSE TO PROPRANOLOL. Annalisa Berzigotti2,1, Eva Erice2,3, Ranka Vukotic2,3, Juan G Abraldes2,3, Juan Carlos Garcia-Pagán2,3, Rosa Gilabert1,3, Jaime Bosch2,3 1Abdominal Ultrasound, Radiology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain. 2Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain. 3CiberEHD, Barcelona, Spain

#285 ISOSORBIDE MONONITRATE FOR PATIENTS WITH ESOPHAGEAL VARICES: SYSTEMATIC REVIEW OF RANDOMIZED TRIALS ON PRIMARY OR SECONDARY PREVENTION Lise L. Gluud1,2, Ebbe Langholz1, Aleksander Krag1,3 of Internal Medicine, Copenhagen University Hospital Gentofte, Hellerup, Denmark. 2Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Copenhagen, Denmark. 3Department of Medical Gastroenterology, Hvidovre University Hospital, Hvidovre, Denmark 1Department

#286 LONG-TERM OUTCOMES (GASTRIC VARICES, PORTAL HYPERTENSIVE GASTROPATHY, RECURRENT ESOPHAGEAL VARICES AND BLEEDING COMPLICATIONS) AFTER ERADICATION OF ESOPHAGEAL VARICES WITH ENDOSCOPIC THERAPY FOR SECONDARY PROPHYLAXIS Raghuwansh P. Sah1, Raghunandan Venkat1, Shankar Khanal1, Hari S. Conjeevaram2, Subrat K. Acharya1 1Gastroenterology and Hepatology, All India Institute of Medical Sciences, New Delhi, India. 2Gastroenterology, University of Michigan, Ann Arbor, MI, USA



POSTER SESSIONS

119A

#287

#291

CIRRHOTIC PATIENTS WITH LARGE ESOPHAGEAL VARICES AND HIGHER AGE HAVE POOR HEMODYNAMIC RESPONSE TO TERLIPRESSIN

ANTIBIOTIC PROPHYLAXIS IN VARICEAL HEMORRHAGE: TIMING, EFFECTIVENESS AND ASSOCIATED CLOSTRIDIUM DIFFICILE RATES

Ashish Kumar2,3, Praveen Sharma2,1, Vibhu V. Mittal1, Nitin Gupta1, Smruti R. Mishra1, Shiv K. Sarin1,2 1Gastroenterology, G B Pant Hospital, New Delhi, India. 2Hepatology, Institute of Liver & Biliary Sciences (ILBS), New Delhi, India. 3Special Centre for Molecular Medicine, Jawaharlal Nehru University (JNU), New Delhi, India

Matthew R. Brown1, Graeme R. Jones2, Kathryn L. Nash1, Mark Wright1, Indra N. Guha1 1Liver Unit, University of Southampton, Southampton, United Kingdom. 2Department of Microbiology, Southampton University Hospital Trust, Southampton, United Kingdom

#288

ADHERENCE TO GUIDELINES IN BLEEDING OESOPHAGEAL VARICES AND THE EFFECT ON OUTCOME—COMPARISON BETWEEN A SPECIALIZED UNIT AND A COMMUNITY HOSPITAL

WORSENING PORTAL HYPERTENSION DURING LONG-TERM MEDICAL TREATMENT IN PATIENTS WITH CIRRHOSIS WHO HAD BEEN CLASSIFIED AS EARLY GOOD-RESPONDERS ON HAEMODYNAMIC CRITERIA: CLINICAL SIGNIFICANCE AND VALIDATION IN AN INDEPENDENT SAMPLE Carlo Merkel1, Massimo Bolognesi1, Piero Amodio1, Annalisa Berzigotti2, Lucia Cavasin1, Ilaria M. Casarotto1, Marco Zoli2, Angelo Gatta1 1Clinical Experimental Medicine, University of Padua, Padova, Italy. 2Department of Internal Medicine, University of Bologna, Bologna, Italy

#289 HIGH DOSES OF β-BLOCKERS AND ALCOHOL ABSTINENCE IMPROVE LONG-TERM OUTCOME IN CIRRHOTIC PATIENTS AFTER AN ACUTE VARICEAL BLEEDING Laura Muntaner, Jose T. Altamirano, Salvador Augustin, Antonio González, Rafael Esteban, Jaime Guardia, Joan Genescà Liver Unit- Internal Medicine, Vall d’Hebron Hospital, Barcelona, Spain

PREVALENCE OF PORTAL VEIN THROMBOSIS IN PATIENTS WITH OBSTRUCTIVE PORTAL VENOPATHY (OPV) DURING HIV INFECTION: IMPACT OF ANTICOAGULATION ON RECANALIZATION Aurelie Plessier1, Anne Gervais2, Pierre-Emmanuel Rautou1, Maud Lemoine4, Dominique Cazals-Hatem3, Claire Francoz1, Hélène Labadie5, Christian De Gennes6, Pauline Campa7, Christophe Piketty8, Bertrand Condat1, Sophie Hillaire10, Violaine Ozenne1, Hugues Aumaitre9, Francois Durand1, Pierre Bedossa3, Dominique Valla1 1Hepatology, AP-HP, Hopital beaujon, Clichy, France. 2APHP, Maladies infectieuses, Hopital Bichat, Paris, France. 3Anatomopathology, AP-HP, Hopital beaujon, Clichy, France. 4Hepatology, AP-HP, Hopital Saint Antoine, Clichy, France. 5Gastroenterology and Hepatology, Hopital Delafontaine,, saint Denis, France. 6Internal medicine, Hôpital Pitié salpétrière,, Paris, France. 7Maladies infectieuses, Hôpital Saint Antoine,, Paris, France. 8Immunologie, Hôpital Georges Pompidou,, Paris, France. 9Maladies infectieuses, Hopital de Perpignan, Perpignan,, France. 10Hepatology, Hopital Foch, Suresnes, France

Lise Hobolth1, Aleksander Krag1, Axel Malchow-Møller2, Vladimir Gancho2, Simon M. Jensen2, Flemming Bendtsen1 1Hvidovre Hospital, Hvidovre, Denmark. 2Svendborg Hospital, Svendborg, Denmark

#293 GUIDELINE ADHERENCE AND SHORT-TERM OUTCOMES IN THE MANAGEMENT OF ACUTE ESOPHAGEAL VARICEAL HEMORRHAGE Brent Lee1, Jennifer Urquhart1, Atif Zaman1, Brian R. Willis2 Health and Science University, Portland, OR, USA. 2Kaiser Permanente, Portland, OR, USA

1Oregon

#294 EVALUATION OF 6-WEEK MORTALITY AFTER ACUTE VARICEAL BLEEDING: ROLE OF CLASSIFICATION AND REGRESSION TREE (CART) ANALYSIS Jose T. Altamirano2,1, Laura Zapata2, Salvador Augustin1, Laura Muntaner1, Jaime Alberto Gonzalez-Angulo2, Ana Laura Ortiz2, Louis Degiau3, Leonardo Camargo4, Joan Genescà1 1Liver Unit-Internal Medicine Department, Hospital Vall dHebron,Barcelona,Spain., Barcelona, Spain. 2Gastroenterology Unit, Hospital Juarez de Mexico, Mexico City, Mexico. 3Endoscopy Unit, Hospital General de Mexico OD, Mexico City, Mexico. 4Faculty of Medicine, Universidad “La Salle”, Mexico City, Mexico

#295 VARIABILITY OF THE HEPATIC VENOUS PRESSURE GRADIENT (HVPG) WITHIN THE CIRRHOTIC LIVER: AN ISSUE OR A TECHNICAL ISSUE? Sara Montagnese1, Lucia Cavasin1, Roberto Vezzaro2, Diego Miotto2, Angelo Gatta1, Carlo Merkel1 1Clinical Experimental Medicine, University of Padua, Padova, Italy. 2Section of Radiology, Department of Diagnostic and Treatment Sciences, University of Padua, Padova, Italy


#290

#292

120A

POSTER SESSIONS

#296

#300

ACQUIRED HYPERCOAGULABLE STATE IN CHRONIC NON-CIRRHOTIC PORTAL VEIN THROMBOSIS Raffa1,

Reverter2,

Seijo1,

Sebastian Juan Carlos Susana Dolors Tassies2, Aina Rodriguez-Vilarrupla1, Rosa Miquel3, Juan G Abraldes1, Jaime Bosch1, Juan Carlos Garcia-Pagán1 1Liver Unit, Hospital Clinic. IDIBAPS and CIBERehd, Barcelona, Spain. 2Hemotherapy and Hemostasis, Hospital Clinic., Barcelona, Spain. 3Pathology, Hospital Clinic., Barcelona, Spain

Complications of Cirrhosis: Ascites and Encephalopathy #297 ASOCIATION OF AQUAPORIN-1 GENE POLYMORPHISMS WITH DILUTIONAL HIPONATREMIA IN LIVER CIRRHOSIS Emilio Fabrega1, Armando R. Guerra-Ruiz2,1, Ana Berja3, María Teresa García-Unzueta3, María Lopez1, Maria Teresa Arias1, José Antonio Amado3, Fernando Pons-Romero1 1Gastroenterology and Hepatology Unit, University Hospital Marques de Valdecilla, Santander, Spain. 2I.F.I.M.A.V., Fundacion Marques de Valdecilla, Santander, Spain. 3Endocrinology Unit, University Hospital Marques de Valdecilla, Santander, Spain

#298 ROLE OF TOLL-LIKE RECEPTOR-4 IN MEDIATING MULTIORGAN FAILURE IN CIRRHOSIS AS A CONSEQUENCE OF A 2ND HIT Naina Shah1, Dipok K. Dhar2, Steven W. Olde Damink2, Max Malago2, Rajeshwar P. Mookerjee1, Nathan Davies1, Rajiv Jalan1 1The Institute of Hepatology, London, United Kingdom. 2Surgery, The Institute of Hepatology, London, United Kingdom S AT U R D AY OCTOBER 31


#299 INCREASED NITRIC OXIDE PRODUCTION (NO) IN LYMPHATIC ENDOTHELIAL CELLS (LYECS) CAUSES IMPAIRMENT OF LYMPHATIC DRAINAGE IN CIRRHOTIC (CH) RATS Jordi Ribera1, Pedro Melgar-Lesmes1, Montserrat Pauta1, Sònia Tugues1, Josefa Ros1, Vicente Arroyo2, Wladimiro Jiménez1, Manuel Morales-Ruiz1 1Biochemistry and Molecular Genetics, Hospital Clínic i Provincial de Barcelona, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain. 2Liver Unit-Institut de Malalties Digestives, Hospital Clínic i Provincial de Barcelona, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain


IN-PATIENT HEPATIC ENCEPHALOPATHY PROTOCOL IMPROVES OUTCOME Abdullah M. Al-Osaimi1, Beth D. Quatrara2, Irene Melo2, Linda M. Romeo2, Brian Zwoyer2, Carl L. Berg1, Stephen H. Caldwell1, Curtis K. Argo1, Patrick G. Northup1, Neeral L. Shah1, Robert C. Harmon1 1Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA, USA. 2Digestive Health InPatient Service, University of Virginia Health system, Charlottesville, VA, USA

#301 EFFECT OF INTRAVENOUS ALBUMIN (STANDARD VS DOSE REDUCED REGIMEN) ON RENAL IMPAIRMENT AND MORTALITY IN PATIENTS WITH CIRRHOSIS AND SPONTANEOUS BACTERIAL PERITONITIS: A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL - INTERIM ANALYSIS OF THE ALTERNATE STUDY Alexandre Araujo1,2, Gabriela Rossi1,2, Antônio B. Lopes1,2, Sandro R. Ness1, Mário R. Álvares-da-Silva1,2 1Gastroenterology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. 2Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

#302 PREVALENCE OF BACTERIAL RESISTANCE IN CIRRHOTIC PATIENTS WITH BACTERIAL INFECTION: A PRELIMINARY REPORT Mauro Borzio1, Francesco Salerno2, Claudia Pedicino1, Massimo Cazzaniga2, Milena Arghittu1, Patrizia Cambieri1, Rosa Simonetti3, A K Burroughs4, Angelo Rossini5, Irene Cacciola6, Alessio Aghemo7, Paolo Angeli8, Sergio Boccia9 1Unità di Gastroenterologia e Microbiologia, Ospedale Predabissi, Melegnano, Italy. 2Internal Medicine, Policlinico San Donato, University, San Donato (MI), Italy. 3Ospedale Cervello, Unità di Gastroenterologia, Palermo, Italy. 4Sheila Sherlock Liver Center, Royal Free Hospital, London, United Kingdom. 5Policlinico universitario, Unità di epatologia, Brescia, Italy. 6Policlinico, Unità di epatologia, Messina, Italy. 7Policlinico, Unità di gastroenterologia, Milano, Italy. 8Policlinico universitario, Medicina clinica e sperimentale, Padova, Italy. 9Ospedale, Unità di gastroenterologia, Padova, Italy

#303 RENAL FAILURE AND HYPONATREMIA ARE FREQUENT COMPLICATIONS OF SKIN INFECTIONS IN PATIENTS WITH CIRRHOSIS AND PREDICT A POOR OUTCOME Gustavo H. Pereira1,2, Mónica Guevara1,2, Marcella Marinelli1,2, Marta Martín-Llahí1,2, Elsa Solá1,2, André Nazar1,2, Cláudia Fagundes1,2, Vicente Arroyo1,2, Pere Gines1,2 1Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain. 2Institut d’Investigacions Biomèdiques August-Pi-Sunyer (IDIBAPS). Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHED)., Barcelona, Spain


POSTER SESSIONS

121A

#304

#307

DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SATAVAPTAN IN THE MANAGEMENT OF RECURRENT ASCITES: THE SPARE-1 STUDY

TOLL-LIKE RECEPTOR (TLR) 2 PROMOTOR AND INTRON 2 POLYMORPHISMS ARE ASSOCIATED WITH INCREASED RISK FOR SPONTANEOUS BACTERIAL PERITONITIS IN LIVER CIRRHOSIS

Florence Wong1, Pere Gines2, Frederik Nevens3, Hans Van Vlierberghe4, Alexander L. Gerbes5, Jean Pierre H. Zarski6, Alvaro Koch7, Salvatore Badalamenti8, Pascal Minini9, Hugh R. Watson10 1Medicine, Toronto General Hospital, Toronto, ON, Canada. 2Medicine, Hospital Clinic, Barcelona, Spain. 3Hepatology, University Hospital, Leuven, Belgium. 4Gastroenterology & Hepatology, Ghent University Hospital, Ghent, Belgium. 5Medicine, Klinikum München-Grosshadern, Munich, Germany. 6Hepato-Gastroenterology, University Hospital of Grenoble, Grenoble, France. 7Medicine, University of Kentucky, Lexington, KY, USA. 8Research & Development, Sanofi-aventis, Chilly-Mazarin, France. 9Research & Development, Sanofi-aventis, Bridgewater, NJ, USA. 10Research & Development, Sanofi-aventis, Chilly-Mazarin, France

#305 THE PROTECTIVE EFFECT OF RIFAXIMIN (1100 MG DAILY) FROM HEPATIC ENCEPHALOPATHY OBSERVED IN A DOUBLE-BLIND PLACEBO CONTROLLED STUDY IS SUBSTANTIATED AND DURABLE OVER THE LONG TERM

#306 RIFAXIMIN SIGNIFICANTLY IMPROVED CRITICAL FLICKER FREQUENCY, AND TIME-WEIGHTED CFF CORRELATED WITH OVERT HEPATIC ENCEPHALOPATHY AS ASSESSED BY CONN SCORE IN A 6 MONTH STUDY Brown1,

Bass2,

Sanyal3,

Poordad4,

Robert S. Nathan Arun J. Fred Muhammad Y. Sheikh5, Kevin D. Mullen6, Samuel Sigal7, Todd Frederick8, Benedict Maliakkal9, Ravikumar Vemuru10, Kunal Merchant11, Shirley Huang11, Audrey L. Shaw11, Enoch Bortey11, William P. Forbes11 1New York Presbyterian Hosptial - Columbia, New York, NY, USA. 2The Liver Center, University of California, San Francisco, San Francisco, CA, USA. 3Virginia Commonwealth University, Richmond, VA, USA. 4Cedar-Sinai Medical Center, Los Angeles, CA, USA. 5University of California San Francisco Fresno, Fresno, CA, USA. 6Metrohealth Medical Center, Cleveland, OH, USA. 7New York Presbyterian Hospital - Weil Cornell Medical Center, New York, NY, USA. 8California Pacific Medical Center, San Francisco, CA, USA. 9University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. 10Permian Gastroenterology, Odessa, TX, USA. 11Salix Pharmaceuticals, Morrisville, NC, USA

#308 CIRRHOSIS LEADS TO IMPAIRED NEUTROPHIL PHAGOCYTOSIS WHICH PARALLELS INCREASED IL-10 CONCENTRATION AND IS REVERSED FOLLOWING LIVER TRANSPLANTATION Nicholas J. Taylor, Yun Ma, (Robin) Daniel Abeles, Munther J. Hussain, Georg Auzinger, Michael A. Heneghan, John G. O’Grady, William Bernal, Diego Vergani, Julia Wendon, Debbie L. Shawcross Institute of Liver Studies & Transplantation, King’s College London, London, United Kingdom

#309 PREDICTION OF 6-MONTH MORTALITY IN PATIENTS WITH ALCOHOLIC CIRRHOSIS Matthieu DEMY1, Jerome Boursier1,2, Sandrine Bertrais2, Elodie Cesbron-Métivier3, Frédéric Oberti1,2, Christophe Pilette3, Paul Cales1,2 1Service d’Hépato-Gastroentérologie, Centre Hospitalier Universitaire, Angers, France. 2Laboratoire HIFIH, Université, Angers, France. 3Serice d’Hépato-Gastroentérologie, Centre Hospitalier, Le Mans, France

#310 IMPROVEMENT OF HYPONATREMIA IN CIRRHOSIS INCREASES SPEED OF COMPLEX INFORMATION PROCESSING Juan Cordoba1,3, Mónica Guevara2,3, Hugh R. Watson4, Solenn Le Guennec4, Pere Gines2,3 1Liver Unit, Hospital Vall Hebron, Barcelona, Spain. 2LIver Unit, Hospital Clinic, Barcelona, Spain. 3CIBEREHD, Barcelona, Spain. 4Sanofi-aventis R&D, Chilly-Mazarin, France

#311 PULMONARY VASODILATION IS MORE SEVERE THAN SYSTEMIC VASODILATION IN BOTH COMPENSATED AND DECOMPENSATED CIRRHOSIS OF LIVER Nitin Gupta, Ashish Kumar, Smruti R. Mishra, Praveen Sharma, Shiv K. Sarin G B Pant Hospital, New Delhi, India

#312 PREDICTIVE FACTORS FOR THE OUTCOME OF PATIENTS WITH ACUTE ON CHRONIC LIVER FAILURE Ivo Graziadei, Karin Nachbaur, Wolfgang Vogel Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria


Fred Poordad1, Nathan Bass2, Arun J. Sanyal3, Muhammad Y. Sheikh4, Kevin D. Mullen5, Samuel Sigal6, Todd Frederick7, Robert S. Brown8, Shobha Joshi9, Kunal Merchant10, Shirley Huang10, Audrey L. Shaw10, Enoch Bortey10, William P. Forbes10 1Liver Disease and Transplant Center, Cedar-Sinai Medical Center, Los Angeles, CA, USA. 2University of California, San Francisco, San Francisco, CA, USA. 3Virginia Commonwealth University, Richmond, VA, USA. 4Univeristy of California San Francisco - Fresno, Fresno, CA, USA. 5Metrohealth Medical Center, Cleveland, OH, USA. 6New York Presbyterian Hospital - Weil Cornell Medical Center, New York, NY, USA. 7California Pacific Medical Center, San Francisco, CA, USA. 8New York Presbyterian Hosptial - Columbia, New York, NY, USA. 9Tulane University School of Medicine Hospital & Clinic, New Orleans, LA, USA. 10Salix Pharmaceuticals, Morrisville, NC, USA

Hans Dieter Nischalke, Cordula Berger, Katharina Aldenhoff, Lydia Thyssen, Martin G. Gentemann, Jacob Nattermann, Tilman Sauerbruch, Ulrich Spengler, Beate Appenrodt Internal Medicine I, University Bonn, Bonn, Germany

122A

POSTER SESSIONS

#313

#318

OVEREXPRESSION OF APELIN RECEPTOR (APJ/AGTRL1) ON PDGFβ ACTIVATED HUMAN STELLATE CELLS IN RELATION TO HUMAN CIRRHOTIC LIVER

PREGNANCY IN PATIENTS WITH CIRRHOSIS – CAN ADVERSE OUTCOMES BE PREDICTED PRIOR TO CONCEPTION?

Hiroaki Yokomori1, Masaya Oda2, Fumihiko Kaneko1, Toshifumi Hibi3 1Internal Medicine, Kitasato University, Kitasato Institute Medical Center, Saitama, Japan. 2Organized Center of Clinical Medicine, International University of Health and Welfare, Tokyo, Japan. 3Internal Medicine, School of Medicine, Keio University, Tokyo, Japan

#314 ROLE OF LONG-TERM MIDODRINE IN PATIENTS WITH CIRRHOSIS AND REFRACTORY OR RECURRENT ASCITES : A PILOT STUDY Virendra Singh1, Sahdeb P. Dhungana2, Navneet Sharma2, Rajesh Vijayverghia3, Chander K. Nain4, Baljinder Singh5, Ashish Bhalla2, Sushil K. Mahi2 1Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 2Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 3Cardiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 4Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 5Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

#315 PREDICTIVE FACTORS OF HOSPITAL MORTALITY IN CIRRHOTIC PATIENTS ADMITTED TO CRITICAL CARE UNITS Alain Huerta, Maria Vega Catalina, Maria Senosiain, Diego Rincon, Cristina Ripoll, Magdalena Salcedo, Ana Matilla, Gerardo Clemente, Rafael Bañares H.G.U. Gregorio Marañón, Madrid, Spain S AT U R D AY OCTOBER 31


#316 ADDITION OF PROBIOTICS TO ANTIBIOTICS DOES NOT IMPROVE ITS EFFICACY IN PREVENTION OF SPONTANEOUS BACTERIAL PERITONITIS: A DOUBLE BLIND PLACEBO-CONTROLLED RANDOMIZED CONTROLLED TRIAL Chandana Pande1,3, Ashish Kumar2,3, Shiv K. Sarin1,2 1Gastroenterology, G B Pant Hospital, New Delhi, India. 2Hepatology, Institute of Liver & Biliary Sciences (ILBS), New Delhi, India. 3Special Centre for Molecular Medicine (SCMM), Jawaharlal Nehru University (JNU), New Delhi, India

#317 RISK FACTORS FOR MORTALITY IN CIRRHOTIC PATIENTS WITH SEPSIS Seng Gee Lim1, Lee Guan Lim1, Xiang Xuan, Eunice Tan2, Yock Young Dan1, Yin-Mei Lee1, Vincent Lai1 1Department of Gastroenterology & Hepatology, National University Health System, Singapore, Singapore. 2NUS High School, Singapore, Singapore


Rachel H. Westbrook, John G. O’Grady, Phillip M. Harrison, John Devlin, Michael A. Heneghan Kings College Hospital, Institute of Liver Studies, London, United Kingdom

#319 PLASMA LEVELS OF APOLIPOPROTEIN A1 ARE DECREASED IN PATIENTS WITH BUDD-CHIARI SYNDROME Jildou Hoekstra1, Simone Talens2, Steffen P. Dirkx2, Sarwa Darwish Murad1, Jonel Trebicka3, Elwyn Elias4, Massimo Primignani5, Juan Carlos Garcia-Pagán6, Dominique Valla7, Frank W. Leebeek2, Dingeman C. Rijken2, Harry L. Janssen1 1Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, Netherlands. 2Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands. 3Department of Internal Medicine I, University Hospitel of Bonn, Bonn, Germany. 4Liver Unit, Queen Elizabeth University Hospital, Birmingham, United Kingdom. 5Gastroenterology and Gastrointestinal Endoscopy Unit, Ospedale Policlinico, Mangiagalli and Regina Elena Foundation, Milan, Italy. 6Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain. 7Department of Hepatology, Hopital Beaujon, AP-HP, INSERM & University Paris-7, Clichy, France

#320 A MICROSATELLITE IN THE PROMOTER REGION OF THE GLS GENE PREDICTS THE RISK OF HEPATIC ENCEPHALOPATHY: FUNCTIONAL ANALYSIS USING LUCIFERASE REPORTER Jose A. Del Campo1, Maria Jover1, Jose L. Royo2, Elena Hoyas1, Lourdes Grande1, Jose J. Galán2, Santos Mañes3, Agustín Ruiz2, Manuel Romero-Gomez1 1Unit for the Clinical Management of Digestive Diseases & ciberehd, Hospital de Valme, Sevilla, Spain. 2Structural genomics, Neocodex S.A, Sevilla, Spain. 3Department of Immunology and Oncology, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Cientificas, Madrid, Spain

#321 PERCUTANEOUS AND SURGICAL INTERVENTIONS IN PATIENTS WITH BUDD-CHIARI SYNDROME-A LONGITUDINAL SINGLE CENTER STUDY COMPARING OUTCOME AND COSTEFFECTIVENESS Meir Mizrahi, Lilah Roemi, Tomer Adar, Daniel Shouval, Allen Bloom, Oren Shibolet internal medicin liver unit, Hadassah medical center, Jerusalem, Israel


POSTER SESSIONS

123A

#322

#327

CIRRHOTIC CARDIOMYOPATHY: RELATIONSHIP WITH HYPERDYNAMIC SYNDROME AND NTERMINAL BRAIN NATRIURETIC PEPTIDE LEVELS

RENAL INSUFFICIENCY IS RELATIVELY INFREQUENT AT FIRST DECOMPENSATION OF LIVER CIRRHOSIS AND IS ASSOCIATED WITH HIGHER RISK OF NOSOCOMIAL INFECTIONS AND POOR PROGNOSIS

Vanesa Bernal1, Isaac Pascual2, Elena Piazuelo3,4, Paula Esquivias3,4, Agustin Garcia-Gil5, Monica Polo-Tomas4, Angel Lanas1,4, Miguel A. Simon1 1Gastroenterology and Hepatology, Lozano Blesa University Hospital, Zaragoza, Spain. 2Cardiology, Lozano Blesa University Hospital, Zaragoza, Spain. 3Instituto Aragones de Ciencias de la Salud (IACS), Zaragoza, Spain. 4CIBERehd, Zaragoza, Spain. 5Liver Transplant Unit, Lozano Blesa University Hospital, Zaragoza, Spain

Carlos Noronha Ferreira1, Teresa Rodrigues2, Helena CortezPinto1, Fatima Serejo1, Fernando Ramalho1, José F. Velosa1 1Serviço de Gastrenterologia e Hepatologia, Hospital de Santa Maria, Lisboa, Portugal. 2Laboratório de Biomatemática, Faculdade de Medicina de Lisboa, Lisboa, Portugal

#323

ASCITES IMPROVES UPON SERUM SODIUM AND MELD FOR PREDICTING MORTALITY IN PATIENTS AWAITING LIVER TRANSPLANTATION

HEPATIC ENCEPHALOPATHY: A DIFFERENT PATHOPHYSIOLOGY FOR DIFFERENT FEATURES? Montagnese1,

Biancardi1,

Carraro2,

Sara Anna Paolo Guido Mannaioni3, Flavio Moroni3, Sami Schiff1, Francesca Campagna1, Donatella Pavanello1, Angelo Gatta1, Piero Amodio1 1Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy. 2Department of Laboratory Medicine, Padua University Hospital, Padua, Italy. 3Department of Pre-clinical and Clinical Pharmacology, University of Florence, Florence, Italy

#324 DEFINING ACUTE-ON-CHRONIC LIVER FAILURE (AOCLF). IS THE IDENTIFICATION OF A PRECIPITATING EVENT (PE) IMPORTANT?

#328

Ma Somsouk1,2, Rachel Kornfield1,2, Scott W. Biggins1,2 1Medicine, Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, CA, USA. 2GI Health Outcomes Policy and Economics Research Program, University of California San Francisco, San Francisco, CA, USA

#329 SYSTEMIC CIRCULATORY DYSFUNCTION IS ASSOCIATED TO INCREASED CONTRACTILITY IN CIRRHOSIS

#325

#330

ACUTE KIDNEY INJURY IN CIRRHOTIC PATIENTS WITH ASCITES: A COMPARATIVE ANALYSIS OF THREE CRITERIA IN RELATION TO HOSPITAL MORTALITY

SERUM OR SALIVARY FREE CORTISOL BETTER EVALUATE ADRENAL DYSFUNCTION IN CIRRHOTIC PATIENTS THAN SERUM TOTAL CORTISOL DOSAGE

Juliana R. de Carvalho, Cristiane A. Villela-Nogueira, Ronir R. Luiz, Paula L. Guzzo, Juliana Rosa, Eduardo Rocha, Henrique Sergio M. Coelho, Renata Perez Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Thierry Thevenot1, Sophie Borot2, Jean-Paul Cervoni1, Agnes RemyMartin3, Remy Sapin4, Carine Richou1, Claire Vanlemmens1, Denis Cléau5, Anne Minello6, Emilie Muel1, Alfred Penfornis2, Vincent Di Martino1, Elisabeth Monnet5 1Service d’Hépatologie et de Soins Intensifs Digestifs, Hôpital Minjoz, Besançon, France. 2Service d’Endocrinologie-Métabolisme et Diabétologie-Nutrition, Hôpital Minjoz, Besançon, France. 3Service de Biochimie Hormonale, Hôpital Minjoz, Besançon, France. 4Service d’Exploration Fonctionnelle par les Isotopes, Hôpital civil de Strasbourg, Strasbourg, France. 5Service d’Hépato-gastroentérologie, Hôpital de Vesoul, Vesoul, France. 6Service d’Hépatogastroentérologie, Hôpital du Bocage, Dijon, France

#326 SYSTEMIC AND NOT CENTRAL OXIDATIVE STRESS IS ASSOCIATED WITH BRAIN EDEMA IN BILE-DUCT LIGATED RATS Xiaoling Yang, Cristina R. Bosoi, Mélanie Tremblay, Christopher F. Rose Neuroscience Research Unit, CRCHUM, Université de Montréal, Montréal, QC, Canada


Cristina Ripoll, Sakib Khalid, Khurram Bari, Guadalupe GarciaTsao Digestive Diseases Section, Yale University School of Medicine and CT-VA Healthcare Sytem, West Haven, CT, USA

Cristina Ripoll1, Raquel Yotti2, Diego Rincón1, Marta Puerto1, Yolanda Benito2, Maria Vega Catalina1, Marta Alhama2, Magdalena Salcedo1, Javier Bermejo2, Rafael Bañares1 1Liver and Transplant Unit. Digestive Diseases Department, Hospital General Universitario Gregorio Marañón. CIBEREHD, Madrid, Spain. 2Non invasive Cardiology. Cardiology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain

124A

POSTER SESSIONS

#331

#336

MINIMAL HEPATIC ENCEPHALOPATHY IS ASSOCIATED WITH MOTOR VEHICLE CRASHES: THE REALITY BEYOND THE DRIVING TEST

THE USE OF NEAR INFRARED SPECTROSCOPY TO EVALUATE DYNAMIC CHANGES IN THE PERIPHERAL MICROCIRCULATION OF CIRRHOSIS

Jasmohan S. Bajaj1, Richard T. Stravitz1, Allyne Topaz1, Christine M. Schubert2, Kia Saeian3, Muhammad Hafeezullah3, Debulon Bell1, Douglas M. Heuman1, Richard K. Sterling1, Velimir A. Luketic1, Arun J. Sanyal1 1Gastroenterology,Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA, USA. 2Biostatistics, Virginia Commonwealth University, Richmond, VA, USA. 3Gastroenterology and Hepatology, Medical College of Wisconsin, Milwauke, WI, USA

Sam J. Thomson1,2, Matthew L. Cowan1, Saif Musa1,2, Robert M. Grounds2, Tony M. Rahman1,2 1Gastroenterology & Hepatology, St George’s Hospital, London, United Kingdom. 2General Intensive Care, St George’s Hospital, London, United Kingdom

#332 CAN PSYCHOMETRIC TESTING DIFFERENTIATE MINIMAL HEPATIC ENCEPHALOPATHY FROM SLEEP APNEA IN CIRRHOSIS? Jasmohan S. Bajaj1, Douglas M. Heuman1, Debulon Bell1, Allyne Topaz1, Richard T. Stravitz1, Richard K. Sterling1, Lisa D. Pisney1, James Wade2, Douglas P. Gibson2, Christine M. Schubert3, Arun J. Sanyal1 1Gastroenterology,Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA, USA. 2Psychology, Virginia Commonwealth University, Plymouth, United Kingdom. 3Biostatistics, Virginia Commonwealth University, Richmond, VA, USA

#333 ORAL AST-120 (SPHERICAL CARBON ADSORBENT) IMPROVES PRURITUS AND LOWERS SERUM BILE ACIDS IN PATIENTS WITH CIRRHOSIS OF VARIOUS ETIOLOGIES



Averell H. Sherker1, John M. Vierling2, Paul Pockros3, Raman Battish1, Caroline LaPlaca4, Michelle Resler4, M. Scott Harris4, Jeffrey D. Bornstein4 1Washington Hospital Center, Washington, DC, USA. 2Baylor College of Medicine, Houston, TX, USA. 3Scripps Clinic, La Jolla, CA, USA. 4Ocera Therapeutics, San Diego, CA, USA

#334 ROLE OF APOPTOSIS IN PATHOGENESIS OF CIRRHOTIC CARDIOMYOPATHY Hongqun Liu, Soon woo Nam, Samuel S. Lee University of Calgary, Calgary, AB, Canada

#335 OVEREXPRESSION OF THE LYMPHATIC MARKER PODOPLANIN IN HUMAN ADVANCED CIRRHOTIC LIVER- REEVALUATIONS OF MICROLYMPHATIC ABNORMALITIES RELATED TO ASCITES FORMATION Hiroaki Yokomori1, Masaya Oda2, Fumihiko Kaneko1, Toshifumi Hibi3 1Internal Medicine, Kitasato University, Kitasato Institute Medical Center, Saitama, Japan. 2Organized Center of Clinical Medicine, International University of Health and Welfare, Tokyo, Japan. 3Internal Medicine, School of Medicine, Keio University, Tokyo, Japan


#337 GLUTAMINE SYNTHETASE (GS) AND THE SINUSOIDAL ENDOTHELIAL CELL (SEC) MARKERS CD34 AND STABILIN-2 (STAB-2) IN EARLY AND LATE CIRRHOSIS: PRELIMINARY RESULTS Paulette Bioulac-Sage1,3, Kai Schledzewski4, Gaëlle Cubel3, Cyrill Géraud4, Sergij Goerdt4, Charles Balabaud2,3 1Pathology, CHU Bordeaux, Bordeaux, France. 2Hepatology, CHU Bordeaux, Bordeaux, France. 3Inserm U889, Université Bordeaux 2, Bordeaux, France. 4UMM - Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Mannheim, Germany

#338 DO EXHALE NO AND DIFFUSION LUNG CAPACITY CORRELATED THE DISEASE SEVERITY IN PATIENTS WITH CHRONIC LIVER DISEASE? Jun Young Jung, Dae Won Jun, Dea Hyun Beak, Byoung Kwan Son, Seong Hwan Kim, Yun Ju Jo, Young Sook Park Eulji Hospital, Seoul, Korea, South

#339 TIPS FOR REFRACTORY ACSITES: A SINGLE CENTRE EXPERIENCE WITH COVERED STENTS Charlotte Pither1, Timothy J. Bryant2, Brian Stedman2, Nicholas Sheron1, Kathryn L. Nash2, Mark Wright1, Nigel Hacking2, Indra N. Guha1 1Liver Unit, University of Southampton, Southampton, United Kingdom. 2Interventional Radiology, Southampton University Hospital Trust, Southampton, United Kingdom

#340 INFECTION IN CIRRHOSIS. A SYSTEMATIC REVIEW OF MORTALITY AND PROGNOSIS: PRELIMINARY EVIDENCE FOR A NEW PROGNOSTIC STAGE Vasiliki Arvaniti1, Gennaro D’Amico2, Giuseppe Fede1, Pinelopi Manousou1, Emmanuel Tsochatzis1, Maria Pleguezuelo1, A K Burroughs1 1The Royal Free Sheila Sherlock Liver Centre, Royal Free Hosital, London, United Kingdom. 2Gastroenterology Unit, Cervello and University of Palermo, Palermo, Italy


POSTER SESSIONS

#341

#345

RENAL AND CIRCULATORY EFFECTS OF PARAMETER-DIRECTED LARGE VOLUME PLASMA EXPANSION IN PATIENTS WITH HEPATORENAL SYNDROME TYPE 1. AN UNCONTROLLED PILOT STUDY

HCV CLEARANCE AFTER PEG IFN PLUS RBV IMPROVES THE COURSE OF HCV CIRRHOSIS REGARDLESS OF PORTAL HYPERTENSION

125A

Andreas Umgelter1, Katrin S. Wagner2, Wolfgang Reindl1, Fabian Geisler1, Wolfgang Huber1, Roland M. Schmid1 12nd Medical Department, Klinikum rechts der Isar, Technical University, Munich, Germany. 2Klinik für Kardiologie und Internistische Intensivmedizin, Klinikum Bogenhausen, Munich, Germany

Vito Di Marco1, Vincenza Calvaruso1, Stefania De Lisi1, Donatella Ferraro2, Paola Pizzillo2, Giuseppe Alaimo1, Sergio Peralta1, Antonio Craxì1 1Gastroenterologia & Epatologia, DIBIMIS,, University of Palermo, Palermo, Italy. 2Cattedra di Virologia, Dipartimento di Scienze per la Promozione della Salute “G.D’Alessandro”, University of Palermo, Palermo, Italy

#342

#346

A PROSPECTIVE SURVEY ON THE TREATMENT AND SURVIVAL OF PATIENTS WITH HEPATORENAL SYNDROME

DEVELOPMENT OF NEW HIGHLY SENSITIVE POINT OF CARE SCREEN FOR SPONTANEOUS BACTERIAL PERITONITIS USING THE LEUKOCYTE ESTERASE METHOD: FINAL RESULTS ON 1,304 EXPERIMENTS

Francesco Salerno1, Massimo Cazzaniga1, Manuela Merli2, Giancarlo Spinzi3, Simone Saibeni4, Andrea Salmi5, Stefano Fagiuoli6, Antonio Spadaccini7, Elisa Trotta8, Roberto G. Romanelli9, Oliviero Riggio2, Savino Bruno4, Paolo Angeli8, Giacomo Laffi9, Maurizio Koch10 1Internal Medicine, Policlinico San Donato, University, San Donato (MI), Italy. 2Unità di Gastroenterologia, Università “La Sapienza”, Roma, Italy. 3Unità di Gastroenterologia, Ospedale Valduce, Como, Italy. 4Unità di Medicina Interna e Epatologia, Ospedale Fatebenefratelli, Milano, Italy. 5Unità di Gastroeneterologia, Ospedale Sant’Orsola, Brescia, Italy. 6Unità di Gastroeneterologia, Ospedali Riuniti, Bergamo, Italy. 7Unità di Gastroeneterologia, Ospedale San Pio da Pietralcina, Vasto, Italy. 8Medina Clinica e Sperimentale, Policlinico Universitario, Padova, Italy. 9Medicina Interna ed Epatologia, Policlinico Careggi, Firenze, Italy. 10Unità di Gastroenterologia, Ospedale San Filippo Neri, Roma, Italy

#343

Andres Cardenas1, Pere Gines3, Paul Marotta2, Frank S. Czerwiec4, John Ouyang4, Anne Sexton4, Mónica Guevara3, Nezam H. Afdhal5 1Institut de Malalties Digestives, Hospital Clinic, University of Barcelona, Barcelona, Spain. 2Transplant Hepatology, University of Western Ontario, London, ON, Canada. 3Liver Unit, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, University of Barcelona, Barcelona, Spain. 4Otsuka Pharmaceutical Development & Commercialization, Rockville, MD, USA. 5Liver Center, Beth Israel Deaconess Medical Center, Boston, MA, USA

#344 A PROSPECTIVE PILOT STUDY OF CIRCULATING ENDOTHELIAL CELLS AS A POTENTIAL NEW BIOMARKER IN PORTAL HYPERTENSION Soha S. Abdelmoneim1,3, Jayant A. Talwalkar1, Patrick S. Kamath1, Mohamed Fathalla1,3, Benjamin R. Kipp2, Michael B. Campion2, Amy C. Clayton2, Kevin C. Halling2, Vijay Shah1 1Gastroenterology Research Unit, Mayo Clinic, Rochester, MN, USA. 2Department of Pathology, Mayo Clinic, Rochester, MN, USA. 3Department of Tropical Medicine and Gastroenterology & Hepatology, Assiut University, Assiut, Egypt

#347 VASOACTIVE DRUGS FOR HEPATORENAL SYNDROME: SYSTEMATIC REVIEW AND METAANALYSIS OF RANDOMIZED TRIALS Lise L. Gluud1,2, Kurt Christensen2, Erik Christensen2,3, Aleksander Krag1,4 1Department of Internal Medicine, Copenhagen University Hospital Gentofte, Hellerup, Denmark. 2Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Copenhagen, Denmark. 3Clinic of Internal Medicine, Bispebjerg University Hospital, Copenhagen, Denmark. 4Department of Medical Gastroenterology, Hvidovre University Hospital, Hvidovre, Denmark

#348 IDENTIFICATION OF PATIENTS WITH DECOMPENSATED CIRRHOSIS AT HIGH RISK FOR DEATH: DOES HEPATIC VENOUS PRESSURE GRADIENT MEASUREMENT IMPROVE THE PREDICTION? Seung Ha Park, Dong Joon Kim, Chan Woo Lee, Jin Ho Kim, Young Mook Kim, Jin Bong Kim, Hyoung Su Kim, Tae Ho Hahn, Sang Hoon Park, Myung Seok Lee Internal Medicine, Hallym University College of Medicine, Gangwon-Do, Korea, South


THE EFFECTS OF A VASOPRESSIN V2 RECEPTOR ANTAGONIST IN THE MANAGEMENT OF PATIENTS WITH CIRRHOSIS AND HYPONATREMIA. SAFETY AND EFFICACY OF ORAL TOLVAPTAN IN THE SALT TRIALS

Michel H. Mendler1,2, Arun K. Agarwal3, Mateen H. Trimzi2, Erika Madrigal1, Matthew M. Tsushima1, Elliot Joo4, Marisela Santiago1, Elissa M. Flores1, Gabriel J. David5, Adrienne D. Workman5, Bruce A. Runyon1 1Division of GI and Liver Diseases, Loma Linda University Medical Center, Loma Linda, CA, USA. 2Transplantation Institute, Loma Linda University Medical Center, Loma Linda, CA, USA. 3Research and Development, Serim Research Corporation, Elkhart, IN, USA. 4Department of Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA. 5School of Medicine, Loma LInda University Medical Center, Loma Linda, CA, USA

126A

POSTER SESSIONS

#349

#354

RISK OF THROMBOEMBOLIC EVENTS (TES) AMONG PATIENTS WITH CIRRHOSIS

A PROSPECTIVE EVALUATION OF FIBROTEST (FT) ACCURACY FOR THE DIAGNOSIS OF CIRRHOSIS IN PATIENTS ADMITTED TO AN INTENSIVE CARE UNIT (ICU)

Ulla Forssen1, Cheryl Enger2, Andrew McAfee2,3, Dimitri Bennett1, Sumitra Shantakumar1 1Oncology R&D, Biometrics and Epidemiology, GlaxoSmithKline, Collegeville, PA, USA. 2i3 Drug Safety, Ann Arbor, MI, USA. 3Department of Emergency Medicine, Brigham and Women’s Hospital, Boston, MA, USA

#350 ASCITIC FLUID INFECTION IN PATIENTS WITH HEPATITIS B VIRUS-RELATED LIVER CIRRHOSIS: CULTURE-NEGATIVE NEUTROCYTIC ASCITES VERSUS SPONTANEOUS BACTERIAL PERITONITIS Seung Up Kim1,5, Do Young Kim1,2, Chun Kyon Lee6, Jun Yong Park1,2, Sun Hye Kim6, Eun Hee Choi3, Sinyoung Kim4, KwangHyub Han1,2, Chae Yoon Chon1,2, Sang Hoon Ahn1,2 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, South. 2Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea, South. 3Department of Biostatistics, Yonsei University College of Medicine, Seoul, Korea, South. 4Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea, South. 5Liver Cirrhosis Clinical Research Center, Seoul, Korea, South. 6National Health Insurance Corporation Ilsan Hospital, Goyang, Korea, South

#351 TREATMENT OF MINIMAL HEPATIC ENCEPHALOPATHY: A RANDOMIZED CONTROLLED TRIAL COMPARING LACTULOSE, PROBIOTICS & L- ORNITHINE L-ASPARTATE WITH PLACEBO



Yen Ngo2, Julien Massard1, Marika Rudler1, Benjamin Pariente1, Mona Munteanu2, Pascal Lebray1, Yves Benhamou1, Vlad Ratziu1, Dominique Thabut1, Thierry Poynard1 1APHP UPMC Liver Cnter, Paris, France. 2Biopredictive, Paris, France

#355 PROGNOSTIC SIGNIFICANCE OF MINIMAL HEPATIC ENCEPHALOPATHY DETECTED BY PSYCHOMETRIC HEPATIC ENCEPHALOPATHY SCORE IN PATIENTS WITH CIRRHOSIS OF LIVER Radha K. Dhiman1, Roshan Kurmi1, Kiran K. Thumburu1, Sunil H. Venkataramarao2, Ritesh Agarwal3, Ajay K. Duseja1, Yogesh K. Chawla1 1Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 2Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 3Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

#356 LONG-TERM FOLLOW-UP OF PATIENTS WITH PORTAL VEIN THROMBOSIS AND MYELOPROLIFERATIVE DISEASE

Vibhu V. Mittal, Praveen Sharma, Barjesh Sharma, Shiv K. Sarin G B Pant Hospital, New Delhi, India

Esmay L. Bresser1, Jildou Hoekstra1, Jasper Smalberg2, Manon C. Spaander1, Frank W. Leebeek2, Harry L. Janssen1 1Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. 2Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands

#352

#357

NON-INVASIVE DIAGNOSIS OF ACUTE ALCOHOLIC HEPATITIS (AAH) WITH ASHTEST IN PATIENTS WITH MADDREY DISCRIMINATIVE FUNCTION (MADDREY DF) OVER 32

UNENHANCED CT SCAN IN ACUTE PORTAL VEIN THROMBOSIS (PVT): AN EASY, ACCURATE AND USEFUL RADIOLOGICAL FINDING FOR DIAGNOSIS AND THROMBOSIS DATING

Dominique Thabut1, Yen Ngo2,1, Mona Munteanu2,1, Nicolas Carbonell3, Marika Rudler1, Julien Massard1, Didier Lebrec4, Thierry Poynard1 1Hepatology Hopital Pitie Salpetriere, APHP UPMC Liver Center, Paris, France. 2Hepatology, BioPredictive, Paris, France. 3Hepatology Hopital St-Antoine, APHP UPMC Liver Center, Paris, France. 4Hepatology, Hopital Beaujon, Clichy, France

Onorina Bruno1, Aurelie Plessier2, Christophe Bureau3, Carine Chagneau-Derrode4, Bertrand Condat2, Dominique Valla2, Valerie Vilgrain1 1Radiology, Hopital Beaujon, Clichy, France. 2Hepatology, AP-HP, Hopital beaujon, Clichy, France. 3Hepatology, CHU Purpan, Toulouse, France. 4Hepatology, CHU La Milletrie, Poitiers, France

#353

HEPATIC VENOUS PRESSURE GRADIENT DOES NOT CORRELATE WITH THE PRESENCE AND THE SEVERITY OF PORTAL HYPERTENSIVE GASTROPATHY IN PATIENTS WITH LIVER CIRRHOSIS

CAN A SHORTER TEST COUNTERACT THE EFFECT OF FATIGUE IN THE DIAGNOSIS OF MINIMAL HEPATIC ENCEPHALOPATHY? Jasmohan S. Bajaj1, Christine M. Schubert2, Allyne Topaz1, Arun J. Sanyal1, Debulon Bell1, Douglas M. Heuman1 1Gastroenterology,Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA, USA. 2Biostatistics, Virginia Commonwealth University, Richmond, VA, USA


#358

Tae-Hee Lee, Yong-Suk Kim, Sun-Moon Kim, Euyi-Heog Im, KyuChan Huh, Young-Woo Choi, Young-Woo Kang Gastroenterology and Hepatology, Konyang Univeristy Hospital, Daejeon, Korea, South


POSTER SESSIONS

127A

#359

#365

PORTAL CAVERNOMA-ASSOCIATED BILIARY CHANGES: AN ULTRASOUND STUDY IN ASYMPTOMATIC PATIENTS

LENALIDOMIDE ATTENUATES ANGIOGENESIS AND THE HYPERDYNAMIC CIRCULATION IN A RAT MODEL OF PREHEPATIC PORTAL HYPERTENSION

Pavel Taimr, Jildou Hoekstra, Manon C. Spaander, Harry L. Janssen Gastroenterology, Erasmus MC, Rotterdam, Netherlands

#360 A NEW LOOK AT THE PANCYTOPENIA OF CIRRHOSIS AND THE EFFECT ON IT OF LIVER TRANSPLANTATION (LT) David G. Koch, Adrian Reuben, Meghan Malone Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, SC, USA

#361 CIRCULATORY DYSFUNCTION AFTER LARGE VOLUME PARACENTESIS IN PATIENTS WITH CIRRHOSIS AND ASCITES Paul D. James, Linda P. Oosterveld, Florence Wong Department of Internal Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

Complications of Cirrhosis: Experimental #362 REDUCTION IN HYPERAMMONEMIA WITH LORNITHINE PHENYLACETATE (OCR-002) IN BILEDUCT-LIGATED (BDL) CIRRHOTIC RATS RESTORES BRAIN ENOS ACTIVITY BY MODULATING THE DDAH-ADMA PATHWAY

#363 INTRAPERITONEAL LPS ENHANCES KUPFFER CELL DEPENDENT PORTAL PRESSURE INCREASE IN FIBROSIS Christian J. Steib, Christina Hartmann, Christoph von Hesler, Josef M. Haertl, Alexander L. Gerbes Department of Medicine II, Ludwig Maximilians Universität, Klinikum Grosshadern, Munich, Germany

#364 NOGO-B IS INDUCED IN HUMAN AND EXPERIMENTAL CIRRHOSIS, AND ITS ABSENCE AMELIORATES PORTAL PRESSURES AFTER BILE DUCT LIGATION Dahai Zhang1, Hui-Chun Huang3, Kazunori Shibao2, Chuhan Chung1, Roberto J. Groszmann1, Yasuko Iwakiri1 1Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA. 2Department of Surgery 1, University of Occupational and Environmental Health, KitaKyushu City, Japan. 3Medicine/Division of Gastroenterology, Taipei Veterans General Hospital, Taipei, Taiwan

#366 BETA-3-ADRENOCEPTOR-AGONISTS LEAD TO INTRAHEPATIC VASODILATION VIA GS/CAMP STIMULATION AND DECREASED RHO-KINASE ACTIVITY IN LIVER CIRRHOSIS Jonel Trebicka1, Martin Hennenberg1, Michaela Granzow1, Sabine Klein1, Wim Laleman2, Frederik Nevens2, Johan Zaagsma3, Joerg Heller1, Tilman Sauerbruch1 1Internal Medicine I, University of Bonn, Bonn, Germany. 2Hepatology, UZ Leuven, Leuven, Belgium. 3Department of Molecular Pharmacology, University Center of Pharmacology, Groningen, Netherlands

#367 RECIRCULATION OF IMMUNE SYSTEM CELLS ACTIVATED IN THE LIVER INITIATES SYSTEMIC INFLAMMATION IN EXPERIMENTAL COMPENSATED CIRRHOSIS Maria Ubeda1,2, Leticia Muñoz1,2, María-José Borrero1,2, Margaret Lario1,2, Ruben Frances2,3, Lourdes Lledó1,2, Jorge Monserrat1,2, Jose Such2,3, Melchor Alvarez-Mon2,4, Agustin Albillos2,5 1Dep. Medicine. Universidad de Alcalá, Alcalá de Henares, Spain. 2Ciberehd, Instituto de Salud Carlos III, Madrid, Spain. 3Hospital General Universitario de Alicante, Alicante, Spain. 4Hospital Universitario Príncipe de Asturias, Universidad de Alcalá, Alcalá de Henares, Spain. 5Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Madrid, Spain

#368 EFFECT OF LONG-TERM ADMINISTRATION OF A CANNABINOID CB1-RECEPTOR ANTAGONIST ON SYSTEMIC HEMODINAMICS, BACTERIAL TRANSLOCATION AND HEPATIC ENCEPHALOPATHY IN ASCITIC CIRRHOTIC RATS Gemma Odena1,3, Ramon Bartoli1,3, Amparo Galan4, Anna Serafin5, Lourdes C. Fluvia1,3, Mireia Miquel3, Rosa María Morillas2,3, Margarita Sala2, Ramon Planas2,3 1Institut Investigacio Germans Trias i Pujol, Badalona, Spain. 2Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. 3CIBEREHD, Barcelona, Spain. 4Biochemistry, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. 5Animal Research, Universitat Autonoma de Barcelona, Bellaterra, Spain


Balasubramaniyan Vairappan, Nathan Davies, Vikram Sharma, Naina Shah, Rajeshwar P. Mookerjee, Rajiv Jalan Liver Failure Group, Institute of Hepatology, University College London, London, United Kingdom

Bernhard Angermayr1, Berit A. Payer1, Thomas Reiberger1, Bernhard Jaeger1, Thomas Hummel1, Philipp Schwabl1, Thomas Horvatits1, Markus Mitterhauser2, Markus Peck-Radosavljevic1 1Gastroenterologie und Hepatologie, Medizinische Universität Wien, Wien, Austria. 2Nuklearmedizin, Medizinische Universität Wien, Wien, Austria

128A

POSTER SESSIONS

#369

#374

TREATMENT OF HYPERAMMONEMIA WITH LORNITHINE PHENYLACETATE (OCR-002) REDUCES PORTAL PRESSURE BY MODULATING HEPATIC NFκB AND HEPATIC ENOS ACTIVITY IN CIRRHOTIC RATS

CORRELATION OF ISHAK STAGE,TRANSIENT ELASTOGRAPHY,HVPG AND COLLAGEN PROPORTIONATE AREA IN HCV TRANSPLANTED PATIENTS

Rajeshwar P. Mookerjee, Balasubramaniyan Vairappan, Vikram Sharma, Naina Shah, Abeba Habtesion, Nathan Davies, Rajiv Jalan Institute of Hepatology, University College London, London, United Kingdom

#370 MONITORING MOTOR EVOKED POTENTIALS IN AWAKE RATS: A GOOD TOOL TO ASSESS HEPATIC ENCEPHALOPATHY Marc Oria1,2, Nicolas Chatauret1,2, Nuria Raguer3, Jose Antonio Arranz4, Juan Cordoba1,2 1Liver Unit, Hospital Vall Hebron, Barcelona, Spain. 2Ciberehd, Barcelona, Spain. 3Neurophysiology, Hospital Vall Hebron, Barcelona, Spain. 4Biochemistry, Hospital Vall Hebron, Barcelona, Spain

#371 ROLE OF GAP JUNCTIONS IN THE INCREASED INTRAHEPATIC VASCULAR RESISTANCE OF CIRRHOTIC RATS Manuel Hernandez-Guerra1,2, Beatriz Abrante2, Ysamar Barrios2, Zaida Adrian1, Yanira González1, Eduardo Salido2, Enrique Quintero1,2 1Liver Unit, Canary Island University Hospital, La Laguna, Spain. 2Research Unit, Canary Island University Hospital, La Laguna, Spain

#372 S AT U R D AY OCTOBER 31


ANALYSIS OF WALL SHEAR STRESS IN DIFFERENT MODELS OF PORTAL HYPERTENSION AND CIRRHOSIS Christophe Van Steenkiste1, Bram Trachet2, Christophe Casteleyn3, Denis Van Loo4, Patrick Segers2, Martine De Vos1, Hans Van Vlierberghe1, Isabelle Colle1 1Department gastroenterology and hepatology, University Ghent, Ghent, Belgium. 2bioMMeda, IBiTech, University Ghent, Ghent, Belgium. 3Department of Morphology, Faculty of Veterinary Medicine, University Ghent, Ghent, Belgium. 4Centre for X-Ray Tomography, University Ghent, Ghent, Belgium

#373 LONGITUDINAL DYNAMIC STUDIES OF PORTOSYSTEMIC SHUNTING IN PORTAL HYPERTENSIVE AND CIRRHOTIC MICE BY QUANTITATIVE MICROSPECT IMAGING Christophe Van Steenkiste1, Steven Staelens2, Steven Deleye2, Filip De Vos2, Stefaan Vandenberghe2, Christophe Van De Wiele3, Hans Van Vlierberghe1, Martine De Vos1, Isabelle Colle1 1department gastroenterology and hepatology, Ghent, Belgium. 2Medical Image and Signal Processing (MEDISIP), Ghent University-IBBT, Ghent, Belgium. 3Nuclear Medicine, Ghent University Hospital, Ghent, Belgium


Graziella Isgro, Vincenza Calvaruso, Pinelopi Manousou, Tu Vinh Luong, Lorenzo Andreana, David W. Patch, Neil Davies, Amar P. Dhillon, A K Burroughs The Sheila Sherlock Hepatobiliary-Pancreatic and Liver Unit, Royal Free Hospital, London, United Kingdom

#375 VASOACTIVE INTESTINAL PEPTIDE REDUCES PORTAL PRESSURE IN PERFUSED CIRRHOTIC RAT LIVER THROUGH ACTIVATION OF VIP RECEPTOR TYPE 2 Ilse Bockx, Katrien Verdrengh, Ingrid Vander Elst, Jos van Pelt, David Cassiman Hepatology, KU Leuven, Leuven, Belgium

#376 ANGIOTENSIN-(1-7) ATTENUATES ANGIOTENSIN II-INDUCED INCREASES IN HEPATIC RESISTANCE VIA NON-MAS RECEPTOR MEDIATED PATHWAY IN CIRRHOTIC RAT LIVER Chandana B. Herath, Zhiyuan Jia, Louise M. Burrell, Peter W. Angus Medicine, The University of Melbourne, Heidelberg Heights, VIC, Australia

#377 THE MICROVASCULATURE OF THE LIVER: A DYNAMIC MATHEMATICAL MODEL FOR THE STUDY OF LIVER DISEASE Chistopher Naugler, Ian R. Wanless Pathology, Dalhousie University, Halifax, NS, Canada

#378 LEADING ROLE OF VASCULAR SMOOTH MUSCLE CELLS IN EXTRAHEPATIC CIRRHOTIC ANGIOGENESIS Jonel Trebicka, Sabine Klein, Michaela Granzow, Esther Raskopf, Martin Hennenberg, Ganesh Ranabhat, Sebastian Gautsch, Volker Schmitz, Tilman Sauerbruch Internal Medicine I, University of Bonn, Bonn, Germany

#379 SORAFENIB ATTENUATES THE PORTAL HYPERTENSIVE SYNDROME BY ANTIANGIOGEMIC, ANTIINFLAMMATORY AND ANTIPROLIFERATIVE MECHANISMS Thomas Reiberger, Bernhard Angermayr, Philipp Schwabl, Nataliya Rohr-Udilova, Markus Peck-Radosavljevic Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria


POSTER SESSIONS

129A

Hepatitis B: Clinical Trials and Treatment

#380 MULTIPLE BONE MARROW-DERIVED CELLS MOBILIZATIONS BY G-CSF ADMINISTRATION IN PATIENTS WITH END STAGE LIVER DISEASE Gaia1,

Olivero1,

Abate1,

Silvia Antonella Maria Lorena Corrado Tarella2, Paola M. Omedè3, Paola Bondesan3, Emanuela Rolle1, Maria Torrani1, Alfredo Marzano1, Mario Rizzetto1, Antonina Smedile1 1Gastrohepatology Unit, AOU San Giovanni Battista of Turin, Turin, Italy. 2Haematology Unit, Ist. Mauriziano of Turin, Turin, Italy. 3Haematology Unit, AOU San Giovanni Battista of Turin, Turin, Italy

#381

#385 HBV REPLICATION MODULATES HBV SPECIFIC ADAPTIVE IMMUNE RESPONSES BY INDUCING AND MAINTAINING T REGULATORY CELL ACTIVITY Nirupma Trehan Pati1, Shyam Kottilil2, Shikha Shrivastava3, Syed Hissar3, Shiv K. Sarin3,1 1institute of Liver and Biliary Sciences, new Delhi, India. 2LIR, NIAID, NIH, Bethesda, MD, USA. 3Department of Gatseroenterology, G B Pant Hopsital, New Delhi, India

#386

THE MULTIKINASE-INHIBITOR SORAFENIB PREVENTS NEOANGIOGENESIS AND HIGHER NO PRODUCTION BY THE HEPATIC ARTERY IN CCL4INDUCED LIVER CIRRHOSIS

ENDOGENOUS CELLULAR MICRORNAS REGULATE REPLICATION OF HEPATITIS B VIRUS IN HUMAN HEPATOCYTES AND STEM/PROGENITOR CELLS AND OFFER NOVEL THERAPEUTIC TARGETS

Alexander Zipprich, Bruno Christ, Thomas Seufferlein, Matthias M. Dollinger First Department of Internal Medicine, Martin-Luther-Universitiy Halle, Halle/Saale, Germany

Mukesh Kumar1, Ankit Shah1, Kang Cheng1, Sanjeev Gupta1,2 and Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA. 2Cancer Center and Diabetes Center, Albert Einstein College of Medicine, Bronx, NY, USA

#382 GAP JUNCTIONS MODULATE THE HEPATIC VASCULAR TONE IN THE NORMAL ISOLATED PERFUSE RAT LIVER Manuel Hernandez-Guerra1,2, Beatriz Abrante2, Ysamar Barrios2, Yanira González1, Zaida Adrian1, Eduardo Salido2, Enrique Quintero1,2 1Liver Unit, Canary Island University Hospital, La Laguna, Spain. 2Research Unit, Canary Island University Hospital, La Laguna, Spain

#383

Nicholas G. Theodorakis, Nicholas J. Skill Surgery, Indiana University, Indianapolis, IN, USA

#384 HEPATIC VEIN TRANSIT TIME (HVTT) OF II GENERATION ULTRASOUND CONTRAST AGENT (USCA): NEW TOOL IN ASSESSMENT OF PORTAL HYPERTENSION? PRELIMINARY RESULTS Luisa Siciliani, Anna Rita Sorbo, Maurizio Pompili, Erica Nicolardi, Valeria Abbate, Laura Riccardi, Gian Ludovico Rapaccini Department of Internal Medicine, Catholic University of ‘Sacro Cuore’, Rome, Italy

#387 A FINITE COURSE OF PEGINTERFERON ALFA-2A RESULTS IN INACTIVE CHRONIC HEPATITIS B AND HBSAG CLEARANCE 5 YEARS POST-TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE DISEASE: BASELINE CHARACTERISTICS AND PREDICTIVE FACTORS OF LONG-TERM RESPONSE Patrick Marcellin1, Teerha Piratvisuth2, Maurizia R. Brunetto3, Ferruccio Bonino4, Patrizia Farci5, Cihan Yurdaydin6, Selim Gurel7, Hans-Peter Kapprell8, Diethelm Messinger9, Richard Batrla10 1Service d’Hepatologie and Centre de Recherches Biologiques Beaujon, Paris, France. 2Department of Internal Medicine, NKC Institute of Gastroenterology and Hepatology, Sonklanagarind Hospital, Hat Yai, Thailand. 3UO Gastroenterologia ed Epatologia, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy. 4Scientific Direction, Foundation IRCCS Policlinico of Milan and University of Pisa, Pisa, Italy. 5Universita di Cagliari, Cagliari, Italy. 6Faculty of Medicine, University of Ankara, Ankara, Turkey. 7Department of Gastroenterology, Uludag University, Uludag, Turkey. 8Abbott GmbH & Co, Wiesbaden, Germany. 9IST GmbH & Co, Mannheim, Germany. 10Hoffmann-La Roche, Basel, Switzerland


GTP CYCLOHYDROLASE AND TETRAHYDROBIOPTERIN IN PORTAL HYPERTENSION

1Medicine

130A

POSTER SESSIONS

#388

#391

LOSS OF HBSAG IN NUCLEOSIDE-NAïVE HBEAG(+) CHRONIC HEPATITIS B PATIENTS FOLLOWING TREATMENT WITH ENTECAVIR OR LAMIVUDINE: EVALUATION OF HBV GENOTYPES

HIGH RATES OF HBEAG SEROCONVERSION AND HBSAG LOSS WITH TENOFOVIR + EMTRICITABINE IN PATIENTS WITH HBV-HIV CO-INFECTION IRRESPECTIVE OF CD4+ CELL COUNT

Robert G. Gish1, Ting-Tsung Chang2, Ching Lung Lai3, Robert A. De Man4, Fred Poordad5, Dong Xu6, Helena Brett-Smith6, Melissa Harris7, Uchenna Iloeje6, Hong Tang7 1Division of Hepatology and Complex GI, Physicians Foundation California Pacific, San Francisco, CA, USA. 2National Cheng Kung University Medical College, Tainan, Taiwan. 3Department of Medicine, University of Hong Kong, Hong Kong SAR, China. 4Erasmus Medical Centre, University Hospital Rotterdam, Rotterdam, Netherlands. 5Department of Hepatology and Liver Transplantation, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 6BristolMyers Squibb Company, Research and Development, Wallingford, CT, USA. 7Bristol-Myers Squibb Company, Research and Development, Plainsboro, NJ, USA

Lana M. Kosi1, Thomas Reiberger1, Karoline Rutter1, Katharina Pfistershammer2, Armin Rieger2, Markus Peck-Radosavljevic1 1Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria. 2Dermatology, Div. of Immunodermatology & Infectious Diseases, Medical University of Vienna, Vienna, Austria

#389 PREVALENCE AND NATURE OF VIRAL MUTATIONS IN CHRONIC HEPATITIS B (CHB) PATIENTS ON ORAL ANTIVIRAL THERAPY (AVT): THE CHARM STUDY



Stuart K. Roberts1, Meng C. Ngu2, Simone I. Strasser3, Jacob George4, Gregory J. Dore5, Stephen Locarnini6, Joe Sasadeusz7, William Sievert8, Kenneth J. Peschell9, Kim Mitchell10, Amanda M. Elsome10 1Department of Gastroenterology, The Alfred Hospital, Melbourne, VIC, Australia. 2Department of Gastroenterology, Concord Repatriation General Hospital, Concord, NSW, Australia. 3AW Morrow Gastroenterology Department, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. 4Storr Liver Unit, Westmead Hosital, Westmead, NSW, Australia. 5Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, Darlinghurst, NSW, Australia. 6Research and Molecular Development, Victorian Infectious Diseases Reference Laboratory, North Melbourne, VIC, Australia. 7Victorian Infectious Diseases Service, Royal Melbourne Hospital, Parkville, VIC, Australia. 8Department of Gastroenterology, Monash Medical Centre, Clayton, VIC, Australia. 9Biometrics, Gilead Sciences Inc, Durham, NC, USA. 10Medical Affairs, Gilead Sciences Pty Ltd, East Melbourne, VIC, Australia

#390 CHARACTERIZATION OF CLEVUDINE-RESISTANT MUTANTS OF HEPATITIS B VIRUS ISOLATED FROM PATIENTS WITH LONG-TERM CLEVUDINE TREATMENT So Young Kwon1, Yong Kwang Park2, Won Hyeok Choe1, Chang Hong Lee1, Byung Kook Kim1, Soon-Young Ko1, Hyo Sun Choi2, Sung Hyun Ahn2, Kyun-Hwan Kim2 1Internal Medicine, Hepatology, Konkuk University School of Medicine, Seoul, Korea, South. 2Phamacology, Konkuk University School of Medicine, Seoul, Korea, South


#392 ON-TREATMENT QUANTIFICATION OF HBSAG IN DIFFICULT-TO-TREAT PATIENTS WITH LAMIVUDINE RESISTANCE CAN HELP IDENTIFY THOSE MOST LIKELY TO ACHIEVE SUSTAINED POST-TREATMENT RESPONSE TO PEGINTERFERON ALFA-2A RESCUE THERAPY Jinlin Hou1, Jian Sun1, Qing Xie2, Xiuhui Li3, Jiming Zhang4, Yuming Wang5, Hao Wang6, Jak Yiu Lai7, Shijun Chen8, Jidong Jia9, Ji-Fang Sheng10, Henry Lik-Yuen Chan11, Jiefei Wang12, Michael Li13, Michael Jiang14, Matei Popescu15, Joesph J.Y. Sung11 1Nanfang Hospital, Guangzhou, China. 2Ruijin Hospital, Shanghai, China. 3You’an Hospital, Beijing, China. 4Huashan Hospital, Shanghai, China. 5Xi’nan Hospital, Changqing, China. 6People’s Hospital, Beijing, China. 7Princess Margaret Hospital, Hong Kong, China. 8Infectious Disease Hospital, Shandong, China. 9Friendship Hospital, Beijing, China. 10The First Affiliated College of Medicine, Zhejiang University, Zhejiang, China. 11Prince of Wales Hospital, Hong Kong, China. 12Public Health Clinical Center Affiliate to Fudan University, Shanghai, China. 13Tuen Mun Hospital, Hong Kong, China. 14Roche, Shanghai, China. 15Roche, Basel, Switzerland

#393 HEPATITIS B VIRUS (HBV) MUTANTS RESISTANT TO NUCLEOSIDE ANALOGS ARE SUSCEPTIBLE TO NON-NUCLEOSIDIC INHIBITORS OF REPLICATION IN VITRO Gaetan Billioud1,2, Christian Pichoud1,2, Johan Neyts4, Fabien Zoulim1,3 1INSERM, Lyon cedex 03, France. 2Université Lyon 1, Lyon, France. 3Hospices civils de Lyon, Lyon, France. 4Rega Institute for Medical Research, Leuven, Belgium

#394 DIAGNOSIS AND MANAGEMENT OF CHRONIC HEPATITIS B IN ASIAN-AMERICAN PATIENTS AMONG PRIMARY CARE PHYSICIANS IN THE UNITED STATES Nimit Upadhyaya, Daniel Salinas-Garcia, Robert Chang, Carol D. Davis, Hong Tang US Pharmaceuticals, Bristol-Myers Squibb Company, Plainsboro, NJ, USA


POSTER SESSIONS

131A

#395

#400

ADD-ON COMBINATION THERAPY WITH ADEFOVIR DIPIVOXIL INDUCES RENAL IMPAIRMENT IN PATIENTS WITH LAMIVUDINEREFRACTORY HEPATITIS B VIRUS

HIGHER SUSTAINED POST-TREATMENT VIROLOGIC RESPONSE FOLLOWING PEGINTERFERON ALFA-2A ± ADEFOVIR COMPARED WITH ADEFOVIR MONOTHERAPY IN HBEAG-POSITIVE PATIENTS

Akihiro Tamori1, Masaru Enomoto1, Sawako Kobayashi1, Shuji Iwai1, Hiroyasu Morikawa1, Hiroki Sakaguchi1, Daiki Habu1, Susumu Shiomi2, Yasuo Imanishi3, Norifumi Kawada1 1Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan. 2Nuclear Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan. 3Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan

Wei-min Ma1, Bo-ping Zhou1,2, Fei-Jian Ao2, Da-qiao Zhou3, Yiwen Hu2, Qing He2, Wei Dai2, Cheng Xu2, Li-jia Chen4, Yan Liu1, Guang Nie1 1Shenzhen Municipal Institute of Hepatology, Shenzhen, China. 2Shenzhen Municipal Third People’s Hospital, Guangdong, China. 3Shenzhen Traditional Chinese Medicine Hospital, Guangzhou, China. 4Peking University Shenzhen Hospital, Peking, China

#396

#401

PHYSICIAN COUNTRY OF BIRTH AND HEPATITIS B VIRUS (HBV) SCREENING PRACTICES OF ASIANAMERICAN PRIMARY CARE PROVIDERS (PCPS) WHO TREAT ASIAN ADULTS LIVING IN THE US

APOPTOTIC ACTIVITY DURING TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS B

Tram Tran1, Anna S. Lok2, Diane Goodwin3, Danny Chu4, W. Ray Kim5, Robin Fisher3, Derek H. Coombs3, Elizabeth A. Fagan3, Franck Rousseau3 1Geffen UCLA School of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA. 2University of Michigan Medical Center, Ann Arbor, MI, USA. 3Gilead Sciences, Inc., Durham, NC, USA. 4Albert Einstein College of Medicine, New York, NY, USA. 5Mayo Clinic College of Medicine, Rochester, MN, USA

#397 PERSISTENCE AND ADHERENCE TO NUCLEOS(T)IDE ANALOG TREATMENT FOR CHRONIC HEPATITIS B

#398 NO BASELINE MUTATIONS IN THE HEPATITIS B VIRUS REVERSE TRANSCRIPTASE WERE DETECTED IN PATIENTS WITH TREATMENT-NAïVE CHRONIC HEPATITIS B USING INNO LIPA HBV DR3: A PROSPECTIVE STUDY Mindie H. Nguyen1, Huy N. Trinh2,3, Ruel T. Garcia2,3, Khanh K. Nguyen2, Huy A. Nguyen2, Carrie R. Wong3, Brian S. Levitt2, Eduardo B. da Silveira2 1Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA. 2San Jose Gastroenterology, San Jose, CA, USA. 3Pacific Health Foundation, San Jose, CA, USA

#399 TENOFOVIR (TDF) IS EFFECTIVE IN LAMIVUDINE(LAM)-RESISTANT CHRONIC HEPATITIS B PATIENTS WHO HARBOR RTA194T AT BASELINE Scott Fung1, Tony Mazzulli1, Morris Sherman1, Vladimir Popovic2 1Medicine, University of Toronto, Toronto, ON, Canada. 2Medical Affairs, Gilead Sciences, Mississauga, ON, Canada

#402 SIRNA CAN BE MODIFIED TO ACTIVATE RIG-I AND CONTROL HBV REPLICATION BY TWO DISTINCT PATHWAYS Gregor Ebert1, Hendrik Poeck2, Gunther Hartmann3, Ulrike Protzer1 1Institute of Virology, Technische Universität München / Helmholtz Zentrum München, Munich, Germany. 2Department of Internal Medicine III, University Hospital Rechts der Isar, Technische Universität München, Munich, Germany. 3Department of Clinical Pharmacology, University Hospital Bonn, Bonn, Germany

#403 META-ANALYSIS: ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE IN PATIENTS WITH LAMIVUDINE-RESISTANT HEPATITIS B VIRUS Hong Tang, Enqiang Chen, Lichun Wang, Jun Lei, Lu Xu Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China

#404 THE BURDEN OF CHRONIC HEPATITIS B IN A MEDIAN ENDEMIC COUNTRY: A MATHEMATICAL APPROACH Mehlika Toy1,2, Fatih Oguz Onder3, Ramazan Idilman4, Jan Hendrik Richardus1,5, A.Mithat Bozdayi6, Zarife Kuloglu7, Aydan Kansu7, Cihan Yurdaydin4 1Public Health, Erasmus Medical Center, Rotterdam, Netherlands. 2LiverDoc, Rotterdam, Netherlands. 3Department of Gastroenterology, Yuksek Ihtisas Hospital, Ankara, Turkey. 4Department of Gastroenterology, School of Medicine, Ankara, Turkey. 5Division of Infectious Diseases Control, Municipal Public Health Service Rotterdam, Rotterdam, Netherlands. 6Hepatology Institute, School of Medicine, Ankara, Turkey. 7Department of Pediatric Gastroenterology and Hepatology, School of Medicine, Ankara, Turkey


Watcharasak Chotiyaputta1, Carolyn Peterson2, Fausta A. Ditah1, Diane Goodwin2, Anna S. Lok1 1Gastroenterology and Hepatology, University of Michigan Health Systems, Ann Arbor, MI, USA. 2Gilead Sciences, Inc, Foster city, CA, USA

Harald Farnik1, W. Peter Hofmann1, Christian M. Lange1, Jorg Trojan1, Christoph Sarrazin1, Stefan Zeuzem1, Eva Herrmann2, Bernd Kronenberger1 1Dept. of Internal Med. 1, Hospital of the Goethe University, Frankfurt, Germany. 2Medicine, Institute of Biostatistics and Mathematical Modeling, Hospital of the Goethe University, Frankfurt, Germany

132A

POSTER SESSIONS

#405

#409

ENTECAVIR AND TENOFOVIR COMBINATION THERAPY IN CHRONIC HEPATITIS B: RESCUE THERAPY IN PATIENTS WITH ADVANCED FIBROSIS AND MULTIPLE PREVIOUS TREATMENT FAILURES. RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY

HBV REPLICATION IN PRIMARY MACAQUE HEPATOCYTES: CROSSING THE SPECIES BARRIER TOWARDS A NEW SMALL PRIMATE MODEL FOR THE EVALUATION OF IMMUNOTHERAPEUTIC STRATEGIES

Petersen1,2,

Lutgehetmann2,

Zoulim3,

Joerg Marc Fabien Martina Sterneck4, Harry L. Janssen5, Thomas Berg6, Peter Buggisch1, Pietro Lampertico7, Vlad Ratziu8, Maria Buti9, Christoph Sarrazin10 1Asklepiosklinik St. Georg, Liver Center Hamburg IFI Institute, University of Hamburg, Germany. 2Department of Gastroenterology, University Hospital Hamburg Eppendorf, Hamburg, Germany. 3Department of Hepatology, Hotel Dieu Hospital Lyon, Lyon, France. 4Department of Hepatobiliary Surgery and Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany. 5Department of Gastroenterology and Hepatology, University Medical Center, Rotterdam, Netherlands. 6Department of Gastroenterology and Hepatology, Charite University Medical Center, Berlin, Germany. 7I Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, University of Milan, Italy. 8Service d Hepato-Gastroenterologie, Universite Pierre et Marie Curie (Paris 6), Paris, France. 9Department of Hepatology, Hospital Vall de Hebron, Barcelona, Spain. 10Department of Medicine, Goethe University Hospital, Frankfurt, Germany

#406 MAJOR METABOLIC CIRCUITS IN THE LIVER REGULATE HEPATITIS B VIRUS AND ARE A POTENTIAL TARGET FOR ANTI VIRAL THERAPY Amir Shlomai1, Yosef Shaul2, Zamir Halpern1 medical center, Tel-Aviv, Israel. 2Weizmann institute of science, Rehovot, Israel

1Sourasky

#407 S AT U R D AY OCTOBER 31


TENOFOVIR DISOPROXIL FUMARATECONTAINING REGIMENS IN PREGNANCY: REPORT FROM THE ANTIRETROVIRAL PREGNANCY REGISTRY Robert S. Brown1, Diane Goodwin2, Kenneth J. Peschell2, Sherry Zhang2, Elizabeth A. Fagan2 1Columbia University College of Physicians and Surgeons, New York, NY, USA. 2Gilead Sciences, Inc., Durham, NC, USA

#408 SIMVASTATIN HAS SIGNIFICANT ANTIVIRAL SYNERGISM IN VITRO WITH ANTI-HBV DRUGS Ted Bader1, Brent Korba2, Michael Bronze1 of Medicine, University of Oklahoma, Oklahoma City, OK, USA. 2Dept of Microbiology, Georgetown University Medical Center, Washington, DC, USA 1Dept

Julie Lucifora1,2, Isabelle E. Vincent1,2, Pascale Berthillon1,2, Tatiana Dupinay1,2, David Durantel1,2, Ulrike Protzer4, Fabien Zoulim1,3, Christian Trepo1,3, Isabelle Chemin1,2 1Molecular pathobiology and new treatments of viral hepatitis, INSERM Unit 871, Lyon, France. 2University Lyon 1, IFR62 Lyon Est, Lyon, France. 3Hepatogastroenterology, Hospices Civils de Lyon, Hôtel Dieu Hospital, Lyon, France. 4Institute of Virology, Technische Universität München, Munich, Germany

#410 EXTENDING PEGINTERFERON ALFA-2A THERAPY IN PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B WHO DID NOT ACHIEVE A RESPONSE AT WEEK 48 CAN LEAD TO HBEAG SEROCONVERSION AND HBSAG CLEARANCE Xiao P. Chen, Xue-Fu Chen, Ji Huang, Wen-Li Chen, Chen Ren, Xiao-jun Ma, X-d Luo Guangdong Academy of Medical Science, Guangdong General Hospital, Guangzhou, China

#411 RISK OF INCIDENT AUTOIMMUNE DISEASES AFTER HEPATITIS B VACCINATION - A LARGE COHORT STUDY IN THE UK GENERAL PRACTICE RESEARCH DATABASE Marco Egbring, Alessandro Ceschi, Gerd A. Kullak-Ublick, Stefan Russmann Clinical Pharmacology, University Hospital Zurich, Zürich, Switzerland

#412 RESPONSE TO TENOFOVIR (TDF)-BASED COMBINATION THERAPY WITH ENTECAVIR (ETV) OR EMTRICITABINE (FTC) OR LAMIVUDINE (LAM) IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) WITH ANTIVIRAL RESISTANCE (AVR) OR PARTIAL RESPONSE (PR) TO PRIOR MONOTHERAPY Carrie R. Wong1, Ruel T. Garcia2,1, Huy N. Trinh2,1, Philip Vutien3, Maureen E. Morgan4, Huy Nguyen2, Khanh Nguyen2, Brian S. Levitt2, Mindie H. Nguyen3 1Pacific Health Foundation, San Jose, CA, USA. 2San Jose Gastroenterology, San Jose, CA, USA. 3Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA. 4Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA

#413 INCIDENCE AND PREDICTORS OF ADEFOVIR RESISTANCE IN CHRONIC HEPATITIS B PATIENTS WITH OR WITHOUT LAMIVUDINE-RESISTANT HBV TREATED WITH 4 YEARS ADEFOVIR DIPIVOXIL Chien-Hung Chen, Chuan-Mo Lee, Tsung-Hui Hu, Chao-Hung Hung, Jing-Houng Wang, Sheng-Nan Lu Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan Denotes AASLD Presidential Poster of Distinction


POSTER SESSIONS

133A

#414

#419

TRANSIENT ELASTOGRAPHY (FIBROSCAN®) IS RELIABLE FOR NON-INVASIVE DIAGNOSIS OF SIGNIFICANT FIBROSIS IN CHRONIC HEPATITIS B WITH MILD TRANSAMINITIS BUT BECOMES LESS RELIABLE AT HIGHER ALT LEVELS

HBSAG CLEARANCE CONTINUES TO INCREASE POST-TREATMENT IN PATIENTS WITH HCV/HBV COINFECTION TREATED WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN: 1.5 YEAR FOLLOW-UP

Jason Chang, Hock-foong Lui, Chee-Kiat Tan, Wan-Cheng Chow Dept of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore

#415 SUBSTITUTION OF ADEFOVIR FOR TENOFOVIR IN PATIENTS WITH CHRONIC HBV RECEIVING COMBINATION THERAPY WHO HAVE INCOMPLETE CONTROL OR VIROLOGICAL BREAKTHROUGH – IS IT WORTHWHILE? William Alazawi1, Rhys Cottle1, Valerie Ross1, Ines Ushiro-Lumb2, Elspeth M. Alstead1, Michael Glynn1, Richard Marley1, Graham R. Foster1 1Digestive Diseases Clinical Academic Unit, Barts & The London School of Medicine, London, United Kingdom. 2Department of Virology, Barts & The London NHS Trust, London, United Kingdom

#416 CLONAL ANALYSIS OF THE QUASISPECIES OF ANTIVIRAL RESISTANT HBV GENOMES IN PATIENTS WITH ENTECAVIR RESISTANCE TREATED WITH RESCUE LAMIVUDINE-ADEFOVIR COMBINATION THERAPY

#417 EFFICACY AND SAFETY OF LAMIVUDINE PLUS ADEFOVIR DE NOVO COMBINATION THERAPY COMPARED TO ENTECAVIR MONOTHERAPY IN CHRONIC HEPATITIS B: A SINGLE CENTRE CLINICAL PRACTICE EXPERIENCE Ivana Carey, Andrea Mendes, Sarah Hughes, Astrid Scalori, Abid Suddle, Kosh Agarwal, Phillip M. Harrison Institute of Liver Studies, Kings College School of Medicine at King’s College Hospital, London, United Kingdom

#418 ADEFOVIR DIPIVOXIL ADD-ON TREATMENT TO LAMIVUDINE RESISTANT HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS. VIROLOGICAL RESPONSE AND DEVELOPMENT OF RESISTANCE AFTER COMBINATION TREATMENT OF AT LEAST 5-YEAR DURATION Irene Rapti1, Evangelini Dimou1, Stephanos J. Hadziyannis1,2 of Medicine & Liver Unit, Henry Dunant Hospital, Athens, Greece. 2Hepatitis Research Laboratory at Evgenidion Hospital, Athens University, Athens, Greece

1Department

#420 SIMULATION MODELING OF THE NATURAL HISTORY OF HEPATITIS B PROGRESSION IN A UNITED STATES ADULT POPULATION – DETERMINING LIFE EXPECTANCIES Tiffany E. Kaiser1, Kenneth E. Sherman1, Mark H. Eckman2 of Digestive Disease, University of Cincinnati, Internal Medicine, Cincinnati, OH, USA. 2Division of General Internal Medicine and Center for Clinical Effectiveness, University of Cincinnati, Internal Medicine, Cincinnati, OH, USA

1Division

#421 LONG-TERM ADEFOVIR DIPIVOXIL MONOTHERAPY FOR UP TO 5 YEARS IN LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B Jung Min Lee1, Jun Yong Park2,3, Do Young Kim2,3, Tin Nguyen4, Sunpyo Hong5, Kwan Sik Lee2,3, Byung Soo Moon2, Kwang-Hyub Han2,6, Chae Yoon Chon2,3, Young Myoung Moon7, Sang Hoon Ahn2,3 1Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, South. 2Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea, South. 3Liver Cirrhosis Clinical Research Center, Seoul, Korea, South. 4Gastroenterology Department, St Vincent’s Hospital, Melbourne, VIC, Australia. 5GeneMatrix, Inc, Seoul, Korea, South. 6Liver Cirrhosis Clinical Research Center, Brain Korea 21 Project for Medical Science, Seoul, Korea, South. 7Internal Medicine, Kwan Dong University College of Medicine, Goyang, Korea, South


Ersin Karatayli1, Ramazan Idilman2, Senem C. Karatayli1, Emrah Cevik1, Ulus S. Akarca3, Sabahattin Kaymakoglu4, A.Mithat Bozdayi1,2, Cihan Yurdaydin1,2 1Ankara University Hepatology Institute, Ankara, Turkey. 2Gastroenterology, Ankara University Faculty of Medicine, Ankara, Turkey. 3Gastroenterology Department, Ege University Faculty of Medicine, Izmir, Turkey. 4Department of Gastroenterohepatology, Istanbul University, Istanbul, Turkey

Chun-Jen Liu1, Wan-Long Chuang2, Chuan-Mo Lee3, Ming-Lung Yu2, Sheng-Nan Lu3, Chia-Yen Dai2, Jee-Fu Huang2, Tsung-Hui Hu3, Chien-Hung Chen3, Chao-Hung Hung3, J. H. Wang3, Shun-Sheng Wu4, L. Y. Liao5, H. T. Kuo6, You-Chen Chao7, S. Y. Tung8, SienSing Yang9, W. W. Su4, Chih-Lin Lin5, Jia-Horng Kao1, Chen-Hua Liu1, Pei-Jer Chen1, Ding-Shinn Chen1 1National Taiwan University College of Medicine, Taipei, Taiwan. 2Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 3Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, Taiwan. 4Changhua Christian Hospital, Changhua, Taiwan. 5Taipei City Hospital, Ren-Ai Branch, Taipei, Taiwan. 6Chi Mei Medical Center, Tainan, Taiwan. 7Tri-Service General Hospital, Taipei, Taiwan. 8Chai-Yi Chang Gung Memorial Hospital, Chiayi, Taiwan. 9Cathay General Hospital, Taipei, Taiwan

134A

POSTER SESSIONS

#422

#425

EFFICACY AND SAFETY OF ENTECAVIR VERSUS ADEFOVIR IN CHRONIC HEPATITIS B PATIENTS WITH EVIDENCE OF HEPATIC DECOMPENSATION

FIVE YEAR TENOFOVIR THERAPY IS ASSOCIATED WITH MAINTAINED VIROLOGIC RESPONSE, BUT SIGNIFICANT DECLINE IN RENAL FUNCTION IN HIV/HBV COINFECTED PATIENTS

Yun -Fan Liaw1, Maria Raptopoulou-Gigi2, Hugo Cheinquer3, Shiv K. Sarin4, Tawesak Tanwandee5, Nancy Leung6, Robert P. Myers7, Robert S. Brown8, Mitchell L. Shiffman9, Jolanta Bialkowska10, Sourav Santra11, Elizabeth L. Cooney11 1Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan. 2Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. 3Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil. 4Department of Gastroenterology,, G. B. Pant Hospital, New Delhi, India. 5Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. 6Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China. 7Liver Unit, University of Calgary, Calgary, AB, Canada. 8Center for Liver Disease and Transplantation, Columbia University Medical Center, Timisoara, Romania. 9McGuire VA Medical Center, Richmond, VA, USA. 10Department of Infectious Diseases, Medical University, Lodz, Poland. 11Research and Development, Bristol-Myers Squibb Company, Wallingford, CT, USA

#423 ENHANCED AND PROLONGED ACTIVATION OF DENDRITIC CELLS IN CHRONIC HEPATITIS B PATIENTS TREATED WITH A COMBINATION OF PEG-IFN AND RIBAVIRIN DOES NOT IMPROVE RESPONSE TO THERAPY COMPARED TO STANDARD PEG-IFN THERAPY Andrea M. Woltman1, Marjoleine L. Op den Brouw1, Arjan Boltjes1, Paula Biesta1, Rekha S. Binda1, Duygu Turgut1, Maria Raptopoulou-Gigi2, Renate G. van der Molen1, Harry L. Janssen1 1Gastroenterology and Hepatology, Erasmus MC, University Hospital, Rotterdam, Netherlands. 2Clinical Immunology Unit, 2nd Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece S AT U R D AY OCTOBER 31


Jurrien G. Reijnders1, Theodora de Vries-Sluijs2, Bettina E. Hansen1, Hans L. Zaaijer3, Jan M. Prins4, Martin Schutten5, Robert A. De Man1, Marchina E. Van der Ende2, Harry L. Janssen1 1Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands. 2Department of Internal Medicine-Infectious Diseases, Erasmus MC University Medical Center, Rotterdam, Netherlands. 3Department of Medical Microbiology (CINIMA), Academic Medical Center, Amsterdam, Netherlands. 4Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, Amsterdam, Netherlands. 5Department of Virology, Erasmus MC, University Medical Center, Rotterdam, Netherlands

#426 HBSAG DECLINE IN CHRONIC HEPATITIS B PATIENTS TREATED WITH POTENT NUCS Rami Moucari1, Marc Bourlière2, Marie-Pierre Ripault1, Corinne Castelnau1, Vincent Mackiewicz3, Agnes Dauvergne4, Asma Kahloun2, Lawrence Serfaty5, Philippe Halfon6, Michelle MartinotPeignoux1, Marie-Hélène Nicolas-Chanoine3, Patrick Marcellin1 1Service d’Hépatologie and INSERM U773, Hôpital Beaujon, Clichy, France. 2Service d’Hépatogastroentérologie, Hôpital Saint Joseph, Marseille, France. 3Service de Microbiologie, Hôpital Beaujon, Clichy, France. 4Service de Biochimie, Hôpital Beaujon, Clichy, France. 5Service d’Hépatologie, Hôpital Saint Antoine, Paris, France. 6Laboratoire Alphabio, Marseille, France

#427

#424

CRITERIA OF UNDETECTABLE HBV DNA LEVEL FOR CESSATION OF LAMIVUDINE TREATMENT IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS: ANALYSIS OF OFF-TREATMENT RESPONSES

ON-TREATMENT SERUM HBSAG LEVEL AT 2 YEARS: STRONG PREDICTOR OF SUSTAINED VIROLOGIC RESPONSE TO TELBIVUDINE FOR UP TO 2 YEARS OFF-TREATMENT IN CHRONIC HEPATITIS B PATIENTS

Young-Joo Jin, Kang Mo Kim, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh, DongJun Yoo Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, South

Wei Cai, Qing Xie, Xiaqiu Zhou, Baoyan An, Guoming Zhao, Hui Wang, Qing Guo, Ruiying Gu Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

#428 LONGITUDINAL ANALYSIS OF INTERLEUKIN-10 AND INTERLEUKIN-12 IN RESPONDERS AND NON-RESPONDERS TO PEGINTERFERON ALFA-2A THERAPY FOR HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS Yu-dong Wang1, Hai-Ying Zhang1, Lei Lu1, Jian Li1, Dewei Ye1, YuiHung Yueng1, Amy Kwok1, April Wong1, George K. Lau2 1Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. 2Cheng Si Yuan (China – International) Hepatitis Research Foundation, Hong Kong, China



POSTER SESSIONS

#429 PREVALENCE OF LAMIVUDINE RESISTANCE MUTATIONS AMONG TREATMENT-NAïVE ENDEMICALLY-EXPOSED CHRONIC HEPATITIS B INDIVIDUALS IS LOW AND NOT LINKED TO DEMOGRAPHIC PREDICTORS Karen A. Ng1, Carla Osiowy2, David K. Wong1,3, Elizabeth Giles2, E. Jenny Heathcote1,3 1Department of Medicine, University of Toronto, Toronto, ON, Canada. 2Bloodborne Pathogens and Hepatitis, National Microbiology Laboratory, Public Health Agency of Canada, Winnepeg, MB, Canada. 3Department of Medicine/Gastroenterology, University Health Network, Toronto, ON, Canada

#430 CORRELATION OF EARLY VIRAL KINETICS AND TREATMENT RESPONSE DURING TENOFOVIR TREATMENT IN CHRONIC HEPATITIS B (CHB) PATIENTS Siddhartha K. Mishra1, Eva Herrmann2, Syed Hissar1, Manoj Kumar1, Sadaf B. Dar1, Shiv K. Sarin1 1Gastroenterology, G.B. Pant Hospital, New Delhi, India. 2Internal Medicine, Johann Wolfgang Goethe-University Hospital, Frankfurt am Main, Germany

#431 TREATMENT-RELATED COMPARED TO SPONTANEOUSLY-OCCURRING HBSAG LOSS IN HBEAG-NEGATIVE CHRONIC HEPATITIS B

135A

#434 IN VITRO TENOFOVIR SENSITIVITY OF HBV POPULATIONS FROM CLINICAL SPECIMENS CONTAINING RTA181T/V AND/OR RTN236T Kathryn M. Kitrinos1, Florence T. Myrick1, Maria Curtis1, James C. Schawalder1, Yuao Zhu1, Fabien Zoulim2, Katyna Borroto-Esoda1 1Gilead Sciences, Durham, NC, USA. 2INSERM, Lyon, France

#435 LAMIVUDINE PROPHYLAXIS OF HEPATITIS B REACTIVATION IN ANTI-HBC SEROPOSITIVE PATIENTS UNDERGOING CHEMOTHERAPY FOR ONCO-HEMATOLOGICAL DISEASES Mauro Viganò1, Barbara Olivero2, Pietro Lampertico1, Daniele Vincenti2, Maria C. Goldaniga2, Floriana Facchetti1, Luca Baldini2, Agostino Cortelezzi2, Giorgio Lambertenghi Deliliers2, Massimo Colombo1 11st Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, University of Milan, Milan, Italy. 2Hematology I – Bone Marrow Transplantation Unit,, Fondazione IRCCS Maggiore Hospital, University of Milan, Milan, Italy

#436 THE EFFICACY OF ENTECAVIR IN CHRONIC HEPATITIS B PATIENTS WITH POOR RESPONSE TO ADEFOVIR THERAPY AFTER DEVELOPMENT OF LAMIVUDINE RESISTANCE

#432

#437

SELF-REPORT (SR) AND VISUAL ANALOGUE SCALE (VAS) FOR ADHERENCE TO ANALOGUES IN HBV TREATED PATIENTS: PROSPECTIVE EVALUATION IN A MONO-CENTRIC COHORT STUDY

QUANTITATIVE HBSAG LEVELS IN PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH LAMIVUDINE AND ADEFOVIR

Philippe Sogni2,1, Hélène Fontaine2,1, Vincent Mallet2,1, Anaïs Vallet-Pichard2,1, Jean-Jacques Quioc2,1, Jean-Baptiste Trabut2,1, Stanislas Pol2,1 1Cochin Hospital, Paris, France. 2Paris Descartes University, Paris, France

#433 SEQUENTIAL THERAPY USING LAMIVUDINE IN ENTECAVIR-TREATED PATIENTS WITH UNDETECTABLE HBV DNA – RESULTS AT 48 WEEKS James Fung, Ching-Lung Lai, John Yuen, Charles Cheng, Chi Hang Wu, Man-Fung Yuen University of Hong Kong, Hong Kong, China

Jean-Pierre Villeneuve, Lorraine Montcalm, Louise Trudel, Hélène Castel, Claire Fournier, Bernard E. Willems Medicine, CHUM, Montreal, QC, Canada

#438 TRENDS AMONGST RHEUMATOLOGISTS’ KNOWLEDGE OF HEPATITIS B REACTIVATION WITH IMMUNOSUPPRESSION - DOES IT MATTER WHERE AND HOW LONG YOU’RE WORKED? Jonathan Stine1, John Charalambopoulos1, Omar S. Khokhar1, Victoria Shanmugam2, James H. Lewis1 1Hepatology Section, Division of Gastroenterology, Department of Medicine, Georgetown University Hospital, Washington, DC, USA. 2Division of Rheumatology, Department of Medicine, Georgetown University Hospital, Washington, DC, USA


Emilia Hadziyannis1, Vasilios Sevastianos2, Anastasia Georgiou1, Stephanos J. Hadziyannis2 1Second Dpt of Medicine, Athens University, School of Medicine, Athens, Greece. 2Henry Dunant Hospital, Athens, Greece

Hyoung Su Kim, Ji Won Park, Woon Geon Shin, Kyung Ho Kim, Jin Heon Lee, Hak Yang Kim, Su Rin Shin, Young Mook Kim, Tae Ho Hahn, Myoung KuK Jang, Sang Hoon Park, Dong Joon Kim, Myung Seok Lee, Choong Kee Park Department of Internal Medicine, Hallym University Medical center, Seoul, Korea, South

136A

POSTER SESSIONS

#439

#443

NONCOMPLIANCE, ANTIVIRAL RESISTANCE, AND VIROLOGIC RESPONSE (VR) IN TREATMENT-NAïVE HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (CHB) ON LONG-TERM THERAPY WITH ENTECAVIR 0.5 MG (ETV) OR ADEFOVIR 10 MG (ADV) IN A REAL-LIFE CLINICAL SETTING

EARLY HBEAG LOSS DURING LAMIVUDINE THERAPY IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS WITH ACUTE EXACERBATION

Nghiem B. Ha1,3, Nghi B. Ha1, Ruel T. Garcia2,1, Huy N. Trinh2,1, Khanh K. Nguyen2, Huy A. Nguyen2, Brian S. Levitt2, Andrew A. Vu1, Mindie H. Nguyen3 1Pacific Health Foundation, San Jose, CA, USA. 2San Jose Gastroenterology, San Jose, CA, USA. 3Division of GI and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA

#440 DOWN-REGULATION OF PD-1 EXPRESSION ON LYMPHOCYTES IN CHRONIC HEPATITIS B PATIENTS WITH PEGYLATED INTERFERON α-2B TREATMENT Ji Chen, Yan Wang, Jie X. Wu, Gui-Qiang Wang Peking University First Hospital, Beijing, China



Cheng-Yuan Peng, Hsueh-Chou Lai, Wen-Pang Su, Po-Heng Chuang Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan

#444 ROSIGLITAZONE SUPPRESSES THE REPLICATION OF HEPATITIS B VIRUS IN HEPG2 CELLS Yuta Wakui, Jun Inoue, Yoshiyuki Ueno, Noriyuki Obara, Keiichi Tamai, Eiji Kakazu, Yasuteru Kondo, Masaaki Shiina, Yoko Yamagiwa, Koji Fukushima, Tooru Shimosegawa Division of Gastroenterology, Tohoku University School of Medicine, Sendai, Japan

#445

#441

EVOLUTION OF HBV MULTIPLE DRUG-RESISTANT STRAINS IN A PATIENT RECEIVING SEQUENTIAL NUCLEOS(T)IDE ANALOGS

ENTECAVIR THERAPY FOR LAMIVUDINE RESISTANT HBV CIRRHOTIC PATIENTS WAITING FOR OLT: VIRAL AND BIOCHEMICAL OUTCOMES AT ONE YEAR

Yan Liu, Chunmei Wang, Yanwei Zhong, Yao Wang, Li Chen, Xiaodong Li, Jiuzeng Dai, Dong Ji, Dongping Xu Viral Hepatitis Research Laboratory, Institute of Infectious Disease, Beijing 302 Hospital, Beijing, China

Adriano M. Pellicelli1, Giorgio -. Barbarini2, Mario Romano3, Caterina Furlan7, Amerigo Paffetti7, Roberto Villani1, Cecilia D’Ambrosio1, Paolo Guarascio1, Giuseppe Cerasari1, Lucia Fondacaro1, Ettore Mazzoni6, Angelo Barlattani9, Fabrizio Mecenate5, Lorenzo Nosotti4, Claudio Puoti10, Aldo Morrone4, Umberto Vespasiani Gentilucci8, Antonio Picardi8, Angela Elena Lusi1, Arnaldo Andreoli1, Fabrizio Soccorsi1 1Liver Unit, San Camillo Forlanini Hospital, Rome, Italy. 2Department of Infectious and Parasitic Disease, Policlinico San Matteo, Pavia, Italy. 3Liver Unit, Ospedale S. Pertini, Rome, Italy. 4Department for Health Migration, National institute for Health Migration and Poverty, Rome, Italy. 5Liver Unit, Ospedale Villa Betania, Rome, Italy. 6Liver Unit, Policlinico Casilino, Rome, Italy. 7Department of Infectious and Tropical Disease, Università di Roma “La Sapienza”, Rome, Italy. 8Clinica Medica, Campus Bio Medico Università, Rome, Italy. 9Liver Unit, ASL RMA, Rome, Italy. 10Liver Unit, Ospedale di Marino, Marino, Italy

#442 TREATMENT RESPONSE TO PEGINTERFERON ALPHA-2A(PEG-IFN) IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS WITH COEXISTING PRECORE AND/OR BASAL CORE PROMOTER MUTATIONS Calvin Pan1, Yim Fong Chan2, Raghav Bansal1 1Mount Sinai Services at Elmhurst Hospital, Mount Sinai School of Medicine, Flushing, NY, USA. 2Hepatitis Research, Medical Procare, Flushing, NY, USA


#446 PRETREATMENT HBV DNA LEVEL IS A GOOD PREDICTIVE FACTOR FOR VIROLOGICAL RESPONSE AFTER 48 WEEKS OF ENTECAVIR TREATMENT IN LAMIVUDINE-REFRACTORY CHRONIC HEPATITIS B Byung Seok Kim, Chang Hyeong Lee, Ka Young Kim, Jae Bum Park Catholic university of Daegu school of Medicine, Daegu, Korea, South

#447 EVOLUTION OF HEPATITIS B VIRUS QUASISPECIE IN SERUM SAMPLES BY ULTRA-DEEP PYROSEQUENCING ANALYSIS OF A PATIENT WITH CHB SEQUENTIALLY TREATED WITH DIFFERENT NUCLEOS(T)IDE ANALOGUES Francisco Rodriguez-Frias1,2, David Tabernero2, Maria Buti3,2, Rosendo Jardi1,2, Josep Quer2,3, Alex Sanchez4, Israel Ortega4, Maria Homs3, Melanie Schaper2, Pilar Fernandez-Fernandez1, Rafael Esteban3,2 1Biochemistry Department, Vall d’Hebron Hospital, Barcelona, Spain. 2CIBERehd, Vall d’Hebron Hospital, Barcelona, Spain. 3Hepatology Department, Vall d’Hebron Hospital, Barcelona, Spain. 4Bioinformatic and Statistic Unit, Research Institute Vall d’Hebron, Barcelona, Spain


POSTER SESSIONS

137A

#448

#452

CLINICAL APPLICABILITY OF HBSAG TITER IN CHRONIC HEPATITIS B PATIENTS WITH UNDETECTABLE HBV DNA BY REAL-TIME PCR ASSAY

HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS TREATED WITH PEGINTERFERON ALFA-2A IS ASSOCIATED WITH SUSTAINED RESPONSE UP TO 5 YEARS POST-TREATMENT: PATIENTS WITH CONTINUOUS HBSAG DECLINE STARTING BEFORE WEEK 24 ACHIEVE HIGHEST RATES OF RESPONSE

Jung Min Lee1, Hyon Suk Kim2, Jun Yong Park3,4, Do Young Kim3,4, Sang Hoon Ahn3,4, Ja Kyung Kim3,4, Yong Han Paik3,4, Kwan Sik Lee3,4, Byung Soo Moon3, Chae Yoon Chon3,4, Young Myoung Moon5, Kwang-Hyub Han3,4 1Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, South. 2Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea, South. 3Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea, South. 4Liver Cirrhosis Clinical Research Center, Seoul, Korea, South. 5Internal Medicine, Kwan Dong University College of Medicine, Goyang, Korea, South

Maurizia R. Brunetto1, Patrick Marcellin2, Ferruccio Bonino3, HansPeter Kapprell4, Diethelm Messinger5, Richard Batrla6 1UO Epatologia, Azienda Ospedaliero Pisana, Pisa, Italy. 2Service d’Hepatologie and Centre de Recherches Biologiques Beaujon, University of Paris, Clichy, France. 3Direzione Scientifica, Foundation IRCCS, Policlinico di Milano and University of Pisa, Pisa, Italy. 4Abbott GmbH & Co, Wiesbaden, Germany. 5IST GmbH, Mannheim, Germany. 6Hoffman-La Roche Ltd, Basel, Switzerland

#449

#453

EMERGENCE OF MULTIPLE DRUG-RESISTANT MUTANTS OF HEPATITIS B VIRUS WITH LONGTERM LAMIVUDINE AND ADEFOVIR BITHERAPY

EXTENDED TREATMENT WITH PEGINTERFERON ALFA-2A BENEFITS PATIENTS WITH HBEAGPOSITIVE CHRONIC HEPATITIS B WITH A PARTIAL RESPONSE AFTER 48 WEEKS OF THERAPY – CLINICAL EXPERIENCE FROM A CHINESE CENTER

Jun Inoue, Yoshiyuki Ueno, Yuta Wakui, Koji Fukushima, Masaaki Shiina, Yoko Yamagiwa, Yasuteru Kondo, Eiji Kakazu, Keiichi Tamai, Noriyuki Obara, Hirofumi Niitsuma, Tooru Shimosegawa Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan

Yue-Yong Zhu, Jing Dong, You-Tao Chen, Jing Chen, Jia-ji Jiang Liver Diseases Research Center, First Affiliated Hospital of Fujian Medical University, Fuzhou, China

#450

#454

ADEFOVIR AND LAMIVUDINE CONCENTRATION AND EFFECT OF COMBINATION THERAPY ON LAMIVUDINE RESISTANT HEPATITIS B VIRUS

TENOFOVIR IS EFFECTIVE SALVAGE THERAPY FOR NUCLEOSIDE-RESISTANT HEPATITIS B

Masataka Tsuge, Fukiko Mitsui, Nobuhiko Hiraga, Michio Imamura, Shoichi Takahashi, Kazuaki Chayama Department of Medicine and Molecular Science, Hiroshima university, Hiroshima, Japan

DOES TENOFOVIR INCREASE THE RISK OF ABNORMAL BONE AND CALCIUM METABOLISM? Catherine Constable1, Kathryn Childs2, Marie-Louise Vachon1, Damaris C. Carriero3, Michael P. Mullen1, Douglas T. Dieterich1, Andrea D. Branch1 1Mount Sinai School of Medicine, New York, NY, USA. 2Kings College, London, United Kingdom. 3Columbia University, New York, NY, USA

#455 EFFECTIVENESS OF LONG-TERM COMBINATION THERAPY WITH ADEFOVIR DIPIVOXIL AND LAMIVUDINE IN PATIENTS WITH ΗΒEAGNEGATIVE CHRONIC HEPATITIS B AND LAMIVUDINE RESISTANCE Spilios Manolakopoulos1, Athanasia Striki1, George V. Papatheodoridis1, Melanie Deutsch1, Maria Mela2, Dimitrios Tzourmakliotis2, Emanuel K. Manesis1, Athanasios J. Archimandritis1 12nd Academic Department of Internal Medicine, Hippokration Hospital of Athens, Athens, Greece. 2Department of Gastrenterology, Polyclinic General Hospital of Athens, Athens, Greece

#456 HBV PRIMARY DRUG RESISTANCE IN AFRICAN IMMIGRANTS AND IN NEWLY DIAGNOSED HIV PATIENTS WITH CHRONIC HEPATITIS B IN SPAIN Marcelle Bottecchia1, Ana Treviño1, Antonio Madejón1, Paula Tuma1, Pablo Rivas1, Maria Dolores Herrero1, Sabino Puente1, Carmen Rodríguez2, Carlos Barros3, Camen de Mendoza1, Javier García-Samaniego1, Vincent Soriano1 1Infectious Disease, Hospital Carlos III - CIBERehd, Madrid, Spain. 2Centro Sanitário Sandoval, Madrid, Spain. 3Hospital de Móstoles, Madrid, Spain


#451

Nitin Sarin1,2, Colina Yim1,2, Jordan J. Feld1,2, E. Jenny Heathcote1,2, David K. Wong1,2 1Liver Centre, Toronto Western Hospital, Toronto, ON, Canada. 2University of Toronto, Toronto, ON, Canada

138A

POSTER SESSIONS

#457

#463

RAPID HBV-DNA CLEARANCE PREDICTS LATE HBSAG LOSS IN ANTI-HBE NEGATIVE CHRONIC HEPATITIS B (CHB) TREATED WITH ADEFOVIR ± LAMIVUDINE

ASSOCIATION OF HLA-DRB1*11 ALLELE WITH POOR EARLY RESPONSE TO ADEFOVIR DIPIVOXIL THERAPY IN PATIENTS WITH LAMIVUDINERESISTANT CHRONIC HEPATITIS B

Gianfranca Stornaiuolo1, Daniela Campisi2, Giuseppina Brancaccio1, Gianluca Cuomo1, Claudio Galli3, Salvatore Nardiello1, Giovanni B. Gaeta1 1Infectious Diseases and Internal Medicine, Second University of Naples, Naples, Italy. 2Microbiology and Virology, Hospital Ca’ Granda, Milan, Italy. 3Abbott Diagnostic Division, Rome, Italy

Sung Eun Kim1, Young-Hwa Chung1, Jeong A. Kim1, Dong-Jun Yoo1, Young-Joo Jin1, Ju Hyun Shim1, Danbi Lee1, Yoon-Seon Lee1, Don Lee1, Soo Hyung Ryu2, Kang Mo Kim1, Young-Suk Lim1, Han Chu Lee1, Yung Sang Lee1, Dong Jin Suh1 1Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, South. 2Internal Medicine, University of Inje College of Medicine, Seoul Paik Hospital, Seoul, Korea, South

#458 KINETICS OF HBSAG LEVELS IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION DURING UP TO 4 YEARS OF TREATMENT WITH ACYCLIC NUCLEOTIDE ANALOGUES Florian van Boemmel1, Friederike J. Bock1, Karin Hensel-Wiegel2, Beate Schlosser1, Michael Biermer1, Balazs Fülöp1, Viola Weich1, Eckart Schott1, Bertram Wiedenmann1, Thomas Berg1 1Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Berlin, Germany. 2Zentralinstitut für Laboratoriumsmedizin und Pathobiochemie, Charité-Universitätsmedizin Berlin, Frankfurt a.M., Germany

#459 HBV GENOTYPE D AND PRECORE MUTATIONS PREDICT VIROLOGIC BREAKTHROUGH AFTER HBEAG LOSS AND SEROCONVERSION



#464 INITIAL HIGH DOSE OF LAMIVUDINE DELAYS THE APPEARANCE OF VIRAL RESISTANCE IN CHRONIC HEPATITIS B PATIENTS Francesco Torre, Edoardo G. Giannini, Monica Basso, Vincenzo Savarino, Antonino Picciotto Department of Internal Medicine, Università di Genova, Genova, Italy

#465 CLINICAL FEATURES AND RISK FACTORS FOR CLEVUDINE RESISTANCE IN TREATMENT-NAïVE CHRONIC HEPATITIS B PATIENTS

David Tabernero, Mayra J. Sanchez, Maria Buti, Francisco Rodriguez-Frias, Rosendo Jardi, Rafael Esteban Liver Center, Hospital Vall d’Hebron, Barcelona, Spain

Hyung Joon Yim, Jeong Han Kim, You-me Choi, Young Kul Jung, Eun Suk Jung, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um, Ho Sang Ryu Internal Medicine, Korea University Medical College, Seoul, Korea, South

#460

#466

PRE-EXISTING ANTIVIRAL-RESISTANT MUTATION MAY BE ASSOCIATED WITH PRIMARY NONRESPONSE TO LAMIVUDINE AMONG TREATMENTNAïVE CHRONIC HEPATITIS B PATIENTS

10 YEARS THERAPY WITH LAMIVUDINE: A RETROSPECTIVE ANALYSIS IN PATIENT WITH CHRONIC HEPATITIS B

Scott Fung1, Florence Wong1, Tony Mazzulli1, Vladimir Popovic2 1Medicine, University of Toronto, Toronto, ON, Canada. 2Medical Affairs, Gilead Sciences Canada, Mississauga, ON, Canada

#461 MAINTENANCE OF VIROLOGIC RESPONSE DURING CONSOLIDATION THERAPY WITH LAMIVUDINE IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS Ki Tae Yoon1, Yeong Muk Kim2, Jeong Heo3, Mong Cho1 1Pusan National University Yangsan Hospital, Yangsan, Korea, South. 2Haedong Hospital, Busan, Korea, South. 3Pusan National University Hospital, Busan, Korea, South

#462 PEGIFNS ARE NOT SATISFACTORY IN GENOTYPE D CHRONIC HBV INFECTION Ayse Oya Övünç Kurdas, Fatih Guzelbulut, Yasemin Gökden, Ebubekir Senates, Züleyha Akkan Çetinkaya, Ayca Gökcen Degirmenci, Bülent Yasar Gastroenterology, Haydarpasa Numune Education and Research Hospital, Istanbul, Turkey Denotes AASLD Presidential Poster of Distinction

Sebastiano Forgia, Andrea Marengo, Silvia Gaia, Silvia Carenzi, Marco Lagget, Mario Rizzetto, Alfredo Marzano Gastro-Hepatology, San Giovanni Battista of Turin, Turin, Italy

#467 A COMPARISON OF 24- AND 48-WEEK OUTCOMES BETWEEN CLEVUDINE AND ENTECAVIR THERAPY IN TREATMENT-NAïVE HEPATITIS B PATIENTS IN KOREA Chihoon Kim, Moon Seok Choi, Byung Chul Yoo, Joon Hyoek Lee, Kwang Cheol Koh, Seung Woon Paik Samsung medical center, Seoul, Korea, South

#468 ‘POOR MAN’S’ QUANTITATIVE HBSAG: POTENTIAL UTILITY OF THE SIGNAL TO CUT-OFF RATIO IN EXISTING QUALITATIVE HBSAG ASSAYS IN THE US Hyung J. Kim, W. Ray Kim, Terry M. Therneau, Joanne T. Benson, Joseph D. Yao Mayo Clinic College of Medicine, Rochester, MN, USA


POSTER SESSIONS

139A

#469

#475

PEGYLATED INTERFERON FOR CHRONIC HEPATITIS B IN ADULTS: A COCHRANE REVIEW

CLINICAL OUTCOMES AFTER ADEFOVIR DISCONTINUATION IN LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B PATIENTS

Khalid Mumtaz, Saeed Hamid, Syed M. Jafri Medicine, Aga Khan University, Karachi, Pakistan

#470 ON-TREATMENT HBSAG AND HBEAG LEVELS AS POTENTIAL PREDICTORS OF DURABLE OFFTREATMENT HBEAG SEROCONVERSION FOR HBEAG-POSITIVE CHB PATIENTS TREATED WITH PEGINTERFERON ALFA-2B NOT CONVENTIONAL INTERFERON ALFA-2B Hui Ma, Ruifeng Yang, Lai Wei Peking University Hepatology Institute, Peking University People’s Hospital, Beijing, China

#471 ACUTE EXACERBATION OF HEPATITIS B VIRUS INFECTION (HBVI) IN PATIENTS UNDERGOING SYSTEMIC CHEMOTHERAPY IN THE ERA OF ANTIVIRAL TREATMENT Wan-Cheng Chow1, Soon Thye Lim2, Miriam Tao2 1Gastroenterology & Hepatology, Singapore General Hospital, Singapore, Singapore. 2Medical Oncology, National Cancer Centre, Singapore, Singapore

#472 CREATINE KINASE ELEVATIONS DURING 4-YEARS OF CONTINUOUS TELBIVUDINE TREATMENT ARE TRANSIENT AND NOT PREDICTIVE OF UNCOMMONLY OBSERVED MUSCLE-RELATED SYMPTOMS

#476 PROFOUND VIROLOGIC RESPONSE IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH ENTECAVIR (ETV) IN HBEAG POSITIVE AND NEGATIVE DISEASE Sumbella F. Baqai1, Debbie Hana Yi3, Robert G. Gish2 Alameda County Medical Center, Oakland, CA, USA. 2Division of Hepatology and Complex GI, California Pacific Medical Center, San Fransisco, CA, USA. 3Albert Einstein College of Medicine, Bronx, NY, USA 1Medicine,

#477 THE EFFICACY OF ANTIVIRAL TREATMENT ON PATIENTS WITH ACUTE-ON-CHRONIC HEPATITIS B LIVER FAILURE WITH LOW VIRAL LOADING Xu Qi-huan, Chen Ni, Shu Xin, Cao Hong, Chen Lu-biao, Zhang Ka, Li Gang Infectious diseases, The 3rd Affiliated hospital of Sun Yat-sen University, Guangzhou, China

#478

#473

DUAL INTERFERENCE OF NOVEL GENE MFGL2 AND TNFR1 AMELIORATES MURINE HEPATITIS VIRUS TYPE 3-INDUCED FULMINANT HEPATITIS IN BALB/CJ MICE

PATIENT-RELATED SYMPTOMS IN INDIVIDUALS WITH CHRONIC HEPATITIS B VIRUS TREATED WITH LAMIVUDINE AND ADEFOVIR OR ADEFOVIR MONOTHERAPY

Sui Gao1, Ming Wang1, Dong Xi1, Huali Ye1, Weiming Yan1, Xiaoping Luo2, Qin Ning1 1Department of Infectious Disease, Tongji Hospital, Wuhan, China. 2Department of Pediatrics, Tongji Hospital, Wuhan, China

1Novartis

Angela C. Martino1, Wendy A. Henderson1, Elenita Rivera2, Jake T. Liang2, Jay H. Hoofnagle2, Marc G. Ghany2 1Symptom Management Branch, Biobehavioral Unit, NINR, NIH, Bethesda, MD, USA. 2LDB, NIDDK, National Institutes of Health, Bethesda, MD, USA

#474 LOW RISK OF MULTIRESISTANT HBV IN A FOLLOW UP STUDY OF LAMIVUDINE WITH ADEFOVIR SWITCH STRATEGY Seng Gee Lim1,2, Aung Myat Oo1, Belinda Mak1, Evelyn S. Koay3, Yin-Mei Lee1,2, Yock Young Dan1,2 1Gastroenterology & Hepatology, National University Hospital, Singapore, Singapore. 2Department of medicine, National university of Singapore, Singapore, Singapore. 3Molecular Diagnostic Laboratory, National University Health System, Singapore, Singapore


Claudio Avila1, Joana Goncalves2 Pharma AG, Basel, Switzerland. 2Novartis Pharmaceuticals, East Hanover, NJ, USA

Young Kul Jung1, Jong Eun Yeon1, Kwang Gyun Lee3, Eun Suk Jung1, Jeong Han Kim2, Ji Hoon Kim1, Yeon Seok Seo3, Hyung Joon Yim2, Jong Jae Park1, Jae Sun Kim1, Young-Tae Bak1, Soon Ho Um3, Ho Sang Ryu3, Kwan Soo Byun1 1Internal Medicine, Korea Univ. Guro Hospital, Seoul, Korea, South. 2Internal Medicine, Korea Univ. Ansan Hospital, Ansan, Korea, South. 3Internal Medicine, Korea Univ. Anam Hospital, Seoul, Korea, South

140A

POSTER SESSIONS

#479 COMPARISON ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY WITH ADEFOVIR MONOTHERAPY IN LAMIVUDINE RESISTANT CHRONIC HEPATITIS B Woo Young Park1, Jaeseok Hwang1, Byoung Kuk Jang1, Jung Woo Shin2, Neung Hwa Park2, Byung Seok Lee3, Joon Hyoek Lee4, Si Hyun Bae6, Won Young Tak7, June Sung Lee8, Chun Kyon Lee9, Soon Koo Baik10, Tae Hee Lee11, Youn Jae Lee5 1Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea, South. 2Internal Medicine, Ulsan university hospital, Ulsan University College of medicine, Ulsan, Korea, South. 3Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea, South. 4Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, South. 5Internal medicine, Inje University College of Medicine, Pusan Paik Hospital, Busan, Korea, South. 6Internal Medicine, Kang-Nam St. Mary’ Hospital, College of medicine, The Catholic University, Seoul, Korea, South. 7Internal Medicine, Kyungpook National University of medicine, Daegu, Korea, South. 8Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Koyang, Korea, South. 9Internal Medicine, National Health Insurance Corporation Ilsan Hospital, Koyang, Korea, South. 10Internal Medicine, Yonsei University Wonju college of Medicine, Wonju, Korea, South. 11Internal Medicine, Konyang University College of Medicine, Daejeon, Korea, South

#480


RESISTANCE SURVEILLANCE FOR UP TO 144 WEEKS IN HBEAG+ AND HBEAG- HEPATITIS B PATIENTS TREATED WITH TENOFOVIR DF SHOWED NO RELATIONSHIP BETWEEN VIROLOGIC BREAKTHROUGH AND EMERGENCE OF GENOTYPIC CHANGES IN HBV POLYMERASE Andrea Snow-Lampart1, Brandi J. Chappell1, Maria Curtis1, Yuao Zhu1, E. Jenny Heathcote2, Patrick Marcellin3, Katyna BorrotoEsoda1 1Biology, Gilead Sciences, Durham, NC, USA. 2Toronto General Hospital, Toronto, ON, Canada. 3Hospital Beaujon, Clichy, France

#481 THREE YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAGNEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102); PRELIMINARY ANALYSIS Patrick Marcellin1, Maria Buti2, Zahary Krastev3, George Germanidis4, Kelly D. Kaita5, Iskren Kotzev6, Peter Buggisch7, Frank Weilert8, Huy N. Trinh9, Selim Gurel10, E. Jenny Heathcote11, Jeff Sorbel12, Jane Anderson12, Elsa Mondou12, Franck Rousseau12 1Hopital Beaujon, University of Paris, Clichy, France. 2Servicio de Medicina Interna Hepatologia, Hospital General Universitari Vall d’Hebron and Ciberehd, Barcelona, Spain. 3University Hospital “St Ivan Rilsky, Sofia, Bulgaria. 4Papageorgiou Peripheral General Hospital of Thessaloniki, Thessaloniki, Greece. 5John Buhler Research Centre, University of Manitoba, Winnipeg, MB, Canada. 6University Hospital “Sveta Marina”, Varna, Bulgaria. 7Medizinische Universitatsklinik Eppendorf, Hamburg, Germany. 8Waikato Hospital, Hamilton, New Zealand. 9San Jose Gastroenterology, San Jose, CA, USA. 10University of Uludag, Bursa, Turkey. 11University of Toronto, Toronto, ON, Canada. 12Gilead Sciences, Durham, NC, USA



#482 EFFICACY AND SAFETY OUTCOMES AFTER 4 YEARS OF TELBIVUDINE TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) Yuming Wang1, Satawat Thongsawat2, Edward J. Gane3, Yun -Fan Liaw4, Jidong Jia5, Michael P. Manns6, Jinlin Hou7, Henry Lik-Yuen Chan8, George V. Papatheodoridis9, Mobin Wan10, Niu Junqi11, Weibin Bao12, Patricia M. Lopez13, Nikolai V. Naoumov13 1Xi Nan Hospital, Chongqing, China. 2Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand. 3Middlemore Hospital, Auckland, New Zealand. 4Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan. 5Capital Medical University, Beijing, China. 6Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany. 7Nanfang Hospital, Southern Medical University, Guangzhou, China. 8Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. 9Hippokration Hospital, Athens, Greece. 10Department of Infectious Diseases, Shanghai, Changhai Hospital, Shanghai, China. 11Department of Hepatology, No. 1 Hospital of Jilin University, Jilin, China. 12Novartis Pharmaceuticals, East Hanover, NJ, USA. 13Novartis Pharma AG, Basel, Switzerland

#483 THREE YEARS OF TENOFOVIR DISOPROXIL (TDF) TREATMENT IN HBEAG-POSITIVE PATIENTS (HBEAG+) WITH CHRONIC HEPATITIS B (STUDY 103), PRELIMINARY ANALYSIS E. Jenny Heathcote1, Edward J. Gane2, Robert A. De Man3, Samuel S. Lee4, Robert Flisiak5, Michael P. Manns6, Konstantin G. Tchernev7, Ayse Oya Övünç Kurdas8, Mitchell L. Shiffman9, Patrick Marcellin10, Jeff Sorbel11, Jane Anderson11, Elsa Mondou11, Franck Rousseau11 1University of Toronto, Toronto, ON, Canada. 2Middlemore Hospital, Auckland, New Zealand. 3Erasmus MC, University Medical Center, Rotterdam, Netherlands. 4University of Calgary, Calgary, AB, Canada. 5Medical University of Bialystok, Bialystok, Poland. 6Medical School of Hannover (MHH), Hannover, Germany. 7Medical University, Sofia, Bulgaria. 8Haydarpapa Numune Hospital, Istanbul, Turkey. 9Virginia Commonwealth University, Richmond, VA, USA. 10Hopital Beaujon, University of Paris, Clichy, France. 11Gilead Sciences, Durham, NC, USA


POSTER SESSIONS

#484 TENOFOVIR DISOPROXIL FUMARATE FOR PATIENTS WITH CHRONIC HEPATITIS B WHO HAVE PREVIOUSLY FAILED LAMIVUDINE AND ADEFOVIR: EFFECTS OF BASELINE SEQUENCE MUTATIONS ON VIROLOGICAL RESPONSE Scott Patterson1, Jacob George2, Simone I. Strasser3, Alice U. Lee4, William Sievert5, Amanda J. Nicoll6, Paul V. Desmond7, Stuart K. Roberts8, Stephen Locarnini9, Scott Bowden9, Peter W. Angus1 1Department of Gastroenterology, Austin Health, Melbourne, VIC, Australia. 2Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Sydney, NSW, Australia. 3AW Morrow GI and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia. 4Concord Repatriation General Hospital, Sydney, NSW, Australia. 5Department of Gastroenterology, Monash Medical Centre, Melbourne, VIC, Australia. 6Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, VIC, Australia. 7Department of Gastroenterology, St Vincents Hospital, Melbourne, VIC, Australia. 8Department of Gastroenterology, The Alfred Hospital, Melbourne, VIC, Australia. 9Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia

#485 TELBIVUDINE PRESERVES TH1 CYTOKINE RESPONSE AND DOWN REGULATES PD-L1 IN MHV-3–INDUCED VIRAL HEPATITIS MODEL Zeguang Wu1, Weiming Yan1, Wei Guo1, Yong Zou1, Hongwu Wang1, Xiaojing Wang1, Xiaojin Yang1, Yulei Lu1, Xiaoping Luo2, Qin Ning1 1Department of Infectious Disease, Tongji Hospital, Wuhan, China. 2Department of Pediatrics, Tongji Hospital, Wuhan, China

#486

Bart Takkenberg1, Hans L. Zaaijer2, Annikki de Niet1, Christine J. Weegink1, Valeska Terpstra3, Maarten Koot4, Marcel Dijkgraaf5, Marcel Beld6, Hendrik W. Reesink1 1AMC Liver Center; Department of Gatroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands. 2Medical Microbiology and Karl Landsteiner Laboratory, Academic Medical Center, Center for Infectious Disease and Immunology (CINIMA), Amsterdam, Netherlands. 3Department of Pathology, Academic Medical Center, Amsterdam, Netherlands. 4Department of Virus Diagnostic Services, Sanquin, Amsterdam, Netherlands. 5Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, Netherlands. 6KIT Biomedical Research, Amsterdam, Netherlands

#487 DIFFERENT KINETICS OF SERUM HBSAG DECLINE IN HBEAG-POSITIVE VS HBEAG-NEGATIVE PATIENTS DURING 3 YEARS OF TELBIVUDINE TREATMENT IN CHRONIC HEPATITIS B (CHB) Karsten Wursthorn1, Mechthild Jung2, Michael P. Manns1, Patricia M. Lopez2, Heiner Wedemeyer1, Nikolai V. Naoumov2 1Hannover Medical School, Hannover, Germany. 2Novartis Pharma AG, Basel, Switzerland

#488 BASELINE HBSAG LEVELS PREDICT HBSAG LOSS IN HBEAG NEGATIVE BUT NOT IN HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA): AN INTERIM ANALYSIS Bart Takkenberg1, Hans L. Zaaijer2, Annikki de Niet1, Christine J. Weegink1, Valeska Terpstra3, Maarten Koot5, Marcel Dijkgraaf4, Peter L. Jansen1, Harry L. Janssen6, Marcel Beld7, Hendrik W. Reesink1 1AMC Liver Center; Department of Gatroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands. 2Medical Microbiology and Karl Landsteiner Laboratory, Academic Medical Center; Center for Infectious Disease and Immunology (CINIMA), Amsterdam, Netherlands. 3Department of Pathology, Academic Medical Center, Amsterdam, Netherlands. 4Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, Netherlands. 5Department of Virus Diagnostic Services, Sanquin, Amsterdam, Netherlands. 6Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, Netherlands. 7KIT Biomedical Research, Amsterdam, Netherlands

#489 TENOFOVIR DF (TDF) FOR CHRONIC HEPATITIS B PATIENTS WITH SUBOPTIMAL RESPONSE TO ADEFOVIR (ADV) OR ADV/LAM TREATMENT: INTERIM ANALYSIS OF THE MULTICENTER PROSPECTIVE OPEN LABEL STUDY OPTIB Massimo Levrero1, Letizia Cimino1, Pietro Lampertico2, Giovanni Raimondo3, Giovanni Battista Gaeta4, Evangelista Sagnelli5, Alfredo Marzano6, Stefano Fagiuoli7, Grazia A. Niro12, Teresa Santantonio8, Vito Di Marco9, Giuseppe Mazzella10, Giovan Giuseppe Di Costanzo11, Mario Angelico13, Silvia Pierconti1, Concetta C. Sava’1 1Dept of Internal Medicine, Sapienza University, Rome, Italy. 21st Gastroenterology Unit, Fondazione IRCCS Maggiore Hospital and University of Milan, Milan, Italy. 3Department of Internal Medicine, University of Messina, Messina, Italy. 4UO Epatiti Virali, Dipartimento di Malattie Infettive, Seconda Università di Napoli, Napoli, Italy. 5Division of Infectious Diseases, Azienda Ospedaliera San Sebastiano, Caserta, Italy. 6Dep. Gastroenterology, Ospedale San Giovanni Battista - Molinette Hosp, Torino, Italy. 7UO Gastroentrologia, Ospedali Riuniti, Bergamo, Italy. 8Clinic of Infectious Diseases, University of Bari, Bari, Italy. 9UO Gastronterologia, University of Palermo, Palermo, Italy. 10Dep. Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy. 11UO Epatologia, Azienda Ospedaliera A. Cardarelli, Napoli, Italy. 12UO Gastroentrologia, IRCCS ‘Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. 13Cattedra di Gastroenterologia, Universita’ di Roma Tor Vergata, Rome, Italy


END OF TREATMENT INTRAHEPATIC HEPATITIS B (HBV) COVALENTLY CLOSED CIRCULAR DNA (CCCDNA) PREDICTS SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH PEGINTERFERON ALFA2A AND ADEFOVIR

141A

142A

POSTER SESSIONS

#490

#492

THREE YEARS EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN ASIANS WITH HBEAG-POSITIVE AND HBEAGNEGATIVE CHRONIC HEPATITIS B, PRELIMINARY ANALYSIS

ON-TREATMENT PREDICTION OF SUSTAINED RESPONSE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGYLATED INTERFERON ALFA-2A

Samuel S. Lee1, E. Jenny Heathcote2, William Sievert3, Huy N. Trinh4, Kelly D. Kaita5, Zobair M. Younossi6, Jacob George7, Mitchell L. Shiffman8, Patrick Marcellin9, Jeff Sorbel10, Jane Anderson10, Elsa Mondou10, Joe Quinn10, Franck Rousseau10 1University of Calgary, Calgary, AB, Canada. 2Toronto Western Hospital, University of Toronto, Toronto, ON, Canada. 3Monash University, Melbourne, VIC, Australia. 4San Jose Gastroenterology, San Jose, CA, USA. 5University of Manitoba Health Science Center, Winnipeg, MB, Canada. 6Inova Fairfax Hospital, Falls Church, VA, USA. 7Storr Liver Unit, Westmead Hospital and University of Sydney, Westmead, NSW, Australia. 8Virginia Commonwealth University Medical Center, Richmond, VA, USA. 9Hopital Beaujon, Clichy, France. 10Gilead Sciences, Durham, NC, USA

#491 BASELINE HBSAG LEVEL AND ON-TREATMENT HBSAG AND HBV DNA DECLINE PREDICT SUSTAINED VIROLOGICAL RESPONSE IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA); AN INTERIM ANALYSIS Takkenberg1,



Zaaijer2,

Niet1,

Bart Hans L. Annikki de Christine J. Weegink1, Valeska Terpstra3, Maarten Koot4, Marcel Dijkgraaf5, Peter L. Jansen1, Harry L. Janssen6, Marcel Beld7, Hendrik W. Reesink1 1AMC Liver Center; Department of Gatroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands. 2Medical Microbiology and Karl Landsteiner Laboratory, Academic Medical Center, Center for Infectious Disease and Immunology (CINIMA), Amsterdam, Netherlands. 3Department of Pathology, Academic Medical Center, Amsterdam, Netherlands. 4Department of Virus Diagnostic Services, Sanquin, Amsterdam, Netherlands. 5Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, Netherlands. 6Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands. 7KIT Biomedical Research, Amsterdam, Netherlands


Vincent Rijckborst1, Bettina E. Hansen1,2, Fehmi Tabak3, Maria Raptopoulou-Gigi4, Necati Örmeci5, Krzysztof Simon6, Ulus S. Akarca7, Robert Flisiak8, Irini Vafiadis-Zouboulis9, Silvio Tripi10, Elke Verhey1, Martijn ter Borg1, Anneke J. van Vuuren1, Harry L. Janssen1 1Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. 2Epidemiology and Biostatistics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. 3Infectious Diseases, Istanbul University Cerrahpasa Medical School, Istanbul, Turkey. 4Second Medical Department, Aristototle University of Thessaloniki, Thessaloniki, Greece. 5Gastroenterology, Ankara University School of Medicine, Ankara, Turkey. 6Dept and Clinic of Infectious Diseases, Hepatology and Acquired Immune Deficiences, Medical University Wroclaw, Wroclaw, Poland. 7Gastroenterology, Ege University Faculty of Medicine, Izmir, Turkey. 8Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland. 9First Department of Propedeutic Medicine, University of Athens Medical School, Athens, Greece. 10Dipartimento di Medicina, Clinica e della Patologie Emergenti, Universita di Palermo, Palermo, Italy

#493 HEPATITIS B VIRUS (HBV) INFECTION IN BELGIUM: PRELIMINARY RESULTS OF THE BELGIAN ASSOCIATION FOR THE STUDY OF THE LIVER (BASL) REGISTRY OF HBSAG CHRONIC CARRIERS Pierre Deltenre1, Wim Laleman2, Marc van Gossum3, Bertrand Vos4, Isabelle Colle5, Michael Adler6, Peter P. Michielsen7, Collins Assene8, Jean Delwaide9, Hans Orlent10, Hendrik Reynaert11, François G. D’Heygere12, Philippe Langlet13, Geert Robaeys14, Chantal de Galocsy15, Dirk Sprengers16, Reginald Brenard17, Lefebvre Véronique18, Marie-Chistine Mairlot19, Jean Henrion1 1Hopital de Jolimont, Haine-Saint-Paul, Belgium. 2KU Leuven, Leuven, Belgium. 3CHU Saint-Pierre, Brussels, Belgium. 4CHU Charleroi, Charleroi, Belgium. 5UZ Gent, Gent, Belgium. 6Hopital Erasme, Brussels, Belgium. 7UZ Antwerpen, Edegem, Belgium. 8Hopitaux Iris Sud Molière, Brussels, Belgium. 9CHU Liège, Liège, Belgium. 10AZ St Jan, Brugge, Belgium. 11UZ Brussels, Brussels, Belgium. 12AZ Groeninge, Kortrijk, Belgium. 13CHU Brugmann, Brussels, Belgium. 14Ziekenhuis Oost-Limburg, Genk, Belgium. 15Hopitaux Iris Sud Bracops, Brussels, Belgium. 16AZ St-Augustinus, Wilrick, Belgium. 17Hopital Saint-Joseph, Gilly, Belgium. 18CHR Namur, Namur, Belgium. 19Clinique Saint-Jean, Brussels, Belgium


POSTER SESSIONS

143A

#494

#497

COMPLETE VIRAL SUPPRESSION (CVS) AND ALT NORMALIZATION ON ENTECAVIR (ETV) THERAPY IN PATIENTS WHO WERE PREVIOUSLY TREATED WITH ADEFOVIR (ADV): A MULTICENTER STUDY

MUTATIONS IN THE PRECORE AND BASAL CORE PROMOTER REGIONS DO NOT INFLUENCE RESPONSIVENESS TO PEGYLATED INTERFERON ALFA-2A TREATMENT FOR HBEAG-NEGATIVE CHRONIC HEPATITIS B

Mindie H. Nguyen1, Huy N. Trinh2,6, Thuan Nguyen3, Son T. Do4, Phuong Tran5, Khanh K. Nguyen2, Huy A. Nguyen2, Nghia H. Nguyen6, Ruel T. Garcia2,6 1Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA. 2San Jose Gastroenterology, San Jose, CA, USA. 3Gastroenterology and Hepatology, Houston, TX, USA. 4Digestive Health Associates of Texas, Plano, TX, USA. 5Asian Medical Village, Chicago, IL, USA. 6Pacific Health Foundation, San Jose, CA, USA

#495 HIGH LEVELS OF HBSAG AND HBV DNA DURING TREATMENT PREDICT FAILURE FOR HBEAG SEROCONVERSION IN HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEGASYS®) AND ADEFOVIR (HEPSERA); AN INTERIM ANALYSIS

#496 SERUM HBSAG AND HBV DNA AMONG HBEAG POSITIVE AND NEGATIVE CHRONIC HEPATITIS B PATIENTS DURING ADEFOVIR DIPIVOXIL THERAPY Desalegn A. Ayana, Jiang Yanfang, Cai Yanjun, Niu Junqi Department of hepatology, First hospital, Changchun, China

#498 TRANSIENT ELASTOGRAPHY (FIBROSCAN) IN CHRONIC HEPATITIS B INFECTION: REDUCE NUMBER OF BIOPSIES & SAVE MONEY Marianne Guirgis1, Suthaharan Manoharan1, Raymond Kwok2, David R. Scott1, Alice U. Lee2, Susan J. Connor1, Miriam Levy1 1Gastroenterolgy Department, Liverpool Hospital, Sydney, NSW, Australia. 2Gastroenterology Department, Concord General Repatriation Hospital, Sydney, NSW, Australia

#499 TELBIVUDINE SUPPRESSED HBV DNA AND HBEAG SIMULTANEOUSLY IN HBEAG-POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS, A TWO-CENTER CLINICAL STUDY Xiaoguang Dou1, Yang Ding1, Shulan Wang2, Qiuju Sheng1, Jingyang Wang1, Lilan Shi1 1Shengjing Hospital Affiliated to China Medical University, Shenyang, China. 2The 6th People’s Hospital of Dalian, Dalian, China

Liver Transplantation #500 DOES HEPATITIS C VIROLOGICAL CLEARANCE AFFECT SURVIVAL AFTER LIVER RETRANSPLANTATION? Kaveh Sharzehi1, Maria D. Hernandez1, Leopoldo Arosemena1, Jang Moon2, Deborah Weppler2, Eugene R. Schiff1, Andreas G. Tzakis2, Paul Martin1 1Center for Liver Diseases, University of Miami Leonard Miller School of Medicine, Miami, FL, USA. 2Liver and GI Transplant Service, University of Miami Leonard Miller School of Medicine, Miami, FL, USA


Bart Takkenberg1, Hans L. Zaaijer2, Annikki de Niet1, Christine J. Weegink1, Valeska Terpstra3, Maarten Koot4, Marcel Dijkgraaf5, Peter L. Jansen1, Harry L. Janssen6, Marcel Beld7, Hendrik W. Reesink1 1AMC Liver Center; Department of Gatroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands. 2Medical Microbiology and Karl Landsteiner Laboratory, Academic Medical Center, Center for Infectious Disease and Immunology (CINIMA), Amsterdam, Netherlands. 3Department of Pathology, Academic Medical Center, Amsterdam, Netherlands. 4Department of Virus Diagnostic Services, Sanquin, Amsterdam, Netherlands. 5Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, Netherlands. 6Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands. 7KIT Biomedical Research, Amsterdam, Netherlands

Vincent Rijckborst1, Bettina E. Hansen1,2, Martijn ter Borg1, Yilmaz Cakaloglu3, Peter Ferenci4, Fehmi Tabak5, Meral Akdogan6, Krzysztof Simon7, Ulus S. Akarca8, Robert Flisiak9, Elke Verhey1, Suzan D. Pas10, Martin Schutten10, Harry L. Janssen1 1Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. 2Epidemiology and Biostatistics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands. 3Gastroenterohepatology, Istanbul University Medical School, Istanbul, Turkey. 4Internal Medicine 3, Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria. 5Infectious Diseases, Istanbul University Cerrahpasa Medical School, Istanbul, Turkey. 6Gastroenterology, Turkiye Yuksek lhtisas Hospital, Ankara, Turkey. 7Dept and Clinic of Infectious Diseases, Hepatology and Acquired Immune Deficiences, Medical University Wroclaw, Wroclaw, Poland. 8Gastroenterology, Ege University Faculty of Medicine, Izmir, Turkey. 9Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland. 10Virology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands

144A

POSTER SESSIONS

#501

#505

TWO MUTATIONS IN HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN DOMAIN E2(424-482) MEDIATE ENHANCED INFECTIVITY OF A VIRAL VARIANT SELECTED DURING RE-INFECTION OF THE LIVER GRAFT

IMPROVING OUTCOMES IN LIVER TRANSPLANTATION FOR HCV AND NON HCV RECIPIENTS

Patric Carolla1, Isabel Fofana1, Samira Fafi-Kremer1,2, Eric Soulier1, Michèle Bastien-Valle1, François-Loic Cosset3, Steven Foung4, Michel Doffoel5, Philippe Wolf6, Françoise Stoll-Keller1,2, Thomas F. Baumert1,5 1Inserm U748 / Université De Strasbourg, Strasbourg, France. 2Laboratoire de Virologie, Hopitaux Universitaires de Strasbourg, Strasbourg, France. 3Inserm U758 / ENS, Lyon, France. 4Department of Pathology, Stanford University Blood Center, Stanford, CA, USA. 5Service d’Hepatogastroenterologie, Hopitaux Universitaires de Strasbourg, Strasbourg, France. 6Pole des Pathologies Digestives, Hepatiques et Transplantation, Hopitaux Universitaires de Strasbourg, Strasbourg, France

#502 IMPACT OF HEPATOCELLULAR CARCINOMA AND IMMUNOSUPPRESSION ON PATIENT & GRAFT SURVIVAL AFTER LIVER TRANSPLANTATION FOR HEPATITIS C: AN SRTR ANALYSIS David Rea1, Rachel Pedersen2, Ross A. Dierkhising2, Michael Charlton1, William Sanchez1, Julie Heimbach1 1William von Liebig Transplant Center, Mayo Clinic, Rochester, MN, USA. 2Division of Biostatistics, Mayo Clinic, Rochester, MN, USA

#503

Rolland C. Dickson1, Surakit Pungpapong1, Burcin Taner1, Andrew P. Keaveny1, Marwan Ghabril2, Jaime Aranda-Michel1, Raj Satyanarayana1, Hugo Bonatti3, Barry Rosser1, Denise M. Harnois1, Justin H. Nguyen1 1Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA. 2Medicine, Clarian/Indiana University, Indianapolis, IN, USA. 3Surgery, University of Virginia, Charlottesville, VA, USA

#506 A RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY, TOLERABILITY, AND SAFETY OF PROPHYLACTIC TREATMENT WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN AFTER ORTHOTOPIC LIVER TRANSPLANTATION (OLT) FOR HEPATITIS C: THE PHOENIX STUDY Natalie H. Bzowej1, David Nelson2, Sammy Saab3, Gregory T. Everson4, Lichen L. Teng5, Avi Prabhakar5, Michael Charlton6 1Liver Transplant, California Pacific Medical Center, San Francisco, CA, USA. 2University of Florida, Gainesville, FL, USA. 3University of California, San Francisco, CA, USA. 4University of Colorado, Denver, CO, USA. 5Roche, Nutley, NJ, USA. 6Mayo Clinic College of Medicine, Rochester, MN, USA

#507 EARLY HDV-RNA KINETICS AFTER LIVER TRANSPLANTATION

Sammy Saab1, Douglas R. Hunt2, Michael A. Stone1, Amy McClune1, Myron J. Tong1,3 1The Pfleger Liver Institute, Los Angeles, CA, USA. 2Harbor-UCLA, Los Angeles, CA, USA. 3Huntington Memorial Hospital, Pasadena, CA, USA

Ingmar Mederacke1, Natalie Filmann2, Birgit Bremer1, Benjamin Heidrich1, Willibroad Chi1, Hans L. Tillmann3, Karsten Wursthorn1, Jens Rosenau1, Thomas C. Bock4, Michael P. Manns1, Eva Herrmann2, Heiner Wedemeyer1 1Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 2Johann Wolfgang GoetheUniversity Hospital, Frankfurt, Germany. 3Duke Clinical Research Institute, Duke University, Durham, NC, USA. 4University of Tuebingen, Tuebingen, Germany

#504

#508

LIVER HISTOLOGY ONE YEAR POST-TRANSPLANT PREDICTS PROGRESSION OF FIBROSIS AND DEFINES SEVERE HCV RECURRENCE FOLLOWING LIVER TRANSPLANTATION

SEVERITY OF HCV RECURRENCE IN TRANSPLANT RECIPIENTS OF DONATION AFTER BRAIN DEATH (DBD) VS DONATION AFTER CARDIAC DEATH (DCD) ALLOGRAFTS

Magdalena Ydreborg1, Amar P. Dhillon2, A K Burroughs3, Martin Lagging1, Pinelopi Manousou3, Johan Westin1 1Department of Infectious Diseases/Clinical Virology, Gothenburg University, Gothenburg, Sweden. 2Department of Histopathology, Royal Free Hospital, London, United Kingdom. 3Liver Transplantation and Hepatobiliary Medicine, Royal Free Hospital, London, United Kingdom

Faisal A. Abaalkhail, Mohammad Mawardi, Kazuhiro Katada, Paul Marotta, Roberto Hernandez-Alejandro London Health Sciences Centre, London, ON, Canada

TIMING OF HEPATITIS C ANTIVIRAL THERAPY PRE AND POST LIVER TRANSPLANATION: A DECISION ANALYSIS MODEL



#509 ANTIVIRAL TREATMENT OUTCOMES IN HISPANIC AND NON-HISPANIC WHITE LIVER TRANSPLANT (LT) RECIPIENTS WITH RECURRENT HEPATITIS C VIRUS (HCV) Rosa M. Valadao, Jennifer C. Lai, Eliana Z. Agudelo, John P. Roberts, Norah Terrault UCSF, San Francisco, CA, USA



POSTER SESSIONS

145A

#510

#514

THE BENEFIT OF ANTIVIRAL THERAPY ON FIBROSIS PROGRESSION DUE TO HCV RECURRENCE AFTER LIVER TRANSPLANTATION (LT): AN ITALIAN MULTICENTER STUDY

RETREATMENT OF LIVER TRANSPLANT (LT) RECIPIENTS NON-RESPONDERS TO PRIOR ANTIVIRAL THERAPY: EFFICACY AND TOLERANCE

Eleonora De Martin1, Marco Senzolo1, Francesca Ponziani2, Raffaella Vigano’3, Luca S Belli3, Giovambattista Pinzello3, Michele Colledan4, Maria F. Donato5, Daniele Di Paolo6, Mario Angelico6, Maria Rendina7, Maurizio Pompili8, Manuela Merli9, Erica Villa10, Francesco P. Russo1, Sara Boninsegna1, Umberto Cillo1, Antonio Gasbarrini8, Pierluigi Toniutto11, Stefano Fagiuoli4, Patrizia Burra1 1Gastroenterology and Liver Transplant Unit, University Hospital of Padua, Padua, Italy. 2Internal Medicine, Policlinico A. Gemelli, Roma, Italy. 3Hepatology and Liver Unit, Ospedale Niguarda, Milan, Italy. 4Gastroenterology and Liver Transplantation Surgery, Ospdeali Riuniti di Bergamo, Bergamo, Italy. 5Gastroenterology, IRCCS Ospedale Maggiore Policlinico, Universita’ di Milano, Milano, Italy. 6Internal Medicine, Universita’-Policlinco Tor Vergata di Roma, Roma, Italy. 7Gastroenterology, Universita’ di Bari, Bari, Italy. 8Internal Medicine, Universita’ Cattolica del Sacro Cuore, Roma, Italy. 9Clinical Medicine, Universita’ “La Sapienza” di Roma, Roma, Italy. 10Universita’ di Modena, Modena, Italy. 11Medical Liver Transplant Unit, Azienda Ospedaliera-Universita’, Udine, Italy

#511 CALCINEURIN INHIBITORS AND OUTCOME OF LIVER TRANSPLANTATION IN HCV-POSITIVE RECIPIENTS: FINAL RESULTS OF A PROSPECTIVE RANDOMIZED STUDY

#512 LONG-TERM EFFICACY OF NUCLEOSIDE MONOTHERAPY IN PREVENTING HBV INFECTION IN HBSAG-NEGATIVE TRANSPLANT RECIPIENTS OF ANTI-HBC-POSITIVE DONOR LIVERS Watcharasak Chotiyaputta1, Shawn J. Pelletier2, Robert J. Fontana1, Anna S. Lok1 1Gastroenterology and Hepatology, University of Michigan Health Systems, Ann Arbor, MI, USA. 2Transplantation Surgery, University of Michigan Health Systems, Ann Arbor, MI, USA

#513 SURVIVAL AND PROGRESSION OF FIBROSIS IN HISPANIC AND NON-HISPANIC LIVER TRANSPLANT (LT) RECIPIENTS WITH HEPATITIS C (HCV) Elizabeth C. Verna1, Rosa M. Valadao2, Erica Farrand1, Elsa Pichardo1, Jennifer C. Lai2, Norah Terrault2, Robert S. Brown1 1The Center for Liver Disease and Transplantation, Columbia University College of Physicians and Surgeons, New York, NY, USA. 2The Liver Center, University of California, San Francisco, San Francisco, CA, USA

#515 SPARING PROTOCOL LIVER BIOPSIES TO EVALUATE POST-TRANSPLANT HEPATITIS C RECURRENCE: DOES TRANSIENT ELASTOGRAPHY MAKE IT POSSIBLE? Cristina Rigamonti1, Maria F. Donato1, Francesca Agnelli1, Mirella Fraquelli2, Giorgio Rossi3, Massimo Colombo1 1First Division of Gastroenterology, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy. 2Second Division of Gastroenterology, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy. 3Liver Transplant Unit, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy

#516 VIRAL LOAD PREDICTS OUTCOME OF HEPATITIS C PATIENTS AFTER LIVER TRANSPLANTATION Ivo Graziadei1, Karin Nachbaur1, Heinz M. Zoller1, Walter Mark2, Wolfgang Vogel1 1Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria. 2Transplant Surgery, Medical University, Innsbruck, Austria

#517 COMPARISON OF PHARMACOKINETIC PROFILE OF NABI-HB® AND HEPAGAM B® IN PATIENTS RECEIVING INTRAVENOUS HEPATITIS B IMMUNOGLOBULIN INFUSION FOLLOWING LIVER TRANSPLANTATION Sumeet K. Asrani1, Maarouf A. Hoteit2, Joanne T. Benson3, Laura J. Myhre2, Michael Ishitani2, Terry M. Therneau3, W. Ray Kim1,2 1Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA. 2The William J. von Liebig Transplant Center, Mayo Clinic College of Medicine, Rochester, MN, USA. 3Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA


Victoria Aguilera1,2, Martin Prieto1,2, Angel Rubin1,2, Blas Risalde1,2, Cecilia Ortiz2,3, Fernando San Juan4, Marina Berenguer1,2 1Hepatology Department, Hospital la Fe, Valencia, Spain. 2Ciberehd, Health Institute Carlos III, Valencia, Spain. 3Experimental Immunity Unit, Hospital la Fe, Valencia, Spain. 4Liver Surgery Department, Hospital la Fe, Valencia, Spain

Angel Rubin2,1, Victoria Aguilera2,1, Federica Gentili4, Martin Prieto2,1, Cecilia Ortiz3,1, Blas Risalde2,1, Raquel Canada3,1, Marina Berenguer2,1 1Ciberehd, Health Institue Carlos III, Valencia, Spain. 2Hepatology Department, Hospital la Fe, Valencia, Spain. 3Experimental Immunity Unit, Hospital la Fe, Valencia, Spain. 4gastroentelogia, Universita’ di Roma “La Sapienza”, Roma, Italy

146A

POSTER SESSIONS

#518

#523

LOW-DOSE HEPATITIS B IMMUNOGLOBULIN AND NUCLEOS(T)IDE ANALOGUES THERAPY FOR POSTTRANSPLANTATION HEPATITIS B RESULTS IN LOW INTRAHEPATIC CCCDNA AND SERUM HBCRAG LEVELS

DONOR AGE AT INITIAL LIVER TRANSPLANT PREDICTS OUTCOMES OF RETRANSPLANTATION IN PATIENTS WITH HEPATITIS C INFECTION

Tetsuya Yasunaka1, Akinobu Takaki1, Takahito Yagi2, Masashi Utsumi2, Ryuichi Yoshida2, Daisuke Sato2, Fusao Ikeda1, Yasuhiro Miyake1, Susumu Shinoura2, Hidenori Shiraha1, Hiroaki Matsuda2, Hirsohi Sadamori2, Yoshiaki Iwasaki1, Kazuhiro Nouso1, Haruhiko Kobashi1, Kazuhide Yamamoto1 1Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine and Dentistry,and Pharmaceutical Science, Okayama-shi, Japan. 2Department of Gastroenterological, Transplant Surgery and Surgical Oncology, Okayama University Graduate School of Medicine and Dentistry,and Pharmaceutical Science, Okayama-shi, Japan

#519 A STATISTICAL MODEL TO STUDY COSTEFFECTIVENESS OF ANTIVIRAL TREATMENT IN HCV RECURRENCE AFTER LIVER TRANSPLANTATION Christoph Logge1, Eik Vettorazzi2, Lutz Fischer1, Björn Nashan1, Martina Sterneck1 1Department of Hepatobiliary and Transplant Surgery, Medical University Center Hamburg Eppendorf, Hamburg, Germany. 2Department of Medical Biometry and Epidemiology, Medical University Center Hamburg Eppendorf, Hamburg, Germany

#520 SERUM AUTOANTIBODIES ARE ASSOCIATED WITH SEVERE RECURRENT HEPATITIS C AFTER LIVER TRANSPLANT



Maria F. Donato1, Eliana Arosio1, Cristina Rigamonti1, Francesca Agnelli1, Giorgio Rossi2, Massimo Colombo1 1First Division of Gastroenterology, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy. 2Liver Transplant Unit, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy

#521 HBIG MAY IMPROVE GRAFT AND PATIENT SURVIVAL AFTER LIVER TRANSPLANTATION Michael R. Marvin1, Guy N. Brock2, Farida Mostajabi2, Nicole Ferguson2, Savitri Appana2, Kadiyala Ravindra1, Mary Eng1, Joseph F. Buell1 1Surgery, Division of Transplantation, University of Louisville, Louisville, KY, USA. 2Bioinformatics and Biostatistics, University of Louisville, Louisville, KY, USA

#522 OUTCOME OF LIVER TRANSPLANTATION (LT) FOR HEPATITIS C (HCV) USING HEPATITIS B CORE ANTIBODY POSITIVE (ANTI-HBC+) GRAFT Rehana Begum, Surakit Pungpapong, Andrew P. Keaveny, Justin H. Nguyen, Rolland C. Dickson Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA


Marwan Ghabril1, Paul Y. Kwo1, Marco A. Lacerda1, Rakesh -. Vinayek1, Raj Vuppalanchi1, Naga P. Chalasani1, Rolland C. Dickson3, Richard S. Mangus2, Rodrigo Vianna2, Jonathan A. Fridell2, Joseph Tector2 1Gastroenterology and Hepatology, Clarian/Indiana University School of Medicine, Indianapolis, IN, USA. 2Transplant Surgery, Clarian/Indiana University School of Medicine, Indianapolis, IN, USA. 3Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA

#524 EFFICACY OF MAINTENANCE SUBCUTANEOUS HEPATITIS B IMMUNE GLOBULIN (HBIG) POSTTRANSPLANT FOR PROPHYLAXIS AGAINST HEPATITIS B RECURRENCE: A PROSPECTIVE “PROOF OF PRINCIPLE” CLINICAL STUDY Janakie Singham, Erica D. Greanya, Kirby Lau, Siegfried Erb, Nilufar Partovi, Eric M. Yoshida Division of Medicine, Department of Gastroenterology, University of British Columbia, Vancouver, BC, Canada

#525 POTENT IN VIVO INHIBITION OF HEPATITIS C VIRUS REPLICATION BY MYCOPHENOLIC ACID IN MICE Qiuwei Pan1, Herold J. Metselaar1, Jaap Kwekkeboom1, Hugo W. Tilanus2, Harry L. Janssen1, Luc J. van der Laan1 1Gastroenterology & Hepatology, Erasmus MC-University Medical Center, Rotterdam, Netherlands. 2Surgery, Erasmus MC-University Medical Center, Rotterdam, Netherlands

#526 NO DISTINCT EFFECTS OF CALCINEURIN INHIBITORS FK506 AND CSA ON INTERFERON-α MEDIATED INHIBITION OF HCV REPLICATION Qiuwei Pan1, Herold J. Metselaar1, Jaap Kwekkeboom1, Hugo W. Tilanus2, Harry L. Janssen2, Luc J. van der Laan2 1Gastroenterology & Hepatology, Erasmus MC-University Medical Center,, Rotterdam, Netherlands. 2Surgery, Erasmus MC-University Medical Center,, Rotterdam, Netherlands

#527 THE IMPACT OF SEVERE FIBROSIS AND ANTIVIRAL THERAPY ON THE COURSE OF RECURRENT HEPATITIS C AFTER LIVER TRANPLANTATION Maria F. Donato1, Cristina Rigamonti1, Francesca Agnelli1, Eliana Arosio1, Giorgio Rossi2, Massimo Colombo1 1First Division of Gastroenterology, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy. 2Liver Transplant Unit, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy


POSTER SESSIONS

#528 IN VIRAL CIRRHOSIS LIVER TRANSPLANT RECIPIENTS CYTOMEGALOVIRUS VIREMIA OR END-ORGAN DISEASE IS AN INDEPENDENT PREDICTOR OF MORTALITY AND SEVERE VIRAL RECURRENCE Rafael Bárcena1, Ana Moreno2, Santos del Campo Terrón1, Alfonso Muriel3, Maria L. Mateos4, Jesús Fortún2, Carmen Quereda2, María J. Pérez-Elías2, José L. Casado2, Javier Nuño5, Javier Graus1, Carlos Arocena1, Carlos Blesa1, Alberto Moreno6, Constantino Varona6, Santiago Moreno2 1Liver-Gastroenterology, Hospital Ramón y Cajal, Madrid, Spain. 2Infectious Diseases, Hospital Ramón y Cajal, Madrid, Spain. 3Clinical Biostatistics, Hospital Ramón y Cajal, Madrid, Spain. 4Microbiology (Viral Section), Hospital Ramón y Cajal, Madrid, Spain. 5General and Digestive Surgery, Hospital Ramón y Cajal, Madrid, Spain. 6Pathology (Liver Section), Hospital Ramón y Cajal, Madrid, Spain

#529 INTERFERON IN THE PREVENTION OF HCC RECURRENCE AFTER RESECTION OF HCV ASSOCIATED HCC: A META-ANALYSIS Ashwani K. Singal1, Bhupinderjit S. Anand2 1Gastroenterology, University of Texas medical Branch, Galveston, TX, USA. 2Gastroenterology, Baylor College of Medicine, Houston, TX, USA

#530 HEPATITIS B VIRAL DNA SELDOM PRESENT IN THE TRANSPLANT LIVER FROM ANTI-HBC-POSITIVE DONORS Jen-Jung Pan1, Seh-Hoon Oh2, Consuelo Soldevila-Pico1, David Nelson1, Chen Liu2 1Medicine, University of Florida, Gainesville, FL, USA. 2Pathology, University of Florida, Gainesville, FL, USA

PROSPECTIVE VALIDATION OF A NON-INVASIVE INDEX FOR PREDICTING LIVER FIBROSIS IN HCVINFECTED LIVER TRANSPLANT RECIPIENTS Salvador Benlloch1, Marina Berenguer1, Victoria Aguilera1, Claudia Barquero1, Laura Heredia2, Jose Rayon2, Martin Prieto1 1Hepatogastroenterology, Hospital Universitario La Fe, Valencia, Spain. 2Pathology, Hospital Universitario La Fe, Valencia, Spain

#532 BODY MASS INDEX DOES NOT AFFECT RATES OF RECURRENCE OF HEPATITIS C VIRUS FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION Scott A. Fink, Elizabeth C. Verna, Jean C. Emond, Robert S. Brown Center for Liver Disease and Transplantation, Columbia University Medical Center, New York, NY, USA

#533 SPLIT RENAL FUNCTION SCANNING DEMONSTRATES LIMITED RECOVERY OF NATIVE RENAL FUNCTION ONE YEAR AFTER COMBINED LIVER AND KIDNEY TRANSPLANTATION IN RECIPIENTS WHO WERE NOT DIALYSIS DEPENDANT Humberto E. Bohorquez, Ari J. Cohen, Ian C. Carmody, Shobha Joshi, David Bruce, Nigel Girgrah, George E. Loss Transplantation Surgery, Ochsner Clinic, New Orleans, LA, USA

#534 LIVER TRANSPLANTATION IN PATIENTS WITH CYSTIC FIBROSIS: AN ANALYSIS OF THE UNOS DATABASE Manuel Mendizabal1,3, Abraham Shaked2, James Cassuto2, K. Rajender Reddy3, Kim M. Olthoff2, Peter L. Abt2 1Liver Unit, Hospital Universitario Austral, Pilar, Argentina. 2Surgery, University of Pennsylvania, Philadelphia, PA, USA. 3Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA

#535 THE IMPACT OF SIROLIMUS ON HEPATITIS C PROGRESSION IN LIVER TRANSPLANT RECIPIENTS Erik Klintmalm, Greg J. McKenna, James Trotter, Edmund Q. Sanchez, Srinath Chinnakotla, Henry B. Randall, Richard Ruiz, Nicholas Onaca, Marlon F. Levy, Robert M. Goldstein, Goran Klintmalm Transplantation, Baylor Regional Transplant Institute, Dallas, TX, USA

#536 A CLINICAL MODEL TO PREDICT MEASURED GLOMERULAR FILTRATION RATE AND RENAL REPLACEMENT THERAPY REQUIREMENT FOLLOWING LIVER TRANSPLANTATION IN PATIENTS WITH END-STAGE LIVER DISEASE Stevan A. Gonzalez1, Linda W. Jennings2, Thomas A. Gonwa3, Emilio D. Poggio4, Goran Klintmalm2, James Trotter5 1Hepatology, Baylor Regional Transplant Institute, Baylor All Saints Medical Center, Fort Worth, TX, USA. 2Transplant Surgery, Baylor Regional Transplant Institute, Baylor University Medical Center, Dallas, TX, USA. 3Nephrology, Mayo Clinic Jacksonville, Jacksonville, FL, USA. 4Nephrology, Cleveland Clinic, Cleveland, OH, USA. 5Hepatology, Baylor Regional Transplant Institute, Baylor University Medical Center, Dallas, TX, USA

#537 NON-INVASIVE DIAGNOSIS OF ACUTE CELLULAR REJECTION IN LIVER TRANSPLANT RECIPIENTS: A PROTEOMIC SIGNATURE VALIDATED BY ELISA Omar Massoud, Kimberly Viker, Anuradha Krishnan, Kimberly Watt, Julie Heimbach, Edith Koehler, Michael R. Charlton Mayo Clinic, Rochester, MN, USA


#531

147A

148A

POSTER SESSIONS

#538

#542

DISEASE-SPECIFIC IMMUNOSUPPRESSION AFTER LIVER TRANSPLANTATION: DISPELLING THE MYTHS

FEATURES OF IMMUNE SENESCENCE IN LIVER TRANSPLANT RECIPIENTS WITH ESTABLISHED GRAFTS

Muhammad F. Dawwas, Christopher J. Watson, Graeme J. Alexander, Alexander E. Gimson Liver Transplant Unit, Addenbrooke’s Hospital, Cambridge, United Kingdom

William Gelson1, Matthew Hoare1, Sarah L. Vowler4, Arun N. Shankar1, Paul Gibbs2, Arne N. Akbar3, Graeme J. Alexander1 1Hepatology, Addenbrooke’s Hospital, Cambridge, United Kingdom. 2Transplantation, Addenbrooke’s Hospital, Cambridge, United Kingdom. 3Immunology, University College Hospital, London, United Kingdom. 4Centre for Applied Medical Statistics, University of Cambridge, Cambridge, United Kingdom

#539 VARIABILITY IN FREE MYCOPHENOLIC ACID EXPOSURE IN ADULT LIVER TRANSPLANT RECIPIENTS DURING THE EARLY POSTTRANSPLANTATION PERIOD Maryline Hornecker1, Anne Sophie Benichou1, Filomena Conti2, Denis Bernard2, Fabrice Taieb1, Olivier Scatton2, Michel Tod1, Yvon Calmus2, Benoit Blanchet1 1Laboratoire de pharmacologie-toxicologie, GH Cochin Saint Vincent de Paul, Paris, France. 2Unité de transplantation hépatique, GH Cochin Saint Vincent de Paul, Paris, France

#540 LIVER TRANSPLANTATION IN POLYCYSTIC LIVER DISEASE: EXCELLENT SURVIVAL AND IMPROVEMENT OF QUALITY OF LIFE Keimpema1,



Nevens2,

Adam3,

Loes van Frederik Rene Robert J. Porte4, Panagiotis Fikatas5, Thomas Becker6, Preben Kirkegaard7, Herold J. Metselaar8, Joost P. Drenth1 1Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands. 2Department of Hepatology, University Hospital Leuven, Leuven, Belgium. 3Centre Hépato-biliaire, AP-HP Hôpital Paul Brousse, Villejuif, France. 4Department of Surgery, University Medical Center Groningen, Groningen, Netherlands. 5Department for General, Visceral an Transplant Surgery, Charite Campus Virchow, Berlin, Germany. 6Department for General, Visceral and Transplant Surgery, Medizinische Hochschule Hannover, Hannover, Germany. 7Department of Surgery and Transplantation, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 8Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, Netherlands

#541 SOCIAL AND MEDICAL FACTORS PREDICT HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS IN THE SPLIT FUNCTIONAL OUTCOMES GROUP (FOG) COHORT Estella M. Alonso1, Karen Martz2, Thomas Webb4, Michael Yi4, Katie Neighbors1, John C. Bucuvalas3, James W. Varni5 1Pediatric Gastroenterology, Children’s Memorial Hospital, Chicago, IL, USA. 2The EMMES Corporation, Rockville, MD, USA. 3Pediatrics, Children’s Hospital Medical Center, Cincinnati, OH, USA. 4General Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 5Pediatrics, Texas A & M University, College Station, TX, USA


#543 RISK FACTORS, RECURRENCE, AND SURVIVAL AFTER RESECTION OF HEPATOCELLULAR CARCINOMA IN NONCIRRHOTIC LIVERS Mazen Albeldawi1, Mohamed S. Soliman2, Ibrahim Hanouneh1, Rocio Lopez3, Nizar N. Zein4 1Internal Medicine, Cleveland Clinic, Cleveland, OH, USA. 2Digestive Disorder Institute, Cleveland Clinic, Cleveland, OH, USA. 3Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA. 4Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, OH, USA

#544 NOVEL RENAL MARKERS AT THE TIME OF TRANSPLANT ASSESSMENT PREDICT IMMEDIATE POST OPERATIVE RENAL DYSFUNCTION AFTER LIVER TRANSPLANTATION Andrew J. Portal1, Mark McPhail3, Matthew J. Bruce1, Iona Coltart1, Andrew J. Slack1, Roy Sherwood2, Debbie L. Shawcross1, Nigel Heaton1, Julia Wendon1, Michael A. Heneghan1 1Institute of Liver Studies, Kings College Hospital, London, United Kingdom. 2Department of Medical Biochemistry, Kings College Hospital, London, United Kingdom. 3Department of Hepatology, Imperial College London, London, United Kingdom

#545 THE OUTCOME OF LIVER TRANSPLANTATION AFTER KIDNEY TRANSPLANTATION John Lake, Daniel Virnig University of Minnesota Medical School, Minneapolis, MN, USA

#546 THE DIAGNOSTIC ACCURACY OF CATEGORY 9 FOR LISTING FOR EARLY LIVER GRAFT DYSFUNCTION Mohammad A. Al-Freah, Elena Dionigi, Georg Auzinger, Elizabeth Sizer, Mohammed Rela, John G. O’Grady, Michael A. Heneghan, Nigel Heaton, William Bernal, Julia Wendon Institute of Liver Studies, Kings College Hospital, London, United Kingdom


POSTER SESSIONS

149A

#547

#552

PRETRANSPLANT CHARACTERISTICS OF LONGTERM LIVER TRANSPLANT SURVIVORS

CONVERSION TO SIROLIMUS FROM CALCINEURIN INHIBITOR BASED IMMUNOSUPPRESSION IS ASSOCIATED WITH IMPROVEMENT IN RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS WITH RENAL INSUFFICIENCY: SYSTEMATIC REVIEW AND METAANALYSIS

Patrick G. Northup1, Curtis K. Argo1, Neeral L. Shah1, Sean C. Kumer2, Timothy M. Schmitt2 1Gastroenterology and Hepatology, University of Virginia Health Systems, Charlottesville, VA, USA. 2Surgery, University of Virginia Health System, Charlottesville, VA, USA

#548

Sumeet K. Asrani1, Michael D. Leise1, Colin P. West2, W. Ray Kim1 of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA. 2Division of General Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA 1Division

ACCURACY OF MEASURED VERSUS CALCULATED GLOMERULAR FILTRATION RATE IN PEDIATRIC PATIENTS WHO HAVE UNDERGONE LIVER TRANSPLANTATION Jason D. Fraser, Vicki Fioravanti, Pablo Aguayo, Robert E. Kane, James Daniel, Walter S. Andrews Liver Transplantation, The Children’s Mercy Hospital, Kansas City, MO, USA

#549 LONGTERM OUTCOME OF LIVER TRANSPLANT RECIPIENTS WITH POOR RENAL FUNCTION AND HIGH MELD SCORE TREATED BY INDUCTION THERAPY WITH BASILIXIMAB Faouzi Saliba1,2, Valérie Delvart1, Philippe Ichai1,2, N’Goama M. Kouassi1, Teresa Maria Antonini1,2, Bruno Roche1,2, Jean-Charles Duclos-Vallée1,3, Rodolphe Sobesky1,2, Daniel Azoulay1, Rene Adam1, Denis X. Castaing1,3, Didier Samuel1,3 1Centre Hepato-Biliaire, AP-HP Hopital Paul Brousse, Villejuif, France. 2Unite 785, INSERM, Villejuif, France. 3UMR-S785, Univ Paris-Sud, Villejuif, France

#550 D’Alessandro1,

IMMUNOREGULATORY EFFECTS OF CONVERSION FROM TACROLIMUS TO SIROLIMUS IN LIVER TRANSPLANT RECIPIENTS Josh Levitsky1,2, James M. Mathew2, Catherine W. Flaa2, Anne Rosen2, Anat R. Tambur2, Joshua Miller2 1Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

#554 MONITORING THE EFFECT OF CSA ON CYTOKINE EXPRESSION IN LIVER TRANSPLANT RECIPIENTS Uta Herden1, Kromminga Arno2, Lutz Fischer1, Bjoern Nashan1, Martina Sterneck1 1Hepatobiliary Surgery and Transplantation, University Hospital Hamburg, Hamburg, Germany. 2Labor Lademannbogen, Hamburg, Germany

#555

HUMORAL REJECTION OF THE LIVER Wai1,

#553

Agni2,

#551 THE IMPACT OF CORONARY RISK FACTORS AND SEVERITY OF CORONARY ARTERY DISEASE ON OUTCOMES AFTER LIVER TRANSPLANTATION Anton I. Skaro1, Daniela P. Ladner1, Colleen L. Jay1, Edward Wang1, Kevin Stroupe2,3, Bridget Smith2,3, Vadim Lyuksemburg1, Amna Daud1, Lorenzo Gallon1, Jane Holl2, Mihai Gheorghiade4, Michael M. Abecassis1 1Department of Surgery, Division of Organ Transplantation, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. 2Institute for Healthcare Studies, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. 3Department of Veterans Affairs, Edward Hines Jr. VA Hospital, Hines, IL, USA. 4Department of Medicine, Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

LIVER TRANSPLANTATION (LT) FOR HCV CIRRHOSIS: ACCURATE DISCRIMINATION OF RECURRENT HEPATITIS C AND ACUTE CELLULAR REJECTION BY MORPHOLOGIC AND CLINICAL FEATURES Jesus M de la Peña2, Santiago Tome1, Francisco Gude1, Jose A Pons2, Javier F. Castroagudin1, Manuel Miras2, Pablo Ramirez2, Juan Bermejo2, Evaristo Varo1, Jeronimo Forteza1 1Hospital Universitario de Santiago, Santiago de Compostela, Spain. 2Hospital Universitario de Murcia, Murcia, Spain

#556 IMPACT OF PRE-OPERATIVE TUMOR VOLUME AND STAGING OF HCC ON TRANSPLANT OUTCOMES: A SINGLE CENTER EXPERIENCE Ali Cheaito1, Atsushi Yoshida1, Dean Y. Kim1, Dilip Moonka2, Kimberly Ann Brown2, Marwan S. Abouljoud1 1Transplant, Henry Ford Hospital, Detroit, MI, USA. 2Hepatology, Henry Ford Hospital, Detroit, MI, USA


Philip Anthony M. Rashmi David F. Lorentzen3, Barbara J. Voss1, Glen E. Leverson1, Luis A. Fernandez1, Joshua D. Mezrich1, David P. Foley1, Michael R. Lucey4, Alexandru Musat4 1Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 2Department of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 3HLA/Molecular Diagnostics Lab, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 4Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

150A

POSTER SESSIONS

#557

#561

METABOLIC SYNDROME IN LIVER TRANSPLANT RECIPIENTS IS ASSOCIATED WITH HIGH PREVALENCE AND CARDIOVASCULAR EVENTS

LONG TERM OUTCOME OF LIVER TRANSPLANTATION IN PATIENTS WITH CYSTIC FIBROSIS

Ido Laish1, Marius Braun2, Eytan Mor3, Yael Harif1, Jaqueline Sulkes4, Ran Tur-Kaspa1, Ziv Ben-Ari1 1Department of Internal Medicine A, Rabin Medical Center, Petah Tiqwa, Israel. 2Liver Institute, Rabin Medical Center, Petah-Tiqva, Israel. 3Department of Organ Transplantation, Rabin Medical Center, Petah Tiqwa, Israel. 4Epidemiology Unit, Rabin Medical Center, Petah Tiqwa, Israel

Joanna K. Dowman1,2, Danie Watson3, Bridget Gunson1,2, Indra van Mourik4, Carla Lloyd4, Deidre Kelly4, Edward Nash3, John Buckels1, David Honeybourne3, Joanna Whitehouse3, Philip N. Newsome2,1 1The Liver Unit, Birmingham Queen Elizabeth Hospital, Birmingham, United Kingdom. 2Centre for Liver Research, University of Birmingham, Birmingham, United Kingdom. 3Department of Respiratory Medicine, Birmingham Heartlands Hospital, Birmingham, United Kingdom. 4The Liver Unit, Birmingham Childrens Hospital, Birmingham, United Kingdom

#558 CONVERSION TO MYCOPHENOLATE MOFETIL MONOTHERAPY IN LIVER TRANSPLANT RECIPIENTS Kriss2,

Abecassis3,

Welti3,

#562 Sotil4,

Michael Michael M. Mary K. Eva Josh Levitsky1 1Hepatology, Northwestern University, Chicago, IL, USA. 2Medicine, Northwestern University, Chicago, IL, USA. 3Division of Transplantation, Northwestern University, Chicago, IL, USA. 4Digestive and Liver Diseases, Columbia University, New York, NY, USA

#559 NON ALCOHOLIC FATTY LIVER DISEASE RECURRENCE IN PATIENTS AFTER LIVER TRANSPLANTATION Jessica L. Mellinger1, Parul Dureja2, Rashmi Agni3, Gregory Avey4, Anthony M. D’Alessandro5, Joshua D. Mezrich5, Adnan Said2 1Internal Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI, USA. 2Gastroenterology, University of Wisconsin Hospitals and Clinics, Madison, WI, USA. 3Pathology, University of Wisconsin Hospitals and Clinics, Madison, WI, USA. 4Radiology, University of Wisconsin Hospitals and Clinics, Madison, WI, USA. 5Surgery, University of Wisconsin Hospitals and Clinics, Madison, WI, USA S AT U R D AY OCTOBER 31


#560 PERIPHERAL CD4+ ADENOSINE TRIPHOSPHATE ACTIVITY LEVELS ALLOW SAFE REDUCTION OF IMMUNOSUPPRESSION IN ORTHOTOPIC LIVER TRANSPLANT (OLT) RECIPIENTS Te1,

Dasgupta2,

Cao3,

Helen S. Kathleen Dingcai Rohit S. Satoskar1, Smruti R. Mohanty1, Nancy Reau1, K. Gautham Reddy1, Giuliano Testa2, J. Michael Millis2, Donald M. Jensen1 1Medicine, Center for Liver Diseases, University of Chicago Medical Center, Chicago, IL, USA. 2Surgery, Section of Transplant Surgery, University of Chicago Medical Center, Chicago, IL, USA. 3Surgery, University of Chicago Medical Center, Chicago, IL, USA

TRANSJUGULAR INTRAHEPATIC PORTO-SYSTEMIC SHUNTS (TIPSS) IN LIVER TRANSPLANT RECIPIENTS – A RETROSPECTIVE CASE CONTROL ANALYSIS OF 2 TRANSPLANT CENTRES IN THE UNITED KINGDOM Andrew King1, Gail S. Masterton2, Bridget Gunson1, Simon Olliff3, Gabriel Oniscu2, Peter C. Hayes2, Dhiraj Tripathi4 1Centre for Liver Research, University of Birmingham, Birmingham, United Kingdom. 2Liver Unit, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom. 3Department of Radiology, Queen Elizabeth Hospital, Birmingham, United Kingdom. 4Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom

#563 INCIDENCE AND RISK FACTORS FOR NEW ONSET DIABETES MELLITUS AFTER LIVER TRANSPLANTATION Elizabeth J. Carey, Bashar Aqel, Thomas J. Byrne, Hugo E. Vargas, Jorge Rakela, David D. Douglas, Harini Chakkera Division of Transplantation Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA

#564 EFFECTIVENESS OF DIETARY INTERVENTION FOR LIVER POST-TRANSPLANT HYPERLIPIDEMIA Jennifer Lambert1, Vincent G. Bain2, Alan B. Thomson2, Michael Tom Clandinin1 1Alberta Institute for Human Nutrition, University of Alberta, Edmonton, AB, Canada. 2Department of Medicine, University of Alberta, Edmonton, AB, Canada

#565 THE OUTCOME AND ROLE OF LIVER TRANSPLANTATION IN WAIT-LISTED PATIENTS WITH CIRRHOSIS ADMITTED TO THE INTENSIVE THERAPY UNIT FOR ORGAN SUPPORT (Robin) Daniel Abeles, William Bernal, Debbie L. Shawcross, Andrew D. Yeoman, Nicholas J. Taylor, Elizabeth Sizer, Georg Auzinger, Michael A. Heneghan, Mohammed Rela, John G. O’Grady, Nigel Heaton, Julia Wendon Institute of Liver Studies, King’s College Hospital, London, United Kingdom



POSTER SESSIONS

#566

#571

INCREASED RISK OF POST-TRANSPLANT CARDIAC EVENTS IN NASH PATIENTS: IS PRE-TRANSPLANT SCREENING USING TRADITIONAL CARDIAC RISK FACTORS SUFFICIENT?

LIVER RE-TRANSPLANTATION AND THE IMPLICATION OF POSITIVE CROSS-MATCH IN ANTIBODY-MEDIATED REJECTION

151A

Lisa B. VanWagner1, Lisa Alvarez1, Jeanne H. Gottstein2, Josh Levitsky2, Mary E. Rinella2 1Internal Medicine, Northwestern University, Chicago, IL, USA. 2Internal Medicine, Division of Hepatology, Northwestern University, Chicago, IL, USA

Triscia Martin1, Jason Schwartz3, David D. Eckels2, Linda Book1 1Department of Pediatrics, University of Utah Hospital, Salt Lake City, UT, USA. 2Department of Pathology/H&I Lab, University of Utah Hospital, Salt Lake City, UT, USA. 3Department of Surgery, Section of Transplantation, University of Utah Hospital, Salt Lake City, UT, USA

#567

#572

NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AND APACHE II SCORE ARE POWERFUL PREDICTORS OF ACUTE KIDNEY INJURY IN PATIENTS UNDERGOING LIVER TRANSPLANTATION

CARDIAC FUNCTION AND AMINOTERMINAL PRO-BRAIN NATRIURETIC PEPTIDE LEVELS IN CIRRHOTIC PATIENTS BEFORE AND AFTER LIVER TRANSPLANTATION

Portal1,

McPhail3,

Bruce1,

Andrew J. Mark Matthew J. Andrew J. Slack1, Roy Sherwood2, Debbie L. Shawcross1, Nigel Heaton1, Julia Wendon1, Michael A. Heneghan1 1Institute of Liver Studies, Kings College Hospital, London, United Kingdom. 2Department of Clinical Biochemistry, Kings College Hospital, London, United Kingdom. 3Department of Hepatology, Imperial College London, London, United Kingdom

#568 PATIENT AND GRAFT SURVIVAL ARE NOT ADVERSELY IMPACTED BY SIMULTANEOUS LIVER/LUNG TRANSPLANTATION Ronald T. Cotton, Ismael Salas de Armas, Jacfranz J. Guiteau, Theresa R. Harring, N. Thao Nguyen, Christine O’Mahony, John A. Goss Michael . DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA

#569

Mohammad A. Al-Freah, Carl Moran, Matthew Foxton, Mohammed Rela, Nigel Heaton, John G. O’Grady, Julia Wendon, Michael A. Heneghan Institute of Liver Studies, Kings College Hospital, London, United Kingdom

#570 DETECTION OF POLYPS, ADENOMAS AND ADVANCED LESIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS: A CASE CONTROL STUDY Bret J. Spier, Daniel Cornett, Andrew J. Walker, Adnan Said Gastroenterology and Hepatology, University of Wisonsin, Madison, WI, USA

#573 IMPACT OF TOBACCO AND ALCOHOL CONSUMPTION ON 3-MONTH MORBIDITY FOLLOWING LIVER TRANSPLANTATION AMONG PATIENTS WHO CONSUMED ALCOHOL AND SMOKED TOBACCO WHILST ON THE WAITING LIST Pascal Perney1, Frédérique Ségalas-Largey2, Gérald Chanques2, Hélène Rigole2, Yohan Duny2, Bertrand Soulié2, Astrid Herrero2, Mickaël Bismuth2, Samir Jaber2, François Blanc2, Dominique G. Larrey2, Georges-Philippe Pageaux2 1CHU Caremeau, Nîmes, France. 2CHU Saint Eloi, Montpellier, France

#574 IMPROVEMENT IN RENAL FUNCTION FOLLOWING CONVERSION TO SIROLIMUS IN LIVER TRANSPLANT RECIPIENTS WITH CHRONIC RENAL INSUFFICIENCY Michael D. Leise, Sumeet K. Asrani, Charles B. Rosen, Rachel Pedersen, Terry M. Therneau, W. Ray Kim Mayo Clinic College of Medicine, Rochester, MN, USA

#575 LONG TERM OUTCOMES OF LIVER TRANSPLANTATION FOR PORPHYRIA Joanna K. Dowman1,2, Bridget Gunson1,2, Darius Mirza1, Michael N. Badminton3, Philip N. Newsome2,1 1The Liver Unit, Birmingham Queen Elizabeth Hospital, Birmingham, United Kingdom. 2Centre for Liver Research, University of Birmingham, Birmingham, United Kingdom. 3Department of Medical Biochemistry & Immunology, Cardiff University, Cardiff, United Kingdom


AN EVALUATION OF PROGNOSTIC INDICATORS IN THE PREDICTION OF OUTCOME FOLLOWING LIVER RETRANSPLANTATION: A SINGLE CENTRE EXPERIENCE

Vanesa Bernal1, Isaac Pascual2, Angel Lanas1,4, Elena Piazuelo3,4, Paula Esquivias3,4, Agustin Garcia-Gil5, Monica Polo-Tomas4, Miguel A. Simon1 1Gastroenterology and Hepatology, Lozano Blesa University Hospital, Zaragoza, Spain. 2Cardiology, Lozano Blesa University Hospital, Zaragoza, Spain. 3Instituto Aragones de Ciencias de la Salud (IACS), Zaragoza, Spain. 4CIBERehd, Zaragoza, Spain. 5Liver Transplant Unit, Lozano Blesa University Hospital, Zaragoza, Spain

152A

POSTER SESSIONS

#576

#582

GBP2 MRNA IN THE PERIPHERAL BLOOD LEUKOCYTES ELEVATED IN THE ACUTE CELLULAR REJECTION OF LIVER TRANSPLANT RECIPIENTS

TARGETED 90 DAY VALGANCICLOVIR (VGC) AND ITS EFFECT ON THE TIMING, FREQUENCY AND SEVERITY OF SYMPTOMATIC POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTIONS

Shogo Kobayashi, Hiroaki Nagano, Naoki Hama, Shigeru Marubashi, Hidetoshi Eguchi, Yutaka Takeda, Masahiro N. Tanemura, Yuichiro Doki, Masaki Mori Osaka University, Suita, Japan

#577 OUTCOMES OF LIVER RETRANSPLANTATION DUE TO ISCHEMIC CHOLANGIOPATHY: COMPARISON OF DONATION AFTER CARDIAC DEATH AND DONATION AFTER BRAIN DEATH GRAFTS Deniz Balci, Darrin L. Willingham, Justin H. Nguyen, Burcin Taner Transplantation, Mayo Clinic Florida, Jacksonville, FL, USA

#578 CARDIOVASCULAR CHANGES AFTER LIVER TRANSPLANTATION Ahmed Ibrahim, Waleed Ahmed, Fatma Barakat, Eileen Chatfield, Marquis E. Hart, Elliot Alpert, Anthony N. DeMaria, Tarek Hassanein University of California, San Diego, San Diego, CA, USA

#579 UNEXPECTED ETIOLOGIES OF CRYPTOGENIC LIVER DISEASE AND INCIDENTAL TUMORS IN ADULT LIVER TRANSPLANTATION: A CLINICALPATHOLOGICAL STUDY IN 815 PATIENTS Jordi Colmenero1, Graciela Castro-Narro1, Alfeu Fleck1, Rosa Miquel2, Juan Carlos Garcia-Valdecasas1, Miquel Navasa1 1Liver Transplantation Unit, Institut Clínic de Malaties Digestives i Metabòliques, CIBERehd, Hospital Clínic, Barcelona, Spain. 2Pathology Unit, Hospital Clínic, Barcelona, Spain S AT U R D AY OCTOBER 31


#580 DISEASE RECURRENCE FOLLOWING ORTHOTROPIC LIVER TRANSPLANTATION (OLT): NONALCOHOLIC STEATOHEPATITIS VS. HEPATITIS C VIRUS INFECTION. Carole Macaron1, Ibrahim Hanouneh1, Rocio Lopez2, Ariel E. Feldstein3, Nizar N. Zein3 1Internal Medicine, The Cleveland Clinic, Cleveland, OH, USA. 2Quantitative Health Sciences, The Cleveland Clinic, Cleveland, OH, USA. 3Gastroenterology and Hepatology, The Cleveland Clinic, Cleveland, OH, USA

#581 HETEROGENOUS INFLAMMATORY CHANGES IN LIVER GRAFTS WITH NORMAL BIOCHEMISTRY William Gelson1, Matthew Hoare1, Esther Unitt1, Christopher Palmer5, Paul Gibbs4, Nicholas Coleman3, Susan Davies2, Graeme J. Alexander1 1Hepatology, Addenbrooke’s Hospital, Cambridge, United Kingdom. 2Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom. 3Oncology, Addenbrooke’s Hospital, Cambridge, United Kingdom. 4Transplantation, Addenbrooke’s Hospital, Cambridge, United Kingdom. 5Centre for Applied Medical Statistics, University of Cambridge, Cambridge, United Kingdom Denotes AASLD Presidential Poster of Distinction

William D. Stableforth1, Amanda Smith3, Tania Feghali1, David J. Mutimer1, Simon Bramhall2, Bridget Gunson1, Tahir Shah1 1Department of Liver Medicine, Birmigham Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom. 2Department of Liver Surgery, Birmingham Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom. 3Department of Pharmacology, Queen Elizabeth Hospital, Birmingham, United Kingdom

#583 A LONGITUDINAL, PROSPECTIVE STUDY ON ADHERENCE TO MEDICAL REGIMEN BEFORE AND AFTER LIVER TRANSPLANTATION Giacomo Germani1, Francesca Gnoato2, Valentina Borella1, Silvia Lazzaro1, Egle Perissinotto3, Marco Senzolo1, Francesco P. Russo1, Eleonora De Martin1, Martina Gambato1, Umberto Cillo4, Giacomo C. Sturniolo1, Patrizia Burra1 1Department of Surgical and Gastroenterological Sciences, Gastroenterology, University of Padua, Padova, Italy. 2Department of Developmental and Socialization Psychology, University of Padua, Padova, Italy. 3Department of Environmental Medicine and Public Health, University of Padua, Padova, Italy. 4Department of Surgical and Gastroenterological Sciences, Surgical Unit, University of Padua, Padova, Italy

#584 TOBACCO SMOKING AND LONG-TERM OUTCOME IN LIVER TRANSPLANTATION Maggie M. Ow, Edward J. Gane, David W. Orr NZ Liver Transplant Unit, Auckland City Hospital, Grafton, Auckland, New Zealand

#585 CLASS III OBESITY IS NOT A CONTRAINDICATION TO LIVER TRANSPLANTATION John C. LaMattina, David P. Foley, Luis A. Fernandez, John Pirsch, Glen E. Leverson, Barbara J. Voss, Anthony M. D’Alessandro, Joshua D. Mezrich Department of Surgery, Division of Transplantation, University of Wisconsin, Madison, WI, USA

#586 COGNITIVE FUNCTION AFTER LIVER TRANSPLANTATION IS DETERMINED BY HEPATIC ENCEPHALOPATHY AND ALCOHOL ETIOLOGY Rita Garcia-Martinez1,2, Carlos Jacas1,2, Juli Alonso1,2, Victor Vargas1,2, Macarena Simon-Talero1, Juan Cordoba1,2 1Liver Unit. Department of Internal Medicine, Hospital Vall Hebron, Barcelona, Spain. 2CIBEREHD, Barcelona, Spain


POSTER SESSIONS

153A

#587

#592

A CROSS-SECTIONAL STUDY OF LIVER-SPECIFIC QUALITY OF LIFE FOLLOWING TRANSPLANTATION

LONG-TERM RESULTS OF LIVER TRANSPLANTATION WITH A NATIONAL PROTOCOL FOR CONTROLLED CARDIAC DEATH DONORS

Daniela P. Ladner1,2, Vadim Lyuksemburg1, Raymond Kang2, Olivia A. Ross2, Zeeshan Butt1,3 1Surgery - Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 2Institute for Healthcare Studies, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 3Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

#588 PREVALENCE AND CLINICAL PREDICTORS OF ABNORMAL OVERNIGHT OXYGENATION IN ADULTS AWAITING LIVER TRANSPLANTATION Aynur Okcay, Virend K. Somers, Fatima H. Sert-Kuniyoshi, Sean M. Caples, Naser M. Ammash, Russell H. Wiesner, Michael J. Krowka Medicine, Mayo Clinic, Rochester, MN, USA

#589 LIVER TRANSPLANTATION IN THE SUPER MORBIDLY OBESE: A SINGLE CENTER EXPERIENCE; SECTION OF ABDOMINAL TRANSPLANTATION, OCHSNER CLINIC FOUNDATION, NEW ORLEANS, LA Scott Seals, Nigel Girgrah, Ari J. Cohen, Ian C. Carmody, Margaret A. Davidson, Humberto E. Bohorquez, David Bruce, Shobha Joshi, Brian Parker, George E. Loss Ochsner Clinic Foundation, New Orleans, LA, USA

#590 RISK OF DEVELOPMENT OF METABOLIC SYNDROME (MS) AFTER ORTHOTOPIC LIVER TRANSPLANTATION (OLT)

#591 POST-LIVER TRANSPLANTATION ASCITES (PLTA): EVOLUTION, EVALUATION AND MANAGEMENT, A TEN-YEAR SINGLE CENTER EXPERIENCE Michele Sazama1, Amir Yosephy1, Kristin L. Mekeel2, Giovanni De Petris3, Sailen G. Naidu4, Alvin C. Silva4, Christopher P. Appleton5, Bashar Aqel1, Thomas J. Byrne1, Elizabeth J. Carey1, David D. Douglas1, Jorge Rakela1, Hugo E. Vargas1 1Transplantation Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA. 2Transplantation Surgery, Mayo Clinic Arizona, Phoenix, AZ, USA. 3Pathology, Mayo Clinic Arizona, Phoenix, AZ, USA. 4Radiology, Mayo Clinic Arizona, Phoenix, AZ, USA. 5Cardiology, Mayo Clinic Arizona, Phoenix, AZ, USA

#593 SOTRASTAURIN, A NOVEL PROTEIN KINASE CINHIBITOR: PHARMACOKINETICS AND CLEARANCE IN LIVER TRANSPLANTATION Alan Slade1, Johann Pratschke2, Umberto Cillo3, Sylvie Stitah4, Peter Neuhaus2, John M. Kovarik4 1TM-Transplantation, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. 2Department of Surgery, Hospital Charité, Berlin, Germany. 3Hepato-Biliary and Liver Transplantation Unit, University of Padova, Padova, Italy. 4Global Development, Novartis Pharmaceuticals, Basel, Switzerland

#594 LONG TERM OUTCOMES OF ASIAN LIVER TRANSPLANT RECIPIENTS Daniela P. Ladner1, Amna Daud1, Edward Wang1, Juan C. Caicedo1, Anton I. Skaro1, Elisa J. Gordon1, Olivia A. Ross2, Michael M. Abecassis1 1Department of Surgery, Division of Organ Transplantation, Northwestern University, Chicago, IL, USA. 2Institute of Healthcare Studies, Northwestern University, Chicago, IL, USA

#595 ANALYSIS OF INHALED ANESTHETIC AGENTS IN CLINICAL LIVER TRANSPLANTATION Richard S. Mangus1, Sandra Kinsella2, Jonathan A. Fridell1, Rodrigo Vianna1, Matthew M. Nobari2, Amanda Sell2, A Joseph Tector1 1Surgery, Transplantation Section, Indiana University, School of Medicine, Indianapolis, IN, USA. 2Anesthesia, Indiana University, School of Medicine, Indianpolis, IN, USA

#596 TRANSPLANTATION AS A TREATMENT FOR DIFFUSE THROMBOSIS OF THE PORTOMESENTERIC SYSTEM Rodrigo Vianna1, Richard Mangus1, Jonathan A. Fridell1, Shekhar Kubal1, Marco A. Lacerda2, Paul Y. Kwo2, A Joseph Tector1 1Surgery, Indiana Univeristy/ Clarian Transplant Center, Indianapolis, IN, USA. 2Medicine, Indiana Univeristy/ Clarian Transplant Center, Indianapolis, IN, USA


María Lourdes Ruiz Rebollo1, Gloria Sánchez-Antolín1, Félix García-Pajares1, PIlar Fernández Orcajo1, Miguel Angel Cítores Pascual2, Manuel González-Sagrado3, Rosario Velicia1, Agustín Caro Patón1 1Hepato-Gastroenterology, Hospital Río Hortega, Valladolid, Spain. 2Surgery, Hospital Río Hortega, Valladolid, Spain. 3INvestigation Unit, Hospital Río Hortega, Valladolid, Spain

Jeroen Dubbeld2, Harm Hoekstra4, Waqar R. R. Farid5, Jan Ringers2, Robert J. Porte4, Herold J. Metselaar5, Andrzej G. Baranski2, Geert Kazemier6, Minneke J. Coenraad1, Aad P. van den Berg3, Bart Van Hoek1 1Gastroenterology & Hepatology, Leiden University Medical Center, Leiden, Netherlands. 2Surgery, Leiden University Medical Center, Leiden, Netherlands. 3Gastroenterology & Hepatology, University Medical Center Groningen, Groningen, Netherlands. 4Surgery, University Medical Center Groningen, Groningen, Netherlands. 5Gastroenterology & Hepatology, Erasmus Medical Center, Rotterdam, Netherlands. 6Surgery, Erasmus Medical Center, Rotterdam, Netherlands

154A

POSTER SESSIONS

#597

#602

DOES KIDNEY TRANSPLANTATION AFFECT THE SURVIVAL OF A SUBSEQUENT LIVER TRANSPLANTATION? SINGLE CENTER EXPERIENCE

THE EFFECT OF SIROLIMUS ON BODY WEIGHT IN LIVER TRANSPLANT RECIPIENTS: CAN WE LIMIT A MAJOR COMORBIDITY ?

Leopoldo Arosemena1, Jang Moon2, Panagiotis Tryphonopoulos2, Seigo Nishida2, Gennaro Selvaggi2, David Levi2, Eddie Island2, Akin Tekin2, Phillip Ruiz3, Pablo A. Bejarano3, Monica T. Garcia3, Deborah Weppler2, Ravi K. Ghanta1, Kaveh Sharzehi1, Dennis Ng1, Maria D. Hernandez1, Kishore Maganty1, Jagadeeshu K. Siram1, Sharad Virmani4, Eugene R. Schiff1, Andreas G. Tzakis2, Paul Martin1 1Center for Liver Diseases, University of Miami Leonard Miller School of Medicine, Miami, FL, USA. 2Liver and GI transplant Service, University of Miami Leonard Miller School of Medicine, Miami, FL, USA. 3Pathology Department, University of Miami Leonard Miller School of Medicine, Miami, FL, USA. 4Internal Medicine, University of Miami Leonard Miller School of Medicine, Miami, FL, USA

Greg J. McKenna, James Trotter, Erik Klintmalm, Edmund Q. Sanchez, Srinath Chinnakotla, Henry B. Randall, Richard Ruiz, Nicholas Onaca, Marlon F. Levy, Robert M. Goldstein, Goran Klintmalm Transplant, Baylor Regional Transplant Institute, Dallas, TX, USA

#598 SYSTEMATIC SCREENING OF HEPATIC OSTEODYSTROPHY IN CIRRHOTIC PATIENTS AWAITING LIVER TRANSPLANTATION Cecile Wibaux2, Isabelle Gerot-Legroux2, Sebastien Dharancy1, Nicole Declerck1, Emmanuel Boleslawski1, Valerie Canva1, Philippe Mathurin1, François R. Pruvot1, Bernard Cortet2 1Hopital Huriez, Transplant Unit, Lille, France. 2Hopital Salengro, Rhumatology Unit, Lille, France

#599 ASSESSMENT OF LIVER STIFFNESS (LS) IN THE RELAPSE OF ALCOHOLIC LIVER DISEASE (RALD) AFTER LIVER TRANSPLANTATION (LT)



Amélie Cannesson, Hamid Aftisse, Emmanuel Boleslawski, Valerie Canva, Nicole Declerck, Philippe Mathurin, François R. Pruvot, Sebastien Dharancy Hopital Huriez, Transplant Unit, Lille, France

#600 RISK FACTORS OF DEVELOPMENT OF BILIARY LEAK AFTER DECEASED DONOR LIVER TRANSPLANTATION Vinay Sundaram1, Deborah Jones1, Nilesh Shah1, Michael E. de Vera1,2, Jawad Ahmad1,2 1University of Pittsburgh, Pittsburgh, PA, USA. 2Starzl Transplantation Institute, PIttsburgh, PA, USA

#601 SIROLIMUS DECREASES FIBROSIS PROGRESSION IN RECURRENT HEPATITIS C DISEASE POST-LIVER TRANSPLANTATION Shirley Tsunoda, Christina Sarubbi, Anh-Thu T. Ha, Kathryn Hollenbach, Eileen Chatfield, Ajai Khanna, Christopher T. Barry, Marquis E. Hart, Tarek Hassanein University of California, San Diego, San Diego, CA, USA


#603 SPONTANEOUS BACTERIAL PERITONITIS IS MORE COMMON IN HEPATITIS C PATIENTS AND IS ASSOCIATED WITH WORSE POST-TRANSPLANT SURVIVAL AND GRAFT LOSS DUE TO HEPATITIS C RECURRENCE Neeral L. Shah1, Timothy M. Schmitt2, Curtis K. Argo1, Abdullah M. Al-Osaimi1, Carl L. Berg1, Patrick G. Northup1 1Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, USA. 2Transplant Surgery, University of Virginia, Charlottesville, VA, USA

#604 RISK FACTORS FOR RECURRENT HEPATOCELLULAR CARCINOMA FOLLOWING LIVER TRANSPLANTATION : A SINGLE CENTER EXPERIENCE Jennifer Price, Guldane Cengiz-Seval, Andrew M. Cameron, Ahmet Gurakar Johns Hopkins Hospital, Baltimore, MD, USA

#605 INCIDENCE AND RISK FACTORS ASSOCIATED WITH DE NOVO AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION Aldo J. Montano-Loza, Vincent G. Bain, Mang M. Ma, Andrew L. Mason Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, AB, Canada

#606 THE IMPACT OF DONORNET ON THE SHORT TERM GRAFT SURVIVAL, DONOR RISK INDEX AND TIME TO LIVER TRANSPLANTATION Elizabeth C. Verna, Erica Farrand, Robert S. Brown The Center for Liver Disease and Transplantation, Columbia University College of Physicians and Surgeons, New York, NY, USA

#607 WITHDRAWN


POSTER SESSIONS

#608

#613

A POTENTIAL MECHANISM FOR PROSPECTIVE IDENTIFICATION OF NON-HEART BEATING GRAFT RECIPIENTS IN ORTHOTOPIC LIVER TRANSPLANTATION

LIVER TRANSPLANTATION OF NON-U.S. RESIDENTS MAY ADVERSELY AFFECT ORGAN DONATION: PERCEPTION VERSUS REALITY

Ronald T. Cotton, Theresa R. Harring, Jacfranz J. Guiteau, N. Thao Nguyen, Ismael Salas de Armas, Christine O’Mahony, John A. Goss Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA

#609 PREDICTORS OF LONG-TERM DONOR FOLLOWUP IN LIVING DONOR LIVER TRANSPLANTATION Caroline Yao1,2, Ephraim Dickinson1,2, Peter Downey1, Michael J. Goldstein1, Dianne LaPointe Rudow1, Benjamin Samstein1, Jean C. Emond1, Robert S. Brown1 1Center for Liver Disease and Transplantation, Columbia University Medical Center, New York, NY, USA. 2Columbia University College of Physicians and Surgeons, New York, NY, USA

#610 ATTITUDES REGARDING ORGAN DONATION AFTER CARDIAC DEATH VERSUS BRAIN DEATH AMONG THE AMERICAN PUBLIC Michael L. Volk1, Gareth Warren1, Renee Anspach2, Mick Couper3, Robert M. Merion4, Peter A. Ubel1 1Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2Sociology, University of Michigan, Ann Arbor, MI, USA. 3Institute for Social Research, University of Michigan, Ann Arbor, MI, USA. 4Surgery, University of Michigan, Ann Arbor, MI, USA

#611

Umberto Cillo3, Alessandro Vitale1,3, Anna Chiara Frigo2, D’Amico Francesco3, Fabio Farinati4, Patrizia Burra4, Davide F. D’Amico3 1Unità di Chirurgia Oncologica, Istituto Oncologico Veneto, IRCCS, Padova, Italy. 2Università di Padova, Unità di Biostatistica ed Epidemiologia, Padova, Italy. 3Azienda-Università di Padova, Unità di Chirurgia Epatobiliare e Trapianto Epatico, Padova, Italy. 4Azienda-Università di Padova, Divisione di Gastroenterologia, Padova, Italy

#612 ESTIMATION OF THE HARM TO THE WAITING LIST AS CRUCIAL FACTOR IN THE SELECTION OF PATIENTS WITH HEPATOCELLULAR CARCINOMA FOR LIVER TRANSPLANTATION Alessandro Vitale1,4, Michael Volk2, Martina Gambato3, D’Amico Francesco4, Patrizia Burra3, Umberto Cillo4 1Unità di Chirurgia Oncologica, Istituto Oncologico Veneto, IRCCS, Padova, Italy. 2University of Michigan Health System, Division of Gastroenterology, Ann Arbor, MI, USA. 3Azienda-Università di Padova, Division of Gastroenterology, Padova, Italy. 4Azienda Università di Padova, Unità di Chirurgia Epatobiliare e Trapianto Epatico, Padova, Italy

Michael L. Volk1, Peter A. Ubel1, Robert M. Merion2 1Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2Surgery, University of Michigan, Ann Arbor, MI, USA

#614 PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS ARE REFERRED FOR LIVER TRANSPLANT WITH WORSE RENAL FUNCTION: IMPLICATIONS FOR MELD SCORE Chan W. Park1, Naoky Tsai2, Linda L. Wong2,1 of Surgery, Univ of Hawaii, Honolulu, HI, USA. 2Transplant Institute, Hawaii Medical Center East, Honolulu, HI, USA

1Dept

#615 USE OF COMBINED HCV AND HEPATITIS B CORE ANTIBODY POSITIVE LIVER GRAFTS IN HCV RECIPIENTS. IMPACT ON GRAFT AND PATIENT SURVIVAL Prithvi Sreenivasan, Jason M. Vanatta, James D. Eason, Satheesh Nair Transplant Institute, University of Tennessee/Methodist University Transplant Institute, Memphis, TN, USA

#616 INFLUENCE OF DONOR-RECIPIENT VARIABLES ON SHORT TERM PATIENT SURVIVAL FOLLOWING LIVER TRANSPLANTATION (LT) Martina Gambato1, Marco Senzolo1, Tullia M. De Feo3, Francesco P. Russo1, Giacomo Germani1, Eleonora De Martin1, Alessandro Vitale2, Alberto Brolese2, Umberto Cillo2, Patrizia Burra1 1Department of Surgical and Gastroenterological Sciences, Gastroenterology, Padova, Italy. 2Department of Surgical and Gastroenterological Sciences, Liver Surgery, Padova, Italy. 3Nord Italia Transplant, Milano, Italy

#617 A PRIORITIZATION MODEL FOR LIVER TRANSPLANTATION BASED ON A DUAL WAITING LIST: A PROSPECTIVE CONTROLLED STUDY Umberto Cillo1, Alessandro Vitale2,1, Patrizia Burra4, Anna Chiara Frigo3, Paolo Angeli5, Martina Gambato4, Giacomo Zanus1, Alberto Brolese1 1Azienda-Università di Padova, Unità di Chirurgia Epatobiliare e Trapianto Epatico, Padova, Italy. 2Unità di Chirurgia Oncologica, Istituto Oncologico Veneto, IRCCS, Padova, Italy. 3Università di Padova, Unità di Biostatistica ed Epidemiologia, Padova, Italy. 4Azienda-Università di Padova, Divisione di Gastroenterologia, Padova, Italy. 5Università di Padova, Clinica Medica V, Padova, Italy


THE SURVIVAL BENEFIT OF LIVER TRANSPLANTATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING TO BRIDGING THERAPIES

155A

156A

POSTER SESSIONS

#618

#622

SYSTEMATIC ERROR IN MELD CALCULATION BY USING SERUM CREATININE MEASUREMENT IN CIRRHOSIS

WHO WILL BE MY LIVER DONOR? CORRELATION BETWEEN DONOR RELATION AND RECIPIENT DISEASE IN LIVING-DONOR LIVER TRANSPLANTATION (LDLT)

Emmanuel Tsochatzis1, Pinelopi Manousou1, Michael Thomas2, Kate Jones1, Evangelia Fatourou1, Giuseppe Fede1, Kurinchi Gurusamy1, Stavroula Daoula1, Vasiliki Arvaniti1, Aikaterini Tsami1, Graziella Isgro1, Lorenzo Andreana1, A K Burroughs1 1The Royal Free Sheila Sherlock Liver Centre and Division of Surgery, Royal Free Hospital, London, United Kingdom. 2Department of Clinical Biochemistry, Royal Free Hospital, London, United Kingdom

#619 EFFICACY OF ANTIVIRAL THERAPY IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HEPATITIS C: IMPACT OF DONOR AGE, GENOTYPE AND VIRAL KINETICS Victoria Aguilera1,2, Angel Rubin1,2, Martin Prieto1,2, Blas Risalde1,2, Cecilia Ortiz3,2, Josep L. Melero1, Marina Berenguer1,2 1Hepatology Department, Hospital la Fe, Valencia, Spain. 2Ciberehd, Health Institute Carlos III, Valencia, Spain. 3Experimental Immunity Unit, Hospital la Fe, Valencia, Spain

#620 LONG-TERM RESULTS OF LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA IN 15 HIV+ PATIENTS Eric Vibert1,3, Maria-Rosa Ghigna4, Rene Adam1, Catherine Guettier4,3, Daniel Azoulay1, Denis X. Castaing1,2, Didier Samuel1,3, Jean-Charles Duclos-Vallée1,2 1Centre Hepato-Biliaire, AP-HP Hopital Paul Brousse, Villejuif, France. 2Unite 785, INSERM, Villejuif, France. 3UMR-S785, Univ Paris-Sud, Villejuif, France. 4Laboratoire Anatomie pathologique, AP-HP Hopital de Bicêtre, Le Kremlin Bicêtre, France S AT U R D AY OCTOBER 31


#621 MULTICENTRIC EVALUATION OF MELD-BASED ORGAN ALLOCATION AND SURVIVAL AFTER LIVER TRANSPLANTATION – THE MEMOSALT STUDY Tobias J. Weismüller1, Panagiotis Fikatas2, Jan Schmidt3, Ana P. Barreiros4, Susanne Beckebaum5, Marcus N. Scherer6, Hartmut Schmidt7, Johann Pratschke2, Michael P. Manns1, Christian P. Strassburg1 1Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 2Abdominal, Visceral and Transplantation Surgery, Charité Universitätsmedizin, Campus Virchow, Berlin, Germany. 3General Surgery, Ruprecht-Karls-University, Heidelberg, Germany. 4First Department of Internal Medicine, Johnannes Gutenberg-University, Mainz, Germany. 5General, Visceral and Transplantation Surgery and Department of Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany. 6Surgery, Regensburg University Hospital, Regensburg, Germany. 7Clinical and Experimental Transplant Hepatology, University Hospital Münster, Münster, Germany

Ephraim Dickinson1,2, Caroline Yao1,2, Peter Downey1,2, Michael J. Goldstein1, Dianne LaPointe Rudow1, Benjamin Samstein1, Jean C. Emond1, Robert S. Brown1 1Center for Liver Disease and Transplantation, Columbia University Medical Center, New York, NY, USA. 2Columbia University College of Physicians and Surgeons, New York, NY, USA

#623 RECURRENCE OF PRIMARY SCLEROSING CHOLANGITIS FOLLOWING DECEASED AND LIVING DONOR LIVER TRANSPLANTATION Aileen Smith, Lesley E. Adcock, Philippe Garzon, David Grant, Eberhard L. Renner, Gary A. Levy, Paul D. Greig, George Therapondos Multiorgan Transplant Program, University of Toronto, Toronto, ON, Canada

#624 ENDOTHELIAL CELL AND PLATELET DERIVED MICROPARTICLES ARE GENERATED IN PATIENTS UNDERGOING LIVER RESECTIONS AND EXHIBIT PRO-COAGULANT PROPERTIES Yara Banz2, Gian Marco Item1, Daniel Candinas1, Guido Beldi1 of Visceral Surgery and Medicine, Bern, Switzerland. 2Department of Pathology, Bern University Hospital, Bern, Switzerland

1Department

#625 PREDICTORS OF DONOR COMPLICATIONS IN LIVING DONOR LIVER TRANSPLANTATION (LDLT): A SINGLE CENTER’S TEN YEAR EXPERIENCE Peter Downey1,2, Ephraim Dickinson1,2, Caroline Yao1,2, Michael J. Goldstein1, Dianne LaPointe Rudow1, Benjamin Samstein1, Jean C. Emond1, Robert S. Brown1 1Center for Liver Disease and Transplantation, University Medical Center, New York, NY, USA. 2Columbia University College of Physicians and Surgeons, New York, NY, USA

#626 RISK FACTORS FOR LITIGATION FOLLOWING SEVERE BILE DUCT INJURY SUSTAINED DURING LAPAROSCOPIC CHOLECYSTECTOMY Thamara Perera, Michael A. Silva, Ankur Shah, Ruth Hardstaff, Simon Bramhall, John Isaac, John Buckels, Darius Mirza Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom

#627 EFFECT OF RFA AND TACE ON RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION: 8 YEAR EXPERIENCE WITH 145 PATIENTS Ali Cheaito1, Atsushi Yoshida1, Dean Y. Kim1, Dilip Moonka2, Kimberly Ann Brown2, Marwan S. Abouljoud1 1Transplant Institute, Henry Ford Hospital, Detroit, MI, USA. 2Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI, USA



POSTER SESSIONS

#628

#633

OUTCOMES OF SIMULTANEOUS LIVER TRANSPLANTATION AND MAJOR CARDIOVASCULAR SURGICAL PROCEDURES. A SINGLE-CENTER EXPERIENCE

COMPARING OUTCOMES OF LIVER TRANSPLANTS FOR PRIMARY LIVER TUMORS, BOTH RARE AND COMMON

Pedro J. Briceno, Ravi K. Ghanta, Mauricio G. Cohen, Paul Martin, Mauro Moscucci, Andreas G. Tzakis, Jang Moon Hepatology, University of Miami, Miami, FL, USA

#629 COMPARATIVE STUDY OF 45 LAPAROSCOPIC LIVER RESECTIONS Stephen Kin Yong Chang1, Eugene, Kee Wee Lim1, Liang Shen2, Rachel, Rui Qi Yu3, Iyer Shridhar Ganpathi1, Davide Lomanto3, Krishnakumar Madhavan3 1Surgery, National University Hospital, Singapore, Singapore, Singapore. 2Dean’s Office (Medicine), National University of Singapore, Singapore, Singapore. 3Surgery, National University of Singapore, Singapore, Singapore

#630 EXTENDED LIVER RESECTION FOR POLYCYSTIC LIVER DISEASE CAN CHALLENGE LIVER TRANSPLANTATION Béatrice Aussilhou1, Claire Francoz3, Catherine Paugam-Burtz2, Ghislaine Doufle2, Francois Durand3, Catherine Hubert1, Jacques Belghiti1 1HBP Surgery, Beaujon Hospital, Clichy, France. 2Anesthesiology, Beaujon Hospital, Clichy, France. 3Hepatology, Beaujon Hospital, Clichy, France

#631 ENDOSCOPIC THERAPY IN THE MANAGEMENT OF BILIARY TRACT COMPLICATIONS, AFTER LIVER TRANSPLANTATION

#632 TRENDS IN LIVER TRANSPLANTATION FOR PRIMARY BILIARY CIRRHOSIS IN THE NETHERLANDS 1988-2008 Edith M. Kuiper1, Bettina E. Hansen1,2, Herold J. Metselaar1, Robert A. De Man1, Elizabeth B. Haagsma3, Bart Van Hoek4, Henk R. van Buuren1 1Hepatology and Gastroenterology, Erasmus University Medical Center, Rotterdam, Netherlands. 2Epidemiology and Biostatistics, Erasmus University Medical Center, Rotterdam, Netherlands. 3Hepatology and Gastroenterology, University Medical Center Groningen, Groningen, Netherlands. 4Hepatology and Gastroenterology, Leiden University Medical Center, Leiden, Netherlands

N. Thao T. Nguyen2, Jacfranz J. Guiteau2, Ronald T. Cotton2, Theresa R. Harring2, Ismael A. Salas de Armas2, Christine O’Mahony1, John A. Goss1 1Abdominal Transplantation & Hepatobiliary Surgery, Baylor College of Medicine, Houston, TX, USA. 2Michael E. DeBakey Department of General Surgery, Baylor College of Medicine, Houston, TX, USA

#634 PREVALENCE OF THROMBOPHILIA AMONGST LIVING RELATED LIVER DONORS- A UK PERSPECTIVE P. T. Cherian, Supriyo Ghatak, Robert P. Sutcliffe, Roopen Arya, Nigel Heaton, Mohamed Rela Institute of Liver Studies, Kings College Hospital, London, United Kingdom

#635 EFFECT OF REMOTE ISCHEMIC PRECONDITIONING ON LIVER INJURY IN PATIENTS UNDERGOING HEPATECTOMY FOR COLO-RECTAL METASTASIS A SINGLE CENTER RANDOMISED CONTROLLED TRIAL Sanjeev Kanoria, Naimish N. Mehta, Alexander Seifalian, Dinesh Sharma, Brian Davidson Liver Transplantation and HPB Surgery, Royal Free Hospital and Medical School, London, United Kingdom

#636 LIVER MOBILIZATION DURING LIVER RESECTION INDUCES IMMEDIATE AND PROFOUND HEPATOCELLULAR DAMAGE IN HUMANS Maartje A. van den Broek1, Johanne G. Bloemen1, Marcel C. van de Poll1, Marc H. Bemelmans1, Ronald M. van Dam1, Cees H. Dejong1, Steven W. Olde Damink1,2 1Surgery, Maastricht University Medical Centre, Maastricht, Netherlands. 2Surgery, University College London Hospital, London, United Kingdom

#637 LAPAROSCOPIC CHOLECYSTECTOMY IN THE CIRRHOTIC PATIENT Callisia N. Clarke, Ralph C. Quillin, Jiang Wang, Dong Sik Kim, Michael Edwards, E. Steve Woodle, Steven M. Rudich, Alex B. Lentsch, Amit D. Tevar Department of Surgery, University of Cincinnati, Cincinnati, OH, USA


Julio M. Veloso, Vitor M. Duarte, Estela Monteiro, Eduardo Barroso Liver Transplant Unit, Hospital Curry Cabral, Lisbon, Portugal

157A

158A

POSTER SESSIONS

Poster Session 2 Sunday, November 1 POSTER VIEWING: 8:00 AM - 5:30 PM Hynes: Exhibit Hall C

#642

Presenters in attendance: 1:00 - 2:30 PM

Claudia Von Montfort1,2, Núria Matias1,2, Juan Caballeria1, Carmen Garcia-Ruiz1,2, Jose C. Fernandez-Checa1,2 1Liver Unit, Hospital Clinic, CIBEREHD, IDIBAPS, Barcelona, Spain. 2IIBB-CSIC, Barcelona, Spain

Those posters identified as AASLD Presidential Poster of Distinction by a ribbon icon have received review scores that place them within the top 10 percent of all posters. We encourage you to make them a priority as you visit the poster sessions.

Alcohol-Related Liver Disease #638 IN-VITRO STEROID RESISTANCE IN SEVERE ALCOHOLIC HEPATITIS PREDICTS TREATMENT RESPONSE AND OUTCOME Alexandra J. di Mambro1,2, Richard Parker2, Anne McCune2, Fiona H. Gordon2, Colin M. Dayan1,2, Peter Collins2,1 1University of Bristol, Bristol, United Kingdom. 2Hepatology, Bristol Royal Infirmary, Bristol, United Kingdom

#639 SERUM ADIPONECTIN INCREASES WITH THE PROGRESSION OF ALCOHOLIC LIVER DISEASE Joo Hyun Sohn, Tae Yeob Kim, Chang Soo Eun, Yong Cheol Jeon, Dong Soo Han Hanyang University Guri Hospital, Guri, Korea, South

#640 URINARY ETHYL GLUCURONIDE AS NOVEL SCREENING TOOL IN PATIENTS PRE AND POST LIVER TRANSPLANTATION IMPROVES DETECTION OF ALCOHOL CONSUMPTION Katharina Staufer1, Hilke Andresen2, Niels Tobias3, Bjoern Nashan1, Martina Sterneck1 1Hepatobiliary and Transplant Surgery, University Clinic of Hamburg, Hamburg, Germany. 2Forensic Medicine, University Clinic of Hamburg, Hamburg, Germany. 3Pharmacology, Klinikum Bremen Mitte, Bremen, Germany S U N D AY NOVEMBER 1


#641 BETAINE PREVENTS THE ACCUMULATION OF ATYPICAL ISOASPARTATE PROTEIN DAMAGE IN LIVERS OF ETHANOL-FED RATS Wayne G. Carter1, Dean J. Tuma2, Kusum K. Kharbanda3 Sciences, University of Nottingham, Nottingham, United Kingdom. 2Department of Internal Medicine, University of Nebraska Medical Centre, Omaha, NE, USA. 3Liver Study Unit, Department of Veterans Affairs Medical Centre, Omaha, NE, USA 1Biomedical


ACETALDEHYDE ENHANCES THE EXPRESSION OF THE MITOCHONDRIAL CHOLESTEROL TRANSPORTING POLYPEPTIDE STAR

#643 HIGH INTRINSIC AEROBIC CAPACITY DOES NOT PROTECT AGAINST HEPATIC STEATOSIS FROM CHRONIC ETHANOL INTAKE Nicholas M. Szary1,2, Grace Uptergrove1,2, R. S. Rector1,2, Suzanne Ridenhour1,2, John P. Thyfault1,3, Steven L. Britton5, Lauren G. Koch5, Matthew L. Bechtold1, Shivendra D. Shukla4, Jamal A. Ibdah1,2 1Gastroenterology, University of Missouri School of Medicine, Columbia, MO, USA. 2HSTMVA Hospital, Columbia, MO, USA. 3Nutrition and Exercise Physiology, University of Missouri, Dublin, Ireland. 4Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, USA. 5Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA

#644 WIF-B CELLS AS A MODEL TO STUDY ETHANOL EFFECTS ON LIPID DROPLET TRAFFICKING Carol A. Casey1, Kusum K. Kharbanda1, Serene M. Lee1, Jacy L. Kubik1, Mark A. McNiven2,3, Benita L. McVicker1 1Internal Medicine, University of Nebraska Medical Center & VAMC, Omaha, NE, USA. 2Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA. 3Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA

#645 IDENTIFICATION OF FN14, A TNF RECEPTOR SUPERFAMILY MEMBER, AS A THERAPEUTIC TARGET IN PATIENTS WITH ALCOHOLIC HEPATITIS Marlene Dominguez, Juan José Lozano, Aurora Loaeza del Castillo, Rosa Miquel, Jordi Colmenero, Montserrat Moreno, Juan Carlos Garcia-Pagán, Vicente Arroyo, Pere Gines, Juan Caballeria, Ramon Bataller Liver Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain

#646 PKCε CONTRIBUTES TO CHRONIC ETHANOLINDUCED STEATOSIS BUT NOT TO INFLAMMATION AND NECROSIS; BEYOND THE TALE OF TWO-HITS? J. Phillip Kaiser1,2, Luping Guo1,2, Juliane I. Beier1,2, Jun Zhang3, Jean Francois Lesgards4, J. David Hoetker4, Brett P. Monia5, Aruni Bhatnagar1,4, Gavin E. Arteel1,2 1Department of Pharmacology & Toxicology, University of Louisville Health Sciences Center, Louisville, KY, USA. 2University of Louisville Alcohol Research Center, University of Louisville Health Sciences Center, Louisville, KY, USA. 3Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 4Department of Medicine, Division of Cardiology, University of Louisville Health Sciences Center, Louisville, KY, USA. 5Isis Pharmaceuticals Inc., Carlsbad, CA, USA


POSTER SESSIONS

159A

#647

#653

ALCOHOL-INDUCED OXIDATIVE STRESS IS ATTENUATED BY PROTEASOME INHIBITOR

CELL CYCLE ARREST IN ALCOHOL-RELATED LIVER DISEASE AND ASSOCIATION OF P21 EXPRESSION WITH MORTALITY

Joan Oliva, Samuel W. French, Fawzia Bardag-Gorce LABioMed at Harbor-UCLA, Torrance, CA, USA

#648 ARGININOSUCCINATE SYNTHASE AND ALCOHOLIC LIVER DISEASE Tung Ming Leung1, YongKe Lu1, Stephen C. Ward2, Natalia Nieto1 Diseases, Mount Sinai School of Medicine, New York, NY, USA. 2Pathology, Mount Sinai School of Medicine, New York, NY, USA

1Medicine/Liver

#649 COMPARISON OF VARIOUS SCORING SYSTEMS FOR PREDICTING SHORT-TERM MORTALITY IN PATIENTS WITH ALCOHOLIC HEPATITIS Joo Hyun Sohn, Tae Teob Kim, Chang Soo Eun, Yong Cheol Jeon, Dong Soo Han Hanyang University Guri Hospital, Guri, Korea, South

#650 A NOVEL SLOW RELEASE FORMULATION OF METADOXINE IMPROVES MOTOR AND COGNITIVE FUNCTION, DECREASES CRAVING AFTER ALCOHOL INGESTION IN HEALTHY VOLUNTEERS: RESULTS OF A PHASE I CLINICAL TRIAL Gadi Lalazar1, Tomer Adar1, Yuval Horwich1, Orli Kampf-Sherf2, Eytan Bachar2, Meir Mizrahi1, Ehud Zigmond1, Nilla Hemed1, Yaron Ilan1 1Liver Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel. 2Department of Psychiatry, Hadassah Hebrew University Medical Center, Jerusalem, Israel

#651 EVALUATION AND MANAGEMENT OF ALCOHOLIC HEPATITIS: A SURVEY OF CURRENT PRACTICES

#652 WHITE CELL COUNT AND PLATELET COUNT ASSOCIATE WITH HISTOLOGICAL ALCOHOLIC HEPATITIS IN JAUNDICED HARMFUL DRINKERS Timothy Hardy1, Stuart Kendrick1, Christopher Wells1, Mark Hudson1, Christopher P. Day2,1, Stephen Stewart1 1Liver Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom. 2Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom

#654 IMPACT OF HEPATITIS C ON THE OUTCOME AND SEVERITY OF ACUTE ALCOHOLIC HEPATITIS Ashwani K. Singal1, Sashidhar V. Sagi2, Steven A. Weinman3, Ned Snyder1 1Gastroenterology, University of Texas medical Branch, Galveston, TX, USA. 2Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA. 3Internal Medicine, University of Kansas, Kansas, KS, USA

#655 SERUM ADIPONECTIN LEVEL IN NON-ALCOHOLIC FATTY LIVER DISEASE Park Jae Jung Department of Internal Medicine, Ewha Medical Research Institute,, Seoul, Korea, South

#656 DECREASED EXPRESSION OF RAB PROTEINS IN RAT HEPATOCYTES AFTER CHRONIC ETHANOL CONSUMPTION; ROLE IN ALTERED LIPID DROPLET TRAFFICKING AND ACCUMULATION Serene M. Lee1, Carol A. Casey1, Benita L. McVicker1, Gina L. Razidlo2,3, Barbara Schroeder2,3, Mark A. McNiven2,3 1Internal Medicine, University of Nebraska Medical Center & VAMC, Omaha, NE, USA. 2Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA. 3Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN, USA

#657 MELD SCORE GREATER THAN 12 IDENTIFY NON SEVERE ALCOHOLIC HEPATITIS PATIENTS WITH A POOR LONG-TERM SURVIVAL Delphine Degré1,2, Arnaud Lemmers1,2, Thierry Gustot1,2, Raphael Marechal1,2, Sylvie Evrard1, Michael Adler1, Olivier Le Moine1,2, Jacques Devière1,2, Christophe Moreno1,2 1Departement of Gastroenterology, hepatopancreatology and digestive oncology, Erasme Hospital, Brussels, Belgium. 2Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium

S U N D AY NOVEMBER 1

Joseph Ahn1, Timothy R. Morgan2, Stanley M. Cohen1 1Rush University, Chicago, IL, USA. 2VA Long Beach, Long Beach, CA, USA

Aloysious Aravinthan1, William Gelson1, Matthew Hoare1, Giada Pietrosi1, Aileen Marshall1, Arun N. Shankar1, Susan Davies2, Michael E. Allison1, Nicholas Coleman3, Graeme J. Alexander1 1Medicine, University of Cambridge, Cambridge, United Kingdom. 2Pathology, University of Cambridge, Cambridge, United Kingdom. 3MRC Cancer Cell unit, Hutchison/Medical Research Council, Cambridge, United Kingdom

160A

POSTER SESSIONS

#658

#663

ALCOHOLIC FOAMY DEGENERATION AND ELEVATED GAMMA GLUTAMYL TRANSFERASE

GP73 REGULATES HEPATOMA CELL MEMBRANE CHARACTERISTICS

Jatinder P. Ahluwalia1, Frank A. Mitros2, Marie H. Hanigan3, Michael D. Voigt4 1Medicine, Div. of Gastroenterology and Hepatology, Southern Illinois University School of Medicine, Springfield, IL, USA. 2Pathology, Univ. of Iowa, Iowa City, IA, USA. 3Cancer Biology Program, Univ. of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 4Internal Medicine, Univ. of Iowa, Iowa City, IA, USA

Lorinda M. Wright1,2, Claus J. Fimmel1,2 of Gastroenterology, Hepatology and Nutrition, Loyola University Medical Center, Maywood, IL, USA. 2Research (151), Edward Hines VA Hospital, Hines, IL, USA

Basic Cell Biology #659 INTRACELLULAR LOCALIZATION OF RADIXIN AND NHERF-1 ON REGULATION OF MRP-2 TRAFFICKING IN HEPATOCYTES Jo Suda1, Lixin Zhu2, Serhan Karvar1 & Liver Diseases, University of Southern California, Los Angeles, CA, USA. 2Digestive Diseases and Nutrition Center, University at Buffalo, SUNY, Buffalo, NY, USA

1Gastrointestinal

#660 HYPOXIA-INDUCED DES-γ-CARBOXY PROTHROMBIN PRODUCTION IN HEPATOCELLULAR CARCINOMA Kazumoto Murata Center for Community Medicine, Jichi Medical University, Shimotsuke, Japan

#661 THROMBIN INHIBITION WITH HIRUDIN IMPAIRS LIVER REGENERATION AFTER PARTIAL HEPATECTOMY IN MICE



1Division

#664 SERINE PHOSPHORYLATION OF OATP1A1 REGULATES ITS TRAFFICKING TO THE PLASMA MEMBRANE AND INTERACTION WITH PDZK1 Jo H. Choi2,3, Pijun Wang1,3, Allan W. Wolkoff1,2 of Hepatology, Albert Einstein College of Medicine, Bronx, NY, USA. 2Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY, USA. 3Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA

1Division

#665 PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) CONTRIBUTES TO LIVER REGENERATION AFTER PARTIAL HEPATECTOMY: ANOTHER ‘TWO-EDGED SWORD?’ Luping Guo1,2, Juliane I. Beier1,2, Hai Zhong1,2, Veronica L. Massey1,2, Xiang Ding1,2, Gavin E. Arteel1,2 1Department of Pharmacology/Toxicology, University of Louisville, Louisville, KY, USA. 2University of Louisville Alcochol Research Center, University of Louisville, Louisville, KY, USA

#666 HEPCIDIN PRODUCTION IS UP-REGULATED BY NON HEPATIC CELL-DERIVED HUMORAL FACTORS AFTER IRON LOADING

Juliane I. Beier1,2, James P. Luyendyk3, Hai Zhong1,2, Gavin E. Arteel1,2 1Pharmacology and Toxicology, University of Louisville Health Science Center, Louisville, KY, USA. 2University of Louisville Alcohol Research Center, University of Louisville, Louisville, KY, USA. 3Pharmacology, Toxicology and Therapeutics, University of of Kansas Medical Center, Kansas City, KS, USA

Yusuke Sasaki1, Yasushi Shimonaka1, Hirotaka Kanada1, Yoshiyuki Moriguchi1, Katsuya Ikuta2, Katsunori Sasaki3, Yutaka Kohgo2 1Product Research Dept., CHUGAI PHARMACEUTICAL CO., LTD., Kamakura, Kanagawa, Japan. 2Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical College, Asahikawa, Hokkaido, Japan. 3Department of Gastrointestinal Immunology and Regenerative Medicine, Asahikawa Medical College, Asahikawa, Hokkaido, Japan

#662

#667

HEPATIC ANTIOXIDATIVE PROTECTION ACTION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA (PPAR-α) AGONIST IS L-FABP DEPENDENT

REGULATORS OF BILE ACID TRANSPORT CAN BE DISTINGUISHED BY THEIR EFFECTS ON THE PLASMA MEMBRANE DISTRIBUTION OF THE BILE ACID TRANSPORTER, NTCP

Guqi Wang1, JIng Yan2, Jing Wang2, Yuewen Gong2,3, Herbert L. Bonkovsky1,5, Frank J. Burczynski2,4 1The Liver-Biliary-Pancreatic Center and the Liver, Digestive, and Metabolic Disorders Laboratory, Carolinas medical center, Charlotte, NC, USA. 2Faculty of Pharmacy, University of manitoba, Winnipeg, MB, Canada. 3Section of Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada. 4Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada. 5Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

John W. Murray, Amar J. Thosani, Pijun Wang, Allan W. Wolkoff Albert Einstein College of Medicine, Bronx, NY, USA


#668 MAL2 SELECTIVELY REGULATES POLYMERIC IGA RECEPTOR DELIVERY FROM THE GOLGI TO THE PLASMA MEMBRANE IN HEPATIC CELLS Julie G. In, Pamela L. Tuma Department of Biology, The Catholic University of America, Washington, DC, USA


POSTER SESSIONS

161A

#669

#674

TGF-BETA SIGNALING IS FUNCTIONAL, BUT ITS SENESCENCE RESPONSE IS DEFECTIVE IN POORLY DIFFERENTIATED HEPATOCELLULAR CARCINOMA CELL LINES

FXR ACETYLATION IN MODULATION OF BILE SALT EXPORT PUMP GENE EXPRESSION

Serif Senturk1, Mehmet Ozturk1,2 of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey. 2Centre de Recherche INSERM - UJF U823, Institut Albert Bonniot, Grenoble, France 1Department

#670 REGULATION OF MITOCHONDRIAL RAFT-LIKE DOMAINS BY CHOLESTEROL DURING TNF/FASMEDIATED HEPATOCELLULAR APOPTOSIS Anna Fernandez1, Valeria Manganelli2, Núria Matias1, Antonella Tinari3, Walter Malorni3, Carmen Garcia-Ruiz1, Mauricio Sorice2, Jose C. Fernandez-Checa1 1Liver Unit, Hospital Clinic, CIBEREHD, IDIBAPS, and IIBB-CSIC, Barcelona, Spain. 2Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. 3Department of Technology and Health, Istituto Superiore de Sanitá, Rome, Italy

#671 CYTOKINES INDUCE APOPTOSIS IN HEPATOCYTES THROUGH INOS/NO AND PUMA PATHWAY Qiang Du1,2, Xinglu Zhang1, Shuting Yang1,2, David A. Geller1,2 1Surgery, University of pittsburgh, Pittsburgh, PA, USA. 2T.E. Starzl Transplatation Institute, University of Pittsburgh, Pittsburgh, PA, USA

#672 MODULATION OF TRANSFORMING GROWTH FACTOR-β1-INDUCED SMAD PHOSPHORYLATION BY EXTRACELLULAR MATRIX RECEPTOR β1INTEGRIN LEADS TO EPITHELIAL-TOMESENCHYMAL TRANSITIONS OF HEPATOMA CELLS Iwata Ozaki1,2, Hiroshi Hamajima2, Shinji Iwane2, Jinghe Xia2, Yasunori Kawaguchi2, Yuichiro Eguchi2, Sachiko Matsuhashi2, Toshihiko Mizuta2 1Health Administration Center, Saga Medical School, Saga University, Saga, Japan. 2Department of Internal Medicine, Saga Medical School, Saga University, Saga, Japan

GENOME-WIDE PROFILING OF PXR REVEALS UNIQUE DNA BINDING PATTERNS AND COEXISTENCE OF DISTINCT EPIGENETIC SIGNATURES RESULTING IN TEMPORAL ACTIVATION OF DRUGPROCESSING GENES AND MIRNAS IN MOUSE LIVER Cui1,

Gunewardena2,

Klaassen1

Y. Sumedha S. Curtis D. 1Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA. 2Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, USA

#675 TRANSCRIPTIONAL MECHANISM OF MIR-206 EXPRESSION AND THE FUNCTION OF MIR-206 IN TUMOR PROGRESSION Li Wang Medicine, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA

#676 GLYCOSYLATION IS A KEY REGULATOR OF HEPATIC FIBROBLAST GROWTH FACTOR RECEPTOR 4 ACTIVITY Vassilis Triantis1, Eirikur Saeland2, Ronald P. Oude Elferink1, Peter L. Jansen1 1Liver Centre, Academic Medical Centre, Amsterdam, Netherlands. 2Department of Molecular Cell Biology and Immunology, VU University Medical Centre, Amsterdam, Netherlands

#677 TLR2 PROMOTES HEPATOCYTE AND CHOLANGIOCYTE APOPTOSIS VIA A P38DEPENDENT MECHANISM Deling Yin, Xiaoli Zhang, Nanchang Xie, Lin Chen, Rolf B. Fritz, Gene LeSage East Tennessee State University, Johnson City, TN, USA

#678 BILE ACIDS REGULATE BILE CANALICULAR FORMATION IN PRIMARY HEPATOCYTES Dong Fu, Yoshiyuki Wakabayashi, Jennifer Lippincott-Schwartz, Irwin M. Arias NICHD, National Institute of Health, Bethesda, MD, USA

#679 RETINOIC ACID REPRESSES CYP7A1 EXPRESSION IN HUMAN HEPATOCYTES AND HEPG2 CELLS VIA RXR AS WELL AS FXR DEPENDENT MECHANISMS Shi-Ying Cai, Hongwei He, Albert Mennone, James L. Boyer Yale University, New Haven, CT, USA

#680 REGULATION OF PEROXISOME PROLIFERATORACTIVATED RECEPTOR GAMMA COACTIVATOR 1α (PGC-1α) BY LYSINE SPECIFIC DEMETHYLASE1 (LSD1) - MEDIATED LYSINE DEMETHYLATION AND ITS IMPLICATIONS FOR FXR TRANSACTIVATION IN LIVER Natarajan Balasubramaniyan, Meena Ananthanarayanan, Martin Walsh, Frederick J. Suchy Department of Pediatrics, Mount Sinai School of Medicine, New York, NY, USA


#673

Sun An-Qiang, Natarajan Balasubramaniyan, Jaeyong Ahn, Frederick J. Suchy Pediatrics, Mt Sinai School of Med, New York, NY, USA

162A

POSTER SESSIONS

#681

#688

BETA-ARRESTIN 2 IS REQUIRED FOR HEPATIC P-38 DEPENDENT APOPTOSIS AND STELLATE CELL ACTIVATION

CHEMOTHERAPY-INDUCED APOPTOSIS IN PANCREATIC CANCER INVOLVES THE P53 FAMILY AND IS MEDIATED VIA THE EXTRINSIC AND THE INTRINSIC PATHWAY

Deling Yin, Nanchang Xie, Xiaoli Zhang, Yi Zhang, Hui Li, Rolf B. Fritz, Gene LeSage East Tennessee State University, Johnson City, TN, USA

#682 PHARMACOLOGICAL BLOCKADE OF 5HT 2B RECEPTOR STIMULATES LIVER GROWTH Murphy1,

#683 INTERNALIZATION AND DEGRADATION OF THE EGF RECEPTOR IN HEPATOCYTES IS REGULATED BY A NOVEL DYNAMIN 2, CIN85, RAB7 COMPLEX THAT MEDIATES LATE ENDOSOMAL DYNAMICS Barbara Schroeder1, Mark A. McNiven1,2 for Basic Research in Digestive Diseases, Mayo Clinic, Rochester, MN, USA. 2Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA 1Center

#684 HINT1 DELETION IMPAIRS LIVER REGENERATION Hora1,

Kristina Gebhardt, Eva-Maria Melcher, Andreas F. Koch, Katja Lorenz, Wolfgang Stremmel, Martina Müller Innere Med. IV, Universität Heidelberg, Heidelberg, Germany

#689 WITHDRAWN

Ebrahimkhani2,

Lindsay B. Mohammad R Luc Maroteaux3, Derek A. Mann1, Fiona Oakley1 1Liver Group, Newcastle University, Newcastle Upon Tyne, United Kingdom. 2Seattle Biomedical Research Institute, SBRI, Seattle, WA, USA. 3INSERM U839, Institut du Fer a Moulin, Paris, France

Maurhofer1,

Ledermann1,

Caroline Olivier Monika Gisele Ferrand2, Jean-Francois Dufour1, Juliette Martin1 1Institute of Clinical Pharmacology, University of Bern, Bern, Switzerland. 2Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland

#685 CHRONIC ALCOHOL CONSUMPTION IMPAIRS STAT3 AND STAT5B NUCLEAR TRANSLOCATION IN HEPATOCYTES David Fernandez1, Dean J. Tuma2, Pamela L. Tuma1 The Catholic University of America, Washington, DC, USA. 2Dept. of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA

1Biology,



#686 K VITAMINS ENHANCE SORAFENIB ANTIPROLIFERATIVE EFFECTS ON HCC CELLS AND INDUCE APOPTOSIS Brian Carr Medical Oncology, Kimmel Cancer Center, Philadelphia, PA, USA

#687 EARLY INDUCTION OF MATRIX METALLOPROTEINASE-9 (MMP-9) IN RESPONSE TO PARTIAL HEPATECTOMY IS IMPAIRED IN THE ENOS KNOCKOUT MICE Yu Mei, Bryan Tackett, Sundararajah Thevananther Pediatrics/Gastroenterology, Hepatology & Nutrition, Texas Children’s Liver Center, Baylor College of Medicine, Houston, TX, USA Denotes AASLD Presidential Poster of Distinction

#690 IDENTIFICATION OF T-CELL FACTOR-4 SPLICING VARIANTS THAT INFLUENCE THE MALIGNANT CHARACTERISTICS OF HEPATOCELLULAR CARCINOMA Orkhontuya Tsedensodnom1,2, Hironori Koga1, Jack R. Wands1, Miran Kim1 1Liver Research Center, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA. 2Department of Molecular biology, Cell Biology and Biochemistry, Brown University, Providence, RI, USA

#691 TISSUE-SPECIFIC FXR-DNA BINDING: GENOMEWIDE LIVER AND INTESTINE BINDING ANALYSIS BY CHIP-SEQ Ann M. Thomas1, Steven Hart1, Xiao-bo Zhong1, Bo Kong1, Jianwen Fang2, Grace L. Guo1 1Pharmacology, Univeristy of Kansas Med Cntr, Kansas City, KS, USA. 2University of Kansas, Lawrence, KS, USA

#692 ANTIPROLIFERATIVE AND PRO-APOPTOTIC EFFECTS OF THE KLF6 SV2 VARIANT IN HUMAN HEPATIC CELLS Naïma Hanoun1,2, Christophe Bureau3,1, Janick Selves4, Louis Buscail2,5, Pierre Cordelier1,2, Jérôme Torrisani1,2 1Inserm U858, Toulouse, France. 2Université de Toulouse, toulouse, France. 3Service d’Hépato-Gastroentérologie, Fédération Digestive de Purpan, CHU Toulouse, toulouse, France. 4Inserm, U563, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, toulouse, France. 5CHU de Toulouse; Service de Gastroentérologie, toulouse, France

#693 INTRACELLULAR SIGNALING PATHWAYS ACTIVATED BY FAS-INDUCED APOPTOSIS IN HEPG2 CELLS PROVIDE POTENTIAL THERAPEUTIC TARGETS FOR THE TREATMENT HEPATOCELLULAR CARCINOMA Francisco Castaneda1,2, Karl J. Oldhafer2 1Molecular Physiology, Max Planck Institute, Dortmund, Germany. 2General and Visceral Surgery, Celle General Hospital, Celle, Germany


POSTER SESSIONS

#694 EFFECT OF CAMP ON AQUAPORIN 8 AND 9 EXPRESSION AND LOCALIZATION IN HEPATOCELLULAR CARCINOMA (HCC) Mattocks2,1,

Padma1,

Sokolov1,

Matthew A. Srikanth Eugene David A. Iannitti1, Iain H. McKillop1,2 1Surgery, Carolinas Medical Center, Charlotte, NC, USA. 2Biology, UNC at Charlotte, Charlotte, NC, USA

#695 PROLIFERATIVE ROLE OF LKB1 IN THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA ASSOCIATED TO NONALCOHOLIC STEATOHEPATITIS Nuria Martínez1, Marta Varela-Rey1, David Fernandez1, Mercedes Vazquez1, Nieves Embade1, Ashwin Woodhoo1, Luis EspinosaHevia5, Luis A. Parada5, Manuel S. Rodriguez4, Shelly C. Lu2,3, Jose M. Mato1, MariaLuz Martinez1 1Metabolomics Unit, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberedh), Derio, Spain. 2Division of Gastrointestinal and Liver Diseases, USC Research Center for Liver Diseases, Southern California, CA, USA. 3Research Center for Alcoholic Liver and Pancreatic Diseases and Cirrhosis, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. 4Proteomics Unit, CIC BioGune, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Derio, Spain. 5Cytogenomics Unit, CIC BioGune, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), Derio, Spain

#696 A NOVEL FUNCTIONAL ROLE OF RETINOIDS IN THE PREVENTION OF IRON-INDUCED OXIDATIVE STRESS IN THE LIVER Goshi Shiota, Hiroyuki Tsuchiya, Tomohiko Sakabe, Yoshiko Hoshikawa Tottori University, Yonago, Japan

#697

Dirk Graf, Katrin Haselow, Ivo P. Münks, Johannes G. Bode, Dieter Haussinger Gastroenterology, Hepatology and Infectiology, Heinrich-Heine University, Düsseldorf, Germany

Biliary Atresia, Viral and Autoimmune Hepatitis #698 A PROSPECTIVE MULTI-CENTERED INVESTIGATION OF VITAMIN SUPPLEMENTATION IN INFANTS WITH BILIARY ATRESIA: INTERIM ANALYSIS FROM THE BILIARY ATRESIA RESEARCH CONSORTIUM (BARC) Benjamin L. Shneider1, Robert B. Abel2, Trivellore Raghumathan2, John C. Magee2, Jorge A. Bezerra3, Barbara Haber4, Saul J. Karpen5, Philip Rosenthal6, Kathleen B. Schwarz7, Ross W. Shepherd8, Frederick J. Suchy12, Peter F. Whitington9, Patricia R. Robuck10, Ronald J. Sokol11 1Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital Pittsburgh, Pittsburgh, PA, USA. 2University of Michigan, Ann Arbor, MI, USA. 3Children’s Hospital Medical Center, Cincinnati, OH, USA. 4Children’s Hospital of Philadelphia, Philadelphia, PA, USA. 5Texas Children’s Hospital, Houston, TX, USA. 6University of California San Francisco, San Francisco, CA, USA. 7Johns Hopkins University, Baltimore, MD, USA. 8Washington University, St. Louis, MO, USA. 9Children’s Memorial Hospital, Chicago, IL, USA. 10National Institutes of Health, Bethesda, MD, USA. 11Children’s Hospital Denver, Denver, CO, USA. 12Mount Sinai School of Medicine, New York, NY, USA

#699 A MULTICENTER CROSS SECTIONAL ASSESSMENT OF QUALITY OF LIFE IN BILIARY ATRESIA PATIENTS AGED 2-25 YEARS Shikha S. Sundaram1, Emily M. Fredericks2, Binita M. Kamath3, Barbara Haber3, Trivellore Raghumathan2, John C. Magee2, Jorge A. Bezerra6, Saul J. Karpen10, Nanda Kerkar7, Philip Rosenthal11, Kathleen B. Schwarz8, Ross W. Shepherd12, Benjamin L. Shneider9, Peter F. Whitington5, Patricia R. Robuck4, Ronald J. Sokol1 1Pediatrics, The Children’s Hospital, University of Colorado Denver School of Medicine, Aurora, CO, USA. 2University of Michigan Medical School, Ann Arbor, MI, USA. 3The Children’s Hospital of Philadelphia, Philadelphia, PA, USA. 4NIDDK, Bethesda, MD, USA. 5Children’s Memorial Hospital, Chicago, IL, USA. 6Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. 7Pediatrics, The Mount Sinai Medical Center, New York, NY, USA. 8Pediatrics, Johns Hopkins University, Baltimore, MD, USA. 9Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA. 10Texas Children’s Liver Center, Houston, TX, USA. 11Pediatrics, University of California San Francisco, San Francisco, CA, USA. 12Pediatrics, Washington University, St. Louis, MO, USA

#700 BEYOND THE BILIRUBIN – EARLY PROGNOSTIC FACTORS FOLLOWING KASAI PORTOENTEROSTOMY IN INFANTS WITH BILIARY ATRESIA Scott Nightingale1, Michael O. Stormon2, Edward V. O’Loughlin2, Albert Shun3, Hugh C. Martin3, Erik La Hei3, Annie Fecteau4, Constance O’Connor1, Simon C. Ling1, Eve A. Roberts1, Vicky L. Ng1 1GI, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, ON, Canada. 2Gastroenterology, The Children’s Hospital at Westmead, Sydney, NSW, Australia. 3Surgery, The Children’s Hospital at Westmead, Sydney, NSW, Australia. 4Surgery, The Hospital for Sick Children, Toronto, ON, Canada


MODULATION OF INTERFERON-α-INDUCED SIGNALLING AND EXPRESSION OF ANTIVIRAL PROTEINS BY HYPEROSMOLARITY AND HYDROPHOBIC BILE ACIDS

163A

164A

POSTER SESSIONS

#701

#707

VIROLOGICAL RESPONSE TO TREATMENT WITH PEGYLATED INTERFERON ALFA-2A OF CHRONIC HEPATITIS B IN CHILDREN

LONG-TERM MANAGEMENT AND PROGNOSIS OF CHILDREN WITH AUTOIMMUNE HEPATITIS: A SINGLE CENTER EXPERIENCE

Malgorzata Pawlowska, Waldemar Halota Dep.of Infectious Diseases&Hepatology, Collegium Medicum N.Copernicus University, Bydgoszcz, Poland

Ronen Arnon1,2, Sanobar Parkar2, Rachel A. Annunziato3, Tamir A. Miloh1,2, Arnond Sakworawich3, Fiona H. Henderling2, Frederick J. Suchy1, Nanda Kerkar1,2 1Pediatrics, Mount Sinai Medical Center, NY, NY, USA. 2RMTI, Mount Sinai Medical Center, NY, NY, USA. 3Fordham University, NY, NY, USA

#702 SHARP DECREASE IN HCV-SPECIFIC INTERFERON-γ AND IL-10 PRODUCTION DURING ANTIVIRAL THERAPY WITH PEGYLATED INTERFERON AND RIBAVIRIN PREDICT SUSTAINED VIROLOGICAL RESPONSE IN CHILDREN WITH CHRONIC HEPATITIS C Ivana Carey, Andrea Mendes, Sanjay Bansal, Pushpa Subramaniam, Maria Serena Longhi, Dita Cebecauerova, Giorgina MieliVergani, Diego Vergani Institute of Liver Studies, Kings College London School of Medicine at King’s College Hospital, London, United Kingdom

#703 THE LONG-TERM EFFECT OF MATERNAL HBEAG ON THE DELAYED SPONTANEOUS HBEAG SEROCONVERSION IN OFFSPRINGS WITH CHRONIC HEPATITIS B VIRUS INFECTION Yu-Ru Tseng, Mei-Hwei Chang, Jia-Feng Wu, Yen-Hsuan Ni, HueyLing Chen, Hong-Yuan Hsu Hong-Yuan Hsu Pediatrics, National Taiwan University Hospital, Taipei, Taiwan

#704 CURE FOR PERINATALLY ACQUIRED HEPATITIS B IN ASIAN CHILDREN: IS IT AN ACHIEVABLE TARGET WITH COMBO THERAPY WITH LAMIVUDINE/INTERFERON? Ujjal Poddar Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

#705 LONG TERM OUTCOME OF CHRONICALLY HBV INFECTED CHILDREN – A 20-YEARS OBSERVATION PERIOD S U N D AY NOVEMBER 1


#708 CHANGES IN BODY MASS INDEX AND BODY COMPOSITION IN CHILDREN TREATED WITH PEGINTERFERON FOR CHRONIC HEPATITIS C IN THE PEDS-C TRIAL Maureen M. Jonas1, William F. Balistreri2, Regino P. Gonzalez-Peralta3, Barbara Haber4, Parvathi Mohan5, Jean P. Molleston6, Karen F. Murray7, Michael Narkewicz8, Philip Rosenthal9, Kathleen B. Schwarz10, Lesley J. Smith11, Bruce Barton12, John A. Shepherd13, Patricia R. Robuck14, Christopher Duggan1 1Gastroenterology, Hepatology & Nutrition, Children’s Hospital Boston, Boston, MA, USA. 2Pediatric Gastroenterology, Hepatology & Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. 3Pediatric Gastroenterology, University of Florida, Gainesville, FL, USA. 4Pediatric Gastroenterology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA. 5Gastroenterology, Hepatology & Nutrition, Children’s National Medical Center, Washington, DC, USA. 6Pediatric Gastroenterology, Indiana University, Indiannapolis, IN, USA. 7Pediatric Gastroenterology, Hepatology & Nutrition, Seattle Children’s Hospital, Seattle, WA, USA. 8Pediatric Gastroenterology, University of Colorado, Denver, CO, USA. 9Pediatrics, University of California, San Francisco, CA, USA. 10Pediatrics, Johns Hopkins University, Baltimore, MD, USA. 11Pediatrics, University of Miami, Miami, FL, USA. 12Maryland Medical Research Institute, Baltimore, MD, USA. 13Radiology and Bioimaging, University of California, San Francisco, CA, USA. 14NIDDK, Bethesda, MD, USA

Cellular Immunobiology, Preservation and Cell Transplantation #709

Stephan Gehring, Thorsten Gumbrich, Fred Zepp, Ulrike Kullmer Kinderklinik, Universitätsmedizin der Johannes Gutenberg-Universität, Mainz, Germany

HYPOTHERMIC MACHINE PERFUSION REDUCES MOLECULAR DAMAGE CASCADES IN HUMAN LIVER TRANSPLANTATION

#706

Scot Henry1, Ben Arrington1, Sean W. Chen2, H. T. Lee2, Jean C. Emond1, James V. Guarrera1 1Surgery, Columbia University Medical Center, New York, NY, USA. 2Anesthesiology, Columbia University Medical Center, New York, NY, USA

GLUTATHIONINE S-TRANSFERASE THETA 1 (GSTT1) MISMATCH DOES NOT ACCOUNT FOR POST LIVER TRANSPLANT DE NOVO AUTOIMMUNE HEPATITIS Tassos Grammatikopoulos1,2, Maria G. Mytilinaiou2, Dimitrios P. Bogdanos2, Richard J. Thompson1,2, Nedim Hadzic1,2, Giorgina Mieli-Vergani1,2, Diego Vergani2 1Paediatric Liver GI & Nutrition Centre, King’s College London School of Medicine at King’s College Hospital, London, United Kingdom. 2Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, London, United Kingdom



POSTER SESSIONS

#710 DOWNREGULATION OF T-LYMPHOCYTE ACTIVATION AND CO-ACTIVATION MARKERS IN HEPATITIS C VIRUS (HCV) INFECTION BEFORE AND AFTER LIVER TRANSPLANTION Cecilia Ortiz3,1, Marina Berenguer2,1, Raquel Canada3,1, Amparo Sempere4, Blas Risalde2,1, Victoria Aguilera2,1, Elena Carmona3,1, Martin Prieto2,1, F. Xavier Lopez-Labrador5,6 1Ciberehd, Health Institute Carlos III, Valencia, Spain. 2Hepatology Department, Hospital la Fe, Valencia, Spain. 3Experimental Immunity Unit, Hospital la Fe, Valencia, Spain. 4Haematology Department, Hospital la Fe, Valencia, Spain. 5CSISP, Dir. Gral. Public Health, Generalitat Valenciana and Cavanilles Institute, University of Valencia, Valencia, Spain. 6CIBER-ESP, Health Institute Carlos III, Valencia, Spain

#711 ROLE OF INDUCIBLE NITRIC OXIDE SYNTHASE AND C-JUN N-TERMINAL KINASE IN MITOCHONDRIAL DYSFUNCTION AND GRAFT INJURY AFTER TRANSPLANTATION OF RAT FATTY LIVERS Hasibur Rehman, Venkat K. Ramshesh, Tom Theruvath, John J. Lemasters, Zhi Zhong Medical University of South Carolina, Charleston, SC, USA

#712 ENGINEERING OF LIVER GRAFTS WITH DE/RECELLULARIZED NATIVE LIVER MATRICES FOR AUXILIARY TRANSPLANTATION Hiroshi Yagi, Alejandro Soto-Gutierrez, Basak Uygun, Maria-Louisa Izamis, Ronald G. Tompkins, Martin L. Yarmush, Korkut Uygun Surgery, Center for Engineering in Medicine, Massachusetts General Hospital, Shriners Hospitals for Children and Harvard Medical School, Boston, MA, USA

#713 THE EFFECT OF CARBON MONOXIDE ON LIVER REGENERATION AFTER HEPATECTOMY Kaori Kuramitsu, Barbara Wegiel, Eva Csizmadia, Leo E. Otterbein, Douglas W. Hanto Surgery, Division of Transplant, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA

REGULATION OF COAGULATION FACTORS DURING LIVER REGENERATION AFTER HEPATECTOMY: MECHANISM OF FACTOR VIII ELEVATION IN PLASMA Kazuo Ohashi1, Kohei Tatsumi1, Yoshihiko Sakurai2, Kenichi Ogiwara2, Akira Yoshioka2, Midori Shima2, Teruo Okano1 1Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University, Tokyo, Japan. 2Department of Pediatrics, Nara Medical University, Kashihara, Japan

#715 AUTOFLUORESCENCE: MODELLING A TOOL FOR ASSESSMENT OF STEATOTIC MARGINAL GRAFTS IN LIVER TRANSPLANTATION Quentin M. Anstee1, Nguyen Thanh Hoa2, Vincent Sauvage2, Danilo Concas1, Adam P. Levene3, Howard Thomas1, Mark R. Thursz1, Daniel Elson2, Robert Goldin3 1Academic Medicine, Imperial College London, London, United Kingdom. 2Department of Biosurgery & Surgical Technology and Institute of Biomedical Engineering, Imperial College London, London, United Kingdom. 3Department of Histopathology, Imperial College London, London, United Kingdom

#716 HEPATIC ISCHEMIA INDUCED IMMEDIATE OXIDATIVE STRESS AFTER REPERFUSION AND DETERMINED THE SEVERITY OF THE REPERFUSION-INDUCED DAMAGE. – IN VIVO DYNAMIC ANALYSIS OF LIVER OXIDATIVE STRESS AND DAMAGE Michitaka Ozaki1, Sanae Haga1,5, S. James Remington2, Naoki Morita4, Takeaki Ozawa3 1Dept of Molecular Surgery, Hokkaido Univ SOM, Sapporo, Japan. 2Department of Physics, University of Oregon, Eugene, OR, USA. 3Department of Chemistry, The University of Tokyo, Tokyo, Japan. 4Research Institute of Genome-based Biofactory, National Institute of Advanced Industrial Science and Technology (AIST), Sapporo, Japan. 5The Japan Society for the Promotion of Science (JSPS), Tokyo, Japan

#717 HEMOGLOBIN-GLUTAMER 200 (OXYGLOBIN®) PRECONDITIONING OF THE LIVER REDUCES COLD ISCHEMIA/REPERFUSION INJURY Stefan A. Topp1, Arne Macher1, Marius Vaassen1, Katja Schmahl2, Anna Katharina Balzer1, Stephan E. Baldus2, Thomas Hohlfeld3, Andreas Krieg1, Nikolas H. Stoecklein1, Wolfram T. Knoefel1 1Dept. of General, Visceral and Pediatric Surgery, University Hospital Düsseldorf, Düsseldorf, Germany. 2Institute of Pathology, University Hospital Düsseldorf, Düsseldorf, Germany. 3Institute of Pharmacology and Clinical Pharmacology, University Hospital Düsseldorf, Düsseldorf, Germany

#718 CALCINEURIN INHIBITORS EFFECTS ON HCVANTIGEN SPECIFIC PBMC RESPONSE OF LIVER TRANSPLANTED PATIENTS WITH VIRAL RECURRENCE Alessandro Perrella2,1, Anna D’Antonio1, Oreste Perrella1, Oreste Cuomo1 1VII Dpt Infectious Disease and Immunology, Hospital D.Cotugno of naples, Naples, Italy. 2Liver Transplant Center, AORN Cardarelli, Naples, Italy


#714

165A

166A

POSTER SESSIONS

#719

#725

HEPATIC X-IRRADIATION-BASED REPOPULATION BY TRANSPLANTED HEPATOCYTES REQUIRES P21 INDUCTION IN THE HOST LIVER

HUMAN MESENCHYMAL STEM CELL-DERIVED HEPATOCYTES IMPROVE REGENERATION OF THE MOUSE LIVER AFTER ACETAMINOPHEN-INDUCED INJURY

Jianqiang Ding1, Yesim Avsar1, Hongchao Zhou2, Jayanta RoyChowdhury1, Chandan Guha2, Namita Roy-Chowdhury1 1Medicine, Genetics, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, New York, NY, USA. 2Radiation Oncology, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, New York, NY, USA

#720 DECELLULARIZED LIVER MATRIX IMPROVES THE SURVIVAL OF HUMAN FETAL HEPATOCYTES IN MOUSE MODELS Ping Zhou1, Daniel B. Cortes Estrada1, Shilpa Lingala2, Mark Zern2, Jan A. Nolta1, Jian Wu2 1Stem Cell Program, University of California, Davis Medical Center, Sacramento, CA, USA. 2Transplant Research Institute, UC Davis Medical Center, Sacramento, CA, USA

#721 SPLENECTOMY ENHANCES THE EFFECT OF BONE MARROW CELL INFUSION ON THE REPAIR OF THE MICROENVIRONMENT IN MICE AND PATIENTS WITH LIVER CIRRHOSIS Takuya Iwamoto, Shuji Terai, Naoki Yamamoto, Kaoru Omori, Takahiro Yamasaki, Isao Sakaida yamaguchi.univ, Ube, Japan

#722 MMP-9 DEFICIENCY REDUCES INTRAPARENCHYMAL HEMORRHAGE IN SMALL LIVER REMNANTS Norifumi Ohashi, Justin H. Nguyen Department of Transplantation, Mayo Clinic, Jacksonville, Jacksonville, FL, USA

#723 TREATMENT OF FULMINANT HEPATIC FAILURE IN RATS USING AMNIOTIC FLUID DERIVED MESENCHYMAL STEM CELLS OVER-EXPRESSING INTERLEUKIN-1 RECEPTOR ANTAGONIST S U N D AY NOVEMBER 1


Yu Bao Zheng, Zhi-liang Gao, Chan Xie, Yutian Chong, Zhixin Zhao, BingLiang Lin, Chaoshuang Lin, Dong-ying Xie, WeiMin Ke Department of Infectious Diseases,, The Third Affiliated Hospital of Sun Yat-Sen University,, Guangzhou, China

#724 REGULATION OF TRANSPLANTED CELL ENGRAFTMENT BY DRUG-INDUCED ALTERATIONS IN HEPATIC SINUSOIDAL MICROCIRCULATION Ralf Bahde1,2, Sorabh Kapoor1, Kuldeep Bhargava3, Kenneth Nichols3, Christopher J. Palestro3, Sanjeev Gupta1,4 1Medicine, Albert Einstein College of Medicine, Bronx, NY, USA. 2German Research Foundation, Bonn, Germany. 3Nuclear Medicine and Molecular Imaging, Long Island Jewish Medical Center, New York, NY, USA. 4Pathology, Albert Einstein College of Medicine, Bronx, NY, USA


Peggy Stock, Matthias M. Dollinger, Sabine Ebensing, Madlen Hempel, Thomas Seufferlein, Bruno Christ Medicine, Martin-Luther-University Halle-Wittenberg, Halle, Germany

#726 PROOF-OF-PRINCIPLE; FOURIER TRANSFORM ION CYCLOTRON RESONANCE MASS SPECTROMETRY (FT-ICR MS) AND COULOMETRIC ELECTROCHEMICAL ARRAY DETECTION (CEAD) COULD AID THE UNDERSTANDING OF CHANGES IN LIVER METABOLISM DURING THE ORTHOTOPIC LIVER TRANSPLANTATION (OLT) Michael A. Silva1, Olga Hrydziuszko2, Thamara Perera1, Chandra S. Bhati1, Douglas A. Richards3, Nick Murphy1, Darius Mirza1, Mark Viant2 1The Liver Unit, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom. 2School of Biosciences, University of Birmingham, Birmingham, United Kingdom. 3Department of Pharmacology, University of Birmingham, Birmingham, United Kingdom

#727 MESENCHYMAL CELLS DERIVED FROM BONE MARROW CELL REDUCE LIVER FIBROSIS AND IMPROVED LIVER FUNCTION IN CCL4-TREATED CIRRHOSIS MICE Takuya Iwamoto, Shuji Terai, Naoki Yamamoto, Kaoru Omori, Takahiro Yamasaki, Isao Sakaida yamaguchi.univ, Ube, Japan

#728 GLUCOSE PRODUCTION OF THE PARTIAL LIVER GRAFT DURING OPERATION PREDICTS POSTOPERATIVE GRAFT FUNCTION AND SURVIVAL IN A PORCINE MODEL Hiroaki Shiba, Dympna Kelly, Xiaocheng Zhu, John J. Fung Liver Transplantation and HPB Surgery, Cleveland Clinic, Cleveland, OH, USA

#729 A NEW COLLAGENASE/PROTEASE PREPARATION FOR ISOLATION OF HUMAN HEPATOCYTES FOR CLINICAL TRANSPLANTATION Roberto Gramignoli1, Fabio Marongiu1, Shringi Sharma2, Kenneth Dorko1, Veysel Tahan1, David A. Geller3, Raman Venkataramanan2, Ewa C S. Ellis4, Stephen C. Strom1 1Pathology, University of Pittsburgh, Pittsburgh, PA, USA. 2Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA. 3Surgery, University of Pittsburgh, Pittsburgh, PA, USA. 4Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden


POSTER SESSIONS

Effectiveness of Clinical Practice and Health Care Delivery #730 PREVALENCE OF LABORATORY MONITORING IN UNTREATED PATIENTS WITH CHRONIC HEPATITIS B: A CLAIMS DATABASE ANALYSIS Edward Kim, Hong Tang, Melissa Harris, Annette Z. Powers, George J. Hanna Research & Development, Bristol-Myers Squibb Company, Plainsboro, NJ, USA

#735 PREDICTORS OF HEPATITIS A AND B VACCINATION AMONG US VETERANS WITH CHRONIC HEPATITIS C VIRUS Jennifer R. Kramer1, Christine Y. Hachem3, Fasiha Kanwal2,3, Hashem B. El-Serag1 1Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, TX, USA. 2Department of Gastroenterolgy and Hepatology, Saint Louis VA Medical Center, Saint Louis, MO, USA. 3Department of Gastroenterology and Hepatology, Saint Louis University, Saint Louis, MO, USA

#736

#731 THE NATURAL HISTORY OF HEPATITIS C TREATMENT FAILURES: A META-ANALYSIS Amit Singal1, Michael L. Volk1, Donald M. Jensen2, Adrian M. Di Bisceglie3, Philip Schoenfeld1 1University of Michigan, Ann Arbor, MI, USA. 2University of Chicago, Chicago, IL, USA. 3Saint Louis University, Saint Louis, MO, USA

INFORMED CONSENT AND DECISION-MAKING AMONG ADULT LIVING DONORS FOR LIVER TRANSPLANTATION: A PILOT STUDY Elisa J. Gordon1,2, Daniela Ladner1, Anton I. Skaro1, Juan C. Caicedo1, Talia B. Baker1, Michael M. Abecassis1 1Surgery, Northwestern University, Chicago, IL, USA. 2Institute for Healthcare Studies, Northwestern University, Chicago, IL, USA

#737

#732 OPTIMIZING LIVER ALLOCATION POLICY Adnan Said1, Safa Erenay3, Mustafa Akan2, Baris Ata4, Oguzhan Alagoz3 1Section of Gastroenterology/Hepatology, University of WisconsinMadison, Madison, WI, USA. 2Carnegie-Mellon University, Pittsburgh, PA, USA. 3University of Wisconsin, Madison, WI, USA. 4Northwestern University, Chicago, IL, USA

OPTIMIZING THE CARE OF PATIENTS WITH CIRRHOSIS AND GASTROINTESTINAL HEMORRHAGE: A QUALITY IMPROVEMENT STUDY Eric A. Johnson, Bret J. Spier, Samantha Borkan, Michael R. Lucey, Adnan Said University of Wisconsin Hospital and Clinics, Madison, WI, USA

#738

#733 RE-TREATMENT OF GENOTYPE 1 HEPATITIS C NON-RESPONDERS AND RELAPSERS TO PRIOR COMBINATION THERAPY: A META-ANALYSIS Singal1,

167A

Waljee1,

Shiffman2,

Amit Akbar K. Mitchell L. Bruce R. Bacon3, Philip Schoenfeld1 1University of Michigan, Ann Arbor, MI, USA. 2Virginia Commonwealth University, Richmond, VA, USA. 3Saint Louis University, Saint Louis, MO, USA

#734

Erik J. Groessl1,2, Kimberly R. Weingart1, Allen L. Gifford4,5, Steven Asch3, Samuel B. Ho1,2 1HSR&D, VA San Diego, San Diego, CA, USA. 2University of California San Diego, La Jolla, CA, USA. 3West Los Angeles VA, Los Angeles, CA, USA. 4Bedford VA,, Bedford, MA, USA. 5Boston University, Boston, MA, USA

James T. Kwiatt, Parin Desai, Samer Gawrieh, Kia Saeian Gastroenterology, Medical College of Wisconsin, Milwaukee, WI, USA

#739 EPIDEMIOLOGY AND EVALUATION OF HBSAGPOSITIVE PREGNANT WOMEN Kara M. Sullivan1, Paola Ricci2 Gastroenterology, University of Minnesota, Minneapolis, MN, USA. 2Internal Medicine, Hepatology, HealthPartners, St Paul, MN, USA 1Pediatric

#740 FORMAL HCV PATIENT EDUCATION IS EFFECTIVE IN IMPROVING PATIENT KNOWLEDGE OF HCV DISEASE IN VULNERABLE POPULATIONS Miranda E. Surjadi1,2, Claudia Ayala1,2, Hal F. Yee1,2, Mandana Khalili1,2 1Medicine, University of California, San Francisco, San Francisco, CA, USA. 2Department of Gastroenterology/Hepatology, San Francisco General Hospital, San Francisco, CA, USA


SELF-MANAGEMENT INTERVENTIONS FOR VETERANS WITH HEPATITIS C

PERFORMANCE FEEDBACK FOR IMPROVING THE CARE OF CIRRHOTICS

168A

POSTER SESSIONS

#741

#747

THE EMORY LIVER TRANSPLANT PROGRAM: EFFECTIVENESS OF A STRUCTURED COMPREHENSIVE QUALITY IMPROVEMENT INITIATIVE

PROJECT ECHO (EXTENSION FOR COMMUNITY HEALTHCARE OUTCOMES): KNOWLEDGE NETWORKS EXPAND ACCESS TO HEPATITIS C (HCV) TREATMENT WITH PEGYLATED INTERFERON AND RIBAVIRIN IN RURAL AREAS AND PRISONS. CARE IS AS EFFECTIVE AS A UNIVERSITY HCV CLINIC

Jennie P. Perryman1, James Spivey2, Stuart J. Knechtle3 Transplant Center, Emory Healthcare, Emory University, Atlanta, GA, USA. 2Medicine, Emory University School of Medicine, Atlanta, GA, USA. 3Surgery, Emory University School of Medicine, Atlanta, GA, USA

1Emory

#742 USE OF DESIRABILITY FUNCTIONS TO EVALUATE HEALTH STATUS IN PATIENTS WITH CIRRHOSIS Chris Gennings1, Douglas M. Heuman2,3, Otis Fulton4, Arun J. Sanyal3 1Biostatistics, Virginia Commonwealth University, Richmond, VA, USA. 2McGuire VA Medical Center, Richmond, VA, USA. 3Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA. 4Metametrics, Durham, NC, USA

#743 PREVENTING LIVER DISEASE BY VACCINATING HIGH-RISK ADULTS FOR HBV Jacqueline R. Avery1, Hope King1, Phillip E. Reichert2, Ying-Ying Yu3, Steve Nickell4 1Division of Viral Hepatitis (DVH), CDC, Atlanta, GA, USA. 2Hepatitis Prevention Program, Florida Department of Health, Tallahassee, FL, USA. 3STD Control Branch, California Department of Health, Richmond, CA, USA. 4Imminization Branch, California Department of Health, Richmond, CA, USA

#744 POOR ADHERENCE TO TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION IS ASSOCIATED WITH DETRIMENTAL HEALTH OUTCOMES Robert W. Baran, Menaka Bhor, Birgitta Dietz, David Laitinen Abbott Laboratories, Abbott Park, IL, IL, USA

#745 S U N D AY NOVEMBER 1


TARGETED SCREENING FOR VIRAL HEPATITIS IN AN ITALIAN COMMUNITY OF 100.000 INHABITANTS Claudia Zani3, Luigi Pasquale2, Maura Bressanelli3, Bruno Paris2, Andrea Patroni1, Francesco Donato2, Massimo Puoti2, Romana Coccaglio3 1Infectious Diseases, University of Brescia, Brescia, Italy. 2ASL Vallecamonica, Vallecamonica, Italy. 3Institute of Hygiene, University of Brescia, Vallecamonica, Italy

#746 MODELS OF INFLUENCE IN CHRONIC LIVER DISEASE Willscott E. Naugler1, Amnon Sonnenberg2,1 1Medicine/GI & Hepatology, Oregon Health & Sciences University, Portland, OR, USA. 2Medicine/Gastroenterology, Portland VA Medical Center, Portland, OR, USA


Sanjeev Arora1, Glen H. Murata1, Karla A. Thornton1, Steven Jenkusky2, Brooke Parish2, Jeffrey C. Dunkelberg1, Paulina Deming3, Summers Kalishman4, Denise Dion1 1Internal Medicine, University of New Mexico, Albuquerque, NM, USA. 2Psychiatry, University of New Mexico, Albuquerque, NM, USA. 3Pharmacy, University of New Mexico, Albuquerque, NM, USA. 4Family Community Medicine, University of New Mexico, Albuquerque, NM, USA

#748 NEW PROCEDURE FOR RAPID SCREENING OF CARRIERS OF HBSAG USING A IMMNOCHROMATOGRAPHIC TEST Evaldo S. Araujo, Carlos E. Melo, Fernanda D. Menegat, Fatima M. Tengan, Antonio A. Barone Infectious Diseases, Hospital das Clínicas FMUSP, São Paulo, Brazil

#749 SUCCESSFUL LINKAGE TO CARE FOLLOWING SCREENING FOR HEPATITIS B VIRUS INFECTION IN THE HEPBLINK PROGRAM W. Ray Kim1, Karen E. Kim2, Robert Tarrell1, Denton Chase5, KeQin Hu3, Naoky CS C. Tsai4 1Mayo Clinic College of Medicine, Rochester, MN, USA. 2University of Chicago, Chicago, IL, USA. 3University of California Irvine, Irvine, CA, USA. 4University of Hawaii, Honolulu, HI, USA. 5Asian Health Communications, Parsippany, NJ, USA

#750 SCREENING FOR HEPATITIS B (HBV) AND HEPATITIS C (HCV) IN A VIETNAMESE COMMUNITY OF NORTHERN VIRGINIA Jillian B. Kallman1,2, Sang V. Tran2, Aimal Arsalla2, Dmitri Haddad2, Maria Stepanova1, Fang Yun2, Valerie J. Wrobel1, Manirath Srishord1,2, Zobair M. Younossi1,2 1Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA. 2Outcomes Research Program, Inova Fairfax Hospital, Falls Church, VA, USA

#751 THE INCREASED COSTS OF DONATION AFTER CARDIAC DEATH LIVER TRANSPLANTATION: CAVEAT EMPTOR Colleen L. Jay1, Anton I. Skaro1, Raymond Kang2, Luke Preczewski1, Jane Holl2, Michael M. Abecassis1 1Department of Surgery, Divison of Organ Transplantation, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. 2Institute for Healthcare Studies, Chicago, IL, USA


POSTER SESSIONS

169A

#752

#755

REIMBURSEMENT POLICIES IN ASIA-PACIFIC FOR CHRONIC HEPATITIS B

COMORBIDITIES, CONCOMITANT MEDICATION USE AND REASONS FOR HOSPITALIZATION IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS: EVIDENCE FROM A US MANAGED CARE DATABASE

Seng Gee Lim1, Deepak N. Amarapurkar2, Henry Lik-Yuen Chan3, Darrell H. Crawford4, Edward J. Gane5, Kwang-Hyub Han6, Shamsuddin M. Ishaque7, Syed M. Jafri8, Jidong Jia9, Jia-Horng Kao10, Laurentius A. Lesmana11, Masashi Mizokami12, Rosmawati Mohamed13, Pham Hoang Phiet14, Teerha Piratvisuth15, Shiv K. Sarin16, Jose D. Sollarno17, Osamu Yokosuka18, Anna S. Lok19 1Department of Gastroenterology & Hepatology, National University Health System, Singapore, Singapore. 2Department of Gastroenterology & Hepatology, Bombay Hospital and Medical Research Centre, Mumbai, India. 3Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. 4School of Medicine, University of Queensland, Brisbane, QLD, Australia. 5New Zealand Liver Unit, Auckland City Hospital, Auckland, New Zealand. 6Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, South. 7Department of Gastrointestinal Liver & Pancreatic Disease, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. 8Department of Medicine, Aga Khan University, Karachi, Pakistan. 9Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. 10Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan. 11Department of Medicine, University of Indonesia, Jakarta, Indonesia. 12Research Center for Hepatitis and Immunology, International Medical Center of Japan, Kounodai Hospital, Kounodai, Japan. 13Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. 14Department of Immunology and Physiopathology, University of Medicine and Pharmacy, Ho Chi Minh City, Viet Nam. 15NKC Institute of Gastroenterology and Hepatology, Prince of Songkla University, Hat Yai, Thailand. 16Department of Gastroenterology, G B Pant Hospital, New Delhi, India. 17Department of Medicine, University of Santo Tomas, Manila, Philippines. 18Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba City, Japan. 19Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI, USA

#753 PRODUCTIVITY COSTS ARE HIGHER AMONG HCV PATIENTS TREATED WITH PEG-R

#754 DISEASE BURDEN AND LIFETIME DIRECT MEDICAL COSTS OF CHRONIC HEPATITIS C INFECTION AMONG IMMIGRANTS LIVING IN CANADA Wendong Chen1, George Tomlinson1, E. Jenny Heathcote2, Murray Krahn1,3 1Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. 2The liver Clinic, Toronto Western Hospital, Toronto, ON, Canada. 3Pharmacy, University of Toronto, Toronto, ON, Canada

#756 DIMENSIONS OF FATIGUE ARE ASSOCIATED WITH LEARNING, MEMORY AND MOTOR DEFICITS AMONG PEOPLE INFECTED WITH THE HEPATITIS C VIRUS (HCV) Carolina Posada, Fatma Barakat, David J. Moore, Steven Woods, Chris Ake, William Perry, Mariana Cherner, Robert K. Heaton, Scott Letendre, Igor Grant, Tarek Hassanein University of California, San Diego, San Diego, CA, USA

#757 NEUROCOGNITIVE FUNCTION AND MOOD CHANGES IN HCV PATIENTS: EFFECT OF DISEASE SEVERITY Fatma Barakat, Mariana Cherner, Deanna L. Oliver, Meghan Carlson, Steven Woods, Robert K. Heaton, Scott Letendre, Igor Grant, William Perry, Tarek Hassanein University of California, San Diego, San Diego, CA, USA

#758 USE OF TELEMEDICINE AND THE “WARM LINE” FOR THE TREATMENT OF HEPATITIS C INFECTION (HCV) IN THE CORRECTIONAL SETTING TO REDUCE BARRIERS TO SPECIALTY CARE Pat Nachin, Marian Kerbleski, Anne Gaglioti, Megan Mahoney, Robert Protell, Lori Kohler, Joanne C. Imperial Department of Family & Community Medicine, Correctional Medicine Consultation Network, University of California, San Francisco, San Francisco, CA, USA

#759 HCV/HIV COINFECTION THERAPY IN A SPECIALIZED COMMUNITY CLINIC: A SINGLE CENTER EXPERIENCE Renee S. Pozza2, Karel Biando2, Fatma Barakat1, Mohamed El Kabany2, Tarek Hassanein1 1University of California, San Diego, San Diego, CA, USA. 2Southern California Liver Centers, San Clemente, CA, USA

#760 DO YOU C WHAT I C? RESULTS OF THE AUSTRALIAN HEPATITIS C NEEDS ASSESSMENT Jacqui Richmond, Helen Tyrrell Hepatitis Australia, Canberra, ACT, Australia


Machaon Bonafede1, Paula B. Chakravarti2, Katy Pan1, Kathleen Wilson1, Cynthia Beam3 1Thomson Reuters Healthcare, Cambridge, MA, USA. 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. 3Human Genome Sciences, Inc., Rockville, MD, USA

Vinod K. Rustgi1, Debanjali Mitra2, Keith L. Davis2, Cynthia Beam3 University Medical Center, Washington, DC, USA. 2RTI Health Solutions, Research Triangle Park, NC, USA. 3Human Genome Sciences, Inc., Rockville, MD, USA 1Georgetown

170A

POSTER SESSIONS

#761

#766

LOW TESTOSTERONE IN CIRRHOTIC PATIENTS WITH MALNUTRITION: IDENTIFYING THE PROPER SEROLOGICAL MARKERS

FUNCTIONAL AND MOLECULAR ALTERATIONS IN CARDIAC PHYSIOLOGY IN MICE WITH BILIARY CIRRHOSIS: POTENTIAL CONTRIBUTING ROLE FOR BILE ACIDS

Amy Gaddis, Guy W. Neff, Tiffany E. Kaiser, Neil Pandya, Nyingi Kemmer University of Cincinnati, Cincinnati, OH, USA

#762 DEVELOPMENT OF COMPETENCY STANDARDS FOR THE HEPATOLOGY NURSE IN AUSTRALIA AND NEW ZEALAND Richmond1,

Fenech2,

Warner3

Jacqui Mary Sherryne 1Gastroenterology, St.Vincent’s Hospital, Fitzroy, VIC, Australia. 2Department Gastroenterology & Hepatology, The Royal Brisbane & Women’s Hospital, Brisbane, QLD, Australia. 3Department of Gastroenterology, Monash Medical Centre, Clayton, VIC, Australia

Experimental Cholestasis #763 IDENTIFICATION OF NUCLEAR RECEPTOR COACTIVATOR 6 (NCOA6/ASC-2) AND MIXED MYELOID LINEAGE LEUKEMIA 3 (MLL3), A HISTONE H3K4 METHYL TRANSFERASE, AS PARTNERS OF THE ASCOM COMPLEX IN FXR TRANSACTIVATION OF BSEP PROMOTER Meena Ananthanarayanan1, Yanfeng Li1, Martin Walsh1, Sailesh Surapureddi2, Joyce Goldstein2, Frederick J. Suchy1 1Department of Pediatrics, Mount Sinai School of Medicine, New York, NY, USA. 2Laboratory of Pharmacology, NIEHS, Research Triangle Park, NC, USA

#764 FOXL1 PROMOTES CHOLANGIOCYTE PROLIFERATION FOLLOWING CHOLESTATIC LIVER INJURY Sara D. Sackett1,2, Yan Gao1, Yonah Esterson1, Akivaga Tsingalia1, Reginald Hurtt1, Klaus H. Kaestner1,2, Linda Greenbaum1 1Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2Genetics, University of Pennsylvania, Philadelphia, PA, USA S U N D AY NOVEMBER 1


#765 THE MECHANISM OF PROTECTIVE EFFECTS OF PPARγ ACTIVATION ON BILE DUCT LIGATIONINDUCED HEPATIC INJURY IN RATS Tomomi Kitagawa, Yukihiro Yokoyama, Toshio Kokuryo, Kiyotaka Kawai, Katsutaka Watanabe, Masato Nagino Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan


Moreshwar S. Desai, Zainuer Shabier, Michael Taylor, Fong Lam, Astrid Kosters, Saul J. Karpen Department of Pediatrics and Texas Liver Center, Baylor College of Medicine, Houston, TX, USA

#767 SEROTONIN MEDIATES BILE ACID HOMEOSTASIS IN A MOUSE MODEL OF CHOLESTASIS BY CONTROLLING BILE ACID TRANSPORTERS Jae-Hwi Jang1, Andreas Rickenbacher1, Achim Weber2, Bruno Stieger3, Wolfgang Moritz1, Rolf Graf1, Pierre A. Clavien1 1Visceral and transplantation surgery, University Hospital Zürich, Zürich, Switzerland. 2Pathology, University Hospital Zürich, Zürich, Switzerland. 3Clinical pharmacology, University Hospital Zürich, Zürich, Switzerland

#768 LIVER-SPECIFIC β-CATENIN KNOCKOUT MICE EXHIBIT CHOLESTASIS AND INCREASED SUSCEPTIBILITY TO BILE ACID-INDUCED LIVER INJURY Jaideep Behari1, Tzu-Hsuan Yeh1, Lindsay K. Krauland1, Baobo Zou1, Satdarshan Monga2,1 1Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 2Pathology, University of Pittsburgh, Pittsburgh, PA, USA

#769 INHIBITION OF UNCOUPLING PROTEIN 2 (UCP2) EXPRESSION BY NEUROPEPTIDE Y LEADS TO DECREASED CHOLANGIOCYTE HYPERPLASIA IN BILE DUCT LIGATED RATS Mellanie White1, Julie Venter1, Shelley Kopriva1, Eugenio Gaudio3, Paolo Onori4, Gianfranco Alpini1,2, Sharon DeMorrow1 1Department of Medicine and Scott & White Digestive Disease Research Center, Texas A&M Health Science Center College of Medicine and Scott & White, Temple, TX, USA. 2Research, Central TX Veterans Health Care System, Temple, TX, USA. 3Human Anatomy, University of Rome “La Sapienza”, Rome, Italy. 4Experimental Medicine, University of L’Aquila, L’Aquila, Italy

#770 ROLE OF THE VITAMIN D NUCLEAR RECEPTOR ON LIVER INJURY IN BILE-DUCT LIGATED MICE Delphine Firrincieli1,2, Colette Rey1,2, Dominique Wendum1,4, Elisabeth Lasnier3, Axelle Cadoret1,2, Mathieu Boissan1,2, Chantal Housset1,5, Nicolas Chignard1,2 1UMR_S 938, UPMC Univ Paris 06, Paris, France. 2UMR_S 938, Inserm, Paris, France. 3Clinical Biochemistry, AP-HP, Saint Antoine Hospital, Paris, France. 4Pathology, AP-HP, Saint Antoine Hospital, Paris, France. 5Clinical Biochemistry, AP-HP, Tenon Hospital, Paris, France


POSTER SESSIONS

171A

#771

#776

C-MET AND GP130 PROTECT FROM SEPTICEMIC LETALITY AFTER BILE DUCT LIGATION IN MICE

EPIDEMIOLOGY OF RECENTLY ACQUIRED HEPATITIS C VIRUS (HCV) INFECTION IN HCV AND HCV/HIV INFECTED PARTICIPANTS IN THE ATAHC STUDY

Arne Giebeler, Michaela Kaldenbach, Stephanie Erschfeld, Christian Trautwein, Konrad L. Streetz Department of Medicine 3, RWTH Aachen, Aachen, Germany

#772 KEAP1/NRF2 SIGNALING AND ANTIOXIDANT ENZYMES IN EXPERIMENTAL CHOLESTASIS Miriam Bueno-Topete1, Abril Martinez-Rizo1, Jaime GonzalezCuevas1, Yadira Sánchez Toscano1, Laura V. Sánchez-Orozco1, Juan Armendáriz Borunda1,2 1Instituto de Biología Molecular en Medicina y Terapia Genica, Universidad de Guadalajara, Guadalajara, Mexico. 2OPD Hospital Civil de Guadalajara, Universidad de Guadalajara, Guadalajara, Mexico

HCV: Epidemiology #773 HEPATITIS C VIRUS (HCV) INFECTION AND REINFECTION IN ILLICIT DRUG USERS Ahmed Barrieshee1, Harout Tossonian1, Jason Grebely4, Jesse D. Raffa3, Lesley Gallagher1, Michelle M. Storms1, Fiona Duncan2, Stanley DeVlaming2, Brian Conway1,2 1Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC, Canada. 2Pender Community health Centre, Vancouver Coastal Health, Vancouver, BC, Canada. 3Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada. 4National Centre in HIV Epidemiology and Clinical Research,, University of New South Wales, sydney, NSW, Australia

#774 IMMEDIATE VERSUS DELAYED ANTIVIRAL TREATMENT IN PATIENTS WITH ACUTE HEPATITIS C: A MODEL-BASED DECISION ANALYSIS

#775 RISK FACTORS FOR PRIMARY HEPATOCELLULAR CARCINOMA IN HOSPITALIZED PATIENTS IN THE UNITED STATES IN 2006 Florence Aslinia, Charles D. Howell University of Maryland Baltimore, Baltimore, MD, USA

#777 A SIMPLE STRATEGY TO SCREEN FOR ACUTE HCV INFECTION AMONG NEWLY INCARCERATED INJECTION DRUG USERS Arthur Y. Kim1,5, Christopher E. Birch1,3, Ellen H. Nagami1,3, Melinda J. Bowen1,6, Georg M. Lauer2, Barbara H. McGovern3,4 1Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, MA, USA. 2Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 3Lemuel Shattuck Hospital, Jamaica Plain, MA, USA. 4Tufts Medical School, Boston, MA, USA. 5Harvard University Center for AIDS Research, Boston, MA, USA. 6University of Massachusetts Medical School, Worcester, MA, USA

#778 NEW TRENDS OF HCV INFECTION IN CHINA REVEALED BY GENETIC ANALYSIS OF FIRST-TIME VOLUNTEER BLOOD DONORS Yongshui Fu1, Wenjie Xia1, Yizhong Wang2, Chunhua Li3, Shuanghu Liu3, Oliver Pybus4, Ling Lu3,6, Kenrad Nelson5 1Guangzhou Blood Center, Guangzhou Blood Center, Guangzhou, China. 2The laboratory of Integrated Biosciences, School of Life Sciences, Sun Yat-sen University, Guangzhou, China. 3Division of Gastroenterology, University of Utah, Salt Lake City, UT, USA. 4Department of Zoology, Oxford University, Oxford, United Kingdom. 5Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. 6Laboratory in Liver Hospital, the Third Affiliated Hospital, Sun Yatsen University, Guangzhou, China

#779 OBSERVATIONAL OUTCOMES IN A COHORT OF WOMEN IDENTIFIED AS HEPATITIS C (HCV) ANTIBODY POSITIVE DURING ROUTINE ANTENATAL CLINIC (ANC) SCREENING Anet A. Alexanian1, Gregory M. Oleszkiewicz1, Thawab Al-Chalabi1, Sowsan Atabani2, David Muir2, Gareth Tudor-Williams3, Ashley S. Brown1 1Liver & Antiviral Unit, Imperial College Healthcare NHS Trust, London, United Kingdom. 2Department of Diagnostic Virology, Imperial College Healthcare NHS Trust, London, United Kingdom. 3Department of Child Health, Imperial College, London, United Kingdom


Sylvie Deuffic-Burban1,2, Helene Castel3,4, Johannes Wiegand5,6, Michael P. Manns5, Heiner Wedemeyer5, Philippe Mathurin1,3, Yazdan Yazdanpanah2,4 1INSERM U795, Faculte de Medecine - Pole recherche, Lille, France. 2EA2694, Faculte de Medecine - Pole recherche, Lille, France. 3Service d’hepato-gastroenterologie, Hopital Huriez CHRU de Lille, Lille, France. 4Service universitaire des maladies infectieuses et du voyageur, CH Dron, Tourcoing, France. 5Department of Gastroenterology and Endocrinology, Hannover Medical School, Hannover, Germany. 6Department of Gastroenterology and Rheumatology, University of Leipzig, Leipzig, Germany

Gail Matthews1, Jason Grebely1, Son T. Pham2, Margaret Hellard3, Pip Marks1, William Rawlinson4, John Kaldor1, Andrew R. Lloyd2, Peter A. White2, Gregory J. Dore1 1National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia. 2School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia. 3Burnet Institute, Melbourne, VIC, Australia. 4Virology Division, SEALS Microbiology, Prince of Wales Hospital, Sydney, NSW, Australia

172A

POSTER SESSIONS

#780

#785

EXAMINING THE INFLUENCE OF MEDICAL COMORBIDITIES ON HEPATITIS C TESTING

CLUSTER OF ACUTE HCV GENOTYPE 4 INFECTIONS AMONG HIV-POSITIVE MEN WHO HAVE SEX WITH MEN (MSM)

Christopher V. Almario1, Maricruz Velez1, Stacey Trooskin2, Victor J. Navarro1 1Division of Gastroenterology and Hepatology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA. 2Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

#781 A PROSPECTIVE SURVEY INCLUDING 17,184 PATIENTS FROM A GERMAN METROPOLITAN AREA REVEALS A HIGH PREVALENCE OF CHRONIC HEPATITIS C VIRUS INFECTION Beate Schlosser1, Diana Domke1, Martin Möckel2, Michael Biermer1, Balazs Fülöp1, Norbert P. Haas4, Hermann Bail4, Christian Müller3, Rudolf Tauber3, Thomas Berg1 1Medizinische Klinik für Gastroenterologie und Hepatologie, Charite Campus Virchow, Berlin, Germany. 2Medizinische Klinik für Kardiologie, Charite Campus Virchow, Berlin, Germany. 3Institut für Laboratoriumsmedizin und Pathobiochemie, Charite Campus Virchow, Berlin, Germany. 4Klinik für für Unfall- und Wiederherstellungschirurgie, Charite Campus Virchow, Berlin, Germany

#782 COST EFFECTIVENESS OF STAT-C AGENTS IN TREATING GENOTYPE 1 CHRONIC HEPATITIS C Patrick G. Northup, Abdullah M. Al-Osaimi, Stephen H. Caldwell, Curtis K. Argo Gastroenterology and Hepatology, University of Virginia Health Systems, Charlottesville, VA, USA

#783 ABNORMALITY OF SERUM LIPIDS IN THE HCV CARRIERS IN EPIDEMIOLOGICAL SURVEY OF JAPANESE LARGE COHORT



Teruo Miyazaki1,2, Akira Honda2,1, Tadashi Ikegami3, Yoshifumi Saitoh3, Takeshi Hirayama3, Yasushi Matsuzaki3,1 1Development for Community Medicine, Tokyo Medical University, Ami, Japan. 2Center for Collaborative Research, Tokyo Medical University Ibaraki Medical Center, Ami, Japan. 3Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Ami, Japan

#784 RISK OF THROMBOEMBOLIC EVENTS (TES) AMONG PATIENTS INFECTED WITH HEPATITIS C Ulla Forssen1, Andrew McAfee2,3, Cheryl Enger2, Dimitri Bennett1, Sumitra Shantakumar1 1Oncology R&D, Biometrics and Epidemiology, GlaxoSmithKline, Collegeville, PA, USA. 2i3 Drug Safety, Ann Arbor, MI, USA. 3Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA


Martin Vogel1, Thijs J. van de Laar2, Julia Henke3, Bernd Kupfer4, Tim Kümmerle5, Heinrich Rasokat6, Stefan Mauss3, Gerd Fätkenheuer5, Sylvia M. Bruisten2, Jürgen K. Rockstroh1 1Department of Internal Medicine I, Bonn University, Bonn, Germany. 2Cluster of Infectious Diseases, Health Service, Amsterdam, Netherlands. 3Center for HIV and Hepatogastroenterology, Dusseldorf, Germany. 4Institute for Virology, Bonn University, Bonn, Germany. 5Department of Internal Medicine I, University of Cologne, Cologne, Germany. 6Clinic and Policlinic for Dermatology and Venerology, University of Cologne, Cologne, Germany

#786 IMPLICATION OF IFNAR POLYMORPHISMS ON CHRONIC HEPATITIS C TREATMENT OUTCOME Rosario Lopez-Rodriguez1, Manuel Roman2, Angel Hernandez-Bartolome1, María J. Borque3, Yolanda Rodriguez-Muñoz.1, Samuel Martin-Vilchez1, Luis Rodrigo4, Abad-Santos Francisco2, Ricardo Moreno-Otero1, Paloma Sanz-Cameno1 1Liver Unit, Hospital Universitario de La Princesa & CIBERehd, ISCIII, Madrid, Spain. 2Clinical Pharmacology Service, ITH, Hospital Universitario de La Princesa, Madrid, Spain. 3Molecular Biology Unit, Hospital Universitario de La Princesa, Madrid, Spain. 4Digestive Service, Hospital Central de Asturias, Oviedo, Spain

#787 HIGH RISK OF HEPATOCELLULAR CARCINOMA IN IMMIGRANT PATIENTS WITH ADVANCED FIBROSIS AND CHRONIC HEPATITIS C IN A CANADIAN TERTIARY REFERRAL CLINIC Wendong Chen1, George Tomlinson1, Murray Krahn1,2, E. Jenny Heathcote3 1Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. 2Pharmacy, University of Toronto, Toronto, ON, Canada. 3The liver Clinic, Toronto Western Hospital, Toronto, ON, Canada

#788 HCV VIRAL EVOLUTION IN HCV/HIV COINFECTED SUBJECTS AFTER INITIATION OF HAART Philippe J. Zamor, Jason Blackard, Christina M. Martin, Kenneth E. Sherman Division of Digestive Diseases, University of Cincinnati, Cincinnati, OH, USA


POSTER SESSIONS

#789

173A

#793

PREDICTORS OF SPONTANEOUS VIRAL CLEARANCE OF HEPATITIS C VIRUS AMONG HIV1 INFECTED INDIVIDUALS. A SINGLE-CENTER COHORT STUDY

DYNAMIC RESPONSE OF INNATE IMMUNITY INDUCED BY TELAPREVIR AND PEG-IFN/RBV TREATMENT AND ITS ASSOCIATION WITH VIROLOGICAL RESPONSE AND HCV VARIANTS

Louise N. Clausen1, Nina Weis2,6, Kristian Schønning3, Mogens Fenger4, Henrik Krarup5, Jens Bukh1,6, Thomas Benfield1,6 1Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark. 2Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark. 3Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Denmark. 4Department of Clinical Biochemistry, Copenhagen University Hospital, Hvidovre, Denmark. 5Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark. 6Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

Yasuhiro Asahina, Itsuko Hirayama, Nobuharu Tamaki, Yutaka Yasui, Tomohiro Tanaka, Mitsuaki Sato, Ken Ueda, Teiji Kuzuya, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Masayuki Kurosaki, Namiki Izumi Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan

#790 EPIDEMIOLOGY AND PHYLOGENETIC ANALYSIS OF HEPATITIS C VIRUS GENOTYPE 4 IN DENMARK Mette B. Eriksen1, Louise B. Jørgensen1, Henrik Krarup2, Alex L. Laursen3, Peer B. Christensen4, Axel Møller5, Poul Schlichting6, Carla Kuiken7, Nina Weis8,9 1Department of Virology, Statens Serum Institut, Copenhagen S, Denmark. 2Department of Clinical Chemestry, Aalborg Hospital, Aalborg, Denmark. 3Department of Infectious Diseases, Skejby Hospital, Aarhus, Denmark. 4Department of Infectious Diseases, Odense University Hospital, Odense, Denmark. 5Department of Internal Medicine, Kolding Hospital, Kolding, Denmark. 6Department of Gastroenterology, Herlev University Hospital, Herlev, Denmark. 7Los Alamos National Laboratory, Los Alamos, New Mexico, Denmark. 8Department of Infectious Diseases, Hvidovre University Hospital, Hvidovre, Denmark. 9Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

#794 GLOBAL REVIEW OF THE RATE OF INTERSTITIAL PNEUMONITIS AMONG HEPATITIS VIRUS CINFECTED PATIENTS TREATED WITH PEGYLATED INTERFERON ± RIBAVIRIN Andreas Tietz1, John Liu2, Michael Peng2, Martin T. Schaerer1, Jonathan Solsky2 1Roche, Basel, Switzerland. 2Roche, Nutley, NJ, USA

#795 CLINICAL EFFICACY AND COST EFFECTIVENESS ANALYSIS OF PEGINTERFERON AND RIBAVIRIN THERAPY IN PATIENTS AFTER CURATIVE TREATMENT FOR HEPATOCELLULAR CARCINOMA ASSOCIATED WITH HEPATITIS C Kaoru Tsuchiya, Yasuhiro Asahina, Nobuharu Tamaki, Sato, Tomohiro Tanaka, Itsuko Hirayama, Yutaka Yasui, Hosokawa, Teiji Kuzuya, Hiroyuki Nakanishi, Jun Masayuki Kurosaki, Namiki Izumi Gastroenterology and hepatology, Musashino Red Cross Tokyo, Japan

Mitsuaki Takanori Itakura, hospital,

#796

HCV: Treatment #791 ANTIVIRAL EFFECTS OF HEME OXYGENASE-1: INHIBITION OF HCV NS3/4A PROTEASE BY BILIVERDIN AND ITS METABOLITES

#792 PRETREATMENT PREDICTION OF VIROLOGICAL RESPONSE TO PEGINTERFERON PLUS RIBAVIRIN THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C USING HEPATIC GENE EXPRESSION PROFILING Masao Honda, Akito Sakai, Mikiko Nakamura, Shuichi Kaneko Kanazawa University, Kanazawa, Japan

Kazuhiko Hayashi, Yoshiaki Katano, Masatoshi Ishigami, Isao Nakano, Hidemi Goto Gastroenterology, Nagoya University, Nagoya, Japan

#797 DIFFERENTIAL SPECIFICITY OF INNATE HOST GENE EXPRESSION ON INTERFERON-MEDIATED ANTIVIRAL EFFECT ON HCV AND HIV Antonios Katsounas1, Astrid C. Frank2, Jun Yang1, Richard A. Lempicki1, Avidan U. Neumann3, Michael A. Polis2, Shyam Kottilil2 1NCI-Frederick, SAIC, Frederick, MD, USA. 2LIR, NIAID/NIH, Bethesda, MD, USA. 3Bar-Ilan University, Ramat Dan, Israel


Zhaowen Zhu1,2, Yi Zhao1,2, Kyle E. Brown1,2, Bruce A. Luxon1, Warren N. Schmidt1,2 1Internal Medicine, University of Iowa, Iowa City, IA, USA. 2Research Service, Veterans Affairs Medical Center, Carver College of Medicine, University of Iowa, Iowa City, IA, USA

MUTATIONS IN THE NS5A REGION OF HEPATITIS C VIRUS GENOTYPE 2A AND CORRELATION WITH RESPONSE TO PEGYLATED-INTERFERON-ALPHA 2B AND RIBAVIRIN COMBINATION THERAPY

174A

POSTER SESSIONS

#798 A MORPHOLINO ANTI-SENSE OLIGOMER SUPPRESSES HEPATITIS C VIRAL REPLICATION IN HUMAN HEPATOCYTES EXPRESSING A FULLLENGTH HCV REPLICON Weihong Hou1,2, Qi Long Lu3, Qing Tian1, Herbert L. Bonkovsky1,2 1Cannon Research Center, Carolinas Medical Center, Charlotte, NC, USA. 2The Liver-Biliary-Pancreatic Center, Carolinas Medical Center, Charlotte, NC, USA. 3Neuromuscular/ALS Center, Carolinas Medical Center, Charlotte, NC, USA

#799 HMG-COA-REDUCTASE INHIBITORS INTERFERE WITH HCV REPLICATION IN VITRO – CONTRIBUTION OF HEME OXYGENASE 1 Elisabeth Lehmann1, Waleed H. El Tantawy2, Matthias Ocker2, Ralf Bartenschlager3, Volker Lohmann3, Gisa Tiegs1, Gabriele Sass1 1Division of Experimental Immunology and Hepatology, University Medical Center Hamburg Eppendorf, Hamburg, Germany. 2Department of Medicine 1, University Hospital Erlangen, Erlangen, Germany. 3Department of Molecular Virology, University of Heidelberg, Heidelberg, Germany

#800 HEPATIC PRR SIGNALING GENE EXPRESSION SHOWS DIFFERENTIAL RESPONSE TO HCV REPLICATION IN RESPONDERS AND NONRESPONDERS TO PEG-IFN PLUS RIBAVIRIN Nobukazu Yuki1, Shinji Matsumoto2, Michio Kato1, Toshikazu Yamaguchi2 1Department of Gastroenterology, Osaka National Hospital, Osaka, Japan. 2BML, Inc., Kawagoe, Japan

#801


ERITHROPOIETIN USE DURING ANTIVIRAL THERAPY IN PATIENTS WITH RECURRENT HEPATITIS C: LACK OF EFFECT ON VIRAL RESPONSE Maria Rodriguez2, Victoria Aguilera2,1, Angel Rubin2,1, Federica Gentili4, Martin Prieto2,1, Cecilia Ortiz3,1, Blas Risalde2,1, Raquel Canada3,1, Marina Berenguer2,1 1Ciberehd, Health Institute Carlos III, Valencia, Spain. 2Hepatology Deparment, Hospital la Fe, Valencia, Spain. 3Experimental Immunity Unit, Hospital la Fe, Valencia, Spain. 4Gastroenterologia, Universita’ di Roma “La Sapienza”, Roma, Italy

#802 LONG TERM FOLLOW-UP OF CHRONIC HEPATITIS C PATIENTS AFTER INTERFERON BASED ANTIVIRAL THERAPY Harald Hofer, Thomas-Matthias Scherzer, Sandra Beinhardt, Karoline Rutter, Albert Stättermayer, Petra E. Steindl-Munda, Peter Ferenci Department of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria



#803 SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) IDENTIFIED IN THE PROMOTER REGION OF THE MXA GENE AT NT -88 AND NT -123 ARE ASSOCIATED WITH RESPONSE TO ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HCV INFECTION Ana Luiza D. Angelo1,2, Lourianne N. Cavalcante3,1, Taisa Machado M. Machado2, Jessica Magalhaes1, Rafael C. Lima1, Maria T. Bendicho3, Mateus P. Fiuza1,3, Denise C. Lemaire2, Luiz G. Lyra1,3, Kiyoko Abe-Sandes2, Andre C. Lyra1,3 1Gastro-Hepatology Unit – c-HUPES/Federal University of Bahia, Brazil., Salvador, Brazil. 2Laboratory of Immunology and Postgraduate Immunology Course – Science Health Institute – Federal University of Bahia, Salvador, Brazil. 3Gastro-Hepatology Unit Hospital Sao Rafael, Salvador, Brazil

#804 EXHAUSTION OF TYPE-I INTERFERON SIGNALING PATHWAY AS A MAJOR MECHANISM FOR LACK OF RESPONSE TO PEG-INTERFERON AND RIBAVIRIN THERAPY IN HIV/HCV CO-INFECTED SUBJECTS Richard A. Lempicki2, Jun Yang2, Henry Masur3, Michael A. Polis1, Shyam Kottilil1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2SAIC-Frederick, Frederick, MD, USA. 3CCMD, CC, NIH, Bethesda, MD, USA

#805 TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN IVDU: LONG TERM (4 YEAR) FOLLOW UP John D. Farley Dr. John Farley Inc., Vancouver, BC, Canada

#806 DISCREPANCY BETWEEN VIROLOGICAL AND BIOCHEMICAL RESPONSES AT THE END OF INTERFERON-BASED THERAPY FOR HEPATITIS C CORRELATES TO HEPATIC STEATOSIS Ming-Lung Yu1,2, Chun-Hao Chen3, Chia-Yen Dai1,2, Jee-Fu Huang2,4, Wan-Long Chuang1,2 1College, Kaohsiung Medical University, Kaohsiung, Taiwan. 2Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 3Department of Internal Medicine, Municipal United Hospital, Kaohsiung, Taiwan. 4Department of Internal Medicine, Municipal Hsiao Kang Hospital, Kaohsiung, Taiwan

#807 INSULIN RESISTANCE INDUCES INTERFERON RESISTANCE IN PRIMARY CULTURE OF RAT HEPATOCYTES. ROLE OF PROTEIN TYROSINE PHOSPHATASE Cristina Rodríguez-Juan, Pablo Solís-Muñoz, Inmaculada GarcíaRuiz, Teresa Díaz-Sanjuán, Erica Gómez-Izquierdo, Teresa MuñozYagüe, José A. Solís-Herruzo Research Center, University Hospital “12 de Octubre”, Madrid, Spain


POSTER SESSIONS

175A

#808

#812

HVPG REPRESENTS AN IMPORTANT BASELINE PREDICTOR OF TREATMENT OUTCOME IN CIRRHOTIC HCV PATIENTS UNDERGOING ANTIVIRAL THERAPY

RETREATMENT WITH PEGINTERFERON (PEG-IFN) ALFA-2B PLUS RIBAVIRIN (RBV) OF CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS WHO WERE NONRESPONDERS TO PEGINTERFERON ALFA-2A: FINAL RESULTS OF ESPECIAL

Thomas Reiberger, Karoline Rutter, Arnulf Ferlitsch, Harald Hofer, Sandra Beinhardt, Peter Ferenci, Markus Peck-Radosavljevic Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria

#809 APPLIED PROTEOMICS IN HCV CO-INFECTION: DIFFERENTIAL EXPRESSION OF SERUM PROTEINS PRIOR TO TREATMENT IS ASSOCIATED WITH RESPONSE TO HCV THERAPY IN HIV COINFECTED INDIVIDUALS Honghui Wang2, Joerg F. Schlaak3, Henry Masur2, Michael A. Polis1, Anthony F. Suffredini2, Shyam Kottilil1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2CCMD, CC, NIH, Bethesda, MD, USA. 3UNIversity of Essen, ESsen, Germany

Stefan Zeuzem1, Moises Diago2, Thorsten Pohle3, Angelo Andriulli4, Ulrich Spengler5, Angelo Gatta6, Andreas Maieron7, Christoph Herold8, Xin Yu9, Rab Faruqi9, Eirum I. Chaudhri9, Lisa Pedicone9 1J.W. Goethe University Hospital, Frankfurt, Germany. 2Hospital General Valencia, Valencia, Spain. 3University of Münster, Münster, Germany. 4Casa Sollievo Sofferenza Hospital, San Giovanni Rotondo, Italy. 5University of Bonn, Bonn, Germany. 6University of Padua, Padova, Italy. 7Elisabethinen Hospital Linz, Linz, Austria. 8Universitätsklinikum Erlangen, Erlangen, Germany. 9ScheringPlough Research Institute, Kenilworth, NJ, USA

#813

#810

COMBINATION ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C IN ILLICIT DRUG USERS: META-ANALYSIS OF PROSPECTIVE STUDIES

PSYCHIATRIC SIDE-EFFECTS AND THE FLUCTUATION IN SEROTONERGIC PARAMETERS DURING TREATMENT OF CHRONIC HEPATITIS CINFECTION WITH PEGINTERFERON AND RIBAVIRINE

Barbara Zanini1, Loredana Covolo2, Francesco Donato2, Alberto Lanzini1 1Unit of Gastroenterology, University of Brescia, Brescia, Italy. 2Institute of Hygiene, Epidemiology and Public Health, University of Brescia, Brescia, Italy

Geert Bezemer1, Bart J. Veldt1, Robert J. de Knegt1, Joost P. Drenth2, Durk Fekkes1, Bettina E. Hansen1, Harry L. Janssen1, Arthur R. Van Gool1 1Erasmus Medical University, Rotterdam, Netherlands. 2Radboud University, Nijmegen, Netherlands

#811 IP-10 MRNA EXPRESSION IN LIVER BIOPSIES PREDICTS FIRST PHASE DECLINE OF PLASMA HCV RNA DURING THERAPY FOR CHRONIC HEPATITIS C VIRUS INFECTION

LEGALON-SIL DOWN-REGULATES HCV CORE AND NS5A EXPRESSION IN HUMAN HEPATOMA LINES EXPRESSING FULL-LENGTH HCV Marjan Mehrab-Mohseni1, Nury Steuerwald1,2, Hossein Sendi1,2, Judy Parsons1, Herbert L. Bonkovsky1,2 1The Liver-Biliary-Pancreatic Center, Carolinas Medical center, Charlotte, NC, USA. 2Department of Biology, University of North Carolina at Charlotte, Charlotte, NC, USA

#815 RETREATMENT OF CHRONIC HEPATITIS CGENOTYPE 1-INFECTED RELAPSERS TO PEGINTERFERON/RIBAVIRIN WITH CONSENSUS INTERFERON/RIBAVIRIN OR WITH EXTENDED DURATION THERAPY PEGINTERFERON/RIBAVIRIN Brian Pearlman1, Carole Ehleben2 1Center for Hepatitis C, Atlanta Medical Center, Medical College of GA, Emory School of Medicine, Atlanta, GA, USA. 2Atlanta Medical Center, Atlanta, GA, USA


Galia Askarieh1, Paolo Pugnale2, Francesco Negro2, Carlo Ferrari3, Avidan U. Neumann4, Jean-Michel Pawlotsky5, Solko W. Schalm6, Stefan Zeuzem7, Johan Westin1, Kristoffer Hellstrand1, Martin Lagging1 1Dept. of Infectious Diseases/Clinical Virology, Gothenburg University, Gothenburg, Sweden. 2Hospital University of Genève, Genève, Switzerland. 3Azienda Ospedaliera di Parma, Parma, Italy. 4Bar-Ilan University, Ramat-Gan, Israel. 5Hôpital Henri Mondor, Université Paris XII, Creteil, France. 6University Hospital Rotterdam Dijkzigt, Rotterdam, Netherlands. 7Dept. of Internal Medicine, J. W. Goethe University Hospital, Frankfurt, Germany

#814

176A

POSTER SESSIONS

#816

#820

INTERFERON ALPHA RECEPTOR 2 EXPRESSION BY PERIPHERAL BLOOD MONOCYTES IN PATIENTS SHOWING A HIGH BASELINE VIRAL LOADS OF HEPATITIS C VIRUS GENOTYPE 1 WITH SUBSTITUTION OF AMINO ACID 70 IN THE CORE REGION

DETERMINANTS OF VIROLOGIC RELAPSE FOLLOWING HEPATITIS C ANTIVIRAL THERAPY: ANALYSIS OF THE CANADIAN POWER PROGRAM

Koji Ishii1, Katsuya Higami1, Misato Sawa1, Mie Shinohara1, Hidenari Nagai2, Masanari Sano3, Toshisuke Morita1, Yasukiyo Sumino1 1Gastroenterology and Hepatology, Toho University, Tokyo, Japan. 2Clinical laboratory, Toho University, Tokyo, Japan. 3Laboratory Medicine, Toho University, Tokyo, Japan

#817 GENOTYPE AND DURATION OF THERAPY ARE CRUCIAL FOR SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C PATIENTS RETREATED AFTER RELAPSE FOLLOWING A PREVIOUS COURSE OF PEGYLATED INTERFERON PLUS RIBAVIRIN Christiane Stern1, Michelle Martinot-Peignoux1, Marie-Pierre Ripault1, Rami Moucari1, Tarik Asselah1, Ana-Carolina Cardoso1, Nathalie Boyer1, Pierre Bedossa2, Patrick Marcellin1 1Service d’Hépatologie and INSERM U773-CRB3, Hôpital Beaujon, Clichy, France. 2Service d’Anatomie-Pathologique, Hôpital Beaujon, Clichy, France

#818 THE INFLUENCE OF LIVER FIBROSIS ON THE OUTCOME OF PEGYLATED INTERFERON AND RIBAVIRIN ANTI-HCV THERAPY: A SUB-ANALYSIS OF THE MIST STUDY



Curtis Cooper1, Victor S. Feinman2, Cameron Ghent3, John D. Farley4, Helga B. Witt-Sullivan5, Jean Robert6, Kevork M. Peltekian7, Marc Poliquin8, Wayne Ghesquiere9, Robert Woolstencroft10, Paul Marotta11 1The Ottawa Hospital, Ottawa, ON, Canada. 2Mount Sinai Hospital, Toronto, ON, Canada. 3University of Western Ontario, London, ON, Canada. 4Private Practice, Vancouver, BC, Canada. 5Hamilton Health Sciences, Hamilton, ON, Canada. 6Centre Sida Amitie des Laurentides, St. Jerome, QC, Canada. 7Dalhousie University, Halifax, NS, Canada. 8Centre L’Actuel, Montreal, QC, Canada. 9Nova Clinical, Victoria, BC, Canada. 10Schering-Plough Canada Inc., Kirkland, QC, Canada. 11London Health Sciences Centre, London, ON, Canada

#821 THE CTLA4 +49 A>G POLYMORPHISM IN HIV+ PATIENTS WITH CHRONIC AND ACUTE HEPATITIS C Jacob Nattermann, Martin Vogel, Monika Michalk, Benjamin Krämer, Daniela Schulte, Christian Koerner, Martin Coenen, Jürgen K. Rockstroh, Tilman Sauerbruch, Ulrich Spengler Internal Medicine I, University of Bonn, Bonn, Germany

#822 EVIDENCE OF A SIGNIFICANT ROLE FOR FASMEDIATED APOPTOSIS IN HCV CLEARANCE DURING PEGYLATED INTERFERON PLUS RIBAVIRIN COMBINATION THERAPY

Gian Maria Prati, Mariagrazia Rumi, Alessio Aghemo, Roberta D’Ambrosio, Stella De Nicola, Massimo Colombo First Division of Gastroenterology, Fondazione Ospedale Maggiore Policlinico IRCCS, University of Milano, Milano, Italy, Milan, Italy

Leonardo L. Schiavon, Janaína L. Narciso-Schiavon, Roberto J. Carvalho-Filho, Juliana P. Sampaio, Philipe N. El Batah, Genimari A. Silva, Claudia T. Carvente, Antonio Eduardo B. Silva, Maria Lucia G. Ferraz Gastroenterology, Hepatitis Section, Federal University of Sao Paulo, Sao Paulo, Brazil

#819

#823

LOW-TO-MODERATE ALCOHOL CONSUMPTION HAS NO IMPACT ON ANTIVIRAL RESPONSE TO COMBINATION THERAPY IN HCV PATIENTS WITH GENOTYPE 2 OR 3

RAPID PREDICTION OF NON-VIROLOGICAL RESPONSE TO PEG-IFNα2B/RIB COMBINATION THERAPY FOR CHRONIC HEPATITIS C BY COMBINATION OF HCV DYNAMICS AND AMINO ACID SUBSTITUTIONS IN THE HCV CORE REGION

Roberto J. Carvalho-Filho1, Hans Verbaan4, Kristian Bjøro2, Helmer Ring-Larsen3, Olav Dalgard2 1Gastroenterology, Hepatitis Section, Federal University of São Paulo, São Paulo, Brazil. 2Medical Department, Rikshospitalet, Oslo, Norway. 3Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences, University of Copenhagen, Oslo, Norway. 4Medical Department, Malmø University Hospital, Malmø, Norway


Hiroaki Hashimoto1, Yoshito Itoh1, Ken Nishimura1, Masahito Minami1, Kohichiroh Yasui1, Hironori Mitsuyoshi1, Kanji Yamaguchi1, Masaki Iwai1, Takeshi Okanoue2, Toshikazu Yoshikawa1 1Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan. 2Hepatology unit, Saiseikai Suita Hospital, Suita, Japan


POSTER SESSIONS

177A

#824

#829

GENOME-WIDE SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS IDENTIFIES A UNIQUE CCL-5 HALPLOTYPE IN HIV/HCV CO-INFECTED NON-RESPONDERS TO PEGYLATED-INTERFERON (PEG-IFN) AND RIBAVIRIN (RBV) THERAPY

PEGYLATED INTERFERON ALFA-2A MONOTHERAPY FOR HEMODIALYSIS PATIENTS WITH ACUTE HEPATITIS C

Richard A. Lempicki2, Joerg F. Schlaak4, Henry Masur3, Michael A. Polis1, Shyam Kottilil1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2sAIC-Frederick, frederick, MD, USA. 3CCMD, CC, NIH, bethesda, MD, USA. 4UNiversity of Essen, Essen, Germany

#825 STRONG PRE-TREATMENT HCV-SPECIFIC T-CELL RESPONSE MAY PREDICT RAPID VIROLOGICAL RESPONSE IN PATIENTS STARTING ANTI-HCV THERAPY Norma I. Rallón1, Vincent Soriano1, Javier García-Samaniego2, Eugenia Vispo1, Mariola López1, Miriam Romero2, Juan GonzálezLahoz1, José M. Benito1 1Infectious Diseases Department, Hospital Carlos III, Madrid, Spain. 2Hepatology Unit, CIBEREHD, Hospital Carlos III, Madrid, Spain

#826 IMPACT OF DIABETES MELLITUS ON INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C PATIENTS TREATED WITH INTERFERON BASED ANTIVIRAL THERAPY Chao-Hung Hung, Chuan-Mo Lee, Sheng-Nan Lu, Jing-Houng Wang, Tsung-Hui Hu, Chien-Hung Chen Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

#827 DISCORDANCE BETWEEN HCV RNA WEEK 24 TEST RESULTS OF THREE DIFFERENT HCV RNA ASSAYS DURING TREATMENT OF CHRONIC HEPATITIS C: OPTIMIZATION OF TREATMENT LENGTH USING THE MOST SENSITIVE HCV RNA ASSAY

#828 THROMBOCYTOPENIA DURING TREATMENT WITH PEGINTERFERON ALFA AND RIBAVIRIN FOR CHRONIC HEPATITIS C IS NOT ASSOCIATED WITH SEVERE BLEEDINGS Robert Roomer, Bettina E. Hansen, Harry L. Janssen, Robert J. de Knegt Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Netherlands

#830 SCREENING FOR AUTOANTIBODIES BEFORE INITIATION OF ANTIVIRAL THERAPY IN CHRONIC HEPATITIS C HAS NO EFFECT ON TREATMENT INITIATION OR OUTCOME Stefan Mauss1, Dietrich Hueppe2, Kaiser Stephan3, Andreas Schober4, Gero Moog5, Juergen Lohmeyer6, Renate Heyne7, Willibold Schiffelholz8, Bernd Moeller9, Marcus Schuchmann10, Frank Ackermann11, Christine John12, Srefan Pape13, Thomas Lutz14, Axel Baumgarten15, Wolfgang Schmidt16, Ulrich Alshuth17, Elmar Zehnter18 1Center for HIV and Hepatogastroenterology, Duesseldorf, Germany. 2Center of Gastroenterology, Herne, Germany. 3Center for Liver and Infectious Diseases, Stuttgart, Germany. 4Center of Gastroenterology, Goettingen, Germany. 5Center of Gastroenterology, Kassel, Germany. 6Justus Liebig University, Giessen, Germany. 7Center of Gastroenterology and Livercenter, Berlin, Germany. 8Center of Gastroenterology, Augsburg, Germany. 9Center of Gastroenterology and Livercenter, Berlin, Germany. 10Hospital of Johannes Gutenberg University, Mainz, Germany. 11Meddata GmbH, Schkeuditz, Germany. 12Center of Gastroenterology, Berlin, Germany. 13Center of Gastroenterology, Paderborn, Germany. 14Practice of internal medicine, Frankfurt am Main, Germany. 15Practice of internal medicine, Berlin, Germany. 16Center of Gastroenterology, Berlin, Germany. 17Hepatitis/HIV/CF, Roche Pharma AG, Grenzach-Wyhlen, Germany. 18Center of Gastroenterology, Dortmund, Germany

#831 SUSTAINED VIROLOGICAL RESPONDERS TO PEGYLATED INTERFERON AND RIBAVIRIN THERAPY MAY SHOW TRANSIENT HCV-RNA POSITIVITY WHEN ADEQUATELY FOLLOWED UP. CLINICAL ASSOCIATIONS AND SIGNIFICANCE OF THIS PHENOMENON DURING 7-YEAR FOLLOWUP OF 506 TREATED PATIENTS Edoardo G. Giannini1, Monica Basso2, Vincenzo Savarino1, Antonino Picciotto2 1Department of Internal Medicine, Gastroenterology Unit, Genova, Italy. 2Department of Internal Medicine, Viral Hepatitis Unit, Genova, Italy


Robert Roomer, Angela Heijens, Martin Schutten, Harry L. Janssen, Robert J. de Knegt Erasmus MC, Rotterdam, Netherlands

Chen-Hua Liu1,2, Cheng-Chao Liang2,3, Chun-Jen Liu1,4, Shih-Jer Hsu2,5, Shih-I Chen5, Hung-Bin Tsai6, Peir-Haur Hung7, Jou-Wei Lin5, Ming-Yang Lai1,4, Pei-Jer Chen2,8, Jun-Herng Chen9, DingShinn Chen1,4, Jia-Horng Kao2,4 1Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 2Graduate Institue of Clinical Medicine, National Taiwan University Hospital, Taipei, Taiwan. 3Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan. 4Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan. 5Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan. 6Internal Medicine, Buddhist General Hospital, Chiayi, Taiwan. 7Internal Medicine, Chiayi Christian Hospital, Chiayi, Taiwan. 8Medical Research, National Taiwan University Hospital, Taipei, Taiwan. 9Pathology, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan

178A

POSTER SESSIONS

#832

#835

PREDICT STUDY FINAL RESULTS: EFFICACY AND SAFETY OF 24-WK REGIMEN OF PEGINTERFERON ALFA-2B PLUS WEIGHT-BASED RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1 (G1) WITH LOW VIRAL LOAD WHO ACHIEVE RAPID VIRAL RESPONSE

THE EFFECTS OF RIBAVIRIN ON SERUM HCV LEVELS BEFORE AND DURING COMBINATION TREATMENT WITH PEGINTERFERON

Antonio Craxi1, Eli. Zuckerman2, Sotirios Koutsounas3, Pavel P. Ogurtsov4, Liliana Chemello5, Mojca B. Maticic6, Xavier Torras7, Moises Diago8, Mariateresa Tartaglione9, Thomas Witthoeft10, Xin Yu11, Eirum I. Chaudhri11, Lisa Pedicone11, Rab Faruqi11 1University of Palermo, Palermo, Italy. 2Carmel Medical Center Liver Unit, Haifa, Israel. 31st Hospital IKA PENTELI, Gastroenterology, Mellisia, Greece. 4Russian University of People Friendship, Moscow, Russia. 5University of Padua, Padova, Italy. 6University Medical Centre Ljubljana, Department of Infectious Diseases and Febrile Illnesses, Ljubljana, Slovenia. 7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 8Hospital General Valencia, Valencia, Spain. 9Cardarelli Hospital, Naples, Italy. 10University Hospital Schleswig Holstein Campus Luebeck, Lubeck, Germany. 11Schering Plough Research Institute, Kenilworth, NJ, USA

#833 INSULIN RESISTANCE IS NOT A RELEVANT PREDICTOR OF SUSTAINED VIROLOGIC RESPONSE IN CHRONIC HEPATITIS C PATIENTS: RESULTS FROM THE ITALIAN HEPATITIS C COHORT STUDY (ITAHECS) COLLABORATIVE GROUP Giovanna Fattovich1, Loredana Covolo2, Michela Pasino1, Eleonora Perini2, Luigi Rossi3, Giorgio Brocco3, Maria Guido4, Laura Peraro1, Caterina Bellotti2, Cecilia Pravadelli1, Massimo Puoti5, Eliseo Minola6, Giovanni B. Gaeta7, Teresa Santantonio8, Giovanni Raimondo9, Raffaele Bruno10, Francesco Donato2 1Gastroenterology Unit, University of Verona, Verona, Italy. 2Institute of Hygiene, University of Brescia, Brescia, Italy. 3Laboratory of Biochemistry, Haematology and Molecular Biology, University of Verona, Verona, Italy. 4University of Padova, Padova, Italy. 5Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy. 6Ospedali Riuniti di Bergamo, Bergamo, Italy. 7University of Naples, Naples, Italy. 8University of Foggia, Foggia, Italy. 9University of Messina, Messina, Italy. 10University of Pavia, Pavia, Italy



EFFICACY AND SAFETY OF ANTIVIRAL THERAPY IN CHRONIC HEPATITIS C (CHC) WITH AUTOIMMUNE HEPATITIS (AIH) FEATURES Helen S. Te1, Erin T. Jenkins2, Rish Pai3, John Hart3, Smruti R. Mohanty1, Nancy Reau1, K. Gautham Reddy1, Rohit S. Satoskar1, Donald M. Jensen1 1Medicine, Center for Liver Diseases, University of Chicago Medical Center, Chicago, IL, USA. 2Medicine, University of Chicago Medical Center, Chicago, IL, USA. 3Pathology, University of Chicago Medical Center, Chicago, IL, USA


Mazen Noureddin, Yaron Rotman, Jordan Feld, Christopher Koh, Adil Abdalla, Emmanuel Thomas, Yoon Park, Theo Heller, Marc G. Ghany, Jay H. Hoofnagle, T. Jake Liang Liver Diseases Branch, NIDDK, NIH, Bethesda, MD, USA

#836 EFFICACY OF TAILORED EXTENTION OF PEGYLATED-INTERFERON AND RIBAVIRIN IN CHRONIC HEPATITS C PATIENTS Hiroki Ikeda1, Michihiro Suzuki1, Norie Yamada1,3, Masaru Okamoto1, Minoru Kobayashi1, Hideaki Takahashi1, Kotaro Matsunaga1, Chiaki Okuse1, Nobuyuki Matsumoto1, Hiroshi Yotsuyanagi2, Kiyomi Yasuda3, Fumio Itoh1 1Department of Internal Medicine, Division of Gastroenterology and Hepatology, St. Marianna University, School of medicine, Kanagawa, Japan. 2Department of Infectious Diseases, Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan. 3Center for liver disease, Kiyokawa hospital, Tokyo, Japan

#837 HEMOGLOBIN DECLINE IS NOT ASSOCIATED WITH SVR AMONG HCV G1-INFECTED PATIENTS IN DAY-TO-DAY CLINICAL PRACTICE Giancarlo Spinzi1, Gianmario Borroni2, Marco Andreoletti3, Aurora Bortoli4, Mariantonietta Casiraghi5, Massimo Cazzaniga6, Roberto Ceriani7, Patrizia Guerzoni8, Giovanna Mandelli1, Barbara Omazzi4, Silvia Paggi1, Natalia Terreni1 1Gastroenterology, Valduce Hospital, Como, Italy. 2Unità Organizzativa Alcoldipendenze, ASL Milano 1, Abbiategrasso-Milano, Italy. 3Medicina Interna, Ospedale Manzoni, Lecco, Italy. 4Gastroenterologia, Ospedale Rho, Rho-Milano, Italy. 5Medicina Interna, Ospedale Legnano, Legnano-Milano, Italy. 6Medicina Interna, IRCCS Policlinico S. Donato, San Donato Milanese-Milano, Italy. 7Medicina Interna ed Epatologia, IRCCS Istituto Clinico Humanitas, Rozzano-Milano, Italy. 8Gastroenterologia, Ospedale Varese, Varese, Italy

#838 EVALUATION OF HCV RNA DECAY 48 HOURS AFTER STARTING COMBINATION THERAPY WITH PEGILATED INTERFERON AND RIBAVIRIN AS A TOOL FOR EARLY PREDICTION OF SUSTAINED VIROLOGIC RESPONSE Giustino Parruti1, Federica Sozio1, Alessandro Pieri1, Ennio Polilli2, Francesco Di Masi1, Luana Cosentino2, Luciana Alterio1, Lamberto Manzoli3 1Internal Medicine, Ospedale Civile dello Spirito Santo, Pescara, Italy. 2Virology and Biochemistry, Ospedale Civile dello Spirito Santo, Pescara, Italy. 3Unit of Epidemiology, Università di Chieti, Chieti, Italy


POSTER SESSIONS

#839

#841

REDUCING DRUG DOSES IN GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C DURING TREATMENT WITH PEGYLATED INTERFERON ALFA2B PLUS RIBAVIRIN DELAYS THE TIMING OF HCV RNA NEGATIVITY OR PREVENTS ITS ATTAINMENT; A PROPENSITY SCORE-MATCHED STUDY

EVOLUTION OF LIVER STIFFNESS AND BIOCHEMICAL TESTS IN HCV TREATED AND UNTREATED PATIENTS. A PROSPECTIVE MULTICENTRE STUDY

Changho Song1, Naoki Hiramatsu1, Tsugiko Oze1, Takayuki Yakushijin1, Kiyoshi Mochizuki1, Kazuho Imanaka2, Sadaharu Iio3, Masahide Oshita4, Hideki Hagiwara5, Eiji Mita6, Toshifumi Ito7, Yoshiaki Inui8, Taizo Hijioka9, Shinji Tamura10, Harumasa Yoshihara11, Yasuharu Imai12, Michio Kato13, Yuichi Yoshida1, Tomohide Tatsumi1, Shinichi Kiso1, Tatsuya Kanto1, Akinori Kasahara1, Tetsuo Takehara1, Norio Hayashi1 1Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan. 2Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan. 3HIgashiosaka City General Hospital, Higashiosaka, Japan. 4Osaka Police Hospital, Osaka, Japan. 5Kansai Rosai Hospital, Amagasaki, Japan. 6National Hospital Organization Osaka National Hospital, Osaka, Japan. 7Osaka Kouseinenkin Hospital, Osaka, Japan. 8Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan. 9National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan. 10Minoh City Hospital, Minoh, Japan. 11Osaka Rosai Hospital, Sakai, Japan. 12Ikeda Municipal Hospital, Ikeda, Japan. 13National Hospital Organization Minami Wakayama Medical Center, Tanabe, Japan

#840 PREDICTION OF EARLY RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN IN CHRONIC HEPATITIS C BASED ON AMINO ACID SUBSTITUTIONS IN THE VIRAL CORE REGION Yuko Inoue1, Naoki Hiramatsu1, Tsugiko Oze1, Takayuki Yakushijin1, Kiyoshi Mochizuki1, Eiji Mita2, Kazuto Fukuda3, Yasuharu Imai3, Michio Kato4, Shinichi Kiso1, Tatsuya Kanto1, Akinori Kasahara1, Tetsuo Takehara1, Norio Hayashi1 1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita-city, Japan. 2National Hospital Organization Osaka National Hospital, Osaka-city, Japan. 3Ikeda Municipal Hospital, Ikeda-city, Japan. 4National Hospital Organization Minami Wakayama Medical Center, tanabe-city, Japan

179A

Stella M. Martinez1, Juliette Foucher2, Jean-Marc Combis3, Sophie Métivier4, Barbara Coco5, Dominique Capron6, Marc Bourlière7, Jean-Pierre Bronowicki8, Isabelle Ollivier-Hourmand9, Marianne Maynard-Muet10, Damien Lucidarme11, Wassil Merrouche2, Maurizia R. Brunetto5, Xavier Forns1, Victor de Ledinghen2,12 1Liver Unit, Hospital Clinic, Barcelona, Spain. 2Hepatology Unit, Hopital Haut-Leveque, Pessac, France. 3Clinique Ambroise Paré, Toulouse, France. 4Hepatology Unit, CHU Purpan, Toulouse, France. 5hepatology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. 6Hepatology Unit, CHU, Amiens, France. 7Hepatology Unit, Clinique Saint Jospeh, Marseille, France. 8CHU, Vandoeuvre les Nancy, France. 9CHU, Caen, France. 10Hotel Dieu, Lyon, France. 11Hopital Saint Philibert, Lomme, France. 12INSERM U889, Universite Victor segalen, Bordeaux, France

#842 EARLY VIROLOGIC KINETICS INFLUENCE TIME FROM BDNA NEGATIVITY TO TMA NEGATIVITY IN HCV TYPE 1-INFECTED PATIENTS RECEIVING PEGINTERFERON ALFA-2B AND RIBAVIRIN (INDIV-1 STUDY GROUP) Viola Weich1, Gerlinde Teuber2, Hartwig Klinker3, Bernd Moeller4, Jens Rasenack5, Holger Hinrichsen6, Tilman Gerlach7, Ulrich Spengler8, Peter Buggisch9, Christoph Sarrazin10, Stefan Zeuzem10, Thomas Berg1 1Charite, Campus virchow, Berlin, Germany. 2Praxis Frankfurt, Frankfurt, Germany. 3Universität Würzburg, Würzburg, Germany. 4Hepatologische Schwerpunktpraxis, Berlin, Germany. 5Medizinische Universitätsklinik, Freiburg, Germany. 6Praxis Kiel, Kiel, Germany. 7Klinikum St Gallen, St Gallen, Switzerland. 8Medizinische Universitätsklinik Bonn, Bonn, Germany. 9Medizinische Universitätsklinik Eppendorf, Hamburg, Germany. 10Medizinische Klinik der Johann Wolfgang Goethe Universität, Frankfurt, Germany

#843 EXTENSION OF COMBINATION THERAPY IN HCV/HIV CO-INFECTED GENOTYPE 1 PATIENTS: EFFECT ON SVR

#844 DISADVANTAGES OF PEGINTERFERON AND RIBAVIRIN TREATMENT IN ELDERLY PATIENTS WITH CHRONIC HEPATITIS C: – AN ANALYSIS USING THE PROPENSITY SCORE METHOD – Hirotoshi Ebinuma, Hidetsugu Saito, Keisuke Ojiro, Nobuhiro Nakamoto, Yoshiyuki Yamagishi, Toshifumi Hibi Internal Medicine, Keio University, Tokyo, Japan


Tarek Hassanein1, Renee S. Pozza2, Karel Biando2, Lisa M. Richards1, Lita Petcharaporn1, Fatma Barakat1, Mohamed El Kabany2 1University of California, San Diego, San Diego, CA, USA. 2Southern California Liver Centers, San Clemente, CA, USA

180A

POSTER SESSIONS


#845

#848

EMERGENCE OF ANTI-ARFP ANTIBODIES IS POSITIVELY ASSOCIATED WITH FAILURE OF IFNALPHA/RIBAVIRIN TREATMENT IN GENOTYPE 1B VIRAHEP C PATIENTS

ANALYSIS OF REASONS FOR TREATMENT INELIGIBILITY IN THE IDEAL STUDY: AFRICAN AMERICANS (AA) VS NON-AFRICAN AMERICANS (NON-AA)

Jose L. Walewski1, Arielle L. Klepper1, Sarah Fishman1, Julio A. Gutierrez1, John Tavis2, Andrea D. Branch1 1Medicine, Mount Sinai School of Medicine, New York, NY, USA. 2Molecular Microbiology and Immunology, Saint Louis University Medical Center, Saint Louis, MO, USA

Michael Melia1, Andrew Muir2, Jonathan McCone3, Mitchell L. Shiffman4, John W. King5, Steven K. Herrine6, Greg Wayne Galler7, Joseph R. Bloomer8, Frederick Nunes9, Kimberly Ann Brown10, Kevin D. Mullen11, Natarajan Ravendhran12, William M. Cassidy13, Reem H. Ghalib14, Navdeep Boparai15, Ruiyun Jiang15, Stephanie Noviello15, Clifford A. Brass15, Janice K. Albrecht15, John G. McHutchison2, Mark S. Sulkowski1 1Medicine/Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2Duke Clinical Research Institute, Durham, NC, USA. 3Mt. Vernon Endoscopy Center, Alexandria, VA, USA. 4Virginia Commonwealth University Medical Center, Richmond, VA, USA. 5Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA, USA. 6Thomas Jefferson University, Philadelphia, PA, USA. 7Kelsey Research Foundation, Houston, TX, USA. 8University of Alabama at Birmingham Liver Center, Birmingham, AL, USA. 9Pennsylvania Hospital, Philadelphia, PA, USA. 10Henry Ford Hospital, Detroit, MI, USA. 11Metro Health Medical Center, Cleveland, OH, USA. 12Digestive Disease Associates, Baltimore, MD, USA. 13Louisiana State University Health Sciences Center, Baton Rouge, Baton Rouge, LA, USA. 14The Liver Institute at Methodist Dallas, Dallas, TX, USA. 15Schering-Plough Research Institute, Kenilworth, NJ, USA

#846 COMPARATIVE ANALYSIS OF IN VIVO ANTIVIRAL EFFECTS AND INDUCTION OF INTERFERONINDUCIBLE GENES BY PEGYLATED-INTERFERON AND ALBINTERFERON ALFA-2B IN HIV/HCV COINFECTED SUBJECTS Alison Murphy1, Marybeth Daucher1, Mani Subramanian2, Michael A. Polis1, Shyam Kottilil1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2Human Genome Sciences, Rockville, MD, USA

#847 SILIBININ FOR TREATMENT OF NONRESPONDERS TO PEGINTERFERON/RIBAVIRIN – SEARCH FOR THE OPTIMAL DOSING SCHEDULE


Thomas-Matthias Scherzer1, Sandra Beinhardt1, Karoline Rutter1, Albert Stättermayer1, Andreas Maieron3, Rudolf E. Stauber4, Michael Gschwantler5, Heidrun Kerschner2, Petra E. SteindlMunda1, Harald Hofer1, Peter Ferenci1 1Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria. 2Department of Clinical Virology, Medical University of Vienna, Vienna, Austria. 3Department of Internal Medicine 4, Hospital Elisabethinen Linz, Linz, Austria. 4Department of Internal Medicine, Medical University of Graz, Graz, Austria. 5Department of Internal Medicine 4, Wilhelminen Hospital, Vienna, Austria


#849 EFFICACY OF A “ON-TREATMENT VIRAL RESPONSE TAILORED REGIMEN” WITH PEGINTERFERON (PEGIFN) ALFA 2B PLUS RIBAVIRIN IN NAïVE GENOTYPE 1 CHRONIC HEPATITIS C (CHC) MEXICAN PATIENTS Juan F. Sanchez-Avila1, Eduardo Cerda1, Jorge Garcia-Leiva1, Alejandro Chavez-Ayala1, Aurora Loaeza del Castillo1, Magdalena Sanchez-Osorio1, Arturo Meixueiro-Daza1, Aldo J. Montano-Loza1, Norma Uribe-Uribe2, Florencia Vargas-Vorackova1, Misael UribeEsquivel1 1Gastroenterology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, City, Mexico. 2Pathology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico


POSTER SESSIONS

#850

#853

OUTCOMES OF A LARGE, INCLUSIVE POPULATION-BASED HEPATITIS C TREATMENT PROGRAM ARE SIMILAR TO RANDOMIZED CONTROLLED TRIALS: INTERIM RESULTS OF THE CANADIAN REDIPEN PROGRAM

STAGE OF FIBROSIS AND RAPID VIROLOGIC RESPONSE PREDICT OUTCOME OF ANTIVIRAL THERAPY IN HCV GENOTYPE 2 AND 3

Curtis Cooper1, Jean Robert2, Victor S. Feinman3, Magdy Elkashab4, Frank H. Anderson5, Linda J. Scully1, Karen E. Doucette6, Helga B. Witt-Sullivan7, Robert J. Bailey6, Robert P. Myers8, John D. Farley9, Barbara Romanoswki6, Robert Woolstencroft10, Nabil Abadir10, Cameron Ghent11 1The Ottawa Hospital, Ottawa, ON, Canada. 2Centre Sida Amitie des Laurentides, St. Jerome, QC, Canada. 3Mount Sinai Hospital, Toronto, ON, Canada. 4Toronto Liver Centre, Toronto, ON, Canada. 5Liver and Intestinal Research Centre, Vancouver, BC, Canada. 6University of Alberta, Edmonton, AB, Canada. 7Hamilton Health Sciences, Hamilton, ON, Canada. 8University of Calgary, Calgary, AB, Canada. 9Private Practice, Vancouver, BC, Canada. 10Schering-Plough Canada Inc., Kirkland, QC, Canada. 11University Western Ontario, London, ON, Canada

#851 CONSENSUS INTERFERON ± RIBAVIRIN RETREATMENT FOR CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN PEGYLATED INTERFERON/RIBAVIRIN NONRESPONDERS/RELAPSERS: OUTCOMES FROM A NATIONAL CLINICAL PRACTICE SETTING Helen S. Yee1,2, Myrna Cozen1,2, Hui Shen1,2, Summer Chapman3, Kathy Tortorice3, Fran Cunningham3, Teresa L. Wright1,4, Sue Currie5, Alexander Monto1,2 1Gastroenterology, Department of Veterans Affairs Medical Center, San Francisco, CA, USA. 2University of California, San Francisco, San Francisco, CA, USA. 3Pharmacy Benefits Management Strategic Healthcare Group, Hines, IL, USA. 4Roche Molecular Diagnostics, Pleasanton, CA, USA. 5Clinical Care Options, Reston, VA, USA

#852

Satawat Thongsawat1, Teerha Piratvisuth2, Chutima Pramoolsinsap3, Anuchit Chutaputti4, Tawesak Tanwandee5, Wolfgang Berger6, Isaya Sukarom7, Sirana Tinmanee7 1Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand. 2Songklanagarind Hospital, Prince of Songkla University, Songkla, Thailand. 3Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 4Phramongkutklao Hospital, Bangkok, Thailand. 5Siriraj Hospital, Mahidol University, Bangkok, Thailand. 6F. Hoffmann-La Roche Ltd, Basel, Switzerland. 7Roche Thailand Ltd, Bangkok, Thailand

Christine Pocha1,2, Denise Buss1, Paul Thuras1,2, Eric Dieperink1,2 C Resource Center, Minneapolis VAMC, Minneapolis, MN, USA. 2Medical School, University of Minnesota, Minneapolis, MN, USA 1Hepatitis

#854 FACTORS PREDICTING ANEMIA IN PATIENTS WITH HCV CIRRHOSIS TREATED WITH STANDARD DOSE PEGYLATED INTERFERON AND RIBAVIRIN Monica Basso1, Edoardo G. Giannini2, Vincenzo Savarino2, Antonino Picciotto1 1Department of Internal Medicine, Viral Hepatitis Unit, Genova, Italy. 2Department of Internal Medicine, Gastroenterology Unit, Genova, Italy

#855 IP-10 PREDICTS THE FIRST PHASE DECLINE IN HCV RNA AND OVERALL VIRAL RESPONSE TO THERAPY FOR CHRONIC HEPATITIS C VIRUS INFECTION IN HIV-1 CO-INFECTED PATIENTS Karolin Falconer1, Galia Askarieh2, Nina Weis3,4, Kristoffer Hellstrand2, Annette Alaeus1, Martin Lagging2 1Dept. of Medicine Solna/Infectious Diseases Unit, Karolinska Institutet, Stockholm, Sweden. 2Dept. of Infectious Diseases and Virology, Gothenburg University, Gothenburg, Sweden. 3Dept. of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Copenhagen, Denmark. 4Dept. of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark

#856 FACTORS AFFECTING EFFICACY IN PATIENTS WITH GENOTYPE 2 CHRONIC HEPATITIS C TREATED BY PEGYLATED INTERFERON ALFA-2B AND RIBAVIRIN: REDUCING DRUG DOSES HAS NO IMPACT ON RAPID AND SUSTAINED VIROLOGICAL RESPONSES Yuko Inoue1, Naoki Hiramatsu1, Tsugiko Oze1, Takayuki Yakushijin1, Kiyoshi Mochizuki1, Hideki Hagiwara2, Masahide Oshita3, Eiji Mita4, Hiroyuki Fukui5, Masami Inada6, Shinji Tamura7, Harumasa Yoshihara8, Eijirou Hayashi9, Atsuo Inoue10, Yasuharu Imai11, Michio Kato12, Takuya Miyagi1, Atsushi Hosui1, Hisashi Ishida1, Shinichi Kiso1, Tatsuya Kanto1, Akinori Kasahara1, Tetsuo Takehara1, Norio Hayashi1 1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita-city, Japan. 2Kansai Rousai Hospital, Amagasaki-city, Japan. 3Osaka Police Hospital, Osaka-city, Japan. 4National Hospital Organization Osaka National Hospital, Osaka-city, Japan. 5Yao Municipal Hospital, Yao-city, Japan. 6Toyonaka Municipal Hospital, Toyonaka-city, Japan. 7Minoh City Hospital, Minoh-city, Japan. 8Osaka Rousai Hospital, Sakai-city, Japan. 9Kinki Central Hospital of Mutual Aid Association of Public School Teachers, Itami-city, Japan. 10Osaka General Medical Center, Osaka-city, Japan. 11Ikeda Municipal Hospital, Ikeda-city, Japan. 12National Hospital Organization Minami Wakayama Medical Center, Tanabe-city, Japan


PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN IS DOMINANT WITH LARGE COSTSAVINGS VERSUS NO TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (CHC), GENOTYPE 2/3: A COST-EFFECTIVENESS ANALYSIS FROM THE THAI PAYER PERSPECTIVE

181A

182A

POSTER SESSIONS

#857

#861

ASSESMENT AND PREDICTION OF SUSTAINED VIROLOGICAL RESPONSE AMONG TREATMENTNAïVE LATINOS WITH, GENOTYPE 1 HCV TREATED WITH STANDARD DOUBLE VERSUS TRIPLE THERAPY WITH AMANTADINE

RESIDUE INTERACTION NETWORKS FOR ANALYZING MOLECULAR RESISTANCE MECHANISMS IN PEPTIDOMIMETIC NS3.4A PROTEASE INHIBITORS FOR HCV

Jorge Mendez-Navarro1,2, Ruby A. Chirino1, Kathleen E. Corey2, Emmanuel C. Gorospe3, Hui Zheng2, Raymond Chung2, Margarita Dehesa-Violante1 1Gastroenterología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS, Mexico, Mexico. 2GI, MGH, Boston, MA, USA. 3Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

#858 PEGINTERFERON ALPHA-2A MAY ACHIEVE HIGHER SUSTAINED VIROLOGICAL RESPONSE THAN PEGINTERFERON ALPHA-2B IN CHRONIC HEPATITIS C: A COCHRANE SYSTEMATIC REVIEW OF RANDOMIZED CLINICAL TRIALS Awad1,

Thorlund1,

Hauser3,

Stimac3,

Tahany Kristian Goran Davor Mahasen Mabrouk2, Christian Gluud1 1Cochrane Hepato-Biliary Group, Cocpenhagen University, Copenhagen, Denmark. 2Endemic Medicine, Cairo University, Cairo, Egypt. 3Clinics of Internal Medicine, Clinical Hospital Centre of Rijeka, Rijeka, Croatia

#859 CORRELATION BETWEEN INTERFERON ALPHA RECEPTOR 2 EXPRESSION BY PERIPHERAL BLOOD MONOCYTES AND EARLY VIRAL RESPONSE IN PATIENTS SHOWING A HIGH BASELINE VIRAL LOADS OF HEPATITIS C VIRUS GENOTYPE 1 WITH SUBSTITUTIONS OF AMINO ACID IN THE CORE AND/OR NO SUBSTITUTIONS IN THE INTERFERON-SENSITIVITY DETERMINING REGION Koji Ishii1, Mie Shinohara1, Katsuya Higami3, Misato Sawa1, Hidenari Nagai1, Masanari Sano2, Toshisuke Morita3, Yasukiyo Sumino1 1Gastroenterology and Hepatology of Internal Medicine, Toho University, Tokyo, Japan. 2Clinical laboratory, Toho University, Tokyo, Japan. 3Laboratory Medicine, Toho University, Tokyo, Japan S U N D AY NOVEMBER 1


#860 EARLY RIBAVIRIN LEVELS PREDICT STEADY STATE CONCENTRATION IN HEPATITIS C PATIENTS Slavenburg4,

Slavenburg1,

Dofferhoff2,

Serena Serena Ton Clemens Richter3, Peter Koopmans5, Corrien Verwey- Van Wissen6, Joost P. Drenth1, David M. Burger6 1Department of Gastroenterology and Hepatology, Radboud University Medical Center Nijmegen, Nijmegen, Netherlands. 2Department of Internal Medicine & Infectious Diseases, CanisiusWilhelmina Hospital, Nijmegen, Netherlands. 3Department of Internal Medicine & Infectious Diseases, Rijnstate Hospital Arnhem, Arnhem, Netherlands. 4Department of Clinical Pharmacy, CanisiusWilhelmina Hospital, Nijmegen, Netherlands. 5Department of Internal Medicine & Infectious Diseases, Radboud University Medical Center Nijmegen, Nijmegen, Netherlands. 6Department of Clinical Pharmacy, Radboud University Medical Center Nijmegen, Nijmegen, Netherlands


Christoph Welsch1,2, Mario Albrecht2, Francisco S. Domingues2, Simone Susser1, Christoph Sarrazin1, Stefan Zeuzem1, Thomas Lengauer2 1Internal Medicine I, J. W. Goethe University Hospital, Frankfurt am Main, Germany. 2Computational Biology and Applied Algorithmics, Max-Planck-Institute for Informatics, Saarbrücken, Germany

#862 IDENTIFICATION OF ALT PATTERNS DURING ANTIVIRAL THERAPY OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 INFECTION ASSOCIATED WITH TREATMENT RESPONSE IN A LARGE GERMAN RETROSPECTIVE MULTICENTER TRIAL (PRACTICE) Bernd Kronenberger1, Gerlinde Teuber1, Stefan Mauss2, Dietrich Hueppe3, Christine John4, Renate Heyne5, Bernd Moeller5, Ralf Link6, Andreas Herrmann7, Axel Baumgarten8, Nektarios Dikopoulos9, Thomas Witthoeft10, Stefan Zeuzem1 1Dept. of Internal Med. 1, Hospital of the Goethe University, Frankfurt, Germany. 2Center for HIV and hepatogastroenterology, Düsseldorf, Germany. 3Center of Gastroenterology, Herne, Germany. 4Center of Gastroenterology, Berlin, Germany. 5Center of Gastroenterology and Livercenter, Berlin, Germany. 6Internal Medicine, St. Josefs-Krankenhaus, Offenburg, Germany. 7Friedrich SchillerUniversitaet, Jena, Germany. 8General Practice, Berlin, Germany. 9Klinik für Innere Medizin I, Universitaetsklinikum Ulm, Ulm, Germany. 10Center of Gastroenterology, Stade, Germany

#863 EXAMINATION OF INHIBITION OF HEPATOCELLULAR CARCINOMA RESULTING FROM TREATMENT OF CHRONIC HEPATITIS C WITH INTERFERON PLUS RIBAVIRIN – HEPATOCELLULAR CARCINOMA IS INHIBITED IN PATIENTS WITH SUSTAINED VIRAL RESPONSE AND SUSTAINED BIOCHEMICAL RESPONSE Jun Nakajima, Atsuyuki Ikeda, Sumio Saito, Toru Kimura, Yukio Osaki gastroenterology, Osaka red cross Hospital, Osaka, Japan

#864 PROTEOME-WIDE ANTI-HCV AND ANTI-HIV ANTIBODY PROFILING USING A NOVEL HIGH THROUGHPUT LUCIFERASE IMMUNOPRECIPITATION SYSTEM FOR PREDICTING AND MONITORING RESPONSE TO HCV TREATMENT IN HIV CO-INFECTED PATIENTS Peter Burbelo2, Joseph A. Kovacs4, Joerg F. Schlaak3, Henry Masur4, Michael A. Polis1, Shyam Kottilil1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2NIDCR, NIH, DHHS, bethesda, MD, USA. 3Gasteroenterology, University of Essen, Essen, Germany. 4CCMD, CCMD, CC, NIH, Bethesda, MD, USA


POSTER SESSIONS

183A

#865

#868

IMPACT OF PEGINTRON MAINTENANCE THERAPY ON BIOMARKERS (FIBROTEST [FT]-ACTITEST [AT]) IN CIRRHOTIC (METAVIR F4) HCV PRIOR NONRESPONDERS: RESULTS FROM THE EPIC3 CIRRHOSIS MAINTENANCE TRIAL

HAEMOGLOBIN REDUCTION AT THE EARLY STAGES OF ANTIVIRAL THERAPY AS A PREDICTOR OF RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C: SINGLE CENTRE EXPERIENCE

Thierry Poynard1, Mona Munteanu1, Massimo Colombo2, Jordi Bruix3, Eugene R. Schiff4, Ruben Terg5, Steven L. Flamm6, Ricardo Moreno-Otero7, Flair J. Carrilho8, Warren N. Schmidt9, Thomas Berg10, Thomas J. McGarrity11, E. Jenny Heathcote12, Fernando L. Goncales13, Moisés Diago14, Antonio Craxi15, Marcelo O. Silva16, Pierre Bedossa17, Navdeep Boparai18, Louis H. Griffel18, Margaret Burroughs18, Clifford A. Brass18, Janice K. Albrecht18 1APHP UPMC-Liver Center, Paris, France. 21st Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, University of Milan, Milan, Italy. 3Centro de Investigación Biomédica en Red de Enfermedades Hepaticas y Digestivas, Liver Unit,Hospital Clinic, University of Barcelona, Barcelona, Spain. 4University of Miami School of Medicine, Miami, FL, USA. 5Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo, Capital Federal, Argentina. 6Northwestern University, Chicago, IL, USA. 7Hospital Universitario de la Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepaticas y Digestivas(Instituto de Salud Carlos III), Madrid, Spain. 8Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, Brazil. 9University of Iowa Hospitals and Clinics, Iowa City, IA, USA. 10Charité, Campus Virchow Klinikum, Universitätsmedizin, Berlin, Germany. 11Milton S. Hershey Medical Center, Hershey, PA, USA. 12University Health Network, Toronto, ON, Canada. 13Department of Medical Clinical, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil. 14Hospital General Universitario deValencia, Valencia, Spain. 15GI and Liver Unit, DIBIMIS, University of Palermo, Palermo, Italy. 16Hospital Universitario Austral, Pilar, Argentina. 17Anatomie Pathologique, Hôpital Beaujon, Clichy, France. 18Schering-Plough Research Institute, Kenilworth, NJ, USA

#866 RETROSPECTIVE ANALYSIS OF PAN ASIAN OUTCOME OF RESPONSE TO THERAPY FOR HEPATITIS C - A MULTICENTER STUDY (REPORT-C STUDY) – INTERIM RESULTS Basu1,2,

Rayapudi2,

Wong3,

#867 RESPECTIVE QUANTIFICATION OF HEPATITIS C VIRUS GENOTYPE 1B CODON 70 WILD AND MUTANT TYPES AND THEIR RESPONSE TO PEGIFN/RBV TREATMENT Hu1,2,

Muroyama1,

Goto3,

Zhongjie Ryosuke Tadashi Norie Kowatari1, Jin-Hai Chang3, Masao Omata3, Naoya Kato1 1Unit of Disease Control Genome Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan. 2Department of Hepatology and Gastroenterology, Beijing You’an Hospital, Capital Medical University, Beijing, China. 3Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

#869 HCV VIRAL KINETICS AND ITS RELATION TO SUSTAINED VIROLOGICAL RESPONSE (SVR)CHANGING THE QUESTIONS WILL CHANGE THE ANSWERS? Ana Lucia A. Ramos1, Luisa Hoffmann1, Juliene A. Ramos1, Renata Perez1,2, Fátima A. Figueiredo1,2, Patricia M. da Silva2, Luis Cristóvão M. Porto2, Edson Rondinelli1, Henrique Sergio M. Coelho1, Cristiane A. Villela-Nogueira1 1Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 2State University of Rio de Janeiro, Rio de Janeiro, Brazil

#870 COMPARATIVE SAFETY, TOLERABILITY, VIRAL AND PHARMACODYNAMIC EFFICACY OF PEGYLATEDINTERFERONS AND ALBINTERFERON ALFA-2B IN HIV/HCV GENOTYPE-1 INFECTED PATIENTS Eva Herrmann3, Mani Subramanian2, Michael A. Polis1, Shyam Kottilil1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2Human Genome Sciences Inc, Rockville, MD, USA. 3Department of Medicine, Institute of Biostatistics, Johann Wolfgang Goethe University, Frankfurt, Germany

#871 COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A (40 KD) PLUS RIBAVIRIN VERSUS NO TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (CHC), GENOTYPE 1 FROM A PAYER PERSPECTIVE IN THAILAND Teerha Piratvisuth1, Chutima Pramoolsinsap2, Anuchit Chutaputti3, Tawesak Tanwandee4, Satawat Thongsawat5, Isaya Sukarom6, Sirana Tinmanee6, Wolfgang Berger7 1Songklanagarind Hospital, Prince of Songkla University, Songkla, Thailand. 2Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 3Phramongkutklao Hospital, Bangkok, Thailand. 4Siriraj Hospital, Mahidol University, Bangkok, Thailand. 5Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand. 6Roche Thailand Ltd, Bangkok, Thailand. 7F. Hoffmann-La Roche Ltd, Basel, Switzerland

#872 THE EXPRESSION KINETICS OF 4-1BB (CD137) IN CHRONIC HEPATITIS C PATIENTS DURING ANTIVIRAL TREATMENT Sang Jin Lee1, Jung Woo Shin1,2, Bo Ryung Park2, chang Jae Kim2, Neung Hwa Park1,2 1Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan, Korea, South. 2Biomedical Research Center, Ulsan University Hospital, Ulsan, Korea, South


P. Patrick Krishna Vincent W. Kenneth Yan3, Niraj James Shah2, Tommy Pacana2, Robert S. Brown1 1Columbia University College of Physicians and Surgeons, New York, NY, USA. 2Forest Hills Hospital, Forest Hills, NY, USA. 3The Chinese University of Hong Kong, Hong Kong, China

Andrea Mendes, Abid Suddle, Phillip M. Harrison, Kosh Agarwal, Ivana Carey Institute of Liver Studies, Kings College School of Medicine at King’s College Hospital, London, United Kingdom

184A

POSTER SESSIONS

#873

#876

NON-COMPLIANCE WITH CURRENT GUIDELINES FOR TREATMENT OF CHRONIC HEPATITIS C (CHC) IS FREQUENT IN DAILY PRACTICE AND MAY LEAD TO AN INCREASE IN SVR: RESULTS OF A LARGE PROSPECTIVE COHORT STUDY

PREDICTORS OF PREMATURE WITHDRAWAL AND DOSE REDUCTIONS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGIFNα2A) PLUS RIBAVIRIN IN A LARGE, MULTINATIONAL, OPEN-LABEL EXPANDED ACCESS PROGRAM

Claus Niederau1, Stefan Mauss2, Dietrich Hueppe3, Elmar Zehnter4, Ulrich Alshuth5 1Klinik für Innere Medizin, St. Josef-Hospital Oberhausen, Akademisches Lehrkrankenhaus, Oberhausen, Germany. 2Center for HIV and Hepatogastroenterology, Duesseldorf, Germany. 3Center of Gastroenterology, Herne, Germany. 4Center of Gastroenterology, Dortmund, Germany. 5Hepatitis/HIV/CF, Roche Pharma AG, Grenzach-Wyhlen, Germany

#874 CHANGES OF AUTONOMIC AND SENSORY NERVE FUNCTION IN PATIENTS WITH CHRONIC HEPATITIS C DURING ANTIVIRAL THERAPY - A FOLLOW-UP STUDY Janos Osztovits1, Evelin Horváth1, Levente Csihi1, Judit Tax1, Margit Abonyi1, Péter L. Lakatos1, Tímea Csák1, Gabriella Beko1, Tamás Tóth1, Péter Kempler1, Tamás Horváth3, Márk Kollai3, Janos Fehér2, Hubert E. Blum4, Ferenc Szalay1 11st Department of Internal Medicine, Semmelweis University, Budapest, Hungary. 22nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary. 3Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Budapest, Hungary. 42nd Department of Internal Medicine, University of Freiburg, Freiburg, Germany

#875 PREDICTIVE FACTORS OF SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH COMPLETE EARLY VIROLOGICAL RESPONSE TO THE TREATMENT OF HEPATITIS C



Montserrat Garcia-Retortillo1, Rosa María Morillas2, Mireia Miquel3, Olga Rodríguez-López7, Isabel Cirera1, Mercedes Vergara3, Margarita Sala2, M Dolors Giménez1, Nuria Cañete1, Marta Gallach3, Mercè Ardèvol4, Marco Antonio Alvarez5, Silvia Montoliu6, Manuel Romero-Gomez7, Ramon Planas2, Ricard Solà1 1Liver Section, Gastroenterology Department, Hospital del Mar, IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain. 2Liver Unit, Gastroenterology Department, CIBERehd, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. 3Liver Unit, Gastroenterology Department, CIBERehd, Corporació Sanitària Parc Taulí, Sabadell, Spain. 4Pharmacy Department, Hospital Germans Trias i Pujol, Badalona, Spain. 5Hospital Sant Joan de Déu, Manresa, Spain. 6Hospital Universitari Joan XXIII, Tarragona, Spain. 7UCM Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla, Spain

Samuel S. Lee1, Stuart K. Roberts2, Hanna Berak3, Geoffrey M. Dusheiko4, Hugh Harley5, Edward J. Gane6, Petr Husa7, Yves J. Horsmans8, Kwang-Hyub Han9, Stephanos J. Hadziyannis10, E. Jenny Heathcote11, Diethelm Messinger12, Andreas Tietz13, Peter Ferenci14 1University of Calgary, Calgary, AB, Canada. 2Alfred Hospital, Melbourne, VIC, Australia. 3Hospital of Infectious Diseases, Warsaw, Poland. 4Centre for Hepatology, Royal Free and University College School of Medicine,, London, United Kingdom. 5Royal Adelaide Hospital, Adelaide, SA, Australia. 6Auckland City Hospital, Auckland, New Zealand. 7Department of Infectious Diseases, Brno, Czech Republic. 8Cliniques Universitaires Saint-Luc (UCL), Brussels, Belgium. 9Severance Hospital, Seoul, Korea, South. 10Henry Dunant Hospital, Athens, Greece. 11University Health Network, Toronto, ON, Canada. 12Biometrics, IST GmbH, Mannheim, Germany. 13Roche, Basel, Switzerland. 14Department of Internal Medicine III, Medical University, Vienna, Austria

#877 AGE 45 YEARS OR YOUNGER IS STRONGLY ASSOCIATED WITH ANTIVIRAL TREATMENT RESPONSE IN HEPATITIS C VIRUS INFECTED PATIENTS Hansen Nanna1, Niels Obel2, Jens Bukh3,4, Nina Weis1,4 1Department of infectious diseases, Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark. 2Department of infectious diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. 3Copenhagen Hepatitis C program (COHEP), Clinical Reasearch Center, Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark. 4Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

#878 SHORT-TERM PEGINTERFERON-α-2A MONOTHERAPY FOR CHRONIC HEPATITIS C PATIENTS WITH LOW HCV RNA LOAD AND IMMEDIATE VIROLOGICAL RESPONSE Masayoshi Yada, Naoki Yamashita, Kenta Motomura, Toshimasa Koyanagi, Shigeru Sakamoto, Akihide Masumoto Department of Hepatology, Iizuka hospital, Iizuka, Japan

#879 NK CELL ACTIVITY COULD PREDICT OUTCOME OF INTERFERON + RIBAVIRIN COMBINATION THERAPY FOR FEMALE PATIENTS WITH CHRONIC HEPATITIS C Yoshimichi Haruna, Takahiro Suzuki, Atsuo Inoue Department of Gastroenterology and Hepatology, Osaka Prefectural General Medical Center, Osaka, Japan



POSTER SESSIONS

185A

#880

#884

TREATMENT COMPLIANCE IN PATIENTS TAKING RIBAPAK® OR RIBAVIRIN 200MG: FINAL ANALYSES FROM THE ADHERE REGISTRY

INSULIN RESISTANCE AND AMINO ACID SUBSTITUTION OF HCV CORE AMINO ACID 70 ARE IMPORTANT FACTORS OF NON-RESPONSE IN PEGINTERFERON ALFA-2B PLUS RIBAVIRIN IN CHRONIC HEPATITIS C WITH GENOTYPE 1B

Vinod K. Rustgi1,2, Imtiaz Alam3, Bennett Cecil4, Alan D. Tice5, Tuesdae Stainbrook6, Kenneth D. Ingram7, Eric B. Thompson8, Kristin Kistler9 1Georgetown University Medical Center, Fairfax, VA, USA. 2Metropolitan Liver Diseases, Fairfax, VA, USA. 3Austin Hepatitis Center, Austin, TX, USA. 4Hepatitis C Treatment Centers, Louisville, KY, USA. 5Infections Limited Hawaii, Honolulu, HI, USA. 6DuBois Regional Medical Center, DuBois, PA, USA. 7Oregon Health & Sciences University, Portland, OR, USA. 8Carolina Digestive Health Associates, Charlotte, NC, USA. 9ProSanos Corp, Harrisburg, PA, USA

Takeshi Okanoue1, Yoshito Itoh2, Eiji Tanaka3, Kentaro Yoshioka4, Namiki Izumi5, Hiromitsu Kumada6 1Hepatology Unit, Saiseikai Suita Hospital, Suita, Japan. 2Department of Gastroenterology, Kyoto Prefectural University of Medicine, Kyoto, Japan. 3Internal Medicine, Shinshu University, Matsumoto, Japan. 4Division of Liver,Biliary Tract and Pancreas, Fujita Health University, Nagoya, Japan. 5Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan. 6Department of Hepatology, Toranomon Hospital, Tokyo, Japan

#881

#885

AMINO ACID SUBSTITUTIONS IN THE HEPATITIS C VIRUS CORE REGION OF GENOTYPE 1B ARE THE IMPORTANT PREDICTOR OF TREATMENT RESITANCE, INSURIN RESISTANCE, AND HEPATOCARCINOGENESIS

COMBINATION THERAPY WITH PEGIFNα-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C PATIENTS WITH NORMAL ALT LEVELS: MATCHED CASECONTROL STUDY BY PROPENSITY SCORE METHOD

Norio Akuta, Fumitaka Suzuki, Miharu Hirakawa, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Mariko Kobayashi, Masahiro Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada Hepatology, Toranomon Hospital, Tokyo, Japan

Nao Kurashige1, Naoki Hiramatsu1, Tsugiko Oze1, Takayuki Yakushijin1, Kiyoshi Mochizuki1, Takuya Miyagi1, Tomohide Tatsumi1, Tatsuya Kanto1, Akinori Kasahara1, Tetsuo Takehara1, Kazuho Imanaka2, Masahide Oshita3, Hideki Hagiwara4, Eiji Mita5, Toshifumi Ito6, Yoshiaki Inui7, Shinji Tamura8, Harumasa Yoshihara9, Yasuharu Imai10, Norio Hayashi1 1gastroenterology and hepatology, Osaka Univ., Suita, Japan. 2Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan. 3Osaka Police Hospital, Osaka, Japan. 4Kansai Rosai Hospital, Amagasaki, Japan. 5Osaka National Hospital, Osaka, Japan. 6Osaka Kouseinenkin Hospital, Osaka, Japan. 7Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan. 8Minoh City Hospital, Minoh, Japan. 9Osaka Rosai Hospital, Sakai, Japan. 10Ikeda Municipal Hospital, Ikeda, Japan

#882 DO PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1, TREATED BY NEW AGENTS IN PHASE 2/3 STUDIES DIFFER FROM THOSE RECEIVING STANDARD OF CARE? Sandra Beinhardt, Albert Stättermayer, Karoline Rutter, ThomasMatthias Scherzer, Harald Hofer, Petra E. Steindl-Munda, Peter Ferenci Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria

#883

Carlo Magni, Fosca Niero, Barbara Argenteri, Riccardo Giorgi, Annalisa Mainini, Carla Pastecchia, Elena Ricci, Monica Schiavini, Roberta Terzi, Maria Concetta Vivirito, Marco Resta Infectious Diseases, Luigi Sacco Hospital, Milan, Italy

THALIDOMIDE WITH PEGINTERFERON ALFA-2B AND RIBAVIRIN IN THE TREATMENT OF NONRESPONDERS GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS (TRITAL): PROOF OF CONCEPT Benjamín Pardo1, Carlos García-Collado2, Lourdes Grande1, Carmen Paradas3, Olga Rodríguez-López1, Ramón Morillo2, Elena Hoyas1, Silvia Artacho Criado2, Benito Dorantes2, Manuel RomeroGomez1 1Unit for the Clinical Management of Digestive Diseases and ciberehd, Hospital de Valme, Sevilla, Spain. 2Unidad de Farmacia, Hospital de Valme, Sevilla, Spain. 3Unidad Clínica de Neurología, Hospital de Valme, Sevilla, Spain


ANTIVIRAL ACTIVITY AND TOLERABILITY BETWEEN PEGYLATED INTERFERON ALPHA-2A AND ALPHA-2B IN NAïVE PATIENTS WITH CHRONIC HEPATITIS C: RESULTS OF A PROSPECTIVE MONOCENTRIC RANDOMIZED TRIAL

#886

186A

POSTER SESSIONS

#887

#890

DETERMINANTS OF ENGAGEMENT IN CARE OF INNER CITY HCV-INFECTED INJECTION DRUG USERS (IDUS)

A PROSPECTIVE OBSERVATIONAL FOLLOW-UP STUDY OF PEGINTERFERON ALFA -2A PLUS RIBAVIRIN TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 AND WITH NORMAL ALT LEVELS: INTERMEDIATE EFFICACY ANALYSIS

Brian Conway1, Harout Tossonian1, Jason Grebely2, Jesse D. Raffa3, Murray Krahn5, Michelle M. Storms1, Elizabeth Knight1, Joel Singer6, Benedikt Fischer4 1Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada. 2National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW, Australia. 3Statistics and Actuarial Sciences, University of Waterloo, Waterloo, ON, Canada. 4Simon Fraser University, Burnaby, BC, Canada. 5University of Toronto, Toronto, ON, Canada. 6the CTN, CIHR Canadian HIV Trials Network, Vancouver, BC, Canada

#888 TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY Gregory J. Dore1, Margaret Hellard2, Gail Matthews1, Jason Grebely1, Paul S. Haber3, Kathy Petoumenos1, Barbara Yeung1, Pip Marks1, Ingrid van Beek4, Geoffrey W. McCaughan5, Peter A. White6, Rosemary A. Ffrench2, William Rawlinson7, Andrew R. Lloyd6, John Kaldor1 1National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia. 2Burnet Institute, Melbourne, VIC, Australia. 3Discipline of Medicine and School of Public Health, University of Sydney, Sydney, NSW, Australia. 4Kirketon Road Centre, Sydney, NSW, Australia. 5Central Clinical School, University of Sydney, Sydney, NSW, Australia. 6School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia. 7Virology Division, SEALS Microbiology, Prince of Wales Hospital, Sydney, NSW, Australia

#889 ASIAN AND WHITE PATIENTS WITH CHRONIC HEPATITIS C (CHC) ACHIEVE SIMILAR RESPONSE RATES WITH PEGINTERFERON (PEG-IFN) ALFA-2B PLUS RIBAVIRIN (RBV) IN GENOTYPES (G) 2 AND 3: SUBANALYSIS OF THE REDD 2/3 STUDY



Michael P. Manns1, Mohd Ismail Merican2, Yaron Ilan3, Yoav Lurie4, Saif M. Abu-Mouch5, Ajit Sood6, D. N. Reddy7, Andrzej Horban8, Sachithanandan Sharmila2, Heiner Wedemeyer1, Xin Yu9, Rab Faruqi9, Eirum I. Chaudhri9, Lisa Pedicone9 1Department of Gastroenterology, Hepatology & Endocrinology, Medical School of Hannover, Hannover, Germany. 2Hospital Selayang, Selangor Darul Ehsan, Malaysia. 3Liver Unit Hadassah University Hospital, Jerusalem, Israel. 4Sourasky Medical Center, Tel Aviv, Israel. 5Hillel-yaffe Medical Center, Hadera, Israel. 6Dayanand Medical College And Hospital, Ludhiana, India. 7Asian Institute of Gastroenterology, Andhra Pradesh, India. 8Warsaw Medical University&Hospital of Infectious Diseases, Warszawa, Poland. 9Schering-Plough Research Institute, Kenilworth, NJ, USA


José L. Calleja1, Belén Ruiz-Antoran2, Javier García-Samaniego3, R. Morillas4, Ricardo Moreno-Otero5, Jose Carlos Erdozain6, F. Nogueras7, D. Suarez8, F. Baños9, Lourdes Grande-Santamaria10, Ricard Solà11, Jose A Pons12, Marco Antonio Alvarez13, M. Jiménez-Pérez14, Fernando Pons1, E. Garcia15, Angeles Castro16, M. Vergara17, Javier Salmeron18, Juan de la Revilla1 1Gastroenterology Department, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain. 2Clinical Pharmacology Department, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain. 3Gastroenterology Department, Carlos III Hospital, Madrid, Spain. 4Gastroenterology Department, Germans Trías i Pujol Hospital, Barcelona, Spain. 5Gastroenterology Department, La Princesa Hospital, Madrid, Spain. 6Gastroenterology Department, La Paz Hospital, Madrid, Spain. 7Gastroenterology Department, Virgen de las Nieves Hospital, Granada, Spain. 8Gastroenterology Department, Arquitecto Marcide-Novoa Santos Hospital, A Coruña, Spain. 9Gastroenterology Department, Consorci Sanitari Integral de LHospitalet, Barcelona, Spain. 10Gastroenterology Department, Valme Hospital, Sevilla, Spain. 11Gastroenterology Department, del Mar Hospital, Barcelona, Spain. 12Gastroenterology Department, Virgen de la Arrixaca Hospital, Murcia, Spain. 13Gastroenterology Department, Altahia de Manresa Hospital, Barcelona, Spain. 14Gastroenterology Department, Carlos Haya Hospital, Malaga, Spain. 15Gastroenterology Department, Gral. de Fuerteventura Hospital, Fuerteventura, Spain. 16Gastroenterology Department, Juan Canalejo Hospital, A Coruña, Spain. 17Gastroenterology Department, Corporació Sanitària Parc Taulí, Barcelona, Spain. 18Gastroenterology Department, San Cecilio Hospital, Granada, Spain

#891 VIRAL HEPATITIS IN IVDUS: A 14-YEAR EXPERIENCE OF A SINGLE LIVER UNIT EPIDEMIOLOGICAL AND CLINICAL DATA Maria Raptopoulou-Gigi, Emmanuel Sinakos, Albana Sykja, Eleni Gigi, Aristea-Lia Bellou, Ioannis Sidiropoulos, Eleni Orfanou 2nd Medical Dpt, Aristotelion University Medical School, Thessaloniki, Greece

#892 PEG-INTERFERON PLUS RIBAVIRIN IN COMPENSATED HCV CIRRHOSIS WITH PORTAL HYPERTENSION: THE ROLE OF RAPID AND EARLY VIROLOGICAL RESPONSE IN PREDICTING THE SUSTAINED VIROLOGICAL RESPONSE Vincenza Calvaruso1, Vito Di Marco1, Piero L. Almasio1, Stefania De Lisi1, Donatella Ferraro2, Paola Pizzillo2, Sergio Peralta1, Antonio Craxì1 1Gastroenterologia & Epatologia, DIBIMIS,, University of Palermo, Palermo, Italy. 2Cattedra di Virologia, Dipartimento d’Igiene “G. D’Alessandro”, University of Palermo, Palermo, Italy


POSTER SESSIONS

187A

#893

#897

CLEARANCE OF HCV IS ASSOCIATED WITH INCREASE IN SERUM ADIPONECTIN IN PATIENTS WITH HEPATITIS C

IS THERE AN ASSOCIATION OF A CTLA4 POLYMORPHISM (SNP CTLA4 [49] A/G) WITH THE DEVELOPMENT OF IFN-ASSOCIATED AITD (AUTOIMMUNE THYROID DISEASE) IN PATIENTS WITH CHRONIC HEPATITIS C AND ANTIVIRAL THERAPY?

Sabina Sabharwal1, Kathleen E. Corey1, Jorge Mendez-Navarro1, Lydia Barlow1, Aymin F. Delgado-Borrego2, Raymond Chung1 1Mass General Hospital, Boston, MA, USA. 2University of Miami Miller School of Medicine, Batchelor Children’s Research Institute, Miami, FL, USA

#894 THE IMPACT OF CHEMICAL DEPENDENCY DIAGNOSIS AND TREATMENT ON TREATMENT OF CHRONIC HEPATITIS C (HCV) IN PATIENTS IN A STABLE INSURED POPULATION Mary Patricia Pauly1, Marcia Russell3, Charlie Moore2, Constance Chia2, Sonia Menenberg2, Gayle L. Witt1, Scott E. Martin3, Boris H. Ruebner4 1Gastroenterology, Kaiser Permanente, Sacramento, CA, USA. 2Chemical Dependency Recovery Program, Kaiser Permanente, Sacramento, CA, USA. 3Pacific Institute for Research and Prevention, Berkeley, CA, USA. 4Department of Pathology, University of California, Davis, Davis, CA, USA

#895 TREATMENT OF HCV POST RENAL TRANSPLANTATION WITH PEGYLATED INTERFERON AND RIBAVIRIN SINGLE CENTER EXPERIENCE Abdulrahman A. Aljumah, Mohamed A. Saeed, Abduljaleel M. Alalwan, Ibrahim H. Altraif Hepatobiliary Science and Liver Transplant, King Abdulaziz Medical City, Riyadh, Saudi Arabia

#896 ANALYSIS OF CAUSES OF RESPONSE FAILURE IN NAïVE PATIENTS WITH CHRONIC HEPATITIS C RECEIVING PEGINTERFERON PLUS RIBAVIRIN

#898 CAUCASIANS VERSUS EGYPTIANS HCV-4 PATIENTS WITH ELEVATED BASELINE HCV-RNA TREATED WITH PEG-IFN α 2A AND RIBAVIRIN. ROLE OF RAPID AND EARLY VIROLOGIC RESPONSE Dimitrios Dimitroulopoulos1, Ioannis Elefsiniotis2, Christos Pavlidis3, Dimitrios Xinopoulos1, Klisthenis Tsamakidis1, Ageliki Ferderigou4, Dimitrios Kypreos1, Sotirios Koutsounas3, Georgios Saroglou2, Emmanouil Paraskevas1 1Gastroenterology, “Agios Savvas” Hospital, Athens, Greece. 2Internal Medicine, “Helena Venizelou” Hospital, Athens, Greece. 3Reference Center for Viral Hepatitis, IKA, Athens, Greece. 4Department of Biochemistry, “Agios Savvas” Hospital, Athens, Greece

#899 VIRAL KINETICS CAN PREDICT VIROLOGICAL RESPONSE IN PREVIOUS NON RESPONDERS HCV PATIENTS TREATED WITH PEGYLATED IFN AND RIBAVIRIN Marion Corouge1, Pierre Deltenre1,2, Valérie Canva1, Mohamed El Nady1, Alexandre Louvet1,3, Hélène Castel1, Faustine Wartel1, Sébastien Dharancy1,3, Jean Henrion2, Philippe Mathurin1,3 1Hopital Huriez, CHRU Lille, Lille, France. 2Hopital de Jolimont, Haine-Saint-Paul, Belgium. 3INSERM U795, CHRU Lille, Lille, France

#900 OPTIMIZING A PREDICTIVE MODEL OF INDIVIDUAL CHANCE FOR SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) FOR REAL LIFE SETTINGS Stefan Mauss1, Dietrich Hueppe2, Elmar Zehnter3, Swantje Richter4, Ulrich Alshuth5, Egbert Wellmann5, Eva Herrmann4 1Center of Gastroenterology and Hepatology, Duesseldorf, Germany. 2Center of Gastroenterology, Herne, Germany. 3Center of Gastroenterology, Dortmund, Germany. 4Klinikum der Johann Wolfgang Goethe Universität, Frankfurt, Germany. 5Roche Pharma AG, Grenzach-Wyhlen, Germany


Montserrat Garcia-Retortillo1, Rosa María Morillas2, Mireia Miquel3, Olga Rodríguez-López7, Isabel Cirera1, Mercedes Vergara3, Helena Masnou2, M Dolors Giménez1, Nuria Cañete1, Marta Gallach3, Mercè Ardèvol4, Marco Antonio Alvarez5, Silvia Montoliu6, Manuel Romero-Gomez7, Ramon Planas2, Ricard Solà1 1Liver Section, Gastroenterology Department, Hospital del Mar, IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain. 2Liver Unit, Gastroenterology Department, CIBERehd, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. 3Liver Unit, Gastroenterology Department, CIBERehd, Corporació Sanitària Parc Taulí, Sabadell, Spain. 4Pharmacy Department, Hospital Germans Trias i Pujol, Badalona, Spain. 5Hospital Sant Joan de Déu, Manresa, Spain. 6Hospital Universitari Joan XXIII, Tarragona, Spain. 7UCM Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla, Spain

Arne Schaefer, Michael Scheurlen, Christian Keicher, Michael R. Kraus Gastroenterology, Med. Klinik und Poliklinik II, University of Wuerzburg, Wuerzburg, Germany

188A

POSTER SESSIONS

#901

#906

IMPACT OF THERAPEUTIC EDUCATION ON THE OUTCOME OF CHRONIC HEPATITIS C TREATMENT

INSULIN RESISTANCE IN CHRONIC HEPATITIS C: SIMILARITIES TO NASH

Christophe Renou1, Pierre Lahmek2, Alexandre Pariente3, Jacques Denis4, Jean-François Cadranel5, Yolande Giraud1, Rose-Marie Régine1, Thierry Morin6, Roger Faroux7, Bernard Nalet8, Claire Wartelle-Bladou9 1CH Hyeres, Hyeres, France. 2CH Le-Raincy-Montfermeil, Montfermeil, France. 3CH Pau, Pau, France. 4CH Sud Francilien, Evry, France. 5CH Creil, Creil, France. 6CH Tarbes, Tarbes, France. 7CH de la Roche sur Yon, la Roche sur Yon, France. 8CH Montélimar, Montélimar, France. 9CH Aix-en-Provence, Aix-en-Provence, France

Hidero Ogino, Masashi Nishikawa, Satoshi Hirai, Akiyoshi Shimatani, Koichiro Matsuda, Katsushi Hiramatsu, Mitsuru Matsuda, Yatsugi Noda Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan

#902 COULD MORE GENOTYPE-1 HCV PATIENTS COMPLETE FUTURE STAT-C REGIMENS IN REAL PRACTICE? Huabin F. Zhang, David Budd Worldwide Health Economics and Pricing, Virology, Johnson & Johnson Pharmaceutical Services, Raritan, NJ, USA

#903 SIGNIFICANT ELEVATION OF EFFICACY WITH PEGIFN AND RIBAVIRIN COMBINATION IS EXPECTED IN PATIENTS WITH SUBSTITUTION OF AMINO ACID 70 IN THE HEPATITIS C CORE REGION OF GENOTYPE 1B AND HIGH VIRAL LOAD WHEN PRETREATMENT INSULIN RESISTANCE IS IMPROVED Yoshiyasu Karino, Joji Toyota, Jun Akaike, Itaru Ozeki, Yasukaki Kuwata, Takahiro Sato, Tomohiro Arakawa, Takumi Ohmura Hepatology, Sapporo Kosei general hospital, Sapporo, Japan

#904 EFFECTS OF HIGH DOSE RIBAVIRIN (RBV), ALINIA (NITAZOXANIDE) AND PEGYLATED INTERFERON (PEG) ALFA-2A IN ATTAINING SUSTAINED VIRAL RESPONSE (SVR) IN TREATMENT OF CHRONIC HEPATITIS C (ERAIS-C TRIAL) - INTERIM RESULTS IN NAïVE GENOTYPE 1 PATIENTS



P. Patrick Basu1,2, Krishna Rayapudi2, Niraj James Shah2, Tommy Pacana2, Robert S. Brown1 1Columbia University College of Physicians and Surgeons, New York, NY, USA. 2Forest Hills Hospital, Forest Hills, NY, USA

#905 TWICE WEEKLY PEG IFN-ALPHA-2A WITH RIBAVIRIN IMPROVES EARLY VIRAL KINETICS OVER STANDARD THERAPY AMONG HIV/HCV CO-INFECTED AFRICAN AMERICAN PATIENTS Alison Murphy1, Michael A. Polis1, Avidan U. Neumann2, Shyam Kottilil1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2BAR-ILAN UNIVERSITY, RAMAT DAN, Israel


Hepatitis D and E #907 HEV INFECTION IN WILD, HOOFED ANIMALS IN THE NETHERLANDS Hendrik W. Reesink1, Saskia Rutjes2, Martijn Bouwknegt2, Peter L. Jansen1, Christine J. Weegink1, Tim C. Schreuder3, Ana Maria de Roda Husman2 1AMC Liver Center; Department of Gatroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands. 2Laboratory for Zoonoses and Environmental Microbiology, National Institute of Public Health and the Environment, Bilthoven, Netherlands. 3Department of Gastroenterology and Hepatology, VU Medical Center, Amsterdam, Netherlands

#908 SEROPREVALENCE AND OUTCOME OF HEPATITIS E INFECTION IN ORGAN-TRANSPLANTED PATIENTS Philippe Colson2, Valérie Moal3, Patrick Borentain1, Mamadou Kaba2, Jean Hardwigsen4, Daniele Botta1, Yves Patrice Le Treut4, René Gérolami1 1Service d’Hépatogastroentérologie, CHU Conception, Marseille, France. 2Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Centre Hospitalo-Universitaire Timone, Marseille, France. 3Service de transplantation rénale, CHU Conception, Marseille, France. 4Service de Transplantation Hépatique, CHU Conception, Marseille, France

#909 SEROLOGICAL AND VIROLOGICAL SURVEY OF HEPATITIS E VIRUS IN HIV-INFECTED PATIENTS Christophe Renou1, Alain Lafeuillade2, Alexandre Pariente3, JeanFrançois Cadranel4, Nicole Pavio5, Thierry Allegre6, Claire Wartelle-Bladou7, Jacques Gaillat8, Frédéric Heluwaert9, Cécile B. Poggi10, Guillaume Penaranda11, Elisabeth Nicand12 1Hôpital de jour, CH Hyères, Hyères, France. 2Service d’infectiologie, CHITS Toulon, Toulon, France. 3Unité d’hépato-gastroen4Service térologie, CH Pau, Pau, France. 5 d’hépato-gastroentérologie, CH Creil, Creil, France. UMR 1161 Virologie AFSSA LERPAZ-ENVA-INRA, Ecole Nationale Vétérinaire d’Alfort, Maisons-Alfort, France. 6Service d’infectiologie, CH Aixen-Provence, Aix-en-Provence, France. 7Service d’hépato-gastroentérologie, CH Aix-en-Provence, Aix-en-Provence, France. 8Service d’infectiologie, CH Annecy, Annecy, France. 9Service d’hépatogastroentérologie, CH Annecy, Annecy, France. 10Service de virologie, CHITS Toulon, Toulon, France. 11Département de Biostatistiques, CDL Pharma, Marseille, France. 12Centre national de référence des hépatites entérotransmissibles, Hôpital du Val-deGrâce, Paris, France


POSTER SESSIONS

189A

#910

#915

HDV- AND HBV-SPECIFIC T CELL RESPONSE PATTERNS IN PATIENTS WITH DELTA HEPATITIS

HEPATITIS E: NOT AN EMERGING DISEASE IN GERMANY BUT A DISEASE WITH SIGNIFICANCE FOR IMMUNOSUPPRESSED PATIENTS

Jan Grabowski1, Pothakamuri V. Suneetha1, Jerzy Jaroszewicz1,2, Verena Schlaphoff1, Birgit Bremer1, Michael P. Manns1, Markus Cornberg1, Heiner Wedemeyer1 1Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 2Department of Infectious Diseases and Hepatology, Medical University in Bialystok, Bialystok, Poland

#911 LONG-TERM, HIGH-DOSE PEGINTERFERON ALFA2A IS AN EFFECTIVE TREATMENT FOR CHRONIC HEPATITIS D Theo Heller1, Yaron Rotman1, Vanessa haynes-Williams1, David E. Kleiner2, Marc G. Ghany1, T. Jake Liang1, Jay H. Hoofnagle1 1Liver Diseases Branch, NIDDK, NIH, Bethesda, MD, USA. 2Laboratory of Pathology, NCI, NIH, Bethesda, MD, USA

#912 FIGATELLU (PIG LIVER SAUSAGE) AS A SOURCE OF HEPATITIS E VIRUS TRANSMISSION TO HUMANS Philippe Colson2, Patrick Borentain1, Benjamin Queyriaux4,3, Valérie Moal5, Mamadou Kaba2, Heyires Laurent1, Didier Raoult2, René Gérolami1 1Service d’Hépatogastroentérologie, CHU Conception, Marseille, France. 2Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, CHU Timone, Marseille, France. 3Cellule Interrégionale d’Epidémiologie Sud, Institut de Veille Sanitaire, Marseille, France. 4Département d’Epidémiologie et Santé Publique, Institut de Médecine Tropicale du Service de Santé des Armées, Marseille, France. 5Centre de Néphrologie et Transplantation Rénale, CHU Conception, Marseille, France

#913 ENTECAVIR MAY BE BENEFICIAL IN A SUBSET OF PATIENTS WITH CHRONIC DELTA HEPATITIS

#914 HEPATITIS DELTA VIRUS RNA LEVEL AND IGM ANTIBODY TITER PREDICT RESPONSE TO PEGINTERFERON THERAPY Sarah Hughes1, Ivana Carey1, Dazhuang Shang1, Matthew J. Bruce1, Mary Horner1, Ian Fletcher1, Timothy J. Cross2, Kosh Agarwal1, Phillip M. Harrison1 1Institute of Liver Studies, King’s College Hospital, London, United Kingdom. 2Hepatology Department, Derriford Hospital, Plymouth, United Kingdom

#916 EFFICACY OF PEGYLATED INTERFERON-BASED TREATMENT IN PATIENTS WITH CIRRHOSIS DUE TO CHRONIC DELTA HEPATITIS: COMPARISON WITH NON-CIRRHOTIC PATIENTS Cihan Yurdaydin1, Gokhan Kabacam1, Yilmaz Cakaloglu2, Andreas Erhardt3, Halil Degertekin4, Selim Gurel5, Stefan Zeuzem6, George N. Dalekos7, Hakan Bozkaya1, Hans P. Dienes8, Michael P. Manns9, Heiner Wedemeyer9 1Gastroenterology Section, Ankara University Medical School, Ankara, Turkey. 2Memorial Hospital, Istanbul, Turkey. 3Gastroenterology, Hepatology and Infectious Disease, Universitat Klinik, Dusseldorf, Germany. 4Gastroenterology, Ufuk University, Ankara, Turkey. 5Gastroenterology, Uludag University, Bursa, Turkey. 6J. W. Goethe University Hospital, Frankfurt, Germany. 7Department of Medicine, Academic Liver Unit, University of Thessaly, Larissa, Greece. 8Pathology Institute, University of Cologne, Cologne, Germany. 9Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

#917 LONG-TERM OUTCOME OF HEPATITIS DELTA: A 14-YEAR SINGLE CENTER EXPERIENCE Beatriz Calle Serrano1, Benjamin Heidrich1, Jerzy Jaroszewicz1,2, Katja Deterding1, Regina Raupach1, Markus Cornberg1, Michael P. Manns1, Heiner Wedemeyer1 1Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany. 2Department of Infectious Diseases and Hepatology, Medical University in Bialystok, Bialystok, Poland S U N D AY NOVEMBER 1

Fatih Oguz Onder1, Mustafa Yakut2, Ramazan Idilman2, Gülseren Seven2, Gökhan Kabaçam2, Ersin Karatayli3, Senem C. Karatayli3, Yasemin Çelik3, Hakan Bozkaya2, A Mithat Bozdayi3, Cihan Yurdaydin2,3 1Gastroenterology Clinic, Türkiye Yüksek Ihtisas Hastanesi, Ankara, Turkey. 2Department of Gastroenterology and Hepatology, Ankara University School of Medicine, Ankara, Turkey. 3Hepatology Institute, Ankara University School of Medicine, Ankara, Turkey

Sven Pischke1, Pothakamuri V. Suneetha1, Ngoc Anh Huy Ho1, Dirk Meyer-Olson2, Hannelore Barg-Hock3, Christian P. Strassburg1, Michael P. Manns1, Matthias Stoll2, Heiner Wedemeyer1 1Gastroenterology, Hannover Medical School, Hannover, Germany. 2Infectiology, Hannover Medical School, Hannover, Germany. 3General, Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany

190A

POSTER SESSIONS

Hepatobiliary Imaging

#922

#918 NEW MALIGNANCY GRADING SYSTEM FOR HEPATOCELLULAR CARCINOMA USING SONAZOID CONTRAST ENHANCED ULTRASONOGRAPHY Tanaka1,2,

Iijima1,2,

Saito2,

Hironori Hiroko Masaki Nobuhiro Aizawa2, Teruhisa Yamamoto2, Hirayuki Enomoto2, Yoshinori Iwata2, Hiroyasu Imanishi2, Soji Shimomura2, Seiichi Hirota4, Syozo Hirota4, Junichi Yamanaka3, Yuji Iimuro3, Jiro Fujimoto3, Shuhei Nishiguchi2 1Ultrasonography Center, Hyogo Medical college, Nishinomiyacity, Japan. 2Division of Hepatobiliary and Pancreatic Medicine, Department of Internal Medicine, Hyogo Medical college, Nishinomiya-city, Japan. 3Division of Hepatobiliary and Pancreatic Medicine, Department of external Medicine, Hyogo Medical college, Nishinomiya-city, Japan. 4Department of Radiology, Hyogo College of Medicine, Nishinomiya, AL, USA

#919 EVALUATION OF MAGNET RESONANCE ELASTOGRAPHY (MRE) AS A NON-INVASIVE METHOD TO ASSESS THE STAGE OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC LIVER DISEASES Beate Schlosser1, Michael Biermer1, Balazs Fülöp1, Eckart Schott1, Patrick Asbach2, Ingolf Sack2, Thomas Berg1 1Departement of gastroenterology and hepatology, Charite Campus Virchow, Berlin, Germany. 2Institut für Radiologie, Charitè Campus Mitte, Berlin, Germany

#920 FOCAL NODULAR HYPERPLASIA AND ADENOMA OF THE LIVER: CONTRAST ENHANCED ULTRASOUND PERFORMANCE Pavel Taimr1, Robert J. de Knegt1, Roy S. Dwarkasing2, Harry L. Janssen1 1Gastroenterology and Hepatology, Erasmus MC, Rotterdam, Netherlands. 2Radiology, Erasmus MC, Rotterdam, Netherlands



FIBROSCAN IS A NON INVASIVE TOOL FOR DETECTING HEPATIC AMYLOIDOSIS Anne Cypierre1,5, Arnaud Jaccard2,4, Annick Rousseau3, AnneLaure Fauchais5, Paul Carrier1, Maryline Debette-Gratien1, Fatima Yagoubi2, Annie Lefebvre1, Elisabeth M. Vidal5, Dominique Bordessoule4, Veronique Loustaud-Ratti1,5 1Fédération Hépatologie, CHU Limoges, LIMOGES, France. 2Centre National de Référence sur les Amyloses, CHU Limoges, LIMOGES, France. 3Service de Pharmacologie, CHU Limoges, LIMOGES, France. 4Service d’hématologie, CHU Limoges, LIMOGES, France. 5Service de Médecine Interne, CHU Limoges, LIMOGES, France


MULTIPOLAR RADIOFREQUENCY ABLATION USING “NO TOUCH” TECHNIQUE IN PATIENTS WITH CIRRHOSIS AND HEPATOCELLULAR CARCINOMA UP TO 5.5 CM: SAFETY AND MEDIUM TERM EFFICIENCY Olivier Seror1, Gisele Nkontchou2, Yves Ajavon1, Nathalie Ganne Carrie2, Veronique Grando2, Nicolas Sellier1, Michel Beaugrand2 1Radiology Unit, Jean Verdier (APHP), Bondy, France. 2Hepatology Unit, AP-HP, Bondy, France

#923 THE COMBINED USE OF FIBROCT AND FORNS INDEX IMPROVES THE NON-INVASIVE DIAGNOSIS OF SIGNIFICANT LIVER FIBROSIS IN HEPATITIS C Reyes Aparcero López1, Elena Hoyas1, Olga Rodríguez-López1, Jose Carlos Perez-Tejada2, Ester Aranda3, Benjamín Pardo1, Lourdes Grande1, Jose A. Del Campo1, Rafael Aznar Méndez2, Emilio Gómez-González3, Manuel Romero-Gomez1 1Unit for the Clinical Management of Digestive Diseases and ciberehd, Hospital de Valme, Sevilla, Spain. 2Unidad de Radiodiagnóstico, Hospital de Valme, Sevilla, Spain. 3Grupo de Física Interdisciplinar, ESI,, Universidad de Sevilla, Sevilla, Spain

#924 MANGANESE ENHANCED MRI PREDICTS THE HISTOLOGICAL GRADE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CIRRHOSIS Robert P. Sutcliffe1, Dylan Lewis2, Mohamed Rela1, Pauline Kane2, Bernard C. Portmann1, John G. O’Grady1, John Karani2, Nigel Heaton1 1Institute of Liver Studies, King’s College Hospital, London, United Kingdom. 2Department of Radiology, King’s College Hospital, London, United Kingdom

#925 A CATHETER-MOUNTED MAGNETIC RESONANCE DETECTOR COIL FOR BILIARY IMAGING: FIRST EX VIVO HUMAN HEPATOBILIARY IMAGES Christopher A. Wadsworth1, Ian R. Young2, Marc Rea3, Munir M. Ahmad2, Shirin Elizabeth Khorsandi4, Brian Davidson4, Shahid Khan1, Simon D. Taylor-Robinson1, Richard R. Syms2 1Department of Hepatology and Gastroenterology, Imperial College London, London, United Kingdom. 2Department of Electrical and Electronic Engineering, Imperial College London, London, United Kingdom. 3MR Imaging Unit, Department of Radiology, Imperial College Healthcare NHS Trust, London, United Kingdom. 4Department of Surgery, Royal Free Hospital, London, United Kingdom


POSTER SESSIONS

191A

#926

#931

A PROSPECTIVE RANDOMIZED STUDY TO ELUCIDATE THE EFFICACY OF COMPUTED TOMOGRAPHY WITH HEPATIC ARTERIOGRAPHY AND ARTERIAL PORTOGRAPHY (CTA/P) AS A PRE-TREATMENT EXAMINATION AMONG PATIENTS WITH SMALL HEPATOCELLULAR CARCINOMA: A PRELIMINARY REPORT

USEFULNESS OF SONAZOID-CONTRAST ENHANCED ULTRASONOGRAPHY FOR HEPATOCELLULAR CARCINOMA: COMPARISON WITH PATHOLOGICAL DIAGNOSIS AND SUPERPARAMAGNETIC IRON OXIDE MAGNETIC RESONANCE IMAGES

Ohki1,

Akahane3,

Yamashiki4,

Takamasa Masaaki Noriyo Eriko Goto2, Kenichiro Enooku2, Takahisa Sato2, Ryota Masuzaki2, Yuji Kondo2, Ryosuke Tateishi2, Shinichi Inoo3, Tadashi Goto2, Shuichiro Shiina2, Haruhiko Yoshida2, Kuni Otomo3, Kazuhiko Koike2, Masao Omata2 1Gastroenterology, Mitsui Memorial Hospital, Tokyo, Japan. 2Gastroenterology, University of Tokyo, Tokyo, Japan. 3Radiology, University of Tokyo, Tokyo, Japan. 4Organ Transplantation Service, University of Tokyo, Tokyo, Japan

#927

Keiko Korenaga1,2, Masaaki Korenaga1,2, Keisuke Hino2, Isao Sakaida1 1Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Japan. 2Department of Hepatology and Pancreatology, Kawasaki Medical Colledge, Kurashiki, Japan

#932 NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS WITH QUANTITATIVE ACOUSTIC RADIATION FORCE METHODS

Silvia Colombo1, Livio Belloli2, Marco Buonocore1, Carlo Jamoletti1, Maurizio Zaccanelli3, Elisabetta Badia3, Paolo Del Poggio1 1Hepatology Unit, Treviglio Hospital, Treviglio (Bg), Italy. 2Italian Association of Voluntary Blood Donors (AVIS), Treviglio (Bg), Italy. 3Blood Bank, Treviglio Hospital, Treviglio (Bg), Italy

Michael Wang1, Mark Palmeri1, Ned Rouze1, Veronica Rotemberg1, Barry Moser2, Cynthia D. Guy3, Anna Mae Diehl4, Manal F. Abdelmalek4, Kathryn Nightingale1 1Biomedical Engineering, Duke University, Durham, NC, USA. 2Biostatistics and Bioinformatics, Duke University, Durham, NC, USA. 3Department of Pathology, Duke University Medical Center, Durham, NC, USA. 4Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA

#928

#933

NON-INVASIVE DIAGNOSIS OF LARGE ESOPHAGEAL VARICES BY FIBROSCAN: STRONG INFLUENCE OF THE CIRRHOSIS AETIOLOGY

QUANTITATIVE EVALUATION OF HAEMODYNAMIC CHANGES IN CHRONIC LIVER DISEASES USING A CONTRAST-ENHANCED ULTRASOUND DEDICATED SOFTWARE

TRUE NORMAL LIVER STIFFNESS MEASUREMENT (LSM) AND ITS DETERMINANTS

Eric Nguyen-Khac1, Pierre Saint-Leger1, Blaise Tramier2, Hugues Coevoet1, Dominique Capron1, Jean Louis Dupas1 1Hepato-Gastroenterology, Amiens University Hospital, Amiens, France. 2Biostatistic department, Aubagne General Hospital, Aubagne, France

#929 EFFICACY OF LIVER STIFFNESS MEASUREMENT USING ACOUSTIC RADIATION FORCE IMPULSE IN COMPARISON WITH FIBROSCAN

#930 DYNAMIC CONTRAST ENHANCED ULTRASOUND IN MONITORING HCC PATIENTS TREATED WITH SORAFENIB: PRELIMINARY RESULTS Maria Assunta Zocco, Andrea Lupascu, Anna C. Piscaglia, Marialuisa Novi, Cristiano Lauritano, Maria Elena Ainora, Michele Santoro, Emanuele Rinninella, Francesca Ponziani, Annalisa Tortora, Roberto Flore, Angelo Santoliquido, Paolo Tondi, Antonio Gasbarrini Internal medicine,Gemelli Hospital, Rome, Italy

#934 CONTRAST-ENHANCED ULTRASOUND FOR THE CHARACTERIZATION OF FOCAL LIVER LESIONS Camilo J. Llamoza Torres, Pilar Soto Escribano, Marissa Vignote Alguacil, Jose Manuel Ángel Rey, Juan Francisco De Dios Vega Aparato Digestivo, Hospital Universitario Reina Sofía, Córdoba, Spain

#935 LIVER STIFFNESS DOES NOT NECESSARILY MEAN FIBROSIS Nora Frulio1, Hervé Laumonier1, Charles Balabaud2, Paulette Bioulac-Sage3, Hervé Trillaud1 1Radiology, Hopital Saint Andre-CHU Bordeaux, Bordeaux, France. 2Hepatology, Hopital Saint Andre-CHU Bordeaux, Bordeaux, France. 3Anatomopathology, Hopital Pellegrin-CHU Bordeaux, Bordeaux, France


Hidetsugu Saito, Hirotoshi Ebinuma, Keisuke Ojiro, Hakusyo Cho, Rumiko Umeda, Shingo Usui, Yoshiyuki Yamagishi, Kanji Wakabayashi, Nobuhiro Nakamoto, Toshifumi Hibi Internal Medicine, Keio University, Tokyo, Japan

Francesco Ridolfi1, Teresa Abbattista2, Francesco Marini1, Caterina Todeschini1, Enrica Ciabattoni2, Anna Livia Iasci1, Paolo Busilacchi2, Eugenio Brunelli1 1ASUR Marche-ZTL4 Senigallia, Unit of GastroenterologyOspedale Civile di Senigallia, Senigallia, Italy. 2ASUR MarcheZTL4 Senigallia, Unit of Radiology-Ospedale Civile di Senigallia, Senigallia, Italy

192A

POSTER SESSIONS

Metabolic Liver Disease

#936 RECIST VERSUS EASL CRITERIA FOR THE EVALUATION OF HCC RESPONSE TO SORAFENIB Massimo Iavarone1, Angelo Sangiovanni1, Matteo A. Manini1, Laura Virginia Forzenigo2, Massimo Colombo1 11st Division of Gastroenterology, Fondazione IRCCS Maggiore Hosptial, University of Milan, Milan, Italy. 2Division of Radiology, Fondazione IRCCS Maggiore Hospital, Milan, Italy

#937 NON-INVASIVE DIAGNOSIS OF LIVER FIBROSIS USING VIRTUAL TOUCH TISSUE QUANTIFICATION Hiroko Iijima1, Hironori Tanaka1, Masaki Saito1, Nobuhiro Aizawa1, Teruhisa Yamamoto1, Hirayuki Enomoto1, Yoshinori Iwata1, Hiroyasu Imanishi1, Soji Shimomura1, Junichi Yamanaka2, Jiro Fujimoto2, Seiichi Hirota3, Tohru Tsujimura4, Shuhei Nishiguchi1 1Division of Hepatobiliary and Pancreatic Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan. 2Division of Hepatobiliary and Pancreatic Medicine, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan. 3Department of Surgical Pathology, Hyogo College of Medicine, Nishinomiya, Japan. 4Department of Pathology, Hyogo College of Medicine, Nishinomiya, Japan

#938 USEFULNESS OF CONTRAST-ENHANCED INTRAOPERATIVE ULTRASONOGRAPHY IN CIRRHOTIC PATIENTS UNDERGOING LIVER RESECTION FOR HEPATOCELLULAR CARCINOMA Yamanaka1,

Sugimoto1,

Iijima2,

Junichi Takaaki Hiroko Hironori Tanaka2, Tadamichi Hirano1, Nobukazu Kuroda1, Toshihiro Okada1, Shinichi Saito1, Yasukane Asano1, Naoki Uyama1, Makoto Satake1, Yasuhiko Yoshida1, Kazuhiro Suzumura1, Yuichi Kondo1, Yuji Iimuro1, Soji Shimomura2, Hideji Nakamura2, Shuhei Nishiguchi2, Jiro Fujimoto1 1Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan. 2Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

#939



USEFULNESS OF HEPATOCYTE PHASE IMAGING OF GD-EOB-DTPA-MRI IN DETECTING BORDERLINE LESIONS WHICH ARE DIFFICULT TO DETECT OTHER IMAGING MODALITIES Tatsuo Inoue, Masatoshi Kudo Gastroenterology and hepatology, Kinki University, Osaka-sayama, Japan

#940 ELEVATION OF HEPATIC SERINE PROTEASE MATRIPTASE-2 (TMPRSS6) EXPRESSION OCCURS IN HEREDITARY HAEMOCHROMATOSIS: IMPLICATIONS FOR DISEASE PATHOGENESIS AND TREATMENT John D. Ryan, Eleanor Ryan, Jennifer Russell, Matthew W. Lawless, John P. Crowe Centre for Liver Disease, Mater Misericordiae University Hospital, Dublin 7, Ireland

#941 WITHDRAWN

#942 ALPHA1-ANTITRYPSIN HETEROZYGOSITY IS A SIGNIFICANT CO-FACTOR FOR PARENCHYMAL LIVER DISEASES William Gelson1, Aneela Masood1, Gerald A. Maguire2, Susan Davies3, William Griffiths1 1Hepatology, Addenbrooke’s Hospital, Cambridge, United Kingdom. 2Clinical Biochemistry, Addenbrooke’s Hospital, Cambridge, United Kingdom. 3Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom

#943 COFFEE AND GLUCURONIDATION: HOW COFFEE INFLUENCES THE TRANSCRIPTIONAL REGULATION OF UDPGLUCURONOSYLTRANSFERASES Sandra Kalthoff, Ursula Ehmer, Nicole Freiberg, Michael P. Manns, Christian P. Strassburg Medical School Hannover, Hannover, Germany

#944 PROSPECTIVE COMPARISON OF PHLEBOTOMY AND LOW-DOSE HYDROXYCHLOROQUINE IN THE TREATMENT OF PORPHYRIA CUTANEA TARDA: AN INTERIM ANALYSIS Ashwani K. Singal1, Csilla Kormos Hallberg2, Chul Lee2, James Grady3, Karl E. Anderson2,1 1Gastroenterology, University of Texas medical Branch, Galveston, TX, USA. 2Preventive Medicine and Community Health and Human Nutrition, University of Texas Medical Branch, Galveston, TX, USA. 3Prevetive Medicine and Community Health, Epidemiology and Biostatistics, University of Texas Medical Branch, Galveston, TX, USA

#945 GENETIC ANALYSIS OF BIRC4/ XIAP AS PUTATIVE MODIFIER GENE IN WILSON DISEASE Karl Heinz Weiss1, Heiko Runz2, Barbara Noe1, Daniel Gotthardt1, Uta Merle1, Peter Ferenci3, Wolfgang Stremmel1, Joachim Fuellekrug1 1Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany. 2Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany. 3Department of Gastroenterology, University Hospital Vienna, Vienna, Austria Denotes AASLD Presidential Poster of Distinction


POSTER SESSIONS

193A

#946

#951

HFE MUTATIONAL ANALYSIS HAS REDUCED THE NEED FOR LIVER BIOPSY AT DIAGNOSIS BUT NOT IMPACTED ON INITIAL DISEASE BURDEN IN HEREDITARY HAEMOCHROMATOSIS PROBANDS

WITHDRAWN

John D. Ryan, Mary T. O’ Neill, Eleanor Ryan, Thomas Kelleher, John P. Crowe Centre for Liver Disease, Mater Misericordiae University Hospital, Dublin 7, Ireland

HIGH URINARY COPPER EXCRETION IN SEVERE LIVER DISEASES CAN OVERLAP VALUES SEEN IN WILSON’S DISEASE

#947 ASSESSMENT OF BILIARY COPPER EXCRETION IN WILSON’S DISEASE (WD) WITH NONINVASIVE IMAGING Ralf Bahde1,2, Sorabh Kapoor1, Kuldeep Bhargava3, Christopher J. Palestro3, Sanjeev Gupta1 1Medicine, Albert Einstein College of Medicine, Bronx, NY, USA. 2German Research Foundation, Bonn, Germany. 3Nuclear Medicine and Molecular Imaging, Long Island Jewish Medical Center, New York, NY, USA

#948 DIFFERENTIAL AND TISSUE-SPECIFIC REGULATION OF HUMAN UDP-GLUCURONOSYLTRANFERASES (UGT) 1A9 AND UGT1A10 BY NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2 (NRF2) AND ARYL HYDROCARBON RECEPTOR (AHR) Sandra Kalthoff, Ursula Ehmer, Michael P. Manns, Christian P. Strassburg Medical School Hannover, Hannover, Germany

#949 THERAPEUTIC ERYTHROCYTAPHERESIS, A NEW TREATMENT FOR NAïVE PATIENTS WITH HEREDITARY HEMOCHROMATOSIS

#950 INDUCTION OF THE UDPGLUCURONOSYLTRANSFERASE (UGT) 1A1 AND UGT1A6 GENE EXPRESSION BY PHENOBARBITAL IN THE LIVER OF HUMANIZED TRANSGENIC UGT1A-MICE Bastian Fakundiny, Ursula Ehmer, Sandra Kalthoff, Nicole Freiberg, Michael P. Manns, Christian P. Strassburg Medical School Hannover, Hannover, Germany

Rodolphe Anty1,2, Ludovic Evesque1, Lilian Badan1, Stephanie Patouraux3, Marie-Christine Saint-Paul3,2, Philippe Gual1,2, PierreMichel Huet1,2, Albert Tran1,2 1Digestive Department, Archet 2 Hospital, Nice, France. 2INSERM U895, Nice, France. 3Pathological Department, Pasteur Hospital, Nice, France

#953 ASSOCIATIONS OF GENETIC VARIANTS OF THE TRANSCRIPTIONAL COACTIVATORS EP300 AND PCAF WITH HEPATOCELLULAR CARCINOMA Abdellah Akil1, Sayeh Ezzikouri1, Abdellah Essaid El Feydi2, Mustapha Benazzouz2, Rajaa Afifi2, Abdelaziz Benjouad3, Mohammed Hassar1, Pascal Pineau4, Soumaya Benjelloun1 1Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca, Morocco. 2Service de Médecine C, CHU Ibn-Sina, Rabat, Morocco. 3Laboratoire de Biochimie et d’Immunologie, Mohammed V University, Rabat, Morocco. 4Unité d’Organisation Nucléaire et Oncogenèse, Institut Pasteur de Paris, INSERM U579,, Paris, France

#954 PATIENTS WITH WILSON DISEASE ARE EXPOSED TO INCREASED OXIDATIVE STRESS - IT DECREASES WITH THE TREATMENT, BUT DOES NOT MODIFY THE PHENOTYPIC MANIFESTATION - LONG TERM STUDY ON PATIENTS WITH WILSON DISEASE Radan Bruha1, Zdenek Marecek2, Libor Vitek1, Martin Lenicek1, Alena Jiraskova1, Pavel Martasek3, Lenka Pospisilova3, Jaromir Petrtyl1, Petr Urbanek2, Sona Nevsimalova5, Peter Ferenci4 14th Intenal Clinic, Charles University, 1st Faculty of Medicine, Prague, Czech Republic. 2Internal Clinic, Central Military Hospital, Prague, Czech Republic. 3Department of Mitochondrial Disorders, Charles University, 1st Faculty of Medicine, Prague, Czech Republic. 4Internal Clinic 4, University of Wien, Wien, Austria. 5Department of Neurogy, Charles University, 1st Faculty of Medicine, Prague, Czech Republic

#955 EFFECTS OF LONG-TERM ETHANOL INGESTION ON HEPATIC IRON METABOLISM IN 2 MOUSE STRAINS Kyle E. Brown2,1, Robert T. Cook1 1University of Iowa, Iowa City, IA, USA. 2Iowa City VAMC, Iowa City, IA, USA


Ger H. Koek5, Eva Rombout-Sestrienkova1, Paulus Noord2, Cees van Deursen4, Mirian Janssen3 1Unit Clinical Affaires, Sanquin Blood Bank, South east Region, Maastricht, Netherlands. 2Unit Research and Development, University Hospital, Nijmegen, Netherlands. 3Vascular Medicine, University Hospital, Nijmegen, Netherlands. 4Internal Medicine, Atrium Medical Center, Heerlen, Netherlands. 5Internal Medicine, division of Gastroenterology/ Hepatology, Maastricht University Medical Center, Maastricht, Netherlands

#952

194A

POSTER SESSIONS

Pediatric Liver Disease and Transplantation #956 PEDIATRIC LIVER TRANSPLANTATION FOR SCLEROSING CHOLANGITIS (PSC) Tamir A. Miloh1, Ravinder Anand2, Wanrong Yin2, Miriam B. Vos3, Nanda Kerkar1, Estella Alonso4 1Mount Sinai Hospital, New-York, NY, USA. 2The EMMES Corporation, Rockville, MD, USA. 3Emory University School of Medicine, Atlanta, GA, USA. 4Children’s Memorial Hospital, chicago, IL, USA

#957 IS THERE A ROLE OF CORTICOSTEROIDS IN PREVENTING GRAFT HEPATITIS AND FIBROSIS IN LIVER ALLOGRAFTS FOLLOWING PAEDIATRIC LIVER TRANSPLANTATION? Wolfram Haller1, Carla Lloyd1, Stefan G. Hubscher2, Rachel M. Brown2, Patrick J. McKiernan1, Deirdre A. Kelly1 1The Liver Unit, Birmingham Children’s Hospital NHS Foundation Trust, Birmingham, United Kingdom. 2Department of Pathology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

#958 INCIDENCE OF VITAMIN D INSUFFICIENCY IN CHILDREN FOLLOWING LIVER TRANSPLANTATION Maria Legarda1, Graham J. Gordon1, Carla Lloyd1, Patrick J. McKiernan1, Deirdre A. Kelly1, Ulrich Baumann2, Nick Shaw3 1Liver Unit, Birmingham Childrens Hospital, Birmingham, United Kingdom. 2Kinderklinik, Medizinische Hochschule Hannover, Hannover, Germany. 3Endocrinology Department, Birmingham Childrens Hospital, Birmingham, United Kingdom

#959


LIVER TRANSPLANTATION FOR PROPIONIC ACIDAEMIA IN CHILDREN: A TERTIARY CENTRE EXPERIENCE Roshni Vara1, Michael Champion2, Anil Dhawan1, Nigel Heaton1, Mohammed Rela1, Giorgina Mieli-Vergani1, Nedim Hadzic1 1Paediatric Liver, GI and Nutrition Centre, King’s College School of Medicine at King’s College Hospital, London, United Kingdom. 2Paediatric Metabolic Unit, Evelina Children’s Hospital, St Thomas’ Hospital, London, United Kingdom


#960 ABCB4 MUTATIONS, IDIOPATHIC PEDIATRIC GALLSTONES AND CONTRACEPTIVE-INDUCED INTRAHEPATIC CHOLESTASIS Milan Jirsa1, Jiri Bronsky2, Erica Makin3, Mark Davenport3, Tomas Jirasek4, Jan Sperl1, Lenka Dvorakova5, Vit Smajstrla6, Jiri Horak7, Jiri Nevoral2, S. Strautnieks3, Richard J. Thompson3, Martin Hrebícek5 1Institute for Clinical and Experimental Medicine, Praha, Czech Republic. 2Department of Pediatrics, Second Faculty of Medicine, Charles University and University Hospital Motol, Praha, Czech Republic. 3Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, London, United Kingdom. 4Department of Pathology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Praha, Czech Republic. 5Institute of Inherited Metabolic Diseases, First Faculty of Medicine, Charles University, Praha, Czech Republic. 6Bormed Private Health Center, Ostrava, Czech Republic. 71st Department of Internal Medicine, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Praha, Czech Republic

#961 THE CHANGING ROLE OF LIVER TRANSPLANTATION IN CHILDREN WITH TYROSINEMIA Ronen Arnon1,2, Rachel A. Annunziato3, Melissa Wasserstein1, Tamir A. Miloh1,2, Brittany Hogan3, Frederick J. Suchy1, Kishore Iyer2, Nanda Kerkar1,2 1Pediatrics, Mount Sinai Medical Center, NY, NY, USA. 2RMTI, Mount Sinai Medical Center, NY, NY, USA. 3Fordham University, NY, NY, USA

#962 NOVEL FIBRINOGEN MUTATION γ314THRÇPRO ÇPRO (FIBRINOGEN AI DUPONT) IDENTIFIED CAUSING HEPATIC FIBRINOGEN STORAGE DISEASE Katryn N. Furuya1,5, Ryan L. Davis2, Anthony M. Savo4, Katrina Conard3, Stephen O. Brennan2 1Pediatric Gastroenterology & Solid Organ Transplant, AI duPont Hospital for Children, Wilmington, DE, USA. 2Pathology, Christchurch School of Medicine, University of Otago, Christchurch, New Zealand. 3Pathology, AI duPont Hospital for Children, Wilmington, DE, USA. 4Surgery and Solid Organ Transplant, AI duPont Hospital for Children, Wilmington, DE, USA. 5Pediatrics, Thomas Jefferson University, Philadelphia, PA, USA

#963 LIVER TRANSPLANTATION FOR PATIENTS WITH MAPLE SYRUP URINE DISEASE: A NEW INDICATION FOR OLD DISEASE? Ronen Arnon1,2, Rachel A. Annunziato3, Melissa Wasserstein1, Tamir A. Miloh1,2, Brittany Hogan3, Frederick J. Suchy1, Kishore Iyer2, Nanda Kerkar1,2 1Pediatrics, Mount Sinai Medical Center, NY, NY, USA. 2RMTI, Mount Sinai Medical Center, NY, NY, USA. 3Fordham University, NY, NY, USA



POSTER SESSIONS

#964

#969

DIFFERENTIAL EXPRESSION PATTERN OF THE RELATED GUIDANCE RECEPTORS NEOGENIN, UNC5B AND NEIGHBOR OF PUNC E11 AND THE GUIDANCE CUES NETRIN-1 AND NETRIN-4 IN DEVELOPING AND ADULT LIVER

PRELIMINARY OBSERVATIONAL STUDY ON EFFICACY AND TOLERABILITY OF PEG-IFN ON 151 PEDIATRIC AND ADOLESCENT CHRONIC HEPATITIS C PATIENTS

Elisabeth Sauer1, Harald M. Curth1, Margarete Odenthal2, Tobias Goeser1, Dirk Nierhoff1 1Gastroenterology and Hepatology, University of Cologne, Cologne, Germany. 2Institute of Pathology, University of Cologne, Cologne, Germany

#965 MECHANISMS OF HEPATOCELLULAR DEATH IN CHILDREN WITH ACUTE LIVER FAILURE OF UNKNOWN AETIOLOGY Ahlam Mustafa1, Ragai R. Mitry1, Kandala Ngianga-Bakwin2, Munther J. Hussain1, Anil Dhawan1 1Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, London, United Kingdom. 2Department of statistics, Warwick Medical School, Coventry, United Kingdom

#966 DETECTION AND FOLLOW-UP OF LIVER FIBROSIS IN CYSTIC FIBROSIS: A ROLE FOR DIAGNOSTIC LIVER BIOPSY AND SERUM MARKERS IN THE EVALUATION OF AND FOLLOW UP OF CYSTIC FIBROSIS LIVER DISEASE Meagan J. Walsh1, Peter J. Lewindon2,1, Ross W. Shepherd3,1, Tamara N. Pereira1, Ristan M. Greer4, Scott Bell5, Grant A. Ramm1 1The Queensland Institute of Medical Research, Herston, QLD, Australia. 2Department of Gastroenterology, The Royal Children’s Hospital, Brisbane, QLD, Australia. 3Department of Paediatrics, Washington University School of Medicine, St Louis, MO, USA. 4The School of Veterinary Science, The University of Queensland, Brisbane, QLD, Australia. 5Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, QLD, Australia

#967

Mortada H. El-Shabrawi1, Nabil A. Mohsen1, Mai M. Sherif2, Hany Riad1, Ahmed M. El Henawy3 1Pediatrics, Cairo University, Cairo, Egypt. 2Clinical Pathology, Cairo University, Cairo, Egypt. 3Pathology, Cairo University, Cairo, Egypt

#968 NON-INVASIVE BIOMARKERS AND PEDIATRIC NON-ALCOHOLIC FATTY LIVER DISEASE; METHODS TO PREDICT DISEASE AND STRATIFY SEVERITY Emer Fitzpatrick1, Ragai R. Mitry2, Alberto Quaglia2, Anil Dhawan1,2 1Department of Pediatric Hepatology, King’s College Hospital, London, United Kingdom. 2Institute of Liver Studies, King’s College Hospital, London, United Kingdom

Hongfei Zhang Pediatric hepatitis, 302 hospital, Beijing, China

#970 RENAL ANOMALIES IN ALAGILLE SYNDROME: PREVALENCE AND CHARACTERIZATION Binita M. Kamath1, Kathleen M. Loomes1, Gisele Podkameni1, Pedro S. Munoz1, David A. Piccoli1, Nancy B. Spinner2, Kevin E. Meyers3 1Division of Gastroenterology, Hepatology and Nutrition, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA. 2Division of Human Molecular Genetics, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA. 3Division of Nephrology, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA

#971 VARICEAL BLEEDING IN CHILDREN WITH PORTAL HYPERTENSION: 12 YEAR EXPERIENCE AT A PEDIATRIC LIVER TRANSPLANT CENTER Tamir A. Miloh1, Dan Turner2, Benjamin L. Shneider3, Sanobar Parkar1, Ronen Arnon1, Frederick J. Suchy1, Kishore Iyer1, Nanda Kerkar1 1Mount Sinai Hospital, New-York, NY, USA. 2Sharee Zedek, Jerusalem, Israel. 3Children’s hospital of Pittsburgh, Pittsburgh, PA, USA

#972 PARENTERAL FISH OIL AS MONOTHERAPY IMPROVES LIPID PROFILE IN PATIENTS WITH PARENTERAL NUTRITION-ASSOCIATED LIVER DISEASE Hau D. Le, Vincent E. de Meijer, Jonathan A. Meisel, Mark Puder Surgery, Children’s Hospital Boston, Boston, MA, USA

#973 SUCCESSFUL USE OF LONG-ACTING OCTREOTIDE FOR INTRACTABLE CHRONIC GASTROINTESTINAL BLEEDING IN CHILDREN Marie O’Meara1,2, Maria Pia Cicalese1, Nedim Hadzic1, Andrea Bordugo3, Giorgina Mieli-Vergani1 1Institute of Liver studies, King’s College London School of Medicine, Kings College Hospital NHS Foundation Trust, London, United Kingdom. 2Department of Pharmacy, Kings College Hospital NHS Foundation Trust, London, United Kingdom. 3Department of Paediatrics, “S Maria degli Angeli” Hospital, Pordenone, Italy


NON-INVASIVE ASSESSMENT OF HEPATIC FIBROSIS AND NECRO-INFLAMMATORY ACTIVITY IN CHILDREN WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION USING FIBROTEST AND ACTITEST

195A

196A

POSTER SESSIONS

#974 THYROID AND HEPATIC HAEMODYNAMIC ALTERATIONS AMONG EGYPTIAN CHILDREN WITH LIVER CIRRHOSIS: ARE THEY INTERRELATED? Zeinab A. El Kabbany1, Rasha T. Hamza2, Ahmed S. Abdel Hakim3, Lamis M. Tawfik4 1pediatrics, Ain shams university, Cairo, Egypt. 2Pediatrics, Ain Shams University, Cairo, Egypt. 3Radiology, Ain Shams University, Cairo, Egypt. 4Clinical Pathology, Ain Shams University, Cairo, Egypt


#978 THE RELATIONSHIP BETWEEN NONALCOHOLIC FATTY LIVER DISEASE AND CORONARY ARTERY DISEASE ; A PROSPECTIVE CASE-CONTROL STUDY IN A SINGLE CENTER Dae Hee Choi1, Myong Ok Park1, Chang Don Kang1, Sung Joon Lee1, Ji Won Lee2, Byung Ryul Cho1 1Internal Medicine, Kangwon National University, Chuncheon, Korea, South. 2Radiology, Kangwon National University, Chuncheon, Korea, South

#979

Steatohepatitis: Clinical #975 A PROSPECTIVE PREVALENCE STUDY OF NAFLD AND NASH UTILIZING ULTRASOUND AND LIVER BIOPSY IN A PRIMARY CARE SETTING Christopher D. Williams, Joel Z. Stengel, Dawn M. Torres, Stephen A. Harrison Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, TX, USA

#976

Yana Davidov1, Bridget Gunson1,2, Abulrahman Saadeddin2, Kishore Gopalakrishnan3, Simon Bramhall2, Stefan Hubscher3, Philip N. Newsome1,2 1Centre for Liver Research, University of Birmingham, Birmingham, United Kingdom. 2Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom. 3Pathology, University of Birmingham, Birmingham, United Kingdom

#980

HIGHER RISK OF PROGRESSION TO LIVER CIRRHOSIS AND HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE

THE “EN BALANCE” 3-MONTH DIABETES EDUCATION PROGRAM FOR HISPANICS LEADS TO SIGNIFICANT IMPROVEMENTS IN NONALCOHOLIC FATTY LIVER DISEASE

Dewei Ye1, Lei Lu1, Wai-Hung Shek2, Hung Yao3, Polly Lam4, WaiKi Lee5, Amy Kwok1, April Wong1, Yui-Hung Yueng1, Yu-dong Wang1, Jian-Gao Fan6, George K. Lau7 1Department of Medicine, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. 2Department of Pathology, Queen Mary Hospital, The University of Hong Kong,, Hong Kong SAR, China. 3Department of Pathology, Princess Margaret Hospital, Hong Kong SAR, China. 4Department of Pathology, Queen Elizabeth Hospital, Hong Kong SAR, China. 5Department of Pathology, Tuen Mun Hospital, Hong Kong SAR, China. 6Department of Gastroenterology, Xinhua Hospital, Shanghai, China. 7Cheng Si Yuan (China-International) Hepatitis Research Foundation, Hong Kong SAR, China

Michel H. Mendler1, Eloy Schulz2, Lorena M. Salto3, Larry Beeson3, Anthony Firek4, Marino De Leon5, Zaida Cordero-MacIntyre6,5 1GI and Liver Diseases, Transplantation Institute, Loma linda University Medical Center, Loma Linda, CA, USA. 2Department of Nuclear Radiology, Loma Linda University Medical Center, Loma Linda, CA, USA. 3School of Public Health, Department of Epidemiology and Biostatistics, Loma Linda University Medical Center, Loma Linda, CA, USA. 4School of Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA. 5Center for Health Disparities and Molecular Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA. 6School of Public Health, Department of Nutrition, Loma Linda University Medical Center, Loma Linda, CA, USA


SURVIVAL AND DISEASE RECURRENCE AFTER LIVER TRANSPLANTATION FOR NON-ALCOHOLIC STEATOHEPATITIS

EFFECTS OF PIOGLITAZONE THERAPY ON HEPATIC FATTY ACID SYNTHESIS, BETAOXIDATION AND HEPATIC STELLATE CELLS: IS THE DRUG MORE THAN AN INSULIN SENSITIZER? Roslina Abdul Rahim2, Philip Kaye3, Ian A. Macdonald2, Andrew J. Bennett2, Guruprasad P. Aithal1 1Nottingham Digestive Disease Centre: Biomedical Research Unit, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom. 2School of Biomedical Sciences, University of Nottingham, Nottingham, United Kingdom. 3Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom


#981 PNPLA3/ADIPONUTRIN GENOTYPE IS STRONGLY ASSOCIATED WITH METABOLIC SYNDROME COMPONENTS AND LIVER DAMAGE IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE Luca Valenti1, Enrico Galmozzi1, Paola Dongiovanni1, Raffaela Rametta1, Ezio Lattuada2, Marco Zappa2, Enrico Mozzi2, Giancarlo Roviaro2, Marco Maggioni4, Ester Vanni3, Elisabetta Bugianesi3, Anna Ludovica Fracanzani1, Silvia Fargion1 1Internal Medicine, Università degli Studi Milano, Ospedale Policlinico IRCCS, Milano, Italy. 2Surgery, Università degli Studi Milano, Ospedale Policlinico Mangiagalli Regina Elena IRCCS, Milano, Italy. 3Gastroenterology, Università di Torino, Torino, Italy. 4Pathology, Ospedale San Paolo, Milano, Italy


POSTER SESSIONS

#982 SENESCENCE MARKER PROTEIN-30 IS INVOLVED IN THE PATHOGENENSIS OF NONALCOHOLIC FATTY LIVER DISEASE AND IT MIGHT BECOME A POTENTIAL MARKER FOR DIAGNOSIS AND STAGING OF NONALCOHOLIC FATTY LIVER DISEASE Takeshi Okanoue1, Hyohun Park1, Toshihide Shima1, Masayuki Mizuno1, Atsushi Umemura1, Mika Nakayama1, Akihito Ishigami2, Mitsuhiro Ohta3, Naoki Maruyama4, Hiroshi Obayashi5 1Hepatology Unit, Saiseikai Suita Hospital, Suita, Japan. 2Faculty of Pharmaceutical Science, Toho University, Chiba, Japan. 3Department of Medical Biochemistry, Kobe Pharmaceutical University, Kobe, Japan. 4Aging Regulation, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. 5Department of Immunology,Institute of Bio-Response Informatics, Kyoto Prefetcural University of Medicine, Tokyo, Japan

#983 WEIGHT LOSS DECREASES ADIPOSE TISSUE INTERLEUKIN-6 EXPRESSION AND IMPROVES INFLAMMATION Alexander R. Moschen1,2, Clemens Molnar3, Sabine Geiger1,2, Ivo Graziadei2, Christoph F. Ebenbichler3, Helmut Weiss4, Arthur Kaser1,2, Herbert Tilg1,2 1Christian Doppler Research Laboratory for Gut Inflammation, Innsbruck Medical University, Innsbruck, Austria. 2Department of Internal Medicine II (Gastroenterology and Hepatology), Innsbruck Medical University, Innsbruck, Austria. 3Department of Internal Medicine I (Metabolic Diseases, Pulmology, Infectious Diseases, Endocrinology, Rheumatology and Angiology), Innsbruck Medical University, Innsbruck, Austria. 4Department of Surgery, SJOG (Saint John of God) Hospital, Salzburg, Austria

#984 DIAGNOSIS OF NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD): SHOULD WE USE CARBOHYDRATE DEFICIENT TRANSFERIN (CDT) TO IDENTIFY SUBJECTS WITH EXCESSIVE ALCOHOL CONSUMPTION ? A PROSPECTIVE STUDY IN GENERAL POPULATION

#985 PREDICTION OF FIBROSIS IN PATIENTS WITH NAFLD USING TRANSIENT ELASTOGRAPHY : A PROSPECTIVE MULTICENTRE STUDY Victor de Ledinghen1,5, Vincent W. Wong2,3, Julien Vergniol1, Grace Wong2,3, Brigitte Le Bail4,5, Angel ML Chim2,3, Juliette Foucher1, Henry Lik-Yuen Chan2,3 1Hepatology Unit, Hopital Haut-Leveque, Pessac, France. 2Medicine and Therapeutics, Chinese University, Hong Kong, China. 3Institute of digestive disease, Chinese University, Hong Kong, China. 4Pathology Unit, Hopital Pellegrin, Bordeaux, France. 5INSERM U889, Universite Victor Segalen, Bordeaux, France

#986 FATTY LIVER PREDICT THE PRESENCE OF CORONARY PLAQUES AND EARLY ATHEROSCLEROSIS INDEPENDENTLY BY VISCERAL FAT ACCUMULATION Yivgainy Rouvman1,3, Marmor Alon3,2, Ina Dvorin4,1, M. Deitzman4, Nimer Assy1,2 1Liver Unit, Ziv Medical Centre, Safed, Israel. 2Liver Unit, Technion, haifa, Israel. 3Cardiology, Ziv Medical Centre, Safed, Israel. 4Radiology, Ziv Medical Centre, Safed, Israel

#987 GENETIC VARIATION IN HORMONE SENSITIVE LIPASE AND ADIPONECTIN CONFERS SUSCEPTIBILITY TO NONALCOHOLIC FATTY LIVER DISEASE Bradley E. Aouizerat1,5, Kiran Bambha2,5, Aynur Unalp-Arida3,5, Linda Ferrell4,5, Nathan M. Bass2,5 1Department of Physiologic Nursing, University of California San Francisco, San Francisco, CA, USA. 2Division of Gastroenterology, University of California San Francisco, San Francisco, CA, USA. 3Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. 4Department of Pathology, University of California San Francisco, San Francisco, CA, USA. 5NASH Clinical Research Network, NIH/NIDDK, Bethesda, MD, USA

#988 HEPATIC ACAT2 ACTIVITY PREDICTS HEPATIC STEATOSIS IN OBESE HUMANS Nathan J. Shores1, Kim Geisinger2, Adolfo Z. Fernandez3, Kylie Kavanagh4, Matthew Davis5, Janet K. Sawyer5, Lawrence L. Rudel5 1Section on Gastroenterology, WFUHS, Winston-Salem, NC, USA. 2Department of Pathology, WFUHS, Winston-Salem, NC, USA. 3Department of Surgery, WFUHS, Winston-Salem, NC, USA. 4Pathology/Comparative Medicine, WFUHS, Winston-Salem, NC, USA. 5Department of Pathology/Lipid Sciences, WFUHS, WinstonSalem, NC, USA

#989 SITES OF INSULIN RESISTANCE IN OBESE NONDIABETIC SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) Kristina M. Utzschneider1,2, Kris V. Kowdley3,2, Matthew M. Yeh2, Steven E. Kahn1,2 1Medicine, VA Puget Sound Health Care System, Seattle, WA, USA. 2University of Washington, Seattle, WA, USA. 3Benaroya Research Institute, Virginia Mason Medical Center, Seattle, WA, USA

#990 A PROSPECTIVE ANALYSIS OF LIVER HISTOLOGY IN PATIENTS WITH MEDICALLY COMPLICATED OBESITY – NAFLD IS COMMON, NASH WITH ADVANCED FIBROSIS IS NOT Tarsila Ribeiro1, Schuyler O. Sanderson1, James Swain1, Kimberly Watt1, Kimberly Viker1, Anuradha Krishnan1, Mario Kondo2, Michael R. Charlton1 1Mayo Clinic, Rochester, MN, USA. 2UNIFESP, Sao Paulo, Brazil


Thierry Poynard1, Pascal Lebray1, Anne Varaud1, Patrick Ingiliz1, Brigitte Varsat2, Yen Ngo3, Mona Munteanu3, Djamila Messous1, Francoise Imbert-Bismut1, Jean Pierre Carrau2, Julien Massard1, Vlad Ratziu1, Jean Pierre Giordanella2 1APHP UPMC Liver Cnter, Paris, France. 2CPAM, Paris, France. 3Biopredictive, Paris, France

197A

198A

POSTER SESSIONS

#991

#996

GENE-ENVIRONMENT INTERACTIONS UNDERLYING THE DEVELOPMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN ADOLESCENCE ARE INFLUENCED BY GENDER

A ROLE FOR LOW HEPATIC COPPER CONCENTRATIONS IN NON-ALCOHOLIC FATTY LIVER DISEASE

Oyekoya T. Ayonrinde1,2, John K. Olynyk1, Craig E. Pennell3,4, Lawrie J. Beilin1, Trevor A. Mori1, Wendy H. Oddy2, Lyle J. Palmer5, Nicole M. Warrington5, Stephen J. Lye6, Leon Adams1,7 1School of Medicine and Pharmacology, The University of Western Australia, Perth, WA, Australia. 2Telethon Institute for Child Health Research, Subiaco, WA, Australia. 3School of Women’s and Infants’ Health, The University of Western Australia, Perth, WA, Australia. 4Obstetrics and Gynaecology, King Edward Memorial Hospital, Subiaco, WA, Australia. 5Centre for Genetic Epidemiology and Biostatistics, The University of Western Australia, Perth, WA, Australia. 6Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada. 7Liver Transplantaion Unit, Sir Charles Gairdner Hospital, Nedlands, WA, Australia

#992 FIRST HUMAN EXPERIENCE WITH A SYNTHETIC FARNESOID X RECEPTOR (FXR) AGONIST - INT747 (6α-ETHYLCHENODEOXYCHOLIC ACID) David Shapiro1, Barrie March2, Lise Eliot1, Romeo duBois3, Mark Pruzanski3 1Intercept Pharmaceuticals, Inc., San Diego, CA, USA. 2PRACS Institute, Ltd., Fargo, ND, USA. 3Intercept Pharmaceuticals, Inc., New York, NY, USA

#993 WITHDRAWN

#994 SPECTRUM OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN BARIATRIC SURGERY PATIENTS WITH NORMAL ALANINE AMINOTRANSFERASE (ALT)



David E. Kleiner1, Paul D. Berk2, Jesse Y. Hsu3, Steven H. Belle3, Anita P. Courcoulas3, Alfons Pomp4, James L. Roerig5, Mark D. Smith6, Bruce M. Wolfe7 1Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA. 2Columbia University, New York, NY, USA. 3University of Pittsburgh, Pittsburgh, PA, USA. 4Cornell University, New York, NY, USA. 5University of North Dakota, Fargo, ND, USA. 6Oregon Weight Loss Surgery, Portland, OR, USA. 7Oregon Health & Science University, Portland, OR, USA

#995 GENETIC VARIATION IN ADIPONECTIN CONFERS SUSCEPTIBILITY TO NONALCOHOLIC FATTY LIVER DISEASE IN LATINO CAUCASIANS Kiran Bambha1,5, Bradley E. Aouizerat2,5, Aynur Unalp-Arida3,5, Linda Ferrell4,5, Nathan M. Bass1,5 1Division of Gastroenterology, University of California San Francisco, San Francisco, CA, USA. 2Department of Physiologic Nursing, University of California San Francisco, San Francisco, CA, USA. 3Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. 4Department of Pathology, University of California San Francisco, San Francisco, CA, USA. 5NASH Clinical Research Network, NIH/NIDDK, Bethesda, MD, USA Denotes AASLD Presidential Poster of Distinction

Elmar Aigner1, Michael P. Strasser2, Guenter Weiss4, Thomas Sonnweber4, Herbert Tilg3, Felix Stickel5, Christian Datz1 1Department of Internal Medicine, General Hospital Oberndorf, Oberndorf, Austria. 2First Department of Medicine, Paracelsus Medical University, Salzburg, Austria. 3Christian Doppler Research Laboratory for Gut Inflammation, Medical University Innsbruck, Innsbruck, Austria. 4Clinical Immunology and Infectious Diseases, Medical University Innsbruck, Innsbruck, Austria. 5Department of Clinical Pharmacology, Medical University Bern, Bern, Switzerland

#997 GENDER AND HORMONAL STATUS ARE ASSOCIATED WITH SEVERITY OF HISTOLOGIC FEATURES AMONG PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE Ayako Suzuki1, Cynthia D. Guy2, Alastair D. Smith1, Eric J. DeMaria3, Yiping Pan1, Melissa M. Smith1, Anna Mae Diehl1, Manal F. Abdelmalek1 1Gastroenterology, Duke University Medical Center, Durham, NC, USA. 2Department of Pathology, Duke University Medical Center, Durham, NC, USA. 3General Surgery, Durham Regional Hospital, Durham, NC, USA

#998 NOVEL ULTRASONIC FIBROSCAN®-BASED STEATOSIS INDEX FOR HEPATIC STEATOSIS QUANTIFICATION IN 618 HCV PATIENTS Michel Beaugrand1, Marianne Ziol2, Victor de Ledinghen3, Catherine Douvin4, Patrick Marcellin5, Raoul Poupon6, Celine Fournier7, Véronique Miette7, Magali C. Sasso7, Laurent Sandrin7 1Hepatology, Hôpital Jean Verdier, Bondy, France. 2Pathotogy, Hôpital Jean Verdier, Bondy, France. 3Hepatology, Hôpital Haut Lévêque, Bordeaux, France. 4Hepatology, Hôpital Henri Mondor, Créteil, France. 5Hepatology, Hôpital Beaujon, Clichy, France. 6Hepatology, Hôpital Saint Antoine, Paris, France. 7Echosens, Paris, France

#999 RISK OF NASH AND SEVERE FIBROSIS IN PATIENTS WITH NAFLD AND LOW VISCERAL ADIPOSITY Anna Ludovica Fracanzani1, Luca Valenti1, Elisabetta Bugianesi2, Ester Vanni2, Luca Miele3, Cristina Bertelli1, Erika Fatta1, Antonio Grieco3, Giulio Marchesini4, Silvia Fargion1 1Internal Medicine, Maggiore Policlinico Hospital Foundation IRCCS, University of Milan, Milan, Italy. 2Division of Gastroenterology, Ospedale S Giovanni Battista, Università di Torino, Torino, Italy. 3Internal Medicine, Università Cattolica di Roma, Roma, Italy. 4Internal Medicine, Università Alma Mater Studiorum Bologna, Bologna, Italy


POSTER SESSIONS

#1000

#1005

PREVALENCE OF HISTOPATHOLOGICAL DIAGNOSIS OF STEATOHEPATITIS AND FIBROSIS IN TYPE 2 DIABETES AND INTEROBSERVER AGREEMENT USING KLEINER CLASSIFICATION

INDEPENDENT PREDICTORS OF FIBROSIS IN PATIENTS WITH CHRONIC LIVER DISEASE

Nathalie C. Leite, Cristiane A. Villela-Nogueira, Gil Fernando C. Salles, Vera Lucia Pannain, Adriana Caroli-Bottino, Claudia Regina L. Cardoso Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

#1001 A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PPAR-ALPHA AGONIST FENOFIBRATE IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) Hari S. Conjeevaram, Barbara J. McKenna, Hellan Kang, Elif A. Oral, Jason Omo, Diane White, Charles F. Burant Gastroenterology, University of Michigan, Ann Arbor, MI, USA

#1002 NONALCOHOLIC STEATOHEPATITIS (NASH) TREATMENT INVOLVING IMPROVEMENT IN LIVER TISSUE FATTY ACID COMPOSITION Masahiko Shimada, Shuhei Yoshida, Morihiko Yoshino Gastroenterology, TMG Asakadai Central General Hospital, Asaka-city, Japan

#1003 HEPATOCELLULAR BALLOONING IN NASH: ACCUMULATION OF SMALL DROPLET FAT, CYTOSKELETAL INJURY AND ENDOPLASMIC RETICULUM DILATION; MORPHOLOGICAL EVIDENCE OF ‘MULTIORGANELLE’ FAILURE Caldwell1,

Ikura2,

Dias3,1,

#1004 EXERCISE CAPACITY IN NASH: EVIDENCE OF SEVERE DECONDITIONING AND ‘METABOLIC OBESITY’ IN BOTH OVERWEIGHT AND OBESE PATIENTS Curtis K. Argo1, Oscar A. Birkhan3,1, Neeral L. Shah1, Abdullah M. Al-Osaimi1, Winsor Simmons1, Arthur L. Weltman2, Stephen H. Caldwell1 1Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA, USA. 2Department of Exercise Physiology, University of Virgina, Charlottesville, VA, USA. 3School of Medicine, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

Ruben D. Aquino1,2, Maria Stepanova1,2, Abdulellah Alsheddi1, Ravindra Gupta2, Fang Yun2, Zobair M. Younossi1,2 1Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA. 2Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA

#1006 NON-ALCOHOLIC STEATOHEPATIS (NASH) IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME (PCOS) Noreen Hossain1,2, Maria Stepanova1, Arian Afendy1,2, Fatema Nader1,2, Nila Rafiq1,2, Zachary D. Goodman3, Zobair M. Younossi1,2 1Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA. 2Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA. 3Armed Forces Institute of Pathology, Washington, DC, USA

#1007 INCREASED DIETARY FRUCTOSE IMPAIRS HEPATIC ATP HOMEOSTASIS IN NAFLD Manal F. Abdelmalek1, Mariana Lazo2, Susanne Bonekamp3, Anna Mae Diehl1, Jeanne M. Clark2,4 1Medicine, Duke University, Durham, NC, USA. 2Epidemiology, The John Hopkins University, Baltimore, MD, USA. 3Radiology, The John Hopkins University, Baltimore, MD, USA. 4Medicine, The John Hopkins University, Baltimore, MD, USA

#1008 RAISED ALT IS ASSOCIATED WITH ETHNICITY IN A LARGE GENERAL POPULATION COHORT IN UK (LOLIPOP STUDY) Julie Parkes1, Scott Harris1, Elizabeth Lightstone2, John Chambers2,3, Jaspal Kooner2,3, Paul Roderick1 1Public Health Sciences & Medical Statistics, University of Southampton, Southampton, United Kingdom. 2Department of Medicine, Imperial College London, London, United Kingdom. 3Department of Cardiology, Ealing Hospital, London, United Kingdom S U N D AY NOVEMBER 1

Stephen H. Yoshihiro Daniela Kosuke Isomoto2, Akito Yabu2, Christopher Moskaluk4, Patcharin Pramoonjago4, Winsor Simmons5, Harriette Scruggs4, Nicholas P. Rosenbaum4, Wilkinson Timothy6, Patsy Toms4, Jan A. Redick7 1Department of GI/Hepatology, University of Virginia, Charlottesville, VA, USA. 2Department of Pathology, Osaka City University, Osaka, Japan. 3Division of GI/Hepatology, Universidade Federal da Bahia, Salvador-Bahia, Brazil. 4Department of Pathology, University of Virginia, Charlottesville, VA, USA. 5Surgical Therapeutic Advancement Center, University of Virginia, Charlottesville, VA, USA. 6Academic Computing Health Sciences, University of Virginia, Charlottesville, VA, USA. 7The Advanced Microscopy Facility, University of Virginia, Charlottesville, VA, USA

199A

200A

POSTER SESSIONS

#1009

#1012

RELATIONSHIP OF STEATOSIS QUANTITY AND ARCHITECTURE WITH OTHER LIVER LESIONS AND METABOLIC SYNDROME IN NAFLD

TREATMENT OF INSULIN RESISTANCE AND NON ALCOHOLIC STEATOHEPATITIS BY ADMINISTRATION OF BETA GLUCOSYLCERAMIDE: RESULTS OF A DOUBLE BLIND PLACEBO CONTROLLED TRIAL

Jerome Boursier1,2, Julien Chaigneau2, Vincent ROULLIER3, Fabrice Lainé4,5, Pierre Henri Ducluzeau6, Jérémy Sandrini7, Sophie Michalak7,2, Isabelle Fouchard-Hubert1,2, Nina Dib1,2, Frédéric Oberti1,2, Sandrine Bertrais2, Gilles Hunault2, Yves Deugnier4,5, Marie Christine Rousselet7,2, Christine Cavaro-ménard3, Yves Gallois8, Christophe Aubé9,2, Paul Cales1,2 1Service d’Hépato-Gastroentérologie, Centre Hospitalier Universitaire, Angers, France. 2Laboratoire HIFIH, Université, Angers, France. 3Laboratoire LISA, Université, Angers, France. 4Service des Maladies du Foie, Hôpital Pontchaillou, Centre Hospitalier Universitaire, Rennes, France. 5CIC Inserm 0203, Centre Hospitalier Universitaire, Rennes, France. 6Service d’Endocrinologie-Diabétologie-Nutrition, Centre Hospitalier Universitaire, Angers, France. 7Département de Pathologie Cellulaire et Tissulaire, Centre Hospitalier Universitaire, Angers, France. 8Laboratoire de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire, Angers, France. 9Service de Radiologie, Centre Hospitalier Universitaire, Angers, France

#1010 A SIMPLE SCORE IS ABLE TO PREDICT THE PRESENCE OF METABOLIC SYNDROME IN SUBJECT WITH FATTY LIVER: THE PRELIMINARY RESULTS OF A LARGE OBSERVATIONAL STUDY (BAGNACAVALLO-STUDY) Marco Domenicali1, Francesco G. Foschi2, Pierluigi Giacomoni3, Sara Savini2, Francesca Dazzani3, Anna Chiara Dall’Aglio2, Pietro Andreone1, Giuseppe Re3, Tino Casetti4, Giuseppe Francesco Stefanini2, Mauro Bernardi1 1Dipartimento Medicina Clinica, Università di Bologna, Bologna, Italy. 2Medicina Interna, Ospedale di Faenza, Faenza, Italy. 3Medicina Interna, Ospedale di Lugo, Ravenna, Italy. 4Gastroenterologia, Ospedale di Ravenna, Ravenna, Italy

#1011 PORTAL INFLAMMATION IS AN INDEPENDENT PREDICTOR OF SEVERE LIVER DISEASE IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE S U N D AY NOVEMBER 1


Hellan Kang1, Joel K K. Greenson2, Mary Ann Y. Huang3, Jason Omo4, Hari S. Conjeevaram1 1Gastroenterology, University of Michigan, Ann Arbor, MI, USA. 2Pathology, University of Michigan, Ann Arbor, MI, USA. 3Gastroenterology, Henry Ford Hospital, Detroit, MI, USA. 4Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA

Gadi Lalazar1, Ehud Zigmond1, Sarah W. Zangen2, Orit Pappo3, Miriam Levy Sklair4, Nilla Hemed1, Itamar Raz2, Yaron Ilan1 1Liver Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel. 2Diabetes Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel. 3Department of Pathology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. 4Department of Radiology, Hadassah Hebrew University Medical Center, Jerusalem, Israel

#1013 EXERCISE THERAPY FOR NONALCOHOLIC STEATOHEPATITIS (NASH) PATIENTS CAN REDUCE INSULIN RESISTANCE IN ADIPOCYTES IN ADDITION TO RESISTANCE IN LIVER AND MUSCLES Masahiko Shimada, Shuhei Yoshida, Morihiko Yoshino Gastroenterology, TMG Asakadai Central General Hospital, Asaka-city, Japan

#1014 PATHOLOGIC SIGNIFICANCES OF BALLOONED HEPATOCYTES IN NON-ALCOHOLIC STEATOHEPATITIS Yoshihiro Ikura1, Yoko Iwasa1, Akito Yabu1, Kosuke Isomoto1, Daniela Dias2, Stephen H. Caldwell2, Makiko Ueda1 1Department of Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan. 2Division of GI/Hepatology, University of Virginia, Charlottesville, VA, USA

#1015 HFE AND NONALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS Ruben Hernaez1, Edwina Yeung1, Jeanne M. Clark1,2, Kris V. Kowdley3, Frederick L. Brancati1,2, Wen Hong L. Kao1 1Epidemiology, Johns Hopkins University, Baltimore, MD, USA. 2General Internal Medicine, Johns Hopkins Hospital, Baltimore, MD, USA. 3Center for Liver Disease, Virginia Mason Medical Center, Seattle, WA, USA

#1016 CCL20 IS A SENSITIVE AND SPECIFIC BIOMARKER FOR FIBROSIS RELATED TO NON-ALCOHOLIC STEATOHEPATITIS IN THE MORBIDLY OBESE Glenn S. Gerhard1,2, Christopher D. Still1, Anthony T. Petrick1, Xin Chu1, Weixing Shi1, Hui Chen2 1Geisinger Clinic, Danville, PA, USA. 2HepGen, Inc., Lewisburg, PA, USA



POSTER SESSIONS

201A

#1017

#1021

COMPARISON OF NAFLD FIBROSIS SCORE AND BARD SCORE IN PREDICTING FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE

THE SERUM LEVELS OF MANGANESE SUPEROXIDE DISMUTASE (MNSOD) ARE ELEVATED IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)

Gabriela E. Ruffillo1, Eduardo Fassio1, Estela Alvarez2, Graciela Landeira1, Cristina G. Longo1, Nora Domínguez1, Gisela Gualano1 1Liver Unit, Hospital Nacional Prof. A. Posadas, El Palomar, Argentina. 2Pathology, Hospital Nacional Prof. A. Posadas, El Palomar, Argentina

Yoichiro Takami1, Hirofumi Uto1, Tsutomu Tamai1, Yuko Sato2, Akihiro Moriuchi1, Keita Funakawa1, Toshio Sakiyama1, Makoto Oketani1, Akio Ido1, Tomoaki Nakajima3, Takeshi Okanoue4, Hirohito Tsubouchi1 1Digestive Disease and Life-style related Disease Health Research, Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. 2Miyazaki Prefectural Industrial Support Foundation, Miyazaki, Japan. 3Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan. 4Department of Hepatology, Saiseikai Suita Hospital, Osaka, Japan

#1018 A NOVEL SERUM-BASED BIOMARKER PANEL FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND NASH-RELATED FIBROSIS Zobair M. Younossi1,3, Nila Rafiq1,3, Sandra Page1,2, Maria Stepanova1,3, Noreen Hossain1,3, Aybike Birerdinc1,2, Zahra Younoszai1,3, Zachary D. Goodman4, Ancha Baranova1,2 1Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA. 2Center for the Study of Genomics in Liver Diseases, Molecular and Microbiology Department, George Mason University, Fairfax, VA, USA. 3Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA. 4Armed Forces Institutes of Pathology, Washington, DC, USA

#1019 FATTY LIVER TAKES ON NEW WEIGHT: INCREASED RISK OF HCC WITHOUT CIRRHOSIS Godambe2,

Brems1,

Dimmock3,

Anjali John J. Elizabeth Sherri Yong2 1Department of Surgery, Loyola University, Maywood, IL, USA. 2Department of Pathology, Loyola University, Maywood, IL, USA. 3Stritch School of Medicine, Loyola University, Maywood, IL, USA

#1020 VASCULAR ADHESION PROTEIN-1 (VAP-1) IS A NOVEL BIOMARKER AND A POTENTIAL ANTIINFLAMMATORY AND ANTI-FIBROTIC TARGET IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

RANDOMIZED CONTROLLED PILOT STUDY USING INTRA-GASTRIC BALLOON FOR THE TREATMENT OF OBESE PATIENTS WITH NON ALCOHOLIC STEATOHEPATITIS (NASH) SIGIFICANTLY IMPROVES NASH ACTIVITY SCORE (NAS) Yin-Mei Lee, How Cheng Low, Lee Guan Lim, Yock Young Dan, Chee Leong Cheng, Aileen Wee, Seng Gee Lim, Khek Yu Ho national university hospital systems, Singapore, Singapore

#1023 PROSPECTIVE EVALUATION OF SERUM BIOMARKERS OF NASH IN PATIENTS WITH CLASS III OBESITY: EVIDENCE FOR AN ENDOCRINE BASIS OF PROGRESSIVE FIBROSIS Edith Koehler, James Swain, Schuyler O. Sanderson, Kimberly Viker, Anuradha Krishnan, Michael Kendrick, Geoffrey Thompson, Florencia G. Que, Michael Sarr, Michael R. Charlton Mayo Clinic, Rochester, MN, USA

#1024 DICHOTOMY IN THE EXPRESSION OF ENDOPLASMIC RETICULUM STRESS AND CHOLESTEROL REGULATOTY GENES BETWEEN PATIENTS WITH ALCOHOLIC AND NONALCOHOLIC STEATOHEPATITIS Carmen Garcia-Ruiz1,2, Marlene Dominguez1, Montserrat Mari1,2, Ramon Bataller1, Juan Caballeria1, Jose C. Fernandez-Checa1,2 1Liver Unit, Hospital Clinic, CIBEREHD, IDIBAPS, Barcelona, Spain. 2IIBB-CSIC, Barcelona, Spain

#1025 EFFECT OF WEIGHT LOSS ON LIVER CERAMIDE BIOSYNTHESIS AND DEGRADATION IN NASH Kittichai Promrat1, Lisa Longato2, Jack R. Wands1,2, Suzanne M. de la Monte2,3 1Gastroenterology and Hepatology, The Warren Alpert Medical School of Brown University, Providence, RI, USA. 2Liver Research Center, The Warren Alpert Medical School of Brown University, Providence, RI, USA. 3Pathology, The Warren Alpert Medical School of Brown University, Providence, RI, USA


Lee C. Claridge1, Nina Westerlund1,2, Emma L. Haughton1, Chris J. Weston1, Patricia F. Lalor1, David J. Smith2, Christopher P. Day3, David H. Adams1 1Centre for Liver Research, University of Birmingham, Birmingham, United Kingdom. 2Biotie Therapies Corp., Turku, Finland. 3Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

#1022

202A

POSTER SESSIONS

#1026

#1031

NASH CLINICAL SCORING SYSTEM AND THE NASH FIBROSIS SCORE: GOOD IN HEPATOLOGY OFFICES – WHAT ABOUT THE REAL WORLD? A PROSPECTIVE ANALYSIS

DIETARY INTAKE AND PHYSICAL ACTIVITY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE – A CANADIAN STUDY

Tarsila Ribeiro1, Schuyler O. Sanderson1, James Swain1, Kimberly Watt1, Kimberly Viker1, Anuradha Krishnan1, Mario Kondo2, Michael R. Charlton1 1Mayo Clinic, Rochester, MN, USA. 2Department of GI, UNIFESP, Sao Paulo, Brazil

#1027 RELATIONSHIP BETWEEN SERUM AUTO ANTIBODIES AND NONALCOHOLIC STEATOHEPATITIS:RESULTS FROM THE NONALCOHOLIC STEATOHEPATITIS CLINICAL RESEARCH NETWORK (NASH CRN) Robert J. Gould3, Laura Wilson4, Aynur Unalp-Arida4, Oscar Cummings1, Kris V. Kowdley3, Naga P. Chalasani1,2, Raj Vuppalanchi1,2 1Indiana University, Indianapolis, IN, USA. 2Clarian Digestive Disease Center, Indianapolis, IN, USA. 3Benaroya Research Institute at Virginia Mason, Seattle, WA, USA. 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

#1028 VISCERAL OBESITY AND HYPOADIPONECTINEMIA ARE SIGNIFICANT DETERMINANTS OF HEPATIC DYSFUNCTION-AN EPIDEMIOLOGIC STUDY OF 3827 JAPANESE SUBJECTSYoshihiro Kamada1, Tadashi Nakamura2, Tohru Funahashi2, Miwa Ryo2, Hitoshi Nishizawa2, Yukiyoshi Okauchi2, Yuichi Yoshida1, Shinichi Kiso1, Iichiro Shimomura2, Norio Hayashi1 1Department of Gastroenterology & Hepatology, Osaka University, Graduate School of Medicine, Suita, Japan. 2Department of Metabolic Medicine, Osaka University, Graduate School of Medicine, Suita, Japan

#1029 COGNITIVE SYMPTOMS ARE PREVALENT IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND UNRELATED TO THE SEVERITY OF LIVER DISEASE S U N D AY NOVEMBER 1


Gulnar E. Fattakhova, David E. Jones, James Frith, Christopher P. Day, Julia L. Newton Biomedical Research Centre in Ageing - Liver Theme, Newcastle University, Newcastle, United Kingdom

#1030 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS RELATED TO NON-ALCOHOLIC FATTY PANCREAS DISEASE (NAFPD) Erwin-Jan M. van Geenen1,5, Mark M. Smits1, Tim C. Schreuder4,1, Elisabeth Bloemena3, Donald L. van der Peet2, Chris J. Mulder1 1gastroenterology, VU-university center, Amsterdam, Netherlands. 2Gastrointestinal Surgery, VU-university center, Amsterdam, Netherlands. 3Pathology, VU-university center, Amsterdam, Netherlands. 4Gastroenterology and Hepatology, Gerle Hospital, Apeldoorn, Netherlands. 5Gastroenterology and Hepatology, Bronovo Hospital, The Haghe, Netherlands


Bianca M. Arendt1, Seham A. Noureldin1, Gail S. Fernandes1, George Therapondos1, Maha Guindi2, E. Jenny Heathcote1, Johane P. Allard1 1Medicine, University Health Network, Toronto, ON, Canada. 2Pathology, University Health Network, Toronto, ON, Canada

#1032 STATINS AND LIVER INJURY IN MORBIDLY OBESE SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE Vipul Aggarwal1,2, Clovis S. Palmer2, Kenneth K. Yan1,2, Andrew R. Lloyd2, Amany Zekry1,2 1Gastroenterology and Hepatology, St George Hospital, Sydney, NSW, Australia. 2School of Medical Science, University of New South Wales, Sydney, NSW, Australia

#1033 RELATIONSHIP OF RETINOL BINDING PROTEIN-4 WITH LIVER INJURY IN MORBIDLY OBESE SUBJECTS Kenneth K. Yan1,2, Clovis S. Palmer2, Andrew R. Lloyd2, Amany Zekry1,2 1Gastroenterology and Hepatology, University of New South Wales, Sydney, NSW, Australia. 2School of Medical Science, University of New South Wales, Sydney, NSW, Australia

#1034 DEVELOPMENT AND EVALUATION OF A LIVER HEALTH PROGRAMME FOR ASYMPTOMATIC SUBJECTS AT RISK OF LIVER DISEASE Raza Malik1, Rajeshwar P. Mookerjee1, Lisa Cheshire1,2, Rajiv Jalan1,2 1Institute of Hepatology, University College London, London, United Kingdom. 2London Clinic, London, United Kingdom

#1035 NOVEL ULTRASOUND-BASED ACOUSTIC RADIATION FORCE ELASTOGRAPHY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) Wataru Tomeno, Masato Yoneda, Yuichi Nozaki, Koji Fujita, Hiroyuki Kirikoshi, Satoru Saito, Atsushi Nakajima Division of Gastroenterology, Yokohama City University, Yokohama, Japan


POSTER SESSIONS

#1036

#1040

UP-REGULATION OF STRESS-INDUCED LIGANDS IS ASSOCIATED WITH ENHANCED HEPATOCYTE APOPTOSIS AND FIBROSIS IN PATIENTS WITH NASH

NON-ALCOHOLIC FATTY LIVER DISEASE IS ASSOCIATED WITH RECURRENT FALLS AND SIGNIFICANT INJURY

Alisan Kahraman1, Peri Kocabayoglu1, Martin Schlattjan1, Sule Yildiz-Meziletoglu1,2, Matthias Schlensak3, Christian Dominik Fingas1, Hideo Andreas Baba4, Guido Gerken1, Ali Canbay1 1Gastroenterology and Hepatology,, University clinic Essen, Essen, Germany. 2Department of Biochemistry, University of Cukurova, Adana, Turkey. 3Department of Surgery, evangelic hospital Dinslaken, Dinslaken, Germany. 4Institute of Pathology, University clinic Essen, Essen, Germany

#1037 COMPARISON OF DIFFERENT BIOMARKERS FOR PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS Sandra Page1,2, Nila Rafiq1,3, Maria Stepanova1,3, Arian Afendy1,3, Aybike Birerdinc1,2, Zachary D. Goodman4, Ancha Baranova2,3, Zobair M. Younossi1,3 1Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA. 2Center for the Study of Genomics in Liver Diseases, Molecular and Microbiology Department, George Mason University, Fairfax, VA, USA. 3Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA. 4Armed Forces Institutes of Pathology, Washington, DC, USA

#1038 FERRITIN IN PATIENTS WITH NASH CORRELATES WITH VASCULAR EVENTS BUT NOT WITH HEPATIC HISTOLOGICAL SEVERITY Pierre M. Gholam1,2, Anthony B. Post1,2, Katherine M. Koval1,2, Gretta H. Jacobs3 1Medicine, Case Western Reserve University, Cleveland, OH, USA. 2Digestive Health Institute, Case Western Reserve University, Cleveland, OH, USA. 3Pathology, Case Western Reserve University, Cleveland, OH, USA

#1039

Eric Y. Khoo2,3, Mary C. Stephenson4, Emily Leverton4, Richard Cross5, Peter G. Morris4, Ian A. Macdonald3, Peter Mansell2,3, Guruprasad P. Aithal1 1Nottingham Digestive Disease Centre: Biomedical Research Unit, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom. 2Department of Diabetes and Endocrinology, University Hospitals NHS Trust, Nottingham, United Kingdom. 3School of Biomedical Sciences, University of Nottingham, Nottingham, United Kingdom. 4Sir Peter Mansfield Magnetic Resonance Centre, University of Nottingham, Nottingham, United Kingdom. 5iQur LtD, Southampton, United Kingdom

James Frith, Lisa Robinson, Katharine Wilton, Christopher P. Day, Julia L. Newton Biomedical Research Centre in Ageing - Liver Theme, Newcastle University, Newcastle, United Kingdom

#1041 IN NASH PATIENTS THE BILE ACID TRANSPORTER NTCP IS UPREGULATED AND ASSOCIATED WITH FIBROSIS Peri Kocabayoglu1, Lars P. Bechmann1, Alparslan Kilicarslan1, Jochen Erhard2, Alisan Kahraman1, Martin Schlattjan1, Margarete Odenthal3, Guido Gerken1, Andreas Geier4, Ali Canbay1 1Gastroenterology and Hepatology,, University clinic Essen, Essen, Germany. 2Surgery, evangelic hospital Dinslaken, Dinslaken, Germany. 3Institut for Pathology, University hospital Cologne, Cologne, Germany. 4Internistic Medicine, Clinic for Gastroenterology and Hepatology, Zurich, Switzerland

#1042 DIAGNOSTIC VALUE OF LIVER INJURY BIOMARKERS, FIBROTEST (FT), STEATOTEST (ST), NASHTEST (NT) IN PATIENTS WITHOUT ADVANCED DISEASE UNDERGOING BARIATRIC SURGERY Antoine Hollebecque1, Mona Munteanu3, Laurent Arnalsteen4, David Buob5, Emmanuelle Leteurtre5, Robert Caiazzo4, Sebastien Dharancy1, Thierry Poynard2, Vlad Ratziu2, Francois Pattou4, Philippe Mathurin1 1Hepato-gastroenterology Department, Hopital Claude Huriez Lille, Lille, France. 2Hepatology, APHP UPMC Liver Center, Paris, France. 3Hepatology, BioPredictive France, Paris, France. 4Endocrine Surgery Department, CHRU Lille, Lile, France. 5Pathology Department, CHRU Lille, Lile, France

#1043 EFFICACY OF LOW-DOSE PIOGLITAZONE FOR THE TREATMENT OF NAFLD PATIENTS IN JAPAN Reiko Yaginuma, Kenichi Ikejima, Kazuyoshi Kon, Kyoko Okumura, Shunhei Yamashina, Satoko Suzuki, Sumio Watanabe Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan

#1044 ASSOCIATION OF HEPATIC FAT AND ENDOTHELIAL FUNCTION IN ADULTS WITH TYPE 2 DIABETES Bethany B. Barone1, Susanne Bonekamp2, Dhananjay Vaidya3, Sandra Lima3, Kerry J. Stewart3, Jeanne M. Clark1,3 1Epidemiology, Johns Hopkins Bloomber School of Public Health, Baltimore, MD, USA. 2Radiology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 3Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA


EFFECT OF MIXED MEAL CHALLENGE ON LIVER FAT CONTENT AND SERUM MARKERS OF LIVER FIBROSIS- DOES FOOD DELIVER AN INVISIBLE SECOND HIT?

203A

204A

POSTER SESSIONS

#1045

#1050

PREVALENCE OF TRANSAMINASE ABNORMALITIES IN GENERAL POPULATION IN XXI CENTURY: PRELIMINARY RESULTS FROM THE BAGNACAVALLO STUDY

DOES MELD NA IMPROVE MORTALITY PREDICTION IN PATIENTS WITH ALCOHOLIC LIVER DISEASE AS COMPARED TO MELD ALONE?

Francesca Dazzani1, Pierluigi Giacomoni1, Francesco G. Foschi2, Marco Domenicali4, Sara Savini2, Anna Chiara Dall’Aglio2, Gaia Saini2, Giuseppe Re1, Tino Casetti3, Pietro Andreone4, Mauro Bernardi4, Giuseppe Francesco Stefanini2 1Internal Medicine, Ospedale di Lugo, Lugo, Italy. 2Inernal Medicine, Ospedale di Faenza, Faenza, Italy. 3Digestive Metabolic Disease, Ospedale di Ravenna, Ravenna, Italy. 4Clinica Medica, Bologna University, Bologna, Italy

#1046 VALLIDITY OF REAL TIME ULTRASOUND IN THE DIAGNOSIS OF HEPATIC STEATOSIS: A PROSPECTIVE STUDY Srinivasan Dasarathy, Arthur J. McCullough Gastroenterology and hepatology, Cleveland Clinic Foundation, Cleveland, OH, USA

#1047 THE PERFORMANCE OF CLINICAL MODELS TO PREDICT NASH AND ADVANCED FIBROSIS IN OBESITY SURGERY PATIENTS Eric R. Kallwitz, Veronica TenCate, Grace Guzman, Joseph Vitello, Jamie L. Berkes, Thomas J. Layden, Scott J. Cotler University of Illinois, Chicago, IL, USA

#1048 HEPATIC EXPRESSION PATTERNS OF INFLAMMATORY AND IMMUNE RESPONSE GENES ASSOCIATED WITH OBESITY, STEATOSIS AND STEATOHEPATITIS IN MORBIDLY OBESE PATIENTS



Brianna Vaa1, Winston Dunn2,1, Patrick S. Kamath1, Vijay Shah1 Research Unit, Mayo Clinic, Rochester, MN, USA. 2Department of Medicine, University of California, San Diego, San Diego, CA, USA 1Gastroenterology

#1051 LIVER HISTOLOGY ACCORDING TO THE PRESENCE OF THE METABOLIC SYNDROME IN OVERWEIGHT AND OBESE PATIENTS An Verrijken1, Sven M. Francque2, Ilse Mertens1, Guy Hubens3, Eric A. Van Marck4, Peter P. Michielsen2, Luc Van Gaal2 1Endocrinology, Diabetology and Metabolism, University Hospital Antwerp, Edegem, Belgium. 2Gastro-enterology Hepatology, University Hospital Antwerp, Edegem, Belgium. 3Abdominal Surgery, University Hospital Antwerp, Edegem, Belgium. 4Pathology, University Hospital Antwerp, Edegem, Belgium

#1052 HYPOVITAMINOSIS D IS ASSOCIATED WITH MILD NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND METABOLIC SYNDROME’S COMPONENTS IN DYSMETABOLIC ADULT PATIENTS Ilaria Barchetta1, Maria Gisella Cavallo1, Francesco Angelico2, Maria Del Ben2, Antonio Fraioli1, Sergio Morini3, Paolo Pozzilli4 1Department of Medical Therapy, Thermal Medicine and Internal Medicine E, Sapienza University of Rome, Rome, Italy. 2Department of Experimental Medicine, Internal Medicine C, Sapienza University, Rome, Italy. 3Ultrastructural and Microscopic Anatomy, University Campus Bio-Medico, Rome, Italy. 4Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy

#1053 HEPATIC STEATOSIS IN HIV/ HEPATITIS C VIRUS CO-INFECTED PATIENTS – A META-ANALYSIS OF THE RISK FACTORS

Adeline Bertola2, Stephanie Bonnafous1,2, Rodolphe Anty1,2, Stephanie Patouraux4, Marie-Christine Saint-Paul4,2, Jean Louis Sadoul3,2, Antonio Iannelli1, Massimo Senni-Buratti1, Jean Gugenheim1,2, Yannick Le Marchand Brustel1,2, Albert Tran1,2, Philippe Gual1,2 1Digestive Department, Archet 2 Hospital, Nice, France. 2INSERM U895, Nice, France. 3Endocrinology Department, Archet 1 Hospital, Nice, France. 4Pathological Department, Archet 1 Hospital, Nice, France

Mariana V. Machado1, António G. Oliveira3, Helena CortezPinto1,2 1Gastrenterologia, Hospital de Santa Maria, Lisbon, Portugal. 2Unidade de Nutrição e Metabolismo, IMM, Faculdade de Medicina de Lisboa, Lisbon, Portugal. 3Bioestatística, Faculdade de Ciências Médicas de Lisboa, Lisbon, Portugal

#1049

#1054

CLINICO-PATHOLOGICAL ANALYSIS OF LIVER INJURY IN 2,054 JAPANESE TYPE2 DIABETES MELLITUS PATIENTS IN ONE BIG DIABETES CLINIC

CRYPTOGENIC CIRRHOSIS IN A REFERENCE CENTER IN BRAZIL: ASSOCIATION WITH NAFLD

Atsushi Umemura1, Hyohun Park2, Mika Nakayama1, Yoshiki Nakajima2, Hisaya Mori2, Masayuki Mizuno1, Toshihide Shima1, Takeshi Okanoue1 1Hepatology Unit, Saiseikai Suita Hospital, Osaka, Japan. 2Diabetology Unit, Saiseikai Suita Hospital, Osaka, Japan


Adriano C. Moraes, Leila Pereira, Helma P. Cotrim, Norma T. Jucá, Victorino S. Barreto Liver Unit, FCM-UPE, RecifePE, Brazil


POSTER SESSIONS

205A

#1055

#1060

IS THERE SIGNIFICANT HETEROGENEITY OF LIPOPROTEIN METABOLISM AMONG PATIENTS WITH NASH?

NONALCOHOLIC FATTY LIVER DISEASE: FEATURES & DIFFERENCES IN AN ETHNO-RACIALLY DIVERSE UNIVERSITY SETTING

Curtis K. Argo1, Neeral L. Shah1, Abdullah M. Al-Osaimi1, Anthony L. McCall2, Winsor Simmons1, Stephen H. Caldwell1 1Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA, USA. 2Division of Endocrinology and Metabolism, University of Virginia Health System, Charlottesville, VA, USA

James H. Tabibian1,2, Mariana Lazo3, Francisco A. Durazo2, HsinChieh Yeh3, Jeanne M. Clark1,3 1Department of Medicine, Johns Hopkins Medical Institution, Baltimore, MD, USA. 2Dumont-UCLA Liver Transplant Center, University of California, Los Angeles, CA, USA. 3Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

#1056 PREVALENCE OF FATTY LIVER DISEASE IN A PATIENT POPULATION WITH HYPERLIPIDEMIA Abdullah M. Al-Osaimi1, William G. Ogg2, James D. Bergin3, Curtis K. Argo1 1Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA, USA. 2Medicine, University of Virginia Health System, Charlottesville, VA, USA. 3Medicine, Cardiology, University of Virginia Health System, Charlottesville, VA, USA

#1057 XE-CT IS A POSSIBLE NEW SCREENING MODALITY AS A SCREENING MODALITY FOR NASH IN NAFLD PATIENTS Suzuki1,

Kobayashi2,

Ikeda2,

Michihiro Minoru Hiroki Hideaki Takahashi2, Norie Yamada2, Masaru Okamoto2, Yoshihiko Nagase1, Yasunobu Fukuda1, Koutarou Matunaga2, Chiaki Okuse2, Nobuyuki Matumoto2, Shiro Maeyama3, Shigeru Sase4, Fumio Itoh2 1Hepatogastroenterology, St.Marianna university(Kawasaki Municipal Tama Hospital), Kawasaki, Japan. 2Hepatogastroenterology, St.Marianna university, Kawasaki, Japan. 3Kita-kashiwa Hospital, Kashiwa, Japan. 4Anzai Medical, Tokyo, Japan

#1058 HIGH LIVER RBP4 EXPRESSION IS ASSOCIATED WITH THE SEVERITY OF FIBROSIS IN NAFLD PATIENTS

#1059 MEASUREMENT OF SERUM FREE CHOLINE SCORE MAY BE USED IN GENERAL PRACTICE AS INITIAL SCREENING TOOLS OF NAFLD BEFORE LIVER BIOPSY Koji Fujita, Yuichi Nozaki, Hironori Mawatari, Masato Yoneda, Hiroyuki Kirikoshi, Satoru Saito, Atsushi Nakajima gastroenterology, Yokohama-city university graduate school of medicine, Yokohama, Japan

THE CHARACTERISTICS AND NATURAL COURSE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN A SINGLE CENTER EXPERIENCE Ramazan Idilman2, Guldane Cengiz-Seval1, Gülseren Seven2, Kubilay Cinar2, Dilsa Mizrak1, Muyesser Sayki-Arslan1, Gökhan Kabaçam2, Yusuf Ustun2, Mustafa Yakut2, Mehmet Bektas2, Ali Ozden2 1Ankara University School of Medicine, Internal Medicine, Ankara, Turkey. 2Ankara University School of Medicine, Gastroenterology, Ankara, Turkey

#1062 AFP IN VIRAL AND NON-VIRAL LIVER DISEASE. COULD THIS HELP CLARIFY CRYPTOGENIC CIRRHOSIS? Nancy Reau, Rohit S. Satoskar, Helen S. Te, Smruti R. Mohanty, K. Gautham Reddy, Donald M. Jensen Hepatology, University of Chicago, Chicago, IL, USA

#1063 INCREASED POSTPRANDIAL PLASMA TRIGLYCERIDES IN RESPONSE TO FRUCTOSE IN CHILDREN WITH NONALCOHOLIC FATTY LIVER DISEASE Miriam Vos1,6, N-Anh Le2,5, Diego R. Martin3, Puneet Sharma3, Craig J. McClain4, Dean Jones2 1Pediatrics, Emory University, Atlanta, GA, USA. 2Medicine, Emory University, Atlanta, GA, USA. 3Radiology, Emory University, Atlanta, GA, USA. 4Medicine, University of Louisville, Louisville, KY, USA. 5Atlanta VA Medical Center, Decatur, GA, USA. 6Children’s Healthcare of Atlanta, Atlanta, GA, USA

#1064 STEATOSIS AND INFLAMMATION ARE TOGETHER ASSOCIATED WITH FIBROSIS PROGRESSION IN PATIENTS WITH NASH Ahmad Al-Rifai1, Elsbeth Henderson1, Nimantha De Alwis2, Alastair D. Burt2, Christopher P. Day2, Stephen Stewart1 1Hepatology, Freeman Hospital, Liver Unit, Newcastle-Upon-Tyne, United Kingdom. 2Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, United Kingdom


Salvatore Petta1, Calogero Cammà1, Vito Di Marco1, Claudio Tripodo2, Francecso Barbaria1, Daniela Cabibi2, Di Cristina Antonietta1, Stefania Grimaudo1, Rosaria Pipitone1, Antonio Craxi1 1Cattedra ed Unità Operativa di Gastroenterologia, DiBiMIS, University of Palermo, Italy, Palermo, Italy. 2Cattedra di Anatomia Patologica, University of Palermo, Italy, Palermo, Italy

#1061

206A

POSTER SESSIONS

#1065 CARDIOVASCULAR RISK SCORING USING PROCAM IN PATIENTS FOLLOWING LIVER TRANSPLANTATION ATTENDING A NURSE-LED HEALTH PROMOTION CLINIC


Joanna Routledge, Hector Vilca-Melendez, Matthew Bowles, Wendy A. Littlejohn, Nigel Heaton Institute of LIver Studies, King’s College Hospital, London, United Kingdom




POSTER SESSIONS

207A

Poster Session 3 Monday, November 2 POSTER VIEWING: 8:00 AM - 5:30 PM Hynes: Exhibit Hall C

#1069

Presenters in attendance: 1:00 - 2:30 PM

Tatyana V. Masyuk, Angela J. Stroope, Brynn N. Radtke, Anatoliy I. Masyuk, Sergio A. Gradilone, Erik L. Ritman, Christopher J. Ward, Nicholas F. LaRusso Mayo Clinic, Rochester, MN, USA

Those posters identified as AASLD Presidential Poster of Distinction by a ribbon icon have received review scores that place them within the top 10 percent of all posters. We encourage you to make them a priority as you visit the poster sessions.

Cholangiocyte Biology #1066 HEDGEHOG SIGNALING IS ABNORMAL IN POLYCYSTIC LIVER DISEASE Anatoliy I. Masyuk1, Sergio A. Gradilone1, Jesus Banales2, Christopher J. Ward1, Bing Q. Huang1, Tatyana V. Masyuk1, Nicholas F. LaRusso1 1Mayo Clinic, Rochester, MN, USA. 2University of Navarra, Pamplona, Spain

#1067 THE ER STRESS TRANSCRIPTION FACTOR XBP1 AFFECTS HOMEOSTATIC CHOLANGIOCYTE BIOLOGY AND REGULATES THEIR INFLAMMATORY RESPONSIVENESS Teresa Fritz1, Barbara Enrich1, Michael J. Albertini1, Alexander R. Moschen2,1, Sebastian Zeissig3, Herbert Tilg2,1, Richard S. Blumberg3, Arthur Kaser1 1Department of Internal Medicine II (Gastroenterology and Hepatology), Innsbruck Medical University, Innsbruck, Austria. 2Christian Doppler Research Laboratory for Gut Inflammation, Innsbruck Medical University, Innsbruck, Austria. 3Division of Gastroenterology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

#1068 INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) STIMULATES LIVER CYST GROWTH IN POLYCYSTIN-2 DEFECTIVE MICE TROUGH AN MTOR- AND VEGF-MEDIATED MECHANISMS THAT CAN BE INHIBITED IN VIVO BY TREATMENT WITH RAPAMYCIN

#1070 CHRONIC ADMINISTRATION OF CONTORTROSTATIN, A DISINTEGRIN FROM SNAKE VENOM, INHIBITS DUCTAL HYPERPLASIA IN BILE DUCT LIGATED RATS BY DECREASED EXPRESSION OF CHOLANGIOCYTE ANGIOGENIC FACTORS Romina Mancinelli4,1, Francis S. Markland8, Steve Swenson8, Paolo Onori5, Sharon DeMorrow1, Guido Carpino7, Shelley Kopriva1, Heather Francis1,3, Shannon S. Glaser1, Julie Venter1, Mellanie White1, Domenico Alvaro6, Luigi Pannarale4, Fanyin Meng1, Gianfranco Alpini1,2, Eugenio Gaudio4 1Department of Medicine & Scott & White Digestive Disease Research center, Texas A&M HSC COM and Scott & White, Temple, TX, USA. 2Research, Central Texas Veterans Health Care System, Temple, TX, USA. 3R&E, Scott & White, Temple, TX, USA. 4Human Anatomy, University of Rome “La Sapienza”, Rome, Italy. 5Experimental Medicine, University of L’Aquila, L’Aquila, Italy. 6Gastroenterology, Polo Pontino, University of Rome “La Sapienza”, Rome, Italy. 7Dept Health Science, University of Rome “Foro Italico”, Rome, Italy. 8Department of Biochemistry and Molecular Biology and Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA

#1071 STIMULATION OF THE H4 HISTAMINE RECEPTOR DECREASES CHOLANGIOCARCINOMA GROWTH AND INVASION VIA INTEGRIN-DEPENDENT MECHANISMS Fanyin Meng2, Gianfranco Alpini2,3, Sharon DeMorrow2, Gabriel A. Frampton2, Julie Venter2, Mellanie White2, Shelley Kopriva2, Valorie Chiasson4, Heather Francis1,2 1R&E, Scott & White and Texas A&M HSC COM, Temple, TX, USA. 2Medicine and Scott & White Digestive Diseases Research Center, Scott & White and Texas A&M HSC COM, Temple, TX, USA. 3Research, Central Texas Veterans Health Care System, Temple, TX, USA. 4Medicine, Texas A&M HSC COM, Temple, TX, USA

#1072 EPIGENETIC REGULATION OF MONOAMINE OXIDASE A EXPRESSION AND SP1 DNA BINDING ACTIVITY BY IL-6 IN HUMAN CHOLANGIOCARCINOMA Gabriel A. Frampton2, Monique Coufal1, Sharon DeMorrow2,1 and White Memorial Hospital, Temple, TX, USA. 2Texas A&M Health Science Center, College of Medicine, Temple, TX, USA

1Scott

M O N D AY NOVEMBER 1

Carlo Spirli1,2, Stefano Okolicsanyi2,4, Romina Fiorotto1,2, Luca Fabris2, Massimiliano Cadamuro2, Xin Tian3, Stefan Somlo3, Mario Strazzabosco1,4 1Internal Medicine, Section of Digestive Diseases and Liver Center, Yale University, New Haven, CT, USA. 2Center for Liver Research (CeliveR), Ospedali Riuniti di Bergamo, Bergamo, Italy. 3Internal Medicine, Section of Nephrology and PKD Center, Yale University, New Haven, CT, USA. 4Clinical Medicine and Prevention, University of Milano-Bicocca, Milan, Italy

MENADIONE SUPPRESSES HEPATIC CYSTOGENESIS IN VITRO AND IN VIVO BY INHIBITING THE CELL CYCLE REGULATOR, CDC25A

208A

POSTER SESSIONS

#1073

#1076

THE α1A-ADRENERGIC RECEPTOR AGONIST, PHENYLEPHRINE, STIMULATES THE PROLIFERATION OF SMALL MOUSE CHOLANGIOCYTES BY ACTIVATION OF THE CA2+DEPENDENT TRANSCRIPTION FACTORS, NFATC1 AND NFATC4

H1 (BUT NOT H3) HISTAMINE RECEPTOR AGONISTS ACCELERATE THE REGROWTH OF THE BILIARY EPITHELIUM FOLLOWING 70% PARTIAL HEPATECTOMY BY INCREASED CHOLANGIOCYTE VEGF EXPRESSION

Glaser1,

DeMorrow1,

Wise1,

Shannon S. Sharon Candace Heather Francis1,2, Julie Venter1, Eugenio Gaudio5, Shelley Kopriva1, Antonio Franchitto5, Yoshiyuki Ueno4, Paolo Onori6, Guido Carpino7, Gianfranco Alpini1,3 1Department of Medicine and Scott & White Digestive Disease Research Center, Texas A&M HSC COM and Scott & White, Temple, TX, USA. 2R&E, Scott & White, Temple, TX, USA. 3Research, Central Texas Veterans Health Care System, Temple, TX, USA. 4Gastroenterology, Tohoku University School of Medicine, Seiryo, Aobaku, Sendai, Japan. 5Human Anatomy, University of Rome “La Sapienza”, Rome, Italy. 6Experimental Medicine, University of L’Aquila, L’Aquila, Italy. 7Department of Health Science, University of Rome “Foro Italico”, Rome, Italy

#1074 HEPATO-RENAL PATHOLOGY IN THE PKD2WS25/- MOUSE, AN ANIMAL MODEL OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE Angela J. Stroope, Brynn N. Radtke, Bing Q. Huang, Tatyana V. Masyuk, Vicente Torres, Erik L. Ritman, Nicholas F. LaRusso Mayo Clinic, Rochester, MN, USA

#1075 KNOCKOUT OF THE GENE FOR SECRETIN INHIBITS BILIARY HYPERPLASIA OF LARGE CHOLANGIOCYTES IN CHOLESTATIC MICE BY AN AUTOCRINE MECHANISM



Shannon S. Glaser1, Eugenio Gaudio4, Paolo Onori5, Julie Venter1, Billy K. Chow7, Antonio Franchitto4, Guido Carpino6, Shelley Kopriva1, Mellanie White1, Ian P. Lam7, Romina Mancinelli4,1, Candace Wise1, Yoshiyuki Ueno8, Fanyin Meng1, Valorie Chiasson3, Gianfranco Alpini1,2 1Department of Medicine and Scott & White Digestive Disease Research Center, Texas A&M Health Science Center College of Medicine and Scott & White, Temple, TX, USA. 2Research, Central TX Veterans Health Care System, Temple, TX, USA. 3Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX, USA. 4Human Anatomy, University of Rome “La Sapienza”, Rome, Italy. 5Experimental Medicine, University of L’Aquila, L’Aquila, Italy. 6Department of Health Science, University of Rome “Foro Italico”, Rome, Italy. 7School of Biological Science, The University of Hong Kong, Hong Kong, China. 8Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan


Gianfranco Alpini1,2, Fanyin Meng2, Eugenio Gaudio5, Paolo Onori4, Antonio Franchitto5, Julie Venter2, Romina Mancinelli5,2, Shelley Kopriva2, Cynthia J. Meininger3, Heather Francis2,6 1Research, Central TX Veterans Health Care System, Temple, TX, USA. 2Medicine and Digestive Disease Research Center, Scott & White and Texas A&M COM, Temple, TX, USA. 3Systems Biology and Translational Medicine, Texas A&M Health Science Center College of Medicine, Temple, TX, USA. 4Experimental Medicine, University of L’Aquila, L’Aquila, Italy. 5Human Anatomy, University of Rome “La Sapienza”, Rome, Italy. 6R&E, Scott & White, Temple, TX, USA

#1077 PROSTATE APOPTOSIS RESPONSE 4 (PAR-4) IS EXPRESSED IN NORMAL CHOLANGIOCYTES, DOWN-REGULATED IN HUMAN CHOLANGIOCARCINOMA AND PROMOTES APOPTOSIS OF NEOPLASTIC CHOLANGIOCYTES WHEN INDUCED PHARMACOLOGICALLY Alessia Torrice1, Manuela Gatto1, Rossella Semeraro1, Cristina Napoli1,2, Gennaro Nuzzo5, Felice Giuliante5, Gianfranco Alpini6, Guido Carpino3, Antonio Franchitto3, Pasquale Bartolomeo Berloco4, Paolo Onori3, Eugenio Gaudio3, Domenico Alvaro1,2 1University of Rome “Sapienza”, Rome, Italy. 2Polo Pontino, Latina, Italy. 3Anatomy, University of Rome “Sapienza”, Rome, Italy. 4Surgery, University of Rome “Sapienza”, Rome, Italy. 5Department of Surgery, Hepatobiliary Unit, Catholic University of the Sacred Heart School of Medicine, Rome, Italy., Rome, Italy. 6Division Research, Central Texas Veterans Health Care System, Scott & White and Texas A & M University Health Science Center College of Medicine, Temple, TX, USA

Fibrosis #1078 MMP-9 PROMOTES THE TRAFFICKING OF TRANSPLANTED BONE MARROW CELLS THAT ATTENUATE HEPATIC FIBROSIS IN CHRONIC CCL4 LIVER INJURY Wei Zhang1, Kengo Kawai2, Terumi Takahara1, Feng Xue3, Haofeng Han1, Hiroshi Kudo1, Yutaka Yata4, Toshiro Sugiyama1 1Third Department of Internal Medicine, University of Toyama, Toyama City, Japan. 2Takaoka Koseiren Hospital, Toyama, Japan. 3Organ Transplantation Center, Renji Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China. 4Maebashi Saiseikai Hospital, Maebashi, Japan


POSTER SESSIONS

209A

#1079

#1083

PIRFENIDONE DECREASES IL-6 AND TNF-ALFA SERUM LEVELS AND INCREASES CB2 RECEPTOR MRNA IN PATIENTS WITH CHRONIC HEPATITIS C

BONE MARROW-DERIVED MESENCHYMAL STEM CELL TRANSPLANTATION TO ENHANCE THE ANTIFIBROTIC EFFECT OF PIOGLITAZONE IN HEPATIC FIBROSIS

Lucia Flores-Contreras1, Ana Sandoval-Rodriguez1, Juan Armendáriz Borunda1,2 1Biologia Molecular, Instituto de Biologia Molecular en Medicina y Terapia Genica, Guadalajara, Mexico. 2OPD Hospital Civil de Guadalajara, Universidad de Guadalajara, Guadalajara, Mexico

#1080 SERUM PROTEOMIC PROFILING IS CAPABLE OF ACCURATELY DETECTING SIGNIFICANT LIVER FIBROSIS IN PATIENTS WITH CHRONIC LIVER DISEASE Matthew L. Cowan1,3, Sam J. Thomson3, Markus Gess3, Daniel M. Forton3,1, Sarah J. Clark3, Phil Rice2, Tony M. Rahman3,1, Sanjeev Krishna1 1Division of Cellular and Molecular Medicine, St George’s, University of London, London, United Kingdom. 2Department of Virology, St George’s Healthcare NHS Trust, London, United Kingdom. 3Department of Hepatology and Gastroenterology, St George’s Healthcare NHS Trust, London, United Kingdom

#1081 REGRESSION OF HEPATIC INFLAMMATION AND FIBROSIS FOLLOWING TRANSPLANTATION OF HUMAN AMNION EPITHELIAL CELLS INTO IMMUNOCOMPETENT MICE William Sievert1,3, Jorge Tchongue3, Dinushka Lourensz3, Vijesh Vaghijiani2, Alison X. Liu3, Ursula Manuelpillai2 1Gastroenterology and Hepatology, Monash Medical Centre, Melbourne, VIC, Australia. 2Centre for Reproduction and Development, Monash Institute of Medical Research, Melbourne, VIC, Australia. 3Centre for Inflammatory Diseases, Monash University, Melbourne, VIC, Australia

#1082 IMPACT OF QUALITY CONTROL ACCEPTED INTERLABORATORY AND INTRAANALYTICAL VARIABILITY ON CALCULATED FIBROTEST/ ACTITEST SCORES FOR THE NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS Olav A. Gressner, Nina Beer, Arkadius Jodlowski, Axel M. Gressner Institute of Clinical Chemistry and Pathobiochemistry/ Central Laboratory, University Hospital of the RWTH Aachen, Aachen, Germany

Mehdi Mohamadnejad1,2, Muhammad A. Sohail1, E. S. Swenson1, Yury Popov3, Deanna Y. Sverdlov3, Anisha Sharma3, Ronald G. Hauser1, Reza Malekzadeh2, Wajahat Z. Mehal1, Detlef Schuppan3 1Section of Digestive Diseases, Yale University, School of Medicine, New Haven, CT, USA. 2Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran. 3Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

#1084 LONGITUDINAL PROSPECTIVE COMPARISON OF FIBROSURE AND FIBROSCAN IN RELATION TO VIROLOGIC RESPONSE IN A PHASE III STUDY OF ALBINTERFERON ALFA-2B AND RIBAVIRIN IN TREATMENT NAïVE CHC PATIENTS Keyur Patel2, Mireen Friedrich-Rust3, Michael Torbenson5, Yan Zhu1, Erik Pulkstenis1, G M. Subramanian1, John G. McHutchison2, David R. Nelson4, Mark S. Sulkowski5, Yves Benhamou6, Stefan Zeuzem3 1Human Genome Sciences, Inc., Rockville, MD, USA. 2Duke Clinical Research Institute, Durham, NC, USA. 3J.W.Goethe University Hospital, Frankfurt, Germany. 4University of Florida-Gainsville, Gainsville, FL, USA. 5Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6Hopital Pitie-Salpetriere, Paris, France

#1085 MYOFIBROBLAST DEPLETION DURING ACUTE CCL4 INJURY DELAYS HEPATOCYTE INJURY AND PROMOTES LIVER REGENERATION Angela Douglass, Matthew C. Wright Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom

#1086 THE BENEFICIAL EFFECT OF ANGIOTENSINBLOCKING AGENT ON LIVER FIBROSIS IN PATIENTS WITH ALCOHOLIC LIVER DISEASE: A RANDOMIZED CONTROLLED TRIAL Moon Young Kim1, Soon Koo Baik1, Yoon Ok Jang1, Chang Jin Yea1, Chan Sik Won1, Jong Won Byun1, Hoon Choi1, Mee-Yon Cho2 1Internal medicine, Yonsei University Wonju college of medicine, Wonju, Korea, South. 2Department of Pathology, Yonsei University Wonju College of Medicine, Wonju, Korea, South

CCL5 EXPRESSION IS A MARKER FOR THE STAGE OF LIVER FIBROSIS IN CHRONIC HEPATITIS C AND IS REGULATED BY THE INNATE IMMUNE SYSTEM Antonios Katsounas1,2, Martin Trippler1, Bo Wang1, Richard A. Lempicki2, Sabine Bein1, Guido Gerken1, Joerg F. Schlaak1 1Dept. of Gastroenterology and Hepatology, University Hospital of Essen, Essen, Germany. 2Laboratory of Bioinformatics and Immunopathogenesis, SAIC-Frederick, Inc. NIAID, Frederick, MD, USA


#1087

210A

POSTER SESSIONS

#1088

#1093

VIRTUALTOUCH ASSESSMENT OF LIVER STIFFNESS: VIRTUAL LIVER PALPATION

FIBRO-C-INDEX – A STANDARDIZED QUANTIFICATION OF LIVER FIBROSIS USING SECOND HARMONIC GENERATION AND TWOPHOTON MICROSCOPY

Fabio Piscaglia, Veronica Salvatore, Alberto Borghi, Fabio Conti, Eugenia Peri, Federica Pietromartire, Pietro Andreone, Luigi Bolondi Dpt. Clinical Medicine, S. Orsola-Malpighi University Hospital, Bologna, Italy

#1089 DISCOVERY OF AN ANTIBODY IN PATIENTS WITH LIVER DISEASE THAT PROMOTES BACTERIAL GROWTH AND IS ASSOCIATED WITH MARKERS OF ENDTOTOXIN EXPOSURE Anand Mehta, Lorena Loarca, Ronald E. Long, Mary Ann Comunale, Timothy M. Block Microbiology and Immunology, Drexel University College of Medicine, Doylestown, PA, USA

#1090 PRELIMINARY EVALUATION OF UBIQUITINPROTEASOME SIGNATURE FOR DIAGNOSIS OF CHRONIC LIVER DISEASES AND ASSESSMENT OF LIVER FIBROSIS Kevin Qu, Ke Zhang, Wanlong Ma, Xi Zhang, Xiuqiang Wang, Anthony Sferruzza, Maher Albitar Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA

#1091 A NOVEL HISTOLOGIC SCORING SYSTEM ACCURATELY IDENTIFIES REGRESSED CIRRHOSIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS OTHERWISE UNDERSTAGED BY BOTH CONVENTIONAL HISTOLOGICAL FIBROSIS STAGING AND SEROLOGICAL MARKERS OF HEPATIC FIBROSIS Venessa Pattullo1, Sandra E. Fischer2, Jordan J. Feld1, David K. Wong1, E. Jenny Heathcote1, Maha Guindi2 1Medicine, University Health Network, Toronto, ON, Canada. 2Pathology, University Health Network, Toronto, ON, Canada

#1092 TRANSDIFFERENTIATION DEPENDENT INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR, AND COLLAGEN α1 TYPE 1 BUT NOT α SMOOTH MUSCLE ACTIN EXPRESSION IN RAT HEPATIC STELLATE CELLS BY PARAXANTHINE, THE PRIMARY METABOLITE OF CAFFEINE



Olav A. Gressner, Birgit Lahme, Axel M. Gressner Institute of Clinical Chemistry and Pathobiochemistry/ Central Laboratory, University Hospital of the RWTH Aachen, Aachen, Germany

Dean Tai1, Nancy Tan2,3, Chiang Huen Kang1, Chee Leong Cheng4, Ser Mien Chia3, Aileen Wee4, Hanry Yu1,3 1Cell and Tissue Engineering, Institute of Bioengineering and Nanotechnology, Singapore, Singapore. 2Department of Pediatrics, KK Women’s and Children’s Hospital, Singapore, Singapore. 3Department of Physiology, National University of Singapore, Singapore, Singapore. 4Department of Pathology, National University Hospital, Singapore, Singapore

#1094 MONITORING OF LIVER FIBROSIS BY MEANS OF MULTIPLEXED LECTIN BINDING ASSAY TARGETING AN ABUNDANT SERUM PROTEIN WITH LIVER FIBROSIS-SPECIFIC GLYCOALTERATION Yasuhito Tanaka1, Atsushi Kuno2, Yuzuru Ikehara2, Kentaro Matsuura1, Fuminaka Sugauchi1, Jun Hirabayashi2, Hisashi Narimatsu2, Masashi Mizokami3 1Dept of Clinical Molecular Info Medicine, Nagoya City University Medical School, Nagoya, Japan. 2Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan. 3Research Center for Hepatitis and Immunology, International Medical Center of Japan Konodai Hospital, Chiba, Japan

#1095 COMBINATION THERAPY WITH TELMISARTAN AND PROPRANOLOL IMPROVES LIVER FIBROSIS IN THE MDR2 KNOCKOUT MOUSE MODEL Sigrid Schulte1, Susanne Mende1, Ingo Strack2, Margarete Odenthal2, Muenevver Demir1, Heike Varnholt2, Hans P. Dienes2, Tobias Goeser1, Hans-Michael Steffen1, Ulrich Toex1 1Department of Gastroenterology and Hepatology, University Hospital of Cologne, Cologne, Germany. 2Department of Pathology, University Hospital of Cologne, Cologne, Germany

#1096 THE ASSESSMENT OF LIVER FIBROSIS IN THE FONTAN CIRCULATION USING STRUCTURAL AND FUNCTIONAL BIOMARKERS Indra N. Guha1, Sumit Bokhandi2, Gruschen Veldtman2 Unit, University of Southampton, Southampton, United Kingdom. 2Congenital Cardiology Unit, Southmapton University Hospital Trust, Southampton, United Kingdom 1Liver

#1097 REDUCED LIVER FIBROSIS: COFFEE OR CAFFEINE? Apurva A. Modi1, Jordan J. Feld2, Yoon Park1, David E. Kleiner3, James E. Everhart4, Jake T. Liang1, Jay H. Hoofnagle1 1Liver Diseases Branch, NIDDK, NIH, Bethesda, MD, USA. 2Division of Gastroenterology, University of Toronto, Toronto, ON, Canada. 3Laboratory of Pathology, NCI, NIH, Bethesda, MD, USA. 4Division of digestive diseases and nutrition, NIDDK, NIH, Bethesda, MD, USA



POSTER SESSIONS

#1098 ACOUSTIC RADIATION FORCE IMPULSE (ARFI): A NEW TECHNOLOGY FOR THE NON-INVASIVE DIAGNOSIS OF LIVER FIBROSIS IN CHRONIC LIVER DISEASES Jerome Boursier1,2, Gael Isselin3, Isabelle Fouchard-Hubert1,2, Frédéric Oberti1,2, Nina Dib1,2, Sandrine Bertrais2, Yves Gallois4,2, Paul Cales1,2, Christophe Aubé3,2 1Service d’Hépato-Gastroentérologie, Centre Hospitalier Universitaire, Angers, France. 2Laboratoire HIFIH, Université, Angers, France. 3Service de Radiologie, Centre Hospitalier Universitaire, Angers, France. 4Laboratoire de Biochimie et Biologie Moléculaire, Centre Hospitalier Universitaire, Angers, France

#1099 EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) IN CHOLANGIOCYTES DOES NOT CONTRIBUTE TO LIVER FIBROSIS David Scholten1,2, Anjali Scholten1, David A. Brenner1, Tatiana Kisseleva1 1Medicine, UCSD, San Diego, CA, USA. 2Medicine, University hospital RWTH, Aachen, Germany

#1100 GUT-DERIVED BACTERIAL PRODUCTS DRIVE PROGRESSION OF LIVER FIBROSIS IN MDR2-/MICE: INVOLVEMENT OF LPS AND TLR4 Klaas Poelstra1,2, Yury Popov1, Deanna Y. Sverdlov1, Anisha Sharma1, Detlef Schuppan1 1Div. of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 2Dept. of Pharmacokinetics, Toxicology & Targeting, University of Groningen, Groningen, Netherlands

#1101 KUPFFER CELLS PREVENT CELL DEATH OF ACTIVATED HEPATIC STELLATE CELLS THROUGH IL1β-MEDIATED NF-κB ACTIVATION Johannes Kluwe, Samuele De Minicis, Pradere Jean-Philippe, Geum-Youn Gwak, Sreedivya Chava, Robert Schwabe Columbia University, New York, NY, USA

#1102 HYPOXIA STIMULATES HEPATOCYTE EPITHELIAL TO MESENCHYMAL TRANSITION BY HYPOXIAINDUCIBLE FACTOR-1α AND TRANSFORMING GROWTH FACTOR-β-DEPENDENT MECHANISMS Bryan L. Copple, Bradley Sullivan, Shan Bai Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA

Martin Roderfeld, Timo Rath, Elke Roeb Gastroenterology, Justus-Liebig-University Giessen, Giessen, Germany

#1104 OSTEOPONTIN, AN EXTRACELLULAR PROTEIN INDUCED IN LIVER INJURY, TRIGGERS A FIBROGENIC RESPONSE IN STELLATE CELLS Raquel Urtasun, Xiaodong Wang, M. Isabel Fiel, Fariba Kalantari, Natalia Nieto Medicine/Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA

#1105 CB2 CANNABINOID RECEPTORS DIRECTLY AFFECT HEPATIC STELLATE CELL ACTIVATION WITH LYMPHOCYTE ALTERATIONS Yosefa Avraham1, Johnny Amer2, Lina Abu Tair2, Sarit Doron2, Elliot M. Berry1, Rifaat Safadi2 1Department of Human Nutrition and Metabolism, Braun School of Public Health, Faculty of Medicine, Hebrew University-Hadassah Medical School, Jerusalem, Israel, Jerusalem, Israel. 2Liver and Gastroenterology Units/Division of Medicine, Hadassah Medical Center, Liver Center, Jerusalem, Israel

#1106 A COMPREHENSIVE ANALYSIS OF COLLAGEN PRODUCTION AND DEGRADATION BY USING TRANSGENIC DUAL REPORTER MICE Yutaka Inagaki1, Sachie Nakao1, Tadashi Moro1,2, Reiichi Higashiyama1, Kenichiro Mikami1, Hiroshi Fukumitsu1, Yoshitaka Ueda1, Isao Okazaki3 1Research Unit for Tissue Remodeling and Regeneration, Tokai University School of Medicine, Isehara, Japan. 2Research Laboratory, Minophagen Pharmaceutical Co. Ltd., Zama, Japan. 3Sanno Hospital, International University of Health and Welfare, Tokyo, Japan

#1107 IMMUNOLOGICAL AND FIBROSIS-RELATED PROPERTIES OF PRIMARY HEPATIC STELLATE CELLS ARE REGULATED BY THE TOLL-LIKE RECEPTOR SYSTEM Bo Wang1,2, Zhongji Meng3, Mengji Lu3, Guido Gerken1, Joerg F. Schlaak1 1Dept. of Gastroenterology and Hepatology, University Hospital of Essen, Essen, Germany. 2Dept. of Gastroenterology, Tongji Hospital, Wuhan, China. 3Institute of Virology, University Hospital of Essen, Essen, Germany

#1108 TRANSIENT HEDGEHOG PATHWAY ACTIVATION AND ACCUMULATION OF HEDGEHOGRESPONSIVE MYOFIBROBLASTS PRECEDE EXPANSION OF LIVER EPITHELIAL PROGENITORS AFTER ACUTE CARBON TETRACHLORIDE INJURY Rafal P. Witek, Thiago A. Pereira, Wing-Kin Syn, Youngmi Jung, Kolade M. Agboola, Steve S. Choi, Anna Mae Diehl Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA


#1103 BONE MARROW DERIVED FIBROCYTES REPRESENT A PIVOTAL CELL POPULATION FOR HEPATIC FIBROGENESIS IN ABCB4-/--MICE

211A

212A

POSTER SESSIONS

#1109

#1115

PROTECTION AGAINST HEPATOCYTE MITOCHONDRIAL DYSFUNCTION DELAYS FIBROSIS PROGRESSION IN MICE

NICOTINE INDUCES STEREOTYPIC FIBROGENIC CHANGES IN HUMAN PRIMARY HEPATIC STELLATE CELLS, VIA PI-3 AND P38 MAP KINASES, TRANSDUCED THROUGH NICOTINIC ACETYLCHOLINE RECEPTORS, UPREGULATED IN HUMAN FIBROTIC NON-ALCOHOLIC STEATOHEPATITIS

Claudia Mitchell1, Marie-Anne Robin2, Meriem Mahrouf-Yorgov1, Alicia Mayeuf1, Abdellah Mansouri3, Bernard Fromenty2, Helene Gilgenkrantz1 1Cochin, INSERM U567, Paris 5 University, Paris, France. 2INSERM U.620, University Rennes 1, Rennes, France. 3INSERM U.773, Centre de Recherche Biomédicale Bichat Beaujon, Paris, France

#1110 EGR-1 DEFICIENCY ENHANCES FIBROSIS AND PROMOTES ACTIVATION OF THE OVAL CELL RESPONSE AFTER CARBON TETRACHLORIDE EXPOSURE IN MICE Michele T. Pritchard1, Laura E. Nagy1,2 1Pathobiology, Cleveland Clinic, Cleveland, OH, USA. 2Gastroenterology, Cleveland Clinic, Cleveland, OH, USA

MMP-13 DELETION PROTECTS MONOCROTALINE INDUCED LIVER INJURY IN MICE George1,

Junpei Soeda1, Maelle Morgan1, Chad Mckee1, Barbara Sigala1, Clare Selden1, Humphrey Julian F. Hodgson1, Tania Roskams4, Anna Mae Diehl3, Jude A. Oben1,2 1Centre for Hepatology, University College London, London, United Kingdom. 2Gastroenterology, Guy’s and St Thomas’ Hospital, London, United Kingdom. 3Gastroenterology, Duke University Medical Center, Durham, NC, USA. 4Pathology, University of Leuven, Leuven, Belgium

#1116 INNATE IMMUNE FUNCTIONS FOR HEPATIC STELLATE CELLS Aidan Maxwell, Derek A. Mann, Jelena Mann ICM, Newcastle University, Newcastle upon Tyne, United Kingdom

#1111

Tsutsumi2,

D’Armiento1

Joseph Mikihiro Jeanine 1Medicine, Columbia University, New York, NY, USA. 2Gastroenterology, Kanazawa Medical University, Ishikawa, Japan

#1112 THIOACETAMIDE-INDUCED HEPATIC FIBROENESIS IS AMELIORATED IN MICE GENETICALLY DISRUPTIVE OF CD1D Sachiko Ishikawa1, Kenichi Ikejima1, Hisafumi Yamagata1, Tomonori Aoyama1, Kazuyoshi Kon1, Kazuyoshi Takeda2, Sumio Watanabe1 1Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan. 2Department of Immunology, Juntendo Universty School of Medicine, Tokyo, Japan

#1113 HEPATIC STELLATE CELLS CONTRIBUTE TO THE MAINTENANCE OF CANCER STEM CELL-LIKE POPULATIONS VIA WNT SIGNALING IN HUH7 HEPATOCELLULAR CARCINOMA CELL LINE Masayuki Adachi, Hajime Higuchi, Ayano Kabashima, Gen Sakai, Motoko Izumiya, Hiromasa Takaishi, Hidetsugu Saito, Toshifumi Hibi Medicine, Keio University School of Medicine, Tokyo, Japan

#1114 M O N D AY NOVEMBER 1


CELLULAR FIBRONECTIN PROMOTES HEPATIC STELLATE CELL MIGRATION VIA A SWITCH FROM α5β1 TO α9β1 SIGNALING Abby Olsen1, David Boettiger2, Rebecca Wells3 1Cell and Molecular Biology Graduate Group, University of Pennsylvania, Philadelphia, PA, USA. 2Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA. 3Department of Medicine, Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA


#1117 DELETION OF PROTEASE ACTIVATED RECEPTOR 2 AMELIORATES LIVER FIBROSIS AND DECREASES TGF β EXPRESSION IN A MURINE MODEL OF CIRRHOSIS Virginia Knight1,2, Jorge Tchongue1, Dinushka Lourensz1, Alison X. Liu1, Peter Tipping1, William Sievert1,2 1Centre for Inflammatory Diseases, Monash University, Melbourne, VIC, Australia. 2Department of Gastroenterology, Monash Medical Centre, Clayton, VIC, Australia

#1118 IL-17A AND IL-17F ACTIVATES PRO-FIBROGENIC SIGNALS IN KUPFFER CELLS AND HEPATIC STELLATE CELL Fanli Meng1,2, Tatiana Kisseleva1, Ekihiro Seki1, David Scholten1, Yonghan Paik1, Kai Wang2, David A. Brenner1 1Department of Medicine, UCSD, La Jolla, CA, USA. 2Department of Hepatology, Qilu Hospital, Shandong University, School of Medicine, Jinan, China

#1119 BILE ACID-INDUCED EGFR ACTIVATION IN QUIESCENT RAT HEPATIC STELLATE CELLS CAN TRIGGER BOTH, PROLIFERATION AND APOPTOSIS Roland Reinehr, Annika Sommerfeld, Dieter Häussinger Clinic for Gastroenterology, Hepatology and Infectiology, University Hospital Düsseldorf, Düsseldorf, Germany


POSTER SESSIONS

213A

#1120

#1126

TREATMENT WITH AN ENDOCANNABINOID CB-1 RECEPTOR ANTAGONIST MODULATES LIVER FIBROSIS IN A RAT MODEL OF ADVANCED CIRRHOSIS

UPTAKE OF T-CELL DERIVED MICROPARTICLES BY HUMAN HEPATIC STELLATE CELLS AND UPREGULATION OF FIBROLYTIC GENES IS DEPENDENT ON ICAM-1 (CD54)

Ferdinando A. Giannone1,2, Marco Domenicali1,2, Maurizio Baldassarre1,2, Gemma Di Pompo1,2, Mauro Bernardi1,2, Paolo Caraceni1,2 1Dipartimento Medicina Clinica, Università di Bologna, Bologna, Italy. 2Center for Biomedical Applied Research (CRBA), University of Bologna, Bologna, Italy

Miroslaw Kornek, Yury Popov, Detlef Schuppan Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, MA, USA

#1121 LENTIVIRAL-MEDIATED RNA INTERFERENCE TARGETING ACE2 AGGRAVATES LIVER FIBROGENESIS Qian Huang, Qing Xie, Cuicui Shi, Hui Wang, Gangde Zhao, Lanyi Lin, Hong Yu, Qing Guo Department of Infectious Disease, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

#1122 INTERACTION BETWEEN HEDGEHOG PATHWAY SIGNALING AND LEPTIN IN RAT HEPATIC STELLATE CELLS Steve S. Choi1,2, Rafal P. Witek1, Wing-Kin Syn1, Alessia Omenetti1, Gamze F. Karaca1, Youngmi Jung1, Vanessa S. Teaberry3, Anna Mae Diehl1 1Medicine/Gastroenterology, Duke University Medical Center, Durham, NC, USA. 2Medicine, Durham Veterans Affairs Medical Center, Durham, NC, USA. 3Department of Surgery, Duke University Medical center, Durham, NC, USA

#1123 CONTROL OF LIVER DISEASES BY A PEPTIDE APTAMER SUPPRESSING TGF-β ACTIVATION REACTION Soichi Kojima1, Mitsuko Hara1, Kumiko Yoshizawa-Kumagaye2, Yuji Nishiuchi2 1Chemical Biology Department, RIKEN ASI, Wako, Japan. 2Saito Res Ctr, Peptide Inst, Ibaraki, Japan

#1124 FUNCTIONAL BIOMARKERS AND THERAPEUTICS TARGETING STEM CELLS IN LIVER FIBROSIS Ying Li1, Zhixing Yao1, Wilma S Jogunoori1, Wenguo Yao1, Kirti Shetty1, Bibhuti Mishra1, Lopa Mishra1,2 1Surgery, Georgetown University, Washington, DC, USA. 2Surgery, Veterans Affairs Medical Center, Washington, DC, USA

FIBROMODULIN, A NOVEL FACTOR MODULATING COLLAGEN I DEPOSITION Elisabetta Mormone, Natalia Nieto Medicine/Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA

CRITICAL ROLE OF TNF RECEPTOR TNFR1 BUT NOT TNFR2 IN HEPATIC STELLATE CELL PROLIFERATION Núria Tarrats1,2, Anna Moles1,2, Albert Morales1,2, Jose C. Fernandez-Checa1,2, Montserrat Mari1,2 1Liver Unit, Hospital Clinic, CIBEREHD, Barcelona, Spain. 2IIBBCSIC, IDIBAPS, Barcelona, Spain

#1128 INSULIN AS A NOVEL STIMULATOR FOR THE INITIAL ACTIVATION OF HEPATIC STELLATE CELLS Cindy Cai, Rosemary O’Neill, Robert S. Britton, Bruce R. Bacon Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO, USA

#1129 MICRORNA-29, DOWNREGULATED DURING LIVER FIBROGENESIS, TARGETS EXPRESSION OF FIBROGENIC MEDIATORS Monika Kwiecinski, Andrea Noetel, Stephanie Schievenbusch, Ingo Strack, Natalia Elfimova, Inga Wedemeyer, Hans P. Dienes, Margarete Odenthal Institute for Pathology, University Hospital, Koeln, Germany

#1130 A CYCLIC RETINOID (NIK-333) REPRESSES FIBROSIS IN THE LIVER OF PLATELET DERIVED GROWTH FACTOR (PDGF)-C TRANSGENIC MICE Hikari Okada1, Masao Honda1, Yoshio Sakai1, Yuki Takebuchi1, Takayoshi Shirasaki1, Taro Yamashita1, Takuji Tanaka2, Jean S. Campbell3, Nelson Fausto3, Shuichi Kaneko1 1Gastroenterology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan. 2Oncologic Pathology, Kanazawa Medical University, Kanazawa, Japan. 3Pathology, University of Washington, Seattle, WA, USA

#1131 SILENCING OF LIVER-SPECIFIC MICRORNA-122 AGGRAVATES ACUTE BUT NOT CHRONIC HEPATOTOXIN-INDUCED LIVER INJURY Rabea A. Hall, Iris Adrian de Biondi, Katrin Hochrath, Susanne N. Weber, Frank Lammert Department of Medicine II, Saarland University Hospital, Homburg, Germany


#1125

#1127

214A

POSTER SESSIONS

#1132

#1137

ROSUVASTATIN PREVENTS LIVER FIBROSIS AND ENZYME-ALTERED LESIONS IN RAT LIVER CIRRHOSIS INDUCED BY A CHOLINE-DEFICIENT LAMINO ACID-DEFINED DIET

SENESCENCE MARKER PROTEIN-30 (SMP30) DEFICIENCY IN MICE AMELIORATES CCL4INDUCED LIVER FIBROSIS VIA DECREASED NUCLEAR EXPRESSION OF P-SMAD2/3 IN HEPATIC STELLATE CELLS AND IMBALANCE BETWEEN ANGIOTENSIN II RECEPTOR TYPE I (AT1) AND TYPE II (AT2) EXPRESSION

Naoki Yamamoto, Koichi Uchida, Shuji Terai, Takahiro Yamasaki, Isao Sakaida Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube Yamaguhchi, Japan

#1133 ETHANOL-MEDIATED CONNECTIVE TISSUE GROWTH FACTOR (CTGF) MRNA EXPRESSION AND PROMOTER ACTIVITY IN HUMAN LX-2 HEPATIC STELLATE CELLS Li

Chen1,

Leask2,

Brigstock1,3

Andrew David for Cell and Developmental Biology, The Research Institute at Nationwide Children’s Hospital, Columbus, OH, USA. 2Division of Oral Biology and Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada. 3Department of Surgery, The Ohio State University, Columbus, OH, USA

1Center

#1134 APELIN MEDIATES THE INDUCTION OF FIBROGENIC SIGNALING PATHWAYS ACTIVATED BY ANGIOTENSIN-II AND ENDOTHELIN-1 IN HUMAN STELLATE CELLS Melgar-Lesmes1,

Casals1,

Ros1,

Pedro Gregori Josefa Vedrana Reichenbach1, Ramon Bataller2, Manuel Morales-Ruiz1, Wladimiro Jiménez1 1Biochemistry & Molecular Genetics Department, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain. 2Liver Unit - Institut de Malalties Digestives, Hospital Clinic i Provincial de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

#1135 SEMAPHORIN 7A IS EXPRESSED IN HEPATIC STELLATE CELLS AND ENHANCES HEPATIC FIBROSIS IN A TGFβ-MEDIATED MECHANISM Samuele De Minicis1, Chiara Rychlicki1, Stefania Saccomanno1, Luciano Trozzi1, Cinzia Candelaresi1, Laura Agostinelli1, Fiorenza Orlando2, Marco Marzioni1, Antonio Benedetti1, Gianluca Svegliati-Baroni1 1Gastroenterology, University of Ancona, Ancona, Italy. 2Research Department, INRCA, experimental for aging unit, Ancona, Italy

#1136



EFFECTS OF OVER-EXPRESSION AND MUTATION OF PTEN ON THE APOPTOSIS OF CULTURED HEPATIC STELLATE CELLS Zhang1,2,

Hao1,3,

An1,2,

Xiaolan Lisen Junyan Lei Liu, Shuming Fang1,2, Dongmei Yao1,2, Huiqing Jiang1,2, Shuang Chen4 1Dept of Gastroentology, The Second Hospital of Hebei Medical University, Shijiazhuang City, China. 2Hebei Key Laboratory of Gastroenterology, The Second Hospital of Hebei Medical University,, Shijiazhuang city, China. 3Dept of Gastroentology, the Affiliated Hospital of North China Coal Medical College, Tangshan city, China. 4Pediatric Department, UCLA MEDICAL School, Cedars-Sinai medical Center, Los Angeles, CA, USA


Jin-Kyu Park, Mi-Ran Ki, Il-Hwa Hong, Ae-Ri Ji, Kyung-Sook Hong, Sang-Joon Park, Kyu-Shik Jeong College of Veterinary Medicine, Kyungpook National University, Daegu, Korea, South

#1138 ACTIVATED HEPATIC STELLATE CELLS, BUT NOT QUIESCENT HEPATIC STELLATE CELLS SUSTAIN THEIR SURVIVAL BY PI3K/AKT/NFKB SIGNAL FROM COLLAGEN SECRETED BY THEMSELVES Naoko K. Birukawa1, Kazuyuki Murase2, Yasushi Sato2, Hiroki Nishita1, Akihiro Yoneda1, Akemi Kosaka1, Naoko Kitamura1, Junji Kato2, Yoshiro Niitsu1 1Department of Molecular Target Exploration, Sapporo Medical University School of Medicine, Sapporo, Japan. 2Forth Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan

#1139 CYCLOOXYGENASE-2 INHIBITION ATTENUATES LPS-INDUCED INFLAMMATORY SIGNALING AND ENHANCES APOPTOSIS OF HEPATIC STELLATE CELLS Manner Wang1, Chuantao Tu1, John M. Luk2, Shiyao Chen1, Jiyao Wang1, Scott L. Friedman1,3, Jinsheng Guo1 1Division of Digestive Diseases, Zhong Shan Hospital, Fu Dan University, Shanghai, China. 2Center for the study of liver disease and department of surgery, The University of Hong Kong, Hong Kong, China. 3Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA

#1140 KNOCKOUT OF THE CB1 RECEPTOR RESULTS IN STRONGER HEPATIC INFLAMMATION PAIRED WITH A DOWNREGULATION OF ECM PRODUCTION IN THE TAA/ETHANOL LIVER FIBROSIS MODEL IN MICE Matthias Stoll, Eckhart G. Hahn, Matthias Ocker, Thaddaeus T. Wissniowski Depart. of Medicine 1, Friedrich-Alexander University, Erlangen, Germany

#1141 STUDY OF CONTRACTILE MECHANISM OF RAT HEPATIC STELLATE CELLS INDUCED BY ENDOTHELIN-1 Lieming Xu1,2, Hong Xu2 Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China. 2Institute of Liver Diseases,shanghai University of TCM, Shanghai, China

1Shuguang


POSTER SESSIONS

#1142

#1148

SUPEROXIDE RADICALS ACTIVATE HEPATIC STELLATE CELL VIA CELLULAR INFLUX THROUGH CHLORIDE CHANNELS

LOWERING COPPER INHIBITS LIPOPOLYSACCHARIDE ENHANCED TGF-β1 SIGNALING BY UP-REGULATING BAMBI AND SMAD7 EXPRESSION IN HUMAN HEPATIC STELLATE CELLS

Jonathan van Tilburg1, Shufan Qi2, Gertjan J. den Hartog2, Aalt Bast2, Ger H. Koek3 1Human Biology, Maastricht University, Maastricht, Netherlands. 2Pharmacology and Toxicology, Maastricht University, Maastricht, Netherlands. 3Internal Medicine, Maastricht University, Maastricht, Netherlands

#1143 HELICOBACTER PYLORI ACCELERATES HEPATIC FIBROSIS BY INCREASING TGF-β1 INDUCED INFLAMMATORY SIGNALING MEDIATED BY MYD88, AP-1 AND NF-κB IN HEPATIC STELLATE CELLS Mi-Ran Ki, Moon-Jung Goo, Kyung-Sook Hong, Il-Hwa Hong, JinKyu Park, Ae-Ri Ji, Sang-Joon Park, Kyu-Shik Jeong College of Veterinary Medicine, Kyungpook National University, Daegu, Korea, South

215A

Ming Song1, Shirish Barve1, Craig J. McClain1,2 University of Louisville, Louisville, KY, USA. 2Louisville VAMC, Louisville, KY, USA

1Medicine/Gastroenterology,

#1149 ATORVASTATIN INHIBITS FIBROGENESIS VIA INHIBITION OF HEPATIC STELLATE CELL ACTIVATION Jonel Trebicka, Michaela Granzow, Sabine Klein, Martin Hennenberg, Annabelle Vogt, Jeremias Klösel, Joerg Heller, Tilman Sauerbruch Internal Medicine I, University of Bonn, Bonn, Germany

#1150

#1144

TGF-β INDUCES CTGF BY COOPERATION OF SEVERAL SIGNALING PATHWAYS AND CAVEOLIN1 IN MOUSE HEPATOCYTES

INHIBITION OF HEPATIC FIBROSIS AND THE INTERACTION BETWEEN PPAR-γ AND RETINOID RECEPTORS

Christoph Meyer, Alexandra Müller, Carolin Stump, Steven Dooley Molecular Hepatology - Alcohol dependent Diseases, Faculty of Medicine Mannheim, Mannheim, Germany

Rafael Bruck1,3, Efrat Sharvit1, Zamir Halpern1,3, Shimon Reif2,3 of Gastroenterology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. 2Pediatrics, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 3Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel 1Department

#1145 THE ROLE OF THE HEPATOCYTE AND CD147 IN PROGRESSIVE LIVER Sarah R. Calabro1, Fiona J. Warner1,3, Auvro Mridha3, Sue McLennan1,3, Bramilla Patkunanathan1, Christine Yee1, Geoffrey W. McCaughan1,2, Nicholas A. Shackel1,2 1Liver Laboratory, Centenary Institute, Sydney, NSW, Australia. 2A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. 3Faculty of Medicine, The University of Sydney, Sydney, NSW, Australia

#1146 HBV PROMOTE HEPATIC STELLATE CELLS PROLIFERATION THROUGH PLATELET-DERIVED GROWTH FACTOR SIGNAL PATHWAY Qixuan Bai, Jidong Jia Liver Research Center, Beijing Friendship Hospital, Capital Medical Univeristy, Beijing, China

BENEFICIAL EFFECTS OF MULTIKINASE INHIBITOR SORAFENIB ON INHIBITING PROLIFERATION AND INDUCING APOPTOSIS IN HEPATIC STELLATE CELL Yan Wang, Juncha Gao, Huiqing Jiang, Department of Gastroenterology, The Second Hospital of Hebei Medical University, Hebei Key Laboratory of Gastroenterology, The Hebei Institute of Gastroenterology, Shijiazhuang, China

ACIDIC SPHINGOMYELINASE PLAYS A PROFIBROGENIC ROLE BY MODULATING HEPATIC STELLATE CELL ACTIVATION AND PROLIFERATION Anna Moles1,2, Núria Tarrats1,2, Albert Morales1,2, Marlene Dominguez1, Ramon Bataller1, Juan Caballeria1, Carmen GarciaRuiz1,2, Jose C. Fernandez-Checa1,2, Montserrat Mari1,2 1Liver Unit, Hospital Clinic, CIBEREHD, IDIBAPS, Barcelona, Spain. 2IIBB-CSIC, Barcelona, Spain

#1152 GUGGULSTERONE ATTENUATES HEPATIC STELLATE CELL ACTIVATION AND SURVIVAL BY INHIBITING NUCLEAR FACTOR KAPPA B ACTIVATION AND INDUCING APOPTOSIS Bo Hyun Kim1, Jong In Yang2, Jung-Hwan Yoon3, Jeong-Hoon Lee3, Goh Eun Chung3, Sun Jung Myung3, Eun Uk Jung4, Seong-Joon Koh3, Yoon Jun Kim3, Hyo-Suk Lee3 1Department of Internal medicine and Hepatology Center, Bundang Jesaeng General Hospital, Seongnam, Korea, South. 2Healthcare Research Institute, Seoul National University Hospital, Seoul, Korea, South. 3Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Korea, South. 4Department of Internal Medicine, Paik Hospital, Inje University, Pusan, Korea, South


#1147

#1151

216A

POSTER SESSIONS


#1153

#1158

INDUCTION OF HO-1 IN MDR2KO MICE PREVENTS FORMATION OF FIBROSIS

BROAD-SPECTRUM MATRIX METALLOPROTEINASE INHIBITION CURBS INFLAMMATION BUT AGGRAVATES FIBROSIS IN A MURINE MODEL OF CHRONIC CARBON TETRACHLORIDE INDUCED INJURY

Roja Barikbin1, Dorothee Schwinge2, Christoph Schramm2, Ansgar W. Lohse2, Gisa Tiegs1, Gabriele Sass1 1Division of Experimental Immunology and Hepatology, University Medical Center Hamburg Eppendorf, Hamburg, Germany. 2Center of Internal Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany

#1154 CONTRACTION OF ACTIVATED HEPATIC STELLATE CELLS IN CIRRHOTIC LIVER IS UP-REGULATED BY ENDOTHELIN-1 INDUCED PHOSPHORYLATION OF CPI-17 AND MYPT1 Masateru Iizuka, Masatoshi Hori, Yoshihito Morizane, Takahisa Murata, Hiroshi Ozaki Department of Veterinary Pharmacology, The University of Tokyo, Tokyo, Japan

#1155 PROTEOMIC BIOMARKERS IN ASSESSMENT OF LIVER FIBROSIS USING SELDI-TOF MS Senem C. Karatayli1, Dilsa Mizrak2, Muyesser Arslan2, Muhip Ozkan3, Berna Savas4, Cihan Yurdaydin1,5, Ramazan Idilman5, A Mithat Bozdayi1,5 1Hepatology Institute, Ankara University, Ankara, Turkey. 2Internal Medicine, Ankara University Faculty of Medicine, Ankara, Turkey. 3Biometry Genetics, Ankara University Faculty of Agriculture, Ankara, Turkey. 4Department of Pathology, Ankara University, Ankara, Turkey. 5Gastroenterology, Ankara University Faculty of Medicine, Ankara, Turkey

#1156 JNK1/2 REGULATE α-SMA IN HEPATIC FIBROSIS OF RATS Il-Hwa Hong, Sang-Joon Park, Jin-Kyu Park, Mi-Ran Ki, Kyung-Sook Hong, Ae-Ri Ji, Kyu-Shik Jeong College of Veterinary Medicine, Kyungpook National University, Daegu, Korea, South

#1157 ATRIAL NATRIURETIC PEPTIDE (ANP) AND C-TYPE NATRIURETIC PEPTIDE (CNP) PREVENTED LIVER FIBROSIS AND HAD THE PROTECTIVE ACTION OF LIVER


Naoki Yamamoto, Noriko Ishigaki, Haiyan Jin, Koichi Uchida, Shuji Terai, Takahiro Yamasaki, Isao Sakaida Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube Yamaguchi, Japan


Vincent E. de Meijer1, Deanna Y. Sverdlov2, Yury Popov2, Jonathan A. Meisel1, Hau D. Le1, Vania Nose’3, Detlef Schuppan2, Mark Puder1 1Department of Surgery, Children’s Hospital Boston, Boston, MA, USA. 2Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 3Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

#1159 THE EFFECTS OF FOCAL ADHESION KINASE GENE SILENCING ON PROLIFERATION AND APOPTOSIS OF HEPATIC STELLATE CELLS Xiaolan Zhang1,2, Shurui Xie1,2, Dongmei Yao1,2, Junyan An1,2, Shuming Fang1,2, Jinfeng Yao1,2, Xuechen Liu1,2, Shuang Chen3 1Dept of Gastroentology, The Second Hospital of Hebei Medical University, Shijiazhuang City, China. 2Hebei Province Key Laboratory, the Second Hospital of Hebei Medical University, Shijiazhuang City, China. 3Pediatric Department, UCLA MEDICAL School, Cedars-Sinai medical Center, Los Angeles, CA, USA

#1160 CALCIFEROL SIGNIFICANTLY INHIBITS PROFIBROGENIC GENE EXPRESSION BY HEPATIC STELLATE CELLS: A POTENTIAL POTENT SUPPLEMENT IN THE THERAPY OF LIVER FIBROSIS Anja Beilfuss1, Robert K. Gieseler1,2, Andreas Zahn1, Guido Marquitan1,2, Guido Gerken1, Scott L. Friedman3, Ali Canbay1 1Gastroenterology and Hepatology,, University clinic Essen, Essen, Germany. 2Division of R&D,Rodos Bio Target GmbH, Medical park Hannover, Hannover, Germany. 3Division of liver diseases, Mount Sinai School of medicine, New York, NY, USA

#1161 SPHINGOSINE 1-PHOSPHATE PROMOTES LIVER REGENERATION IN RATS AFTER PARTIAL HEPATECTOMY: ROLE OF SINUSOIDAL ENDOTHELIAL CELLS MIGRATION Ling Fu1, Tsuneo Kitamura2,3, Kazuhisa Iwabuchi1, Syozo Ichinose1, Mitsuaki Yanagida1, Hideoki Ogawa1, Toshihide Maruyama2,3, Sumio Watanabe3, Kenji Takamori1 1Institute for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan. 2Division of Gastroenterology, Department of Internal Medicine 1, Juntendo University Urayasu Hospital, Chiba, Japan. 3Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan


POSTER SESSIONS

#1162 TWEAK PROMOTES LIVER PROGENITOR CELL PROLIFERATION IN VIVO AND IN VITRO; REGULATION OF THE REGENERATIVE RESPONSE IN THE MURINE CDE-INDUCED CHRONIC LIVER INJURY MODEL Janina E. Tirnitz-Parker1,3, Cornelia S. Viebahn2, Aniela Jakubowski4, John K. Olynyk1,3, George Yeoh2,3, Belinda Knight5 1Medicine and Pharmacology, University of Western Australia, Fremantle, WA, Australia. 2Biomedical, Biomolecular and Chemical Sciences, University of Western Australia, Crawley, WA, Australia. 3Western Australian Institute for Medical Research, Perth, WA, Australia. 4Biogen Idec Inc., Cambridge, MA, USA. 5Institute for Stem Cell Research, MRC Centre for Regenerative Medicine, Edinburgh, United Kingdom

#1163 DEVELOPMENT AND CHARACTERIZATION OF AN IMMORTALIZED CELL LINE DERIVED FROM MOUSE HEPATIC SINUSOIDAL ENDOTHELIAL CELLS Robert C. Huebert1, Helen Hendrickson1, Kumaravelu Jagavelu1, Ann F. Liebl1, Patrick L. Splinter2, Nicholas F. LaRusso2, Raul A. Urrutia1, Vijay Shah1 1Gastroenterology Research Unit, Mayo Clinic, Rochester, MN, USA. 2GI Basic Research, Mayo Clinic, Rochester, MN, USA

#1164 PARACRINE PLATELET-DERIVED GROWTH FACTOR (PDGF) SIGNALLING, RATHER THAN EPITHELIALMESENCHYMAL TRANSITION (EMT), MEDIATES CANCER-ASSOCIATED FIBROBLAST RECRUITMENT IN CHOLANGIOCARCINOMA Luca Fabris1,2, Massimiliano Cadamuro2, Lidia Moserle3, Luigi Dall’Olmo1, Giorgia Nardo3, Silvia Lecchi2, Carlo Spirli2,4, Stefano Indraccolo5, Lajos Okolicsanyi1, Mario Strazzabosco4,6 1Surgical and Gastroenterological Sciences, University di Padova, Padova, Italy. 2Center for Liver Research, Ospedali Riuniti di Bergamo, Bergamo, Italy. 3Dept of Oncology and Surgical Sciences, University of Padova, Padova, Italy. 4Internal Medicine, Section of Digestive Diseases and Liver Center, Yale University, New Haven, CT, USA. 5Istituto Oncologico Veneto, IRCCS, Padova, Italy. 6Clinical Medicine and Prevention, Universita di Milano-Bicocca, Milano, Italy

#1165 INHIBITION OF M3 MUSCARINIC RECEPTOR (M3R) ACTIVATION AUGMENTS AZOXYMETHANE (AOM)-INDUCED EXPRESSION OF EPITHELIAL CELL ADHESION MOLECULE IN BILE DUCTULES AND OVAL CELLS

#1166 THE CHEMOKINE CXCL4 (PF4) IS A PLATELETDERIVED MEDIATOR OF HCV-INDUCED AND EXPERIMENTAL LIVER FIBROSIS Mirko Moreno Zaldivar1, Katrin Pauels1, Marie-Luise Berres1, Petra Schmitz1, Ralf Weiskirchen2, Christian Trautwein1, Hermann Wasmuth1 1Medical Department III, University Hospital Aachen, Aachen, Germany. 2Institute of Clinical Chemistry and Pathobiochemistry, University Hospital Aachen, Aachen, Germany

#1167 HEPATITIS C VIRUS DIRECTLY ACTIVATES HEPATIC STELLATE CELLS VIA THE TOLL-LIKE RECEPTOR 3 SIGNALING PATHWAY Bo Wang1,2, Martin Trippler1, Mengji Lu3, Ruth Broering1, Guido Gerken1, Joerg F. Schlaak1 1Dept. of Gastroenterology and Hepatology, University Hospital of Essen, Essen, Germany. 2Dept. of Gastroenterology, Tongji Hospital, Wuhan, China. 3Institute of Virology, University Hospital of Essen, Essen, Germany

#1168 TNF-ALPHA SIGNAL IS IMPORTANT TO REPAIR CIRRHOTIC LIVER BY BONE MARROW CELL INFUSION Takuro Hisanaga1, Shuji Terai1, Takuya Iwamoto1, Taro Takami1, Naoki Yamamoto1, Isao Sakaida1, Hiroshi Nishina2 1Department of Gastroenterology and Hepatology, Graduate School of Medicine, Yamaguchi University, Ube City, Japan. 2Department of Developmental and Regenerative Biology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan

#1169 HEPATITIS C VIRUS CORE PROTEIN INDUCES FIBROGENIC ACTIONS OF HEPATIC STELLATE CELLS VIA TOLL-LIKE RECEPTOR 2 Martin Coenen, Hans Dieter Nischalke, Benjamin Krämer, Christian Koerner, Daniela Schulte, Jacob Nattermann, Tilman Sauerbruch, Ulrich Spengler Department of Internal Medicine, University of Bonn Medical Center, Bonn, Germany

#1170 DEVELOPMENT AND VALIDATION OF A NOVEL ELISA FOR MMP-9 MEDIATED TYPE III COLLAGEN: A NEW SERUM MARKER OF EXTRACELLULAR MATRIX REMODELLING IN LIVER FIBROSIS Sanne S. Veidal1,2, Natasha Barascuk1,2, Lise Larsen1, Morten A. Karsdal1,2 1Assay Development, Nordic Bioscience, Herlev, Denmark. 2University of Southern Denmark, Health, Odense, Denmark

#1171 EPIGENETICALLY INHERITED RESISTANCE TO LIVER FIBROSIS Jelena Mann, Xin Xu, Fiona Oakley, Aidan Maxwell, Ahmed M. Elsharkawy, Derek A. Mann, Alastair D. Burt ICM, Newcastle University, Newcastle upon Tyne, United Kingdom


Nirish Shah1, Brian Shiu1, Angelica Belo1, Roxana Samimi1, Kunrong Cheng1, Cinthia Drachenberg2, Jasleen Shant1, Jean-Pierre Raufman1, Sandeep Khurana1 1Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD, USA. 2Pathology, University of Maryland School of Medicine, Baltimore, MD, USA

217A

218A

POSTER SESSIONS

Hepatobiliary Cancer: Experimental (1) #1172 INHIBITION OF HEDGEHOG SIGNALING SENSITIZES HUMAN CHOLANGIOCARCINOMA CELLS TO TRAIL-MEDIATED APOPTOSIS VIA TRAILR1/DR4 UP-REGULATION Satoshi Kurita, Justin L. Mott, Steven F. Bronk, Martin E. FernandezZapico, Gregory Gores Mayo Clinic College of Medicine, Rochester, MN, USA

#1173 THE ROLE OF PPARγ IN THE GROWTH INHIBITION OF HEPATOCELLULAR CARCINOMA Jun Yu, Bo Shen, Eagle Chu, Shiyan Wang, Chung-Wah Wu, KinFai Cheung, Alfred S. Cheng, Henry Lik-Yuen Chan, Joseph JY Sung Institute of Digestive Disease and Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China

#1174 S100A4, AN EARLY MARKER OF EPITHELIALMESENCHYMAL TRANSITION, IS ASSOCIATED WITH POOR PROGNOSIS AND STRONG METASTATIC POTENTIAL IN CHOLANGIOCARCINOMA Luca Fabris1,2, Massimiliano Cadamuro2, Lidia Moserle3, Giorgia Nardo3, Luigi Locatelli2,4, Romina Fiorotto2,4, Michele Colledan2, Aurelio Sonzogni2, Alberto Furlanetto5, Stefano Indraccolo6, Lajos Okolicsanyi1, Mario Strazzabosco4,7 1Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy. 2Center For Liver Research (CeLiveR), Ospedali Riuniti di Bergamo, Bergamo, Italy. 3Dept of Oncology and Surgical Sciences, University of Padova, Padova, Italy. 4Internal Medicine, Section of Digestive Diseases and Liver Center, Yale University, New Haven, CT, USA. 5Dept of Pathology, Treviso Regional Hospital, Treviso, Italy. 6Istituto Oncologico Veneto, IRCCS, Padova, Italy. 7Clinical Medicine and Prevention, University of Milano-Bicocca, Milano, Italy

#1175


PIGMENT EPITHELIUM-DERIVED FACTOR SUPPRESSES APOPTOSIS THROUGH LYSOSOMAL DEGRADATION OF BCL-XL IN HEPG2 CELLS Takumi Kawaguchi1,2, Sho-ichi Yamagishi3, Minoru Itou2, Koji Okuda4, Shuji Sumie2, Ryoko Kuromatsu2, Eitaro Taniguchi2, Hironori Koga2,5, Masaru Harada6, Takato Ueno5,2, Michio Sata1,2 1Department of Digestive Disease Information & Research, Kurume University School of Medicine, Kurume, Japan. 2Department of Medicine, Kurume University School of Medicine, Kurume, Japan. 3Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan. 4Department of Surgery, Kurume University School of Medicine, Kurume, Japan. 5Research Center for Innovative Cancer Therapy, and the 21st Century Center of Excellence Program for Medical Science, Kurume University, Kurume, Japan. 6Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan



#1176 TLR4-DEPENDENT NANOG+ CANCER STEM CELLS EXHIBIT DEFECTIVE TGF-β SIGNALING Keigo Machida1,2, Jian-Chang Liu2, Hyeongnam Jeong2, Lopa Mishra3, Hidekazu Tsukamoto1,4 1Southern California Research Center for Alcoholic Liver and Pancreatic Diseases and Cirrhosis, Los Angeles, CA, USA. 2Molecular Microbiology and Immunology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. 3Georgetown University, Washington, WA, USA. 4Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA

#1177 IMMUNOTHERAPY OF ORTHOTOPIC ESTABLISHED HEPATOCELLULAR CARCINOMA (HCC) BY TUMORLYSATE PULSED DENDRITIC CELLS ENGINEERED TO EXPRESS CD40L IN MICE Annabelle Vogt1, Georges Decker1, Esther Raskopf1, Volker Schmitz1, Tilman Sauerbruch1, Wolfgang H. Caselmann2, Maria A. Gonzalez-Carmona1 1Department of Internal Medicine, University of Bonn, Bonn, Germany. 2Bavarian State Ministry of the Environment and Public Health, Munich, Germany

#1178 TARGETED EXPRESSION OF CYCLOOXYGENASE-2 IN THE LIVER PROMOTES HEPATOCARCINOGENESIS Guiying Li1,2, Chang Han1, Lihong Xu1, Kyu Lim1,3, Tong Wu1 1Department of Pathology, University Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, Jilin University, Changchun, China. 3Department of Biochemistry, Chungnam National University College of Medicine, Chungnam, Korea, South

#1179 EPIGENETIC SYLENCING AND TRANSCRIPTIONAL REGULATION OF MIRNAS MODULATED IN HUMAN HCCS Natalia Pediconi1,2, Valeria Schinzari1,4, Stefania Vossio1,4, Cecilia Scisciani1,2, Rossana De Iaco1,3, Massimo Levrero1,2 1Dept of Internal Medicine, Sapienza University, Rome, Italy. 2AIRC ROC, Rome Oncogenomic Center, Rome, Italy. 3Laboratory of Gene Expression, A. Cesalpino Foundation, Rome, Italy. 4Laboratoire Associé INSERM U785, INSERM and Sapienza University of Rome, Rome, Italy

#1180 OVER-EXPRESSION OF MICORNA-21 PROMOTES METASTATIC PHENOTYPE OF HEPATOCELLULAR CARCINOMA BY TARGETING THE TUMOR SUPPRESSOR, RHOB Erin Connolly, Koenraad Van Doorslaer, Leslie E. Rogler, Charles E. Rogler Medicine Division of Hepatology, Albert Einstein College of Medicine, Bronx, NY, USA


POSTER SESSIONS

219A

#1181

#1186

GALECTIN 3 IS A SURVIVAL PROTEIN AND PLAYS A ROLE IN THE DEVELOPMENT OF HCC IN MICE

MOLECULAR THERAPY OF HEPATOCELLULAR CARCINOMA WITH SORAFENIB COMBINED WITH ABROGATION OF EGFR SIGNALING WITH XL647 (EGFR/HER2/NU/VEGFR INHIBITOR) COMPARED TO ERLOTINIB IN VIVO

Joy Jiang1, Fiona Scott1, Yong Li1, Nobuko Serizawa1, Sridevi Devaraj1, Daniel K. Hsu2, Fu-Tong Liu2, Natalie Torok1 1Internal Medicine, GI/Hep, UC Davis, Sacramento, CA, USA. 2Dermatology, UC Davis, Sacramento, CA, USA

#1182 GENE EXPRESSION SIGNATURE OF PUTATIVE CANCER STEM CELLS PREDICTS SURVIVAL OF HCC PATIENTS Jens U. Marquardt1, Chiara Raggi1, Jesper B. Andersen1, Deakwan Seo1, Itzhak Avital2, Agnes Holczbauer1, Valentina M. Factor1, Snorri S. Thorgeirsson1 1LEC, NCI, NIH, Bethesda, MD, USA. 2Surgery Branch, NCI, NIH, Bethesda, MD, USA

#1183 EPITHELIAL-MESENCHYMAL TRANSITION INDUCED BY TRANSFORMING GROWTH FACTORβ1 AGGRAVATES INVASIVE GROWTH OF CHOLANGIOCARCINOMA Yasunori Sato, Norihide Yoneda, Xiang Shan Ren, Motoko Sasaki, Kenichi Harada, Yasuni Nakanuma Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan

#1184 SYNERGISTIC ANTITUMORAL EFFECT OF SUBCUTANEOUS INOCULATION WITH AFPPULSED DC COMBINED WITH INTRATUMORAL INJECTION OF IL-12-EXPRESSING DC IN ESTABLISHED HEPATOCELLULAR TUMORS (HCC) IN VIVO Maria A. Gonzalez-Carmona1, Annabelle Vogt1, Esther Raskopf1, Volker Schmitz1, Tilman Sauerbruch1, Wolfgang H. Caselmann2 1Department of Internal Medicine, University of Bonn, Bonn, Germany. 2Bavarian State Ministry of the Environment and Public Health, Munich, Germany

#1185 TARGETING CADHERIN-17 INACTIVATES WNT SIGNALING AND INHIBITS TUMOR GROWTH IN LIVER CARCINOMA

#1187 SUSTAINED ACTIVATION OF WNT/β-CATENIN PATHWAY AS A MECHANISM BEHIND SPONTANEOUS HEPATOCELLULAR CARCINOMA IN FXR KNOCKOUT MICE Andy Wolfe, Grace L. Guo, Udayan Apte Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA

#1188 WHOLE GENOME SEQUENCING: A COMPREHENSIVE CATALOG OF MUTATIONS AND REARRANGEMENT IN HCC Paulette Bioulac-Sage1, Fabien Calvo2, Bruno Clement3, Françoise Degos4, Ivo G. Gut5, Mark Lathrop5, Gilles Thomas6, Jessica Zucman-Rossi7,8 1CHU Bordeaux, Bordeaux, France. 2Institut National du Cancer, Paris, France. 3Inserm, Rennes, France. 4Department of hepatology, APHP, Beaujon Hospital, Clichy, France. 5Centre National de Génotypage, Evry, France. 6Fondation Synergie Lyon, Lyon, France. 7Inserm U674, Paris, France. 8Université Paris Descartes, Paris, France

#1189 COMMON HCC CELL LINES REPRESENT ONLY A SUBGROUP OF HUMAN HCC CASES Frank Staib, Melda Karakus, Markus Krupp, Thorsten Maass, Peter R. Galle, Andreas Teufel Department of Medicine I, Johannes Gutenberg University, Mainz, Germany

#1190 LOSS OF HNF1α FUNCTION IN HUMAN HEPATOCELLULAR ADENOMAS LEADS TO SPECIFIC ABERRANT ACTIVATION OF ONCOGENIC PATHWAYS Laura Pelletier1,2, Sandra Rebouissou1,2, Jessica Zucman-Rossi1,2, Alain Paris3, Paulette Bioulac-Sage4,5, Sandrine Imbeaud6 1U674, Inserm, Paris, France. 2Institut Universitaire d’Hématologie, Université Paris 7 Denis Diderot, Paris, France. 3UMR 1089, INRA, Toulouse, France. 4U889, Inserm, Bordeaux, France. 5CHU Bordeaux, Hôpital Pellegrin, Bordeaux, France. 6UMR 7091, CNRS, Villejuif, France


John Luk1, Lingxiao Liu2, Lars Zender3, Scott Lowe3, Hongyue Dai4, Hsiang Fu Kung5, Irene Ng1, Ronnie Poon1, Jianhua Wang2 1University of Hong Kong, Hong Kong, China. 2Fudan University, Shanghai, China. 3HHMI and Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA. 4Merck Research Laboratoires, Seattle, WA, USA. 5The Chinese University of Hong Kong, Hong Kong, China

Beatriz Minguez1, Sara Toffanin1, Anja Lachenmayer1, Laia Cabellos1, Analisa DiFeo2, Pedro Melgar-Lesmes3, Radoslav Savic1, Swan N. Thung1, Scott L. Friedman1, Josep M. Llovet1,4 1Liver Cancer Program. Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA. 2Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, USA. 3Biochemistry and Molecular Genetics, IDIBAPS, CIBERehd, Hospital Clínic, Barcelona, Spain. 4BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, Barcelona, Spain

220A

POSTER SESSIONS

#1191

#1196

THIAZOLIDINEDIONES INHIBIT HEPATIC TUMOUR FORMATION IN HBV TRANSGENIC MICE BY A PPARγ-INDEPENDENT REGULATION OF NUCLEOPHOSMIN

HCC STROMA INDUCES THE DIFFERENTIATION OF TOLEROGENIC DENDRITIC CELLS

Mirko Tarocchi1, Elisabetta Ceni1, Tommaso Mello1, Simone Polvani1,2, Francesca Buccoliero1, Laura Cioni1, Barbara Ottanelli1, Valeria Foresta1, Stefano Milani1, Andrea Galli1 1Department of Clinical Pathophysiology/Gastroenterology Unit, University of Florence, Florence, Italy. 2FiorGen Foundation, Sesto Fiorentino, Italy

#1192 THE ATPASE PONTIN IS OVEREXPRESSED IN HEPATOCELLULAR CARCINOMA AND COREGULATED WITH REPTIN THROUGH A NEW POST-TRANSLATIONAL MECHANISM Valérie Haurie1, Ludovic Ménard1, Christian Touriol2, Danièle Taras1, Charles Balabaud1, Paulette Bioulac-Sage1, Hervé Prats2, Jessica Zucman-Rossi3, Jean Rosenbaum1 1INSERM U889, Universite Bordeaux 2, Bordeaux, France. 2INSERM U858, Université Paul Sabatier, Toulouse, France. 3INSERM U674, Université Paris Diderot Paris, Paris, France

#1193 THE ROLE OF TUMOR SUPPRESSOR MICRORNAS IN HEPATOCELLULAR CARCINOMA Natalia Elfimova1, Andrea Noetel1, Heike Varnholt2, Jasmin Riemer1, Monika Kwiecinski1, Maria J. Quasdorff3, Hans P. Dienes1, Margarete Odenthal1 1Pathology, University Hospital of Cologne, Cologne, Germany. 2Pathology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3Gastroenterology and Hepatology, University Hospital of Cologne, Cologne, Germany

#1194 INHIBITION OF HISTONE METHYLTRANSFERASE G9A HAS ANTICANCER EFFECTS IN MOUSE AND HUMAN HEPATOMA CELLS THROUGH INDUCING CDK INHIBITOR P21 AND PROAPOPTOTIC TRANSCRIPTION FACTOR GADD153/CHOP Hong Lu, Ye Li, Xiao-bo Zhong, Curtis D. Klaassen Pharmacology, Toxicology & Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA

#1195



NOVEL MECHANISM OF ACYCLIC RETINOIDINDUCED APOPTOSIS IN HEPATOCELLULAR CARCINOMA CELLS - DUAL INDUCTION OF CASPASE 3 AND TRANSGLUTAMINASE DEPENDENT APOPTOTIC PATHWAYS Hideki Tatsukawa1, Tetsuro Sano2, Naoto Ishibashi3, Masataka Okuno4, Hisataka Moriwaki4, Soichi Kojima1 1Mol. Ligand Biol Resch Team, RIKEN, Wako, Japan. 2Pharmaceutical Development, Pharmaceutical Division, KOWA Company, Tyuou, Japan. 3Tokyo New Drug Research Laboratories, Pharmaceutical Division, KOWA Company, Higashimurayama, Japan. 4Department of Gastroenterology, Gifu University School of Medicine, Gifu, Japan


Anand N. Bhatt, Stuart M. Curbishley, Emma L. Haughton, Miroslava Blahova, David H. Adams Center for Liver Research, University Hospital Birmingham, Birmingham, United Kingdom

#1197 RELATIONSHIP BETWEEN FUNCTIONAL POLYMORPHISM IN THE AURORA A GENE AND SUSCEPTIBILITY OF HEPATOCELLULAR CARCINOMA Hikmet Akkiz1, Süleyman Bayram2,1, Aynur Bekar1, Ersin Akgöllü1, Macit U. Sandikci1, Burhan Özdil1, Figen Doran3, Ilhan Tuncer3 1Medical Faculty Department of Gastroenterology, Çukurova University, Adana, Turkey. 2Department of Biology, Natural and Applied Science Institute, Çukurova University, Adana, Turkey. 3Medical Faculty Department of Pathology, Çukurova University, Adana, Turkey

#1198 THE ADAPTOR PROTEIN EBP50 COOPERATES WITH EGFR TO CONTROL BILIARY CANCER CELL SCATTERING AND MIGRATION Audrey Clapéron1, Nathalie Guedj2,3, Martine Mergey1, Blandine de Singly1, Yves Chrétien1, Valérie Paradis2,3, Chantal Housset1, Laura Fouassier1 1Inserm UMRS_938 & UPMC Univ Paris 06, Paris, France. 2Pathology, Beaujon hospital, Clichy, France. 3Inserm U773, Paris, France

Inflammation and Immunobiology #1199 HEPATOCYTE SPECIFIC ABLATION OF TAK1 INDUCES SPONTANEOUS HEPATITIS AND LIVER FIBROSIS Sayaka Inokuchi, Kouichi Miura, David A. Brenner, Ekihiro Seki Department of Medicine, University of California, San Diego, School of Medicine, La Jolla, CA, USA

#1200 CYTOSOLIC PHOSPHOLIPASE A2α ATTENUATES FAS-INDUCED LIVER INJURY IN MICE Guiying Li1,2, Chang Han1, Tong Wu1 of Pathology, University Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, Jilin University, Changchun, China

1Department


POSTER SESSIONS

221A

#1201

#1206

PROMOTION OF THE EXPRESSION OF LAP ON NKT LYMPHOCYTES BY ORAL ADMINISTRATION OF ANTI CD3 MONOCLONAL ANTIBODIES ALLEVIATES IMMUNE MEDIATED HEPATITIS: A NOVEL METHOD FOR INDUCTION OF REGULATORY T CELLS

HEPATIC TOLL-LIKE RECEPTOR 4 MEDIATES ACUTE HEPATIC INJURY IN SEPTIC SHOCK AND HEPATIC ISCHEMIA

Efrat Orenbuch-Harroch1, Gadi Lalazar1, Madi El-Haj1, Ami Ben Ya’acov1, Ehud Zigmond1, Dimitri Kanovich1, Howard Weiner2, Yaron Ilan1 1Liver Unit, Department of Medicine, Hadassah Medical Center, Jerusalem, Israel. 2Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

#1202

Ziv Ben-Ari1,2, Reut Fallach2,4, Orna Avlas2,4, Nadir Askenasy5, Yelena Chepurko2, Roni Cohen2,4, Asher Shainberg4, Orit Pappo3, Edith Hochhauser2 1Liver Institute, Rabin Medical Center and the Sackler school of medicine, Petah-Tiqva, Israel. 2The Liver and Cardiac Research Laboratory, Felsenstein Medical Research Center, Petah-Tiqva, Israel. 3Histopathology Department, Rabin Medical Center, Petah-Tiqva, Israel. 4Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel. 5Frankel Laboratory, Center for Stem Cell Research, Felsenstein Medical Research Center, Petah-Tiqva, Israel

MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN REGULATES CD1D-RESTRICTED ANTIGEN PRESENTATION OF HEPATOCYTES AND CONTROLS NKT CELL HOMEOSTASIS VIA CD1DMEDIATED APOPTOSIS

#1207

Sebastian Zeissig1, Kazumoto Murata3, Zongyi Hu3, Arthur Kaser2, Stephanie K. Dougan1, Erez Scapa1, David E. Cohen1, Jake T. Liang3, Richard S. Blumberg1 1Department of Medicine, Gastroenterology Division, Boston, MA, USA. 2Gastroenterology Division, Innsbruck Medical University, Innsbruck, Austria. 3LIVER DISEASES BRANCH, NIDDK, National Institutes of Health, Bethesda, MD, USA

Annette Erhardt1, Claudia Wegscheid1, Ulf Panzer2, Gisa Tiegs1 1Division of Experimental Immunology and Hepatology, University Medical Center Hamburg Eppendorf, Hamburg, Germany. 2Medical Clinic III, University Medical Center Hamburg Eppendorf, Hamburg, Germany

#1203 INTERLEUKIN-33 INHIBITS HEPATITIS B VIRUS REPLICATION IN THE LIVER OF TRANSGENIC MICE

AGGRAVATION OF LIVER DAMAGE AND LOSS OF IMMUNOLOGICAL TOLERANCE IN CXCR3DEFICIENT MICE IN THE MURINE MODEL OF CONCANAVALIN A-INDUCED LIVER INJURY

#1208 LOSS OF IMMUNOLOGICAL TOLERANCE IN CCR5DEFICIENT MICE IN THE MURINE MODEL OF CONCANAVALIN A-INDUCED LIVER INJURY

#1204

Claudia Wegscheid1, Ulf Panzer2, Gisa Tiegs1, Annette Erhardt1 1Division of Experimental Immunology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 2Medical Clinic III, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

SLA/LP-INDUCED IL6 AND IL17-ASSOCIATED AUTOIMMUNE HEPATITIS IN MICE

#1209

Jiang Yanfang, Cai Yanjun, Qin Junjie, Niu Junqi Department of hepatology, First hospital, Changchun, China

Christina Weiler-Normann, Marcial Sebode, Antonella Carambia, Ansgar W. Lohse, Christoph Schramm, Johannes Herkel Department of Medicine I, University Medical Centre HamburgEppendorf, Hamburg, Germany

#1205 THE SCAVENGER RECEPTOR D6 MODULATES LIVER DAMAGE AND FIBROGENESIS DURING TOXIC INJURY BY DEGRADATION OF INFLAMMATORY CHEMOKINES

Yury Popov1, Vincent E. de Meijer2, Deanna Y. Sverdlov1, Anisha Sharma1, Mark Puder2, Detlef Schuppan1 1Gatroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 2Surgery, Children’s Hospital, Boston, MA, USA

#1210 FOXP3+ REGULATORY T CELLS UNDERLIES MALE RESISTANCE TO EXPERIMENTAL TYPE 2 AUTOIMMUNE HEPATITIS Pascal Lapierre1, Kathie Béland1, Caroline Martin1, Fernando Alvarez1, Fernando Alvarez1,2 1Gastroenterology, hepatology and nutrition, CHU Sainte-Justine, Montreal, QC, Canada. 2Department of Pediatrics, University of Montreal, Montreal, QC, Canada


Marie-Luise Berres1, Mirko Moreno Zaldivar1, Petra Schmitz1, Katrin Pauels1, Sergio A. Lira2, Frank Tacke1, Christian Trautwein1, Hermann Wasmuth1 1Medical Department III, University Hospital Aachen, Aachen, Germany. 2Immunology Institute, Mount Sinai School of Medicine, New York, NY, USA

ATTENUATED BILIARY FIBROSIS IN MDR2-/- MICE FED OMEGA-3 FATTY ACID-ENRICHED DIET

222A

POSTER SESSIONS

#1211

#1216

INFLAMMATION-MEDIATED ACTIVATION OF LIVER HEPCIDIN EXPRESSION IS SUPPRESSED BY ALCOHOL: ROLE OF STAT3 PROTEIN

IFN-α RENDERS MONOCYTES MORE SENSITIVE TO ENDOGENOUS IL-10, RESULTING IN SUPPRESSED IL-12P70 PRODUCTION UPON TLR LIGATION

Duygu Dee Harrison-Findik, Lisa Gerjevic, Erdal Eroglu Internal Medicine/ Gastroenterology and Hepatology Section, University of Nebraska Medical Center, Omaha, NE, USA

Bisheng Liu, Harry L. Janssen, Andre Boonstra Gastroenterology and Hepatology, Erasmus MS, Rotterdam, Netherlands

#1212

#1217

SAME BLOCKS THE UP REGULATION OF TOLL-LIKE RECEPTOR SIGNALING IN MALLORY-DENK BODY FORMING HEPATOCYTES

DENDRITIC CELLS PROTECT AGAINST LIVERISCHEMIA REPERFUSION VIA A TLR9 AND IL-10DEPENDENT MECHANISM

Fawzia Bardag-Gorce, Joan Oliva, Jun Li, Barbara A. French, Samuel W. French LABioMed at Harbor-UCLA, Torrance, CA, USA

Zubin M. Bamboat, Lee M. Ocuin, Vinod P. Balachandran, Hebroon Obaid, Ronald P. DeMatteo Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

#1213 ACCUMULATION OF FUNCTIONAL REGULATORY T CELLS IN ACTIVELY INFLAMED LIVER IN MOUSE DENDRITIC CELL-BASED AUTOIMMUNE HEPATIC INFLAMMATION Chisato Saeki, Masanori Nakano, Tsunekazu Oikawa, Hiroki Takahashi, Sadamu Honma, Mikio Zeniya Jikei University School of Medicine, Tokyo, Japan

#1214 IMMUNOLOGICAL CLUSTER ANALYSIS IN ABCB4 KNOCKOUT MICE AS MODEL OF PROGRESSIVE INTRAHEPATIC CHOLESTASIS: PERIPHERAL LEUKOCYTE POPULATIONS DISCRIMINATE THE MUTANT PHENOTYPE Hochrath1,

Hall1,

Adler2,3,

Wang4,

Katrin Rabea A. Thure Yu Helmut Fuchs3, Valérie Gailus-Durner3, Martin Hrabé de Angelis3,5, Dirk H. Busch2, Frank Lammert1 1Department of Medicine II, Saarland University, Homburg, Germany. 2Institute for Medical Microbiology, Immunology and Public Health, TU Munich, Munich, Germany. 3German Mouse Clinic, Institute for Experimental Genetics, Helmholtz Zentrum München German Research Center for Enviromental Health, Munich, Germany. 4Institute for Bioinformatics and System Biology, Helmholtz Zentrum München - German Research Center for Enviromental Health, Munich, Germany. 5Lehrstuhl für Experimentelle Genetik, TU München, Freising-Weihenstephan, Germany

#1215 HEPATOCYTE-SPECIFIC IRF3 SIGNALING PROTECTS FROM ALCOHOL-INDUCED LIVER INJURY IN MICE THROUGH REGULATION OF MONOCYTE/MACROPHAGE-DERIVED CYTOKINES VIA TYPE-I INTERFERONS M O N D AY NOVEMBER 1


Jan Petrasek1, Bharath Nath1, Angela Dolganiuc1, Istvan Hritz2, Karen Kodys1, Donna Catalano1, Evelyn A. Kurt-Jones1, Pranoti Mandrekar1, Gyongyi Szabo1 1Department of Medicine, University of Massachusetts Medical Center, Worcester, MA, USA. 22nd Department of Medicine, Semmelweis University, Budapest, Hungary


#1218 EFFECTS OF HEPATITIS B VIRUS PRECORE OR ENVELOPE ANTIGEN ON TOLL-LIKE RECEPTOR SIGNALING PATHWAY IN HUMAN HEPATOMA CELL LINES Wu Shuang, Tatsuo Kanda, Makoto Arai, Fumio Imazeki, Osamu Yokosuka Department of Medicine and Clinical Oncology, Chiba University,Graduate School of Medicine, Chiba, Japan

#1219 REDEFINING ABETALIPOPROTEINEMIA AS AN IMMUNOGICAL DISEASE INVOLVING CD1D Sebastian Zeissig1, Stephanie K. Dougan1, Yvonne Junker5, Zhangguo Chen1, Arthur Kaser4, Susan M. Kennedy2, Marina Cuchel3, Anna Raper3, Amanda L. Baer3, Daniel J. Rader3, Nicholas O. Davidson2, Richard S. Blumberg1 1Department of Medicine, Gastroenterology Division, Boston, MA, USA. 2Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO, USA. 3Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. 4Division of Gastroenterology, Innsbruck Medical University, Innsbruck, Austria. 5Gastroenterology Division, Beth Israel Deaconess Medical Center, Boston, MA, USA

#1220 INTERPLAY OF HEPATIC AND MYELOID STAT3 IN FACILITATING LIVER REGENERATION VIA TEMPERING INNATE IMMUNITY Hua Wang1, Ogyi Park1, Fouad Lafdil1, Kezhen Shen1, Norio Horiguchi1, Shi Yin1, Xin-Yuan Fu3, George Kunos2, Bin Gao1 1NIAAA/NIH, Bethesda, MD, USA. 2NIAAA/NIH, Bethesda, MD, USA. 3Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indianapolis, IN, USA


POSTER SESSIONS

223A

#1221

#1226

HIGH EMR2-EXPRESSED NEUTROPHILS IN CIRRHOTIC PATIENTS REPRESENTED APOPTOSISPRONE BUT ACTIVATED NEUTROPHILS AND COULD PREDICT THE SUBSEQUENT DEVELOPMENT OF BACTERIAL COMPLICATIONS AND MORTALITY

SPLENIC FIBROCYTES (“EMERGENCY” CELLS) FACILITATE IMMUNE DEFENSES IN RESPONSE TO LIVER INJURY OR STRESS

Tsung-Nan Lin1, Hsi-Hsien Lin2, Yu-Pin Ho1, Chun-Jung Lin1, ChauTing Yeh1, Cheng-Tang Chiu1, I-Shyan Sheen1, Chun-Yen Lin1,2 1Department of Hepatogastroenterology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. 2Department of Microbiology and Immunology, Chang Gung University, Taoyuan, Taiwan

#1222 TIRAP CONTRIBUTES TO GALACTOSAMINE/LIPOPOLYSACCHARIDEINDUCED ACUTE LIVER INJURY IN MICE Arunmani Mani, Sundararajah Thevananther Pediatrics/Gastroenterology, Hepatology & Nutrition, Texas Children’s Liver Center, Baylor College of Medicine, Houston, TX, USA

#1223 KUPFFER CELLS AND STELLATE CELLS PROMOTE ALCOHOL-MEDIATED LIVER INJURY THROUGH TLR4 Ekihiro Seki1, Sayaka Inokuchi1, Hidekazu Tsukamoto2, David A. Brenner1 1Medicine, UCSD, La Jolla, CA, USA. 2Pathology, University of Southern California, Los Angels, CA, USA

#1224 UNRESTRICTED CONSTITUTIVE ACTIVITY OF GLYCOGEN SYNTHASE KINASE 3 (GSK3) INHIBITS ANTI-INFLAMMATORY AND FAVORS PRO-INFLAMMATORY CYTOKINE PRODUCTION IN LPS-STIMULATED IMMUNE CELLS FROM PATIENTS WITH ADVANCED CIRRHOSIS Thierry Gustot1,2, Marika Rudler3,5, Nicolas Coant3, Sonia Gandoura3, Cecile Guichard3, Wael Abdel-Razek2, Kévin Ragot4, Arnaud Galbois3, Zéra Tellier3, Gérard H. Lizard4, Eric OgierDenis3, Didier Lebrec2,3, Richard Moreau2,3 1Gastroenterology, Erasme Hospital, Brussels, Belgium. 2Hépatologie, Beaujon, Paris, France. 3Centre de recherche Biomédicale 3, INSERM U773, Université Paris VII, Denis Diderot, Paris, France. 4INSERM U866, Faculté des Sciences Gabriel, Dijon, France. 5Hépatologie, Pitié-Salpétrière, Paris, France

Tatiana Kisseleva1, Maren von Köckritz-Blickwede3, Shauna McGillivray3, Donna R. Reichart2, Gerhard Wingender5, MengYun Chou1, Joseph Witztum Witztum1, Christopher K. Glass2, Victor Nizet3,4, David A. Brenner1 1Department of Medicine, UCSD, La Jolla, CA, USA. 2Department of Cellular and Molecular Medicine, University of California, La Jolla, CA, USA. 3Department of Pediatrics, University of California, La Jolla, CA, USA. 4Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, La Jolla, CA, USA. 5La Jolla Institute of Allergy and Immunology, La Jolla, CA, USA

#1227 GLOBAL GENE EXPRESSION ANALYSIS IN BILE DUCT LIGATED CIRRHOTIC RATS: CLUSTERED GENES IN THE TLR PATHWAY MAY MIMIC CHANGES IN GENE PROFILE IN ACUTE-ONCHRONIC LIVER FAILURE Naina Shah1, Dipok K. Dhar2, Daniel Frampton3, Nathan Davies1, Max Malago2, Steven W. Olde Damink2, Rajeshwar P. Mookerjee1, Rajiv Jalan1 1Hepatology, The Institute of Hepatology, London, United Kingdom. 2Surgery, The Institute of Hepatology, London, United Kingdom. 3Bioinformatics, University College London, London, United Kingdom

#1228 TOLL-LIKE RECEPTOR-4 /LPS SIGNALING PATHWAYS CONTRIBUTE TO THE EARLY CYTOKINE ACTIVATION AFTER PARTIAL HEPATECTOMY IN MICE Javier Vaquero, Jean S. Campbell, Jamil Haque, Ryan S. McMahan, Nelson Fausto Pathology, University of Washington, Seattle, WA, USA

#1229 MONOCYTES FROM CHRONIC HCV PATIENTS ARE FUNCTIONALLY ALTERED WITH DISTINCT REGULATION OF BACTERIAL AND VIRAL RECOGNITION PATHWAYS Bisheng Liu, Harry L. Janssen, Andre Boonstra Gastroenterology and Hepatology, Erasmus MS, Rotterdam, Netherlands

#1230

HIGH FREQUENCY OF POLYFUNCTIONAL NATURAL KILLER CELLS IS LINKED WITH STRONG HBV-SPECIFIC T HELPER TYPE 1 IMMUNE RESPONSE AND CONTROL OF HBV REPLICATION

CHROMATIN MODIFICATIONS VIA HISTONE DEACETYLATION REGULATE THE INFLAMMATORY RESPONSE IN LIPOPOLYSACCARIDE (LPS)STIMULATED IMMUNE CELLS FROM PATIENTS WITH ADVANCED CIRRHOSIS

Ivana Carey, Andrea Mendes, Sanjay Bansal, Giorgina Mieli-Vergani, Diego Vergani Institute of Liver Studies, Kings College London School of Medicine at King’s College Hospital, London, United Kingdom

Sonia Gandoura1, Thierry Gustot4,2, Kévin Ragot3, Gérard H. Lizard3, Didier Lebrec1,2, Richard Moreau1,2 1Centre de recherche Biomédicale 3, INSERM U773, Université Paris VII, Denis Diderot, Paris, France. 2Hépatologie, Hôpital Beaujon, Paris, France. 3INSERM U866, Faculté des Sciences Gabriel, Dijon, France. 4Gastroenterology, Erasme Hospital, Brussels, Belgium


#1225

224A

POSTER SESSIONS

#1231

#1236

THE INNATE IMMUNE SYSTEM PLAYS A SIGNIFICANT ROLE IN A MURINE AUTOIMMUNE HEPATITIS MODEL INDUCED BY CONA THROUGH A KEY MOLECULE, MYD88

EFFECTIVE ANTITUMOR IMMUNE RESPONSES OF OK432-STIMULATED MONOCYTE-DERIVED DENDRITIC CELLS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

Keisuke Ojiro, Hirotoshi Ebinuma, Nobuhiro Nakamoto, Kanji Wakabayashi, Hakusyo Cho, Rumiko Umeda, Shingo Usui, Yoshiyuki Yamagishi, Takanori Kanai, Hidetsugu Saito, Toshifumi Hibi Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University, Tokyo, Japan

Masaaki Kitahara, Yasunari Nakamoto, Eishiro Mizukoshi, Shuichi Kaneko Kanazawa University, Kanazawa, Japan

#1232 LIVER SINUSOIDAL ENDOTHELIAL CELLS VETO TH1-CYTOKINE PRODUCTION BY DENDRITIC CELLSTIMULATED CD4 T CELLS DEPENDENT ON IL-10 AND PD-1 Christian Frenzel, Antonella Carambia, Natalie Schunk, Ansgar W. Lohse, Johannes Herkel Department of Medicine I, University Medical Centre HamburgEppendorf, Hamburg, Germany

#1233 A CORRELATIVE INCREASE OF CD4(+)CD25(HIGH)FOXP3(+) REGULATORY T CELL SUBSETS AND PLASMACYTOID DENDRITIC CELLS IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA Yoshiko Takata1, Yasunari Nakamoto1, Akiko Nakada2, Takeshi Terashima1, Eishiro Mizukoshi1, Shuichi Kaneko1 1Gastroenterology, Kanazawa University, Kanazawa-city, Japan. 2Otsuka Pharmaceutical Co.,Ltd., Tokyo, Japan

#1234 COMBINING H&E, MULTIPLEX QUANTUM DOT IMMUNOSTAINING AND WHOLE SLIDE IMAGING FOR LIVER BIOPSY EVALUATION Kumiko Isse, John G. Lunz, Susan Specht, Cara Lyle, Yoshiaki Mizuguchi, Anthony J. Demetris Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

#1235



#1237 BIOLUMINESCENT IMAGING OF CD8 T CELL FUNCTION IN THE LIVER Dirk Stabenow1, Marianne K. Frings1, Christina Trück1, Katja Gärtner1, Margarete Odenthal2, Hans P. Dienes2, Karin Cederbrandt3, Ulrike Protzer4, Percy A. Knolle1 1Institutes for Molecular Medicine and Experimental Immunology, University Hospital Bonn, Bonn, Germany. 2Institute for Pathology, University Hospital Cologne, Cologne, Germany. 3Astra Zeneca, Södertälje, Sweden. 4Institute of Virology, Technische Universität München/ Helmholtz Zentrum München, Munich, Germany

#1238 ROLE OF MULTIPLE REGULATORY T CELL POPULATIONS IN CONTROLLING IMMUNITY TO HEPATITIS C VIRUS INFECTIONS Mark Claassen, Robert J. de Knegt, Harry L. Janssen, Andre Boonstra Laboratory of Gastroenterology and Hepatology, Erasmus MC University Medical Centre Rotterdam, Rotterdam, Netherlands

#1239 DIFFERENTIAL REGULATION OF T AND B LYMPHOCYTES BY PD-1 AND SOCS-1 SIGNALING IN HEPATITIS C VIRUS-ASSOCIATED NONHODGKIN’S LYMPHOMA Zhi Q. Yao1,2, Lei Ni1, Zhi P. Dong1, Chunlan Zhang1, Ashley D. Frazier1, Ying Zhang1, Xiao Y. Wu1, Penny Thayer2, Jonathan P. Moorman1,2 1Division of Infectious Diseases, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA. 2Department of Medicine, James H. Quillen VA Medical Center, Johnson City, TN, USA

FEASIBILITY OF IL-10 PRODUCING REGULATORY TYPE 1 CELLS FOR THE MONITORING OF VIABLE HEPATOCELLULAR CARCINOMA THROUGH LOCAL ABLATION THERAPY

#1240

Naruyasu Kakita1, Tatsuya Kanto1, Ichiyo Itose1, Satomi Takebe1, Michiyo Inoue1, Tokuhiro Matsubara1, Koyo Higashitani1, Masanori Miyazaki1, Hideki Miyatake3, Mitsuru Sakakibara1, Naoki Hiramatsu1, Tetsuo Takehara1, Akinori Kasahara2, Norio Hayashi1 1Department of Gastroenterology and Hepatology, OSAKA univ, Suita, Japan. 2Department of General medicine, Osaka Univ, Suita, Japan. 3Osaka police hospital, osaka, Japan

Mark Claassen, Robert J. de Knegt, Harry L. Janssen, Andre Boonstra Laboratory of Gastroenterology and Hepatology, Erasmus MC University Medical Centre Rotterdam, Rotterdam, Netherlands

HIGH NUMBERS OF INTRAHEPATIC REGULATORY T CELLS IN CHRONIC HCV PATIENTS ARE NEGATIVELY LINKED TO SEVERITY OF DISEASE

#1241 RESTORING HEPATITIS B VIRUS-MEDIATED IMMUNE TOLERANCE BY ADEFOVIR DIPIVOXIL AND ENTECAVIR THERAPY Jiang Yanfang, Jin Qinglong, Yan Hongqing, Niu Junqi Department of hepatology, First hospital, Changchun, China



POSTER SESSIONS

#1242

#1247

PATTERNS OF HCV CD4+ T CELL IMMUNODOMINANCE IN A LARGE COHORT OF SUBJECTS WITH DIFFERENT STAGES AND OUTCOMES OF HCV INFECTION

GUT BACTERIA PROMOTE CONCANAVALIN AINDUCED T CELL MEDIATED HEPATITIS IN MICE

Julian Schulze zur Wiesch1, Lia Lewis-Ximenez2, Laura L. Reyor3, William W. Kwok4, Barbara H. McGovern5, Ansgar W. Lohse1, Raymond Chung3, Todd M. Allen3, Arthur Y. Kim3, Georg M. Lauer3 11. Medizinische Klinik, Universitätsklinikum Eppendorf, Hamburg, Germany. 2Departmento de Virologia, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro, Brazil. 3Massachusetts General Hospital, Boston, MA, USA. 4Benaroya Research Institute, Seattle, WA, USA. 5Lemuel Shattuck Hospital, Tufts University, Boston, MA, USA

#1243 THE ANTI-INFLAMMATORY AND ANTIPROLIFERATIVE PROPERTIES OF THE NFKB1 (P50) GENE PROTECT AGAINST HEPATOCELLULAR CARCINOMA Roben G. Gieling, Vidya Rajasekaran, Diana Jurk, Ahmed M. Elsharkawy, Alastair D. Burt, Fiona Oakley, Derek A. Mann Liver Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

#1244 DISSOCIATION OF LIVER INFLAMMATION AND NECROSIS INDUCED BY HEPATOTOXIN CARBON TETRACHLORIDE IN MYELOID CELL-SPECIFIC STAT3 KNOCKOUT MICE Norio Horiguchi, Fouad Lafdil, Ogyi Park, Hua Wang, Partha Mukhopadhyay, Pal Pacher, Bin Gao NIAAA/NIH, Bethesda, MD, USA

#1245 PHAGOCYTOSIS OF APOPTOTIC CHOLANGIOCYTES BY MACROPHAGES TRIGGERS REVERSAL OF BILIARY FIBROSIS VIA MMP-9 INDUCTION Yury Popov1, Deanna Y. Sverdlov1, Ramakrishnan K. Bhaskar1, Gunda Millonig2,1, Eleonora Patsenker3, Anisha Sharma1, Stephan Krahenbuhl4, Lukas Krahenbuhl5, Detlef Schuppan1 1Gatroenterology, Beth Israel Deaconess, Boston, MA, USA. 2Salem Medical Center, University of Heidelberg, Heidelberg, Germany. 3Institute of Clinical Pharmacology, University of Bern, Bern, Switzerland. 4Dept. of Clinical Pharmacology & Toxicology and Research, University Hospital, Basel, Switzerland. 5Dept. of Surgery, Hôpital Cantonal, Fribourg, Switzerland

#1246

Shan Zeng1, Qing-yin Zhang1, Rosa H Rosario2, Wu Qu2, Ann Marie Schmidt2, Jean C. Emond1 1Division of Liver Diseases and Transplantation,, College of Physicians & Surgeons, Columbia University, New York, NY, USA. 2Division of Surgical Science, Department of Surgery, College of Physicians & Surgeons, Columbia University, New York, NY, USA

Aaron Roberts, Gakuhei Son, Richard J. Milton, Ian N. Hines Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

#1248 SPECIFIC ROLE OF THE INTERLEUKIN-17 IN NEUTROPHIL RECRUITMENT INTO THE LIVER AFTER ISCHEMIA/REPERFUSION Hiroshi Kono, Masahito Ogiku, Naohiro Hosomura, Hideki Fujii First Department of Surgry, University of Yamanashi, Chuo, Japan

#1249 ROLE OF SPINGOSINE KINASE IN MITOCHONDRIAL DYSFUNCTION AND INFLAMMATION AFTER HEPATIC ISCHEMIAREPERFUSION IN MICE Yanjun Shi1, Hasibur Rehman1, Venkat K. Ramshesh1, John J. Lemasters1, Charles D. Smith2,1, Zhi Zhong1 1Medical University of South Carolina, Charleston, SC, USA. 2Apogee Biotechnology Corporation, Hummelstown, PA, USA

#1250 GENETIC DELETION OF INTESTINAL ALKALINE PHOSPHATASE ACTIVATES RESIDENT HEPATIC CELLS AND LEADS TO AN INFLUX OF IMMUNE CELLS WITHIN THE LIVER Klaas Poelstra1,2, Detlef Schuppan1, Yury Popov1, Jose L. Millan4, Madhu S. Malo3, Richard A. Hodin3 1Div. of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 2Dept. of Pharmacokinetics, Toxicology & Targeting, University of Groningen, Groningen, Netherlands. 3Dept.of Surgery, Massachusetts General Hospital, Boston, MA, USA. 4Burnham Institute for Medical Research, La Jolla, CA, USA

#1251 DENDRITIC CELLS PROTECT AGAINST ACUTE ALCOHOLIC LIVER INJURY IN MICE BY MODULATING INFLAMMATION AND CYTOKINE EXPRESSION Costica Aloman1, David A. Sastre1, Jingjing Jiao1, Scott L. Friedman1, Miriam Merad2 1Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA. 2Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY, USA

#1252 MYELOID STAT3 DEFICIENCY EXACERBATES T CELL HEPATITIS VIA PROMOTING PREFERENTIALLY TH1 RESPONSE AND TH17 TO A LESSER EXTENT Fouad Lafdil1, Hua Wang1, Ogyi Park1, Weici Zhang2, Yuki Moritoki2, Shi Yin1, M. Eric Gershwin2, Zhe-Xiong Lian2, Bin Gao1 1Section on liver biology, NIH / NIAAA, Rockville, MD, USA. 2Division of Rheumatology, University of California, Davis, CA, USA


RECEPTOR FOR AGE (RAGE)-DEPENDENT SUPPRESSION OF GLYOXALASE-1 IN MASSIVE HEPATECTOMY

225A

226A

POSTER SESSIONS

#1253

#1258

EARLY GROWTH RESPONSE (EGR)-1 PROMOTES HEPATOPROTECTION AND ATTENUATES PROGRESSIVE LIVER INJURY AFTER ACUTE CARBON TETRACHLORIDE EXPOSURE IN MICE

THE ROLE OF CD147 IN INTRAHEPATIC INFLAMMATORY INJURY

Michele T. Pritchard1, Jessica I. Cohen1,3, Sanjoy Roychowdhury1, Laura E. Nagy1,2 1Pathobiology, Cleveland Clinic, Cleveland, OH, USA. 2Gastroenterology, Cleveland Clinic, Cleveland, OH, USA. 3Nutrition, Case Western Reserve Univsersity, Cleveland, OH, USA

#1254 HEPATIC TUBERCULOSIS-ASSOCIATED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME COMPARED TO ANTIRETROVIRAL NAIVE HIV POSITIVE PATIENTS WITH HEPATIC TUBERCULOSIS Mark W. Sonderup1, Helen Wainwright2, Henry N. Hairwadzi1, C. W. Spearman1 1Division of Hepatology, Department of Medicine, University of Cape Town, Cape Town, South Africa. 2Department of Anatomical Pathology, University of Cape Town, Cape Town, South Africa

#1255 15-DEOXY-∆12,14-PROSTAGLANDIN J2 PREVENTS INFLAMMATORY RESPONSE AND ENDOTHELIAL CELL DAMAGE IN RATS WITH ACUTE OBSTRUCTIVE CHOLANGITIS OBSTRUCTIVE CHOLANGITIS Yukihiro Yokoyama, Katsutaka Watanabe, Toshio Kokuryo, Kiyotaka Kawai, Tomomi Kitagawa, Takashi Seki, Akifumi Nakagawa, Masato Nagino Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

#1256 CLEVER-1 MEDIATES TRANSMIGRATION OF CD4 LYMPHOCYTE SUBSETS ACROSS HEPATIC SINUSOIDAL ENDOTHELIUM Shishir Shetty1, Chris J. Weston1, Ye H. Oo1, Nina Westerlund1, Janine Youster1, Stefan G. Hubscher2, Marko Salmi3, Sirpa T. Jalkanen3, Patricia F. Lalor1, David H. Adams1 1Centre for Liver Research, University of Birmingham, Birmingham, United Kingdom. 2Department of Pathology, University of Birmingham, Birmingham, United Kingdom. 3Medicity Research Laboratory, Turku University, Turku, Finland

#1257 CHARACTERIZATION AND ROLE OF T REGULATORY LYMPHOCYTES IN CHRONIC HEPATITIS C PATHOGENESIS M O N D AY NOVEMBER 1


Nathalie Sturm1,2, Marie-Ange Thelu2, Xavier Camous2, Guéorgui Dimitrov2, Muhammad Ramzan2, Tania Dufeu-Duchesne2, Vincent Leroy2,3, Jean Pierre H. Zarski2,3, Patrice N. Marche2, Evelyne Jouvin-Marche2 1Department of pathology, CHU Albert Michallon, Grenoble, France. 2INSERM/UJF U823, Institut Albert Bonniot, Grenoble, France. 3Department of Hepato-Gastroenterology, CHU Albert Michallon, Grenoble, France


Tina L. Iemma1,2, David Bowen1,2, Sarah Richardson1,2, Bramilla Patkunanathan1, Sue McLennan2, Fiona J. Warner1,2, Nicholas A. Shackel1,2 1Liver Laboratory, Centenary Institute, Sydney, NSW, Australia. 2Medicine, Sydney University, Sydney, NSW, Australia

#1259 BACTERIAL INFECTIONS AND SEPSIS IN CIRRHOTIC PATIENTS INCREASE APOPTOSIS OF CIRCULATING LEUCOCYTES Vincenza Precone, Gianfranca Stornaiuolo, Adelaide Ilario, Salvatore Nardiello, Giovanni B. Gaeta Dept Infectious Dis, Second University, Naples, Italy

#1260 A DEFICIENCY IN ASIALOGLYCOPROTEIN RECEPTOR FUNCTION RENDERS MICE MORE SUSCEPTIBLE TO INFLAMMATORY LIVER INJURY FOLLOWING ANTI-CD3 ANTIBODY INJECTION: A POTENTIAL LINK BETWEEN ALCOHOL AND DYSREGULATED HEPATIC IMMUNE FUNCTION Benita L. McVicker, Dean J. Tuma, Geoffrey M. Thiele, Natalia Osna, Carol A. Casey Internal Medicine, University of Nebraska Medical Center & VAMC, Omaha, NE, USA

#1261 VITAMIN D RECEPTOR GENETIC POLYMORPHISMS AND THE OCCURRENCE OF HEPATOCELLULAR CARCINOMA IN HUMAN LIVER CIRRHOSIS Davide Bitetto1, Ezio Fornasiere1, Elisabetta Fontanini2, Edmondo Falleti2, Annarosa Cussigh2, Elisa Fumolo1, Sara Bignulin1, Sara Cmet2, Carlo Fabris1, Pierluigi Toniutto1, Rosalba Minisini3, Mario Pirisi3 1Medical Liver Transplant Unit, University of Udine, Udine, Italy. 2Laboratory Medicine, University of Udine, Udine, Italy. 3Department of Clinical and Experimental Medicine, University of Eastern Piedmont “A. Avogadro”, Novara, Italy

#1262 EXPRESSION IMBALANCE OF ANGIOPOIETIN/TIE2 SYSTEM IN MONOCYTES AND MONOCYTE DERIVED CELLS FROM CHRONIC HEPATITIS C PATIENTS Yolanda Rodriguez-Muñoz.1, Samuel Martin-Vilchez1, María J. Borque2, Rosario Lopez-Rodriguez1, Angel Hernandez-Bartolome1, Maria Trapero-Marugan1, María Chaparro1, Ricardo MorenoOtero1, Paloma Sanz-Cameno1 1Liver Unit, Hospital Universitario de La Princesa & CIBERehd, ISCIII, Madrid, Spain. 2Molecular Biology Unit, Hospital Universitario de La Princesa, Madrid, Spain


POSTER SESSIONS

227A

#1263

#LB10

INHIBITION OF THE KUPFFER CELLS DETERIORATES AND SPLENECTOMY PREVENTS MORTALITY IN A RAT SEPTIC PERITONITIS MODEL

A NOVEL ENGINEERED FORM OF HEPATOCYTE GROWTH FACTOR, 1K1 PROTECTS HUMAN HEPATOCYTES FROM APOPTOSIS AND PROMOTES PROLIFERATION, AND REVERSES FIBROSIS IN VIVO IN MICE – A PRELUDE TO A PHASE I CLINICAL STUDY

Hiroshi Kono, Masahito Ogiku, Hideki Fujii First Department of Surgry, University of Yamanashi, Chuo, Japan

Late-breaking Posters #LB7 DEVELOPMENT OF ALN-TTR, AN RNAI THERAPEUTIC FOR THE TREATMENT OF TRANSTHYRETIN AMYLOIDOSIS

Jacob Ross1, Ermanno Gherardi2, Noemi Mallorqui2, Myrddin Rees3, Humphrey Julian F. Hodgson1, Clare Selden1 1Centre for Hepatology at the Royal Free, University College Medical School, London, United Kingdom. 2Laboratory of Molecular Biology, Medical Research Council, Cambridge, United Kingdom. 3Department of Surgery, Basingstoke and North Hampshire Hospital NHS Trust, Basingstoke, United Kingdom

Rene Alvarez1, Todd Borland1, Qingmin Chen1, Stuart Milstein1, Tuyen Nguyen1, Greg Hinkle1, Satya Kuchimanchi1, Jason Costigan1, Violeta Ristoiu1, Gang Wang1, Geoffrey Cole1, Robert Dorkin1, Akin Akinc1, Lubomir Nechev1, Verbena Kosovrasti1, Lubomir S. Tchangov1, Mark Tracy1, Christina Gamba-Vitalo1, Lloyd B. Jeffs2, Ian MacLachlan2, Peter Lutwyche2, Tania Ribiero3, Maria Joao Saraiva3, Dinah W. Sah1 1Alnylam Pharmaceuticals, Cambridge, MA, USA. 2Tekmira Pharmaceuticals, Burnaby, BC, Canada. 3Molecular Neurobiology Group, Institute for Molecular and Cell Biology, IBMC, Porto, Portugal

Jennifer Brudno1,3, Rodrigo T. Calado1, Thomas D. Boyer2, Neal S. Young1 1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. 2Department of Medicine, University of Arizona, Tucson, AZ, USA. 3Clinical Research Training Program, NIH-Pfizer, Bethesda, MD, USA

#LB8

#LB12

DEVELOPMENT OF IN VIVO MULTIPHOTON MICROSCOPY FOR IMAGING AND QUANTIFICATION OF HEPATOBILIARY METABOLISM IN NORMAL AND OF ACETAMINOPHEN-TREATED MICE Li1,

Wang1,

Lee1,

Feng Chieh Sheng Shun Yu Yang Hsuan-Shu Lee2,3, Chen Yuan Dong1 1Physics, National Taiwan University, Taipei, Taiwan. 2Biotechnology, National Taiwan University, Taipei, Taiwan. 3Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

#LB9 PHASE II TRIAL OF SORAFENIB COMBINED WITH DOXORUBICIN ELUTING BEAD-TRANSARTERIAL CHEMOEMBOLIZATION (DEB-TACE) FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): INTERIM SAFETY AND EFFICACY ANALYSIS

CONSTITUTIONAL TELOMERASE MUTATIONS CAUSING TELOMERE EROSION ARE GENETIC RISK FACTORS FOR DEVELOPMENT OF CIRRHOSIS

CLEAVAGE OF MAVS IN THE LIVER OF PATIENTS WITH CHRONIC HEPATITIS C CORRELATES WITH A REDUCED ACTIVATION OF THE ENDOGENOUS INTERFERON SYSTEM Pantxika Bellecave3, Magdalena Sarasin-Filipowicz2,1, Olivier Donze4, Audrey Kennel3, Jerome Gouttenoire3, Etienne Meylan5,6, Luigi Terracciano7, Jurg Tschopp5, Christoph Sarrazin8, Thomas Berg9, Darius Moradpour3, Markus H. Heim1,2 1Gastroenterology and Hepatology, University Hospital Basel, Basel, Switzerland. 2Department of Biomedicine, University Basel, Basel, Switzerland. 3Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. 4Apotech Corporation, Epalinges, Switzerland. 5Department of Biochemistry, University of Lausanne, Epalinges, Switzerland. 6Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. 7Pathology Institute, University Basel, Basel, Switzerland. 8Department of Medicine I, J. W. Goethe University Hospital, Frankfurt, Germany. 9Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Charité Campus Virchow-Klinikum, Berlin, Germany

#LB13 RESOLUTION OF HCV CHRONIC HEPATITIS WITH IMMUNOTHERAPY USING HEPATITIS C VIRUS RECOMBINANT VACCINIA VIRUS IN PERSISTENT INFECTION MODEL MICE

L AT E B R E A K I N G POSTERS

Satoshi Sekiguchi1, Yoshimi Tobita1, Tomoko Chiyo1, Kiminori Kimura2, Michinori Kohara1 1Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. 2Liver Unit, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan


Diane K. Reyes1, Nilofer Azad2, Ihab R. Kamel1, Ayman A. Koteish3, James P. Hamilton3, Timothy M. Pawlik4, Michael A. Choti4, Jean-Francois H. Geschwind1 1Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2Medical Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3Hepatology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

#LB11

228A

POSTER SESSIONS

#LB14

#LB17

HEPATITIS C VIRUS (HCV) ANTIBODY SEROCONVERSION IN A U.S. HIV-INFECTED MALE CLINICAL TRIALS POPULATION

ANTIVIRAL ACTIVITY, PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PSI-7851, A NOVEL NUCLEOTIDE POLYMERASE INHIBITOR FOR HCV, FOLLOWING SINGLE AND 3 DAY MULTIPLE ASCENDING ORAL DOSES IN HEALTHY VOLUNTEERS AND PATIENTS WITH CHRONIC HCV INFECTION

Marisa Holubar1, Lynn E. Taylor1, Kunling Wu2, Ronald Bosch2, Kenneth H. Mayer1, Karen T. Tashima1 1Medicine, Brown University, Providence, RI, USA. 2Statistical & Data Analysis Center, Harvard School of Public Health, Boston, MA, USA

#LB15 GI-5005 THERAPEUTIC VACCINE PLUS PEGIFN/RIBAVIRIN IMPROVES END OF TREATMENT RESPONSE AT 48 WEEKS VERSUS PEGIFN/RIBAVIRIN IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS McHutchison2,

Jacobson3,

Boyer4,

John G. Ira M. Thomas D. Eugene R. Schiff5, Gregory T. Everson6, William M. Lee7, Paul Pockros8, Richard M. Chasen9, John M. Vierling10, Eric Lawitz11, Marcelo Kugelmas12,13, Naoky Tsai14, Brian R. Armstrong15, Timothy C. Rodell1, David Apelian1 1Cinical Development and Regulatory Affairs, GlobeImmune, Louisville, CO, USA. 2Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA. 3Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 4University of Arizona, Tucson, AZ, USA. 5Center for Liver Diseases, University of Miami, Miami, FL, USA. 6Department of Medicine, University of Colorado Denver, Aurora, CO, USA. 7Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. 8The Scripps Clinical Research Center, La Jolla, CA, USA. 9Maryland Digestive Disease Research, Laurel, MD, USA. 10Department of Medicine and Surgery, Baylor College of Medicine, Houston, TX, USA. 11Alamo Medical Research, San Antonio, TX, USA. 12South Denver Gastroenterology, PC, Englewood, CO, USA. 13Center for Disease of the Liver and Pancreas, Swedish Medical Center, Englewood, CO, USA. 14University of Hawaii, Honolulu, HI, USA. 15QST Consultations, Allendale, MI, USA

#LB16


VIROLOGICAL RESPONSE AND SAFETY OF BI 201335 PROTEASE INHIBITOR, PEGINTERFERON ALFA 2A AND RIBAVIRIN TREATMENT OF HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGINTERFERON / RIBAVIRIN



Stanislas Pol1, Thomas Berg2, Maurizio Bonacini3, Marcus Schuchmann4, Jay Lalezari5, Andreas Erhardt6, Marc Bourlière7, Michael P. Manns8, Chan L. Yong9, Gerhard Steinmann10, Jerry O. Stern9, Joe Scherer9, Wulf O. Boecher10 1Pôle Médico-Chirurgical Hépatologie, Hôpital Cochin, Paris, France. 2Virchow-Klinikum, Charite, Berlin, Germany. 3CPMC Research Institute, San Francisco, CA, USA. 4Internal Medicine 1, University Hospital, Mainz, Germany. 5Quest Clinical Research, San Francisco, CA, USA. 6Internal Medicine, University Hospital, Duesseldorf, Germany. 7Hopital St. Joseph, Marseilles, France. 8Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 9Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA. 10Department of Clinical Research, Boehringer-Ingelheim GmbH, Biberach an der Riss, Germany


Maribel Rodriguez-Torres1, Eric Lawitz2, Stephen Flach3, Jill M. Denning4, Efsevia Albanis4, William Symonds4, M. M. Berrey4 1Fundación de Investigación de Diego, Santurce, PR, USA. 2Alamo Medical Research, Ltd, San Antonio, TX, USA. 3Covance Clinical Research Unit, Inc., Madison, WI, USA. 4Pharmasset, Inc., Princeton, NJ, USA

#LB18 ANTIVIRAL ACTIVITY, SAFETY AND PHARMACOKINETICS OF IDX184, A LIVERTARGETED NUCLEOTIDE HCV POLYMERASE INHIBITOR, IN PATIENTS WITH CHRONIC HEPATITIS C Jay Lalezari1, David Asmuth2, Arnaldo Casiró3, Hugo E. Vargas4, Gloria Dubuc Patrick5, Wei Liu5, Keith Pietropaolo5, Xiao-Jian Zhou5, John Sullivan-Bólyai5, Douglas L. Mayers5 1Quest Clinical Research, San Francisco, CA, USA. 2Clinical and Translational Science Center-University of California Davis, Sacramento, CA, USA. 3Aclires, Hospital Privado Modelo, Buenos Aires, Argentina. 4Mayo Clinic Arizona, Phoenix, AZ, USA. 5Idenix Pharmaceuticals, Inc., Cambridge, MA, USA

#LB19 A UNIQUE THERAPY FOR HCV INHIBITS MICRORNA-122 IN HUMANS AND RESULTS IN HCV RNA SUPPRESSION IN CHRONICALLY INFECTED CHIMPANZEES: RESULTS FROM PRIMATE AND FIRST-IN-HUMAN STUDIES Elisabeth S. Hildebrandt-Eriksen1, Yu Z. Bagger1, Troels B. Knudsen2, Andreas Petri1, Robert Persson1, Hanne M. Boergesen1, John G. McHutchison3, Arthur A. Levin1 1Santaris Pharma, Hoersholm, Denmark. 2PhaseOne Trials A/S, Hvidovre, Denmark. 3Duke Clinical Research Institute, Durham, NC, USA

#LB20 THE BENEFICIAL EFFECT OF VITAMIN D WITH COMBINED PEG INTERFERON AND RIBAVIRIN FOR CHRONIC HCV INFECTION Saif M. Abu-Mouch1,3, Zvi Fireman2, Jacob Jarchovsky3, Nimer Assy4 1Hepatology, Hillel Yaffe M.C., Hadera, Israel. 2Gastroenterology, Hillel Yaffe M.C., Hadera, Israel. 3Internal Medicine B, Hillel Yaffe M.C., Hadera, Israel. 4Hepatology, Ziv M.C, Safed, Israel


POSTER SESSIONS

229A

#LB21

#1265

HUMAN GENETIC VARIANTS LINKED TO CHRONIC HEPATITIS B ARE ASSOCIATED WITH EXPRESSION OF HLA-DPA1 AND HLA-DPB1

A 35 BASE PAIR (BP) RNA MOTIF IN THE 5’UNTRANSLATED REGION (5’UTR) OF MULTIDRUG RESISTANCE PROTEIN 2 (MRP2; ABCC2) STIMULATES TRANSLATION OF DOWNSTREAM OPEN READING FRAMES (ORFS) AND FUNCTIONS AS AN INTERNAL RIBOSOMAL ENTRY SITE (IRES)

Thomas R. O’Brien1, Ludmila Prokunina-Olsson1, Ruth Pfeiffer1, Dennis L. Maeder1, Indu Kohaar1, Meredith Yeager1,2, Eric Schadt3,4 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. 2NCI Core Genotyping Facility, SAIC-Frederick, Inc., NCI-Frederick,, Gaithersburg, MD, USA. 3Sage Bionetworks, Seattle, WA, USA. 4Pacific Biosciences, Menlo Park, MD, USA

#LB22 MASSIVE INTRAHEPATIC PRODUCTION OF IGM AND IGG ANTIBODIES TO HBCAG, WITH COMPLEMENT DEPOSITION, PROVIDES EVIDENCE FOR A MAJOR ROLE OF HUMORAL IMMUNITY IN THE PATHOGENESIS OF HBV-ASSOCIATED ACUTE LIVER FAILURE Patrizia Farci1, Giacomo Diaz2, Zhaochun Chen1, Sugantha Govindarajan3, Ashley B. Tice1, Liane Agulto1, Stefania Pittaluga4, Denali Boon1, Claro Yu1, Ronald E. Engle1, Mark Haas5, Robert H. Purcell1, Fausto Zamboni6 1Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 2Dipartimento di Scienze e Tecnologie Biomediche, University of Cagliari, Cagliari, Italy. 3Laboratory of Pathology, Rancho Los Amigos Medical Center, University of Southern California, Downey, CA, USA. 4Laboratory of Pathology, Hematopathology Section, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 5Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6Chirurgia Generale e Centro Trapianti, Azienda Ospedaliera G. Brotzu, Cagliari, Italy

#LB23 THE NOVEL IMMUNOREGULATORY ROLE OF CD244 AND ITS INHIBITORY POTENTIAL ON VIRUS-SPECIFIC CD8+ T-CELL FUNCTION IN CHRONIC HEPATITIS B INFECTION Bijan Raziorrouh1, Winfried Schraut1, Norbert Grüner1, Axel Ulsenheimer1, Helmut M. Diepolder1, Maria C. Jung2 1Medical Dep. II, University hospital Munich Grosshadern, Munich, Germany. 2Leberzentrum, Munich, Germany

Tianyong Zhao, Baoxiang Yan, Mary Vore Graduate Center for Toxicology, University of Kentucky, Lexington, KY, USA

#1266 IS BILIRUBIN A PROTECTIVE FACTOR IN OBSTRUCTIVE CHOLESTASIS? Lucie Muchova1, Katerina Vanova1, Martin Lenicek1, Martin Vejrazka2, Hendrik J. Vreman3, Ronald J. Wong3, Libor Vitek1,4 1Institute of Clinical Biochemistry and Laboratory Diagnostics, Charles University in Prague, Prague 2, Czech Republic. 2Department of Medical Chemistry, Charles University, Prague, Czech Republic. 3Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. 4Fourth Department of Internal Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic

#1267 LOCALIZATION, FUNCTION AND REGULATION OF START DOMAIN PROTEIN STARD4 Daniel Rodriguez-Agudo1, Shunlin Ren1, Dalila Marques1, Kaye Redford1, Gregorio Gil2, William M. Pandak1 1Internal Medicine, Virginai Commonwealth University/VA medical Center, Richmond, VA, USA. 2Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA

#1268 CFTR DEFICIENCY PROMOTES DISRUPTION OF THE ENTEROHEPATIC CIRCULATION OF BILE ACIDS VIA GALLBLADDER EMPTYING DEFECT Dominique Debray1, Dominique Rainteau1, Stéphanie Lerondel2, Lydie Humbert1, Véronique D. Barbu1, Claude Wolf1, CharlesHenry Cottart1, Chantal Housset1 1UMR_S 938 & IFR 65, UPMC Univ Paris 06 & Inserm, Paris, France. 2Institut de Transgénose Centre d’Imagerie du Petit Animal, CDTA-CNRS, Orléans, France

Organic Anion Transport, Bilirubin and Bile Acid Metabolism SYNTAXIN 2 ASSOCIATES WITH THE BILE ACID TRANSPORTER BSEP(ABCB11) AND REGULATES ITS APICAL EXPRESSION


Daniel F. Ortiz, Maria M. Bernal_Ayala Physiology, Tufts University, Boston, MA, USA


#1264

230A

POSTER SESSIONS

#1269

#1274

BALB-ABCB4 KNOCKOUT MICE LACKING THE HEPATOBILIARY PHOSPHOLIPID TRANSPORTER AS MODEL OF HEPATIC OSTEODYSTROPHY

HEPATIC OVEREXPRESSION OF ABCB11 ENHANCES DIETARY CHOLESTEROL ABSORPTION YET DECREASES SERUM CHOLESTEROL LEVELS IN MICE

Katrin Hochrath1, Birgit Rathkolb2,3, Kateryna Butuzova2,3, Wolfgang Hans3, Thure Adler3,4, Yu Wang5, Helmut Fuchs3, Valérie Gailus-Durner3, Dirk H. Busch4, Eckhard Wolf2, Martin Hrabé de Angelis3,6, Frank Lammert1 1Department of Medicine II, Saarland University, Homburg, Germany. 2Institute of Molecular Animal Breeding and Biotechnology, LMU Munich, Munich, Germany. 3Institute of Experimental Genetics, Helmholtz Zentrum München - German Research Center for Environmental Health, Munich, Germany. 4Institut für Medizinische Mikrobiologie, Immunologie und Hygiene, TU München, Munich, Germany. 5Institute for Bioinformatics and System Biololgy, Helmholtz Zentrum München - German Research Center for Environmental Health, Munich, Germany. 6Lehrstuhl für Experimentelle Genetik, TU München, Freising-Weihenstephan, Germany

#1270 BILIARY EXCRETION AND CHOLERETIC EFFECT OF 3α, 6α, 7α, 12α-(OH) 4-5β-CHOLYL TAURINE (6αOH-TC): ROLE OF MRP2 AND P-GLYCOPROTEIN Vandana Megaraj1, Takashi Iida2, Mary Vore1 1Graduate Centre for Toxicology, University of Kentucky, Lexington, KY, USA. 2Chemistry, Nihon University, Setagaya, Japan

#1271 DEPENDING UPON MURINE STRAIN, TRANSIENT OR CHRONIC HYPERHOMOCYSTEINEMIA SECONDARY TO PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE (PEMT) ACTIVITY IS AN ESSENTIAL CONCOMITANT OF CHOLESTEROL (CH) GALLSTONE CHOLELITHOGENESIS Ji Zhang1,2, Diane E. Handy3,4, Joseph Loscalzo3,4, Martin C. Carey1,2 1Medicine/Gastroenterology, Brigham and Women’s Hospital, Boston, MA, USA. 2Medicine/Gastroenterology, Harvard Medical School, Boston, MA, USA. 3Medicine/Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA, USA. 4Medicine/Cardiovascular Medicine, Harvard Medical School, Boston, MA, USA

#1272 ESSENTIAL FATTY ACID DEFICIENCY IN MICE IS ASSOCIATED WITH HEPATIC BILE SALT SYNTHESIS AND REDUCED ILEAL FGF15 EXPRESSION



Sabina Lukovac, Leonie Los, Frans Stellaard, Edmond H. Rings, Henkjan J. Verkade Pediatrics, University Medical Center Groningen, Groningen, Netherlands

#1273 MICRORNA REGULATION OF CHOLESTEROL 7αHYDROXYLASE (CYP7A1) GENE EXPRESSION IN HUMAN HEPATOCYTES Tiangang Li, Kwang-Hoon Song, Erika Owsley, John Chiang Department of Integrative Medical Sciences, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH, USA


Anne Henkel, Richard M. Green Northwestern University, Chicago, IL, USA

#1275 DETECTION OF DIFFERENTIAL GENE EXPRESSION IN SREBP RESPONSIVE GENES IN THE LIVER OF LACTATING RATS USING EXON ARRAYS Antony T. Athippozhy1, Liping Huang2, Tianyong Zhao1, Clavia R. Wooton-Kee1, Paiboon Jungsuwadee1, Arnold J. Stromberg2, Mary Vore1 1Graduate Center for Toxicology, University of Kentucky, Lexington, KY, USA. 2Department of Statistics, University of Kentucky, Lexington, KY, USA

#1276 ORAL GLYCOCHOLIC ACID TREATMENT OF PATIENTS WITH BILE ACID AMIDATION DEFECTS IMPROVES GROWTH AND FAT-SOLUBLE VITAMIN ABSORPTION James E. Heubi1, Kenneth D. Setchell2, Philip Rosenthal3, Sohela Shah4, Donna Buckley5, Pinky Jha2, Wujuan Zhang2, Carol Jean Potter7, David Suskind6, Laura N. Bull4 1Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. 2Mass Spectrometry Laboratory, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. 3Liver Center and Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA. 4UCSF Liver Center Laboratory, Department of Medicine, University of California San Francisco, San Francisco, CA, USA. 5General Clinical Research Center, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. 6Pediatrics, University of Washington, Seattle, WA, USA. 7Pediatrics, The Ohio State University, Columbus, OH, USA

#1277 PHOSPHOLIPID CHANGES IN HEPATIC FATTY ACIDS OF HCV ASSOCIATED STEATOHEPATITIS: MAXIMIZING THE VALUE OF LIVER BIOPSIES Lee Hagey, Lindsay Bauman, Fatma Barakat, Deanna L. Oliver, Lita Petcharaporn, Alan F. Hofmann, Tarek Hassanein University of California, San Diego, San Diego, CA, USA

#1278 NITRIC OXIDE-MEDIATED INHIBITION OF TAUROCHOLATE UPTAKE IN HUH-NTCP CELLS Christopher M. Schonhoff, Mohammed S. Anwer Biomedical Sciences, Tufts Cummings School of Veterinary Medicine, North Grafton, MA, USA


POSTER SESSIONS

Stem Cells and Gene Expression #1279 ONCOSTATIN M ABOLISHES EPCAM+ LIVER CANCER STEM CELLS THROUGH HEPATOCYTIC DIFFERENTIATION Taro Yamashita, Masao Honda, Kouki Nio, Shuichi Kaneko Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

#1280 IDENTIFICATION OF HEPATIC STEM CELLS BY MONITORING OF NUCLEOSTEMIN PROMOTER ACTIVITY Haruhiko Shugo1,2, Masako Ohmura1, Kazuhito Naka1, Yasunari Nakamoto2, Shuichi Kaneko2, Atsushi Hirao1 1Cancer Research Institute, Kanazawa University, Kanazawa, Japan. 2Gastroenterology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

#1281 STAGE-SPECIFIC MODULATION OF MIR-145 EXPRESSION DURING DIFFERENTIATION OF HUMAN INDUCED PLURIPOTENTIAL STEM (IPS) CELLS INTO HEPATOCYTES Yong Chen1, Namita Roy-Chowdhury1, Xia Wang1, Chandan Guha2, Jayanta Roy-Chowdhury1 1Albert Einstein College of Med, Bronx, NY, USA. 2Medicine, Genetics, Marion Bessin Liver Research Center, Albert Einstein College of Medicine, New York, NY, USA

#1282 LOSS OF β2SP EXPANDS HEPATIC PROGENITOR CELLS FOLLOWING ACUTE LIVER INJURY Arun Thenappan, Ying Li, Kirti Shetty, Lynt B. Johnson, Lopa Mishra Surgery, Georgetown University, Washington, DC, USA

#1283 POTENTIAL FOR HEPATOGENIC DIFFERENTIATION AND THERAPEUTIC EFFECTS OF PLACENTADERIVED STEM CELLS

#1284 DERIVATION OF HEPATIC PROGENITORS FROM HUMAN EMBRYONIC STEM CELLS Shinichiro Ogawa1,3, Barbara Corneo2, Cristina Nostro1, ValerieGouon Evans2, Farida Sarangi1, Stefan Irion1, Marion Kennedy1, Gordon Keller1 1McEwen centre for regenerative medicine, Toronto, ON, Canada. 2Gene and Cell medicine, Mount Sinai School of Medcine, New York, NY, USA. 3Hepato-Billiary Surgery and Liver Transplant Surgery, Shinshu University, Matsumoto, Japan

#1285 ADIPOSE-DERIVED MESENCHYMAL STEM CELLS EXPRESS LIVER SPECIFIC MARKERS AND EXHIBIT MIGRATION IN INJURED LIVER MODEL SYSTEM Romy Zemel1, Larisa Bachmetov1, Hila Gitman1, Dima Azarov2, Leonid A. Eidelman2, Abraham Amir3, Dean D. Ad-El3, Ran TurKaspa4 1Molecular Hepatology Lab. Felsenstein Medical Research Center, Rabin Medical Center, Tel-Aviv University, Petach-Tikva, Israel. 2Anesthesiology, Rabin Medical Center, Petach-Tikva, Israel. 3Plastic Surgery, Rabin Medical Center, Petach-Tikva, Israel. 4Liver Institute & Medicine D, Rabin Medical Center Tel-Aviv University, Petach-Tikva, Israel

#1286 CHRONIC ELEVATED SYSTEMIC GLUCOCORTICOCOID RESULTS IN WIDESPREAD PANCREATIC-HEPATIC TRANS-DIFFERENTIATION IN VIVO Karen Wallace, Steven A. White, James A. Shaw, Alastair D. Burt, Matthew C. Wright Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom

#1287 THE TRANS-DIFFERENTIATION OF PANCREATIC ACINAR CELLS INTO HEPATOCYTES IS MEDIATED BY A SUPPRESSION OF WNT SIGNALLING ACTIVITY Karen Wallace1, Carylyn J. Marek1,2, Stefan Hoppler2, Matthew C. Wright1 1Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom. 2School of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom

#1288 RECREATING EX-VIVO HUMAN FETAL LIVER PROGENITOR CELL NICHE Yock Young Dan1, Guan Huei Lee1, Hanry Yu2,3, Peng Cheang Wong4, Seng Gee Lim1 1Medicine/Gastroenterology and Hepatology, National University of Singapore. NUHS, Singapore, Singapore. 2Dept of Physiology, National University Singapore, Singapore, Singapore. 3Institute of Bioengineering and Nanotechnology, A*STAR, Singapore, Singapore. 4Obstetrics and Gynecology, National University of Singapore. NUHS, Singapore, Singapore


Gi Jin Kim1, Seong-Gyu Hwang2,3, Jieun Jung1, Ji-Ye Song2, KyungSun Shin4, Min-Jae Lee5, Gwang Il Kim6, Sung Won Kwon7, Won Hee Kim3, Kyu Sung Rim3 1Department of Biomedical Science, CHA University, Seoul, Korea, South. 2Institue for Clinical Research, CHA University, Seongnam, Korea, South. 3Department of Internal Medicine, CHA university Bundang CHA Hospital, Seongnam, Korea, South. 4Chabiotech Co., Ltd, Seoul, Korea, South. 5School of Veterinary Medicine, Kangwon National University, Chuncheon, Korea, South. 6Department of Pathology, CHA university Bundang CHA Hospital, Seongnam, Korea, South. 7Department of Surgery, CHA university Bundang CHA Hospital, Seongnam, Korea, South

231A

232A

POSTER SESSIONS

#1289

#1295

MESENCHYMAL STEM CELL-DERIVED TROPHIC FACTORS ACCELERATE LIVER REGENERATION

HUMAN LIVER PROGENITOR CELL LINES ARE READILY ESTABLISHED FROM NON-TUMOROUS TISSUE ADJACENT TO HEPATOCELLULAR CARCINOMA

Suomi Fouraschen1, Jeroen de Jonge1, Qiuwei Pan2, Geert Kazemier1, Herold J. Metselaar2, Jaap Kwekkeboom2, Hugo W. Tilanus1, Luc J. van der Laan1 1Surgery, Erasmus MC-University medical center Rotterdam, Rotterdam, Netherlands. 2Gastroenterology and Hepatology, Erasmus MC-University Medical center, Rotterdam, Netherlands

#1290 STEM CELLS RESIDE IN HUMAN EXTRAHEPATIC BILE DUCT (HEHB) TISSUE AND CAN GIVE RISE TO HEPATOCYTES, CHOLANGIOCYTES, AND PANCREATIC β-LIKE ISLET CELLS Vincenzo Cardinale1, Yunfang Wang2, Domenico Alvaro1, Lola M. Reid2 1Clinical Medicine, Division of Gastroenterology, Sapienza University of Rome, Rome, Italy. 2University of North Carolina School of Medicine, Chapel Hill, NC, USA

#1291 THE ELECTRON MICROSCOPICAL ANALYSIS FOR CELL LINEAGE OF BONE MARROW CELL DIFFERENTIATION IN CIRRHOSIS MICE Yamamoto1,

Terai1,

Iwamoto1,

Naoki Shuji Takuya Tsuyoshi Ishikawa1, Taro Takami1, Kaoru Omori1, Koichi Uchida1, Takahiro Yamasaki1, Hiroshi Nishina2, Isao Sakaida1 1Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube Yamaguchi, Japan. 2Development and Regenerative Biology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-Ku Tokyo, Japan

#1292 DIFFERENTIATION OF HUMAN ADIPOSE TISSUE STEM CELLS INTO HEPATOCYTES: ROOM FOR IMPROVEMENT James Lue1, Jeffrey S. Glenn2 1Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA. 2Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA, USA

#1293 BONE MARROW MESENCHYMAL STEM CELL STIMULATE HEPATOMA CELLS PROLIFERATION AND AGGRESSIVITY THROUGH AKT PHOSPHORYLATION Chan Xie, Zhi-liang Gao, Yubao Zheng infectious disease department, the third affiliated hospital of Sun Yat-sen University, Guangzhou, China M O N D AY NOVEMBER 1


#1294 ROLE OF BONE-MARROW DERIVED CELLS IN PROGRESSIVE LIVER INJURY AND CARCINOGENESIS Melanie A. Eckersley-Maslin1,2, Sarah Richardson1,2, Rosa Lam1, Fiona J. Warner1,2, Geoffrey W. McCaughan1,2, Nicholas A. Shackel1,2 1Liver Laboratory, Centenary Institute, Sydney, NSW, Australia. 2Medicine, Sydney University, Sydney, NSW, Australia Denotes AASLD Presidential Poster of Distinction

Aibin K. Zhang3, John K. Olynyk1,2, Roslyn M. London3, Frederik K. Schulz3, Philippe Giguère-Simmonds3, Luc Delriviere4, Harsha Chandraratna4, Kathy Hardy3, Shusen Zheng5, George Yeoh3 1School of Medicine & Pharmacology, University of Western Australia, Fremantle, WA, Australia. 2Gastroenterology, Fremantle Hospital, Fremantle, WA, Australia. 3School of Biomedical, Biomolecular & Chemical Sciences, University of Western Australia, Perth, WA, Australia. 4Liver Transplant Unit, Sir Charles Gairdner Hospital, Perth, WA, Australia. 5Hepatobiliary Surgery, University School of Medicine, Hangzhou, China

#1296 ACTIVATION OF CANONICAL WNT SIGNALING PATHWAY PROMOTES PROLIFERATION AND SELFRENEWAL OF RAT HEPATIC OVAL CELL LINE WBF344 IN VITRO Ying Zhang, Fukui Zhang, Bao-En Wang Beijing Friendship Hospital, Beijing, China

#1297 DUAL NATURE OF EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING SYSTEM IN GASTROINTESTINAL CANCER SIDE POPULATION CELLS Takeshi NIshimura1, Toshifumi Azuma2, Akiko Yokoyama2, Hiromi Ochiai2, Hidetsugu Saito1, Toshifumi Hibi1 1Internal Medicine, Division of Gastroenterology, Keio University, School of Medicine, Tokyo, Japan. 2Biochemistry, Tokyo Dental College, Chiba, Japan

#1298 MICRORNA-199A-3P TARGETS MTOR IN HUMAN HEPATOCELLULAR CARCINOMA Francesca Fornari1, Laura Gramantieri1, Maddalena Milazzo1, Daniela Pollutri1, Gian Luca Grazi1, Massimo Negrini2, Luigi Bolondi1 1Clinical Medicine and CRBA, University of Bologna, Bologna, Italy. 2Dipartimento di Medicina Sperimentale e Diagnostica, University of Ferrara, Ferrara, Italy


POSTER SESSIONS

233A

#1299

#1304

S-ADENOSYLMETHIONINE STABILIZES DUALSPECIFICITY MAPK PHOSPHATASE PROTEIN (DUSP1) BY INHIBITING PROTEASOMAL ACTIVITY: IMPLICATION IN THE PATHOGENESIS AND CHEMOPREVENTION OF HEPATOCELLULAR CARCINOMA

SMALL PROTEIN-MEDIATED INHIBITION OF FRIZZLED-7 DISPLAYS ANTITUMOR PROPERTIES IN HEPATOCELLULAR CARCINOMA

Maria Lauda Tomasi1,2, Komal Ramani1, Ainhoa Iglesias-Ara1, Tony W. Li1, Fawzia Bardag-Gorce3, Francesco Feo2, Rosa M. Pascale2, Jose M. Mato4, Shelly C. Lu1 1Medicine, Division of Gastroenterology & Liver, Keck School of Medicine USC, Los Angeles, CA, USA. 2Biomedical Sciences, Division of Experimental Pathology and Oncology, University of Sassari, Sassari, Italy. 3Pathology, Harbor-UCLA Medical Center, Torrance, CA, USA. 4Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), CIC bioGUNE, Derio, Spain

#1300 THE ANTIOXIDANT TRANSCRIPTION FACTOR NFE2-RELATED FACTOR 2 (NRF2) UP-REGULATES EXPRESSION OF THE HUMAN BILE SALT EXPORT PUMP (BSEP) Jittima Weerachayaphorn, Shi-Ying Cai, Carol J. Soroka, James L. Boyer Yale University, New Haven, CT, USA

#1301 ROLE OF APE/REF-1 IN HEPATOCELLULAR CARCINOMA PROGRESSION: A CANDIDATE THERAPEUTIC TARGET? Zhen Yang1,3, Sun Yang1,2, Frank L. Meyskens1,2 1Chao Family Comprehensive Cancer Center, University of California-Irvine, Orange, CA, USA. 2Medicine, University of California-Irvine, Orange, CA, USA. 3GI, Shandong Provincial Hospital, Jinan, China

#1302 INFLAMMATORY AND ONCOGENIC SIGNALING SUPPRESS MIR-29 EXPRESSION IN CHOLANGIOCARCINOMA CELLS Justin L. Mott1, Satoshi Kurita1, Sophie Cazanave1, Nathan Werneburg1, Steven F. Bronk1, Martin E. Fernandez-Zapico2, Gregory Gores1 1Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA. 2Oncology, Mayo Clinic, Rochester, MN, USA

#1303

Qiuwei Pan1, Hugo W. Tilanus2, Harry L. Janssen1, Luc J. van der Laan2 1Gastroenterology & Hepatology, Erasmus MC-University Medical Center, Rotterdam, Netherlands. 2Surgery, Erasmus MC-University Medical Center, Rotterdam, Netherlands

#1305 LOSS OF β2SP DELAYS HEPATOCYTE PROLIFERATION FOLLOWING PARTIAL HEPATECTOMY Arun Thenappan, Ying Li, Kirti Shetty, Lynt Johnson, Lopa Mishra Surgery, Georgetown University, Washington, DC, USA

#1306 SPRR2A INDUCES EPITHELIAL-MESENCHYMAL TRANSFORMATION (EMT) THROUGH DEPRESSION OF MIR-200C/141 TRANSCRIPTION Yoshiaki Mizuguchi1,2, Susan Specht1,2, John G. Lunz1,2, Kumiko Isse1,2, Anthony J. Demetris1,2 1Pathology, University of Pittsburgh, Pittsburgh, PA, USA. 2Thomas E. Starzl Transplantation Institute, Pittsburgh, PA, USA

#1307 A NOVEL TRANSFER FACTOR SPECIFIC TO FEMALE CELLS MAY BE INVOLVED IN THE SEXUAL DIFFERENCE IN THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN HCV-INFECTED PATIENTS THROUGH OSTEOPONTIN EXPRESSION IN THE LIVER Kazuhiro Hamaoka1, Sumiko Nagoshi1, Kayoko Sugawara1, Mie Inao1, Kayoko Naiki1, Nobuaki Nakayama1, Kenji Fujiwara2, Satoshi Mochida1 1Department of Gastroenterology and Hepatology, Saitama Medical University, Moroyama-Machi, Japan. 2Yokohama Rosai Hospital for Labor Welfare Corporation, Yokohama, Japan

#1308 DELTANP73 CONFERS CHEMORESISTANCE IN HEPATOCELLULAR CARCINOMA BY BLOCKING APOPTOSIS SIGNALING VIA DEATH RECEPTORS AND MITOCHONDRIA André Schuster1, Niels Steinebrunner1, Catharina Sandig1, Andreas F. Koch1, Peter H. Krammer2, Wolfgang Stremmel1, Martina Müller1 1Innere Med. IV, Universität Heidelberg, Heidelberg, Germany. 2Tumor Immunology, DKFZ, Heidelberg, Germany


CELL-TO-CELL TRANSMISSION OF SMALL RNA BETWEEN HEPATOCYTES EXTENDS THE REACH OF RNA INTERFERENCE-BASED THERAPY FOR HEPATITIS C

Sarah Beseme1, Xavier Sainsily1, Lydie Lefrancois1, Miran Kim2, Jack R. Wands2, Naoki Fujii4, Pierre Jalinot3, Christian Trepo1, Ludmila Vitvitski1, Fabien Zoulim1, Philippe Merle1 1871, INSERM, Lyon, France. 2Medicine and pathology, The Liver Research Center, PROVIDENCE, RI, USA. 3UMR 5665, Laboratoire de Biologie Moléculaire de la Cellule, LYON, France. 4Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital, MEMPHIS, TN, USA

234A

POSTER SESSIONS

#1309

#1313

POLO-LIKE KINASE 1, A NEW GENE TARGET IN HEPATOCELLULAR CARCINOMA

THE ROLES OF FOXP3 IN THE IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT OF HEPATOCELLULAR CARCINOMA

Seng Gee Lim1, Wei Chuen Mok2, May Chin, Theresa Tan3, Shanthi Wasser4 1Department of Gastroenterology & Hepatology, National University Health System, Singapore, Singapore. 2Agency for Science, Technology and Research, Singapore, Singapore. 3Department of Biochemistry, National University of Singapore, Singapore, Singapore. 4Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore

#1310 LET-7 FAMILY NEGATIVELY REGULATES BCL-XL EXPRESSION AND INDUCES APOPTOSIS IN COOPERATION WITH SORAFENIB IN HUMAN HEPATOCELLULAR CARCINOMA Satoshi Shimizu, Tetsuo Takehara, Takahiro Kodama, Hayato Hikita, Masashi Yamamoto, Akira Sasakawa, Keisuke Kohga, Akio Uemura, Ryotaro Sakamori, Takuya Miyagi, Atsushi Hosui, Hisashi Ishida, Tomohide Tatsumi, Naoki Hiramatsu, Tatsuya Kanto, Norio Hayashi Department of Gastroenterology and hepatology, Osaka University graduate school of medicine, Suita, Osaka, Japan

#1311 IN VIVO MOLECULAR IMAGING FOR TRANSGENIC EXPRESSION AND ANTITUMOR EFFECT IN A MOUSE HEPATOMA MODEL BY ADENOVIRUS HARBORING CANCER-TARGETING TRANS-SPLICING RIBOZYME AND LIVER SELECTIVE PROMOTER Jin-Sook Jeong1, Sang Young Han2, Seung-Wook Lee3, In-Hoo Kim4 1Pathlogy and Medical Research Center for Cancer Molecular Therapy, Dong-A University College of Medicine, Busan, Korea, South. 2Internal Medicine, Dong-A University College of Medicine, Busan, Korea, South. 3Molecular Biology and Institute of Nanosensor and Biotechnology, Dankook University, Juk Jeon, Geung-gi, Korea, South. 44)Molecular Imaging and Therapy Branch, Research Institute and Hospital, National Cancer Center, Go Yang, Geung-gi, Korea, South

#1312 HEME INDUCES DEGRADATION OF 5AMINOLEVULINIC ACID SYNTHASE-1 (ALAS1) PROTEIN IN MITOCHONDRIA OF HUMAN LIVER CELLS



Qing Tian1, Weihong Hou1,2, Ting Li1, Jianyu Zheng1, Herbert L. Bonkovsky1,2 1Cannon Research Center, Carolinas Medical Center, Charlotte, NC, USA. 2The Liver-Biliary-Pancreatic Center and the Liver, Digestive, and Metabolic Disorders Laboratory, Carolinas Medical Center, Charlotte, NC, USA


Heng-Hui Zhang1, Li Wang2,1, Xing-Wang Xie1, Hao Luo1, Yan-Hui Chen1, Ran Fei1, Xue-Yan Wang1, Ming-Hui Mei2, Lai Wei1, HongSong Chen1 1Peking University People’s Hospital,, Peking University Hepatology Institute, Beijing, China. 2Guilin Medicial University, Guilin, China

#1314 SINGLE-STRANDED OLIGONUCLEOTIDE CORRECTION OF THE ORNITHINE TRANSCARBAMYLASE POINT MUTATION IN NEONATAL SPF/ASH MICE Betsy T. Kren, Phillip Y. Wong, Clifford J. Steer Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA

#1315 MICRORNA-20A ENHANCES REPLICATION OF HEPATITIS B VIRUS Jin-Wook Kim, Hyeong-June Myeong, Hee-Seop Kim, Je-Hyeok Jang, Sang Hyub Lee, Sook-Hyang Jeong Internal medicine, Seoul National University Bundang Hospital, Seongnam, Korea, South

#1316 WNT PATHWAY ACTIVATION IN HEPATOCELLULAR CARCINOMA - IDENTIFICATION OF THE WNT COACTIVATOR PYGO2 AS A CANDIDATE ONCOGENE Radoslav Savic1, Philippa Newell1, Augusto Villanueva2, Sara Toffanin1,4, Yujin Hoshida3, Derek Y. Chiang3, Laia Cabellos1, Beatriz Minguez1, Anja Lachenmayer1, Helena Cornella2, Victoria Tovar2, Clara Alsinet2, Judit Peix2, Swan N. Thung1, Sasan Roayaie1, Myron E. Schwartz1, Jordi Bruix2, Vincenzo Mazzaferro4, Scott L. Friedman1, Josep M. Llovet1,2 1Mount Sinai Liver Cancer Program - Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA. 2HCC Translational Research Lab, BCLC, Liver Unit, CIBERehd, Hospital Clínic, Barcelona, Spain. 3Cancer Program, The Broad Institute of Harvard and MIT, Cambridge, MA, USA. 4Gastrointestinal Surgery and Liver Transplantation Unit, National Cancer Institute, Milan, Italy

#1317 AUTOPHAGY ACTIVATION IN STARVATION PROMOTES CELL SURVIVAL IN HEPATOCELLULAR CARCINOMA Ying-Hong Shi1, Jian Zhou1, Shuang-Jian Qiu1, Xiao-Ming Yin2, Jia Fan1 1Liver Cancer Institute, Zhongshan Hospital, Shanghai, China. 2Department of Pathology, Pittsburgh, PA, USA


POSTER SESSIONS

235A

#1318

#1324

TARGETED NANOCAPSULES FOR HEPATIC CELLTYPE AND TUMOR-SPECIFIC IN VIVO DELIVERY OF PLASMIDS OR DRUGS

NOTCH SIGNALING PATHWAY REGULATES P57KIP2 EXPRESSION IN HUMAN HEPATOCELLULAR CARCINOMA

Betsy T. Kren1, Vicci L. Korman2, Diane Tobolt2, Gretchen M. Unger2 1Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA. 2GeneSegues, Inc., Chaska, MN, USA

Manuela Minguzzi1, Catia Giovannini1,2, Francesca Fornari1,2, Laura Gramantieri1, Pasquale Chieco1, Luigi Bolondi1,2 1Center for Applied Biomedical Research, S.Orsola- Malpighi University Hospital, Bologna, Italy. 2Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy

#1319 IDENTIFICATION OF MIRNA EXPRESSION PROFILES DIFFERENTIATING HEPATITIS C GENOTYPE 1 AND 3 LIVER INJURY

#1325

William M. d’Avigdor2, Michael Stapelberg2, Geoffrey W. McCaughan1,2, Maggie Y. Lee2, Fiona J. Warner2, Nicholas A. Shackel1,2 1A. W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia. 2Liver Laboratory, Centenary Institute, Sydney, NSW, Australia

Jaime Chu1, Chinweike Ukomadu2, Kirsten C. Sadler3,4 1Pediatrics, Mount Sinai School of Medicine, New York, NY, USA. 2Medicine, Brigham and Women’s Hospital, Boston, MA, USA. 3Medicine, Mount Sinai School of Medicine, New York, NY, USA. 4Developmental and Regenerative Biology, Mount Sinai School of Medicine, New York, NY, USA

#1320

#1326

HUR MEDIATES RNA DESTABILIZING PROPERTIES OF THE 3’UNTRANSLATED REGION OF THE RAT APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER

ZEBRAFISH HOMOLOGUE OF MAID (ZHM) IS MARKER PROTEIN OF ZEBRAFISH LIVER TUMORS INDUCED BY DEN

UHRF1 PHOSPHORYLATION IS IMPORTANT FOR LIVER DEVELOPMENT IN ZEBRAFISH

Frank Chen, Benjamin L. Shneider Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital Pittsburgh, Pittsburgh, PA, USA

Koichi Fujisawa, Shuji Terai, Toshihiko Matsumoto, Shinya Kuwashiro, Issei Saeki, Taro Takami, Naoki Yamamoto, Isao Sakaida Gastroenterology and Hepatology, Yamaguchi univ., Ube, Japan

#1321

#1327

ANALYSES OF THE ANTIANGIOGENETIC AND ANTITUMOR EFFECTS OF INTERFERONS

UHRF1 IS UPREGULATED IN HEPATOCELLULAR CARCINOMA AND REGULATES THE EXPRESSION OF INTERFERON GENES

Hirayuki Enomoto1, Tohru Tsujimura2, Hideji Nakamura1, Hiroyasu Imanishi1, Masaki Saito1, Teruhisa Yamamoto1, Yoshinori Iwata1, Hironori Tanaka1, Soji Shimomura1, Hiroko Iijima1, Shuhei Nishiguchi1 1Division of Hepatobiliary and Pancreatic Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan. 2Division of Molecular Pathology, Hyogo College of Medicine, Nishinomiya, Japan

Raksha Mudbhary1, Augusto Villanueva2, Katy N. Krahn1, Josep M. Llovet1,2, Kirsten C. Sadler1 1Division of Liver Diseases/Dept. of Medicine; Department of Developmental and Regenerative Biology, Mount Sinai School of Medicine, NY, NY, USA. 2HCC Translational Research Laboratory BCLC Group, CIBERehd, IDIBAPS, Liver Unit, Hospital Clinic of Barcelona, Barcelona, Spain

#1322 MCL-1 IS A RELEVANT P53 FAMILY TARGET GENE IN HEPATOCELLULAR CARCINOMA Agnes Pelc1, Heiko M. Mundt1, Andreas F. Koch1, Katja Lorenz1, Henning Schulze-Bergkamen2, Wolfgang Stremmel1, Martina Müller1 1Innere Med. IV, Universität Heidelberg, Heidelberg, Germany. 2NCT, Universität Heidelberg, Heidelberg, Germany

GENE EXPRESSION PROFILES IN REGENERATING RAT LIVERS TREATED WITH SHRNA TARGETING CMET AND EGFR Shirish Paranjpe, William C. Bowen, George K. Michalopoulos Pathology, University of Pittsburgh, Pittsburgh, PA, USA

#1328 CHRONIC HEPATITIS B REACTIVATION IN CANCER PATIENTS RECEIVING CHEMOTHERAPEUTIC AGENTS: THE CASE FOR SCREENING Robin Mendelsohn1, Satish Nagula1, Kent Sepkowitz2, Andrew D. Zelenetz3, Mini Kamboj2, Emmy Ludwig1 1Gastroenterology and Nutrition Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 2Infectious Disease Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 3Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA


#1323

Viral Hepatitis: Co-morbidities

236A

POSTER SESSIONS

#1329 PSYCHIATRIC SIDE EFFECTS TO INTERFERONα/RIBAVIRIN ARE ASSOCIATED WITH DISTINCT ISG20 AND FNBP-1 EXPRESSION PROFILES IN THERAPEUTIC RESPONDERS (SVR) AND NONRESPONDERS (NR) IN HIV AND HCV COINFECTION Antonios Katsounas1, Joseph J. Rasimas2, Richard A. Lempicki1, Jun Yang1, Shyam Kottilil3 1NCI-Frederick, SAIC, Bethesda, MD, USA. 2NIMH/NIH, Bethesda, MD, USA. 3LIR, NIAID/NIH, Bethesda, MD, USA

#1330 LOW VITAMIN D SERUM LEVEL IS RELATED TO SEVERE FIBROSIS AND LOW RESPONSIVENESS TO IFN-BASED THERAPY IN GENOTYPE 1 CHRONIC HEPATITIS C Salvatore Petta1, Calogero Cammà1, Concetta Scazzone2, Claudio Tripodo3, Vito Di Marco1, Antonino Bono2, Daniela Cabibi3, Giusalba Licata1, Rossana Porcasi3, Giulio Marchesini4, Antonio Craxi1 1Cattedra ed Unità Operativa di Gastroenterologia, DiBiMIS, University of Palermo, Italy, Palermo, Italy. 2Dipartimento di Biotecnologie Mediche e Medicina Legale, Palermo, Italy. 3Cattedra di Anatomia Patologica, University of Palermo, Italy, Palermo, Italy. 4Dipartimento di Medicina e Gastroenterologia, “Alma Mater Studiorum,” University of Bologna, Italy., Bologna, Italy

#1331 INSULIN SENSITIVITY AND VARIABILITY OVERTIME IN PATIENTS WITH HEPATITIS C VIRUS (HCV) INFECTION USING DIRECT MEASUREMENTS: IMPACT OF HOST AND VIRAL FACTORS Mandana Khalili1,3, Fahim Abbasi2, Claudia Ayala1,3, Gerald M. Reaven2, Jacquelyn J. Maher1,3 1University of California San Francisco, San Francisco, CA, USA. 2Stanford School of Medicine, Palo Alto, CA, USA. 3San Francisco General Hospital, San Francisco, CA, USA

#1332


CHARACTERISTICS OF HBV-HIV INFECTED PATIENTS WITH PERSISTENT HBV REPLICATION: A MULTICENTER NATIONWIDE STUDY (MULTIVIRVHB) Vincent Thibault1, Catherine Gaudy2, Philippe Colson3, Joel Gozlan4, Nathalie Schnepf5, Pascale Trimoulet6, Coralie Pallier7, Karine Saune8, Michel Branger9, Marianne Coste-Burel10, Patrick Soussan11, Francoise Roudot-Thoraval12 1Virology - CERVI, Pitie-Salpetriere Hospital, Paris cedex 13, France. 2Virology, Hopital Tours, Tours, France. 3Virology, Hopital Marseille, Marseille, France. 4Virology, Hopital Saint Antoine, Paris, France. 5Virology, Hopital Lariboisiere, Paris, France. 6Virology, CHU Pellegrin, Bordeaux, France. 7Virology, CHU Bicetre, Kremlin Bicetre, France. 8Virology, CHU Toulouse, Toulouse, France. 9Virology, Hopital Bichat, Paris, France. 10Virology, CHU Nantes, Nantes, France. 11Virology, Hopital Tenon, Paris, France. 12Public Health, Hopital H Mondor, Creteil, France



#1333 OUTCOMES FOLLOWING RENAL TRANSPLANTATION IN PATIENTS WITH CHRONIC HEPATITIS C BASED ON SEVERITY OF FIBROSIS ON PRE TRANSPLANT LIVER BIOPSY Nader Dbouk, Samir Parekh Division of Digestive Diseases, Emory University, Atlanta, GA, USA

#1334 HEPATIC STEATOSIS IS ASSOCIATED WITH SEVERE FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B Salvatore Petta1, Vito Di Marco1, Calogero Cammà1, Fabio Salvatore Macaluso1, Marcello Maida1, Daniela Cabibi2, Sabrina Ingrao2, Giuseppe Pizzolanti3, Antonio Craxi1 1Cattedra ed Unità Operativa di Gastroenterologia, DiBiMIS, University of Palermo, Italy, Palermo, Italy. 2Cattedra di Anatomia Patologica, University of Palermo, Italy, Palermo, Italy. 3Cattedra ed Unità Operativa di Endocrinologia, University of Palermo, Italy, Palermo, Italy

#1335 SUSTAINED VIROLOGICAL RESPONSE FOLLOWING CHRONIC HEPATITIS C TREATMENT IMPROVES INSULIN RESISTANCE Calvin H. Chan1, Ross D. Hansen2, Brett E. Jones1 & Hepatology, Royal North Shore Hospital, Sydney, NSW, Australia. 2Gastrointestinal Investigation Unit, Royal North Shore Hospital, Sydney, NSW, Australia

1Gastroenterology

#1336 HEPATITIS C CO-INFECTION SENSITIZES CD4+ T CELLS TOWARDS FAS-INDUCED APOPTOSIS IN VIREMIC HIV-POSITIVE PATIENTS Christian Koerner, Felix Tolksdorf, Daniela Schulte, Benjamin Krämer, Martin Coenen, Hans Dieter Nischalke, Tilman Sauerbruch, Jacob Nattermann, Jürgen K. Rockstroh, Ulrich Spengler Internal Medicine I, University of Bonn, Bonn, Germany

#1337 FACTORS ASSOCIATED WITH IMPAIRMENT OF INSULIN SECRETION IN HCV INFECTION: IMPACT OF LATINO ETHNICITY Sun H. Kim2, Claudia Ayala1,3, Jacquelyn J. Maher1,3, Mandana Khalili1,3 1University of California San Francisco, San Francisco, CA, USA. 2Stanford School of Medicine, Palo Alto, CA, USA. 3San Francisco General Hospital, San Francisco, CA, USA

#1338 HOSPITALIZATION TRENDS FOR HIV POSITIVE PATIENTS COINFECTED WITH HEPATITIS B (HBV) OR HEPATITIS C VIRUS (HCV): A POPULATIONBASED STUDY FROM 1993 TO 2005 Carla S. Coffin, Abdel Aziz M. Shaheen, Gilaad G. Kaplan, Robert P. Myers University of Calgary Liver Unit, Division of Gastroenterology, University of Calgary, Calgary, AB, Canada


POSTER SESSIONS

237A

#1339

#1345

CHANGES IN HBV MOLECULAR EPIDEMIOLOGY IN ACUTE HEPATITIS B IN NEAPOLITAN AREA: A CONSEQUENCE OF HBV MASS VACCINATION AND INCREASED IMMIGRATION

CHANGES IN PLASMA BLYS LEVELS IN PATIENTS WITH HCV MIXED CRYOGLOBULINEMIC VASCULITIS DURING TREATMENT WITH RITUXIMAB

Nicola Coppola1, Addolorata Masiello1, Gilda Tonziello1, Raffaella Pisapia1, Mariantonietta Pisaturo1, Caterina Sagnelli1, Vincenzo Messina2, Valentina Iodice1, Evangelista Sagnelli1 1Medicina Pubblica Clinica e Preventiva, Second University of Naples, Naples, Italy. 2Malattie Infettive, A.O.R.N. S. Sebastiano e S. Anna, Caserta, Italy

Shyam Kottilil1, Thi Migone3, Koneti Rao2, Mani Subramanian3, Michael Sneller1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2LCID, NIAID/NIH, Bethesda, MD, USA. 3Human Genome Sciences, Rockville, MD, USA

#1340

COMBINATION OF RIBAVIRIN INCREASES THE RISK OF SEVERE DEPRESSION IN CHRONIC HEPATITIS C PATIENTS VERSUS CHRONIC HEPATITIS B PATIENTS TREATED WITH INTERFERON

HCV INFECTION IS ASSOCIATED WITH HIGH COMORBIDITY BURDEN IN EUROPE Huabin F. Zhang1, Douglas Mills2, Samuel Wagner2, Deborah Freedman2 1Worldwide Health Economics and Pricing, Johnson & Johnson Pharmaceutical Services, Raritan, NJ, USA. 2Consumer Health Sciences, Princeton, NJ, USA

#1341 QUALITY OF CARE OF CHRONIC HEPATITIS B VIRUS IN A MANAGED CARE SETTING Theodore Sy2, Jennifer L. Nguyen1, Amandeep K. Sahota2 Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA. 2Gastroenterology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA

1Internal

#1342

#1346

Yi-Wen Huang1,2, Rui-Ting Hu1,3, Tzung-Yi Tsai4, Ching-Jui Chang5, Ding-Shinn Chen2,6, Jia-Horng Kao2,7, Sien-Sing Yang1,3 1Liver Unit, Cathay General Hospital Medical Center, Taipei, Taiwan. 2Division of Gastroenterology, Department of Internal Medicine, National Taiwan University College of Medicine and Hospital, Taipei, Taiwan. 3School of Medicine, Fu-Jen Catholic University College of Medicine, Taipei, Taiwan. 4Department of Nursing, Cathay General Hospital Medical Center, Taipei, Taiwan. 5Department of Psychiatry, Cathay General Hospital Medical Center, Taipei, Taiwan. 6Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. 7Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

WHOLE GENOME TRANSCRIPTIONAL PROFILING IN PBMC ILLUSTRATES UNIQUE PATHOGENIC CHARACTERISTICS OF B CELL DEPLETION THERAPY IN HCV MIXED CRYOGLOBULINEMIC VASCULITIS

#1347

Shyam Kottilil1, Xiaozhen Zhang1, Jun Yang2, Richard A. Lempicki2, Michael Sneller1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2SAIC-Frederick, Frederick, MD, USA

#1348

#1343

Thomas Sersté1,2, Marcel Nkuize1, Marc van Gossum1, Marijke Reynders3, Robert Scheen3, Jean-Pierre Mulkay1 1Hepato Gastroenterology, UMC SAINT PIERRE, Brussels, Belgium. 2Hepatology, Beaujon AP-HP, Clichy, France. 3Microbiology, UMC Saint Pierre, Brussels, Belgium

EFFECT OF HIV ON LEVELS OF SERUM MARKERS OF LIVER INFLAMMATION AND FIBROSIS IN HEPATITIS C VIRUS CO-INFECTION Marina Nunez, Abbie Beltz, Kevin High Infectious Diseases, Wake Forest University Health Sciences, Winston Salem, NC, USA

#1344

Jeffrey Karsdon1, William M. Huang2, Li-Jun Mi3 1Neonatology, Department of Pediatrics, New York Downtown Hospital, New York, NY, USA. 2Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, New York Downtown Hospital, New York, NY, USA. 3Out-Patient Division, Department of Medicine, New York Downtown Hospital, New York, NY, USA

METABOLIC DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS C: IMPACT OF GENOTYPE AND ETHNICITY

#1349 MODIFICATIONS OF T-LYMPHOCYTE SUBSETS BY PEGIFN+RBV IN HIV-HCV COINFECTED PATIENTS WITH OR WITHOUT CONCOMITANT HAART Thomas Reiberger1, Lana M. Kosi1, Wolfgang Sieghart1, Peter Heil2, Armin Rieger2, Markus Peck-Radosavljevic1 1Gastroenterology & Hepatology, Medical University of Vienna, Vienna, Austria. 2Dermatology, Div. of Immunodermatology & Infectious Diseases, Medical University of Vienna, Vienna, Austria


MOTHERS WITH CHRONIC HEPATITIS B (CHB) MAY HAVE AN INCREASED RATE OF LATE PRETERM DELIVERIES

WITHDRAWN

238A

POSTER SESSIONS

#1350

#1354

ANTIVIRAL THERAPY WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN NON-PERMANENTLY INCREASES BONE MINERAL DENSITY IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C

RISK FACTORS ASSOCIATED WITH DEVELOPMENT OF ACUTE RENAL FAILURE IN NON-FULMINANT ACUTE HEPATITIS A

Dietmar M. Klass1, Jochen Klaus1, Oguzhan Gülsahin1, Christoph Hartmann1, Guido Adler1, Michael Fuchs2 1Dept. of Internal Medicine I, University Hospital Ulm, Ulm, Germany. 2Hepatology Section, Division of Gastroenterology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA

#1351 DOES ILLICIT DRUG USE AGGRAVATE LIVER DISEASE IN HIV/HCV INFECTION? Janet E. Forrester1, Martin S. Rhee3, Kyung-Jin Yeum2, Jeffrey B. Blumberg2, Tamsin A. Knox1 1Public Health & Family Medicine, Tufts University School of Medicine, Boston, MA, USA. 2Jean Meyer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA. 3Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, USA

#1352 MICROALBUMINURIA IN HEPATITIS C GENOTYPE 4: RELATION TO LIVER HISTOLOGY, VIRAL LOAD, AND EFFECT OF TREATMENT Moutaz F. Derbala5,6, Fatma M. Shebl1,7, Awad H. Rashid2, Aliaa M. Amer3, Abdulbari Bener4 1Division of Cancer Epidemiology and Genetics, Infections & Immunoepidemiology Branc, National Cancer Institute,, Rockville, MD, USA. 2Department of Nephrology, Hamad Medical Corporation, Doha, Qatar. 3Department of Laboratory Medicine and Histopathology,Hematology Section, Hamad Medical Corporation, Doha, Qatar. 4Deptrtment of Medical Statistics and Epidemiolog, Hamad Medical Corporation, Doha, Qatar. 5Department of Gastroenterology and Hepatology, Hamad Medical Corporation, Doha, Qatar. 6Medicine, Weill Cornell Medical College in Qatar,, Doha, Qatar. 7Epidemiology department, Natioal Liver Institute, Menoufia, Egypt

#1353 HEPATITIS B PREVALENCE AND FLARE IN ASIAN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH DISEASE MODIFYING ANTI-RHEUMATIC DRUG (DMARD) THERAPY – SHOULD ALL HIGH RISK PATIENTS BE TESTED FOR HBV PRIOR TO DMARD THERAPY?



Owen Bebb, Victoria J. Appleby, Paul Southern, Philip Helliwell, Sulleman Moreea Bradford Royal Infirmary, Bradford, United Kingdom


Jong Kyu Park1, Sang Gyune Kim1, Young Seok Kim1, Jae Young Jang2, Soung Won Jeong2, Sae Hwan Lee2, Jong Ho Moon1, Hong Soo Kim3, Moon Sung Lee1, Boo Sung Kim1 1Soon Chun Hyang University Hospital, Bucheon, Korea, South. 2Soon Chun Hyang University Hospital, Seoul, Korea, South. 3Soon Chun Hyang University Hospital, Cheonan, Korea, South

#1355 PREVALENCE OF HCV-POSITIVE STATUS AND GENOTYPE IN B-CELL NON HODGKIN’S LYMPHOMA PATIENTS IN A POPULATION FROM CENTRAL ITALY Adriano M. Pellicelli1, Valerio Zoli2, Daniele Remotti3, Mario Romano4, Massimo Marignani5, Giorgio -. Barbarini6, Lorenzo Nosotti7, Ettore Mazzoni8, Antonio Picardi9, Umberto Vespasiani Gentilucci9, Amerigo Paffetti10, Caterina Furlan10, Fabrizio Mecenate12, Angelo Barlattani11, Fabrizio Soccorsi1, Arnaldo Andreoli1 1Liver Unit, San Camillo Forlanini Hospital, Rome, Italy. 2Hematology, San Camillo Forlanini Hospital, Rome, Italy. 3Histology, San Camillo Forlanini Hospital, Rome, Italy. 4Liver Unit, Sandro Pertini Hospital, Rome, Italy. 5Digestive and Liver Disease, Azienda Ospedaliera Sant’Andrea, Rome, Italy. 6Infectious and Parasitic Diseases, Policlinico San Matteo, Pavia, Italy. 7Medicine of Migration, National Institute for Migrant Health and Poverty, Rome, Italy. 8Liver Unit, Policlinico Casilino Hospital, Rome, Italy. 9Clinical Medicine, Campus Bio-Medico University, Rome, Italy. 10Infectious and Tropical Diseases, University “La Sapienza, Rome, Italy. 11Liver Unit, ASLRMA, Rome, Italy. 12Liver Unit, Villa Betania Hospital, Rome, Italy

#1356 THE BURDEN OF DELTA HEPATITIS PROJECTED USING A MATHEMATICAL MODEL IN A DELTA HEPATITIS ENDEMIC COUNTRY Mehlika Toy1,2, Fatih Oguz Onder3, Ramazan Idilman4, Hakan Bozkaya4, Halil Degertekin5, Kendal Yalcin6, Solko W. Schalm2,7, Cihan Yurdaydin4 1Public Health, Erasmus Medical Center, Rotterdam, Netherlands. 2LiverDoc, Rotterdam, Netherlands. 3Department of Gastroenterology, Yuksek Ihtisas Hospital, Ankara, Turkey. 4Department of Gastroenterology, School of Medicine, Ankara, Turkey. 5Department of Gastroenterology and Hepatology, Ufuk University Medical School, Ankara, Turkey. 6Department of Gastroenterology, Dicle University Medical School, Diyarbakir, Turkey. 7Department of Gastroenterology and Hepatology,, Erasmus MC University Medical Center, Rotterdam, Netherlands


POSTER SESSIONS

Viral Hepatitis: Virology and Pathogenesis #1357 MYELOID DENDRITIC CELLS AS A THERAPEUTIC TARGET FOR IMMUNE RESTORATION BY HCV NS3 PROTEASE INHIBITOR IN CHRONIC HEPATITIS C PATIENTS Masanori Miyazaki, Tatsuya Kanto, Tokuhiro Matsubara, Koyo Higashitani, Naruyasu Kakita, Michiyo Inoue, Ichiyo Itose, Mitsuru Sakakibara, Naoki Hiramatsu, Tetsuo Takehara, Akinori Kasahara, Norio Hayashi Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan

#1358 PML-DEFICIENCY DETERMINES LIVER TUMOR DEVELOPMENT IN CHRONIC HCV INFECTION Kerstin Herzer1, Anna Carbow1, Sandra Weyer1, Stephan Kanzler2, Stefan Biesterfeld3, Peter R. Galle2 11st Dept of Medicine, Johannes Gutenberg-University, Mainz, Germany. 22nd Dept of Medicine, Leopoldina Clinic, Schweinfurt, Germany. 3Dept of Pathology, Johannes Gutenberg-University, Mainz, Germany

#1359 HCV INDUCES TGF-β1 EXPRESSION THROUGH GENERATION OF ROS AND NFκB ACTIVATION Wenyu Lin, Wei-Lun Tsai, Run-Xuan Shao, Lee F. Peng, Woo Jin Chung, Sabina Sabharwal, Hong Zhao, Jae-Young Jang, Lydia Barlow, Jorge Mendez-Navarro, Eileen Sun, Raymond Chung Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

#1360 INCREASED NK CELL ACTIVITY PROTECTS AGAINST HCV INFECTION IN HIGH-RISK LONGTERM EXPOSED INDIVIDUALS Lucy Golden-Mason1,2, Andrea Cox3, Hugo R. Rosen1,2 1GI/Hepatology, University of Colorado HSC, Aurora, CO, USA. 2Integrated Department of Immunology, National Jewish Hospital, Denver, CO, USA. 3Medicine, Johns Hopkins Medical Inst., Baltimore, MD, USA

#1361 CELL-TYPE SPECIFIC GENE EXPRESSION SIGNATURE IN LIVER UNDERLIES RESPONSE TO INTERFERON THERAPY IN CHRONIC HEPATITIS C INFECTION

#1362 EXPRESSION OF THE GROWTH ARREST AND DNA DAMAGE PROTEIN GADD45β IS INHIBITED BY HEPATITIS C VIRUS IN FULL-LENGTH HCV ORF TRANSGENIC MICE AND HCV-INFECTED PATIENTS WITH HEPATOCELLULAR CARCINOMA Martin Higgs1,2, Herve Lerat1,2, Jean-Michel Pawlotsky1,2 Mondor Hospital, University of Paris 12, Creteil, France. 2INSERM U955, Creteil, France

1Henri

#1363 STIMULATION OF LIVER-RESIDENT, BUT NOT CIRCULATING PLASMACYTOID DENDRITIC CELLS WITH TOLL-LIKE RECEPTOR AGONISTS RESULTS IN HIGH LEVELS OF INTERFERON ALPHA SECRETION DURING CHRONIC HCV INFECTION Huiming Hon1,3, Luke Shen2, James R. Spivey3, Allan D. Kirk2, Arash Grakoui1 1Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA, USA. 2Surgery, Emory University, Atlanta, GA, USA. 3Medicine, Emory University, Atlanta, GA, USA

#1364 IFN-ALPHA STIMULATED NK CELLS ARE CAPABLE OF KILLING HCV-INFECTED HEPATOMA CELLS VIA TRAIL Kerstin A. Stegmann1,2, Sandra Ciesek1,3, Niklas K. Björkström2, Markus Cornberg1, Michael P. Manns1, Thomas Pietschmann3, Hans-Gustaf Ljunggren2, Heiner Wedemeyer1 1Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 2Department of Medicine, Karolinska Institutet, Center for Infectious Medicine, Stockholm, Sweden. 3Department of Experimental Virology, Twincore; Hannover Medical School, Hannover, Germany and Helmholtz Centre for Infection Research, Braunschweig, Hannover, Germany

#1365 POSSIBLE PATHOGENECITIES OF HCV REPLICATION IN HUMAN LYMPHOID CELLS: POTENTIAL ROLE IN HUMAN AUTOIMMUNE DISEASES Yasuteru Kondo1, Yoshiyuki Ueno1, Keigo Machida3, Eiji Kakazu1, Koju Kobayashi2, Masaaki Shiina1, Keiichi Tamai1, Jun Inoue1, Noriyuki Obara1, Yuta Wakui1, Koji Fukushima1, Michael M. Lai4,3, Tooru Shimosegawa1 1Gastroenterology, Tohoku University Hospital, Sendai, Japan. 2Tohoku University School of Health Science, Sendai, Japan. 3Molecular and Microbiology and Immunology, Keck School of Medicine, USC, Los Angeles, CA, USA. 4National Cheng Kung University, Tainan, Taiwan

#1366 EVALUATION OF HEPATITIS C VIRUS RNA IN B CELLS AS A PREDICTIVE FACTOR FOR RESPONSE OF ANTIVITHERAPY IN PATIENTS WITH CHRONIC HEPATITIS C Takayoshi Ito, Momoko Inokuchi, Manabu Uchikoshi, Yuu Shimozuma, Kazumasa Hiroishi, Michio Imawari Gastroenterology, Showa University School of Medicine, Tokyo, Japan


Limin Chen, Ivan Borozan, Jing Sun, Maha Guindi, Jordan J. Feld, E. Jenny Heathcote, Aled Edwards, Ian McGilvray University of Toronto, Toronto, ON, Canada

239A

240A

POSTER SESSIONS

#1367

#1372

EFFECT OF THE CCR5D32 POLYMORPHISM ON THE NATURAL COURSE OF HEPATITIS C IN A SINGLE SOURCE OUTBREAK

HEME OXYGENASE 1 [HMOX1] EXPRESSION IS UP-REGULATED BY HCV IN HUMAN HEPATOMA CELLS AND IS NORMALIZED THROUGH IFN TREATMENT

Jacob Nattermann1, Joerg Timm3, Hans Dieter Nischalke1, Monika Michalk1, Agathe Hartmann1, Manfred Wiese2, Michael Roggendorf3, Tilman Sauerbruch1, Ulrich Spengler1 1Internal Medicine I, University of Bonn, Bonn, Germany. 2Hospital St. Georg, Leipzig, Germany. 3Institute of Virology, Essen University Hospital, University of Duisburg-Essen, Essen, Germany

Hossein Sendi1,2, Marjan Mehrab-Mohseni1, Nury Steuerwald1,2, Herbert L. Bonkovsky1,2 1The Liver-Biliary-Pancreatic Center,, Carolinas Medical Center, Charlotte, NC, USA. 2Department of Biology, University of North Carolina at Charlotte, Charlotte, NC, USA

#1368

#1373

DUAL TIM-3/PD-1 EXPRESSION ON NONEFFECTOR CD4+ T CELLS AND HCV-SPECIFIC CD8+ T CELLS IS ASSOCIATED WITH DEVELOPMENT OF PERSISTENCE IN ACUTE HCV INFECTION

INTERFERON-α-SIGNALING IN NATURAL KILLER CELLS IS IMPAIRED IN CHRONIC HEPATITIS C VIRUS INFECTION

1GI/Hepatology,

Lucy Hugo R. University of Colorado HSC, Aurora, CO, USA. 2Medicine, VA Hospital, Denver, CO, USA. 3Integrated Department of Immunology, National Jewish Hospital, Denver, CO, USA

Takuya Miyagi1,2, Tetsuo Takehara1,2, Satoshi Shimizu1, Kumiko Nishio1, Keisuke Kohga1, Tomohide Tatsumi1, Norio Hayashi1,2 1Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan. 2Global Center of Excellence Program, Osaka University, Suita, Japan

#1369

#1374

HEDGEHOG SIGNALING, STELLATE CELL/ENDOTHELIAL CELL CROSS-TALK AND PROGRESSION OF VIRAL HEPATITIS

KINETICS AND FUNCTIONAL ANALYSIS OF HCVSPECIFIC T CELL RESPONSES IN SUBJECTS EXPOSED TO HEPATITIS C

Thiago A. Pereira1, Rafal P. Witek1, Wing-Kin Syn1, Steve S. Choi1, Youngmi Jung1, Gamze F. Karaca1, Alessia Omenetti1, Fausto E. Pereira2, Anna Mae Diehl1 1Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA. 2Nucleo de Doencas Infecciosas, Centro de Ciencias da Saude, Universidade Federal do Espirito Santo, Espirito Santo, Brazil

Sanaa Kamal2,1, Hoda Mansour3, Iman Fathy3, Maha Sobhy3, Amany Sayed3, Ahmed Ismail3, Dalia Ghoraba2 1Gastroenterology, Tufts School of Medicine, Boston, MA, USA. 2Hepatology, Gastroenterology and Tropical Medicine, Ain Shams University, Cairo, Egypt. 3Immunology, EGYBLOO VACSERA, Cairo, Egypt

#1370

HCV INDUCES INSULIN RESISTANCE BY DECREASING TYROSINE IRS1 PHOSPHORYLATION IN JFH1 INFECTED HEPATOCYTES

Rachel

McMahan1,3,

Golden-Mason1,3,

Rosen1,2

THE PROTECTIVE EFFECT OF HLA-B27 IN HEPATITIS C VIRUS INFECTION REQUIRES PRESENCE OF A GENOTYPE-SPECIFIC IMMUNODOMINANT CD8+ T CELL EPITOPE Neumann-Haefelin2,6,

Timm4,

Schmidt1,

Christoph Joerg Julia Karen Fitzmaurice5, Susan McKiernan5, Dermot Kelleher5, Daniela Huzly3, Michael Roggendorf4, Todd M. Allen6, Hubert E. Blum1, Robert Thimme1 1Departmnet of Medicine II, University Hospital Freiburg, Freiburg, Germany. 2Centre of Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany. 3Department of Virology, University Hospital Freiburg, Freiburg, Germany. 4Department of Virology, University Hospital Essen, Essen, Germany. 5Trinity Centre for Health Sciences, St. James’ Hospital, Dublin, Ireland. 6Ragon Institute, Massachusetts General Hospital, Boston, MA, USA M O N D AY NOVEMBER 1


#1371 CYTOKINE PROFILES IN HCV EXPOSED BUT UNINFECTED CASES WITH APPARENT RESISTANCE TO HCV INFECTION Usama Warshow1, Antonio Riva2, Prem H. Thurairajah1, Doha Hegazy1, Shilpa Chokshi2, Matthew E. Cramp2,3 1Hepatology Research Group, Insititue of Biomedical and Clinical Research, Plymouh, United Kingdom. 2Institute of Hepatology, University College London, London, United Kingdom. 3Department of Hepatology, Derriford Hospital, Plymouth, United Kingdom


#1375

Woo Jin Chung1,2, Sabina Sabharwal1, Andrew W. Tai1, Wenyu Lin1, Run-Xuan Shao1, Jae-Young Jang1, Wei-Lun Tsai1, Hong Zhao1, Eileen Sun1, Lee F. Peng1, Raymond Chung1 1Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. 2Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea, South

#1376 INCREASED CD4+ CD25+ REGULATORY T CELLS DURING ACUTE HEPATITIS C SUPPRESSES T CELL RESPONSES AND FAVORS PERSISTENCE OF HEPATITIS C VIRUS INFECTION Sanaa Kamal2,1, Iman Fathy3,2, Amany Sayed3, Maha Sobhy3,2, Ahmed Ismail3, Amal Abdel Baki3, Hoda Mansour3 1Gastroenterology, Tufts School of Medicine, Boston, MA, USA. 2Gastroenterology and Tropical Medicine, Ain Shams University, Cairo, Egypt. 3Immunology, Vacsera, Cairo, Egypt


POSTER SESSIONS

#1377

#1381

HIGH ISG-15 EXPRESSION IS CORRELATED WITH NON-RESPONSE (NR) IN HIV/HCV CO-INFECTED SUBJECTS TREATED WITH PEG-INTERFERON AND RIBAVIRIN

REACTIVATION OF EPSTEIN-BARR VIRUS IN PATIENTS WITH CHRONIC HEPATITIS C

Antonios Katsounas1,3, Richard A. Lempicki1, Joerg F. Schlaak3, Guido Gerken3, Michael A. Polis2, Shyam Kottilil3 1NCI-Frederick, SAIC, Bethesda, MD, USA. 2LIR, NIAID/NIH, Bethesda, MD, USA. 3Dept. of Gastroenterology and Hepatolgy, University of Essen, Essen, Germany

#1378 BILE ACID LEVELS AS A HOST FACTOR AFFECTING ANTIVIRAL TREATMENT RESPONSE BUT NOT VIRAL REPLICATION IN HEPATITIS C PATIENTS Rika Iwata1, Bruno Stieger2,3, Joachim C. Mertens1, Oliver Goetze1, Karim Sabrane1, Athanasios Vergopoulos5, Julia Braun4, Beat Mullhaupt1,6, Andreas Geier1,6 1Department of Internal Medicine, Division Gastroenterology & Hepatology, University Hospital Zürich, Zürich, Switzerland. 2Department of Internal Medicine, Division of Clinical Pharmacology, University Hospital Zürich, Zürich, Switzerland. 3Zurich Center for Integrative Human Physiology (ZIHP), University of Zürich, Zürich, Switzerland. 4Biostatistics Unit, Institute of Social und Preventive Medicine, University of Zürich, Zürich, Switzerland. 5Institute for Clinical Chemistry, University Hospital Zürich, Zürich, Switzerland. 6Swiss Hepatopancreatobiliary (HPB)-Center, Swiss Hepatopancreatobiliary (HPB)-Center, Zürich, Switzerland

#1379 A COMMON POLYMORPHISM IN THE ABCB11 GENE ENCODING FOR THE BILE SALT EXPORT PUMP IS ASSOCIATED WITH PROGRESSION TO CIRRHOSIS IN HEPATITIS C INFECTION Rika Iwata1, Bruno Stieger2,3, Joachim C. Mertens1,7, Pascal Frei1, Julia Braun4, Athanasios Vergopoulos5, Karim Sabrane1, Ina V. Martin6, Oliver Goetze1, Beat Mullhaupt1,7, Andreas Geier1,7 1Department of Internal Medicine, Division Gastroenterology & Hepatology, University Hospital Zürich, Zürich, Switzerland. 2Department of Internal Medicine, Division of Clinical Pharmacology, University Hospital Zürich, Zürich, Switzerland. 3Zurich Center for Integrative Human Physiology (ZIHP), University of Zürich, Zürich, Switzerland. 4Biostatistics Unit, Institute of Social und Preventive Medicine, University of Zürich, Zürich, Switzerland. 5Institute for Clinical Chemistry, University Hospital Zürich, Zürich, Switzerland. 6Department of Internal Medicine II, Aachen University (RWTH) University Hospital (UKA), Aachen, Germany. 7Swiss Hepatopancreatobiliary (HPB)-Center, University Hospital Zürich, Zürich, Switzerland

#1380

Clovis S. Palmer1, Andrew R. Lloyd1, Amany Zekry1,2 of Medical Science, University of New South Wales, Sydney, NSW, Australia. 2Gastroenterology and Hepatology, St George Hospital, Sydney, NSW, Australia 1School

Yuu Shimozuma, Takayoshi Ito, Manabu Uchikoshi, Momoko Inokuchi, Kazumasa Hiroishi, Michio Imawari Department of gastroenterology, Showa University School of Medicine, Tokyo, Japan

#1382 INTERACTION OF HEPATITIS C VIRUS (HCV) WITH P53 FAMILY-INDUCED APOPTOSIS SIGNALING PATHWAYS – IMPLICATIONS FOR VIRAL CLEARANCE AND HEPATOCARCINOGENESIS Katja M. Schoeler, Andreas F. Koch, Wolfgang Stremmel, Martina Müller Department of Internal Medicine IV, Hepatology and Gastroenterology, University Hospital Heidelberg, Heidelberg, Germany

#1383 ANALYSIS OF HCV-SPECIFIC FOXP3+CD25+CD127-CD4+ REGULATORY T-CELL CLONES FROM PATIENTS WITH DIFFERENT OUTCOMES OF HCV INFECTION Bettina Langhans1, Ingrid Braunschweiger1, Simone Arndt1, Wibke Schulte1, Natascha Vidovic2, Laura E. Layland3, Achim Hoerauf3, Johannes Oldenburg2, Tilman Sauerbruch1, Ulrich Spengler1 1Department of Internal Medicine I, University of Bonn, Bonn, Germany. 2Institute for Experimental Hematology and Transfusion Medicine, University of Bonn, Bonn, Germany. 3Institute of Medical Microbiology, Immunology and Parasitology, University of Bonn, Bonn, Germany

#1384 HCV IN PERIPHERAL BLOOD MONONUCLEAR CELLS ARE PREDOMINANTLY CARRIED ON THE SURFACE OF NATURAL KILLER CELLS IN HIV/HCV CO-INFECTED INDIVIDUALS Ven Natarajan2, Allison Hazen2, Michael A. Polis1, Joseph A. Kovacs3, Shyam Kottilil1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2Laboratory of Molecular Cell biology, SAIC-Frederick, Frederick, MD, USA. 3CCMD, CC, NIH, Bethesda, MD, USA

#1385 GENOME-WIDE SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS IDENTIFIES A UNIQUE INTEGRIN BETA 5 (ITGB5) HAPLOTYPE IN ADVANCED LIVER FIBROSIS PATIENTS Richard A. Lempicki2, Joerg F. Schlaak3, Alison Murphy1, Shyam Kottilil1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2SAIC-Frederick, Frederick, MD, USA. 3University of Essen Hospital, Essen, Germany


HEPATIC MICRORNAS EXPRESSION IN OBESE SUBJECTS WITH CHRONIC HCV

241A

242A

POSTER SESSIONS

#1386

#1391

HIV INFECTION INCREASES HCV-INDUCED HEPATOCYTE APOPTOSIS

INCREASED CTL CROSS-RECOGNITION OF HCV EPITIOPE VARIANTS IS MORE IMPORTANT THAN CTL AVIDITY IN DETERMINING RECOVERY IN HEPATITIS C

Jae Young Jang, Run-Xuan Shao, Wenyu Lin, Woo Jin Chung, WeiLun Tsai, Hong Zhao, Sabina Sabharwal, Andrew W. Tai, Lee F. Peng, Raymond Chung Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

#1387 IN VIVO EVIDENCE OF ALTERED HEPATOCYTE AUTOPHAGIC RESPONSE IN LIVERS FROM PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION

Rachel McMahan1, Lucy Golden-Mason1,3, Salvador Benlloch4, Hugo R. Rosen1,2 1GI/Hepatology, University of Colorado HSC, Aurora, CO, USA. 2Medicine, VA Hospital, Denver, CO, USA. 3Integrated Department of Immunology, National Jewish Hospital, Denver, CO, USA. 4Hepatogastroenterology, Hospital Universitario La Fe, Valencia, Spain

#1392 INTERRELATIONSHIP BETWEEN OXIDATIVE STRESS, MITOCHONDRIAL DYSFUNCTION AND CELL DEATH IN HCV INFECTION

Pierre-Emmanuel Rautou1,2, Dominique Cazals-Hatem4,2, Gerard Feldmann2,3, Tarik Asselah1,2, Alain Grodet2,3, Abdellah Mansouri2,3, Sylvie Mosnier4, Didier Lebrec1,2, Pierre Bedossa4,2, Patrick Marcellin1,2, Dominique Valla1,2, Richard Moreau1,2 1Service d’Hépatologie, Hopital Beaujon; Assistance PubliqueHôpitaux de Paris, Clichy, France. 2INSERM U773, Centre de Recherche Bichat-Beaujon CRB3, Clichy, France. 3Université Denis Diderot-Paris 7, Clichy, France. 4Service d’Anatomie Pathologique, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France

Roosevelt V. Campbell1,2, Aparna Rachamallu3, Steven A. Weinman2 1Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA. 2Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA. 3Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA

#1388

#1393

EVALUATION OF THE NITRIC OXIDE (NO) ROLE IN THE DOWN-REGULATION OF HCV INDUCED BY ACETYLSALICYLIC ACID

EXPRESSION OF 2B4 (CD244) AND ITS EFFECT ON VIRUS-SPECIFIC CD8+ T CELLS - ANOTHER IMPORTANT COSTIMULATORY MOLECULE FOR THE CONTROL OF VIRAL HEPATITIS?

Clara P. Rios-Ibarra1, Ana Maria G. Rivas-Estilla1, Salvador SaidFernández2, Victor M. Torres-de la-Cruz2 1Biochemistry and Molecular Medicine, School of Medicine, UANL, Monterrey, NL, Mexico. 22Centro de Investigación Biomédica del Noreste, IMSS, Monterrey, NL, Mexico

#1389



Verena Schlaphoff, Jerzy Jaroszewicz, Suneetha V. Pothakamuri, Jan Grabowski, Kerstin A. Stegmann, Michael P. Manns, Heiner Wedemeyer, Markus Cornberg Gastroenterology, Hepatology, Endocrinology, Hanover Medical School, Hannover, Germany

CYCLOOXYGENASE-2 GENE PROMOTER HAPLOTYPES AFFECT SUSCEPTIBILITY TO HEPATITIS C VIRUS INFECTION AND THE DISEASE PROGRESSION

#1394

Masashi Sakaki1, Reiko Makino2, Kazumasa Hiroishi1, Michio Imawari1 1Department of Gastroenterology, Showa University School of Medicine, Tokyo, Japan. 2Clinical Research Laboratory, Showa University School of Medicine, Tokyo, Japan

Alessandro Perrella, Anna D’Antonio, Costanza Sbreglia, Oreste Perrella VII Dpt Infectious Disease and Immunology, Hospital D.Cotugno of naples, Naples, Italy

#1390

NON-INVASIVE MEASUREMENT OF CHOLESTEROL METABOLISM IN PATIENTS WITH HCV INFECTION BY USING SERUM MARKER STEROLS

EVALUATION OF A PROLIFERATION-INDUCING LIGAND (APRIL) AS AN IMMUNOLOGICAL MARKER OF LYMPHOPROLIFERATIVE DISORDERS IN PATIENTS WITH CHRONIC HEPATITIS C Manabu Uchikoshi, Takayoshi Ito, Yuu Shimozuma, Momoko Inokuchi, Kazumasa Hiroishi, Michio Imawari Department of Gastroenterology, Showa University School of Medicine, Tokyo, Japan


A STRONG HCV SPECIFIC IFN-γ RESPONSE WITHIN FIRST WEEK OF ACUTE HEPATITIS CHARACTERIZES WHO RESOLVES INFECTION

#1395

Tadashi Ikegami1, Akira Honda1,2, Makoto Nakamuta3, Teruo Miyazaki2,4, Takeshi Hirayama1, Yoshifumi Saitoh1, Yasushi Matsuzaki1,4 1Division of Gastroenterology and Hepatology, Tokyo Medical University, Ami, Inashiki, Japan. 2Collaborative Research Center, Tokyo Medical University, Ibaraki Medical Center, Ami, Inashiki, Japan. 3Department of Gastroenterology, National Kyusyu Medical Center, Fukuoka City, Japan. 4Department of Development for Community Medicine, Tokyo Medical University, Tokyo, Japan


POSTER SESSIONS

243A

#1396

#1400

IFN-α1, -α2, -α5, -α8, -α21 AND IFN-γ ARE NOT RESPONSIBLE FOR THE INDUCTION OF PROGNOSTICALLY RELEVANT INTERFERONSTIMULATED GENES IN THE LIVER OF PATIENTS WITH CHRONIC HEPATITIS C

DIFFERENTIAL INTRA-HEPATIC T-CELL SIGNALLING ASSOCIATED WITH GB VIRUS C IN HCV/HIV COINFECTION

Martin Trippler, Ruth Broering, Lena Poggenpohl, Guido Gerken, Joerg F. Schlaak Dept. of Gastroenterology and Hepatology, University Hospital of Essen, Essen, Germany

#1397 HIV ENHANCES HCV REPLICATION BY ITS INTERACTION WITH MADCAM EXPRESSING HEPATOCELLULAR CARCINOMA CELLS Xiaozhen Zhang, Marybeth Daucher, Shyam Kottilil LIR, NIAID, NIH, Bethesda, MD, USA

#1398 HCV ACTIVATES THE UNFOLDED PROTEIN RESPONSE BY INCREASING OXIDATIVE STRESS IN A JNK-, P38 MAPK-, AND MEK-DEPENDENT MANNER Wei-Lun Tsai, Wenyu Lin, Run-Xuan Shao, Lee F. Peng, Woo Jin Chung, Jae-Young Jang, Sabina Sabharwal, Hong Zhao, Kathleen Corey, Jorge Mendez-Navarro, Eileen Sun, Lydia Barlow, Raymond Chung Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

#1399 A UNIQUE SET OF SPECIFIC ALTERATIONS OF CD56DIM EFFECTOR NK CELLS IN HCV INFECTED PATIENTS : DECREASED NKG2D AND EXPRESSION OF THE NEGATIVE COSIGNALING MOLECULE PD1 BUT NOT BTLA Daniel R. Olive1, Francisco Zambrano-Zaragoza1, Rene Gerolami2, Philippe Halfon3, Marc Bourlière4, Diana Herrera1, Francoise Gondois-Rey1, Alessandro Moretta5, Ivan Hirsch1, Andrea De Maria6 1Tumor Immunology, Institut Paoli Calmettes INSERM UMR891, Marseille, France. 2Service de Gastro –entérologie, Hôpital de la Conception, France, Hôpital de la Conception, Marseille, France. 3Alphabio, Alphabio, Marseille, France. 4Service d’Hepato Gastroentérologie, Hôpital Saint Joseph, Marseille, France. 5Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, Genova, Italy. 6Centro di Eccellenza per la Ricerca Biomedica, Università di Genova, Genova, Italy

Mark D. Berzsenyi1, David J. Woollard2, Catriona A. McLean3, Scott Preiss4, Victoria M. Perreau5, Michael R. Beard6, Scott Bowden4, Shuo Li2, Stuart K. Roberts1 1Department of Gastroenterology, Alfred Hospital, Melbourne, VIC, Australia. 2Burnet Institute for Medical Research and Public Health, Melbourne, VIC, Australia. 3Department of Pathology, Alfred Hospital, Melbourne, VIC, Australia. 4Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia. 5Neuroproteomics & Neurogenomics Platform and Centre for Neuroscience, University of Melbourne, Melbourne, VIC, Australia. 6School of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA, Australia

#1401 COMPARISON OF GROWTH FACTOR/CANCER SIGNALING PATHWAYS IN HEPATOMA DERIVED HUH-7 VS. LIVER PROGENITOR HEPARG CELLS Joseph Park, David Tong, Shigenobu Kawai, Jack R. Wands, Jisu Li Liver Research Center, RI Hospital and the Warren Alpert Medical Shcool of Brown University, Providence, RI, USA

#1402 HEPATITIS C VIRUS PROMOTES HUMAN HEPATIC STELLATE CELLS MIGRATION Samuel Martin-Vilchez1, Yolanda Rodriguez-Muñoz.1, Rosario Lopez-Rodriguez1, Pedro Majano Rodriguez2, Francisca Molina Jimenez2, Rafael Aldabe3, Angel Hernandez-Bartolome1, Ricardo Moreno-Otero1, Paloma Sanz-Cameno1 1Liver Unit, Hospital Universitario “La Princesa”, CIBERehd and ISCIII, Madrid, Spain. 2Molecular Biology Unit, Hospital Universitario “La Princesa”, CIBERehd and ISCIII., Madrid, Spain. 3University of Navarra, CIMA, Pamplona, Spain

#1403 CELLULAR DISTRIBUTION OF CLAUDIN 1 IN LIVER TISSUE IN HEPATITIS C AND OTHER LIVER DISEASES Doha Hegazy1, Phillip Edwards2, Usama Warshow1, Matthew E. Cramp1 1Institute of Biomedical and Clinical Sciences, Peninsula College of Medicine and Dentistry, Plymouth, United Kingdom. 2Derriford Hospital, Histopathology, Plymouth, United Kingdom


244A

POSTER SESSIONS


#1404

#1408

A GENOME-WIDE GENETIC SCREEN FOR HOST FACTORS REQUIRED FOR HEPATITIS C VIRUS PROPAGATION

INDUCTION OF CXCR3- AND CCR5-ASSOCIATED CHEMOKINES DURING ACUTE HEPATITIS C VIRUS (HCV) INFECTION

Qisheng Li1, Abraham L. Brass2,3, Aylwin Ng4, Ramnik Xavier4, T. Jake Liang1, Stephen J. Elledge5 1Liver Diseases Branch, NIDDK, NIH, Bethesda, MD, USA. 2Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard Medical School, Boston, MA, USA. 3Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 4Center for Computational and Integrative Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 5Department of Genetics, Harvard Medical School, Division of Genetics, Brigham and Women’s Hospital, Howard Hughes Medical Institute, Boston, MA, USA

Marija Zeremski1, Giles Hooker2,3, Marla A. Shu4, Queenie Brown1, Don C. Des Jarlais5, Leslie H. Tobler6, Barbara Rehermann7, Michael P. Busch6,8, Brian R. Edlin4, Andrew Talal1 1Medicine/GI, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY, USA. 2Statistical Sciences, Cornell University, Ithaca, NY, USA. 3Biological Statistics and Computational Biology, Cornell University, Ithaca, NY, USA. 4Medicine, State University of New York Downstate College of Medicine, Brooklyn, NY, USA. 5Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York, NY, USA. 6Blood Systems Research Institute, San Francisco, CA, USA. 7Immunology Section, Liver Diseases Branch, NIDDK, National Institutes of Health, Bethesda, MD, USA. 8University of California, San Francisco, CA, USA

#1405 TOLL-LIKE RECEPTOR 2 -196 TO -174 DELETION/INSERTION POLYMORPHISM INFLUENCES THE SUSCEPTIBILITY TO HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C Hans Dieter Nischalke, Cordula Berger, Barbara Reich, Katharina Aldenhoff, Martin Coenen, Jacob Nattermann, Tilman Sauerbruch, Ulrich Spengler Department of Internal Medicine I, University of Bonn, Bonn, Germany

#1406 HCV AND SOCS3 ARE RECIPROCALLY INHIBITORY IN CELL CULTURE Run-Xuan Shao, Wenyu Lin, Lee F. Peng, Woo Jin Chung, Jae-Young Jang, Sabina Sabharwal, Jorge Mendez-Navarro, Wei-Lun Tsai, Hong Zhao, Raymond Chung Massachusetts General Hospital, Boston, MA, USA

#1407 GENOME WIDE TRANSRIPTIONAL PROFILING OF HEPATOMA CELLS IDENTIFIES GENES SIGNIFICANT FOR HCV ENTRY, PATHOGENESIS AND RESPONSE TO INTERFERON Xiaozhen Zhang1, Marybeth Daucher1, Jun Yang2, Richard A. Lempicki2, Shyam Kottilil1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2SAIC-Frederick, frederick, MD, USA

#1409 IN-VITRO AND IN-VIVO CHARACTERIZATION OF A NEW GENOTYPE 2B HCV CLONE AND 2B/JFH1 INTERGENOTYPIC CHIMERA AND ANALYSES OF THE FACTOR THAT REGULATE INTERFERON SENSITIVITY Gouki Suda1, Naoya Sakamoto1, Yasuhiro Itsui1, Mina Nakagawa1, Megumi Tasaka-Fujita1, Yuki Nishimura-Sakurai1, Kako Mishima1, Yuko Onuki1, Machi Yamamoto1, Seishin Azuma1, Sei Kakinuma1, Michio Imamura2, Kazuaki Chayama2, Mamoru Watanabe1 1tokyo medical and dental university,department of Gastroenterology and Hepatology, Tokyo,Japan, Tokyo, Japan. 2Department of Medicine and Molecular Science, Graduate School of Biomedical Science, Hiroshima University, Hirosima, Japan

#1410 IN-VITRO REPLICATION AND INTERFERON SENSITIVITY OF CORE AA 70 AND 91 MUTANT HCV CELL CULTURE Yusuke Funaoka1, Naoya Sakamoto1,2, Gouki Suda1, Yasuhiro Itsui1, Mina Nakagawa1,2, Kako Mishima1, Yuko Onuki1, Machi Yamamoto1, Seishin Azuma1, Sei Kakinuma1, Mamoru Watanabe1 1Department of Gastroenterology and Hepatology, Tokyo Medical And Dental University, Tokyo, Japan. 2Department for Hepatitis Control, Tokyo Medical and Dental University, Tokyo, Japan

#1411


KINETIC ANALYSIS OF VIRAL REBOUND AND DRUG-RESISTANT VIRAL VARIANT DYNAMICS IN PATIENTS TREATED WITH ITMN-191 (R7227) MONOTHERAPY SUGGEST A HIGH BARRIER TO VIRAL ESCAPE Christoph Sarrazin1, Sharlene Lim2, Xiaoli Qin2, Simone Susser1, Christian M. Lange1, Williamson Z. Bradford2, Stefan Zeuzem1, Karl Kossen2, Isabel Najera3, Scott Seiwert2 1J.W. Goethe Universität, Frankfurt, Germany. 2InterMune, Brisbane, CA, USA. 3Roche Palo Alto LLC, Palo Alto, CA, USA



POSTER SESSIONS

#1412

#1417

UPTAKE AND TRAFFICKING OF CELL CULTUREDERIVED HEPATITIS C VIRUS (HCVCC) IN HUMAN DENDRITIC CELLS Melanie

Lambotin1,

Baumert1,2,

Barth1

Thomas F. Heidi U748, Université de Strasbourg, Strasbourg, France. 2Hôpitaux Universitaires de Strasbourg, Service d’Hépatogastroentérologie, Strasbourg, France

1Inserm

#1413 MENOPAUSE IS ASSOCIATED WITH INCREASED HCV RNA LEVEL IN PATIENTS WITH CHRONIC HEPATITIS C Stern1,

Moucari1,

Martinot-Peignoux1,

Christiane Rami Michelle Tarik Asselah1, Ana-Carolina Cardoso1, Vincent Mackiewicz2, Marie-Hélène Nicolas-Chanoine2, Pierre Bedossa3, Patrick Marcellin1 1Service d’Hépatologie and INSERM U773-CRB3, Hôpital Beaujon, Clichy, France. 2Service de Microbiologie, Hôpital Beaujon, Clichy, France. 3Service d’Anatomie-Pathologique, Hôpital Beaujon, Clichy, France

#1414 ANTIVIRAL EFFECTS OF INTERFERON-INDUCED PROTEINS GBP-1 AND ITS INTERACTIONS WITH HEPATITIS C VIRUS NS5B PROTEIN Yasuhiro Itsui1,3, Naoya Sakamoto2, Mina Nakagawa2, Yuko Sekine-Osajima1, Megumi Tasaka-Fujita1, Yuki Nishimura-Sakurai1, Gouki Suda1, Yuko Onuki1, Kako Mishima1, Machi Yamamoto1, Takako Watanabe1, Mayumi Ueyama1, Yusuke Funaoka1, Seishin Azuma1, Sei Kakinuma1, Tsunehito Yauchi3, Mamoru Watanabe1 1Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan. 2Department for Hepatitis Control, Tokyo Medical and Dental University, Tokyo, Japan. 3Department of Gastroenterology, Soka Munipital Hospital, Saitama, Japan

#1415 IN VIVO ENDOPLASMIC RETICULUM STRESS IN PATIENTS WITH CHRONIC HEPATITIS C Tarik Asselah1, Ivan Bièche2, Abdellah Mansouri1, Ingrid Laurendeau2, Dominique Cazals-Hatem1, Gerard Feldmann1, Pierre Bedossa1, Valerie Paradis1, Michèle Martinot-Peignoux1, Didier Lebrec1, Cécile Guichard1, Eric Ogier-Denis1, Michel Vidaud1, Zerra Tellier3, Vassili Soumelis4, Patrick Marcellin1, Richard Moreau1 1Hôpital Beaujon, Clichy, France. 2INSERM U745, Paris, France. 3LFFB, Courtaboeauf, France. 4Institut Curie, Paris, France

#1416

Lin Liu1,2, Brian E. Fisher1, Andrea Cox1, Stuart C. Ray1 of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA. 2Division of Infectious Diseases, Southwest Hospital of Third Military Medical University, Chongqing, China

ROLE OF ESCRT PROTEINS IN BUDDING OF HEPATITIS C VIRUS Keiichi Tamai1, Yoshiyuki Ueno1, Yuta Wakui1, Noriyuki Obara1, Eiji Kakazu1, Jun Inoue1, Yasuteru Kondo1, Yoko Yamagiwa1, Masaaki Shiina1, Koji Fukushima1, Koju Kobayashi2, Tooru Shimosegawa1 1Department of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan. 2Division of Clinical Investigation, Tohoku University School of Health Sciences, Sendai, Japan

#1418 PERTURBATION OF HCV REPLICATION BY MICRORNAS WHICH ARE REGULATED BY HCV INFECTION Hisashi Ishida Department of Gastroenterology and Hepatology, Osaka University, Suita, Japan

#1419 EVIDENCE FOR REPLICATION AND RELEASE OF HEPATITIS C VIRUS FOLLOWING THE EX VIVO INFECTION OF CULTURED HUMAN LIVER SLICES WITH VIRAL STRAINS OF GENOTYPES 1 AND 2 Sylvie Lagaye1, Michelina Nascimbeni1, Miriam Triyatni2, Pierre Bourdoncle3, Stanislas Pol1, Bertrand Saunier1 1Immunology, Institut Cochin, Paris, France. 2MSS, LVD, NIAID, NIH, Bethesda, MD, USA. 3Cell Imaging, Institut Cochin, Paris, France

#1420 MOLECULAR SIGNATURES AND PREDICTED ANTIGEN PROFILES OF HEPATITIS C VIRUS ENVELOPE GLYCOPROTEINS ACCORDING TO RESPONSE TO ANTIVIRAL TREATMENT Rémy Moenne-Loccoz1, Caroline Razafinjatovo1, Francois T. Habersetzer2, Ahmed Ananna2, Michel Doffoel2, Samira Fafi-Kremer1,3, Jean-Pierre Gut1,3, Thomas F. Baumert1,2, Françoise StollKeller1,3, Evelyne Schvoerer1,3 1Inserm Unit 748 and University of Strasbourg, Strasbourg, France. 2Service d’Hépato-gastroentérologie, Nouvel Hôpital Civil, Strasbourg, France. 3Virology Laboratory, University Hospital, Strasbourg, France

#1421 SPECIFIC RNA STRUCTURES AND MUTATIONS IMPLICATED FOR HCV RNA REPLICATION AND VIRUS PARTICLE FORMATION IN CULTURED CELLS Asako Murayama, Tomoko Date, Daisuke Akazawa, Takanobu Kato, Tetsuro Suzuki, Takaji Wakita Virology II, National Institute of Infectious Diseases, Tokyo, Japan


HEMIGENOMIC ANALYSIS REVEALS RAPID HVR-1 EVOLUTION IS ASSOCIATED WITH SPONTANEOUS CLEARANCE OF PRIMARY HUMAN HEPATITIS C VIRUS INFECTION 1Division

245A

246A

POSTER SESSIONS

#1422

#1427

ASSOCIATION BETWEEN NAIVE REGULATORY T (TREG) CELLS AND HCV-SPECIFIC IMMUNE RESPONSES IN PATIENTS WITH CHRONIC HEPATITIS C

THE HNRNP H1 MODULATES PRODUCTION OF HCV PARTICLES THROUGH INTERACTION WITH HCV CORE PROTEIN AND HCV IRES RNA

Norma I. Rallón1, Vincent Soriano1, Javier García-Samaniego2, Mariola López1, Miriam Romero2, Clara Restrepo1, Sara Lozano1, Alejandra Peris1, Juan González-Lahoz1, José M. Benito1 1Infectious Diseases Department, Hospital Carlos III, Madrid, Spain. 2Hepatology Unit, CIBEREHD, Hospital Carlos III, Madrid, Spain

#1423 AN INTERLEUKIN-12 FAMILY CYTOKINE, IL-27 INHIBITS HEPATITIS C VIRUS REPLICATION IN VITRO BOTH DIRECTLY AND SYNERGISTICALLY WITH INTERFéRON ALPHA Astrid C. Frank2, Antonios Katsounas1, Jennifer Bharucha1, Tomozumi Imamichi1, Shyam Kottilil2 1NCI-Frederick, SAIC, Bethesda, MD, USA. 2NIAID/NIH, Bethesda, MD, USA

#1424 TELAPREVIR TREATMENT TO A HUMAN HEPATOCYTE CHIMERIC MOUSE WITH GENETICALLY ENGINEERED HEPATITIS C VIRUS INFECTION Michio Imamura1, Nobuhiko Hiraga1, Fukiko Mitsui1, Masataka Tsuge1, Shoichi Takahashi1, Naohiro Kamiya2, Eiji Iwao2, Kazuaki Chayama1 1Department of Medicine and Molecular Science, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. 2Pharmacology laboratory (liver diseases), Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan

#1425 A NOVEL SYSTEM FOR MONITORING GENOTYPE 1A HEPATITIS C VIRUS RNA REPLICATION AND ANTIVIRAL DRUG RESISTANCE IN CELL CULTURE Tetsuro Shimakami1, MinKyung Yi2, Nigel Bourne3, Stanley M. Lemon2 1Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. 2Center for Hepatitis Research, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. 3Pediatrics, University of Texas Medical Branch, Galveston, TX, USA

#1426



THE SUBSTITUTIONS IN AMINO ACID 70 AND 75 IN THE HEPATITIS C VIRUS GENOTYPE 1B CORE REGION CORRELATE WITH LIVER STEATOSIS AND THE SUBSTITUTIONS IN AMINO ACID 91 CORRELATE WITH HEPATIC OXIDATIVE STRESS IN PATIENTS WITH CHRONIC HEPATITIS C Yoshihiko Tachi, Yoshiaki Katano, Kazuhiko Hayashi, Masatoshi Ishigami, Isao Nakano, Hidemi Goto Gastroenterology, nagoya univ, Nagoya, Japan


Ikuo Shoji, Hak Hotta Department of Microbiology, Kobe University Graduate School of Medicine, Kobe, Japan

#1428 ANTI-HEPATITIS C VIRAL ACTIVITIES BY INDUCIBLE STAT1 ACTIVATION Luyu Yao1, Huijia Dong3, Haizhen Zhu4, David R. Nelson2, Chen Liu3, Louis Lambiase1, Xiaoyu Li1 1Medicine/GI Division, University of Florida-Jacksonville, Jacksonville, FL, USA. 2Medicine/GI Division, University of Florida, Gainesville, FL, USA. 3Pathology, University of Florida, Gainesville, FL, USA. 4Biomedical Engineering Center, Hunan University, Changsha, China

#1429 EARLY AND VERYEARLY VIRAL LOAD KINETICS ON PEGIFN+RBV THERAPY IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV INFECTION Cecilia Ortiz3,1, F. Xavier Lopez-Labrador4,5, Victoria Aguilera2,1, Raquel Canada3,1, Maria Jose Centelles3, Ruth Llusar3, Ainhoa Garcia3, Martin Prieto2,1, Blas Risalde2,1, Marina Berenguer2,1 1Ciberehd, Health Institute Carlos III, Valencia, Spain. 2Hepatology Department, Hospital la Fe, Valencia, Spain. 3Experimental Immunity Unit, Hospital la Fe, Valencia, Spain. 4Public Health Department, Generalitat Valenciana CSISP Evol. Genetics, Institut Cavanilles, University of Valencia, Valencia, Spain. 5Ciberesp, Health Institute Carlos III, Valencia, Spain

#1430 IDENTIFICATION OF HOST MICRORNAS THAT BLOCK HCV REPLICATION IN VITRO AS POTENTIAL TARGETS FOR TREATMENT OF HCV Xiaozhen Zhang, Marybeth Daucher, Shyam Kottilil LIR, NIAID, NIH, Bethesda, MD, USA

#1431 LA PROTEIN REQUIRED FOR HCV IRES-DIRECTED TRANSLATION IS INDUCED BY HCV INFECTION AND ACTIVATES HUMAN TELOMERASE ACTIVITY IN HUH-7.5 CELLS Takayoshi Shirasaki1,2, Masao Honda1,2, Hideki Mizuno1, Tetsuro Shimakami1, Hikari Okada1, Yuki Takebuchi1, Yoshio Sakai1, Shuichi Kaneko1 1Department of Gastroenterology, Kanazawa University, Kanazawa Ishikawa, Japan. 2Division of Health Sciences, Kanazawa University, Kanazawa Ishikawa, Japan

#1432 ACUTE HEPATITIS C INFECTION IS ASSOCIATED WITH HYPOLIPIDEMIA Kathleen E. Corey1, Jorge Mendez-Navarro1, Vilas Patwardhan2, Raymond Chung1 1Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA. 2MGH, Boston, MA, USA


POSTER SESSIONS

#1433 A SET OF INTERFERON-INDUCED GENES IN PBMC AS PREDICTIVE FACTOR FOR HCV TREATMENT RESPONSE: A PILOT STUDY Catherine François1, Veronique Descamps1, Etienne Brochot1, Sandrine Castelain1, Eric Nguyen-Khac2, Dominique Capron2, Gilles Duverlie1 1Virology, University of Picardie Jules Verne, Amiens, France. 2Hepato-Gastroenterology, Amiens University Hospital, Amiens, France

#1434 DYNAMICS OF CD81 EXPRESSION IN AMANTADINE TREATED CHRONIC HCV INFECTION Martin W. Welker1, Michael von Wagner1, Vincent Zimmer2, Wolf P. Hofmann1, Albrecht Piiper1, Christoph Sarrazin1, Eva Herrmann3, Stefan Zeuzem1, Bernd Kronenberger1 1Medizinische Klinik 1, Universitätsklinikum Frankfurt, Frankfurt, Germany. 2Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg, Germany. 3Institut für Biostatistik und mathematische Modellierung des Fachbereichs Medizin, Johann Wolfgang Goethe-Universität, Frankfurt, Germany

#1435 THE EFFECT OF INTERFERON-BETA AND RIBAVIRIN COMBINATION THERAPY ON MICRORNA122 EXPRESSION ON THE HUMAN HEPATOMA CELL LINE HUH7/CON1 Bangdong Gong, Qing Xie, Xiaogang Xiang, Gangde Zhao, Hong Yu Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

#1436 VIRAL DYNAMICS AND EARLY VIRAL RESPONSE AT WEEK 4 IN CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGINTERFERON α2B AND RIBAVIRIN Aurora Loaeza del Castillo1, S. Sixtos-Alonso2, F. Sanchez-Avila2, M. Uribe2 1Medicine, Instituto Nacional de Ciencias Medicas y Nutricion “Salvador Zubiran”, Mexico city, Mexico. 2Gastroenterology, Instituto Nacional de Ciencias Medicas y Nutrición “Salvador Zubiran”, Mexico city, Mexico

247A

#1438 HEPATITIS B VIRUS (HBV) TRANSMISSION RATE AMONG CHILDREN BORN TO CHINESEAMERICAN MOTHERS WITH CHRONIC HEPATITIS B (CHB) IN THE NEW YORK DOWNTOWN AREA Li-Jun Mi1, Jeffrey Karsdon2, William M. Huang3, Betty Chiang4, Marc G. Ghany5, Giuseppe Del Priore6, Eric Poon7,8, Michelle Leong8, Robert S. Brown9 1Out-Patient Division, Department of Medicine, New York Downtown Hospital, New York, NY, USA. 2Neonatology, Department of Pediatrics, New York Downtown Hospital, New York, NY, USA. 3Maternal-Fetal Medicine, Department of Obstertrics & Gynecology, New York Downtown Hospital, New York, NY, USA. 4Hepatitis Medical Sciences, Gilead Sciences, Inc., Foster City, CA, USA. 5Liver Disease Branch, National Institutes of Health, NIDDK, Bethesda, MD, USA. 6Department of Obstetrics & Gynecology, New York Downtown Hospital, New York, NY, USA. 7Department of Pediatrics, New York Downtown Hospital, New York, NY, USA. 8Chinese Community Partnership for Health, New York, NY, USA. 9Division of Liver Disease and Transplantation, Columbia University Medical Center, New York, NY, USA

#1439 LIVER REGENERATION IN UPA/SCID MICE INDUCED CCCDNA CLEARANCE IN THE MAJORITY OF HEPADNAVIRUS INFECTED HEPATOCYTES Joerg Petersen1, Marc Lutgehetmann2,3, Ansgar W. Lohse2, Tassilo Volz2, Maura Dandri2 1Asklepiosklinik St. Georg, Liver Center Hamburg IFI Institute, University of Hamburg, Germany. 2Department of Medicine, University Hospital Hamburg Eppendorf, Hamburg, Germany. 3Department of Microbiology, University Hospital Hamburg Eppendorf, Hamburg, Germany

#1440 HEPATITIS B VIRUS INDUCES INTERLEUKIN-8 (IL-8) PRODUCTION IN HEPATOCYTES AND IL-8 IN TURN INHIBITS INTERFERON ALFA ANTIVIRAL ACTIVITY Teresa Pollicino1, Luigi Bellinghieri1,2, Giuseppina Raffa1, Agnese Restuccia1, Diana Teti2, Giovanni Raimondo1 1Internal Medicine, University Hospital of Messina, Messina, Italy. 2Experimental Pathology and Microbiology, University Hospital of Messina, Messina, Italy

#1437 OXIDATIVE STRESS INDUCES ANTI-HCV STATUS VIA THE ACTIVATION OF MEK-ERK1/2 SIGNALING PATHWAY M O N D AY NOVEMBER 1

Masahiko Yano1,2, Masanori Ikeda2, Ken-ichi Abe2, Yoshinari Kawai2, Misao Kuroki2, Kyoko Mori2, Hiromichi Dansako2, Yasuo Ariumi2, Yasunobu Matsuda1, Shougo Ohkoshi1, Yutaka Aoyagi1, Nobuyuki Kato2 1Department of Gastroenterology and Hepatology, Niigata University Graduate School, Niigata, Japan. 2Department of Tumor Virology, Okayama University Graduate School, Okayama, Japan

248A

POSTER SESSIONS

#1441

#1445

PREVALENCE OF HEPATITIS B “E” ANTIGEN NEGATIVE ACTIVE HEPATITIS IN ALASKA NATIVE PERSONS WITH CHRONIC HEPATITIS B INFECTION: A PROSPECTIVE 7 YEAR FOLLOW-UP STUDY

PERSISTENCE AT LOW-LEVELS OF ANTIVIRAL RESISTANT HEPATITIS B VIRUS (HBV) QUASISPECIES AND EXTRAHEPATIC WILD-TYPE VIRAL RESERVOIRS DESPITE ANTIVIRAL PROPHYLAXIS AFTER LIVER TRANSPLANTATION (LT)

Brian J. McMahon1,2, Lisa Bulkow2, Stephen Livingston1, Chriss E. Homan1, Susan Negus1, Mary Snowball1, Sandra S. Chaves3, Dale Hu3, Michael Bruce2 1Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK, USA. 2Arctic Investigations Program, National Centers for Division of Emerging Infections and Surveillance Services, National Center for Preparedness, Detection and Control of Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK, USA. 3Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA

#1442 ROLE OF APOBEC3A AND APOBEC3B GENES IN CHRONIC HEPATITIS B VIRUS INFECTION Hiromi Abe1,2, Hidenori Ochi2, Masataka Tsuge2, Nobuhiko Hiraga2, Michio Imamura2, Shoichi Takahashi2, Kazuaki Chayama1,2 1Center for Genomic Medicine Laboratory for Digestive Diseases, Riken Yokohama Institute, Hiroshima, Japan. 2Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan

#1443 DETECTION OF VIRUS-SPECIFIC CD4+ T-CELLS IN HBV INFECTION VIA CD154 AND THEIR RESPONSIVENESS TO PD-1 BLOCKADE Bijan Raziorrouh1, Malte H. Heeg1, Winfried Schraut1, Norbert Grüner1, Axel Ulsenheimer1, Martin Waechtler2, Daniela Nowack1, Helmut M. Diepolder1, Maria C. Jung1,3 1Medical Dep. II, University hospital Munich Grosshadern, Munich, Germany. 2Medical Dep. I, Klinikum Schwabing, Munich, Germany. 3Leberzentrum, Munich, Germany

#1444 CHARACTERIZATION OF TWO HCC SUBGROUPS RELATED TO HBV INFECTION: ASSOCIATION BETWEEN VIRAL AND HEPATOCYTE GENETIC FEATURES Ladeiro1,2,



Boyault1,

Bioulac-Sage3,4,

Yannick Sandrine Paulette Jessica Zucman-Rossi1,2 1U674, Inserm, Paris, France. 2Paris Descartes, Université, Paris, France. 3U889, Inserm, Bordeaux, France. 4Service d’Anatomie Pathologique, CHU Hôpital Pellegrin, Bordeaux, France


Carla S. Coffin1, Patricia M. Mulrooney-Cousins2, John P. Roberts4, Thomas I. Michalak2, Sammy Saab3,4 1University of Calgary Liver Unit, Division of Gastroenterology, Faculty of Medicine, University of Calgary, Calgary, AB, Canada. 2Molecular Virology and Hepatology Research Group, Division of Biomedical Sciences, Faculty of Medicine, Memorial University, St. Johns, NF, Canada. 3Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. 4Department of Surgery, University of California, San Francisco, San Francisco, CA, USA

#1446 SERUM HBSAG LEVELS REFLECT INTRACELLULAR HBSAG, BUT NOT CCCDNA OR TOTAL LIVER HBV DNA IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B Emanuel K. Manesis1, George V. Papatheodoridis2, Dina Tiniakos3, Emilia Hadziyannis2, Olga P. Agelopoulou3, Thalia Syminelaki3, Christos Papaioannou2, Theodoros Nastos4, Peter Karayannis4 1Division of Internal Medicine, Athens University Medical School, Athens, Greece. 2Academic Department of Medicine, Athens University School of Medicine, Hippokration General Hospital, Athens, Greece. 3Laboratory of Histology and Embryology, Athens University School of Medicine, Hippokration General Hospital, Athens, Greece. 4Department of Medicine, Hepatology Section, Division of Medicine, Imperial College, London, United Kingdom

#1447 IMPACT OF HEPATITIS B E ANTIGEN-NEGATIVITY ON THE REPLICATION OF ENTECAVIR-RESISTANT HEPATITIS B VIRUS STRAINS: A COMPREHENSIVE ANALYSIS Samad Amini-Bavil-Olyaee, Ulf Herbers, Tom Luedde, Christian Trautwein, Frank Tacke Dept of Internal Medicine III, University Hospital Aachen, Aachen, Germany

#1448 SYNERGISTIC EFFECT OF OBESITY AND ALCOHOL ON RISK OF HEPATOCELLULAR CANCER IN MEN: A PROSPECTIVE COHORT STUDY Rohit Loomba2, Hwai-I Yang3,4, Uchenna Iloeje1, Chien-Jen Chen3,4 Squibb, Wallingford, CT, USA. 2Division of Gastroenterology, University of California at San Diego, La Jolla, CA, USA. 3Genomics Research Center, Academia Sinica, Taipei, Taiwan. 4Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan 1Bristol-Myers


POSTER SESSIONS

249A

#1449

#1453

MILD-TO-MODERATE ELEVATION OF ALANINE AMINOTRANSFERASE MAY INCREASE LIVER STIFFNESS MEASUREMENT BY TRANSIENT ELASTOGRAPHY IN PATIENTS WITH CHRONIC HEPATITIS B

IDENTIFICATION OF NOVEL HEPATITIS B VIRUS (HBV) T-CELL EPITOPES AND ESCAPE MUTATIONS IN ASIAN INDIVIDUALS WITH CHRONIC HBV INFECTION USING A POPULATION BASED APPROACH

James Fung, Ching-Lung Lai, Charles Cheng, Chi Hang Wu, Danny Wong, Man-Fung Yuen University of Hong Kong, Hong Kong, China

Christopher P. Desmond1,2, Silvana Gaudieri3,4, Ian James3, Katja Pfafferott3, Abha Chopra3, George K. Lau5, Stephen Locarnini6, Peter A. Revill6, Caroline F. Day7, Sarah Chivers7, Adam Gordon2,7, Scott Bowden6, Anna Ayres6, Paul V. Desmond9,8, Alex J. Thompson8,6, Stuart K. Roberts2, Simon A. Mallal3,10, Sharon R. Lewin1,11 1Medicine, Monash University, Melbourne, VIC, Australia. 2Gastroenterology, Alfred Hospital, Melbourne, VIC, Australia. 3Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, WA, Australia. 4Centre of Forensic Science and School of Anatomy and Human Biology, University of Western Australia, Perth, WA, Australia. 5Department of Medicine, The University of Hong Kong, Hong Kong, China. 6Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia. 7Gastroenterology, Box Hill Hospital, Melbourne, VIC, Australia. 8Gastroenterology, St Vincent’s Hospital, Melbourne, VIC, Australia. 9Medicine, University of Melbourne, Melbourne, VIC, Australia. 10Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth, WA, Australia. 11Infectious Diseases, Alfred Hospital, Melbourne, VIC, Australia

#1450 IMPACT OF WILD-TYPE (WT) AND MUTANT HBX ON CYCLINE-DEPENDENT KINASE INHIBITOR P21WAF1/CIP1 EXPRESSION AND CELL CYCLE PROGRESSION AND POTENTIAL ROLE IN HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT Eva.yuehua Huang1, Munira Hussain1, Shuping Tong2, Anna S. Lok1 1Division of Gastroenterology and Hepatology, University of Michigan Health Systems, Ann Arbor, MI, USA. 2The Liver Research Center, Rhode Island Hospital and Brown Medical School, Providence, RI, USA

#1451 STRESS-RELATED PROTEINS DERIVED FROM HBVINFECTED-HEPATOCYTES ENHANCE THE SECRETORY FUNCTIONS OF REGULATORY T CELLS Yasuteru Kondo1, Yoshiyuki Ueno1, Masashi Ninomiya1, Yuta Wakui1, Jun Inoue1, Masaaki Shiina1, Eiji Kakazu1, Keiichi Tamai1, Koju Kobayashi2, Koji Fukushima1, Noriyuki Obara1, Tomoo Kobayashi4, Motoyasu Ishii3, Hirofumi Niitsuma1, Yasuhito Tanaka5, Tooru Shimosegawa1 1Gastroenterology, Tohoku University Hospital, Sendai, Japan. 2Tohoku University School of Health Science, Sendai, Japan. 3Gastroenterology, Miyagi Social Insurance Hospital, Sendai, Japan. 4Tohoku Rosai Hospital, Sendai, Japan. 5Clinical Molecular Informative Medicine, Nagoya City University, Nagoya, Japan

#1452 TLR AGONIST INDUCED IFN-γ RESPONSES BY NK AND NKT CELLS IN CHRONIC HEPATITIS B INFECTION Dilip Ratnam1,2, Kumar Visvanathan2,3, William Sievert1,2 Monash Medical Centre, Clayton, VIC, Australia. 2Medicine, Monash University, Clayton, Melbourne, VIC, Australia. 3Infectious Diseases, Monash Medical Centre, Clayton, Melbourne, VIC, Australia

1Gastroenterology,

#1454 THE EXPRESSION OF INTRAHEPATIC HBV CORE ANTIGEN IS ASSOCIATED WITH ACTIVE LIVER INFLAMMATION IN LOW VIREMIC E ANTIGENNEGATIVE CHRONIC HEPATITIS B PATIENTS Yi-Hsiang Huang1,2, Hung-Hsu Hung1, Che-Chang Chan1,2, ChungRu Lai3, Han-Chieh Lin1, Shou-Dong Lee1 1Division of Gastroenterology, Taipei Veterans General Hospital, Taipei, Taiwan. 2Institue of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. 3Department of Pathology, Taipei Veterans General Hospital, Taipei, Taiwan

#1455 IL-15 STIMULATION WITH PD-1/PD-L1/2 BLOCKADE ENHANCES HBV-SPECIFIC EFFECTOR CD8+ T CELL IMMUNITY IN HIV POSITIVE AND NEGATIVE HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS Nirupma Trehan Pati2, Marybeth Daucher1, Alison Murphy1, Shiv K. Sarin2, Richard T. Davey1, Shyam Kottilil1 1LIR, NIAID, NIH, Bethesda, MD, USA. 2Institute of Liver and Biliary Sciences, New Delhi, India

TWO SUBTYPES OF HEPATITIS B-RELATED ACUTE LIVER FAILURE: DIFFERENCES IN PATHOGENESIS AND OUTCOME Doan Y. Dao1, Hejun Yuan1, Jody A. Balko1, Corron Sanders1, Nahid Attar1, Mamta K. Jain1, Linda S. Hynan2, William M. Lee1 1Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. 2Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA


#1456

250A

POSTER SESSIONS

#1457

#1460

A GENOME-WIDE ASSOCIATION STUDY IDENTIFIES GENETIC VARIANTS IN THE HLA-DP LOCUS ASSOCIATED WITH CHRONIC HEPATITIS B

VIRAL QUASISPECIES EVOLUTION PATTERN IN CHRONIC HEPATITIS B PATIENTS WITH LAMIVUDINE TREATMENT

Kentaro Matsuura1,2, Yasuhito Tanaka1, Nao Nishida3, Shuhei Hige4, Yasuhiro Asahina5, Masayuki Kurosaki5, Yoshito Itoh6, Masaaki Korenaga7, Keisuke Hino7, Eiji Mita8, Eiji Tanaka9, Satoshi Mochida10, Kenji Oyama11, Masao Honda12, Yoichi Hiasa13, Fuminaka Sugauchi2, Katsushi Tokunaga3, Masashi Mizokami14 1Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 2Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 3Department of Human Genetics, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan. 4Department of Internal Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan. 5Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan. 6Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan. 7Division of Hepatology and Pancreatology, Kawasaki Medical College, Kurashiki, Japan. 8Department of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka, Japan. 9Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan. 10Department of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan. 11Second Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan. 12Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Knazawa, Japan. 13Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan. 14Research Center for Hepatitis and Immunology, Kohnodai Hospital International Medical Center of Japan, Ichikawa, Japan

Yan Cheng1, Stephane Guindon2, Peizhen Hu1, Allen Rodrigo3, Seng Gee Lim1,4 1Department of Medicine, National University of Singapore, Singapore, Singapore. 2Department of Statistics, University of Auckland, Auckland, New Zealand. 3Bioinformatics Institute and the Allan Wilson Center for Molecular Ecology and Evolution, University of Auckland, Auckland, New Zealand. 4Gstroenterology & Hepatology, National University Hospital, Singapore, Singapore

#1458 COMBINED T1653 AND T1762/A1764 TRIPLE MUTATION SYNERGISTICALLY INCREASED BASAL CORE PROMOTER ACTIVITY Eun Young Cho, Chang Soo Choi, Haak Cheoul Kim, Yong Hwan Ahn, Bong Jun Yang gastroenterology and hepatology, wonkwang university, Iksan, Korea, South

#1459 HEPATITIS B VIRUS IN VITRO INFECTION OF HUMAN LIVER PROGENITOR CELLS



Massimiliano Paganelli1, Dung N. Khuu1, Mustapha Najimi1, Ivone Malla1, Benoit Kabamba-Mukadi2, Patrick Goubau2, Etienne M. Sokal1 1Pediatric Hepatology and Cell Therapy Lab, Université Catholique de Louvain, Brussels, Belgium. 2Virology Lab, Université Catholique de Louvain, Brussels, Belgium


#1461 HBV GENOTYPE AND BASAL CORE PROMOTER/PRECORE MUTATIONS ARE ASSOCIATED WITH HEPATITIS B-RELATED ACUTEON-CHRONIC LIVER FAILURE WITHOUT PREEXISTING LIVER CIRRHOSIS Dongping Xu, Xiaoqiang Ren, Zhihui Xu, Yan Liu, Yanwei Zhong, Siyu Bai, Liming Liu, Xiaodong Li, Ning Ding Viral Hepatitis Research Laboratory, Institute of Infectious Diseases, Beijing 302 Hospital, Beijing, China

#1462 DISCRIMINATIVE ROLE OF THE NEW AND OLD CUTOFF ALANINE TRANSAMINASE VLUES AS PEDICTORS OF LIVER FIBROSIS IN HEPATITIS B GENOTYPE-D PATIENTS Faisal M. Sanai1, Khalid I. Bzeizi1, Mohammed A. Babatin5, Ahmed Helmy3, Mohammed Q. Khan3, Abdallah S. AlMdani1, Hamad I. Al-Ashgar3, Abdullah S. AlGhamdi5, Haziz Albiladi5, Ahmed A. Al-Qahtani4, Ahmed A. Al-Akwaa6, Ayman Abdo2 1Gastroenterology, Riyadh Military Hospital, Riyadh, Saudi Arabia. 2Gastroenterology, King Khalid University Hospital, Riyadh, Saudi Arabia. 3Gastroenterology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. 4Virology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. 5Gastroenterology, King Fahad General Hospital, Jeddah, Saudi Arabia. 6Gastroenterology, King Abdulaziz Medical City, AlAhsa, Saudi Arabia

#1463 HBSAG SERUM LEVELS DISTINGUISH ACTIVE FROM INACTIVE INFECTION IN GENOTYPE D HBEAG NEGATIVE/ANTI-HBE POSITIVE CARRIERS Maurizia R. Brunetto1, Filippo Oliveri1, Piero Colombatto1, Francesco Moriconi1, Pietro Ciccorossi1, Barbara Coco1, Veronica Romagnoli1, Beatrice Cherubini1, G. Moscato2, A. M. Maina1, Daniela Cavallone1, Ferruccio Bonino3,4 1Liver Unit - University Hospital of Pisa, Pisa, Italy. 2Central Laboratory - University Hospital of Pisa, Pisa, Italy. 3University of Pisa, Pisa, Italy. 4Fondazione IRCCS Policlinico of Milan, Milano, Italy


POSTER SESSIONS

251A

#1464

#1469

PROSPECTIVE LONGITUDINAL COMPARISON OF TRANSIENT ELASTOGRAPHY (FIBROSCAN) AND FIBROTEST FOR DISCRIMINATING INACTIVE HEPATITIS B CARRIERS FROM HBEAG-NEGATIVE DISEASE

IMPAIRED CHEMOKINE RECEPTORS BUT NOT T REGULATORY CELLS EXPRESSION IS PARTIALLY RESTORED AFTER VACCINATION IN NEWBORNS BORN TO HBV POSITIVE MOTHERS

Laurent Castera1,2, Pierre-Henri Bernard2, Brigitte Le Bail3, Juliette Foucher1,2, Pascale Trimoulet4, Wassil Merrouche1, Victor de Ledinghen1, Patrice Couzigou1 1Hepatogastroenterology, Hopital Haut Leveque, CHU Bordeaux, Pessac, France. 2Hepatogastroenterology, Hopital St Andre, CHU Bordeaux, Bordeaux, France. 3Pathology, Hopital Pellegrin, CHU Bordeaux, Bordeaux, France. 4Virology, Hopital Pellegrin, CHU Bordeaux, Bordeaux, France

#1465 LIVER STIFFNESS AND HISTOLOGICAL FEATURES IN HEALTHY PERSONS, AND PATIENTS WITH OCCULT HEPATITIS B, CHRONIC ACTIVE HEPATITIS B, AND HEPATITIS B-RELATED CIRRHOSIS James Fung, Ching-Lung Lai, See-Ching Chan, David But, Walter Wai Kay Seto, Charles Cheng, Danny Wong, Chung-Mau Lo, Sheung Tat Fan, Man-Fung Yuen University of Hong Kong, Hong Kong, China

#1466 HEPATITIS B VIRUS CORE-RELATED ANTIGEN AS A USEFUL MARKER FOR THE COMPREHENSION OF HBV STATUS IN HEPATOCYTES Shuhei Hige, Makoto Chuma, Tomoe Kobayashi, Hiromasa Horimoto, Takuya Sho, Mitsuru Nakanishi, Masahiro Asaka Gastroenterology, Hokkaido University, Sapporo, Japan

#1467 IN VITRO SUSCEPTIBILITY OF HBV STRAINS ISOLATED FROM HIV-HBV COINFECTED PATIENTS WITH DELAYED RESPONSE TO TENOFOVIR DF Olivier Lada1, Anne Gervais2, Michel Branger3, Benedicte Roquebert3, Gilles Peytavin4, Giles Collin3, Gil Fraqueiro2, Rami Moucari1, Laurence Leclere1, Michelle Martinot-Peignoux1, Sophie Matheron2,5, Patrick Marcellin1,5 1service d’hépatologie, Hopital Beaujon and INSERM CRB3, Clichy, France. 2Service des maladies infectieuses et tropicales, AP-HP Hopital Bichat Claude Bernard, Paris, France. 3Service de virologie, AP-HP Hopital Bichat Claude Bernard, Paris, France. 4Service de pharmacie clinique, AP-HP Hopital Bichat Claude Bernard, Paris, France. 5Universite Denis Diderot-Paris7, Paris, France

#1468

Olivier Lada1, Roberto J. Carvalho-Filho1, Rami Moucari1, MariePierre Ripault1, Laurence Leclere1, Tarik Asselah1,2, Corinne Castelnau1, Michelle Martinot-Peignoux1, Nathalie Boyer1,2, Michel Vidaud3, Patrick Marcellin1,2 1service d’hépatologie, Hopital Beaujon and INSERM CRB3, Clichy, France. 2Universite Denis Diderot-Paris 7, Paris, France. 3Service de Biochimie, AP-HP, Hopital Beaujon, Clichy, France

#1470 DYNAMICS OF HBV-SPECIFIC CTL RESPONSE IN PATIENTS WITH ACUTE HEPATITIS B Jun Li, Yaping Han, Yufeng Wan, Bo Liu, Zuhu Huang Department of Infectious Diseases, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China

#1471 A NONINVASIVE MODEL FOR PREDICTING SIGNIFICANT FIBROSIS IN CHRONIC HEPATITIS B Yeon Seok Seo1, Kwang Gyun Lee1, Eun Suk Jung1, Ji Hoon Kim1, Hyonggin An2, Bora Keum1, Hyung Joon Yim1, Yoon Tae Jeen1, Jong Eun Yeon1, Hoon Jai Chun1, Kwan Soo Byun1, Soon Ho Um1,3, Chang Duck Kim1, Ho Sang Ryu1 1Internal Medicine, Korea University College of Medicine, Seoul, Korea, South. 2Biostatistics, Korea University College of Medicine, Seoul, Korea, South. 3Liver Cirrhosis Clinical Research Center, Seoul, Korea, South

#1472 THE STATUS OF HBV CORE INTERNAL DELETIONS IN CHRONIC HEPATITIS B PATIENTS WITH HBEAG SEROCONVERSION SPONTANEOUSLY, INDUCED BY INTERFERON OR LAMIVUDINE TREATMENT Yan Cheng1, Peizhen Hu1, Bee Leng Seet1, Seng Gee Lim1,2 of Medicine, National University of Singapore, Singapore, Singapore. 2Gastroenterology & Hepatology, National University Hospital, Singapore, Singapore 1Department

#1473 PREVALENCE, RISK FACTORS AND PROFILE OF CHRONIC HEPATITIS B VIRUS INFECTION IN PREGNANT WOMEN IN INDIA: STUDY ON TWENTY THOUSAND PREGNANT WOMEN Chandana Pande1,3, Shiv K. Sarin1,2, Sharda Patra4, Kazila Bhutia4, Siddhartha K. Mishra1, Sangeeta Pahuja5, Manjula Jain5, Shikha Shrivastava1, Sadaf B. Dar1, Shubha S. Trivedi4, Ashish Kumar2,3 1Gastroenterology, G B Pant Hospital, New Delhi, India. 2Hepatology, Institute of Liver & Biliary Sciences (ILBS), New Delhi, India. 3Special Centre for Molecular Medicine (SCMM), Jawaharlal Nehru University (JNU), New Delhi, India. 4Obstetrics & Gynaecology, Lady Hardinge Medical College, New Delhi, India. 5Blood Bank, Pathology, Lady Hardinge Medical College, New Delhi, India


PRIMARY RESISTANCE MUTATIONS PREEXIST IN HBV MONOINFECTED PATIENTS WHO DO NOT RESPOND TO ADEFOVIR THERAPY

Shikha Shrivastava1, Nirupma T. Pati1,2, Chandana Pande1, Kazila Bhutia3, Sharda Patra3, Shubha S. Trivedi3, Shiv K. Sarin1,2 1Gastroenterology, G B Pant Hospital, New Delhi, India. 2Research, Institute of Liver And Biliary Sciences, New Delhi, India. 3Gynecology, LHMC Hospital, New Delhi, India

252A

POSTER SESSIONS

#1474

#1478

LOW PREVALENCE OF HEPATITIS B VIRUS (HBV) DNA POLYMERASE/REVERSE TRANSCRIPTASE (RT) MUTATIONS IN A COHORT OF 472 TREATMENTNAïVE PATIENTS WITH CHRONIC HEPATITIS B (CHB)

EFFICIENT HEPATITIS B VIRUS SECRETION REQUIRES M PROTEIN EXPRESSION BUT NOT OVERPRODUCTION OF SUBVIRAL PARTICLES

Mindie H. Nguyen1, Ruel T. Garcia2,3, Huy N. Trinh2,3, Huy A. Nguyen2, Khanh K. Nguyen2, Brian S. Levitt2 1Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA. 2San Jose Gastroenterology, San Jose, CA, USA. 3Pacific Health Foundation, San Jose, CA, USA

Tamako A. Garcia1, Jisu Li1, Camille C. Sureau2, Jack R. Wands1, Shuping Tong1 1Liver Research Center, RI Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA. 2Laboratoire de Virologic Moleculaire, INTS, Paris, France

#1479

#1475

ALTERED PHENOTYPE AND FUNCTION OF NATURAL KILLER CELLS IN CHRONIC HEPATITIS B

DEVELOPMENT OF PRECORE AND BASIC CORE PROMOTER HBV MUTATIONS IN CHRONIC HEPATITIS B GENOTYPES D AND A. A PROSPECTIVE STUDY IN A CAUCASIAN POPULATION

Eric Tjwa1, Gertine van Oord1, Joost P. Hegmans2, Harry L. Janssen1, Andrea M. Woltman2 1Hepatology and Gastroenterology, Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands. 2Pulmonary Medicine, Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands

Evangelini Dimou1,2, Irene Rapti1,2, Ageliki Kostamena2, Andreas Laras2, Stephanos J. Hadziyannis1,2 1Department of Medicine and Liver Unit, Henry Dunant Hospital, Athens, Greece. 2Hepatitis Research Laboratory at Evgenidion Hospital, Athens University, Athens, Greece

#1476 DETECTION OF HEPATITIS B COVALENTLY CLOSED CIRCULAR DNA (CCCDNA) IN PARAFFINEMBEDDED AND CRYO-PRESERVED LIVER BIOPSIES OF CHRONIC HEPATITIS B PATIENTS Bart Takkenberg1, Hans L. Zaaijer2, Valeska Terpstra3, Annikki de Niet1, Christine J. Weegink1, Maarten Koot4, Marcel Dijkgraaf5, Peter L. Jansen1, Hendrik W. Reesink1, Marcel Beld6 1AMC Liver Center; Department of Gatroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands. 2Medical Microbiology and Karl Landsteiner Laboratory, Academic Medical Center, Center for Infectious Disease and Immunology (CINIMA), Amsterdam, Netherlands. 3Department of Pathology, Academic Medical Center, Amsterdam, Netherlands. 4Department of Virus Diagnostic Services, Sanquin, Amsterdam, Netherlands. 5Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, Netherlands. 6KIT Biomedical Research, Amsterdam, Netherlands

#1477 QUANTITATIVE HBEAG AND HBSAG: LEVELS CORRELATE WITH HEPATITIS B VIRAL LOAD AND QUASI SPECIES SUGGESTING A SINGLE CONTROL MECHANISM



Miriam Levy1, Sally L. Ayesa1, Robert Porritt3, Michael Maley3, Tin Nguyen2, Tim Shaw2, Stephen J. Tattersall1, Anna Ayres2, Stephen Locarnini2 1Gastroenterology and Hepatology, Liverpool Hospital, Sydney, NSW, Australia. 2Molecular Research and Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia. 3Microbiology and Infectious Diseases, Liverpool Hospital, Sydney, NSW, Australia


#1480 SERUM HEPATITIS B VIRUS DNA LEVEL AT ONE YEAR POST HEPATITIS B E ANTIGEN SEROCONVERSION PREDICTS SUBSEQUENT LIVER CIRRHOSIS DEVELOPMENT Taichung Tseng1, Chun-Jen Liu2, Chia-Chi Wang1, Pei-Jer Chen2, Ming-Yang Lai2, Ding-Shinn Chen2, Jia-Horng Kao2 1Buddhist Tzu Chi General Hospital Taipei Branch, Taipei, Taiwan. 2National Taiwan University Hospital, Taipei, Taiwan

#1481 WITHDRAWN

#1482 QUANTITATIVE HBS ANTIGEN LEVELS IN THE CONTEXT OF DIFFERENT PHASES OF PERSISTENT HEPATITIS B VIRUS INFECTION Jerzy Jaroszewicz1,2, Beatriz Calle Serrano1, Jerome Schlue3, Katja Deterding1, Karsten Wursthorn1, Regina Raupach1, Michael P. Manns1, Robert Flisiak2, Heiner Wedemeyer1, Markus Cornberg1 1Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany. 2Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland. 3Department of Pathology, Medical School Hannover, Hannover, Germany

#1483 THE BINDING AFFINITY OF BETA2GLYCOPROTEIN I TO HEPATITIS B SURFACE ANTIGEN IN CHRONIC HEPATITIS B PATIENTS He Chuan, Jing Xue, Jiang Yanfang, Gao Pujun Department of hepatology, First Hospital, Jilin University, Changchun, China


POSTER SESSIONS

253A

#1484

#1489

BETA2-GLYCOPROTEIN I AS A NOVEL FACTOR IN THE PROGRESS OF HEPATOCELLULAR CARCINOMA

STANDARDIZED META-ANALYSIS OF FIBROTESTFIBROSURE (FT) DIAGNOSTIC VALUE FOR THE DIAGNOSIS OF FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS B

Jing Xue, He Chuan, Jiang Yanfang, Gao Pujun Department of hepatology, First Hospital, Jilin University, Changchun, China

#1485 THE DIFFERENT OUTCOMES OF HEPATITIS B VIRUS INFECTION WITH BASAL CORE PROMOTER T1762/A1764, PRECORE A1896 AND P REGION MUTATIONS Jinxin Zheng, Zheng Zeng, Yingying Zheng, Yanyan Yu Peking University First Hospital, Beijing, China

#1486 IS PREVIOUS EXPOSURE TO HEPATITIS B A RISK FACTOR FOR PANCREATIC CANCER? Jeffrey Tang1, Lois Lamerato2, Michael J. Sheehan2, Richard Krajenta2, Stuart C. Gordon1 1Gastroenterology, Henry Ford Health System, Detroit, MI, USA. 2Biostatistics and Research Epidemiology, Henry Ford Health System, Detroit, MI, USA

#1487 HEPATITIS B VACCINATION WITH OR WITHOUT HEPATITIS B IMMUNOGLOBULIN (HBIG) AT BIRTH TO BABIES BORN OF HBSAG POSITIVE MOTHERS PREVENTS OVERT HBV TRANSMISSION BUT MAY NOT PREVENT OCCULT HBV INFECTION IN BABIES Chandana Pande1,4, Shiv K. Sarin1,2, Ashish Kumar2,4, Siddhartha K. Mishra1, Sharda Patra3, Shikha Shrivastava1, Kazila Bhutia3, Poppy Hazarika3, Shubha S. Trivedi3 1Gastroenterology, G B Pant Hospital, New Delhi, India. 2Hepatology, Institute of Liver & Biliary Sciences, New Delhi, India. 3Obstetrics & Gynaecology, Lady Hardinge Medical College, New Delhi, India. 4Special Centre for Molecular Medicine (SCMM), Jawaharlal Nehru University (JNU), New Delhi, India

#1488 HEPATITIS B VIRUS GENOTYPE G (HBV/G) HAS A HIGHER REPLICATION CAPACITY THAN BOTH THE CO-INFECTING HBV/A AND HBV/A/G RECOMBINANT STRAINS WITHIN A SINGLE PATIENT Jamie Borlang, Carla Osiowy Bloodborne Pathogens and Hepatitis, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada

Yen Ngo1,2, Mona Munteanu1,2, Dominique Thabut1,3, Françoise Imbert-Bismut1,4, Djamila Messous1,4, Julien Massard1,3, Pascal Lebray1,3, Joseph Moussalli1,3, Yves Benhamou1,3, Vlad Ratziu1,3, Thierry Poynard1,3 1Hepatology, APHP UPMC Liver Center, Paris, France. 2Hepatology, Biopredictive, Paris, France. 3Hepatology, Hopital Pitie Salpetriere, Paris, France. 4Biochemistry, Hopital Pitie Salpetriere, Paris, France

#1490 ANALYSIS OF INFECTIVITY OF HEPATITIS B VIRUS (HBV) MUTANTS RESISTANT TO NUCLEOSIDE ANALOGS Gaetan Billioud1,2, Christian Pichoud1,2, Malika Ait-goughoulte1,2, Katyna Borroto-Esoda3, Fabien Zoulim1,4 1INSERM, Lyon cedex 03, France. 2Université Lyon 1, LYON, France. 3Gilead Sciences, Foster city, CA, USA. 4Hospices civils de Lyon, LYON, France

#1491 INTERACTIONS BETWEEN HEPATITIS B VIRUS AND AFLATOXIN B1 IN THE HEPARG CELL MODEL: EFFECTS ON VIRAL REPLICATION, ADDUCT FORMATION AND REPAIR, AND P53 RESPONSE Myriam Lereau1,2, Ahmad Besaratinia3, Gerd P. Pfeifer3, Pierre Hainaut2, Isabelle Chemin1 1INSERM U871, Lyon, France. 2IARC, Lyon, France. 3City of Hope National Medical Center, Duarte, CA, USA

#1492 MODULATION OF IFNα/β TRANSCRIPTOME BY HEPATITIS B VIRUS REPLICATION Barbara Testoni1,2, Julie Lucifora3, Laura Belloni1,2, Cecilia Scisciani2,3, David Durantel4,5, Fabien Zoulim4,6, Massimo Levrero1,3 1Dept of Internal Medicine, Sapienza University, Rome, Italy. 2Laboratory of Gene Expression,, A. Cesalpino Foundation, Rome, Italy. 3Laboratoire Associé INSERM U785, INSERM, Rome, Italy. 4INSERM U871, INSERM, Lyon, France. 5Université Lyon 1, Lyon, France. 6Hôtel Dieu Hospital, Lyon, France

#1493 THERAPEUTIC VIROLOGICAL RESPONSE RESTORES IMPAIRED CAPACITY OF MYELOID DENDRITIC CELLS IN CHRONIC HEPATITIS B VIRUS INFECTION M O N D AY NOVEMBER 1

Koyo Higashitani, Tatsuya Kanto, Masanori Miyazaki, Michiyo Inoue, Tokuhiro Matsubara, Naruyasu Kakita, Mitsuru Sakakibara, Naoki Hiramatsu, Tetsuo Takehara, Akinori Kasahara, Norio Hayashi Department of Gastroenterology and Hepatology, Osaka University. Graduate School of Medicine., Suita city, Japan

254A

POSTER SESSIONS

#1494

#1499

CLINICAL SIGNIFICANCE OF A NOVEL HIGHSENSITIVITY HEPATITIS B SURFACE ANTIGEN IMMUNOASSAY IN PATIENTS WITH HEPATITIS B VIRUS INFECTION

SERIAL HBV-DNA LEVELS OVER 10 YEARS AFTER SPONTANEOUS HBEAG SEROCONVERSION IN PATIENTS WITH SUSTAINED REMISSION

Fuminaka Sugauchi1, Yasuhito Tanaka2, Fuat Kurbanov2, shunsuke nojiri1, Kentaro Matsuura1, Sonia Roman3, Panduro Arturo3, JongHong Kang4, Kiyoaki Ito5, Takashi Joh1, Masashi Mizokami5 1Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 2Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. 3Department of Molecular Biology in Medicine, Civil Hospital of Guadalajara, Jalisco, Mexico. 4Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan. 5Research Center for Hepatitis and Immunology, Kohnodai Hospital International Medical Center of Japan, Ichikawa, Japan

#1495 TRANSFORMING GROWTH FACTOR-β1 GENE POLYMORPHISMS ARE ASSOCIATED WITH PROGRESSION OF LIVER FIBROSIS IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION Guo Jianchun, Lou Guoqiang Department of liver disease, Hangzhou sixth hospital, Zhejiang chinese medical university, Hangzhou, China

#1496 INHIBITION OF HEPATITIS B VIRUS WITH RNAI BASED ON MICRORNA Tang Tongyu, Jiang Yanfang, Cai Yanjun, Niu Junqi Department of hepatology, First hospital, Changchun, China

#1497 PREVALENCE OF OCCULT HEPATITIS B AMONG ANTI-HEPATITIS B CORE POSITIVE BLOOD DONORS Paul A. Schmeltzer, Susan D. Rouster, Kenneth E. Sherman Gastroenterology, University of Cincinnati, Cincinnati, OH, USA

#1498 NO INCREASE IN INTRAHEPATIC MONONUCLEAR CELL OR STELLATE CELL ACTIVATION IN HIV-HBV CO-INFECTED INDIVIDUALS WITH ADVANCED HIV AND MILD LIVER DISEASE



David M. Iser1,2, Alison J. Boyd3, Anchalee Avihingsanon4, Alex J. Thompson1,6, Tin Nguyen1,6, Gail Matthews5, Scott Bowden6, Stephen Locarnini6, John Slavin3, Paul V. Desmond1, Gregory J. Dore5, Kiat Ruxrungtham4, Sharon R. Lewin2,7 1Dept of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, VIC, Australia. 2Infectious Diseases Unit, Alfred Hospital, Melbourne, VIC, Australia. 3Department of Pathology, St. Vincent’s Hospital, Melbourne, VIC, Australia. 4HIV-NAT and Chulalongkorn University, Bangkok, Thailand. 5National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, VIC, Australia. 6Victorian Infectious Diseases Reference Laboratory, North Melbourne, VIC, Australia. 7Department of Medicine, Monash University, Melbourne, VIC, Australia


Yi-Cheng Chen, Yun-Fan Liaw Liver Research Unit, Chang Gung Memorial Hospital and University, Taoyuan, Taiwan

#1500 IRF-3 IS INVOLVED IN THE RESTRICTION OF BACULOVIRUS-TRIGGERED HBV REPLICATION IN HEPARG CELLS Julie Lucifora3, Marion Gruffaz1, Malika Ait-Goughoulte1, Olivier Hantz1, Ulrike Protzer3, David Durantel1,2, Fabien Zoulim1,2 1INSERM, U871, and Université de Lyon, Lyon, France. 2Hospices civils de Lyon (HCL), liver unit, Lyon, France. 3Institute of virology, Munchen, Germany


POSTER SESSIONS

Poster Session 4 Tuesday, November 3 POSTER VIEWING: 8:00 AM - 1:00 PM Hynes: Exhibit Hall C Presenters in attendance: 10:00 - 11:30 AM Those posters identified as AASLD Presidential Poster of Distinction by a ribbon icon have received review scores that place them within the top 10 percent of all posters. We encourage you to make them a priority as you visit the poster sessions.

Autoimmune Liver Disease and Cholestasis #1501

255A

#1505 MITOCHONDRIAL APOTOPES: A KEY FOR BILIARY SPECIFICITY IN PRIMARY BILIARY CIRRHOSIS Ana Lleo1,2, Guanghua Rong1,5, Masanobu Tsuda1, Carlo Selmi1,2, Pietro Invernizzi1,2, Mauro Podda2, Judy Van de Water1, Renqian Zhong5, Howard J. Worman6, Gregory J. Gores3, Aftab A. Ansari4, M. Eric Gershwin1 1Internal Medicine, University of California, Davis, Davis, CA, USA. 2Division of Internal Medicine and Liver Unit, San Paolo School of Medicine, University of Milan, Milan, Italy. 3Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA. 4Pathology, Emory University School of Medicine, Atlanta, GA, USA. 5Laboratory Medicine, ChangZheng Hospital, Second Military Medical University, Shanghai, China. 6College of Physicians and Surgeons, Department of Medicine, Columbia University, New York, NY, USA

#1506

NOVEL ROLE FOR HEDGEHOG PATHWAY ACTIVATION IN THE PATHOGENESIS OF PRIMARY SCLEROSING CHOLANGITIS

HLA-C MAY CONTRIBUTE CRITICALLY TO THE GENETIC SUSCEPTIBILITY OF PRIMARY SCLEROSING CHOLANGITIS

Vanessa S. Teaberry1, Gamze F. Karaca2, Rafal P. Witek2, WingKin Syn2, Alessia Omenetti2, Youngmi Jung2, Steve S. Choi3, Anna Mae Diehl2 1Surgery, Duke University, Durham, NC, USA. 2Medicine, Duke University, Durham, NC, USA. 3Medicine, Durham VA Medical Center, Durham, NC, USA

Johannes R. Hov1,2, Ana Lleo3,4, Carlo Selmi3,4, Bente Woldseth1, Luca Fabris5, Mario Strazzabosco6,7, Tom H. Karlsen1,2, Pietro Invernizzi4 1Department of Medicine and Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway. 2Faculty Division Rikshospitalet, Faculty of Medicine, University of Oslo, Oslo, Norway. 3Department of Translational Medicine, Universita degli Studi di Milano, Rozzano, Italy. 4Division of Internal Medicine and Hepatobiliary Immunopathology Unit, IRCCS Istituto Clinico Humanitas, Rozzano, Italy. 5Department of Surgical and Gastroenterological Sciences, University of Padova; Center for Liver Research (CeLiveR), Ospedali Riuniti di Bergamo, Italy. 6Department of Clinical Medicine and Prevention, University of Milan-Bicocca, Monza, Italy. 7Liver Center, Yale University, New Haven, CT, USA

#1502 CANAL OF HERING LOSS: MINIMAL CHANGE DIAGNOSTIC BIOPSIES IN PRIMARY BILIARY CIRRHOSIS? Arathi R. Komarla1, Fahad Khan1, Henry C. Bodenheimer1, Neil D. Theise2,1 1Medicine, Division of Digestive Diseases, Beth Israel Medical Center of Albert Einstein College of Medicine, New York, NY, USA. 2Pathology, Beth Israel Medical Center, New York, NY, USA

#1503 FENOFIBRATE IMPROVES LIVER BIOCHEMISTRIES IN PRIMARY BILIARY CIRRHOSIS Cynthia Levy1, Joy A. Peter1, Jill C. Keach2, Janice L. Petz2, Keith D. Lindor2, Roniel Cabrera1, Virginia C. Clark1, Roberto J. Firpi1, Giuseppe Morelli1, Consuelo Soldevila-Pico1, David R. Nelson1 1Liver Unit, University of Florida, Gainesville, FL, USA. 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA

#1504 LOSS OF CAPACITY TO RECOVER FROM ACIDOSIS ON REPEAT EXERCISE IS STRONGLY ASSOCIATED WITH FATIGUE IN PRIMARY BILIARY CIRRHOSIS (PBC)

THE MODULATION OF AUTOIMMUNE CHOLANGITIS IN MURINE PBC BY DELETION OF IL-12P40 Katsunori Yoshida1, Guo-Xiang Yang1, Weici Zhang1, Masanobu Tsuda1, Koichi Tsuneyama2, Aftab A. Ansari3, Zhe-Xiong Lian1, Yuki Moritoki1, Kazuichi Okazaki4, Ian R. Mackay5, M. Eric Gershwin1 1Internal Medicine, University of California, Davis, Davis, CA, USA. 2Pathology, University of Toyama School of Medicine, Toyama, Japan. 3Pathology, Emory University School of Medicine, Atlanta, GA, USA. 4The Third Department of Internal Medicine, Kansai Medical University, Hirakata, Japan. 5Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, Australia

T U E S D AY NOVEMBER 3

Kieren G. Hollingsworth1, Julia L. Newton3, Andy Blamire1, Roy Taylor1,2, David E. Jones2,3 1Newcastle Magnetic Resonance Centre, Newcastle University, Newcastle, United Kingdom. 2Institute of Cellular Medicine, Newcastle University, Newcastle, United Kingdom. 3Biomedical Research Centre in Ageing, Newcastle University, Newcastle, United Kingdom

#1507

256A

POSTER SESSIONS


#1508

#1513

INTERLEUKIN-17 AND TNFα INDUCES VCAM-1 EXPRESSION BY CHOLANGIOCYTES AND LEADS TO PERSISTENCE OF α4β1 EXPRESSING LYMPHOCYTES IN THE PORTAL TRACTS IN CHRONIC INFLAMMATORY LIVER DISEASES

GENETIC POLYMORPHISM OF FC RECEPTOR-LIKE 3 (FCRL3) GENE IS ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS IN JAPANESE BUT NOT IN ITALIAN

Elizabeth Humphreys, Claire L. Russell, Vanessa Banz, David H. Adams, Simon C. Afford, Bertus Eksteen Centre for Liver Research, University Of Birmingham, Birmingham, United Kingdom

#1509 MOUSE MAMMARY TUMOR VIRUS TRIGGERS VIRAL CHOLANGITIS IN THE NOD.C3C4 MOUSE MODEL OF PRIMARY BILIARY CIRRHOSIS Benchamas Subsin, Min Chen, Safwat Girgis, Andrew L. Mason Department of Medicine, University of Alberta, Edmonton, AB, Canada

#1510 A MODULATION OF MICROENVIRONMENT BY SENESCENT BILIARY EPITHELIAL CELLS IN THE PATHOGENESIS OF BILE DUCT LESIONS IN PRIMARY BILIARY CIRRHOSIS Motoko Sasaki, Masami Miyakoshi, Yasunori Sato, Yasuni Nakanuma Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan

#1511 LOSS OF TOLERANCE TO PYRUVATE DEHYDROGENASE COMPLEX-E2 (PDC-E2) AND PRIMARY BILIARY CIRRHOSIS (PBC)-SPECIFIC NUCLEAR ANTIGENS IN THE ABSENCE OF BIOCHEMICAL OR HISTOLOGICAL EVIDENCE OF PBC Prasun K. Jalal1, Puneet Shroff1, Gary L. Norman2, M. Eric Gershwin4, Stephen A. Geller3, Patrick S. Leung4, Rise Stribling1, John A. Goss1, John M. Vierling1 1Medicine and Surgery, Baylor College of Medicine, Houston, TX, USA. 2INOVA Diagnostics, San Diego, CA, USA. 3Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 4Division of Rheumatology, Allergy and Clinical Immunology Genome and Biomedical Sciences, University of California at Davis, Davis, CA, USA

#1512 IDENTIFICATION OF THE β- AND γ-SUBUNITS OF F1-ATPASE AS TARGET ANTIGENS IN ANTIM2/PDC-E2 NEGATIVE PRIMARY BILIARY CIRRHOSIS (PBC) Beate Preuss1, Joern Dengjel2, Stefan Stevanovic3, Reinhild Klein4 Medicine, University of Tuebingen, Tuebingen, Germany. 2Institute for Advanced Studies-LIFENET, University of Freiburg, Freiburg, Germany. 3Institute for Cell Biology, Department of Immunology, University of Tuebingen, Tuebingen, Germany. 4Internal Medicine II, University of Tuebingen, Tuebingen, Germany


1Internal


Atsushi Tanaka1, Saeko Nezu2, Kentaro Kikuchi3, Akitaka Shibuya4, Hiromasa Ohira5, Pietro Invernizzi6, Hajime Takikawa1 1Medicine, Teikyo University, School of Medicine, Tokyo, Japan. 2The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan. 3The Fourth Department of Internal Medicine, Teikyo University Mizonokuchi Hospital, Kanagawa, Japan. 4Department of Gastroenterology, Kitazato University School of Medicine, Kanagawa, Japan. 5Department of Internal Medicine II, Fukushima Medical University School of Medicine, Fukushima, Japan. 6Division of Internal Medicine and Hepatobiliary Immunopathology Unit, IRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Italy

#1514 A POSSIBLE INVOLVEMENT OF AUTOPHAGY IN THE PROCESS OF BILIARY EPITHELIAL SENESCENCE IN PRIMARY BILIARY CIRRHOSIS Motoko Sasaki, Masami Miyakoshi, Yasunori Sato, Yasuni Nakanuma Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan

#1515 THE LONG-TERM EFFECT OF URSODEOXYCHOLIC ACID ON LIVER BIOCHEMISTRIES IN PRIMARY BILIARY CIRRHOSIS Edith M. Kuiper1, Bettina E. Hansen1,2, W. Lesterhuis3, R. J. Robijn4, J. C. Thijs5, L. G. Engels6, Ger H. Koek7, M. N. Aparicio8, M. J. Kerbert-Dreteler9, Henk R. van Buuren1 1Hepatology and Gastroenterology, Erasmus University Medical Center, Rotterrdam, Netherlands. 2Epidemiology and Biostatistics, Erasmus University Medical Center, Rotterdam, Netherlands. 3Hepatology and Gastroenterology, Albert Schweitzer Hospital, Dordrecht, Netherlands. 4Hepatology and Gastroenterology, Rijnstate Hospital, Arnhem, Netherlands. 5Internal Medicine, Bethesda Hospital, Hoogeveen, Netherlands. 6Hepatology and Gastroenterology, Orbis Medical Center, Sittard, Netherlands. 7Hepatology and Gastroenterology, Maastricht University Medical Center, Maastricht, Netherlands. 8Hepatology and Gastroenterology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands. 9Internal Medicine, Medical Spectrum Twente, Enschede, Netherlands

#1516 INCREASED RATE OF SMOKING IN PBC PATIENTS COMPARED TO UNAFFECTED CONTROLS AMONG INDIVIDUALS CARRYING THE MINOR ALLELE OF A POLYMORPHISM IN THE TNF PROMOTER: EVIDENCE OF GENE-ENVIRONMENT INTERACTION? Brian D. Juran1, Elizabeth J. Atkinson2, Joseph J. Larson2, Erik M. Schlicht1, Konstantinos Lazaridis1 1CBRDD, Mayo Clinic, Rochester, MN, USA. 2Biostatistics, Mayo Clinic, Rochester, MN, USA


POSTER SESSIONS

257A

#1517

#1521

DIAGNOSTIC AND CLINICAL SIGNIFICANCE OF ANTI-RO52 ANTIBODIES IN 609 CASES WITH PRIMARY BILIARY CIRRHOSIS FROM UK, SPAIN AND GREECE

ANALYSIS OF HLA-DRB1 POLYMORPHISM IN JAPANESE PATIENTS WITH PRIMARY BILIARY CIRRHOSIS(PBC) - HLA-DRB1 POLYMORPHISM DETERMINES THE RELATIVE RISK OF ANTINUCLEAR ANTIBODIES FOR THE DISEASEPROGRESSION IN PBC-

Maria G. Mytilinaiou1, Albert Pares2, Elias S. Spyrou3,4, Eirini I. Rigopoulou3,4, George N. Dalekos3,4, Diego Vergani1, Dimitrios P. Bogdanos1 1Liver Immunopathology, Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, London, United Kingdom. 2Liver Unit, Institut de Malalties Digestives CIBEREHD, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain. 3Department of Medicine, Division of Internal Medicine and Research Laboratory of Internal Medicine, Larissa Medical School, University of Thessaly, Larissa, Greece. 4Research Group of Investigational Medicine, Institute of Biomedical Research and Technology, Centre for Research and Technology-Thessaly (CE.RE.TE.TH), Larissa, Greece

#1518 FATIGUE AND MORTALITY RISK IN PRIMARY BILIARY CIRRHOSIS: AN EIGHT YEAR FOLLOW-UP STUDY Ahmad Al-Rifai1, Julia L. Newton2,3, David E. Jones2,1 Freeman Hospital, Liver Unit, Newcastle-Upon-Tyne, United Kingdom. 2Institute of Cellular Medicine1, Newcastle University, Newcastle Upon Tyne, United Kingdom. 3Institute for Ageing & Health, Newcastle University, Newcastle Upon Tyne, United Kingdom

1Hepatology,

#1519 ASYMPTOMATIC PRIMARY BILIARY CIRRHOSIS. IDENTIFICATION OF AN EXTREMELY BENIGN FORM IN A LARGE COHORT OF PATIENTS Albert Pares For the Spanish Group of Chronic Cholestasis, Hospital Clinic, CIBERehd, IDIBAPS, Barcelona, Spain

#1520 NORMALIZATION OF ALKALINE PHOSPHATASE INDICATES IMPROVED PROGNOSIS IN PRIMARY SCLEROSING CHOLANGITIS Peter P. Stanich1, Einar Bjornsson2, Keith D. Lindor2 of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA. 2Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA

1Department

Minoru Nakamura1,4, Michio Yasunami2, Hisayoshi Kondo3, Yoshihiro Aiba1, Atsumasa Komori1, Kiyoshi Migita1, Hiroshi Yatsuhashi1, Makoto Nakamuta4, Shigeki Hayashi4, Akira Saito4, Koichi Honda4, Masaaki Shimada4, Yukio Watanabe4, Michiyasu Yagura4, Hiroshi Kohno4, Kazuhiro Sugi4, Hajime Ota4, Tatsushi Komatsu4, Tomohiko Mannami4, Michiaki Koga4, Takeaki Satoh4, Eiichi Takesaki4, Tetsuo Yamamoto4, Yukio Oohara4, Naohiko Masaki4, Hiromi Ishibashi1 1Clinical Research Center, NHO Nagasaki Medical Center, Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Omura, Japan. 2Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan. 3Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. 4Headquarters of PBC Research, National Hospital Organization Study Group for Liver Disease in Japan (NHOSLJ), Omura, Japan

#1522 FATIGUE IN PSC PATIENTS WITH AND WITHOUT INFLAMMATORY BOWEL DISEASE Ahmad Al-Rifai1, Martin I. Prince1, Elsbeth Henderson1, David E. Jones2,1, Julia L. Newton3, Mark Hudson1 1Hepatology, Freeman Hospital, Liver Unit, Newcastle-Upon-Tyne, United Kingdom. 2Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, United Kingdom. 3Institute for Ageing & Health, Newcastle University, Newcastle-upon-Tyne, United Kingdom

#1523 B CELL DEPLETION WITH ANTI-CD20 AMELIORATES AUTOIMMUNE CHOLANGITIS BUT EXACERBATES COLITIS IN DNTGF-βRII MICE Yuki Moritoki1,2, Zhe-Xiong Lian1, Keith D. Lindor3, Joseph Tuscano4, Koichi Tsuneyama5, Weici Zhang1, Yoshiyuki Ueno2, Robert Dunn6, Marilyn R. Kehry6, Ross L. Coppel7, Aftab A. Ansari9, Ian R. Mackay8, M. Eric Gershwin1 1Internal Medicine, University of California, Davis, Davis, CA, USA. 2Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan. 3Gastroenterology and Hepatology, Mayo Clinic Foundation, Rochester, MN, USA. 4Hematology and Oncology, University of California at Davis, Sacramento, CA, USA. 5Diagnostic Pathology, University of Toyama, Graduate School of Medicine and Pharmaceutical Science, Toyama, Japan. 6Biogen Idec, San Diego, CA, USA. 7Microbiology, Monash University, Clayton, VIC, Australia. 8Biochemistry and Molecular Biology, Monash University, Clayton, VIC, Australia. 9Pathology, Emory University School of Medicine, Atlanta, GA, USA


258A

POSTER SESSIONS

#1524

#1529

THE ROLE OF HERPES SIMPLEX VIRUS TYPE 1 IN THE INDUCTION OF PROMYEOLOCYTIC LEUKAEMIA SPECIFIC RESPONSES IN PRIMARY BILIARY CIRRHOSIS

BIOCHEMICAL RESPONSE TO TREATMENT IN PRIMARY BILIARY CIRRHOSIS IS ASSOCIATED WITH LOWER PATIENT REPORTED SYMPTOM SCORES

Polychronis Pavlidis1, Maria G. Mytilinaiou1, Andreas Koutsoumpas1, Eirini I. Rigopoulou2, Diego Vergani1, Dimitrios P. Bogdanos1 1Liver Immunopathology, Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, London, United Kingdom. 2Department of Medicine, Division of Internal Medicine and Research Laboratory of Internal Medicine, Larissa Medical School, University of Thessaly, Larissa, Greece

Nadya Al-Harthy, Teru Kumagi, Catalina Coltescu, Gideon M. Hirschfield Liver Centre, Toronto Western Hospital/University of Toronto, Toronto, ON, Canada

#1525 ANTIMITOCHONDRIAL ANTIBODIES (AMA) IN PRIMARY BILIARY CIRRHOSIS (PBC) STRONGLY REACT WITH EPITOPES OF THE CATALYTIC DOMAIN OF THE PYRUVATE DEHYDROGENASE E2-SUBUNIT (PDC-E2) Reinhild Klein1, Sandra Buck1, Michael Gregor2, Christoph P. Berg2 1Internal Medicine II, University of Tuebingen, Tuebingen, Germany. 2Internal Medicine I, University of Tuebingen, Tuebingen, Germany

#1526 PRURITUS, BUT NOT MAYO RISK SCORE IS ASSOCIATED WITH SEVERELY IMPAIRED QUALITY OF LIFE IN PRIMARY SCLEROSING CHOLANGITIS Daniel Gotthardt1, Miriam Bruhin1, Dieter Schellberg2, Karl Heinz Weiss1, Wolfgang Stremmel1, Jana Juenger2, Peter Sauer1 1Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany. 2Internal Medicine II, University Hospital Heidelberg, Heidelberg, Germany

#1527 PRESENCE OF AUTOANTIBODIES TO THE MUSCARINIC ACETYLCHOLINE RECEPTOR M3 (M3ACHR) IN PRIMARY BILIARY CIRRHOSIS (PBC) AND ITS CO-OCCURRING AUTOIMMUNE DISORDERS Christoph P. Berg2, Sorin Tunaru1, Gerburg M. Stein2, Stefan Offermanns1, Reinhild Klein3 1Pharmacology, University of Heidelberg, Heidelberg, Germany. 2Internal Medicine I, University of Tuebingen, Tuebingen, Germany. 3Internal Medicine II, University of Tuebingen, Tuebingen, Germany

#1528 OVERLAP OF AUTOIMMUNE HEPATITIS WITH PRIMARY BILIARY CIRRHOSIS: EVALUATION OF A NEW SCORING SYSTEM



Einar Bjornsson1,2, Matthias H. Neuhauser2, Sombat Treeprasertsuk2, Felicity B. Enders2, Marina G. Silveira2, Jayant A. Talwalkar2, Keith D. Lindor2 1Section of Gastroenterology and Hepatology, Department of Internal Medicine, Gothenburg, Sweden. 2Mayo Clinic, Rochester, MN, USA


#1530 PREGNANCY AND PRIMARY BILIARY CIRRHOSIS: CROSS-SECTIONAL AND RETROSPECTIVE ANALYSES DEMONSTRATE A HIGH PREVALENCE OF SYMPTOMS AND A RISK OF DISEASE PROGRESSION Teru Kumagi, Nadya Al-Harthy, Catalina Coltescu, Gideon M. Hirschfield Liver Centre, Toronto Western Hospital / University of Toronto, Toronto, ON, Canada

#1531 A EFFICACY AND TOLERABILITY OF MODAFINIL FOR THE TREATMENT OF DAYTIME SOMNOLENCE AND FATIGUE IN PRIMARY BILIARY CIRRHOSIS David E. Jones, Claire McDonald, Julia L. Newton Biomedical Research Centre in Ageing - Liver Theme, Newcastle University, Newcastle, United Kingdom

#1532 ASSESSMENT OF 479 PATIENTS WITH AUTOIMMUNE LIVER DISEASES ACCORDING TO THE IAIHG SCORING SYSTEM FOR AUTOIMMUNE HEPATITIS DOES NOT SUPPORT THE CONTENTION OF OVERLAP SYNDROMES AS SEPARATE DIAGNOSTIC ENTITIES Kirsten M. Boberg1, Ansgar W. Lohse2, Elke M. Hennes2, Hans P. Dienes3, E. Jenny Heathcote4, Roger W. Chapman5, Erik Schrumpf1 1Medical Dept., Oslo University Hospital, Rikshospitalet, Oslo, Norway. 2Dept. of Medicine, University Medical Centre HamburgEppendorf, Hamburg, Germany. 3Institute of Pathology, University Medical Centre, Cologne, Germany. 4Division of Gastroenterology, Toronto Western Hospital, Toronto, ON, Canada. 5Gastroenterology Unit, John Radcliffe Hospital, Oxford, United Kingdom

#1533 AUTOIMMUNE HEPATITIS PRECEDES THE ONSET OF TERMINAL ILEITIS IN THE SAMP1/YITFC MOUSE MODEL OF CROHN’S DISEASE Marco Brogi1, Cominelli Fabio3, Muhammadreza A. Sachedina2, Sharon B. Hoang2, Tania Roskams4, Massimo Pinzani1,3, Theresa T. Pizarro2 1Medicina Interna, Università di Firenze, Firenze, Italy. 2Department of Pathology, Case Western Reserve University, Cleveland, OH, USA. 3Division of Gastroenterology and Hepatology, Case Western Reserve University, Cleveland, OH, USA. 4Department of Pathololgy, University of Leuven, Leuven, Belgium


POSTER SESSIONS

#1534

#1539

AGE RELATED DECREASE IN LIVER REGULATORY T CELLS,STAT 1 AND JNK PHOSPHORYLATION IS ASSOCIATED WITH ATTENUATED CONCANAVALIN A INDUCED HEPATITIS: A MECHANISM FOR AGEDEPENDENT PROTECTION FROM IMMUNE MEDIATED LIVER DAMAGE

INHIBITION OF TH17-CELLS ENHANCES THE SUPPRESSOR FUNCTION OF DE NOVO GENERATED T-REG IN PATIENTS WITH AUTOIMMUNE HEPATITIS

Gadi Lalazar, Ron Cialic, Ami Ben-Ya’acov, Madi El Haj, Dimitry Kanovitch, Yoav Lichtenstein, Yehudit Shabat, Yaron Ilan Liver Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel

#1535 EARLY PREDICTORS OF CORTICOSTEROID TREATMENT FAILURE IN ICTERIC PRESENTATIONS OF AUTOIMMUNE HEPATITIS Andrew D. Yeoman, Rachel H. Westbrook, Paola Maninchedda, Michael A. Heneghan Institute of Liver Stiudies, Kings College Hospital, London, United Kingdom

#1536 PRIMARY SCLEROSING CHOLANGITIS ASSOCIATED WITH ELEVATED IMMUNOGLOBULING4 (IGG4): CLINICAL CHARACTERISTICS AND RESPONSE TO IMMUNOSUPPRESSIVE THERAPY Einar Bjornsson1,2, Marina G. Silveira2, Suresh Chari2, Andrea Gossard2, Naoki Takahashi2, Thomas C. Smyrk2, Keith D. Lindor2 1Section of Gastroenterology and Hepatology, Department of Internal Medicine, Gothenburg, Sweden. 2Mayo Clinic, Rochester, MN, USA

#1537 REGULATORY T-CELL INABILITY TO CURB AUTOANTIGEN SPECIFIC EFFECTOR T-CELL FUNCTION IN THE LIVER MAY CONTRIBUTE TO THE PERPETUATION OF LIVER DAMAGE IN AUTOIMMUNE HEPATITIS Pengyun Wang, Maria Serena Longhi, Haibin Su, Wayel Jassem, Nigel Heaton, Giorgina Mieli-Vergani, Diego Vergani, Yun Ma Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, London, United Kingdom

#1538 REPRESSION OF RORγT TRANSLATION PROMOTES DE NOVO GENERATION OF EFFECTIVE T-REG IN PATIENTS WITH AUTOIMMUNE HEPATITIS Maria Serena Longhi, Giorgina Mieli-Vergani, Yun Ma, Diego Vergani Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, London, United Kingdom

259A

Maria Serena Longhi, Giorgina Mieli-Vergani, Yun Ma, Diego Vergani Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, London, United Kingdom

#1540 PREGNANCY OUTCOMES IN AUTOIMMUNE HEPATITIS Rachel H. Westbrook, Andrew D. Yeoman, Ian G. McFarlane, John G. O’Grady, Phillip M. Harrison, John Devlin, Michael A. Heneghan Kings College Hospital, Institute of Liver Studies, London, United Kingdom

#1541 DEMONSTRATION OF AN HEPATOCYTE CANALICULAR LOCALIZATION OF CYP2D6, THE TARGET OF LIVER KIDNEY MICROSOME TYPE 1 AUTOANTIBODIES, MARKERS OF TYPE 2 AUTOIMMUNE HEPATITIS Elvire Beleoken2,3, Fouad El Rabaa2,3, Brigitte Grosse4, Mohammad Z. Mustafa2,3, Didier Samuel1,2, Catherine Johanet3,5, Doris Cassio4, Jean-Charles Duclos-Vallée1,3, Eric Ballot2,5 1Centre Hepato-Biliaire, AP-HP Hopital Paul Brousse, Villejuif, France. 2Unite 785, INSERM, Villejuif, France. 3UMR-S785, Univ Paris-Sud, Villejuif, France. 4Unite 757, INSERM, Orsay, France. 5Laboratoire Immunologie, AP-HP Hopital Saint Antoine, Paris, France

#1542 NEW SCORING CLASSIFICATION FOR OVERLAP SYNDROME Debapriya De, Priti Marwaha, Kusal Mihindukulasuriya, Bruce R. Bacon Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, MO, USA

#1543 TREATMENT OF PATIENTS PRESENTING WITH AUTOIMMUNE HEPATITIS-PRIMARY BILIARY CIRRHOSIS OVERLAP SYNDROME Priti Marwaha, Debapriya De, Kusal Mihindukulasuriya, Bruce R. Bacon Department of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St Louis, MO, USA


260A

POSTER SESSIONS


#1544

#1549

SOLUBLE LIVER ANTIGEN ANTIBODIES IN AUTOIMMUNE HEPATITIS TYPE 1: PREVALENCE AND CORRELATION TO CLINICAL AND BIOCHEMICAL FINDINGS AND RESPONSE TO TREATMENT

COMMON VARIANTS IN THE PREGNANE X RECEPTOR GENE MAY CONTRIBUTE TO THE GENETIC SUSCEPTIBILITY TO INTRAHEPATIC CHOLESTASIS OF PREGNANCY IN A SOUTHAMERICAN POPULATION SAMPLE

Elze M. Oliveira1, Patricia M. Oliveira1, Carla Matos1, Alessandra Dellavance2, Luis Andrade2, Valéria Lanzoni3, Ivonete Silva1, Antonio Eduardo B. Silva1, Maria Lucia G. Ferraz1, Renata Perez4 1Gastroentelology, Federal University of São Paulo, São Paulo, Brazil. 2Reumatology, Federal University of São paulo, São Paulo, Brazil. 3Patology, Federal University of São paulo, São Paulo, Brazil. 4Gastroenterology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

#1545 INTRAHEPATIC CD25+CD122- TCRγδ T CELLS IN PATIENTS WITH AUTOIMMUNE HEPATITIS PRODUCE MORE IL-17 THAN IFN-γ Pengyun Wang1, Maria Serena Longhi1, Munther J. Hussain1, Roshni Vara2, Tassos Grammatikopoulos2, Pushpa Subramaniam2, Giorgina Mieli-Vergani1, Diego Vergani1, Yun Ma1 1Institute of Liver Studies, King’s College London School of Medicine at King’s College Hospital, London, United Kingdom. 2Paediatric Liver Centre, King’s College Hospital, London, United Kingdom

#1546 GENE EXPRESSION PROFILE IN INTRAHEPATIC CHOLESTASIS OF PREGNANCY Annarosa Floreani1, Diego Caroli1, Alessia Memmo2, Elisa Vidali2, Davide Colavito3, Antonello D’Arrigo3, Daniela Pizzuti1, Alberta Leon3, Nora Cazzagon1, Maria Teresa F. Gervasi2 1Dept. of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy. 2Dept. of Obstetrics and Gynaecology, Azienda Ospedaliera, Padova, Italy. 3Research & Innovation S.p.A., Padova, Italy

#1547 METALLOTHIONEIN EXPRESSION IN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS Lee M. Bass, Hehuang Xie, Songtao Yu, Padmini Malladi, Marcelo B. Soares, Peter F. Whitington Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

#1548 BODY MASS INDEX IN THE GENERAL POPULATION IS ASSOCIATED WITH THE COMMON P.A444V VARIANT OF THE ABC TRANSPORTER FOR BILE SALTS


Marcin Krawczyk, Monica A. Rusticeanu, Frank Grünhage, Frank Lammert Department of Medicine II, Saarland University Hospital, Homburg/Saar, Germany


Gustavo O. Castaño3,4, Adriana L. Burgueño1, Tomas Fernández Gianotti1, Carlos J. Pirola1, Silvia Sookoian1,2 1Department of Molecular Genetics and Biology of Complex Diseases, Institute of Medical Research A Lanari-IDIM, University of Buenos Aires- National Council of Scientific and Technological Research (CONICET), Ciudad Autonoma de Buenos Aires, Argentina. 2Laboratory of Clinical and Molecular Hepatology, Institute of Medical Research A Lanari-IDIM, University of Buenos AiresNational Council of Scientific and Technological Research (CONICET), Ciudad Autonoma de Buenos Aires, Argentina. 3Department of Medicine and Surgery, Hospital Abel Zubizarreta, Ciudad Autonoma de Buenos Aires, Argentina. 4Research Council of GCBA, GCBA, Ciudad Autonoma de Buenos Aires, Argentina

#1550 VARIATIONS IN THE INDUCTION OF UDPGLUCURONOSYLTRANSFERASE EXPRESSION IN HUMAN HEPATOCYTES EXPOSED TO RIFAMPICIN Mélanie Verreault, Sophie Pâquet, Marie-Michèle Charest, Luc Bouchard, Olivier Barbier Laboratory of Molecular Pharmacology, Faculty of Pharmacy, Laval University, Québec, QC, Canada

#1551 HUMAN UDP-GLUCURONOSYLTRANSFERASE (UGT)1A3 CONJUGATES NORURSODEOXYCHOLIC ACID IN THE LIVER Jocelyn Trottier1, Diala El Husseini1, Martin Perreault1, Sophie Pâquet1, Patrick Caron1, Michael H. Trauner2, Olivier Barbier1 1Laboratory of Molecular Pharmacology, Faculty of Pharmacy, Laval University, Québec, QC, Canada. 2Medical University of Graz, Graz, Austria

#1552 VALUE OF ROUTINE BILE COLLECTION DURING ERCP FOR MICROBIOLOGICAL ANALYSIS: RESULTS OF A PROSPECTIVE STUDY AND CLINICAL IMPACT ON MANAGEMENT OF CHOLANGITIS Ahmed Negm1, Anja Schott1, Ralf-Peter Vonberg2, Andrea Schneider1, Michael P. Manns1, Jochen Wedemeyer1, Tim O. Lankisch1 1Gastroenterology, Hepatology & Endocrinology, Medical School Hannover, Hannover, Germany. 2Institute of Medical Microbiology and Hospital Epidemiology, Medical School Hannover, Hannover, Germany


POSTER SESSIONS

#1553 PREDICTORS OF FETAL GESTATIONAL AGE AND BIRTH WEIGHT IN WOMEN DIAGNOSED WITH INTRAHEPATIC CHOLESTASIS OF PREGNANCY Michelle Rook1, Eric Vittinghoff4, Philip Rosenthal1,2, Laura N. Bull7,3, Juan Vargas5,6 1Pediatrics, UCSF, San Francisco, CA, USA. 2Surgery, UCSF, San Francisco, CA, USA. 3Medicine, UCSF, San Francisco, CA, USA. 4Epidemiology & Biostatistics, UCSF, San Francisco, CA, USA. 5Obstetrics & Gynecology, San Francisco General Hospital, San Francisco, CA, USA. 6Obstetrics & Gynecology, UCSF, San Francisco, CA, USA. 7UCSF Liver Center Laboratory, UCSF, San Francisco, CA, USA

HCV Therapy: Preclinical and Clinical Development #1554 TREATMENT OF GENOTYPE 2 OR 3 HEPATITIS C VIRUS INFECTION WITH PEGYLATED INTERFERON AND WEIGHT BASED RIBAVIRIN: A METAANALYSIS COMPARING SHORT TERM [12-16 WKS] VS. REGULAR DURATION [24 WKS] TREATMENT Ashwani K. Singal1, Bhupinderjit S. Anand2 1Gastroenterology, University of Texas medical Branch, Galveston, TX, USA. 2Gastroenterology, Baylor College of Medicine, Houston, TX, USA

#1555 SVR RESULTS IN CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS DOSED WITH SCH 900518 AND PEGINTERFERON ALFA-2B FOR 2 WEEKS, FOLLOWED BY PEGINTERFERON ALFA-2B AND RIBAVIRIN FOR 24/48 WEEKS: AN INTERIM ANALYSIS Joep de Bruijne1, Jilling F. Bergmann2, Christine J. Weegink1, Richard Molenkamp3, Janke Schinkel3, Michelle A. Treitel4, Eric A. Hughes4, Andre A. van Vliet5, Robert J. de Knegt2, Hendrik W. Reesink1, Harry L. Janssen2 1Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands. 2Department of Gastroenterology and Hepatology, Erasmus MC University Hospital, Amsterdam, Netherlands. 3Department of Medical Microbiology, Academic Medical Center, Amsterdam, Netherlands. 4ScheringPlough Research Institute, Kenilworth, NJ, USA. 5PRA International, Zuidlaren, Netherlands

#1556 HIGHLY EFFECTIVE PEGINTERFERON ALPHA-2A PLUS RIBAVIRIN COMBINATION THERAPY FOR CHRONIC HEPATITIS C IN PATIENTS WITH HEMOPHILIA

#1557 SIGNIFICANT HEMOGLOBIN (HB) DECLINE DURING PEGYLATED INTERFERON AND RIBAVIRIN THERAPY IN HCV GENOTYPE 1 IS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR): AN ANALYSIS FROM THE CHARIOT STUDY William Sievert1, Gregory J. Dore2, Geoffrey W. McCaughan3, Motoko Yoshihara4, Darrell H. Crawford5, Wendy Cheng6, Martin Weltman7, William Rawlinson8, Bishoy Rizkalla4, Philip I. McCloud4, Stuart K. Roberts9 1Gastroenterology and Hepatology Unit, Monash Medical Centre, Melbourne, VIC, Australia. 2National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW, Australia. 3Royal Prince Alfred Hospital, Sydney, NSW, Australia. 4Roche Products, Sydney, NSW, Australia. 5Greenslopes Hospital, Brisbane, QLD, Australia. 6Royal Perth Hospital, Perth, WA, Australia. 7Nepean Hospital, Sydney, NSW, Australia. 8SEALS Microbiology, Sydney, NSW, Australia. 9Alfred Hospital, Melbourne, VIC, Australia

#1558 SIGNIFICANT CONTINUOUS VIRAL LOAD DECLINE IN TREATMENT-NAIVE HCV GENOTYPE 1 PATIENTS AFTER THERAPEUTIC PEPTIDE VACCINATION WITH IC41 Christoph S. Klade1, Alexander von Gabain1, Michael P. Manns2 AG, Vienna, Austria. 2Hannover Medical School, Center for Internal Medicine, Hannover, Germany

1Intercell

#1559 COMPARISON BETWEEN CNI-TREATED PATIENTS WHO RECEIVED STEROIDS OR WERE STEROIDFREE: 12-MONTH PLANNED INTERIM ANALYSIS OF THE REFINE TRIAL Les Lilly1, Andreas G. Tzakis2, Goran Klintmalm3, Federico G. Villamil4, Robert M. Jones5, John P. Roberts6, Tania Roskams7, Hans Prestele8, Fernando T. Kawakami8 1Hepatology Transplant Unit, University Health Network, Toronto, ON, Canada. 2Department of Surgery, Jackson Memorial Hospital, Miami, FL, USA. 3Department of Transplant, Baylor U Medical Center, Dallas, TX, USA. 4Liver Unit, Fundacion Favaloro, Buenos Aires, Argentina. 5Liver Transplant Unit, Austin Hospital, Melbourne, VIC, Australia. 6Liver and Kidney Transplant Service, UCSF, San Francisco, CA, USA. 7Liver Research Unit, University of Leuven, Leuven, Belgium. 8Novartis Pharma, Basel, Switzerland

#1560 ANA773, AN ORAL INDUCER OF ENDOGENOUS INTERFERONS THAT ACTS VIA TLR7, REDUCED SERUM VIRAL LOAD IN PATIENTS CHRONICALLY INFECTED WITH HCV Harry L. Janssen1, Joep de Bruijne2, Jilling F. Bergmann1, Daphne Hotho1, Robert J. de Knegt1, Christine J. Weegink2, Andre A. van Vliet3, Jeroen van de Wetering3, Simon P. Fletcher4, Lisa A. Bauman4, Boreth Eam4, Maria V. Sergeeva4, Tim W. Harding4, Mohamad H. Rahimy4, James R. Appleman4, James L. Freddo4, Hendrik W. Reesink2 1Erasmus Medical Center, Rotterdam, Netherlands. 2Academic Medical Center, Amsterdam, Netherlands. 3PRA International, Groningen, Netherlands. 4Anadys Pharmaceuticals, San Diego, CA, USA


Hyun Woong Lee1, Hyung J. Kim1, Youn-Jae Lee2, Sung Jae Park2, Eun Kyung Baek1, Ki-Seong Kim1, Bong Ki Cha1, Seung-Yong Lee1, Hyoung-Chul Oh1, Chang Hwan Choi1, Jung Uk Kim1, Jae Hyuk Do1, Jae G. Kim1, Sae Kyung Chang1 1Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea, South. 2Internal Medicine, Inje University College of Medicine, Seoul, Korea, South

261A

262A

POSTER SESSIONS


#1561

#1564

STANDARD VERSUS HIGH DOSE RIBAVIRIN IN COMBINATION WITH PEGINTERFERON ALFA-2A (40KD) IN GENOTYPE 1 (G1) HCV PATIENTS COINFECTED WITH HIV: FINAL RESULTS OF THE PARADIGM STUDY

THYMOSIN ALFA-1 (Tα1) IN ASSOCIATION WITH PEG-IFN ALFA-2A AND RIBAVIRIN (RBV) FOR RETREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS NON-RESPONDERS TO PEG-IFNS AND RBV.PHASE III MULTICENTER EUROPEAN STUDY

Maribel Rodriguez-Torres1, Jihad Slim2, Laveeza Bhatti3, Richard K. Sterling4, Mark S. Sulkowski5, Tarek Hassanein6, Rosário Serrão7, Ricard Solà8, Sharon Passe9, Saray Stancic9 1Fundacion de Investigacion de Diego, Santurce, PR, USA. 2St. Michael’s Medical Center, Newark, NJ, USA. 3Aids Healthcare Foundation, LA, CA, USA. 4Virginia Commonwealth University, Richmond, VA, USA. 5Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6University of California San Diego, San Diego, CA, USA. 7Hospital São João, Porto, Portugal. 8Hospital del Mar, Barcelona, Spain. 9Roche, Nutley, NJ, USA

Alessia Ciancio1, Pietro Andreone2, Stephan Kaiser3, Alessandra Mangia4, Michele Milella5, Ricard Solà6, Stanislas Pol7, Epaminondas Tsianos8, Alfonso De Rosa9, Roberto Camerini9, Mario Rizzetto1 1Gastroenterology, University of Torino, Torino, Italy. 2Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Bologna, Italy. 3Gastroenterology, Hepatology, Infectivology, University of Tubingen, Tubingen, Germany. 4Gasroenterology, IRCCS San G. Rotondo, San G. Rotondo, Italy. 5Infective Disease Unit, University of Bari, Bari, Italy. 6Hospital del Mar, Barcelona, Spain. 7Hopital Necker, Paris, France. 8Liver-Gastroenterology, University of Ioannina, Ioannina, Greece. 9Research and Development, Sigma-Tau SpA, Pomezia, Italy

#1562 TAILORED ANTIVIRAL THERAPY BY MODELLING THE DECLINE OF HCV INFECTED HEPATOCYTES ALLOWS FOR ACCURATE DIVERSIFICATION OF TREATMENT DURATION IN RESPONDER PATIENTS WITH SIGNIFICANT SAVINGS. Piero Colombatto1, Veronica Romagnoli1, Luigi Civitano1, Pietro Ciccorossi1, A. M. Maina1, Filippo Oliveri1, Barbara Coco1, Beatrice Cherubini1, Daniela Cavallone1, Francesco Moriconi1, Ferruccio Bonino2,3, Maurizia R. Brunetto1 1Hepatology Unit - University Hospital of Pisa, Pisa, Italy. 2University of Pisa, Pisa, Italy. 3Fondazione IRCCS Policlinico of Milan, Pisa, Italy

#1563 ANTIVIRAL ACTIVITY AND SAFETY OF TMC435 COMBINED WITH PEGYLATED INTERFERON AND RIBAVIRIN IN HEPATITIS C PATIENTS WITH GENOTYPE-1 WHO HAD PREVIOUS EXPOSURE TO TMC435 Hendrik W. Reesink1, Joep de Bruijne1, Christine J. Weegink1, Oliver Lenz2, Kenneth Simmen2, Monika Peeters2, Goedele De Smedt3, Vanitha Sekar2, Rene Verloes2 1Academic Medical Centre, Amsterdam, Netherlands. 2Tibotec BVBA, Mechelen, Belgium. 3Tibotec Inc, Yardley, PA, USA

#1565 TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IMPROVED RATES OF SUSTAINED VIROLOGIC RESPONSE (SVR) IN “DIFFICULT-TOCURE” PATIENTS WITH CHRONIC HEPATITIS C (CHC): A POOLED ANALYSIS FROM THE PROVE1 AND PROVE2 TRIALS Gregory T. Everson1, Geoffrey M. Dusheiko2, Peter Ferenci3, Katia Alves4, Leif Bengtsson4, Lindsay McNair4, John G. McHutchison5, Andrew Muir5, Jean-Michel Pawlotsky6, Stefan Zeuzem7 1University of Colorado Denver, Denver, CO, USA. 2Royal Free and University College School of Medicine, London, United Kingdom. 3University of Vienna, Vienna, Austria. 4Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA. 5Duke University Medical Center, Durham, NC, USA. 6Hôpital Henri Mondor, Créteil, France. 7Johann Wolfgang Goethe University Medical Center, Frankfurt/Main, Germany

#1566 PEGYLATED INTERFERON ALFA-2A VS PEGYLATED INTERFERON ALFA-2B, PLUS RIBAVIRIN, FOR CHRONIC HEPATITIS C GENOTYPE 4 PATIENTS: A RANDOMIZED CONTROLLED TRIAL


Sanaa Kamal2,1, Dalia Ghoraba2, Leila Nabegh2, Imad Nasser3, Mona Motaoe2, Mohamed E. Sayed2, Iman Gohary2 1Gastroenterology, Tufts School of Medicine, Boston, MA, USA. 2Gastroenterology and Tropical Medicine, Ain Shams University, Cairo, Egypt. 3Patholgy, BIDMC, Boston, MA, USA



POSTER SESSIONS

263A

#1567

#1570

EFFICACY AND SAFETY RESULTS OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT NAïVE SUBJECTS WITH CHRONIC HEPATITIS C GENOTYPE 2 OR 3

HEPATITIS C (HCV) -3 STUDY: DAY-90 PROTOCOL BIOPSY(PB) GRADE IS A SURROGATE MARKER FOR SEVERE HCV RECURRENCE (R), ON PB, AT YEARS 1 AND 2 POST LIVER TRANSPLANTATION (OLT)

Yves Benhamou16, David R. Nelson15, Wan-Long Chuang14, Eric Lawitz13, Robert Flisiak12, Jens Rasenack11, Wieslaw Kryczka10, Chuan-Mo Lee9, Maribel Rodriguez-Torres8, Vincent G. Bain7, Eugene R. Schiff6, Mong Cho5, Ewa Janczewska-Kazek4, ChengYuan Peng3, Erik Pulkstenis1, G M. Subramanian1, John G. McHutchison2 1Human Genome Sciences, Inc., Rockville, MD, USA. 2Duke Clinical Research Institute, Durham, NC, USA. 3China Medical University Hospital, Taichung, Taiwan. 4Niepubliczny Zaklad Opieki Zdrowotnej, Czeladz, Poland. 5Pusan National University Hospital, Buson, Korea, South. 6University of Miami, Miami, FL, USA. 7University of Alberta, Edmonton, AB, Canada. 8Fundacion de Investigacion de Diego, Santurce, PR, USA. 9Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. 10Wojewodzki Szpital Zespolony, Kielce, Poland. 11Universitaetsklinik Freiburg, Freiburg, Germany. 12Uniwersytet Medyczny, Bialystok, Poland. 13Alamo Medical Research, San Antonio, TX, USA. 14KMUH, Kaohsiung, Taiwan. 15University of Florida-Gainesville, Gainsville, FL, USA. 16Hopital Pitie-Salpetriere, Paris, France

#1568 SAFETY AND ANTIVIRAL ACTIVITY OF NS5B POLYMERASE INHIBITOR MK-3281, IN TREATMENT-NAïVE GENOTYPE 1A, 1B AND 3 HCV-INFECTED PATIENTS Diana M. Brainard1, Matt S. Anderson1, Amelia Petry1, Kristien Van Dyck1, Inge De Lepeleire1, Kenneth Sneddon1, Corinne E. Cummings1, Robert B. Nachbar1, Richard J. Barnard1, Peng Sun1, Paul Panorchan1, Joseph B. Sanderson2, Emmanuel Udezue3, Frank Wagner4, Marian Iwamoto1, Jeffrey Chodakewitz1, John A. Wagner1 1Merck & Co., Inc., Whitehouse Station, NJ, USA. 2Chiltern (Early Phase) Limited, Dundee, United Kingdom. 3Chiltern Place, Slough, United Kingdom. 4Charité Research Organisation, Berlin, Germany

#1569 ADVANCED FIBROSIS IN GENOTYPE 1 HCV INFECTED PATIENTS RECEIVING ANTIVIRAL THERAPY IS ASSOCIATED WITH VIROLOGIC RELAPSE INDEPENDENT OF RAPID (RVR) AND EARLY (EVR) VIROLOGIC RESPONSE Geoffrey W. McCaughan1, Stuart K. Roberts2, Martin Weltman3, Darrell H. Crawford4, William Sievert5, Wendy Cheng6, William Rawlinson7, Motoko Yoshihara8, Philip I. McCloud8, Bishoy Rizkalla8, Gregory J. Dore9 1Royal Prince Alfred Hospital, Sydney, NSW, Australia. 2Alfred Hospital, Melbourne, VIC, Australia. 3Nepean Hospital, Sydney, NSW, Australia. 4Greenslopes Hospital, Brisbane, QLD, Australia. 5Monash Medical Centre, Melbourne, VIC, Australia. 6Royal Perth Hospital, Perth, WA, Australia. 7SEALS Microbiology Prince of Wales Hospital, Randwick, NSW, Australia. 8Roche Products, Sydney, NSW, Australia. 9National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW, Australia

Goran Klintmalm1, Carlos G. Fasola2, Linda W. Jennings1, Baylor HCV-3 Study Group3 1Transplantation Services, Baylor University Medical Center, Dallas, TX, USA. 2Transplantation Services, Emory University Hospital, Atlanta, GA, USA. 3Baylor Hepatitis C-3 Group, Baylor University Medical Center, Dallas, TX, USA

#1571 VIROLOGIC AND METABOLIC RESPONSES IN CHRONIC HEPATITIS C (CHC) PATIENTS WITH INSULIN RESISTANCE (IR) TREATED WITH PIOGLITAZONE AND PEGINTERFERON ALFA-2A PLUS RIBAVIRIN John M. Vierling1, Fayez M. Hamzeh2, Ellen L. Lentz2, Stephen Harrison3 1Medicine and Surgery, Baylor College of Medicine, Houston, TX, USA. 2Roche, Nutley, NJ, USA. 3Medicine, Brooke Army Medical Center, Fort Sam Houston, TX, USA

#1572 SIMILAR RATES OF INTERSTITIAL FINDINGS ON CHEST X-RAY IN HCV PATIENTS TREATED WITH ALBINTERFERON ALFA-2B OR PEGINTERFERON ALFA-2A John G. McHutchison2, Stefan Zeuzem4, Mark S. Sulkowski3, David R. Nelson6, Yves Benhamou5, Yanming Yin7, G M. Subramanian1, Paul W. Noble8 1Human Genome Sciences, Inc., Rockville, MD, USA. 2Duke Clinical Research Institute, Durham, NC, USA. 3Johns Hopkins Center for Viral Hepatitis, Baltimore, MD, USA. 4J.W. Goethe University Hospital, Frankfurt, Germany. 5Hopital Pitie Salpetriere, Paris, France. 6University of Florida - Gainsville, Gainsville, FL, USA. 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. 8Division of Pulmonary, Allergy & Critical Care Medicine, Duke University School of Medicine, Durham, NC, USA

#1573 THE ONE-YEAR ANTIFIBROTIC PENTOXYPHILLIN/ALPHA-TOCOPHEROL ASSOCIATION DOES NOT LIMIT LIVER FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C – ANRS HC 10. Hélène Fontaine1, Sandrine Fernandes1,2, Nadia Squalli2, Bertrand Nalpas1, Pierre Bedossa2, Jean-Didier Grange2, Albert Tran2, Jerome Guechot2, Sophie Candon2, Francoise Imbert-Bismuth2, Stanislas Pol1,2 1Institut Cochin, Université Paris Descartes, CNRS (UMR 8104), Paris ; APHP, Groupe Hospitalier Cochin Saint-Vincent de Paul, Unité d’Hépatologie; Inserm, U567, Paris, France., Paris, France. 2ANRS, Paris, France T U E S D AY NOVEMBER 3

264A

POSTER SESSIONS

#1574

#1577

PEGINTERFERON ALFA-2A (40KD) (PEGIFNα2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIES

BASELINE PLATELET COUNT PREDICTS SUSTAINED VIRAL RESPONSE (SVR) IN THE TREATMENT OF CHRONIC HEPATITIS C WITH PEG-IFN α-2B AND RIBAVIRIN: RESULTS FROM THE GERMAN PEG-IFN α-2B OBSERVATIONAL STUDY

Marcellin1,

Jensen2,

Roberts3,

Patrick Donald M. Stuart K. Stephanos J. Hadziyannis4, Gregory J. Dore5, Moisés Diago6, Martin Weltman7, Geoffrey W. McCaughan8, Wendy Cheng9, Darrell H. Crawford10, William Sievert11, William Rawlinson12, Jonathan Solsky13, Andreas Tietz14, Mario Rizzetto15 1Hôpital Beaujon, Clichy, France. 2Center for Liver Diseases, Chicago, IL, USA. 3The Alfred Hospital, Prahran, VIC, Australia. 4Henry Dunant Hospital, Athens, Greece. 5National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW, Australia. 6Hospital General De Valencia, Valencia, Spain. 7Nepean Hospital, Sydney, NSW, Australia. 8Royal Prince Alfred Hospital, Sydney, NSW, Australia. 9Royal Perth Hospital, Perth, WA, Australia. 10Greenslopes Hospital, Brisbane, QLD, Australia. 11Monash Medical Centre, Melbourne, VIC, Australia. 12SEALS Microbiology, Sydney, NSW, Australia. 13Roche, Nutley, NJ, USA. 14Roche, Basel, Switzerland. 15University of Torino, UOADU Gatro-Epatologia, Torino, Italy

#1575 REPEATED ADMINISTRATIONS OF IPH1101 IN MONOTHERAPY OR COMBINED WITH LOW DOSE IL-2 (2 M IU) IN PATIENTS CHRONICALLY INFECTED WITH HEPATITIS C VIRUS: EFFICACY, SAFETY AND IMMUNO-MONITORING RESULTS FROM A PHASE 2 STUDY Jean-Pierre Zarski5, Nebil Abdelli6, Taoufik Najjar7, Thong Dao3, Nabyl Ben Mami8, Regine Rouzier4, Marc Marzetto1, Lucile Beautier1, Jean-Pierre Girre1, Patrick Squiban1, Helene Sicard1, Christian Trepo2 1R&D Department, Innate Pharma, Marseille, France. 2Hepato-gastro-enterologie, Hopital Hotel Dieu, Lyon, France. 3Hepato-gastroenterologie, CHU de Caen, Caen, France. 4Hepato-gastro-enterologie et transplantation, Hopital St Eloi, Montpellier, France. 5Hepato-gastro-enterologie, CHU Grenoble, Grenoble, France. 6Hopital Militaire, Tunis, Tunisia. 7Hopital Charles Nicole, Tunis, Tunisia. 8Hopital La Rabta, Tunis, Tunisia

#1576 ACCELERATED CLINICAL TRIAL DESIGN TO ASSESS THE SAFETY, TOLERABILITY AND ANTI-VIRAL ACTIVITY OF PHX1766, A NOVEL HCV NS3/4A PROTEASE INHIBITOR, IN HEALTHY VOLUNTEERS AND CHRONIC HEPATITIS C PATIENTS



Daphne Hotho1, Joep de Bruijne2, Anne-Marie O’Farrell5, Teresa Boyea5, Jack Li5, Christine J. Weegink2, Janke Schinkel3, Richard Molenkamp3, Jeroen van de Wetering4, Andre A. van Vliet4, Harry L. Janssen1, Robert J. de Knegt1, Hendrik W. Reesink2 1Gastroenterology and Hepatology, Erasmus MC Rotterdam, Rotterdam, Netherlands. 2Gastroenterology and Hepatology, AMC, Amsterdam, Netherlands. 3Virology, AMC, Amsterdam, Netherlands. 4PRA International, Groningen, Netherlands. 5Phenomix Corporation, San Diego, CA, USA


Stefan Mauss1, Elmar Zehnter2, Michael P. Manns8, Gerlinde Teuber4, Tarek Dahhan5, Stephan Kaiser6, Ulrike Meyer7, Thomas Witthoeft9, Bernd Moeller10, Nektarios Dikopoulos11, Jochen Brack12, Manfred Bilzer13, Gudrun Tossing13, Dietrich Hueppe3 1Medical Group Practice, Düsseldorf, Germany. 2Gastroenterological Practice, Dortmund, Germany. 3Medical Group Practice, Herne, Germany. 4Johann Wolfgang Goethe University, Frankfurt, Germany. 5Medical Practice, Backnang, Germany. 6University of Tübingen, Tübingen, Germany. 7Medical Practice, Berlin, Germany. 8Medical High School Hannover, Hannover, Germany. 9University of Lübeck, Lübeck, Germany. 10Medical Practice, Berlin, Germany. 11University of Ulm, Ulm, Germany. 12Hospital Nord Ochsenzoll, Hamburg, Germany. 13essex pharma GmbH, München, Germany

#1578 SHORTENING OF TREATMENT DURATION IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 2 AND 3 - IMPACT OF RIBAVIRIN DOSE - RESULTS OF A RANDOMIZED MULTICENTRE TRIAL Andreas Maieron1, Sigrid Metz-Gercek2, Thomas-Matthias Scherzer4, Hermann Laferl3, Gabriele Fischer5, Martin Bischof6, Petra E. Steindl-Munda4, Rudolf E. Stauber8, Alexander Ziachehabi1, Harald Hofer4, Michael Gschwantler7, Wolfgang Vogel9, Peter Ferenci4 1Gastroenterology and Hepatology, Elisabethinen Hospital Linz, Linz, Austria. 2Hygiene, Microbiology, Tropical Medicine, Elisabethinen Hospital Linz, Linz, Austria. 3Internal Medicine, KaiserFranz-Josef-Hospital, Vienna, Austria. 4Internal Medicine III, Medical University Vienna, Vienna, Austria. 5Dept. of Psychiatry, Medical University Vienna, Vienna, Austria. 6Internal Medicine IV, Hospital Rudolfstiftung, Vienna, Austria. 7Internal Medicine IV, Wilhelminenhospital, Vienna, Austria. 8Internal Medicine, Medical University Graz, Graz, Austria. 9Gastroenterology and Hepatology, Medical University Innsbruck, Insbruck, Austria

#1579 BASELINE AND ONTREATMENT PREDICTORS OF SVR TO PEGINTERFERON ALFA-2A THERAPY AND RIBAVIRIN IN HCV GENOTYPE (GT) 1 TREATMENT NAIVE PATIENTS: NEW INSIGHTS FROM THE CHARIOT STUDY Martin Weltman1, Gregory J. Dore2, William Sievert3, Geoffrey W. McCaughan4, Darrell H. Crawford5, Wendy Cheng6, William Rawlinson7, Motoko Yoshihara8, Philip I. McCloud8, Bishoy Rizkalla8, Stuart K. Roberts9 1Nepean Hospital, Sydney, NSW, Australia. 2National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW, Australia. 3Monash Medical Centre, Melbourne, VIC, Australia. 4Royal Prince Alfred Hospital, Sydney, NSW, Australia. 5Greenslopes Hospital, Brisbane, QLD, Australia. 6Royal Perth Hospital, Perth, WA, Australia. 7SEALS Microbiology, Sydney, NSW, Australia. 8Roche Products, Sydney, NSW, Australia. 9Alfred Hospital, Melbourne, VIC, Australia


POSTER SESSIONS

265A

#1580

#1583

PILOT STUDY OF LEAD-IN NITAZOXANIDE PLUS PEGYLATED ALPHA-2A INTERFERON AND RIBAVIRIN IN HCV-GENOTYPE 1 NONRESPONDERS WITH CIRRHOSIS: INTERIM RESULTS

IPH1101 FIRST GENERATION γδ T CELL AGONIST. EX VIVO AND IN VIVO ANTIVIRAL FUNCTIONS OF γδ T CELLS FROM CHRONICALLY INFECTED HCV PATIENTS TREATED IN PHASE 2 STUDY

Boris Yoffe1,2, Ketevan Gasitashvili2, Vladimir Khaoustov2 1Michael E. DeBakey VA Medical Center, Houston, TX, USA. 2Baylor College of Medicine, Houston, TX, USA

#1581

Cecile Bonnafous1, Bruna Faria1, Sophie Ingoure1, Philippe Benech2, Florence Joly2, Philippe Halfon3, Mourad Bouzidi3, JeanPierre Girre1, Hélène Sicard1 1Research & Development, Innate Pharma, Marseille, France. 2Prediguard, Marseille, France. 3Genoscience, Marseille, France

TREATMENT-INDUCED LATE ANEMIA, BUT NOT EARLY ANEMIA, IS ASSOCIATED WITH HIGHER SVR RATES AMONG ALL GENOTYPES TREATED WITH PEG-IFN α-2B AND RIBAVIRIN IN THE REALLIFE SETTING

#1584

Gerlinde Teuber5, Stefan Mauss1, Elmar Zehnter2, Michael P. Manns4, Tarek Dahhan6, Stephan Kaiser7, Ulrike Meyer8, Thomas Witthoeft9, Bernd Moeller10, Nektarios Dikopoulos11, Jochen Brack12, Manfred Bilzer13, Gudrun Tossing13, Dietrich Hueppe3 1Medical Group Practice, Düsseldorf, Germany. 2Gastroenterological Practice, Dortmund, Germany. 3Medical Group Practice, Herne, Germany. 4Medical High School Hannover, Hannover, Germany. 5Johann Wolfgang Goethe University, Frankfurt, Germany. 6Medical Practice, Backnang, Germany. 7University of Tübingen, Tübingen, Germany. 8Medical Practice, Berlin, Germany. 9University of Lübeck, Lübeck, Germany. 10Medical Practice, Berlin, Germany. 11University of Ulm, Ulm, Germany. 12Hospital Nord Ochsenzoll, Hamburg, Germany. 13essex pharma GmbH, München, Germany

Alessandra Mangia1, Franco Bandiera2, Adriano M. Pellicelli3, Eleonora Brigida Annicchiarico4, Mario Romano5, Nicola Minerva6, Donato Bacca7, Giuseppe Montalto8, Nicola Minerva9, Maurizio Russello10, Leonardo Mottola1, Raffaele Cozzolongo11, Gianfranco Iafrancesco12, Angelo Andriulli1 1Liver Unit and Gastroenterology Division, IRCCS, San Giovanni Rotondo, Italy. 2Ospedale Civile Sassari, Sassari, Italy. 3Ospedale “S.Camillo”, Roma, Italy. 4Università Cattolica, Roma, Italy. 5Ospedale “S.Pertini”, Roma, Italy. 6Ospedale Civile Canosa, Canosa, Italy. 7Ospedale Civile Casarano, Casarano, Italy. 8Università di Palermo, Palermo, Italy. 9Clinica “Santa Rita”, Bari, Italy. 10Ospedale “G.Garibaldi”, Catania, Italy. 11IRCCS “De Bellis”, Castellana Grotte, Italy. 12Ospedale “S.Sebastiano”, Frascati, Italy

#1582

COMBINATION THERAPY WITH NUCLEOSIDE POLYMERASE R7128 AND PROTEASE R7227/ITMN-191 INHIBITORS IN GENOTYPE 1 HCV INFECTED PATIENTS: INTERIM RESISTANCE ANALYSIS OF INFORM-1 COHORTS A-D

RESPONSE-GUIDED THERAPY (RGT) FOR BOCEPREVIR (BOC) COMBINATION TREATMENT? – RESULTS FROM HCV SPRINT-1 Paul Y. Kwo1, Eric Lawitz2, Jonathan McCone3, Eugene R. Schiff4, John M. Vierling5, David Pound6, Mitchell Davis7, Joseph S. Galati8, Stuart C. Gordon9, Natarajan Ravendhran10, Lorenzo Rossaro11, Frank H. Anderson12, Ira M. Jacobson13, Raymond Rubin14, Kenneth Koury15, Navdeep Boparai15, Eirum I. Chaudhri15, Clifford A. Brass15, Janice K. Albrecht15 1Medicine, Division of Gastroenterology/Hepatology, Indiana University School of Medicine, Indianapolis, IN, USA. 2Alamo Medical Research, San Antonio, TX, USA. 3Mount Vernon Endoscopy Center, Alexandria, VA, USA. 4University of Miami Center for Liver Diseases, Miami, FL, USA. 5Baylor College of Medicine, Houston, TX, USA. 6Indianapolis Gastroenterology Research Foundation, Indianapolis, IN, USA. 7South Florida Center of Gastroenterology, Wellington, FL, USA. 8Liver Specialists of Texas, Houston, TX, USA. 9Henry Ford Hospital, Detroit, MI, USA. 10Digestive Disease Associates, Baltimore, MD, USA. 11University of California-Davis, Sacramento, CA, USA. 12The Liver & Intestinal Research Center, Galveston, TX, USA. 13Weill Medical College of Cornell University, New York, NY, USA. 14Digestive Healthcare of Georgia, Atlanta, GA, USA. 15Schering-Plough Research Institute, Kenilworth, NJ, USA

EXTENDED DURATION OF THERAPY WITH PEGINTERFERON ALPHA2B (PEGIFN) AND WEIGHT BASED RIBAVIRIN (RBV) IN HCV PATIENTS WITH GENOTYPE 3 INFECTION

#1585

Sophie Le Pogam1, Milloni Chhabra1, Samir Ali1, Jun-Mei Yan1, Mariola J. Ilnicka1, Hyunsoon Kang1, Jennifer M. Wong1, Alan Kosaka1, Aren Ewing1, Amritha Seshaadri1, Abel De La Rosa3, Williamson Z. Bradford2, Klaus Klumpp1, Nancy Shulman1, Patrick F. Smith1, Nick Cammack1, Isabel Najera1 1Roche Palo Alto LLC, Palo Alto, CA, USA. 2Intermune, Brisbane, CA, USA. 3Pharmasset, Princeton, NJ, USA

#1586 ANA598 DISPLAYS POTENT IN VITRO ANTIVIRAL ACTIVITY AGAINST DIVERSE CLINICAL ISOLATES OF GENOTYPE 1 HCV IN A TRANSIENT REPLICON SHUTTLE VECTOR SYSTEM Richard E. Showalter, Peggy A. Thompson, Kevin Steffy, James R. Appleman Anadys Pharmaceuticals, San Diego, CA, USA


266A

POSTER SESSIONS

#1587

#1592

AVL-181 DEMONSTRATES PROLONGED INHIBITION OF HCV NS3 PROTEASE ACTIVITY IN VIVO THAT DIRECTLY CORRELATES WITH PROLONGED MOLECULAR TARGET OCCUPANCY

CLONAL ANALYSIS OF MUTATIONS SELECTED IN THE HCV NS3 PROTEASE DOMAIN OF GENOTYPE 1 NON-RESPONDERS SEQUENTIALLY TREATED WITH BOCEPREVIR (SCH503034) AND/OR PEGYLATED INTERFERON ALFA-2B (PEG-IFN α-2B)

Deqiang Niu, Margit Hagel, Thia St.Martin, Lixin Qiao, Russell Karp, Mariana Nacht, Russell C. Petter, Michael P. Sheets, Hugues Bernard, Juswinder Singh, William Westlin Avila Therapeutics, Waltham, MA, USA

#1588 CONTROLLED RELEASE NITAZOXANIDE IN COMBINATION WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN RESULTS IN HIGH EARLY VIROLOGIC RESPONSE RATES FOR TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4 Emmet B. Keeffe1,2, Asem Elfert3, Sabry Abousaif3, Jean-François Rossignol1,2 1The Romark Institute for Medical Research, Romark Laboratories, Tampa, FL, USA. 2Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA. 3Department of Gastroenterology and Hepatology, University of Tanta, Tanta, Egypt

#1589 DECREASE OF SOCS–3 BY ME3738 CONTRIBUTES TO ITS SYNERGISTIC ANTI–HCV EFFECTS WHEN COMBINED WITH TYPE I INTERFERON Yoichi Hiasa, Yoshio Tokumoto, Ichiro Konishi, Masanori Abe, Hidehiro Murakami, Bunzo Matsuura, Morikazu Onji Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan

#1590 POTENTIAL FOR RAPID AND PROLONGED THERAPEUTIC BENEFIT IN HCV THROUGH PROTEIN SILENCING OF NS3 PROTEASE WITH AVL-181 Margit Hagel1, Deqiang Niu2, Hugues Bernard1, Russell Karp1, Lixin Qiao2, Mariana Nacht1, Russell C. Petter2, Michael P. Sheets1, Juswinder Singh2, Thia St.Martin1, William Westlin1 1Preclinical Research, Avila Therapeutics, Waltham, MA, USA. 2Drug Discovery, Avila Therapeutics, Waltham, MA, USA

#1591 A PHASE 1B DOSE-RANGING STUDY OF 4 WEEKS OF PEG-INTERFERON (IFN) LAMBDA (PEG-RIL-29) IN COMBINATION WITH RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS (HCV) INFECTION Muir1,



Shiffman2,

Zaman3,

Yoffe4,

Andrew Mitchell L. Atif Boris Juan Carlos Lopez-Talavera5, Sherri Souza6, Diana F. Hausman6, Eric Lawitz7 1Duke University, Durham, NC, USA. 2VCU Medical Center, Richmond, VA, USA. 3Oregon Health Sciences University, Portland, OR, USA. 4Baylor College of Medicine, Houston, TX, USA. 5BristolMyers Squibb, New York, NY, USA. 6ZymoGenetics Inc, Seattle, WA, USA. 7Alamo Medical Research, San Antonio, TX, USA


Johannes Vermehren1, Simone Susser1, Ursula Karey1, Nicole Forestier1, Christian M. Lange1, Eric A. Hughes2, Robert Ralston2, Xiao Tong2, Stefan Zeuzem1, Christoph Sarrazin1 1Medizinische Klinik 1, Klinikum der J. W. Goethe-Universität, Frankfurt/Main, Germany. 2Schering Plough Research Institute, Kenilworth, NJ, USA

#1593 IMO-2125, A TLR9 AGONIST, INDUCES TH1-TYPE CYTOKINES AND INTERFERONS WITH POTENT ANTI-HCV ACTIVITY IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS AND PLASMACYTOID DENDRITIC CELLS Lakshmi Bhagat, Dong Yu, Anthony F. Trombino, Tim Sullivan, Ekambar R. Kandimalla, Sudhir Agrawal Idera Pharmaceuticals, Cambridge, MA, USA

#1594 PHARMACOKINETICS/PHARMACODYNAMICS (PK/PD) OF COMBINATION R7227 AND R7128 THERAPY FROM INFORM-1 DEMONSTRATES SIMILAR EARLY HCV VIRAL DYNAMICS WHEN R7227 IS COMBINED WITH EITHER PEGIFN/RIBAVIRIN (SOC) OR R7128 Peter N. Morcos1, Rohit Kulkarni1, David Ipe1, Shasha Jumbe1, Jonathan Tran1, Williamson Z. Bradford2, William Symonds3, Williamson Z. Bradford2, Edward J. Gane4, Stuart K. Roberts5, Nancy Shulman1, Patrick F. Smith1 1Roche, Palo Alto, CA, USA. 2Intermune, Brisbane, CA, USA. 3Pharmasset, Princeton, NJ, USA. 4Auckland Clinical Studies, Auckland, New Zealand. 5The Alfred, Melbourne, VIC, Australia

#1595 ANTIVIRAL ACTIVITY OF THE NONIMMUNOSUPPRESSIVE CYCLOPHILIN INHIBITOR SCY-635 IN COMBINATION WITH INVESTIGATIONAL AND APPROVED ANTI-HCV AGENTS Sam Hopkins1, Zhuhui Huang2, Andrew Scribner1, Michael Peel1 Incorporated, Durham, NC, USA. 2Southern Research Incorporated, Frederick, MD, USA

1Scynexis

#1596 A COMBINATION OF A NOVEL CYCLOPHILIN INHIBITOR AND A NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR SYNERGISTICALLY INHIBITS VIRAL REPLICATION AND SUPPRESSES THE EMERGENCE OF RESISTANCE Christopher M. Owens, Tiffany W. Poon, Jiang Long, Yao-Ling Qiu, Guoqiang Wang, Lijuan Jiang, Yat Sun Or Enanta Pharmaceuticals, Inc., Watertown, MA, USA


POSTER SESSIONS

267A

#1597

#1601

GENE EXPRESSION PROFILES INDUCED BY IMO2125, AN AGONIST OF TOLL-LIKE RECEPTOR 9, IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS

SIGNIFICANT IMPROVEMENT OF THE PHARMACOKINETIC PROFILE OF A HYPERGLYCOSYLATED CONSENSUS TYPE 1 INTERFERON

Weiwen Jiang, Lakshmi Bhagat, Dong Yu, Jimmy X. Tang, Ekambar R. Kandimalla, Sudhir Agrawal Idera Pharmaceuticals, Inc, Cambridge, MA, USA

#1598 FLAVONOIDS, A NOVEL CLASS OF HCV RNADEPENDENT RNA POLYMERASE INHIBITORS Abdelhakim Ahmed-Belkacem1, Rozenn Brillet1, Coralie Pallier1, Czeslaw Wychowski2, Jean-Francois Guichou3, Jean-Michel Pawlotsky1 1Henri Mondor Hospital, University of Paris 12, Creteil, France. 2Institut de Biologie de Lille, Lille, France. 3University of Montpellier, Montpellier, France

#1599 BI 207127 IS A POTENT HCV RNA POLYMERASE INHIBITOR DURING 5 DAYS MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS C Dominique G. Larrey1, Yves Benhamou2, Ansgar W. Lohse3, Christian Trepo4, Christian Moelleken5, Jean-Pierre Bronowicki6, Markus H. Heim7, Keikawus Arastéh8, Jean-Pierre Zarski9, Marc Bourlière10, Reiner Wiest11, José L. Calleja12, Jaime Enríquez13, Andreas Erhardt14, Heiner Wedemeyer15, Tilman Gerlach16, Thomas Berg17, Jerry O. Stern18, Katherine Wu18, Nasri Abdallah19, Gerhard Nehmiz20, Wulf O. Boecher20, Frank M. Berger21, Juergen Steffgen20 1INSERM632-CIC Hôpital Saint Eloi, Montpellier, France. 2Hôpital La Pitié Salpétrière, Paris, France. 3Universitätsklinikum HamburgEppendorf, Hamburg, Germany. 4Hôpital Hotel Dieu, Lyon, France. 5Universitätsklinik, Bochum, Germany. 6Hôpital de Brabois, Nancy, France. 7Universitätsspital, Basel, Switzerland. 8Epimed GmbH, Berlin, Germany. 9Hôpital Michalon, Grenoble, France. 10Hôpital Saint Joseph, Marseille, France. 11Klinikum der Universität, Regensburg, Germany. 12Clinica Puerta de Hierro, Madrid, Spain. 13Hospital de la Santa Creu I Sant Pau, Barcelona, Spain. 14Universitätsklinikum, Düsseldorf, Germany. 15Medizinische Hochschule, Hannover, Germany. 16Kantonsspital, St. Gallen, Switzerland. 17Charité Berlin Campus Virchow-Klinikum, Berlin, Germany. 18Boehringer Ingelheim, Ridgefield, CT, USA. 19Boehringer Ingelheim, Reims, France. 20Boehringer Ingelheim, Biberach, Germany. 21Boehringer Ingelheim, Ingelheim, Germany

#1600 PREDICTION OF VIROLOGICAL RESPONSE TO INTRAVENOUS SILIBININ AND PEGIFN/RBV IN PREVIOUS NONRESPONDERS BY SERUM IP-10 LEVELS

#1602 COMBINATION OF IDX184, A NUCLEOTIDE PRODRUG POLYMERASE INHIBITOR, WITH OTHER CLASSES OF HCV INHIBITORS IS ADDITIVE TO SYNERGISTIC IN THE HCV REPLICON IN VITRO Lisa Lallos, Massimiliano LaColla, Ilaria Serra, John P. Bilello, Mary A. Soubasakos, Bin Li, Ronald J. Panzo, Joshua M. Gillum, Angelina Bonin, Maria Seifer, David N. Standring Idenix Pharmaceuticals, Inc., Cambridge, MA, USA

#1603 DYNAMICS OF PLASMACYTOID DENDRITIC CELLS AS A PREDICTOR OF RELAPSE REGARDLESS OF VIROLOGICAL RESPONSE IN PEGYLATED INTERFERON-α AND RIBAVIRIN THERAPY IN CHRONIC HEPATITIS C PATIENTS Tatsuya Kanto, Ichiyo Itose, Michiyo Inoue, Tsugiko Oze, Tokuhiro Matsubara, Koyo Higashitani, Naruyasu Kakita, Masanori Miyazaki, Mitsuru Sakakibara, Naoki Hiramatsu, Tetsuo Takehara, Akinori Kasahara, Norio Hayashi Department of Gastroenterology and Hepatology, Osaka university Graduate School of Medicine, Suita, Japan

#1604 A COMBINATION OF A NOVEL CYCLOPHILIN INHIBITOR AND A NOVEL PUTATIVE NS5A INHIBITOR WITH POTENT ANTI-HCV ACTIVITY SYNERGISTICALLY INHIBITS VIRAL REPLICATION AND CURES REPLICON CELLS IN THE PRESENCE OR ABSENCE OF INTERFERON-α Christopher M. Owens, Tiffany W. Poon, Jiang Long, Ce Wang, Guoqiang Wang, Yao-Ling Qiu, Lijuan Jiang, Yat Sun Or Enanta Pharmaceuticals, Inc., Watertown, MA, USA

#1605 NOVEL 2′-F-2′-C-METHYLPURINE NUCLEOTIDE ANALOGS ARE ACTIVE INHIBITORS OF HCV REPLICATION AND LACK CROSS-RESISTANCE WITH OTHER NUCLEOS(T)IDE ANALOGS Angela M. Lam1, Christine L. Espiritu1, Holly Micolochick Steuer1, Eisuke Murakami1, Congrong Niu1, Meg Keilman1, David N. Frick2, Julie A. Heck2, Michael J. Sofia1, Dhanapalan Nagarathnam1, Wonsuk Chang1, Pamulapati G. Reddy1, Bruce S. Ross1, Byoung-Kwon Chun1, Peiyuan Wang1, Hai-Ren Zhang1, Suguna Rachakonda1, Donghui Bao1, Michael J. Otto1, Phillip A. Furman1 1Pharmasset Inc., Princeton, NJ, USA. 2Biochemistry and Molecular Biology, New York Medical College, Princeton, NJ, USA


Karoline Rutter1, Thomas Reiberger1, Judith H. Aberle2, ThomasMatthias Scherzer1, Sandra Beinhardt1, Albert Stättermayer1, Harald Hofer1, Heidrun Kerschner2, Petra E. Steindl-Munda1, Heidemarie Holzmann2, Peter Ferenci1 1Dpt of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria. 2Clinical Virology, Medical University of Vienna, Vienna, Austria

Jin Hong, Hua Tan, Qingling Zhang, Bruce T. Bryan, Leo Beigelman, Lawrence M. Blatt Alios Biopharma, South San Francisco, CA, USA

268A

POSTER SESSIONS


#1606

#1610

EX VIVO TARGETING OF ADENOVIRAL PARTICLES TO DENDRITIC CELLS ENHANCES THEIR MATURATION AND THE INDUCTION OF IMMUNE RESPONSES AGAINST HEPATITIS C VIRUS

THE ASSOCIATION OF BASE LINE GGTP LEVEL AND SVR IN TREATMENT NAIVE PATIENTS WITH CHRONIC HEPATITIS C PATIENT

Itziar Echeverria1, Alexander Pereboev2, Leyre Silva1, Aintzane Zabaleta1, Jose I. Riezu-Boj1, Marta Bes3, Maria Cubero3, Francisco Borras-Cuesta1, Juan J. Lasarte1, Juan I. Esteban3, Jesus Prieto1,4, Pablo Sarobe1 1Division of Hepatology and Gene Therapy, University of NavarraCenter for Applied Medical Research, Pamplona, Spain. 2Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 3Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Universitari Vall d’Hebron, Barcelona, Spain. 4CIBERehd, University Clinic,, University of Navarra, Pamplona, Spain

#1607

Nigelarani Vakeesan, Xinyu Zhao, Michael D. Bernstein Internal medicine, Coney Island Hospital, Brooklyn, NY, USA

#1611 PHARMACOLOGICAL PROPERTIES AND IN VITRO CHARACTERIZATION OF INX-189, A LIVER TARGETED PHOSPHORAMIDATE NUCLEOSIDE ANALOGUE INHIBITOR OF NS5B Joseph Patti, Brenda Ames, Dawn Byrant, Stanley D. Chamberlain, Babita S. Ganguly, Elena Gorovits, Andrea Hall, Damound S. Hunley, Jeff T. Hutchins, Alexander Kolykhalov, Yule Liu, Jerry Muhammad, Nicholas Raja, John Vernachio, Robin Walters, Jin Wang, Geoffrey W. Henson Inhibitex, Inc., Alpharetta, GA, USA

GENOTYPIC AND PHENOTYPIC ANALYSIS OF SAMPLES FROM HCV-INFECTED SUBJECTS TREATED WITH BMS-650032 IN A SINGLE ASCENDING DOSE STUDY

HCV: Diagnosis and Natural History

Fiona McPhee, Dennis Hernandez, Amy Sheaffer, Min Lee, Paul Falk, Fei Yu, Guangzhi Zhai, Susan Chaniewski, Claudio Pasquinelli Research and Development, Bristol-Myers Squibb Company, Princeton, NJ, USA

RELATIONSHIP OF IRON [FE] AND HFE GENETIC VARIATIONS TO PROGRESSION AND OUTCOMES OF ADVANCED CHRONIC HEPATITIS C IN THE HALT-C TRIAL

#1608 OPEN-LABEL PHASE IB PILOT STUDY TO EVALUATE THE ANTIVIRAL EFFICACY OF COADMINISTRATION OF SIMVASTATIN AND SERTRALINE IN CHRONIC HEPATITIS C (CHC) PATIENTS Keyur Patel1, Seng Gee Lim2, Chow Wan Cheng3, Eric Lawitz4, Hans L. Tillmann1, Narinder Chopra5, John C. Randle5, John G. McHutchison1 1Department of GI & Hepatology, Duke Clinical Research Institute and DUMC, Durham, NC, USA. 2GI and Hepatology, National University Hospital, Singapore, Singapore. 3Gastroenterology, Singapore General Hospital, Singapore, Singapore. 4Alamo Medical Research, San Antonio, TX, USA. 5CombinatoRx Inc., Cambridge, MA, USA

#1609 A NEWLY SYNTHESIZED SERINE PALMYTOILTRANSFERASE INHIBITOR, NA808, HAS A ROBUST ANTIVIRAL EFFECT TO HEPATITIS C VIRUS VIA HINDERING HOST-VIRUS INTERACTIONS


Yuichi Hirata1, Masayuki Sudoh2, Yuko Tokunaga1, Yoshimi Tobita1, Takuya Umehara1, Takuo Tsukuda2, Michinori Kohara1 1Department of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. 2Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan


#1612

Richard W. Lambrecht1, Deepa Naishadham2, Richard K. Sterling3, Thomas E. Rogers4, Chihiro Morishima5, Anne M. Stoddard2, Herbert L. Bonkovsky6 1Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA. 2New England Research Institutes, Watertown, MA, USA. 3Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA. 4Department of Pathology, UTSW, Dallas, TX, USA. 5Department of Pediatrics, University of Washington, Seattle, WA, USA. 6Carolinas Medical Center, Charlotte, NC, USA

#1613 AGING OF HEPATITIS C INFECTED PERSONS IN THE UNITED STATES: A MULTIPLE COHORT MODEL OF HCV PREVALENCE AND DISEASE PROGRESSION Gary L. Davis1, Miriam J. Alter2, Hashem B. El-Serag3, Thierry Poynard4, Linda W. Jennings1 1Division of Hepatology/Liver Transplant, Baylor University Hospital Dallas, Dallas, TX, USA. 2Infectious Disease Epidemiology Program, University of Texas Medical Branch, Galveston, TX, USA. 3Dept of Medicine, Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA. 4Hepato Gastro Groupe Hospital, Pitie Salpetriere, Paris, France


POSTER SESSIONS

#1614 ACCUMULATION OF IFN-α INSENSITIVE CD8+ LYMPHOCYTES WITH DOUBLE STRAND DNA BREAKS IN PROGRESSIVE HCV INFECTION Matthew Hoare1, Arun N. Shankar1, Simon Rushbrook1, Susan Davies2, Arne N. Akbar3, Graeme J. Alexander1 1Department of Medicine, University of Cambridge, Cambridge, United Kingdom. 2Department of Pathology, University of Cambridge, Cambridge, United Kingdom. 3Department of Immunology, University College London, London, United Kingdom

#1615 EARLY LOSS OF EXPOSURE TO ESTROGENS IS CRITICAL IN DETERMINING ENTITY OF FIBROSIS AND RESPONSE TO IFN IN WOMEN WITH HEPATITIS C Aimilia Karampatou1, Paola Elena Pazienza1, Barbara Lei1, Alfredo Di Leo2, Antonio Francavilla2, Erica Villa1 1Gastroenterology, University of Modena and Reggio Emilia, Modena, Italy. 2Gastroenterology, University of Bari, Bari, Italy

#1616 SERUM APOLIPOPROTEIN CIII LEVELS ARE INDEPENDENTLY ASSOCIATED WITH HEPATIC FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION Jennifer V. Rowell1, Alexander J. Thompson2, Keyur Patel2, Xiang Q. Lao3, Sunil Suchindran3, John R. Guyton1, John G. McHutchison2, Jeanette McCarthy3 1Medicine, Division of Endocrinology, Metabolism and Nutrition, Duke University, Durham, NC, USA. 2GI/Hepatology Research Program, Duke Clinical Research Institute, Duke University, Durham, NC, USA. 3Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA

#1617 INCIDENCE OF END-STAGE LIVER DISEASE AND DEATH AMONG 585 HIV/HCV COINFECTED ADULTS ACCORDING TO BASELINE FIBROSIS STAGE Mark S. Sulkowski1, Berkeley Limketkai1, Shruti H. Mehta2, Michael Torbenson1, Yvonne M. Higgins1, Sherilyn Brinkley1, David L. Thomas1 1Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2Epidemiology, Johns Hopkins University School of Public Health, Baltimore, MD, USA

269A

#1618 HEPATITIS C VIRUS (HCV)-SPECIFIC T-CELL RESPONSES ARE OFTEN DETECTABLE AMONG HEMODIALYSIS PATIENTS AT RISK OF OCCULT HCV INFECTION Juan Antonio Quiroga1, Guillermina Barril2, Mario Espinosa3, Dolores Arenas4, Juan García Valdecasas5, Emilio González Parra6, Nuria Garcia-Fernandez7, José María Alcazar8, MCarmen Sanchez-Gonzalez9, Pilar Martínez Rubio10, Silvia Llorente1, Inmaculada Castillo1, Javier Bartolomé1, Vicente Carreño1 1Fundacion Estudio Hepatitis Virales, Madrid, Spain. 2Nephrology, HU La Princesa, Madrid, Spain. 3Nephrology, H.Reina Sofia, Cordoba, Spain. 4Nephrology, H.Perpetuo Socorro, Alicante, Spain. 5Nephrology, H.Clinico Universitario, Granada, Spain. 6Nephrology, H.Central de la Defensa, Madrid, Spain. 7Nephrology, CU Navarra, Pamplona, Spain. 8Nephrology, H.12 de Octubre, Madrid, Spain. 9Nephrology, HU La Paz, Madrid, Spain. 10Dialysis, FMC El Pilar, Madrid, Spain

#1619 NATURAL CLEARANCE OF HEPATITIS C VIRUS (HCV) RNA IN CHRONIC HCV CARRIERS: A LONG-TERM COHORT STUDY IN AN ENDEMIC AREA OF HCV INFECTION IN JAPAN Hisayoshi Watanabe1, Takafumi Saito1, Yuko Nishise1, Yayoi Sasaki1, Chikako Sato1, Rika Ishii1, Hiroaki Haga1, Mai Sanjo1, Kazuo Okumoto1, Junitsu Ito1, Koji Saito1, Haruhide Shinzawa2, Sumio Kawata1 1Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, Japan. 2Okitama Public General Hospital, Yamagata, Japan

#1620 VALIDATION OF A PANEL OF GENETIC MARKERS (CRS7) IN PREDICTING CIRRHOSIS, FIBROSIS PROGRESSION (FP) AND CLINICAL OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) IN THE HALT-C TRIAL Teresa M. Curto1, Anna S. Lok2, Robert J. Lagier3, Charles M. Rowland3, John Sninsky3, James E. Everhart4 1New England Research Institutes, Watertown, MA, USA. 2Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI, USA. 3Celera, Alameda, CA, USA. 4NIDDK, NIH, Bethesda, MD, USA

#1621 CHRONIC HEPATITIS C (CHC) WITH AUTOIMMUNE HEPATITIS (AIH) FEATURES IS ASSOCIATED WITH MORE ADVANCED FIBROSIS Erin T. Jenkins1, Rish Pai2, John Hart2, Rohit S. Satoskar3, Smruti R. Mohanty3, Nancy Reau3, K. Gautham Reddy3, Donald M. Jensen3, Helen S. Te3 1Medicine, University of Chicago Medical Center, Chicago, IL, USA. 2Pathology, University of Chicago Medical Center, chicago, IL, USA. 3Medicine, Center for Liver Diseases, University of Chicago Medical Center, Chicago, IL, USA T U E S D AY NOVEMBER 3

270A

POSTER SESSIONS


#1622

#1625

INSULIN RESISTANCE AND HEPATIC STEATOSIS ARE BOTH INDEPENDENTLY ASSOCIATED WITH ADVANCED HEPATIC FIBROSIS IN CHRONIC HEPATITIS C INFECTION: ANALYSIS OF THE ACHIEVE 1 AND ACHIEVE 2/3 COHORTS

SERUM FIBROSIS MARKERS ARE ASSOCIATED WITH CLINICAL OUTCOMES AND HISTOLOGICAL PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) AND ADVANCED FIBROSIS

Alexander J. Thompson2, Keyur Patel2, Hans L. Tillmann2, Jeanette McCarthy3, Stefan Zeuzem4, Yves Benhamou5, David R. Nelson6, Mark S. Sulkowski7, Michael Torbenson7, Erik Pulkstenis1, G M. Subramanian1, John G. McHutchison2 1Human Genome Sciences, Inc., Rockville, MD, USA. 2GI/Hepatology Research Program, Duke Clinical Research Institute, Durham, NC, USA. 3Institute for Genome Sciences & Policy, Duke University Medical Center, Durham, NC, USA. 4J. W. Goethe University Hospital, Frankfurt, Germany. 5Hopital Pitie Salpetriere, Paris, France. 6University of Florida-Gainsville, Gainsville, FL, USA. 7Johns Hopkins Center for Viral Hepatitis, Baltimore, MD, USA

#1623 ACOUSTIC RADIATION FORCE IMPULSE IMAGING PREDICTS ADVANCED FIBROSIS AND CIRRHOSIS IN CHRONIC HEPATITIS C PATIENTS Shih-Jer Hsu1,2, Chen-Hua Liu2,3, Jia-Horng Kao2,3, Ding-Shinn Chen2,3 1Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yunlin County, Taiwan. 2Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan. 3Department of Internal Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan

#1624 IP-10 CHEMOKINE AS A MARKER OF SUSTAINED VIROLOGICAL RESPONSE (SVR) TO CONVENTIONAL THERAPY AND FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) INFECTION Eduardo Cerda, Arturo Meixueiro-Daza, Juan F. Sanchez-Avila, Aurora Loaeza del Castillo, Magdalena Sanchez-Osorio, Jorge Garcia-Leiva, Alejandro Chavez-Ayala, Misael Uribe, Florencia Vargas-Vorackova, Aldo J. Montano-Loza Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, México city, Mexico

Robert J. Fontana1, Anna S. Lok1, Jules L. Dienstag5, Deepa Naishadham6, Herbert L. Bonkovsky2, Elizabeth C. Wright7, Zachary D. Goodman3, Richard K. Sterling4 1Divison of Gastroenterology, Department of Internal Medicine, University of Michigan Hospital, Ann Arbor, MI, USA. 2Department of Medicine, Carolina Medical Center, Charlotte, NC, USA. 3Department of Pathology, Armed Forces Institute of Pathology, Washington, DC, USA. 4Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA. 5Department of Medicine, Massachussetts General Hospital, Boston, MA, USA. 6Bio Statistics, New England Research Institute, Boston, MA, USA. 7Liver Disease Research Branch, National Institutes of Health, Bethesda, MD, USA

#1626 CHRONIC HEPATITIS C INFECTION IS ASSOCIATED WITH LOWER RATES OF HOSPITALIZATION FOR CORONARY HEART DISEASE Kathleen E. Corey1, Hui Zheng1, Vinod K. Rustgi2, Raymond Chung1 1MGH, Boston, MA, USA. 2Metropolitan Research, Georgetown University Medical Center, Fairfax, VA, USA

#1627 HEPATIC IMPAIRMENT MEASURED BY QUANTITATIVE TESTS OF LIVER FUNCTION (QLFTS) PREDICTS CLINICAL OUTCOME IN PATIENTS WITH ADVANCED FIBROSIS: RESULTS FROM THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL Gregory T. Everson1, John C. Hoefs2, Mitchell L. Shiffman3, Timothy R. Morgan2, Richard K. Sterling3, Teresa M. Curto5, David Wagner4, Elizabeth C. Wright6, James E. Everhart6 1Transplant Center and Hepatology, University of Colorado, Aurora, CO, USA. 2Division of Gastroenterology and Hepatology, University of California, Irvine, Irvine, CA, USA. 3Section of Hepatology, VCU, Richmond, VA, USA. 4Metabolic Solutions, Nashua, NH, USA. 5New England Research Institute, Watertown, MA, USA. 6NIDDK, Bethesda, MD, USA

#1628 PREDICTIVE VALUE OF FIB-4 INDEX FOR HEPATOCELULAR CARCINOMA DEVELOPMENT IN CHRONIC HEPATITIS C


Masayuki Kurosaki Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan



POSTER SESSIONS

271A

#1629

#1634

PAIRED BIOPSIES ILLUSTRATE RACIAL DIFFERENCES IN FIBROSIS PROGRESSION IN HCV PATIENTS

APOLIPOPROTEIN B ASSOCIATED HEPATITIS C VIRUS (HCV): A MINORITY OF TOTAL VIRAL LOAD IN PATIENTS WITH CHRONIC HCV

Veronica TenCate1, Jennifer E. Layden-Almer2, Marla Wolfert3, Katherine M. Johnson3, Scott J. Cotler1, Grace Guzman4, Thomas J. Layden1 1Gastroenterology, University of Illinois, Chicago, IL, USA. 2Infectious Disease, University of Illinois, Chicago, IL, USA. 3Internal Medicine, University of Illinois, Chicago, IL, USA. 4Pathology, University of Illinois, Chicago, IL, USA

Simon Bridge, David A. Sheridan, Daniel Felmlee, Soren U. Nielsen, Dermot Neely, Geoffrey L. Toms, Margaret F. Bassendine Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom

#1630 AGE, INSULIN RESISTANCE AND STEATOSIS ARE INDEPENDENT RISK FACTORS FOR FIBROSIS PROGRESSION IN UNTREATED PATIENTS WITH MILD CHRONIC HEPATITIS C: A PROSPECTIVE STUDY WITH REPEAT BIOPSIES Christiane Stern1, Ana-Carolina Cardoso1, Rami Moucari1, Michelle Martinot-Peignoux1, Marie-Pierre Ripault1, Nathalie Boyer1, Pierre Bedossa2, Patrick Marcellin1 1Service d’Hépatologie and INSERM U773-CRB3, Hôpital Beaujon, Clichy, France. 2Service d’Anatomie-Pathologique, Hôpital Beaujon, Clichy, France

#1631 HEPATITIS C AND MENOPAUSE: INTERPLAY OF AGE, GENDER, HCV REPLICATION AND ACTIVITY IN PROGRESSION AND CONSEQUENCE FOR THERAPY Eric Trépo1, François Bailly2, Christophe Moreno1, Arnaud Lemmers1, Christian Trepo2, Michael Adler1, Pierre Pradat2 1Hepatogastroenterology, Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium. 2Hepatogastroenterology, Hotel-Dieu, Hospices Civils de Lyon, Lyon, France

#1632 RESPECTIVE USEFULNESS OF FIBROTEST AND TRANSIENT ELASTROGRAPHY TO DIFFERENTIATE INACTIVE CARRIER STAGE FROM HBEAGNEGATIVE CHRONIC HEPATITIS B Vincent Leroy, Marie Noelle Hilleret, Sylvie Larrat, Nathalie Sturm, Jean Charles Renversez, Jean Pierre H. Zarski CHU de Grenoble, Grenoble, France

#1633 SEVERITY OF LIVER STEATOSIS AFFECTS PROGRESSION OF DISEASE IN MONOINFECTED PATIENTS BUT NOT IN HCV/HIV CO-INFECTED PATIENTS

INDEPENDENT AND PROSPECTIVE COMPARISON OF 9 SURROGATE MARKERS FOR THE DIAGNOSIS OF LIVER FIBROSIS IN CHRONIC HEPATITIS C Jean Pierre H. Zarski1,2, Nathalie Sturm2,3, Jerome Guechot4, Adeline Paris5 1Gastroenterology and Hepatology, CHU de Grenoble, Grenoble, France. 2INSERM UJF U-823, IAPC, Grenoble, France. 3Department of Pathology, CHU de Grenoble, Grenoble, France. 4Department of Biology, Hopital St Antoine AP-HP, Paris, France. 5INSERM CIC 003, CHU de Grenoble, Grenoble, France

#1636 FIBROSPECT II (FS II) SCORE OVERESTIMATES THE DEGREE OF FIBROSIS IN CHRONIC HEPATITIS C (CHC) PATIENTS WITH SIGNIFICANT RENAL DYSFUNCTION Noura M. Sharabash1, Donald M. Jensen2, Dingcai Cao3, Nancy Reau2, Smruti R. Mohanty2, Rohit S. Satoskar2, K. Gautham Reddy2, Mary S. Hammes4, Helen S. Te2 1Medicine, University of Chicago Medical Center, Chicago, IL, USA. 2Medicine, Center for Liver Diseases, University of Chicago, Chicago, IL, USA. 3Surgery, University of Chicago, Chicago, IL, USA. 4Medicine, Section of Nephrology, University of Chicago, Chicago, IL, USA

#1637 NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS B AND C PATIENTS: A COMPARISON OF THE GALACTOSE - AND METHACETIN BREATH TESTS, THE SERUM MARKERS HYALURONIC ACID, APRI AND FIBROTEST AND TRANSIENT ELASTOGRAPHY TO LIVER BIOPSY Krista J. Stibbe1, Claudia Verveer1, Jan Francke1, Bettina E. Hansen2, Pieter E. Zondervan3, Ernst J. Kuipers1, Robert J. de Knegt1, Anneke J. van Vuuren1 1Gastroenterology & Hepatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands. 2Biostatistcs, Erasmus MC, University Medical Center, Rotterdam, Netherlands. 3Pathology, Erasmus MC, University Medical Center, Rotterdam, Netherlands

#1638 DECREASE IN PLATELETS, WHILE STILL WITHIN NORMAL RANGE, CORRELATE WITH INCREASE IN HEPATIC FIBROSIS IN CHRONIC HEPATITIS C INFECTION Arema A. Pereira, Brandon Aden, Maya Gambarin-Gelwan, Kristen M. Marks, Andrew Talal, Ira M. Jacobson Center for the Study of Hepatitis C, Department of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, NY, USA


Maribel Rodriguez-Torres1,2, Norbert Brau3, Jose F. RodriguezOrengo1,4, Grisell Ortiz-Lasanta1, Omar Segarra-Alonso1, Acisclo M. Marxuach1 1Fundación de Investigación de Diego, Santurce, PR, USA. 2Ponce School of Medicine, Ponce, PR, USA. 3Bronx Veterans Affairs Medical Center and Mount Sinai School of Medicine, New York, NY, USA. 4Biochemistry Department, UPR School of Medicine-Medical Sciences Campus, San Juan, PR, USA

#1635

272A

POSTER SESSIONS


#1639

#1644

HEPATIC FIBROSIS REGRESSION IN THE SETTING OF PERSISTENT VIREMIA IN CHRONIC HEPATITIS C: A DUAL BIOPSY STUDY

RESILIENCE AFFECTS THE QUALITY OF LIFE IN PATIENTS WITH CHRONIC HEPATITIS C

Venessa

Pattullo1,

Heathcote1,

Guindi2

E. Jenny Maha University Health Network, Toronto, ON, Canada. 2Pathology, University Health Network, Toronto, ON, Canada

1Medicine,

#1640 LOW DIAGNOSIS ACCURACY OF FIBROTEST AND FIB-4 IN HCV-INFECTED HEMODIALYSIS AND KIDNEY RECIPIENTS Hélène Fontaine, Bertrand Nalpas, Anaïs Vallet-Pichard, Vincent Mallet, Stanislas Pol Hepatology Unit, Cochin Hospital, Paris, France

#1641 THE FIB-4 INDEX IS ACCURATE TO ASSESS LIVER FIBROSIS BEFORE AND DURING TREATMENT IN CHRONIC HEPATITIS B. Vincent Mallet, Anaïs Vallet-Pichard, Bertrand Nalpas, Hélène Fontaine, Philippe Sogni, Stanislas Pol Institut Cochin, Université Paris Descartes, CNRS (UMR 8104); Inserm, U567; APHP, Groupe Hospitalier Cochin Saint-Vincent de Paul, Unité d’Hépatologie, Paris, France

#1642 THE POINT OF CARE 13C METHACETIN BREATH TEST ACCURATELY ASSESSES INFLAMMATION, FIBROSIS AND PROGNOSIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C AND NORMAL ALT: A NON INVASIVE LIVER FUNCTION TEST Gadi Lalazar1, Beat Mullhaupt2, Tomer Adar1, Oliver Goetze2, Meir Mizrahi1, Rifaat Safadi1, Ehud Zigmond1, Nilla Hemed1, Yaron Ilan1 1Liver Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel. 2Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland

#1643 MEASUREMENT OF SPLEEN STIFFNESS BY TRANSIENT ELASTOGRAPHY INCREASES THE ACCURACY OF DETECTION OF PORTAL HYPERTENSION IN HCV CIRRHOSIS


Vincenza Calvaruso1, Vito Di Marco1, Fabrizio Bronte1, Giusalba Licata1, Daniela Cabibi2, Nicola Alessi1, Fabio Simone1, Calogero Cammà1, Antonio Craxì1 1Gastroenterologia & Epatologia, DIBIMIS,, University of Palermo, Palermo, Italy. 2Anatomia Patologica, University of Palermo, Palermo, Italy


Carlo Selmi1, Alessia M. Giorgini2, Claudio A. Cocchi2, Francesca Meda1, Scrignaro Marta3, Cristina Monticelli3, Maria Elena Magrin3, Mauro Podda1, Massimo Zuin2 1Department of Internal Medicine, University of Milan, IRCCS Istituto Clinico Humanitas, Rozzano, Italy. 2San Paolo School of Medicine, University of Milan, Milan, Italy. 3Department of Psychology, University of Milan-Bicocca, Milan, Italy

#1645 SELF-REPORTED COGNITIVE SYMPTOMS ARE COMMONLY ASSOCIATED WITH UNDERLYING NEUROCOGNITIVE IMPAIRMENT IN HEPATITIS C INFECTED PATIENTS REFERRED FOR ANTIVIRAL TREATMENT Markus Gess2,1, Matthew L. Cowan2,1, Sarah J. Clark1, Nick Tatman1, Daniel M. Forton2,1 1Department of Gastroenterology and Hepatology, St George’s Hospital, London, United Kingdom. 2Cellular and Molecular Medicine, St George’s University of London, London, United Kingdom

#1646 SERUM CK-18 LEVELS ARE ASSOCIATED WITH ADVANCED FIBROSIS BUT NOT STEATOSIS IN CHRONIC HEPATITIS C PATIENTS Alexander J. Thompson, Hans L. Tillmann, John G. McHutchison, Keyur Patel Duke Clinical Research Institute, Duke University Medical Centre, Durham, NC, USA

#1647 APOLIPOPROTEIN E GENOTYPING AND FIBROSIS PROGRESSION AMONG PATIENTS WITH INITIALLY MILD CHRONIC HEPATITIS C AND PERSISTENTLY NORMAL TRANSAMINASES: AN AID TO CLINICAL DECISION MAKING? Carlo Smirne1, Carmen Vandelli2, Carlo Fabris3, Rosalba Minisini1, Andrea Cerutti1,4, Rachele Rapetti1, Edmondo Falleti5, Davide Bitetto3, Pierluigi Toniutto3, Mario Pirisi1 1Clinical and Experimental Medicine, University of Eastern Piedmont “A. Avogadro”, Novara, Italy. 2Department of Internal Medicine, University of Modena and Reggio Emilia, Reggio Emilia, Italy. 3Medical Liver Transplant Unit, University of Udine, Udine, Italy. 4Unitè de Hepacivirus, Institut Pasteur, Paris, France. 5Laboratory Medicine, University of Udine, Udine, Italy


POSTER SESSIONS

273A

#1648

#1653

INFLUENCE OF GENETIC ANCESTRY DETERMINED BY PEOPLE SPECIFIC ALLELES (PSA) ANALYSIS ON LIVER FIBROSIS OF AN ADMIXED POPULATION WITH CHRONIC HEPATITIS C

USEFULNESS OF HCV-RNA DETECTION IN ULTRACENTRIFUGED SERUM FOR THE DIAGNOSIS OF OCCULT HCV INFECTION IN HEMODIALYSIS PATIENTS

Lourianne N. Cavalcante1,3, Kiyoko Abe-Sandes2, Ana Luiza D. Angelo1,2, Denise C. Lemaire2, Leila S. Souza1, Eilane S. Azevedo1, Joao Marcos D. Carvalho1, Taisa Machado M. Machado2, Patricia S. Brandão2, Nelma P. Santana1, Luiz G. Lyra1,3, Andre C. Lyra1,3 1Gastrohepatology Unit – Federal University of Bahia, Brazil, Salvador, Brazil. 2Laboratory of Immunology and Postgraduate Immunology Course – Science Health Institute – Federal University of Bahia, Salvador, Brazil. 3Gastrohepatology Unit - Hospital Sao Rafael, Salvador, Brazil

Inmaculada Castillo1, Guillermina Barril2, Javier Bartolomé1, Dolores Arenas3, Mario Espinosa4, Secundino Cigarran5, José María Alcazar6, Nuria Garcia-Fernandez7, Emilio González Parra8, Pilar Caro9, Pilar Martínez Rubio10, Juan García Valdecasas11, Silvia Llorente1, Juan Antonio Quiroga1, Vicente Carreño1 1Fundacion Estudio Hepatitis Virales, Madrid, Spain. 2Nephrology, H. Princesa, Madrid, Spain. 3Nephrology, H. Perpetuo Socorro, Alicante, Spain. 4Nephrology, H. Reina Sofía, Córdoba, Spain. 5Nephrology, H. Da Costa, Burela, Spain. 6Nephrology, H. 12 de Octubre, Madrid, Spain. 7Nephrology, C. Universitaria de Navarra, Pamplona, Spain. 8Nephrology, H. central de la Defensa, Madrid, Spain. 9Nephrology, Clínica Rúber, Madrid, Spain. 10Nephrology, FMC El Pilar, Madrid, Spain. 11Nephrology, H. Clínico, Granada, Spain

#1649 DETECTION OF INTERMEDIATE STAGES OF LIVER FIBROSIS IN CHRONIC HEPATITIS C WITH PERFUSION COMPUTED TOMOGRAPHY Maxime Ronot1, Tarik Asselah2, Valérie Paradis3, Patrick Marcellin2, Bernard E. Van Beers1, Valérie Vilgrain1 1Service de Radiologie, Hôpital Beaujon,, Clichy, France. 2Service d’Hépatologie, Hôpital Beaujon,, Clichy, France. 3Service d’Anatomie-Pathologique, Hôpital Beaujon,, Clichy, France

#1650 LONG-TERM EVALUATION OF FIBROSIS BY TRANSIENT ELASTOGRAPHY IN PATIENTS CLEARING HCV ON ANTIVIRAL THERAPY Calvaruso1,

Almasio1,

Pizzillo2,

#1654 DIAGNOSIS OF OCCULT HCV INFECTION WITHOUT PERFORMING A LIVER BIOPSY Javier Bartolomé1, Inmaculada Castillo1, Juan Antonio Quiroga1, Guillermina Barril2,1, Vicente Carreño1 1Fundacion Estudio Hepatitis Virales, Madrid, Spain. 2Nephrology, HU La Princesa, Madrid, Spain

#1655 QUANTITATIVE HCV CORE ANTIGEN AND HCVRNA KINETICS IN HCV INFECTED PATIENTS OVER A PERIOD OF UP TO 8 YEARS

Vincenza Piero L. Paola Rosa Di Stefano2, Vito Di Marco1, Claudia Cottone1, Salvatore Petta1, Anna Calì1, Antonio Craxì1 1Gastroenterologia & Epatologia, DIBIMIS,, University of Palermo, Palermo, Italy. 2Cattedra di Virologia, Dipartimento di Scienze per la Promozione della Salute “G.D’Alessandro”, University of Palermo, Palermo, Italy

Ingmar Mederacke1, Regina Raupach1, Michael P. Manns1, Heiner Wedemeyer1, Hans L. Tillmann2 1Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 2Duke Clinical Research Institute, Duke University, Durham, NC, USA

#1651

#1656

PERCUTANEOUS LIVER BIOPSY: PURVEY OF THE GASTROENTEROLOGIST OR RADIOLOGIST?

THE EXTENT OF LIVER FIBROSIS MEASURED USING TRANSIENT ELASTOMETRY PREDICTS MORTALITY IN HIV PATIENTS WITH LIVER CIRRHOSIS

Rohit Talwani1,2, Harris G. Yfantis3, Yolanda Flores1, Robert G. Knodell1 1Medicine, Baltimore Veterans Affairs Medical Center, Baltimore, MD, USA. 2Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. 3Pathology, Baltimore Veterans Affairs Medical Center, Baltimore, MD, USA

#1652 USEFULNESS OF MEASUREMENT OF SERUM HIGH-DENSITY LIPOPLOTEIN-PHOSPHOLIPID AS THE PREDICTOR OF THE NVR TO HEPATITIS C THERAPY WITH PEGYLATED INTERFERON AND RIBAVIRIN

#1657 AMINO ACID SUBSTITUTIONS IN THE HEPATITIS C VIRUS CORE REGION WERE INDUCED BY AGING AND SEVER HEPATIC FIBROSIS Masaaki Korenaga1,2, Keiko Korenaga1, Isao Sakaida2, Keisuke Hino1 1Division of Hepatology and Pancreatology, Kawasaki Medical College, Kurashiki Okayama, Japan. 2Department of Gastroenterology and Hepatology, Graduate School of Medicine, Yamaguchi University, Ube, Japan


Hironori Mawatari, Masato Yoneda, Koji Fujita, Yuichi Nozaki, Hiroyuki Kirikoshi, Yoshiyasu Shinohara, Wataru Tomeno, Atsushi Nakajima, Satoru Saito Gastroenterology Division, Yokohama City University School of Medicine, Yokohama, Japan

Paula Tuma1, Inmaculada Jarrin2, Julia del Amo2, Jose Medrano1, Eugenia Vispo1, Pablo Labarga1, Luz Martin-Carbonero1, Pablo Barreiro1, Vincent Soriano1 1Infectious Disease Department, Hospital Carlos III, Madrid, Spain. 2National Center of Epidemiology, Instituto de Salud Carlos III, Madrid, Spain

274A

POSTER SESSIONS


#1658

#1663

SEMEN CHARACTERISTICS IN HEPATITIS C VIRUS (HCV) INFECTED PATIENTS. RELATIONSHIP BETWEEN SEMEN CHARACTERISTICS AND ASSISTED REPRODUCTION TECHNOLOGIES (ART) PRACTICE

PREDICTION OF HCV-RELATED MORTALITY IN BELGIUM USING A MATHEMATICAL MODELING APPROACH: IMPACT OF CURRENT TREATMENT PRACTICE AND DIFFERENT SCENARIOS IMPROVING SCREENING, ACCESS TO TREATMENT AND TREATMENT EFFICACY

Anne Gervais Histologie, Hopital Bichat, Paris, France

#1659 EXCESSIVE ALCOHOL INTAKE DRASTICALLY IMPACTS TRANSPLANT-FREE SURVIVAL: A LONGITUDINAL STUDY IN HCV CIRRHOTIC PATIENTS Mohamed El Nady1, Pierre Deltenre1,2, Marion Corouge1, Valérie Canva1, Alexandre Louvet1,3, Hélène Castel1, Faustine Wartel1, Sébastien Dharancy1,3, Jean Henrion2, Philippe Mathurin1,3 1Hôpital Huriez CHRU Lille, Lille, France. 2Hopital de Jolimont, Haine-Saint-Paul, Belgium. 3INSERM U795 CHRU Lille, Lille, France

#1660 COMPARATIVE STUDY OF PROGNOSTIC VALUE OF NON-INVASIVE DIAGNOSTICS METHODS OF LIVER FIBROSIS (DOPPLER ULTRASONOGRAPHY, ELASTOGRAPHY AND FIBROTEST) IN PATIENTS WITH CHRONIC VIRAL HEPATITES B AND C Chavdar Pavlov, Vladimir Ivashkin, Vladimir Ivashkin Sechenov Moscow Medical Academy, Moscow, Russia

#1661 NEW REFERENCE INTERVAL FOR SERUM ALT DOES NOT IDENTIFY HEPATIC PATHOLOGICAL CHANGES IN CHRONIC HCV GENOTYPE 4 PATIENTS Gamal E. Esmat1, Maissa Elraziky1, Khattab Hani1, Iman M. Hamza1, Ahmed F. Soliman1, Hani Khattab2, Badawi Elkholi3 1Tropical Medicine, Cairo University, Cairo, Egypt. 2Pathology, Cairo University, Cairo, Egypt. 3Clinical Pathology, Cairo University, Cairo, Egypt

#1662 EARLY SPONTANEOUS RESOLUTION OF ACUTE HEPATITIS C DEPENDS ON THE HCV GENOTYPES AND THE LEVELS OF HCV RNA Yoo-Kyung Cho1, Young Nam Kim2, Byung-Cheol Song1 1Internal Medicine, Jeju National University School of Medicine, Jeju National University Hospital, Jeju, Korea, South. 2Internal Medicine, Cheju Halla Hospital, Jeju, Korea, South

Pierre Deltenre1,2, Christophe Moreno3, Philippe Mathurin2,4, Michael Adler3, Alexandre Louvet2,4, Hélène Castel2, Valérie Canva2, Jean Henrion1, Sylvie Deuffic-Burban4,5 1Hopital de Jolimont, Haine-Saint-Paul, Belgium. 2Hopital Huriez, CHRU Lille, Lille, France. 3Hôpital Erasme, Brussels, Belgium. 4INSERM U795, CHRU Lille, Lille, France. 5EA 2694, Faculté de Médecine de Lille, Lille, France

#1664 PROSPECTIVE CLINICAL TRIAL ON THE ACCURACY OF NON-INVASIVE TESTS TO PREDICT LIVER FIBROSIS IN CHRONIC HCV PATIENTS Anca Trifan, Camelia Cojocariu, Catalin Sfarti, Carol Stanciu Institute of Gastroenterology and Hepatology, University of Medicine and Pharmacy Gr. T. Popa, Iasi, Romania

#1665 INDETERMINATE HCV GENOTYPE PATTERNS IN AFRICAN INMIGRANTS IN SPAIN. Antonio Madejon1, Sabino Puente1,2, Marta Sanchez-Carrillo1, Pablo Rivas1,2, Marcelle Bottecchia1, Vincent Soriano1, Javier García-Samaniego1 1Hepatology and Infectious Diseases Departments, CIBERehd, Hospital Carlos III, Madrid, Spain. 2Tropical Medicine Department, Hospital Carlos III, Madrid, Spain

Hepatobiliary Cancer: Clinical #1666 RISK FACTORS FOR THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (HCC) IN A PROSPECTIVE COHORT OF 446 AMERICAN PATIENTS WITH CIRRHOSIS UNDERGOING SURVEILLANCE Amit Singal, Hari S. Conjeevaram, Robert J. Fontana, Sherry Fu, Whitney Wright, Fred Askari, Grace L. Su, Anna S. Lok, Jorge A. Marrero University of Michigan, Ann Arbor, MI, USA

#1667 A RANDOMISED PHASE II TRIAL OF A DRUG ELUTING BEAD IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA BY TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION


Riccardo Lencioni1, Katerina Malagari2, Thomas Vogl3, Frank Pilleul4, Alban Denys5, Anthony Watkinson6, Johannes Lammer7 1Diagnostic Imaging and Intervention, University of Pisa, Pisa, Italy. 2University of Athens, Athens, Greece. 3University of Frankfurt, Frankfurt, Germany. 4Centre Hospitalier Universitaire, Lyon, France. 5Centre Hospitalier Universitaire, Lausanne, Switzerland. 6Royal Devon and Exeter Hospital, Exeter, United Kingdom. 7University of Vienna, Vienna, Austria Denotes AASLD Presidential Poster of Distinction


POSTER SESSIONS

#1668 CELL-DEPENDENT RESPONSE OF BMS-582664 (BRIVANIB) IN HEPATOCELLULAR CARCINOMA CELLS: GENE EXPRESSION PROFILING STUDY Joong-Won Park1, Sun-Young Kong2, Nam Oak Lee1, Chang-Min Kim1 1Center for Liver Cancer, National Cancer Center, Goyang, Korea, South. 2Center for Clinical Services, National Cancer Center, Goyang, Korea, South

#1669 STAGE AND TREATMENT APPROACH OF HEPATOCELLULAR CARCINOMA (HCC) IN SPAIN. AN ANALYSIS IN 60 UNITS INCLUDING 701 PATIENTS María Varela1, Maria Elisa Reig2, Manuel De la Mata3, Ana Matilla4, Javier Bustamante5, Sonia Pascual6, Juan Turnes7, Carles Aracil8, Adolfo del Val9, Juan M. Pascasio10, Valle Cadahía1, Jordi Bruix2 1Liver Unit, Hospital Universitario Central de Asturias., Oviedo, Spain. 2BCLC Group. Liver Unit, Hospital Clínic. IDIBAPS. University of Barcelona. CIBERehd., Barcelona, Spain. 3Liver Unit, Hospital Universitario Reina Sofía.CIBERehd. Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)., Córdoba, Spain. 4Liver Unit, Hospital General Universitario Gregorio Marañón., Madrid, Spain. 5Liver Unit, Hospital de Cruces, Bilbao, Spain. 6Liver Unit, Hospital General Universitario de Alicante. CIBERehd, Alicante, Spain. 7Gastroenterology and Hepatology, Complejo Hospitalario de Pontevedra., Pontevedra, Spain. 8Gastroenterology and Hepatology, Hospital Universitario Arnau de Vilanova. Lleida. Institut de Recerca Biomèdica. IRBLleida., Lleida, Spain. 9Digestive Medicine, Hospital Universitario Dr. Peset. Universidad de Valencia., Valencia, Spain. 10Unidad de Gestión Clínica de Enfermedades Digestivas., Hospital Universitario Virgen del Rocío. Universidad de Sevilla., Sevilla, Spain

#1670 RADIOEMBOLIZATION WITH YTTRIUM-90 FOR HEPATOCELLULAR CARCINOMA: WHO BENEFITS? ANALYSIS OF A 291 PATIENT COHORT Laura M. Kulik2, Ahsun Riaz1, Robert Lewandowski1, Mary Mulcahy3, Michael M. Abecassis4, Riad Salem1,2 1Radiology, Northwestern University, Chicago, IL, USA. 2Hepatology, Northwestern University, Chicago, IL, USA. 3Medical Oncology, Northwestern University, Chicago, IL, USA. 4Transplant Surgery, Northwestern University, Chicago, IL, USA

#1671 EFFICACY OF HIGH-DOSE CONFORMAL RADIOTHERAPY (CRT) COMBINED TO TRANSARTERIAL CHEMOEMBOLIZATION (TACE) FOR SINGLE HEPATOCELLULAR CARCINOMA (HCC) NODULE

#1672 THE IMPACT OF NEOADJUVANT CHEMORADIATION ON THE TUMOR BURDEN PRIOR TO LIVER TRANSPLANTATION IN UNRESECTABLE NON-METASTATIC CHOLANGIOCARCINOMA Chakri Panjala1, Justin H. Nguyen2, Raouf E. Nakhleh3, Denise M. Harnois1 1Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, FL, USA. 2Transplant Surgery, Mayo Clinic, Jacksonville, FL, USA. 3Pathology, Mayo Clinic, Jacksonville, FL, USA

#1673 REDUCED LIVER TOXICITY IN INTERMEDIATESTAGE HEPATOCELLULAR CARCINOMA PATIENTS TREATED BY CHEMOEMBOLIZATION WITH DRUG ELUTING BEADS: RESULTS FROM THE PRECISION V RANDOMIZED TRIAL Riccardo Lencioni1, Katerina Malagari2, Thomas Vogl3, Frank Pilleul4, Alban Denys5, Anthony Watkinson6, Johannes Lammer7 1Diagnostic Imaging and Intervention, University of Pisa, Pisa, Italy. 2University of Athens, Athens, Greece. 3University of Frankfurt, Frankfurt, Germany. 4Centre Hospitalier Universitaire, Lyon, France. 5Centre Hospitalier Universitaire, Lausanne, Switzerland. 6Royal Devon and Exeter Hospital, Exeter, United Kingdom. 7University of Vienna, Vienna, Austria

#1674 INFLUENCE ON PATIENTS SURVIVAL OF TEMPORAL CHANGES IN INDICATIONS TO TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA NOT SUITABLE FOR CURATIVE TREATMENT. AN ITA.LI.CA. MULTICENTER STUDY IN 2,042 PATIENTS Edoardo G. Giannini1, Giorgia Bodini1, Marina Corbo1, Vincenzo Savarino1, Franco Trevisani2, Maria Anna Di Nolfo3, Paolo Del Poggio4, Luisa Benvegnu5, Fabio Farinati6, Marco Zoli2, Franco Borzio7, Eugenio Caturelli8, Maria Chiaramonte9 1Cattedra di Gastroenterologia, Dipartimento di Medicina Interna, Università di Genova, Genova, Italy. 2Dipartimento di Medicina Clinica, Alma Mater Studiorum-Università di Bologna, Bologna, Italy. 3Divisione di Medicina, Ospedale Bolognini, Seriate, Italy. 4Divisione di Medicina, Ospedale Treviglio-Caravaggio, Treviglio, Italy. 5Dipartimento di Medicina Clinica e Sperimentale, Università di Padova, Padova, Italy. 6Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Università di Padova, Padova, Italy. 7Dipartimento di Medicina, Unità di Gastroenterologia, Ospedale Fatebenefratelli, Milano, Italy. 8Unità di Gastroenterologia, Ospedale Belcolle, Viterbo, Italy. 9Cattedra di Gastroenterologia, Università dell’Aquila, L’Aquila, Italy


Philippe Merle1,2, Marie Cuinet3, Denis Marion3, Emmanuel Maillard1, Virginie Wautot4, Christian Trepo1,2, Fabien Zoulim1,2, Francoise Mornex4 1U871, INSERM, Lyon, France. 2Hepatology, Hotel-Dieu, Lyon, France. 3Radiology, Hotel-Dieu, Lyon, France. 4Radiotherapy, CHLS, Pierre-Benite, France

275A

276A

POSTER SESSIONS

#1675 FIRST-IN-MEN DEMONSTRATION OF SORAFENIB PLUS TACE FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA (SOCRATES TRIAL) Andreas Erhardt1, Frank T. Kolligs2, Matthias M. Dollinger3, Eckart Schott4, Ansgar W. Lohse5, Michael Bitzer6, Frank Lammert8, Christiane Gog7, Marcus Schuchmann9, Dirk Blondin10, Christian Ohmann11, Dieter Häussinger1 1Klinik für Gastroenterologie, Hepatologie und Infektiologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany. 2Medizinische Klinik und Poliklinik II - Grosshadern, Klinikum der Universität München, München, Germany. 3Klinik und Poliklinik für Innere Medizin I, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany. 4Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie, Charité, Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany. 5I. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany. 6Abteilung für Gastroenterologie, Hepatologie, Infektiologie, Universitätsklinikum Tübingen, Tübingen, Germany. 7Johann Wolfgang Goethe-Universität, Klinik für Allgemein- und Viszeralchirurgie, Frankfurt, Germany. 8Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg, Germany. 9I. Med. Klinik u. Poliklinik, Klinikum der Johannes Gutenberg-Universität, Mainz, Germany. 10Institut für Radiologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany. 11Koordinierungszentrum für Klinische Studien (KKS), Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany

#1676 EMERGENCE OF ADVERSE CARDIOVASCULAR EVENTS AFTER LONG TERM SORAFENIB TREATMENT FOR ADVANCED HEPATOCELLULAR CARCINOMA (HCC) Maria Elisa Reig1, Alejandro Forner1, Carlos Rodriguez de Lope1, Jordi Rimola2, Carmen Ayuso2, Carlos A. Mestres3, Josep M. Llovet1, Jordi Bruix1 1BCLC group.Liver Unit, Hopital Clinic de Barcelona.IDIBAPS.CIBEREHD, Barcelona, Spain. 2BCLC group.Radiology Department, Hospital Clinic de Barcelona, Barcelona, Spain. 3Servicio de cirugia cardiovascular, Hopital Clinic de Barcelona, Barcelona, Spain

#1677 LONG-TERM OUTCOME AFTER SURGERY IS SUPERIOR TO THAT AFTER RADIOFREQUENCY ABLATION IN CHILD-PUGH CLASS A PATIENTS WITH SINGLE SMALL HEPATOCELLULAR CARCINOMA Won Kyoung Yun, Moon Seok Choi, Byung Chul Yoo, Joon Hyoek Lee, Kwang Cheol Koh, Seung Woon Paik, Juhee Maeng, HyunChin Cho Department of Medicine, Samsung Medical Center,Sungkyunkwan University School of Medicine, Seoul, Korea, South


#1678 ASSOCIATION BETWEEN TYPE 2 DIABETES MELLITUS AND HEPATOCELLULAR CARCINOMA: ROLE OF INSULIN RESISTANCE AND HYPERINSULINEMIA Valter Donadon1, Massimiliano Balbi1, Giovanni Della Valentina1, Silvia Grazioli1, Pietro Casarin1, Michela Ghersetti1, Rita Gardenal1, Dal Mas Maria1, Giorgio Zanette2, Cesare Miranda2 13rd Internal Medicine, AO S. Maria degli Angeli, Pordenone, Italy. 2Diabetic Clinic, AO S. Maria degli Angeli, Pordenone, Italy

#1679 LOW RISK OF HEPATOCELLULAR CARCINOMA IN UDCA-TREATED PATIENTS WITH PRIMARY BILIARY CIRRHOSIS. RENEWED RECOMMENDATIONS FOR SURVEILLANCE Edith M. Kuiper1, Bettina E. Hansen1,2, R. P. Adang3, Karin C. Van Nieuwkerk4, Robin Timmer5, Joost P. Drenth6, P. Spoelstra7, Johannes T. Brouwer8, J. P. Kuyvenhoven9, Henk R. van Buuren1 1Hepatology and Gastroenterology, Erasmus University Medical Center, Rotterdam, Netherlands. 2Epidemiology and Biostatistics, Erasmus University Medical Center, Rotterdam, Netherlands. 3Hepatology and Gastroenterology, VieCuri Medical Center, Venlo, Netherlands. 4Hepatology and Gastroenterology, VU University Hospital, Amsterdam, Netherlands. 5Hepatology and Gastroenterology, St Antonius Hospital, Nieuwegein, Netherlands. 6Hepatology and Gastroenterology, Radboud University Hospital Nijmegen, Nijmegen, Netherlands. 7Hepatology and Gastroenterology, Medical Center Leeuwarden, Leeuwarden, Netherlands. 8Hepatology and Gastroenterology, Reinier de Graaf Gasthuis, Delft, Netherlands. 9Hepatology and Gastroenterology, Kennemer Gasthuis, Haarlem, Netherlands

#1680 RADIOEMBOLIZATION WITH Y-90 GLASS MICROSPHERES IN ADVANCED HEPATOCELLULAR CARCINOMA: SAFETY, RESPONSE AND SURVIVAL IN A EUROPEAN COHORT OF 108 PATIENTS Philip Hilgard1,2, Gerald Antoch3, Amr H. El Fouly2, Monia Hamami4, Andre Scherag5, Judith M. Ertle2, Andreas Paul6, Andreas Bockisch4, Guido Gerken2 1Dept. for Gastroenterology, Academic Teaching Hospital EVK, Muelheim, Germany. 2Dept. for Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany. 3Dept. for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany. 4Dept. for Nuclear Medicine, University Hospital Essen, Essen, Germany. 5Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany. 6Dept. of General, Visceral and Transplantation Surgery, University Hospital Essen, Essen, Germany

#1681 TUMOR ASSOCIATED ANTIGEN-SPECIFIC CD8+ TCELL RESPONSES WOULD SUPPRESS RECURRENCE OF HEPATOCELLULAR CARCINOMA


Kazumasa Hiroishi, Hiroyoshi Doi, Toshiyuki Baba, Junichi Eguchi, Shigeaki Ishii, Ayako Hiraide, Masashi Sakaki, Manabu Uchikoshi, Yuu Shimozuma, Risa Ohmori, Takayoshi Ito, Michio Imawari Department of Gastroenterology, Showa University School of Medicine, Tokyo, Japan



POSTER SESSIONS

277A

#1682

#1686

EXPRESSION OF METASTATIC TUMOR ANTIGEN 1 MRNA IN HEPATOCELLULAR CARCINOMA AND SURROUNDING LIVER TISSUES

ADHERENCE TO SCREENING, INCIDENCE, PREDICTORS, AND PROGNOSIS FOR HEPATOCELLULAR CARCINOMA (HCC) IN A COHORT OF U.S. PATIENTS WITH CIRRHOSIS AND CHRONIC HEPATITIS B (CHB) WITHOUT CIRRHOSIS

Dong Dae Seo3, Young-Hwa Chung1, Jeong A. Kim1, Dong-Jun Yoo1, Young-Joo Jin1, Ju Hyun Shim1, Danbi Lee1, Sung Eun Kim1, Yoon-Seon Lee1, Don Lee1, Sung Hoon Kim4, SooHyun Yang4, Young Joo Lee2 1Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, South. 2Hepatobiliary Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, South. 3Internal Medicine, University of Inje College of Medicine, Sanggye Paik Hospital, Seoul, Korea, South. 4Internal Medicine, Korea Veterans’ Hospital, Seoul, Korea, South

#1683 TIME-TO-PROGRESSION ANALYSIS OF SECONDLINE TREATMENT WITH BRIVANIB IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC HEPATOCELLULAR CARCINOMA Richard S. Finn1, Joong-Won Park2, Yoon-Koo Kang3, Christine Baudelet4, Ian Walters5 1Geffen School of Medicine, Los Angeles, CA, USA. 2National Cancer Center, Goyang, Korea, South. 3University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, South. 4Bristol-Myers Squibb, Braine L’Alleud, Belgium. 5Bristol-Myers Squibb, Wallingford, CT, USA

#1684 PRIMARY LIVER CANCER (PLC) IN HCV-RELATED CIRRHOSIS WITH OR WITHOUT HIV COINFECTION. A COLLABORATIVE STUDY BETWEEN TWO FRENCH PROSPECTIVE COHORTS (ANRS CO13 HEPAVIH AND ANRS CO12 CIRVIR) Valerie Bourcier1, Maria Winnock2, Mohand Ait Ahmed1, Elodie Pambrun2, Isabelle Poizot martin6, Sylvie Chevret3, Cendrine Chaffaut3, Philippe Sogni4, Jean Claude Trinchet1, Dominique Salmon5 1Hepatology unit, Jean verdier APHP - Paris 13 University, Bondy, France. 2Inserm U593 – ISPED, Pellegrin hospital, Bordeaux, France. 3DBIM, Saint-Louis hospital, Paris, France. 4Hepatology unit, Cochin hospital, Paris, France. 5Infectious Diseases- Internal Medicine Department, Cochin hospital - Paris 5 Descartes University, Paris, France. 6Hematology Unit, Sainte-Marguerite hospital, Marseille, France

#1685 INCIDENCE OF HEPATOCELLULAR CARCINOMA IN HIV / HEPATITIS B OR C CO-INFECTED INDIVIDUALS IN THE HAART ERA Martin Vogel1, Oliver Friedrich1, Jan-Christian Wasmuth1, Evrim Anadol1, Carolynne Schwarze-Zander1, Bernd Holleczek2, Jürgen K. Rockstroh1, Ulrich Spengler1 1Department of Internal Medicine I, Bonn University, Bonn, Germany. 2Saarland Cancer Registry, Saarbruecken, Germany

Carrie R. Wong1, Huy N. Trinh2,1, Ruel T. Garcia2,1, Huy Nguyen2, Khanh Nguyen2, Brian S. Levitt2, Mindie H. Nguyen3 1Pacific Health Foundation, San Jose, CA, USA. 2San Jose Gastroenterology, San Jose, CA, USA. 3Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA

#1687 ETIOLOGICAL PATTERNS OF HEPATOCELLULAR CARCINOMA AND IMPLICATIONS FOR SURVEILLANCE. AN ITALIAN MULTICENTER STUDY Tommaso Stroffolini1, Franco Trevisani2, Giovambattista Pinzello3, Franco Brunello4, Maurizio A. Tommasini5, Massimo Iavarone6, Vito Di Marco7, Fabio Farinati8, Paolo Del Poggio9, Franco Borzio10, Mauro Borzio11, Eugenio Caturelli12, Maria Anna Di Nolfo13, Giovanni B. Gaeta14 1Infectious and Tropical Diseases, Policlinico, Rome, Italy. 2Internal medicine, University, Bologna, Italy. 3Ospedale Niguarda, Milan, Italy. 4Ospedale Molinette, Turin, Italy. 5Istituto Humanitas, Rozzano, Italy. 6Gastroenterology, University, Milan, Italy. 7Gastroenterology, University, Palermo, Italy. 8Ospedale, Treviglio, Italy. 9Gastroenterology, University, Padua, Italy. 10Internal Medicine, Fatebenefratelli, Milan, Italy. 11Gastroenterology, Ospedale, Melegnano, Italy. 12Ospedale, Viterbo, Italy. 13Ospedale Bolognini, Seriate, Italy. 14Dept Infectious Dis, Second University, Naples, Italy

#1688 A MAJOR ROLE FOR SENESCENCE AND IMMORTALITY GENE NETWORK IN HEPATOCELLULAR CARCINOMA Ayca Arslan-Ergul1, Sevgi Bagislar1,2, Ozlen Konu1, Nuri Ozturk1, Hilal Ozdag3, Ahmet R. Ozturk1, Esra Erdal4, Sedat Karademir5, Ozgul Sagol6, Dilsa Mizrak7, Hakan Bozkaya7, Biter Bilen1, H. Gokhan Ilk8, Ozlem Ilk9, Rengul Cetin-Atalay1, Mehmet Ozturk1,2 1Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey. 2CR INSERM-UJF, Institut Albert Bonniot, Grenoble, France. 3Biotechnology Institute, Ankara University, Ankara, Turkey. 4Department of Medical Biology, Dokuz Eylul University, Izmir, Turkey. 5Dept. Surgery, Dokuz Eylul University, Izmir, Turkey. 6Dept. Pathology, Dokuz Eylul University, Izmir, Turkey. 7Department of Gastroenterology, Ankara University, Ankara, Turkey. 8Dept. Electrical and Electronic Engineering, Ankara University, Ankara, Turkey. 9Department of Statistics, Middle East Technical University, Ankara, Turkey

#1689 RATE OF CURATIVE TREATMENT FOR EARLY STAGE HEPATOCELLULAR CANCER—RESULTS FROM LIVER CANCER RESEARCH NETWORK T U E S D AY NOVEMBER 3

Fasiha Kanwal1, Alex Befeler2, Chun Xu1, Angelique Zeringue1, Adrian M. Di Bisceglie2 1Saint Louis VA Medical Center and Saint Louis University, Saint Louis, MO, USA. 2Saint Louis University, Saint Louis, MO, USA

278A

POSTER SESSIONS


#1690

#1695

GENOME-WIDE DNA METHYLATION PROFILING IN HEPATITIS C-RELATED HEPATOCELLULAR CARCINOMA

REAL-TIME VIRTUAL SONOGRAPHY AND SONAZOID: NOVEL AND PRECISION NAVIGATION TOOLS FOR PERCUTANEOUS RADIOFREQUENCY ABLATION OF HEPATOCELLULAR CARCINOMA

Anja Lachenmayer1, Yujin Hoshida3, Sara Toffanin1, Jun Lu3, Beatriz Minguez1, Laia Cabellos1, Derek Y. Chiang3, Jordi Bruix2, Myron E. Schwartz1, Sasan Roayaie1, Augusto Villanueva2, Radoslav Savic1, Vincenzo Mazzaferro4, Scott L. Friedman1, Josep M. Llovet1,2 1Liver Cancer Program, Division of Liver Diseases, New York, NY, USA. 2HCC Translational Research Lab, BCLC Group, Liver Unit, IDIBAPS, CIBERehd, Hospital Clínic, Barcelona, Barcelona, Spain. 3Cancer Program, The Broad Institute of Harvard and MIT, Cambridge, MA, USA. 4Gastrointestinal Surgery and Liver Transplantation Unit, National Cancer Institute, Milan, Italy

Yasuji Komorizono, Katsumi Sako, Toshihiko Shibatou Hepatology, Nanpuh Hospital, Kagoshima, Japan

#1696 CLINICAL PREDISPOSITION OF METASTASIS TUMOR ANTIGEN 1 OVEREXPRESSION IN PATIENTS WITH HBV-ASSOCIATED HEPATOCELLULAR CARCINOMA

Myeong Jun Song Internal Medicine, College of Medicine, WHO collaborating Center on Viral Hepatitis, The Catholic University of Korea, Seoul, Korea, South

Young-Joo Jin1, Young-Hwa Chung1, Jeong A. Kim1, Dong-Jun Yoo1, Ju Hyun Shim1, Danbi Lee1, Sung Eun Kim1, Dong Dae Seo4, Yoon-Seon Lee1, Neung Hwa Park5, Eunsil Yu2, Young Joo Lee3 1Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, South. 2Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, South. 3Hepatobiliary Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, South. 4Internal Medicine, University of Inje College of Medicine, Sanggye Paik Hospital, Seoul, Korea, South. 5Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, South

#1692

#1697

THE INFLUENCE OF TREATMENT ASSIGNMENT ON PROGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC) ACCORDING TO THE BCLC STAGING SYSTEM

MANAGEMENT OF HEPATOCELLULAR CARCINOMA AT A TERTIARY REFERRAL CENTER OFFERING LIVER TRANSPLANTATION

#1691 CORRELATION BETWEEN RPL36 EXPRESSION AND CLINICOPATHOLOGICAL FEATURES IN HEPATOCELLULAR CARCINOMA : PROGNOSTIC IMPLICATION OF A NOVEL GENE RPL36 IN HUMAN HEPATOCELLULAR CARCINOMA

Delia D’Avola1,4, Mercedes Iñarrairaegui1, Fernando Pardo2, Fernando Rotellar2, Jose I. Bilbao3, Antonio Martinez-Cuesta3, Alberto Benito3, Felix Alegre1, Jose Ignacio Herrero1,4, Jorge Quiroga1,4, Jesus Prieto1,4, Bruno Sangro1,4 1Liver Unit, Clinica Universitaria, Pamplona, Spain. 2HPB Surgery, Clinica Universitaria, Pamplona, Spain. 3Radiology, Clinica Universitaria, Pamplona, Spain. 4CIBERehd, Pamplona, Spain

#1693 PARENCHYMAL FIBROSIS AND CANCER-SPECIFIC OUTCOMES FOLLOWING LIVER RESECTION IN PATIENTS WITH HBV-ASSOCIATED HEPATOCELLULAR CARCINOMA (HCC) Spiros P. Hiotis1, Fotini Manizate1, M. Isabel Fiel2, Daniel Labow1, Sasan Roayaie1, Myron E. Schwartz1 1Surgery, Mount Sinai School of Medicine, New York, NY, USA. 2Pathology, Mount Sinai School of Medicine, New York, NY, USA

#1694


WITHDRAWN


Janice H. Jou, Po-Hung Chen, Alison Jazwinski, Iliana S. Bouneva, Alastair D. Smith, Andrew Muir Duke University Medical Center, Durham, NC, USA

#1698 ASSESSMENT OF TUMOR PERFUSION BY PERFUSION CT IS ABLE TO REGISTER TREATMENT EFFICACY AND PREDICT TUMOR PROGRESSION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB. DIFFERENCES BETWEEN RESPONDING AND NON RESPONDING PATIENTS UNDERGOING SORAFENIB THERAPY Maria Elisa Reig1, Jordi Rimola2, Alejandro Forner1, Carlos Rodriguez de Lope1, Carmen Ayuso2, Josep M. Llovet1, Jordi Bruix1 1BCLC group. Liver Unit, Hospital Clinic de Barcelona.IDIBAPS.CIBEREHD, Barcelona, Spain. 2BCLC group.Radiology Department, Hopital Clinic de Barcelona, Barcelona, Spain


POSTER SESSIONS

279A

#1699

#1704

ALPHA-FETOPROTEIN AND DES-GAMMA CARBOXYPROTHROMBIN ARE INDEPENDENT PREDICTORS OF EARLY STAGE HEPATOCELLULAR CARCINOMA

UBIQUITIN-PROTEASOME SIGNATURE FOR DETECTION OF HEPATOCELLULAR CARCINOMA (HCC)

Jorge Marrero1, Myron E. Schwartz2, Mindie H. Nguyen3, Alex Befeler4, K. Rajender Reddy5, Lewis R. Roberts6, Denise M. Harnois7, Yinghui Wang8, Paul Wagner9, Ziding Feng8 1University of Michigan, Ann Arbor, MI, USA. 2Mt Sinai Medical Center, New York, NY, USA. 3Stanford University, Palo Alto, CA, USA. 4St Louis University, St Louis, MO, USA. 5University of Pennsylvania, Philadelphia, PA, USA. 6Mayo Clinic, Rochester, MN, USA. 7Mayo Clinic, Jacksonville, FL, USA. 8Fred Hutchinson Cancer Center, Seattle, WA, USA. 9National Cancer Institute, Bethesda, DC, USA

#1700 MICRO RNA EXPRESSION IN FIBROSIS AND HEPATOCELLULAR CARCINOMA RELATED TO NON-ALCOHOLIC FATTY LIVER DISEASE Aileen Marshall1,2, Claudia Kutter2, James Hadfield2, Michael E. Allison1, Duncan Odom2, Graeme J. Alexander1 1Department of Medicine, University of Cambridge, Cambridge, United Kingdom. 2Cancer Genomics, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

#1701 WHOLE GENOME RNA EXPRESSION PROFILING OF ERCP BILIARY BRUSHINGS IN BILIARY TRACT CANCER Michael H. Chapman1,2, Fausto Andreola1, Neomal S. Sandanayake1,2, James S. Dooley3, Stephen P. Pereira1,2 1Institute of Heptology, University College London, London, United Kingdom. 2Department of Gastroenterology, Univeristy College London Hospitals NHS Foundation Trust, London, United Kingdom. 3Centre for Hepatology (Royal Free Campus), UCL Medical School, London, United Kingdom

#1702 INTERFERON COMBINED 5-FLUOROURACIL PLUS CISPLATIN HEPATIC ARTERIAL INFUSION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA Tatsuya Yamashita, Kuniaki Arai, Hajime Sunagozaka, Teruyuki Ueda, Eishiro Mizukoshi, Akito Sakai, Yasunari Nakamoto, Masao Honda, Shuichi Kaneko Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan

#1703 RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN AFRICAN AMERICAN AND NONHISPANIC WHITE PATIENTS WITH HEPATITIS C CIRRHOSIS

Kevin Qu, Ke Zhang, Wanlong Ma, Hai-Rong Li, Xi Zhang, Xiuqiang Wang, Anthony Sferruzza, Maher Albitar Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, USA

#1705 INDUCTION OF ANTIGEN SPECIFIC IMMUNITY AGAINST HCC WITH ASPARTATE-β-HYDROXYLASE AND DENDRITIC CELL VACCINE Masafumi Shimoda, Rolf I. Carlson, Jack R. Wands Liver Research Center, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA

#1706 FAVORABLE OUTCOME PREDICTORS OF NEOADJUVANT PROTOCOL LIVER TRANSPLANTATION FOR UNRESECTABLE CHOLANGIOCARCINOMA: MAYO CLINIC FLORIDA EXPERIENCE Chakri Panjala1, Justin H. Nguyen2, Raouf E. Nakhleh3, Denise M. Harnois1 1Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, FL, USA. 2Transplant Surgery, Mayo Clinic, Jacksonville, FL, USA. 3Pathology, Mayo Clinic, Jacksonville, FL, USA

#1707 VASCULAR COMPLICATIONS AFTER NEOADJUVANT PROTOCOL LIVER TRANSPLANTATION FOR SELECTIVE UNRESECTABLE HILAR CHOLANGIOCARCINOMA: MAYO CLINIC FLORIDA EXPERIENCE Chakri Panjala1, Denise M. Harnois1, Justin H. Nguyen2 & Hepatology, Mayo Clinic, Jacksonville, FL, USA. 2Transplant Surgery, Mayo Clinic, Jacksonville, FL, USA

1Gastroenterology

#1708 HLA-DRB1*13 ALLELE PREDISPOSES THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS B Ju Hyun Shim1, Young-Hwa Chung1, Jeong A. Kim1, Sung Eun Kim1, Dong-Jun Yoo1, Young-Joo Jin1, Danbi Lee1, Dong Dae Seo2, Yoon-Seon Lee1, Sung Hoon Kim3, Don Lee1, SooHyun Yang3, Kang Mo Kim1, Young-Suk Lim1, Han Chu Lee1, Yung Sang Lee1, Dong Jin Suh1 1Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, South. 2Internal Medicine, University of Inje College of Medicine, Sanggye Paik Hospital, Seoul, Korea, South. 3Internal Medicine, Korea Veterans’ Hospital, Seoul, Korea, South

Eric R. Kallwitz, Jennifer Layden, Manish Dhamija, Jamie L. Berkes, Thomas J. Layden, Scott J. Cotler University of Illinois, Chicago, IL, USA T U E S D AY NOVEMBER 3

280A

POSTER SESSIONS


#1709

#1713

A PROSPECTIVE STUDY OF MEASUREMENTS OF FOUR TUMOR MARKERS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)

CD133, A CANCER STEM CELL MARKER, IS A PREDICTOR OF THE EFFECTIVENESS OF S1+PEGIFNα-2B THERAPY AGAINST ADVANCED HEPATOCELLULAR CARCINOMA

Kentaroh Yamamoto1, Hiroshi Imamura1, Yutaka Matsuyama2, Hitoshi Ikeda3, Gary L. Norman4, Zakera Shums4, Taku Aoki1, Kiyoshi Hasegawa1, Yoshifumi Beck1, Yasuhiko Sugawara1, Norihiro Kokudo1 1Department of Surgery, Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division,Graduate School of Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. 2Department of Biostatistics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. 3Department of Clinical Laboratory Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. 4INOVA Diagnostic, Inc, San Diego, CA, USA

#1710 INFLAMMATORY PSEUDOTUMOUR MIMICKING MASS-FORMING CHOLANGIOCARCINOMA OF THE LIVER Keun Soo Ahn1,5, Koo Jeong Kang1, Yong Hoon Kim1, Kyung Sik Park2, Jaeseok Hwang2, Yu Na Kang3, Jung Hyeok Kwon4 1Surgery, Keimyung University, Daegu, Korea, South. 2Interal Medicine, Keimyung University, Daegu, Korea, South. 3Pathology, Keimyung University, Daegu, Korea, South. 4Radiology, Keimyung University, Daegu, Korea, South. 5Surgery, Seoul National University Bun-Dang Hospital, Seong Nam, Korea, South

#1711 GIANT SYMPTOMATIC HEPATIC CAVERNOUS HEMANGIOMAS ARE EFFECTIVELY TREATED BY PERCUTANEOUS ULTRSONOGRAPHY-GUIDED RADIOFREQUENCY ABLATION Soo Young Park, Won Young Tak, Dong Seok Lee, Min Kyu Jung, Seong Woo Jeon, Chang Min Cho, Young Oh Kweon, Sung Kook Kim, Yong Hwan Choi Hepatology, Kyungpook National University Hospital, Daegu, Korea, South

#1712 PREDICTORS OF SURVIVAL FOLLOWING RADIOEMBOLIZATION USING 90Y-LABELED RESIN MICROSPHERES IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC): RESULTS FROM A EUROPEAN MULTI-CENTER EVALUATION


Bruno Sangro1, Roberto Cianni2, Samer Ezziddin3, Daniele Gasparini4, Rita Golfieri5, Frank T. Kolligs6, Livio Carpanese7 1Liver Unit, Clinica Universitaria, and CIBEREHD, Pamplona, Spain. 2Radiology, Ospedale S.M.Goretti, Latina, Italy. 3Nuklear Medizin, Universitätsklinik Bonn, Bonn, Germany. 4Radiology, Azienda Ospedaliera S. M. della Misericordia, Udine, Italy. 5Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy. 6Medicine II, LMU Klinikum der Universität München Campus Grosshadern, Munich, Germany. 7Interventional Radiology, IFO Regina Elena National Cancer Institute, Rome, Italy


Satoru Hagiwara1, Masatoshi Kudo1, Mami Yamaguchi1, Kazuomi Ueshima1, Hobyung Chung1, Ah-Mee Park2, Hiroshi Munakata2 1Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan. 2Biochemistry, Kinki University School of Medicine, Osaka-Sayama, Japan

#1714 TREATMENT TRADE-OFF FOR ABLATION OR HEPATIC RESECTION FOR SMALL HCC Michele Molinari1, Mark J. Walsh1, Paul D. Renfrew1, Norman M. Kneteman2, William Helton3 1Surgery, QEII Health Science Centre, Halifax, NS, Canada. 2Surgery, University of Alberta, Edmonton, AB, Canada. 3surgery, St Raphael Hospital, New Heaven, CT, USA

#1715 PROGNOSTIC SIGNIFICANCE OF ALPHAFETOPROTEIN (AFP) AND DES-γ-CARBOXY PROTHROMBIN IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) UNDERGOING HEPATECTOMY Kentaroh Yamamoto1, Hiroshi Imamura1, Yutaka Matsuyama2, Mariko Tanaka3, Michiro Takahashi1, Takeaki Ishizawa1, Yousuke Inoue1, Kiyoshi Hasegawa1, Taku Aoki1, Yoshifumi Beck1, Yasuhiko Sugawara1, Masatoshi Makuuchi1, Norihiro Kokudo1 1Department of Surgery, Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division,Graduate School of Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. 2Department of Biostatistics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan. 3Department of Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

#1716 SAFETY PROFILE OF SORAFENIB (SO) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): A PROSPECTIVE EVALUATION Sebastien Dharancy1, Stéphane Cattan2, Olivier Romano2, Valerie Canva2, Hélène Castel1, Emmanuel Boleslawski3, Stéphanie Truant3, Mohammed Hebbar2, François R. Pruvot3, Philippe Mathurin1 1Hopital Huriez, Hepatology Unit, Lille, France. 2Hopital Huriez, Oncology Unit, Lille, France. 3Hopital Huriez, Transplant Unit, Lille, France

#1717 ANTITUMOR ACTIVITY OF A NOVEL ANGIOGENESIS INHIBITOR BIBF1120 FOR HEPATOCELLULAR CARCINOMA AND A NEW PHARAMACODYNAMIC BIOMARKER IN BLOOD SAMPLES Masatoshi Kudo1, Kanae Kudo1,2, Tokuzo Arao2, Kazuto Nishio2 1Department of Gastroenterology & Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan. 2Department of Genome, Kinki University School of Medicine, Osaka-Sayama, Japan


POSTER SESSIONS

281A

#1718

#1722

FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA (HCC) DEVELOPED IN THE ABSENCE OF SIGNIFICANT FIBROSIS

SAFETY OF SORAFENIB TREATMENT FOR INTERMEDIATE/ ADVANCED HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH CHILD’S A, B OR C: INITIAL RESULTS IN TWO EXPERIENCED CENTERS IN BRAZIL

Jean-Frédéric Blanc1,5, Hervé Laumonier4, Christophe Laurent3, Antonio sa-Cunha3, Jean Saric3, Laurent Possenti1, Charles Balabaud1,5, Paulette Bioulac-Sage2,5 1Hepatology, CHU Bordeaux, Bordeaux, France. 2Pathology, CHU Bordeaux, Bordeaux, France. 3Surgery, CHU Bordeaux, Bordeaux, France. 4Radiology, CHU Bordeaux, Bordeaux, France. 5Inserm U 889, University Bordeaux 2, Bordeaux, France

#1719 STEREOTACTIC BODY RADIATION THERAPY USING CYBERKNIFE FOR PRIMARY HEPATOCELLULAR CARCINOMA INELIGIBLE FOR LOCAL ABLATION THERAPY OR SURGICAL RESECTION Si Hyun Bae1, Jung Hyun Kwon1, Jeong Won Jang1, Myeong Jun Song1, Jong Young Choi1, Seung Kew Yoon1, Gyu Won Chung1, Byung Ock Choi2, Hong Seok Jang2 1Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, South. 2Radiation Oncology, College of Medicine, The Catholic of University of Korea, Seoul, Korea, South

#1720 HIGHER SENSITIVITY IN THE DIAGNOSIS OF THE HEPATOCELLULAR CARCINOMA BY ADDITIONAL MEASUREMENT OF LENS CULINARIS AGGLUTININ-REACTIVE AFP (AFP-L3)AND DESGAMMA-CARBOXYPROTHROMBIN (DCP) Judith M. Ertle1, Marc Wichert3, Robert Kueper4, Guido Gerken1, Philip Hilgard2, Ali Canbay1, Joerg F. Schlaak1 1Gastroenterology and Hepatology, University Hospital Essen/Germany, Essen, Germany. 2Department of internal medicine, Evangelisches Krankenhaus/Mülheim/Ruhr, Mülheim/Ruhr, 3Central Germany. Laboratory, University Hospital Essen/Germany, Essen, Germany. 4Wako Chemicals GmbH, Neuss, Germany

#1721 A STUDY OF 1086 PATIENTS WITH HEPATOCELLULAR CARCINOMA OVER TWO DECADES AND THE IMPACT OF A POSITIVE FAMILY HISTORY AND SCREENING PROGRAMS Boon Bee George Goh, Jason Chang, Wai-Choung Ong, CheeKiat Tan Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore

Rogério C. Alves1,2, Daniele Alves1, Carla Mattos2, Silvia Soares1, Michelle Harriz1, Henio Vanini1, Mario Kondo2, Betty Guz1, Otavio Gampel1, Paula Poletti1 1Gastroenterology /Oncology, Hospital do Servidor Público Estadual, São Paulo, Brazil. 2Hepatology, Hospital A.C. Camargo, São Paulo, Brazil

#1723 DONOR SOURCE AND QUALITY DO NOT AFFECT OUTCOME IN HCC PATIENTS UNDERGOING LIVER TRANSPLANTATION Karim J. Halazun, Abbas Rana, Benjamin Samstein, Michael J. Goldstein, James V. Guarrera, Tomoaki Kato, Jean C. Emond Department of Transplant Surgery, Columbia University, New York, NY, USA

#1724 PATIENTS WITH HIGH BODY MASS INDEX (BMI) ARE MORE LIKELY TO DEVELOP INFLAMMATORY HEPATOCELLULAR ADENOMA (IHCA) THAN ANY OTHER TYPE OF HEPATOCELLULAR ADENOMA (HCA) Paulette Bioulac-Sage1,2, Hervé Laumonier3, Jessica Zucman-Rossi4, Charles Balabaud1,5 1U889, Université Bordeaux 2, Bordeaux, France. 2Pathology, CHU Bordeaux, Bordeaux, France. 3Radiology, CHU Bordeaux, Bordeaux, France. 4U674, Inserm, Paris, France. 5Hepatology, CHU Bordeaux, Bordeaux, France

#1725 IMMUNOLOGICAL FACTORS ASSOCIATED WITH PROLONGED RECURRENCE-FREE SURVIVAL FOLLOWING TRANSCATHETER HEPATIC ARTERIAL EMBOLIZATION WITH OK432-STIMULATED DENDRITIC CELL TRANSFER INTO HEPATOCELLULAR CARCINOMA Yasunari Nakamoto1, Eishiro Mizukoshi1, Masaaki Kitahara1, Fuminori Arihara1, Yoshio Sakai1, Kaheita Kakinoki1, Yui Fujita1, Yohei Marukawa1, Kuniaki Arai1, Tatsuya Yamashita1, Naofumi Mukaida1, Kouji Matsushima2, Osamu Matsui1, Shuichi Kaneko1 1Kanazawa University, Kanazawa, Japan. 2University of Tokyo, Tokyo, Japan

#1726 PREDICTIVE FACTORS OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HCV-RELATED ADVANCED FIBROSIS AND SUSTAINED VIROLOGICAL RESPONSE


Ana Carolina F. Cardoso, Roberto J. Carvalho-Filho, Christiane Stern, Claudio G. Figueiredo-Mendes, Nathalie Giuily, MariePierre Ripault, Tarik Asselah, Michelle Martinot-Peignoux, Pierre Bedossa, Patrick Marcellin Hepatology Service, Hopital Beaujon, INSERM U773 - CRB3, Clichy, France

282A

POSTER SESSIONS


#1727

#1732

CLINICOPATHOLOGICAL EVALUATION FOR THE RISK FACTORS OF HEPATOCELLULAR CARCINOMA ARISING IN PATIENTS WITH ALCOHOLIC LIVER DISEASE REGARDING METABOLIC SYNDROME

CISPLATIN PHARMACOKINETIC IN NORMAL SWINES TREATED WITH TRANSCATHETER ARTERIAL CHEMO-EMBOLISATION

Makiko Taniai, Etsuko Hashimoto, Nobuyuki Torii, Katsutoshi Tokushige, Keiko Shiratori Tokyo Women’s Medical University, Tokyo, Japan

#1728 LOCOREGIONAL THERAPIES AS A BRIDGE TO TRANSPLANT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA Sonali S. Sakaria1, Renumathy Dhanasekaran2, Mark Pankonin3, Samir Parekh1, Hyun S. Kim2 1Division of Digestive Diseases, Emory University, Decatur, GA, USA. 2Division of Interventional Radiology and Image Guided Medicine, Emory University, Atlanta, GA, USA. 3Internal Medicine, Emory University, Atlanta, GA, USA

Pierre Guibert1, François Bouculat1, Pascal Chabrot2, Anne LegerEnreille4, Pierre J. Déchelotte3, Gilles Bommelaer1, Emmanuel Buc5, Denis Pezet5, Louis Boyer2, Armand Abergel1 1Service d’Hépato-gastroentérologie, CHU Clermont-Ferrand, Clermont-Ferrand Cedex 1, France. 2Service de Radiologie Vasculaire, CHU Clermont-Ferrand, Clermont-Ferrand Cedex 1, France. 3Service d’Anatomo-pathologie, CHU Clermont-Ferrand, Clermont-Ferrand Cedex 1, France. 4Service de Pharmacologie, Centre Jean Perrin, Clermont-Ferrand, France. 5Service de Chirurgie Digestive, CHU Clermont-Ferrand, Clermont-Ferrand Cedex 1, France

#1733

#1729

PRE-OPERATIVE STAGING CONUNDRUM OF CHOLANGIOCARCINOMA AND ITS IMPACT ON CANDIDATE SELECTION AND OUTCOME FOLLOWING NEO-ADJUVANT PROTOCOL LIVER TRANSPLANTATION

INDUCTION OF ANTIGEN-SPECIFIC T-CELLS BY VACCINATION WITH TUMOR LYSATE AND HBSAG-LOADED AUTOLOGOUS MONOCYTEDERIVED DENDRITIC CELLS IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

Chakri Panjala1, Justin H. Nguyen2, Raouf E. Nakhleh3, Denise M. Harnois1 1Gastroenterology & Hepatology, Mayo Clinic, Jacksonville, FL, USA. 2Transplant Surgery, Mayo Clinic, Jacksonville, FL, USA. 3Pathology, Mayo Clinic, Jacksonville, FL, USA

Phillip M. Harrison1, Joti R. Bhalla2, James O’Beirne1, Farzin Farzaneh2 1Liver Studies & Transplantation, Kings College London, London, United Kingdom. 2Haematological & Molecular Medicine, Kings College London, London, United Kingdom

#1730 90Y RADIOEMBOLIZATION USING RESIN MICROSPHERES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND PORTAL VEIN THROMBOSIS Mercedes Iñarrairaegui1, Kenneth G. Thurston3, Macarena Rodriguez4, Antonio Martinez-Cuesta5, Jose I. Bilbao5, Delia D’Avola1,2, Felix Alegre1, Bruno Sangro1,2 1Liver Unit, Clinica Universitaria, Pamplona, Spain. 2CIBERehd, Pamplona, Spain. 3SIrtex Medical US Holdings Inc., Wilmington, MA, USA. 4Nuclear Medicine, Clinica Universitaria, Pamplona, Spain. 5Interventional Radiology, Clinica Universitaria, Pamplona, Spain

#1731 SHOULD MANAGEMENT AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC) BE TAILORED TO AGE? A CASE-CONTROL STUDY Ozenne1,

Goutte1,

Bouattour1,2,


Violaine Nathalie Mohamed Marie-Pierre Vullierme3, Corinne Castelnau1, Dominique Valla1, Valerie Paradis4, Francoise Degos1, Olivier Farges5 1Hepatology, Hopital Beaujon, Clichy, France. 2Oncology, Hopital Beaujon, Clichy, France. 3Radiology, Hopital Beaujon, Clichy, France. 4Pathology, Hopital Beaujon, Clichy, France. 5Hepato-Biliary Surgery, Hopital Beaujon, Clichy, France


#1734 SUB-SELECTIVE INTRA-ARTERIAL (IA) INFUSION CHEMOTHERAPY WITHOUT EMBOLIZATION IN THE TREATMENT OF HEPATOCELLULAR CANCER Melissa A. Wallman1, John Donovan2, John R. Daniels1, Michelle Hart1, Sue Hanks3, Michael Katz3, Edward G. Grant3, Anthony ElKhoueiry1, Syma Iqbal1 1Medicine/Oncology, Univ Southern California, Los Angeles, CA, USA. 2Medicine/Hepatology, Univ Southern California, Los Angeles, CA, USA. 3Radiology, Univ Southern California, Los Angeles, CA, USA

#1735 ROLE OF VIRAL INFECTION IN INTRAHEPATIC CHOLANGIOCARCINOMA AND CANCERS OF THE BILIARY TREE: A CASE-CONTROL STUDY IN JAPAN Sei-ichiro Kojima, Tatehiro Kagawa, Naruhiko Nagata, Makoto Numata, Norihito Watanabe, Tetsuya Mine Gastroenterology, Tokai University, Isehara, Japan

#1736 THE EXPRESSION OF NERVE GROWTH FACTOR-β CORRELATED WITH LYMPH NODE METASTASIS AND NERVE INFILTRATION IN HUMAN HILAR CHOLANGIOCARCINOMA Chao Liu Memorial Hospital, Sun Yat-sen University, Guangzhou, China


POSTER SESSIONS

#1737

283A

#1743

PROBABILITY TRADE-OFFS FOR SMALL HCCS Molinari1,

Kneteman2,

Walsh1,

Michele Norman M. Mark J. Paul D. Renfrew1, William Helton3 1Surgery, Dalhousie University, Halifax, NS, Canada. 2Surgery, University of Alberta, Edmonton, AB, Canada. 3Surgery, St. Raphael Hospital, New Heaven, CT, USA

#1738 ANGIOGENESIS IN BENIGN HUMAN HEPATIC TUMORS A ROLE FOR ANG-1/TIE-2 ? Annette S. Gouw1, Wenjiao Zeng1, Marijke Buiskool1, Inge Platteel1, Marius C. van den Heuvel1, Sibrand Poppema1, Koert P. De Jong2, Grietje Molema1 1Pathology & Medical Biology, University Medical Center Groningen, Groningen, Netherlands. 2Surgery, HPB division, University Medical Center Groningen, Groningen, Netherlands

#1739 CHARACTERISTICS OF HEPATOCELLULAR CARCINOMA GENERATED IN NON-DAMAGED LIVER Satoshi Kaihara, Kenji Uryuhara, Ryo Hosotani Surgery, Kobe City Medical Center General Hospital, Kobe, Japan

#1740 CLINICAL OUTCOME OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WITH EXTRAHEPATIC METASTASIS AT INITIAL PRESENTATION: DOES TRANSARTERIAL CHEMOEMBOLIZATION IMPROVE SURVIVAL IN THESE PATIENTS? Dong-Jun Yoo, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, YoungHwa Chung, Yung Sang Lee, Dong-Jin Suh, Ju Hyun Shim, YoungJoo Jin Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, South

#1741 EFFECT OF POSTOPERATIVE IRRADIATION AT POSITIVE SURGICAL MARGIN IN HILAR BILIARY CANCER Shogo Kobayashi, Hiroaki Nagano, Shigeru Marubashi, Hidetoshi Eguchi, Yutaka Takeda, Masahiro N. Tanemura, Yuichiro Doki, Masaki Mori Surgery, Osaka University, Suita, Japan

#1742 IN PATIENTS WITH HCV CIRRHOSIS ONGOING INFECTION,HCV GENOTYPE 3 IS ASSOCIATED WITH AN INCREASED RISK OF HCC Gisele Nkontchou1, Mounia Lhabadie1, Mounir Aout3, Yazid Baazia3, Jean Claude Trinchet1, Eric Vicaut3, Emmanuel Gordien2, Michel Beaugrand1 1Hepatology Unit, AP-HP, Bondy, France. 2Virology Unit, Avicenne APHP, Bobigny, France. 3URC, Lariboisiere APHP, Paris, France

THE NATURAL HISTORY OF HEPATIC MACROREGENERATIVE NODULES DEVELOPING IN CIRRHOTIC PATIENTS DURING SURVEILLANCE WITH ULTRASOUND (US) Angelo Sangiovanni1, Cristina Della Corte1, Matteo A. Manini1, Massimo Iavarone1, Sara Vavassori1, Raffaella Romeo1, Mirella Fraquelli2, Laura Virginia Forzenigo3, Guido Ronchi1, Alessio Aghemo1, Massimo Colombo1 11st Division of Gastroenterology, Foundation IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy. 22nd Division of Gastroenterology, Foundation IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy. 3Division of Radiology, Foundation IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy

#1744 ANALYSIS OF CHROMOSOMAL ALTERATIONS IN HEPATOCELLULAR CARCINOMAS RELATED TO METABOLIC SYNDROME Valerie Paradis1,2, Miguel Albuquerque1, Lucie Hernandez3, Stephane Zalinski4, Samuel Quentin3, Jacques Belghiti4, Jean Soulier3, Pierre Bedossa1,2 1Pathology, Beaujon hospital, Clichy, France. 2U773, Inserm, Paris, France. 3Institut Universitaire Hématologie, Saint Louis hospital, Paris, France. 4Hepatobiliary surgery, Beaujon hospital, Clichy, France

#1745 THE EXPRESSION AND SIGNIFICANCE OF C-KIT, CD90, CD133 AND EPCAM IN HEPATOCELLULAR CARCINOMA WITH BILE DUCT TUMOR THROMBI Chao Liu Memorial Hospital, Sun Yat-sen University, Guangzhou, China

#1746 ARGON GAS-BASED CRYOABLATION FOR HEPATOCELLULAR CARCINOMA Minoru Tanabe1, Taizo Hibi1, Masakazu Ueda1, Go Wakabayashi2, Yuko Kitagawa1 1Department of Surgery, School of Medicine, Keio University, Tokyo, Japan. 2Department of Surgery, Iwate Medical University, Morioka, Japan

#1747 TREATMENT OF HEPATOCELLULAR CARCINOMA WITH MAJOR PORTAL VEIN THROMBOSIS AND EXTRAHEPATIC METASTASIS BY CONCURRENT CHEMORADIATION THERAPY WITH INTRAARTERIAL/SYSTEMIC INTERFERON-α AND 5-FLUOROURACIL: A PILOT STUDY Taizo Hibi, Minoru Tanabe, Noriyuki Tani, Masakazu Ueda, Koichi Aiura, Shigeyuki Kawachi, Masahiro Shinoda, Yuko Kitagawa Department of Surgery, Keio University School of Medicine, Tokyo, Japan


284A

POSTER SESSIONS


#1748

#1753

SERUM SODIUM IS A PREDICTOR OF SURVIVAL FOR “INTERMEDIATE HCC” TREATED WITH TRANSARTERIAL CHEMIOEMBOLIZATION (TACE)

CLINICAL AND RADIOLOGIC FEATURES OF HEPATIC NEUROENDOCRINE TUMORS TO BE DIFFERENTIATED FROM HEPATOCELLULAR CARCINOMA

Vittoria Vero, Simona Racco, Maria L. Gabrieli, Maurizio Pompili, Giuseppe Marrone, Alessandra Forgione, Marco Biolato, Consuelo Cefalo, Carmine Di Stasi, Luca Miele, Gian Ludovico Rapaccini, Antonio Grieco Catholic University of Rome, Rome, Italy

#1749 STEATOHEPATITIC-HEPATOCELLULAR CARCINOMA (SH-HCC): A DISTINCTIVE TYPE OF HCC IN HCVCIRRHOSIS (HCV-C) Marcela Salomao1, Woojin M. Yu1, Robert S. Brown3, Jean C. Emond2, Jay H. Lefkowitch1 1Department of Pathology, Columbia University Medical Center, New York, NY, USA. 2Department of Surgery, Columbia University Medical Center, New York, NY, USA. 3Center for Liver disease and Transplantation, Columbia University Medical Center, New York, NY, USA

#1750 BIOSPECIMEN BANKING IN THE ERA OF PERSONALIZED GENOMIC MEDICINE Jacfranz J. Guiteau1,2, Ronald T. Cotton1,2, N. Thao T. Nguyen1, Theresa R. Harring1, Ismael A. Salas de Armas1, Christine O’Mahony1, Marie-Claude Gingras1,2, John A. Goss1 1Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA. 2Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA

#1751 A HIGH RATE OF POTENTIALLY CURATIVE THERAPY FOR HEPATOCELLULAR CARCINOMA (HCC) IN REFERRAL CENTERS Mohamed Bouattour1,2, Violaine Ozenne1, Nathalie Goutte1, Marie-Pierre Vullierme3, Dominique Valla1, Jacques Belghiti4, Pierre Bedossa5, Olivier Farges4, Francoise Degos1 1Hepatology, Hopital Beaujon, Clichy, France. 2Oncology, Hopital Beaujon, Clichy, France. 3Radiology, Hopital Beaujon, Clichy, France. 4Hepato-Biliary Surgery, Hopital Beaujon, Clichy, France. 5Pathology, Hopital Beaujon, Clichy, France

#1752 SURVIVAL RATE IN 434 PATIENTS WITH HEPATOCELLULAR CARCINOMA


Gabi I. Kirchner1, Niels Zorger2, Hans-Juergen Schlitt3, Reiner Wiest1, Frank Klebl1, Stefan A. Farkas3, Ina Zuber-Jerger1, Juergen Schoelmerich1 1Internal Medicine I, University Hospital of Regensburg, Regensburg, Germany. 2Diagnostic Radiology, University Hospital of Regensburg, Regensburg, Germany. 3Surgery, University Hospital of Regensburg, Regensburg, Germany


Dong-Jun Yoo1, Young-Hwa Chung1, Young-Joo Jin1, Ju Hyun Shim1, Sung Eun Kim1, Danbi Lee1, Yoon-Seon Lee1, Don Lee1, Kang Mo Kim1, Young-Suk Lim1, Han Chu Lee1, Yung Sang Lee1, Dong Jin Suh1, Eunsil Yu2 1Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, South. 2Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, South

#1754 DELAY IN TREATMENT OF EARLY-STAGE HEPATOCELLULAR CARCINOMA USING RADIOFREQUENCY ABLATION IMPACTS THE SURVIVAL OF CIRRHOTIC PATIENTS IN A SURVEILLANCE PROGRAM Mark L. Fernandes1,2, Jenny Limquiaco2,3, Chen-Chun Lin2, ChunJung Lin2, Wei-Ting Chen2, Shi-Ming Lin2 1Gastroenterology and Hepatology, National University Healthcare System, Singapore, Singapore. 2Hepato-gastroenterology, Chang Gung Memorial Hospital, Taipei, Taiwan. 3Medicine, University of the Philippines-Philippine General Hospital, Manila, Philippines

#1755 SORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA MEETING THE MILAN CRITERIA AWAITING LIVER TRANSPLANTATION: A COSTUTILITY ANALYSIS Alessandro Vitale1,4, Michael L. Volk2, Fabio Farinati3, Umberto Cillo4 1Unità di Chirurgia Oncologica, Istituto Oncologico Veneto, IRCCS, Padova, Italy. 2University of Michigan Health System, Division of Gastroenterology, Ann Arbor, MI, USA. 3Azienda -Università di Padova, Division of Gastroenterology, Padova, Italy. 4Azienda-Università di Padova, Unità di Chirurgia Epatobiliare e Trapianto Epatico, Padova, Italy

#1756 TRANSARTERIAL CHEMOEMBOLIZATION OF INTRAHEPATIC CHOLANGIOCARINOMAS WITH IRINOTECAN-ELUTING BEADS: PRELIMINARY RESULTS Jan Harder1, Wulf Euringer2, Mathias Langer2, Robert Thimme1, Hubert E. Blum1, Hans Christian Spangenberg1 1Gastroenterology, University Medical Center, Freiburg, Germany. 2Radiology, University Medical Center, Freiburg, Germany


POSTER SESSIONS

285A

#1757

#1762

A NOVEL TRANSARTERIAL CHEMOEMBOLIZATION USING A MIXTURE OF CISPLATIN AND IODIZED OIL, AND DEGRADABLE STARCH MICROSPHERES FOR HEPATOCELLULAR CARCINOMA: A RANDOMIZED STUDY

HEPATIC ARTERIAL INFUSION CHEMOTHERAPY WITH HIGH-DOSE 5-FLUOROURACIL, CISPLATIN ± INTERFERON-ALFA FOR THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA WITH PORTAL VEIN TUMOR THROMBOSIS

Issei Saeki, Takahiro Yamasaki, Yohei Harima, Kousuke Okita, Makoto Segawa, Yuhki Yamaguchi, Koichi Uchida, Shuji Terai, Isao Sakaida Gastroenterology & Hepatology, Yamaguchi University, Ube-shi, Japan

Jong Ryul Eun, Heonju Lee, Tae Nyeun Kim, Jae Woon Kim, Jae Chun Jang Yeungnam University College of Medicine, Daegu, Korea, South

#1758 EFFECTS OF THE MTOR INHIBITOR RAPAMYCIN IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: A PHASE I/II TRIAL

#1763 OBSERVATION OF MICROBUBBLES AND MONITORING OF INTRAHEPATIC PRESSURE DURING RADIOFREQUENCY ABLATION AND PERCUTANEOUS ETHANOL INJECTION

Maximilian Schöniger-Hekele, Christian Müller Department of Gastroenterology and Hepatology, Medical University of Vienna, Internal Medicine III, Vienna, Austria

Chiaki Kawamoto, Atsushi Yamauchi, Naoya Miyagi, Keiko Kaneko, Toru Aoyama, Kazuhito Kani, Koji Yakabi Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan

#1759

#1764

PHYSICIAN-DRIVEN SCREENING FOR HEPATOCELLULAR CARCINOMA IN AN AT-RISK POPULATION IS ABLE TO DIAGNOSE EARLY STAGE DISEASE AND IMPROVE OUTCOME – A STUDY OF 710 PATIENTS FOLLOWED UP OVER 5 YEARS

EXPRESSION OF VEGF, COX2 AND PCNA IN CIRRHOSIS SURROUNDING HEPATOCELLULAR CARCINOMA IS RELATED TO TUMORAL RECURRENCE AFTER LIVER TRANSPLANTATION

Chee-Kiat Tan, Jason Chang, Wan-Cheng Chow Dept of Gastroenterology and Hepatology, Singapore General Hospital, Singapore, Singapore

#1760 SMALL INTESTINAL BACTERIAL OVERGROWTH AS A PREDICTIVE FACTOR FOR DEVELOPMENT OF DIARRHEA IN HCC PATIENTS TREATED WITH SORAFENIB Marialuisa Novi1, Cristiano Lauritano1, Emanuele Rinninella1, Michele Santoro1, Annalisa Tortora1, Andrea Lupascu1, Federico Barbaro1, Pietro Manuel Ferraro2, Francesca Fiore1, Anna C. Piscaglia1, Maria Assunta Zocco1, Antonio Gasbarrini1 1Internal medicine eand gastroenterology, Rome, Italy. 2Division of Nephrology and Dialysis, Renal Program, Rome, Italy

#1761 SAFETY PROFILE OF SORAFENIB IN CONJUNCTION WITH LOCOREGIONAL THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA Chung1,

Dadabhai1,

Black1,

Cohen2,

Chan Y. Alia S. Martin Gary Phyllis A. Dowling1, Frank Friedenberg1 1Gastroenterology, Temple University School of Medicine, Philadelphia, PA, USA. 2Interventional Radiology, Temple University School of Medicine, Philadelphia, PA, USA

Ana Campillo1, Maria Jose Morandeira2, Tomas Castiella2, Carlos Sostres1, Sara Lorente1, Estela Solanas3, Agustin Garcia-Gil1, Trinidad Serrano1 1Liver Transplantation. Digestive Diseases Department, Lozano Blesa University Hospital, Zaragoza, Spain. 2Pathology Department, Lozano Blesa University Hospital, Zaragoza, Spain. 3Aragon Health Sciences Institute, Zaragoza, Spain

#1765 PROPOSAL OF A SURVEILLANCE PROGRAM FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS C USING COMPREHENSIVE RISK SCORING SYSTEM AND STRATUM SPECIFIC LIKELIHOOD RATIO Ryosukte Tateishi, Haruhiko Yoshida, Takahisa Sato, Ryota Masuzaki, Takamasa Ohki, Eriko Goto, Kenichiro Enooku, Yuji Kondo, Tadashi Goto, Shuichiro Shiina, Kazuhiko Koike, Masao Omata Department of Gastroenterology, The University of Tokyo, Tokyo, Japan

#1766 EFFICACY OF HEPATIC ARTERIAL INFUSION OF FLOXURIDINE IN ADVANCED HEPATOCELLULAR CARCINOMA UNTREATABLE WITH CONVENTIONAL TREATMENT Sang Young Han, Sung Wook Lee, Yang Hyun Baek Liver Center, Dong-A Univ. Hospital, Busan, Korea, South


286A

POSTER SESSIONS


#1767

#1772

CHEMOEMBOLIZATION WITH EPIRUBICIN DRUG ELUTING BEADS TO TREAT EARLY AND INTERMEDIATE HEPATOCELLULAR CARCINOMA

A STUDY ON FACTORS INFLUENCING THE ECTOPIC RECURRENCE OF LIVER CANCER FOLLOWING RADIOFREQUENCY ABLATION

Antonio Nicolini2, Angelo Sangiovanni1, Massimo Iavarone1, Laura Martinetti2, Matteo A. Manini1, Silvia Crespi2, Massimo Colombo1 11st Division of Gastroenterology, Foundation IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy. 2Division of Radiology, Fondazione IRCCS Maggiore Hospital, Milan, Italy

shunsuke nojiri, Etsuko Iio, Katsuhiro Senda, Noboru Shinkai, Tomokatsu Miyaki, Fuminaka Sugauchi, Takashi Joh nagoya city university, nagoya, Japan

#1768 OUTCOME OF MULTIMODAL THERAPIES BASED ON TRANSARTERIAL CHEMO-LIPIODOLIZATION FOR PATIENTS WITH UNRESECTABLE HUGE (>10 CM) HEPATOCELLULAR CARCINOMA Jin Dong Kim, Si Hyun Bae, Jung Hyun Kwon, Jeong Won Jang, U Im Chang, Chang Wook Kim, Jong Young Choi, Seung Kew Yoon, Se Hyun Cho, Joon-Yeol Han, Jin Mo Yang, Young Sok Lee, Chang Don Lee, Kyu Won Chung Internal Medicine, The Catholic University of Korea, Seoul, Korea, South

#1769 METHYLATION FREQUENCY OF P16, SOCS-1, RASSF1A, APC AND GSTP1 PROMOTERS IN TUMOROUS, NON-TUMOROUS AND METASTATIC LIVER TUMOR SAMPLES FROM HCV-POSITIVE PATIENTS WITH HCC IN JAPAN

#1773 COMMON GENETIC VARIATION IN THE P53/MDM2 NETWORK AND CHOLANGIOCARCINOMA SUSCEPTIBILITY Vincent Zimmer1, Frank Grünhage1, Gunter Assmann2,3, Tilman Sauerbruch4, Frank Lammert1, Aksana Höblinger4 1Department of Medicine II, Saarland University Hospital, Homburg, Germany. 2Department of Medicine I, Saarland University Hospital, Homburg, Germany. 3José-Carreras-Research Center, Saarland University Hospital, Homburg, Germany. 4Department of Internal Medicine I, University of Bonn, Bonn, Germany

#1774 PHASE I STUDY OF PAZOPANIB (PAZ) IN HEPATOCELLULAR CARCINOMA (HCC): DETERMINATION OF MTD AND EVALUATION OF CLINICAL ACTIVITY, PHARMACOKINETICS (PK), AND PHARMACODYNAMIC (PD) CHANGES IN DYNAMIC CONTRAST ENHANCED MRI (DCE-MRI)

Eric J. Formeister1, Masato Tsuchiya1, Igor Pogribny2, Ivan Rusyn1 of Environmental Sciences and Engineering, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA. 2Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, AR, USA

Thomas Yau1, Pei-Jer Chen2, C. Martin Curtis3, Philip S. Murphy4, A. Benjamin Suttle3, Thangam Arumugham3, Jeffrey P. Hodge3, Mohammed M. Dar3, Ronnie T. Poon1 1Queen Mary Hospital, Hong Kong, China. 2National Taiwan University Hospital, Taipai, Taiwan. 3GlaxoSmithKline Research and Development Oncology Unit, Research Triangle Park, NC, USA. 4GlaxoSmithKline Research and Development Oncology Unit, Stockley Park, United Kingdom

#1770

#1775

LATENT HEPATITIS B IS AN ADDITIONAL RISK FACTOR FOR HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS C

SIGNIFICANCE OF VASCULAR ENDOTHELIAL GROWTH FACTOR, BASIC FIBROBLAST GROWTH FACTOR AND ANGIOGENIN IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

1Department

Arvind Reddy, Milton G. Mutchnick, Murray N. Ehrinpreis, Elizabeth J. May, Firdous A. Siddiqui Gastroenterology, Wayne State University, Detroit, MI, USA

#1771 SIGNIFICANCE OF ELEVATED MIDKINE LEVELS IN HBV-HCV INDUCED CIRRHOSIS AND HEPATOCELLULAR CARCINOMA


Nuray Yazihan2,3, Haluk Ataoglu3,4, Hakan Bozkaya5, Dilsa Mizrak5, Fatih Oguz Onder5, Burcu Yener3, Ozden Uzunalimoglu1 1Turkish Hepatology Foundation, Ankara, Turkey. 2Pathophysiology, Ankara University, Faculty of Medicine, Ankara, Turkey. 3Molecular Biology, Ankara University, Faculty of Medicine, Ankara, Turkey. 4Microbiology, Ankara University, Faculty of Medicine, Ankara, Turkey. 5Gastroenterology, Ankara University, Faculty of Medicine, Ankara, Turkey


Yogesh K. Chawla1, Balkrishan Sharma1, Radhika Srinivasan2, Anuradha Chakraborty3, Naveen Kalra4, Ajay K. Duseja1, Radhakrishan Dhiman1, Niranjan Khandelwal4, Arunanshu Behera5 1Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. 2Cytopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. 3Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. 4Radiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. 5General Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India


POSTER SESSIONS

287A

#1776

#1781

EXPRESSION OF ALPHA-TAXILIN MAY REFLECT MALIGNANT POTENTIAL OF HEPATOCELLULAR CARCINOMA

PILOT STUDY OF SYSTEMIC COMBINATION THERAPY OF S-1, ORAL FLUOROPYRIMIDINE ANTICANCER DRUG, AND CISPLATIN FOR ADVANCED HEPATOCELLULAR CARCINOMA WITH EXTRAHEPATIC METASTASES

Natsuko Ohtomo1, Tomoaki Tomiya1, Yasushi Tanoue1, Yukiko Inoue1, Takako Nishikawa1, Naoko Watanabe2, Hitoshi Ikeda2, Kazuhiko Koike1, Yasuji Seyama3, Norihiro Kokudo3, Junji Shibahara4, Hiromichi Shirataki5, Kenji Fujiwara6 1Gastroenterology, University of Tokyo, Tokyo, Japan. 2Clinical Laboratory, University of Tokyo Hospital, Tokyo, Japan. 3Hepato-Biliary-Pancreatic Surgery, University of Tokyo, Tokyo, Japan. 4Pathology, University of Tokyo, Tokyo, Japan. 5Molecular and Cell Biology, Dokkyo University School of Medicine, Mibu, Japan. 6Yokohama Rosai Hospital, Yokohama, Japan

#1777 RADIOLOGIC-PATHOLOGIC CORRELATION OF HEPATOCELLULAR CARCINOMA TREATED WITH CHEMOEMBOLIZATION Ahsun Riaz1, Robert Lewandowski1, Laura M. Kulik2, Mary Mulcahy3, Michael M. Abecassis4, Riad Salem1,2 1Radiology, Northwestern University, Chicago, IL, USA. 2Hepatology, Northwestern University, Chicago, IL, USA. 3Medical Oncology, Northwestern University, Chicago, IL, USA. 4Transplant Surgery, Northwestern University, Chicago, IL, USA

#1778 INTRAHEPATIC BILIARY CYSTADENOMA: DISTINCTIVE GENDER-RELATED CLINICOPATHOLOGICAL DIFFERENCES Deborah Giusto, Shriram Jakate Pathology, Rush University Medical Center, Chicago, IL, USA

#1779 OUTCOMES AND FACTORS INFLUENCING SURVIVAL IN CIRRHOTIC PATIENTS WITH SPONTANEOUS RUPTURE OF HEPATOCELLULAR CARCINOMA Hiroyuki Kirikoshi, Satoru Saito, Masato Yoneda, Koji Fujita, Hironori Mawatari, Yuichi Nozaki, Atsushi Nakajima Gastroenterology division, Yokohama City University Graduate School of Medicine, Yokohama, Japan

#1780 MODELING VARIABILITY IN HEPATOCELLULAR CARCINOMA GROWTH Rebecca A. Miksad1, Benjamin P. Geisler1, Elizabeth M. Gaughan2, Jesse L. Wei3, Darren D. Brennan3, Kuan-Chi Lai1, Zsofia K. Stadler4, Brian M. Gill2, Michelle Lai5, Keith E. Stuart6 1Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 2Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. 3Radiology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 4Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 5Hepatology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 6Oncology, Lahey Clinic, Burlington, MA, USA

Yoshio Katamura, Hiroshi Aikata, Yoshimasa Hashimoto, Yuko Nagaoki, Yuki Kimura, Tomokazu Kawaoka, Shintaro Takaki, Koji Waki, Akira Hiramatsu, Yoshiiku Kawakami, Shoichi Takahashi, Kazuaki Chayama Hiroshima univirsity, Hiroshima, Japan

#1782 PREVALENCE AND NATURAL HISTORY OF PORTAL VEIN THROMBOSIS, EVALUATED BY CONTRAST ENHANCED ULTRASONOGRAPHY (CEUS), IN PATIENTS WITH HEPATOCELLULAR CARCINOMA Anna Ludovica Fracanzani1, Angelo Sangiovanni2, Larry Burdick1, Sara Vavassori2, Cristina Bertelli1, Daniela Bignamini1, Massimo Iavarone2, Silvia Fargion1, Massimo Colombo2 1Internal Medicine, Maggiore Policlinico Hospital Foundation IRCCS, University of Milan, Milan, Italy. 2Division of Gastoenterology, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli & Regina Elena, Milan, Italy

#1783 CLINICAL CHARACTERISTICS AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA WITH LOWER SERUM VALUES OF BOTH AFP AND PIVKA-II Do Young Kim1,2, Soung Min Jeon1, Jun Yong Park1,3, Sang Hoon Ahn1,2, Ja Kyung Kim1,3, Kwan Sik Lee1,2, Chae Yoon Chon1,2, Kwang-Hyub Han1,3 1Internal Medicine Division of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea, South. 2Yonsei Liver Cancer Special Clinic, Yonsei University College of Medicine, Seoul, Korea, South. 3Liver Cirrhosis Clinical Research Center, Seoul, Korea, South

#1784 FIELD PRACTICE WITH SORAFENIB IN ADVANCED HCC: EFFECTIVENESS CONFIRMED, REDUCED TOLERABILITY COMPARED TO REGISTRATION TRIALS Massimo Iavarone1, Angelo Sangiovanni1, Laura Virginia Forzenigo2, Massimo Colombo1 11st Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, University of Milan, Milan, Italy. 2Division of Radiology, Fondazione IRCCS Maggiore Hospital, Milan, Italy

#1785 RFA OF HCC IN PATIENTS WITH AND WITHOUT CIRRHOSIS


Andrea Salmi1, Renato Turrini1, Giovanna Lanzani1, Antonella Savio3, Livio Anglani2 1Gastroenterology Unit, Ospedale S. Orsola Fatebenefratelli, Brescia, Italy. 2IRCCS Statistical department, Ospedale San Giovanni di Dio Fatebenefratelli, Brescia, Italy. 3Pathology Department, Ospedale San Orsola Fatebenefratelli, Brescia, Italy

288A

POSTER SESSIONS


Hepatobiliary Cancer: Experimental (2)

#1786 COMBINED SORAFENIB AND YTTRIUM-90 RADIOEMBOLIZATION IN THE TREATMENT OF ADVANCED HCC: PRELIMINARY RESULTS Chaudhury1,

Hassanain1,

Prosanto Chaudhury Mazen Carmine G. Nudo2, Jeanne Bouteaud1, Tatiana Cabrera3, David Valenti3, Peter Metrakos1 1Surgery, McGill University Health Center, Montreal, QC, Canada. 2Gastroenterology, McGill University Health Centre, Montreal, QC, Canada. 3Radiology, McGill University Health Center, Montreal, QC, Canada

#1787 COMPARATIVE ASSESSMENT OF TURKEY’S IMPACT ON HEPATOCELLULAR CARCINOMA RESEARCH Nuray Yazihan1,2, Hakki H. Yilmaz3, Murat Tuncer4, Dilara Karadeniz3, Cihan Yurdaydin5, Ozden Uzunalimoglu6 1Pathophysiology Department, Ankara University, Faculty of Medicine,, Ankara, Turkey. 2Moleculer Biology Unit, Ankara University, Faculty of Medicine,, Ankara, Turkey. 3Public Finances, Ankara University, Faculty of Political Sciences, Ankara, Turkey. 4Cancer Control, Head of Department, Republic of Turkey, Ministry Of Health, Ankara, Turkey. 5Gastroenterology, Ankara University, Faculty of Medicine,, Ankara, Turkey. 6Turkish Hepatology Foundation, Ankara, Turkey

#1788 ADHERENCE TO HCC SCREENING GUIDELINES IN CHRONIC HEPATITIS B IS HINDERED BY COMPLIANCE WITH FOLLOW-UP Nancy Reau, Rohit S. Satoskar, Helen S. Te, Smruti R. Mohanty, K. Gautham Reddy, Donald M. Jensen Hepatology, University of Chicago, Chicago, IL, USA

#1789 CONTRAST-ENHANCED ULTRASOUND IN THE DIAGNOSIS OF HEPATOCARCINOMA DETECTED IN PATIENTS WITH A FOCAL LIVER LESION AND LIVER DISEASE Camilo J. Llamoza Torres, Pilar Soto Escribano, Marissa Vignote Alguacil, Juan Francisco De Dios Vega Aparato Digestivo, Hospital Universitario Reina Sofía, Córdoba, Spain

#1790 TOTAL AFP AND AFP-L3% MEASURED BY LIQUID PHASE BINDING ASSAY IN INDIVIDUALS WITH INCREASED SERUM AFP AND NO EVIDENCE OF HEPATOCELLULAR CARCINOMA Emilia Hadziyannis1, John Koskinas1, Dimitrios Vassilopoulos1, Anastasia Georgiou1, Athanasios J. Archimandritis1, Stephanos J. Hadziyannis2 1Second Dpt of Medicine, Athens University, School of Medicine, Athens, Greece. 2Henry Dunant Hospital, Athens, Greece

#1791 ONCOGENIC TRANSFORMATION OF HUMAN HEPATOCYTES WITH DEFINED CELLULAR ONCOGENES Naoki Oishi1, Yasunari Nakamoto1, Masao Honda1, Seishi Murakami2, Shuichi Kaneko1 1Department of Gastroenterology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan. 2Department of Signal Transduction, Cancer Research Institute, Kanazawa University, Kanazawa, Japan

#1792 PPARδ ACTIVATES STAT3 SIGNALING PATHWAY IN HUMAN HEPATOCELLULAR CARCINOMA CELLS Chang Han1, Guiying Li1,2, Tong Wu1 of Pathology, University Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, Jilin University, Changchun, China

1Department

#1793 BORTEZIMIB SPECIFICALLY INHIBITS THE PROLIFERATION OF HEPATOCELLULAR CARCINOMA Issei Saeki, Shuji Terai, Koichi Fujisawa, Naoki Yamamoto, Taro Takami, Takahiro Yamasaki, Isao Sakaida Gastroenterology & Hepatology, Yamaguchi University, Ube-shi, Japan

#1794 MECHANISMS OF ANTI-ANGIOGENIC EFFECT OF VEGF TRAP (AFLIBERCEPT) FOR HEPATOCELLULAR CARCINOMA IN MICE Takuji Torimura1,3, Takato Ueno3,1, Hideki Iwamoto1,3, Toru Nakamura1,3, Hirohisa Yano2, Michio Sata1,3 1Department of Medicine, division of Gastroenterology, Kurume University, Kurume City, Japan. 2Pathology, Kurume University, Kurume, Japan. 3Liver Cancer division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Japan

#1795 MOUSE MODELS FOR HUMAN LIVER CANCER STEM CELL SYNDROME Zhixing Yao1, Ying Li1, Wilma S Jogunoori1, Hong Cao1, Wenguo Yao1, Bibhuti Mishra1, Lopa Mishra1,2 1Surgery, Georgetown University, Washington, DC, USA. 2Surgery, Veterans Affairs Medical Center, Washington, DC, USA

#1796 THE β2 SPECTRIN INTERACTS WITH SMAD3/CMYC TO REPRESS TELOMERASE REVERSE TRANSCRIPTASE (TERT) IN HEPATOCELLULAR CANCER PROGRESSION


Zhongxian Jiao1, Zhixing Yao1, Wilma S Jogunoori1, Wenguo Yao1, Lopa Mishra1,2, Bibhuti Mishra1 1Georgetown University, Washington, DC, USA. 2Veterans Affairs Medical Center, Washington, DC, USA



POSTER SESSIONS

#1797 FORCED EXPRESSION OF METHIONINE ADENOSYLTRANSFERASE 1A (MAT1A) IN HUMAN HEPATOMA CELLS SUPPRESSES IN VIVO TUMORIGENICITY BY REDUCING PROLIFERATION AND ANGIOGENESIS WHILE ENHANCING APOPTOSIS Jiaping Li1, Komal Ramani1, Heping Yang1, Meng Xia1, Jose M. Mato2, Shelly C. Lu1 1Medicine, Keck School of Medicine USC, Los Angeles, CA, USA. 2Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), CIC bioGUNE, Derio, Spain

#1798 CK2 CONTRIBUTES TO HEPATOCELLULAR CARCINOMA BY TRIGGERING NFKAPPAB ACTIVITY AND WNT SIGNALLING Gabriele Sass1, Nina Klinger2, Stefanie Buerbank2, Said Hashemolhosseini3, Claus Hellerbrand4, Daniel Neureiter5, Henning Wege6, Matthias Ocker7, Gisa Tiegs1 1Division of Experimental Immunology and Hepatology, University Medical Center Hamburg Eppendorf, Hamburg, Germany. 2Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen, Erlangen, Germany. 3Institute of Biochemistry, University of Erlangen, Erlangen, Germany. 4Department of Internal Medicine I, University of Regensburg, Regensburg, Germany. 5Institute of Pathology, Salzburger Landeskliniken, Paracelsus Private Medical University, Salzburg, Austria. 6Department of Gastroenterology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 7Department of Medicine 1, University Hospital Erlangen, Erlangen, Germany

#1799 DEVELOPMENT AND VALIDATION OF AN SCFV SPECIFIC FOR HUMAN GLYPICAN-3 FOR THERAPY OF HEPATOCELLULAR CARCINOMA Yonghai Li2, Aizhi Zhao3, Hong Li2, Oluwasayo Adeyemo2, Daniel Elkin2, Nathalie Scholler3, David E. Kaplan2,1 1Research & Gastroenterology, Philadelphia Veterans Administration Medical Center, Philadelphia, PA, USA. 2Medicine/Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA. 3Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA

#1800 EVIDENCE OF CANCER STEM CELLS IN PRIMARY HUMAN HEPATOCELLULAR CARCINOMA

#1801 FUNCTIONAL POLYMORPHISMS OF CYCLOOXYGENASE-2 GENE AND RISK FOR HEPATOCELLULAR CARCINOMA Hikmet Akkiz1, Süleyman Bayram2,1, Aynur Bekar1, Ersin Akgöllü1, Macit U. Sandikci1, Burhan Özdil1, Figen Doran3, Ilhan Tuncer3 1Department of Biology, Natural and Applied Science Institute, Çukurova University, Adana, Turkey. 2Medical Faculty Department of Gastroenterology, Çukurova University, Adana, Turkey. 3Medical Faculty Department of Pathology, Çukurova University, Adana, Turkey

#1802 GROWTH OF HUMAN HEPATOCELLULAR CARCINOMA IN VIVO IS ASSOCIATED WITH TUMOR-RECRUITMENT OF MESENCHYMAL STEM CELLS AND THEIR SECRETED TROPHIC FACTORS Qiuwei Pan1, Hugo W. Tilanus2, Harry L. Janssen1, Luc J. van der Laan2 1Gastroenterology & Hepatology, Erasmus MC-University Medical Center, Rotterdam, Netherlands. 2Surgery, Erasmus MC-University Medical Center, Rotterdam, Netherlands

#1803 STROMAL CO-CULTURE ENHANCE CHEMOTHERAPY RESISTANCE OF LIVER CANCER CELLS Joerg Schrader, Timothy T. Gordon-Walker, Rebecca Aucott, Stuart J. Forbes, John P. Iredale MRC University of Edinburgh Centre for Inflammation Research, Edinburgh, United Kingdom

#1804 INACTIVATION OF CYCLIN E1 BUT NOT OF CYCLIN E2 INHIBITS CHEMICALLY INDUCED HEPATOCARCINOGENESIS IN MICE Nives Moro1, Nikolaus Gassler2, Yulia A. Nevzorova1, Peter Sicinski3, Christian Trautwein1, Christian Liedtke1 1Dept. of Medicine III, University Hospital Aachen, Aachen, Germany. 2Institute of Pathology, University Hospital Aachen, Aachen, Germany. 3Dana-Farber Cancer Institute, Boston, MA, USA

#1805 ACTIVATION OF MTOR COMPLEX 2 IN HEPATOCELLULAR CARCINOMA: IN VITRO EVALUATION AS A NOVEL THERAPEUTIC TARGET Augusto Villanueva1, Helena Cornella1, Victoria Tovar1, Yujin Hoshida3, Clara Alsinet1, Derek Y. Chiang3, Judit Peix1, Beatriz Minguez2, Daniela Sia1, Sara Toffanin2, Radoslav Savic2, Anja Lachenmayer2, Swan N. Thung4, Sasan Roayaie5, Myron E. Schwartz5, Jordi Bruix1, Vincenzo Mazzaferro6, Scott L. Friedman2, Josep M. Llovet1,2 1BCLC, Liver Unit, CIBERehd, Hospital Clinic, Barcelona, Spain. 2Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA. 3Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA, USA. 4Pathology, Mount Sinai School of Medicine, New York, MA, USA. 5Surgical Oncology, Mount Sinai School of Medicine, New York, MA, USA. 6Gastrointestinal Surgery and Liver Transplantation Unit, National Cancer Institute, Milan, Italy


Federico Colombo1, Ines Martin-Padura3, Alessandra Cattaneo1, Silvia Mazzucchelli1, Francesca Baldan1, Barbara Foglieni5, Giorgio Rossi2, Vincenzo Mazzaferro4, Francesco Bertolini3, Daniele Prati5, Laura Porretti1 1Regenerative Medicine Department, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy. 2Liver Transplant Unit, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy. 3Emato-Oncology Laboratory, European Institute of Oncology, Milan, Italy. 4Department of Surgery, National Cancer Institute, Milan, Italy. 5Hematology Department, Ospedale “A. Manzoni”, Lecco, Italy

289A

290A

POSTER SESSIONS


#1806

#1810

OVEREXPRESSED WILMS’ TUMOR 1 GENE IN HEPATOCELLULAR CARCINOMA ACCELERATES TUMOR GROWTH AND ONCOGENIC POTENTIAL

TRANSCRIPTOME ANALYSIS AND SORAFENIB EFFECTS ON HGF/CMET PATHWAY IN LIVER CANCER CELL LINES

Kazuhiro Uesugi, Yoichi Hiasa, Toshie Mashiba, Yoshio Tokumoto, Ichiro Konishi, Masanori Abe, Hidehiro Murakami, Bunzo Matsuura, Morikazu Onji Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan

Anna C. Piscaglia1, Nathalie Saulnier1, Marta Barba1, Laura Castellini1, Valentina Tesori2, Mariachiara Campanale1, Flaminia Purchiaroni1, Valentina Cesario1, Tommaso Galeotti2, Giovanbattista Pani2, Antonio Gasbarrini1 1Internal Medicine, Catholic University of Rome, Roma, Italy. 2General Pathology, Catholic University of Rome, Roma, Italy

#1807 HEPATOCELLULAR CARCINOMA IN THE FUMARYL ACETOACETATE HYDROLASE KNOCKOUT MOUSE IS NOT A CONSEQUENCE OF CELL FUSION Mehdi Mohamadnejad1, Diane S. Krause2, E. S. Swenson3 Sciences, University of Tehran, Tehran, Iran. 2Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA. 3Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA 1Medical

#1808 DUAL ACTION OF A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR ON VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION IN HUMAN HEPATOCELLULAR CARCINOMA CELLS: INVOLVEMENT OF DISCOIDIN DOMAIN RECEPTOR 2 AND INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR

#1811 NOT HBX BUT FUSION HBX TRANSLATED FROM HBV INTEGRANT IS ASSOCIATED WITH THE DEVELOPMENT AND PROGRESSION OF HEPATOCELLULAR CARCINOMA Ryosuke Muroyama1, Norie Kowatari1, Zhongjie Hu1, Jin-Hai Chang2, Motoyuki Otsuka2, Masao Omata2, Naoya Kato1 1Unit of Disease Control Genome Medicine, Institute of Medical Science, University of Tokyo, Tokyo, Japan. 2Department of Gastroenterology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

#1812 INCIDENCE OF AFLATOXIN B1-INDUCED HEPATIC TUMORS IS INCREASED IN HEPATITIS VIRUS C TRANSGENIC MICE AS COMPARED TO WILD TYPE C57BL/6J STRAIN

Nam Oak Lee1, Joong-Won Park1, Ju Hyun Shim1, Ji Hoon Kim1, Jung Ahn Lee1, Sun-Young Kong2, Yeon-Su Lee3, Kyung Tae Kim3 1Center for Liver Cancer, National Cancer Center, Goyang, Korea, South. 2Center for Clinical Services, National Cancer Center, Goyang, Korea, South. 3Functional Genomics Branch, National Cancer Center, Goyang, Korea, South

Emmanuelle Jeannot1, Gary A. Boorman2, Svitlana Shymonyak1, Oksana Kosyk1, Ivan Rusyn1 1ESE, The UNC Gillings School of Global Public Health, UNC, Chapel Hill, NC, USA. 2Environmental Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA

#1809

#1813

MULTITYROSINKINASE INHIBITION BY SORAFENIB INCREASES NECROSIS SIZE AFTER RADIOFREQUENCY ABLATION IN RAT LIVER BUT ACTIVATES COMPENSATORY GROWTH SIGNALLING

TRANSARTERIAL INFUSION CHEMOTHERAPY USING CISPLATIN-LIPIODOL SUSPENSION WITH OR WITHOUT EMBOLIZATION FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA


Joachim C. Mertens1,4, Ina V. Martin2, Schmitt Johannes1, Pascal Frei1, Oliver Goetze1, Andreas H. Mahnken3, Beat Mullhaupt1,4, Andreas Geier1,4 1Department of Internal Medicine, Division of Gastroenterology & Hepatology, University Hospital Zürich, Zürich, Switzerland. 2Department of Gastroenterology & Hepatology, University Hospital Aachen (UKA), RWTH Aachen, Aachen, Germany. 3Clinic for Interventional Radiology, University Hospital Aachen (UKA), RWTH Aachen, Aachen, Germany. 4Swiss Hepatopancreatobiliary (HPB)Center, University Hospital Zürich, Zürich, Switzerland


Tomokazu Kawaoka, Hiroshi Aikata, Yoshimasa Hashimoto, Yoshio Katamura, Shintaro Takaki, Kouji Waki, Akira Hiramatu, Shoichi Takahashi, Kazuaki Chayama Graduate School of Biomedical Science Hiroshima University, Hiroshima, Japan

#1814 EPIGENETIC REGULATION OF HOMEOBOX GENES IN LIVER CANCER Hongyan Liu1, Bilian Jin2, Keith D. Robertson2, Chen Liu1 1Department of Pathology, University of Florida, Gainesville, FL, USA. 2Biochemistry, University of Florida, Gianesville, FL, USA


POSTER SESSIONS

291A

#1815

#1820

CAUSAL RELATIONSHIP BETWEEN LOSS OF β2SPECTRIN AND OVER EXPRESSION OF IGF2 IN HEPATOCELLULAR CANCER

ACCUMULATION OF NEOPLASTIC TRAITS PRIOR TO SPONTANEOUS IN VITRO TRANSFORMATION OF RAT CHOLANGIOCYTES DETERMINES SUSCEPTIBILITY TO ACTIVATED ERBB-2

Zhixing Yao1, Wilma Jogunoori1, Hong Cao1, Wenguo Yao1, Bibhuti Mishra1, Lopa Mishra1,2 1Surgery, Georgetown University, Washington, DC, USA. 2Surgery, Veterans Affairs Medical Center, Washington, DC, USA

#1816 TRANSCRIPTIONAL REGULATION OF THE NA/I SYMPORTER NIS GENE BY P53, P63 AND P73 IN HUMAN CHOLANGIOCARCINOMA (CCA) AND AND HEPATOCELLULAR (HCC) CELLS Francesca Guerrieri1,2, Valeria Schinzari1,2, Julie Herve3, Christian Brechot4, Didier Samuel3, Jamila Faivre3, Massimo Levrero1,5 1LEA INSERM U785, INSERM and Sapienza University of Rome, Rome, Italy. 2Laboratory of Gene Expression, A. Cesalpino Foundation, Rome, Italy. 3INSERM U785, INSERM, Villejuif, France. 4Merieaux Alliance, Lyon, France. 5Dept of Internal Medicine, Sapienza University, Rome, Italy

#1817 ULTRACONSERVED NON-CODING RNA GENES ARE ABERRANTLY EXPRESSED AND CAN BE MODULATED BY INTERLEUKIN-6 IN HUMAN MALIGNANT CHOLANGIOCYTES Chiara Braconi1, Takayuki Kogure1, Jinmai Jiang2, Nianyuan Huang1, Neil Mehta1, Thomas Schmittgen2, Tushar Patel1 1Internal Medicine, Ohio State University, Columbus, OH, USA. 2Division of Pharmaceutics, Ohio State University, Columbus, OH, USA

#1818 A NOVEL SMALL MOLECULE, FLLL32 MAY BE THERAPEUTICALLY USEFUL FOR CHOLANGIOCARCINOMA BY INHIBITING CONSTITUTIVE JAK2/STAT3 SIGNALING AND MODULATING BOTH MCL-1 EXPRESSION AND MITOCHONDRIAL FUNCTION Takayuki Kogure1, Chiara Braconi1, Nianyuan Huang1, Chenglong Li2, InHee Park2, James Fuchs2, Eric B. Schwartz2, Pui-Kai Li2, Tushar Patel1 1Internal Medicine, The Ohio State University, Columbus, OH, USA. 2Medicinal Chemistry and Pharmacognosy, The Ohio State University, Columbus, OH, USA

#1819 HEPATIC PROGENITOR AND TUMOR CELLDERIVED MICROVESICLES MODULATE NK CYTOTOXIC RESPONSE David R. Mills, Helen M. Callanan, DongQin Yang, Kate E. Brilliant, Rebecca A. Rozich, Alexander S. Fye, Douglas C. Hixson Medicine, Rhode Island Hospital/The Warren Alpert Medical School of Brown University, Providence, RI, USA

David R. Mills, Rebecca A. Rozich, Kate E. Brilliant, Helen M. Callanan, DongQin Yang, Douglas C. Hixson Medicine, Rhode Island Hospital/The Warren Alpert Medical School of Brown University, Providence, RI, USA

#1821 MODULATION OF BILIARY NEUROPEPTIDE Y (NPY) EXPRESSION REGULATES CHOLANGIOCARCINOMA CELL GROWTH AND INVASION BY AN AUTOCRINE MECHANISM Sharon DeMorrow1, Eugenio Gaudio4, Julie Venter1, Paolo Onori5, Mellanie White1, Shelley Kopriva1, Gabriel A. Frampton1, Monique Coufal1, Heather Francis1,3, Shannon S. Glaser1, Candace Wise1, Antonio Franchitto4, Giammarco Fava6, Guido Carpino7, Gianfranco Alpini1,2 1Department of Medicine and Scott & White Digestive Disease Research Center, Texas A&M Health Science Center College of Medicine, Temple, TX, USA. 2Research, Central TX Veterans Health Care System, Temple, TX, USA. 3R&E, Scott & White, Temple, TX, USA. 4Human Anatomy, University of Rome “La Sapienza”, Rome, Italy. 5Experimental Medicine, University of L’Aquila, L’Aquila, Italy. 6Gastroenterology, Universita` Politecnica delle Marche, Ancona, Italy. 7Department of Health Science, University of Rome “Foro Italico”, Rome, Italy

#1822 ASSOCIATION BETWEEN SERIAL CHANGES OF SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR/ INSULIN-LIKE GROWTH FACTOR-2 LEVELS AND THE SHORT PERIOD RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; A PROSPECTIVE STUDY Jong Hyeok Park1, Soo Hyung Ryu1, Jeong A. Kim2, Young Mal Kim1,2, Jung Hwan Lee1, You Sun Kim1, Jeong Seop Moon1 1Department of Internal Medicine, University of Inje College of Medicine, Seoul Paik Hospital, Seoul, Korea, South. 2Lab of genomic research, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, South

#1823 EXPRESSION OF CANCER STEM CELL MARKERS IN HEPATOCELLULAR CARCINOMA AND HEPATOMA CELL LINES Shilpa Lingala1, Yi Yao Cui1, Xiaoli Chen1, Vijay Khatri2, Mark Zern1, Boris H. Ruebner3, Jian Wu1 1Dept. of Internal Medicine, Division of Gastroenterology & Hepatology, University of California, Davis Medical Center, Sacramento, CA, USA. 2Department of Surgical Oncology, University of California, Davis Medical Center, Sacramento, CA, USA. 3Department of Pathology, University of California, Davis Medical Center, Sacramento, CA, USA T U E S D AY NOVEMBER 3

292A

POSTER SESSIONS

#1824

#1830

BMI-1 GENE IS UPREGULATED IN EARLY-STAGE HEPATOCELLULAR CARCINOMA AND CORRELATES WITH ATP-BINDING CASSETTE TRANSPORTER B1 (ABCB1) EXPRESSION

ODN CPG B IN COMBINATION WITH RFA SEEMS TO CAUSE A CELLULAR BASED CANCER VACCINATION IN THE VX2 HEPATOMA IN RABBITS

Kathryn Effendi, Taisuke Mori, Mina Komuta, Yohei Masugi, Wenlin Du, Michiie Sakamoto Pathology, School of Medicine, Keio University, Tokyo, Japan

Thaddaeus T. Wissniowski, Deike Strobel, Eckhart G. Hahn, Matthias Ocker Depart. of Medicine 1, Friedrich-Alexander University, Erlangen, Germany

#1825 GENE EXPRESSION IN NON-TUMORAL LIVER TISSUE AND RISK OF RECURRENCE OF HEPATOCELLULAR CARCINOMA IN HEPATITIS C VIRUS-POSITIVE SUBJECTS

Heptotoxicity and Drug Metabolism #1831

Masato Tsuchiya1,2, Joel S. Parker1, Hiroshi Kono2, Masanori Matsuda2, Hideki Fujii2, Ivan Rusyn1 1Environmental Sciences & Engineerings, University of North Carolina, Chapel Hill, NC, USA. 2First Surgery, University of Yamanashi, Chuo, Japan

TNF-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL)-INDUCED CELL DEATH REQUIRES CASPASE-DEPENDENT CELLULAR INHIBITOR OF APOPTOSIS 1 AND 2 (CIAP1 AND CIAP2) DEGRADATION

#1826

Maria Eugenia Guicciardi, Steven F. Bronk, Gregory Gores Mayo Clinic College of Medicine, Rochester, MN, USA

CHRONIC ADMINISTRATION OF VALPROIC ACID INHIBITS HUH7 TUMORS XENOGRAFTS IN NUDE MICE BUT NOT ACTIVATES NOTCH-1 SIGNALING Marcel C. Machado, Marta Bellodi-Privato, Nilza Molan, Marcia S. Kubrusly, Luiz Augusto C. D’Albuquerque Gastroenterology, Sao Paulo University, Sao Paulo, Brazil

#1827 ACTIVATION OF THE TRANSCRIPTION FACTOR ARYL HYDROCARBON RECEPTOR INCREASES IL17 AND INHIBITS IL6 SUPPRESSING THE GROWTH OF HEPATOCELLULAR CARCINOMA: A NOVEL METHOD FOR NUCLEAR RECEPTOR DEPENEDENTTREGS DIRECTED ANTI TUMOR THERAPY Meir Mizrahi1, Ami Ben-Ya’acov1, Gadi Lalazar1, Tomer Adar1, Yoav Lichtenstein1, Yehudit Shabat1, Francisco Quintana2, Howard Weiner2, Yaron Ilan1 1internal medicin liver unit, Hadassah medical center, Jerusalem, Israel. 2Center for Neurological Disease, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

#1828 A POTENTIAL NOVEL THERAPEUTIC TARGET: USE SYNTHETIC SHP AGONISTS TO ACTIVATE APOPTOSIS AND INHIBIT TUMOR GROWTH Li Wang Medicine, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA

#1829 DEVELOPMENT OF ALN-VSP: AN RNAI THERAPEUTIC FOR LIVER MALIGNANCIES



Iva Toudjarska1, Adam Judge2, Joshua Brodsky1, Kevin McClintock2, Susan D. de Jong2, Ellen Ambegia2, Tim Buck1, Akin Akinc1, Tim Racie1, Lloyd B. Jeffs2, Ed Yaworski2, Jared Gollob1, Ian MacLachlan2, Dinah W. Sah1, David Bumcrot1 1Alnylam Pharmaceuticals, Inc., Cambridge, MA, USA. 2Tekmira Pharmaceuticals Corp, Vancouver, BC, Canada


#1832 MECHANISM FOR REPRESSION OF TUMOR NECROSIS FACTOR (TNF) α-INDUCED TRANSCRIPTION OF NF-κB TARGET GENE A20 BY MODERATE HEPATOCYTE GLUTATHIONE DEPLETION Huan Lou, Neil Kaplowitz Medicine, University of Southern California, Los Angeles, CA, USA

#1833 INHIBITION OF GLYCOGEN SYNTHASE KINASE 3β ATTENUATES BILE ACID APOPTOSIS IN HEPATOCYTES Kathleen Ponzetti, Anna Gates, Cynthia R. Webster Clinical Sciences, Tufts Cummings School of Veterinary Medicine, Grafton, MA, USA

#1834 ANGIOTENSIN II PROTECTS RAT HEPATOCYTES FROM BILE ACID- INDUCED APOPTOSIS Golnar Karimian1, Manon Buist-Homan1, Rob H. Henning2, Johannes G. Burgerhof3, Klaas Nico Faber1, Han Moshage1 1Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Netherlands. 2Clinical Pharmacology, University of Groningen, Groningen, Netherlands. 3Epidemiology, University of Groningen, Groningen, Netherlands


POSTER SESSIONS

293A

#1835

#1840

MODULATION OF MIRNAS BY BILE ACIDS: FROM APOPTOSIS TO CELL PROLIFERATION TO LIVER REGENERATION

THE NOS-3 OVEREXPRESSION INDUCES AN ENHANCED SUSCEPTIBILITY TO FAS-INDUCED CELL DEATH IN HEPATOMA CELL LINE

Rui E. Castro1,2, Duarte S. Ferreira1, Pedro M. Borralho1,2, Yan Zeng4, Aaron L. Sarver5, Clifford J. Steer2,3, Betsy Kren2, Cecilia Maria M. Rodrigues1 1Molecular and Cell Biology of Eukaryotic Systems Group, iMed, Faculty of Pharmacy, University of Lisbon, Lisboa, Portugal. 2Department of Medicine, University of Minnesota, Minneapolis, MN, USA. 3Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, USA. 4Department of Pharmacology, University of Minnesota, Minneapolis, MN, USA. 5Bioinformatics Support and Services, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA

Rosario I. Bello1, Gustavo Ferrín1,3, Clara I. Linares1, Sandra González-Rubio1, Ana B. Hidalgo1, Isidora Ranchal1,3, Raúl González1,3, Patricia Aguilar-Melero1, Pilar Barrera1,3, Manuel De la Mata1,3, Sten Orrenius2, Boris Zhivotovsky2, Jordi Muntané1,3 1Liver Research Unit, Reina Sofía University Hospital, Córdoba, Spain. 2Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 3Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREH o Ciberehd), Instituto de Salud Carlos III, Madrid, Spain

#1836 TAUROCHENODEOXYCHOLATE INDUCED HEPATOCYTE CELL DEATH IS MEDIATED BY A PI3K P110γ DEPENDENT SIGNALING PATHWAY Simon Hohenester1, Anna Gates2, Ulrich Beuers1, Mohammed S. Anwer3, Cynthia R. Webster2 1AMC Liver Center, University of Amsterdam, Amsterdam, Netherlands. 2Department of Clinical Sciences, Tufts Cummings School of Veterinary Medicine, North Grafton, MA, USA. 3Department of Biomedical Sciences, Tufts Cummings School of Veterinary Medicine, North Grafton, MA, USA

#1837 P53 ENHANCES APOPTOSIS AND INSULIN RESISTANCE IN THE LONG-EVANS RAT MODEL OF ALCOHOLIC LIVER DISEASE (ALD) BY ACTIVATING NOVEL DOWNSTREAM TARGETS GENES Zoltan Derdak, Jack R. Wands Liver Research Center, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA

#1838 STRAIN-SPECIFIC GENETIC DIFFERENCES IN APOPTOSIS AFTER CHALLENGE OF INBRED MICE WITH THE CHEMICAL CARCINOGEN DIETHYLNITROSAMINE Susanne N. Weber, Frank Lammert Department of Medicine II, Saarland University Hospital, Homburg, Germany

#1839 AUTOPHAGY IS ACTIVATED AS A PRO-SURVIVAL MECHANISM TO PROTECT AGAINST ETHANOLINDUCED HEPATOTOXICITY Wen-Xing Ding1, Xiaoyun Chen1, Hong-Min Ni1, Donna B. Stolz2, Binfeng Lu3, Dahn L. Clemens4, Xiao-Ming Yin1 1Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA. 2Department of Cell Biology and Physiology, University of Pittsburgh, Pittsburgh, PA, USA. 3Immunology, University of Pittsburgh, Pittsburgh, PA, USA. 4Internal Medicine, University of Nebraska, Omaha, NE, USA

#1841 POTENTIATION OF CISPLATIN CYTOTOXICITY BY BETA-PHENYLETHYL ISOTHIOCYANATE IN CHOLANGIOCARCINOMA CELLS Yan Zhou1, Rolf B. Fritz1, Xiaoli Zhang1, Peng Huang2, Gene LeSage1 1Department of Internal Medicine, East Tennessee State University, Johnson City, TN, USA. 2Department of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

#1842 OSW-1 INDUCES CALCIUM-DEPENDENT APOPTOSIS IN CHOLANGIOCARCINOMA Yan Zhou1, Rolf B. Fritz1, Celia Garcia-Prieto2, Zhendong Jin3, Peng Huang2, Gene LeSage1 1Department of Internal Medicine, East Tennessee State University, Johnson City, TN, USA. 2Department of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. 3College of Pharmacy, Division of Medicinal & Natural Products Chemistry, The University of Iowa, Iowa City, IA, USA

#1843 REGULATION OF STEATOSIS AFTER ACUTE ETHANOL ADMINISTRATION Terrence M. Donohue, Casey S. Trambly, Natalia A. Osna Research, Omaha VA Medical Center, Omaha, NE, USA

#1844 DEFICIENCY OF ARGININOSUCCINATE SYNTHASE ATTENUATES LIVER INJURY BY DECREASING THE INDUCTION OF NITRIC OXIDE SYNTHASE-2 Yongke Lu1, Stephen C. Ward2, Natalia Nieto1 1Medicine/Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA. 2Pathology, Mount Sinai School of Medicine, New York, NY, USA

#1845 ETHANOL AFFECTS EXPRESSION OF RECEPTORS FOR HCV ENTRY IN LIVER CELLS


Lee Austin1, Kusum K. Kharbanda1, Michael R. Beard2, Natalia A. Osna1 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. 2Molecular biology, University of Adelaide, Adelaide, SA, Australia

294A

POSTER SESSIONS


#1846

#1851

COMBINED EFFECTS OF HEPATITIS C VIRUS AND ETHANOL ON MHC-CLASS I-RESTRICTED ANTIGEN PRESENTATION IN LIVER CELLS

INHIBITION OF THE OXIDATIVE STRESS REDUCES HEPATIC IRON OVERLOADED THROUGH THE UPREGULATION OF HEPCIDIN LEVEL IN TRANSGENIC MICE EXPRESSING THE HEPATITIS C VIRUS POLYPROTEIN

Natalia A. Osna1, Ronda L. White1, Terrence M. Donohue1, Steven A. Weinman2, Carol A. Casey1, Kusum K. Kharbanda1 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. 2Department of Medicine, University of Kansas Medical Center, Kansas City, MO, USA

#1847 ACTIVATION OF NRF2-ANTIOXIDANT RESPONSE ELEMENT (ARE) PATHWAY DECREASES HEPATIC APOPTOSIS AND ENHANCES CELLULAR PROLIFERATION IN HEPATIC ISCHEMIA REPERFUSION INJURY David P. Foley1, Scott Nelson1, Delinda A. Johnson2, Jeffrey A. Johnson2 1Surgery, University of Wisconsin, Madison, WI, USA. 2School of Pharmacy, University of Wisconsin, Madison, WI, USA

#1848 THE PROTECTIVE EFFECT OF MITOCHONDRIAL SUPEROXIDE ANION SCAVENGING BY SOD MIMETICS DEPENDS ON THE LEVEL OF GSH Claudia Von Montfort1,2, Núria Matias1,2, Carmen Garcia-Ruiz1,2, Jose C. Fernandez-Checa1,2 1Liver Unit, Hospital Clinic, CIBEREHD, Barcelona, Spain. 2IIBBCSIC, IDIBAPS, Barcelona, Spain

#1849 THE NUCLEAR RECEPTOR LXRα CONTROLS BILIRUBIN SYNTHESIS AND METABOLISM Jenny Kaeding, Diala El Husseini, Stéphane Gosselin, Patrick Caron, Olivier Barbier Laboratory of Molecular Pharmacology, CHUQ Research Center, Faculty of Pharmacy, Laval University, Québec, QC, Canada

Masaaki Korenaga1,2, Sohji Nishina1, Keiko Korenaga1, Isao Sakaida2, Keisuke Hino1 1Division of Hepatology and Pancreatology, Kawasaki Medical College, Kurashiki Okayama, Japan. 2Department of Gastroenterology and Hepatology, Graduate School of Medicine, Yamaguchi University, Ube, Japan

#1852 DIETARY OMEGA-3 FATTY ACID SUPPLEMENTATION AGGRAVATES HEPATIC INJURY AND FIBROSIS IN ACUTE AND CHRONIC CARBON TETRACHLORIDE ADMINISTRATION IN MICE Vincent E. de Meijer1, Yury Popov2, Deanna Y. Sverdlov2, Hau D. Le1, Jonathan A. Meisel1, Detlef Schuppan2, Mark Puder1 1Department of Surgery, Children’s Hospital Boston, Boston, MA, USA. 2Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA

#1853 KRÜPPEL-LIKE FACTOR 6 AND ITS SPLICE VARIANTS ARE SENSITIVE TO REACTIVE OXYGEN SPECIES AND MODULATE TNFα LEVELS Raquel Urtasun, Francisco Javier Cubero, Natalia Nieto Medicine/Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA

#1854 VITAMIN C DEFICIENCY INCREASES THE BINUCLEATION OF HEPATOCYTES IN SENESCENCE MARKER PROTEIN-30 (SMP30) KNOCKOUT MICE

HEPATIC ACTIVATION OF C-MYC ONCOGENE BY NATIVE AND PEROXIDIZED LINOLEIC ACID

Jin-Kyu Park, Il-Hwa Hong, Mi-Ran Ki, Ae-Ri Ji, Kyung-Sook Hong, Sang-Joon Park, Kyu-Shik Jeong College of Veterinary Medicine, Kyungpook National University, Daegu, Korea, South

Nataliya Rohr-Udilova1, Heidi Berger2, Hubert Hayden1, Wolfgang W. Huber2, Michael Murkovic3, Klaus Stolze4, Markus PeckRadosavljevic1 1Internal Medicine III, Medical University of Vienna, Vienna, Austria. 2Internal Medicine I, Medical University of Vienna, Vienna, Austria. 3Institute of Food Chemistry and Technology, Technical University of Graz, Graz, Austria. 4Department of Biomedical Sciences, Veterinary University of Vienna, Vienna, Austria

GLYCOSPHIGLIPIDS PROTECT LIVER INJURY DUE TO HMG-COA REDUCTASE INHIBITORS BY PROMOTION OF NKT LYMPHOCYTES, SUPPRESSION OF IL17, AND ACTIVATION OF STAT3: AN IMMUNE-DEPENDENT ALLEVIATION OF DILI

#1850

#1855

Meir Mizrahi, Tomer Adar, Gadi Lalazar, Ami Ben-Ya’acov, Yoav Lichtenstein, Yehudit Shabat, Dimitri Kanovich, Yaron Ilan internal medicin liver unit, Hadassah medical center, Jerusalem, Israel

#1856


WITHDRAWN



POSTER SESSIONS

295A

#1857

#1861

FIVE NOVEL SINGLE NUCLEOTIDE POLYMORPHISMS IN THE UGT1A6 GENE MAY BE PROTECTIVE IN TOXIC LIVER INJURY

EARLY PLATELET AGGREGATION AS AN INDICATOR OF SEVERITY OF ILLNESS IN ACETAMINOPHEN-INDUCED ACUTE LIVER FAILURE

Chang H. Kim1, Tae Kyum Kim2, Hyun Jeong Kim2, Eui Yul Choi2, Dong Joon Kim3 1Statistics and Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA. 2Biomedical Science, Hallym University, Gangwon-Do, Korea, South. 3Internal Medicine, Hallym University College of Medicine, Gangwon-Do, Korea, South

Mark McPhail1,2, Charalambos G. Antoniades1,2, Timothy J. Cross3, Elizabeth Sizer2, Georg Auzinger2, William Bernal2, Julia Wendon2 1Department of Hepatology, Division of Medicine, Imperial College London, London, United Kingdom. 2Institute of Liver Studies, Liver Intensive Care Unit, Kings College Hospital, London, United Kingdom. 3Department of Hepatology, Derriford Hospital, Derriford Road, Plymouth, United Kingdom

#1858 IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY IS CHARACTERIZED BY VARIABLE PATTERNS OF CYTOKINES, CHEMOKINES, AND AUTOANTIBODIES Jinze Li1, Xu Zhu1, Feng Liu1, Ping Cai1, Corron Sanders2, William M. Lee2, Jack Uetrecht1 1Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada. 2University of Texas Southwestern Medical Center, Dallas, TX, USA

#1859 RELEVANCE OF MANGANESE SUPEROXIDE DISMUTASE (SOD2 VAL16ALA) AND GLUTATHIONE PEROXIDASE1 (GPX1 PRO198LEU) FUNCTIONAL POLYMORPHISMS IN PATIENTS WITH IDIOSYNCRATIC DRUG-INDUCED LIVER INJURY (DILI) Raul Andrade1, Carmen Martinez2, Eugenia Ulzurrun1, Elena Garcia-Martin3, C. Stephens1, Gloria Pelaez4, Manuel RomeroGomez5, Agustin Castiella6, Ramon Planas7, Carlos Guarner8, German Soriano8, Yolanda Borraz1, M. I. Lucena1, Jose A. Agúndez2 1Liver unit and Clinical pharmacology, Hospital Virgen de la Victoria. CIBERehd, Malaga, Spain. 2Pharmacology, University of Extremadura. RIRAAF, Badajoz, Spain. 3Biochemistry, Molecular Biology and Genetics, University of Extremadura. RIRAAF, Badajoz, Spain. 4Liver unit and Clinical pharmacology, Torrecardenas Hospital, Ameria, Spain. 5Liver unit and Clinical pharmacology, Nuestra Senora de Valme Hospital. CIBERehd, Sevilla, Spain. 6Liver Unit and Clinical pharmacology, Mendaro Hospital, Guipuzcoa, Spain. 7Liver unit and Clinical pharmacology, Germans Trias y Pujol Hospital, Barcelona, Spain. 8Liver unit and Clinical pharmacology, San Pau Hospital. CIBERehd, Barcelona, Spain

#1860 SERUM METABOLIC PROFILING REVEALS NOVEL BIOMARKERS ASSOCIATED WITH LIVER INJURY Jonathan Barr2, Cristina Alonso2, Ruben Suero2, Azucena Castro2, Esperanza Gonzalez1, Javier Conde-Vancells1, Shelly C. Lu3, Jose M. Mato1, Juan M. Falcon-Perez1 1Metabolomics Unit, CIC bioGUNE, CIBERehd, Derio, Spain. 2OWL Genomics, Derio, Spain. 3Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, USC, Los Angeles, CA, USA

#1862 POLYCHLORINATED BIPHENYL (PCB) EXPOSURES ARE ASSOCIATED WITH ALT ELEVATION IN AMERICAN ADULTS: NHANES 2003-2004 Matthew C. Cave1,3, Savitri Appana2, Mihir Patel1,3, Keith C. Falkner1,3, Craig J. McClain1,4, Guy N. Brock2 1Medicine/Gastroenterology, University of Louisville, Louisville, KY, USA. 2School of Public Health and Information Sciences, University of Louisville, Louisville, KY, USA. 3UofL Alcohol Research Center, University of Louisville, Louisville, KY, USA. 4Louisville VAMC, Louisville, KY, USA

#1863 ANABOLIC STEROID ASSOCIATED TO LIVER INJURY IN BODYBUILDERS: A RISK FACTOR TO TASH Helma P. Cotrim1, Paulo A. Schwingel2,1, Bernardo Cruz R. Sales1, Carlos Eduardo R. Almeida1, Crimério R. Santos2, Antonio Ricardo C. Andrade1 1Medicine, Universidade Federal da Bahia, Salvador, Brazil. 2Laboratório de Pesquisa do Exercício, Faculdade Social da Bahia, Salvador, Brazil

#1864 ROLE OF CASPASES IN MODULATING THE INFLAMMATORY RESPONSE AFTER ACETAMINOPHEN HEPATOTOXICITY Hartmut Jaeschke, David Williams, Mary Lynn Bajt KUMC, Kansas City, KS, USA

#1865 A PROSPECTIVE STUDY OF ACETAMINOPHEN THERAPEUTIC MISADVENTURE: DURATION OF INTAKE AND HEAVY DRINKING ARE 2 KEY FACTORS Faustine Wartel, Helene Castel, Sebastien Dharancy, Alexandre Louvet, Benoît Quesnel, Erika Parmentier-Decrucq, Valérie Canva, Pierre Deltenre, Philippe Mathurin Service des Maladies de l’Appareil Digestif, CHRU Lille, Lille, France


296A

POSTER SESSIONS


#1866

#1872

DRUG INDUCED LIVER INJURY: AN INCREASINGLY COMMON CONDITION?

CLINICAL FEATURES OF HEPATOPORTAL SCLEROSIS IN HIV INFECTED PATIENTS. EVOLUTION AFTER WITHDRAWAL OF DIDANOSINE

Michael Miller1, Hasnain Jafferbhoy1, Heather Tannahill2, Max Groome2, John F. Dillon1 1Biomedical Research Institute, University of Dundee, Dundee, United Kingdom. 2Ninewells Hospital and Medical School, NHS Tayside, Dundee, United Kingdom

#1867 ALTERATIONS OF FAK AND SRC LIVER LEVELS FOLLOWING EITHER THIOACETAMIDE OR CARBON TETRACHLORIDE ADMINISTRATION Athina Zira, Dimitrios Toumpanakis, Apostolos Zarros, Vassilios Stolakis, Constantinos Giaginis, Stamatios E. Theocharis Forensic Medicine and Toxicology, University of Athens, Medical School, Athens, Greece

#1868 TOLL-LIKE RECEPTORS: NOVEL REGULATORS OF HEPATIC DRUG METABOLISM AND TOXICITY Romi Ghose, Tao Guo, Adarsh S. Gandhi Pharmaceutics, University of Houston, Houston, TX, USA

#1869

Hugo Fainboim1, Silvia Paz1, Teresa Schroder1, Jorge A. Benetucci2, Estela Alvarez3 1Liver Unit, Hospital F. J. Muñiz, Buenos Aires, Argentina. 2FUNDAI, Hospital F. J. Muñiz, Buenos Aires, Argentina. 3Pathology Unit, Hospital Posadas, Buenos Aires, Argentina

#1873 VALIDATION OF THE AST TO PLATELET RATIO INDEX (APRI) IN PREDICTING LIVER FIBROSIS IN METHOTREXATE-ASSOCIATED LIVER DISEASE Lily Dara1,2, Rima Mercado1,2, Kisha A. Mitchell2, Joseph K. Lim2 1Department of Medicine, Griffin Hospital, Derby, CT, USA. 2Yale Liver Center, Yale University School of Medicine, New Haven, CT, USA

Steatohepatitis: Experimental and Translational #1874

EVEN STEROIDS MAY NOT BE IMMUNE TO CAUSING DRUG-INDUCED HEPATITIS

PNPLA3 GENOTYPE: RELATIONSHIP TO SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE

Gerond Lake-Bakaar2, Richa Uppal3, Xiaoquan Zhang1, Daryl Lau1 Beth Israel Deaconess Medical Center, Boston, MA, USA. 2Medicine, Cornell University Medical Center, New York, NY, USA. 3Medicine, New York Downtown Hospital, New York, NY, USA

Ahmad Al-Serri, Christopher P. Day, Ann K. Daly Newcastle University, Newcastke, United Kingdom

1Medicine,

#1870

#1875 LIPID ACCUMULATION INHIBITS INDUCTION OF AUTOPHAGY IN THE MOUSE LIVER

THE 15 AND 30 MINUTES SAMPLING OF 13CBREATH TESTING ARE ABLE TO PREDICT SEVERE HEPATIC FIBROSIS AND SEVERITY OF LIVER DISEASE

Yoshihiro Inami, Shunhei Yamashina, Kousuke Izumi, Hiroo Fukada, Kazuyoshi Kon, Kenichi Ikejima, Sumio Watanabe Gastroenterology, Juntendo University, Tokyo, Japan

Luca Miele, Marcello Candelli, Giuseppe Marrone, Maria Assunta Zocco, Marco Biolato, Giovanni Gigante, Simona Racco, Consuelo Cefalo, Maurizio Pompili, Gian Ludovico Rapaccini, Antonio Grieco, Antonio Gasbarrini Catholic University of Rome, Rome, Italy

PHARMACOLOGIC INHIBITION OF JNK ABROGATES INFLAMMATORY SIGNALING IN MURINE STEATOHEPATITIS

#1871 FEASIBILITY OF PORCINE HEPATOCYTES AS METABOLISING SYSTEMS FOR TESTING OF TERATOGENS AND THEIR PROTERATOGENS Ilka Böhme, Madlen Hempel, Sandra Brueckner, Bruno Christ Department of Internal Medicine, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany

#1876

Mary E. Rinella, Marc S. Elias, Jeanne H. Gottstein, Richard M. Green Department of Medicine, Northwestern University, Division of Hepatology, Chicago, IL, USA

#1877 IMPROVED HEPATIC STEATOSIS IN OBESE MICE AND RATS AFTER SUSTAINED TREATMENT WITH THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST, EXENDIN-4


James Trevaskis, Peter Griffin, Carrie Wittmer, Don Aumann, Krystyna Tatarkiewicz, Nicole C. Kesty, David Parkes, Jonathan D. Roth, Steve Chen Amylin Pharmaceuticals, San Diego, CA, USA



POSTER SESSIONS

#1878 LACK OF INVARIANT NATURAL KILLER T CELLS ELICITS LIVER INFLAMMATION AND PREDISPOSES TO LIVER FIBROSIS IN MICE FED WITH HIGH-FAT DIET Kumiko Nishio, Takuya Miyagi, Tetsuo Takehara, Akio Uemura, Satoshi Shimizu, Takahiro Kodama, Hayato Hikita, Wei Li, Akira Sasakawa, Tomohide Tatsumi, Norio Hayashi Osaka university, Suita, Japan

#1879 PATHWAYS MEDIATING OXIDATIVE TISSUE DAMAGE IN NONALCOHOLIC FATTY LIVER DISEASE Michael Berk, Samjhana Thapaliya, Laura J. Dixon, Ariel E. Feldstein Cell Biology, Cleveland Clinic, Cleveland, OH, USA

#1880 MELATONIN AMELIORATES METHIONINE CHOLINE DEFICIENT DIET INDUCED NONALCOHOLIC STEATOHEPATITIS IN RATS Veysel Tahan1,2, Ozlen Atug2, Hakan Akin2, Fatih Eren3, Gulgun Tahan3, Ozlem Tarcin4, Hafize Uzun5, Osman C. Ozdogan2, Orhan Tarcin6, Nese Imeryuz2, Mehmet F. Ozguner7, Cigdem Celikel8, Erol Avsar2, Nurdan Tozun2 1Human Research, Hepatocyte Transplantation, University of Pittsburgh, Pittsburgh, PA, USA. 2Department of Gastroenterology, Marmara University School of Medicine, Istanbul, Turkey. 3Institute of Gastroenterology, Marmara University, Istanbul, Turkey. 4Department of Endocrinology, Kosuyolu Heart and Research Hospital, Istanbul, Turkey. 5Department of Biochemistry, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey. 6Division of Gastroenterology, Gumussuyu Military Hospital, Istanbul, Turkey. 7Department of Physiology, Suleyman Demirel University, School of Medicine, Isparta, Turkey. 8Department of Pathology, Marmara University School of Medicine, Istanbul, Turkey

#1881 NON ALCOHOLIC STEATOHEPATITIS SENSITIZES TO POLY I:C INDUCED LIVER DAMAGE AND LEADS TO DECREASED ANTIVIRAL IMMUNE RESPONSE BY REDUCING MITOCHONDRIAL ASSOCIATION OF THE ANTIVIRAL SIGNALING PROTEIN (MAVS) Timea Csak, Angela Dolganiuc, Bharath D. Nath, Jan Petrasek, Karen Kodys, Gyongyi Szabo Department of Medicine, University of Massachusetts Medical Center, Worcester, MA, USA

#1882 EZETIMIBE PREVENTS METABOLIC SYNDROMERELATED STEATOHEPATITIS EXACERBATED BY TRANS-FATTY ACID IN KK-AY MICE

#1883 PALMITATE ACTIVATES THE UNFOLDED PROTEIN RESPONSE WITH CHOP EXPRESSION IN HEPATOCYTES Harmeet Malhi1,2, Randal J. Kaufman2,3 and Hepatology, Mayo Clinic, Rochester, MN, USA. 2Biological Chemistry, Univeristy of Michigan, Ann Arbor, MI, USA. 3Howard Hughes Medical Institute, Univeristy of Michigan, Ann Arbor, MI, USA 1Gastroenterology

#1884 PNPLA3 VARIANTS CONFER INCREASED RISK FOR LIVER BUT NOT METABOLIC DISEASE Elizabeth K. Speliotes1,2, Johannah L. Butler3, Cameron Palmer3, Sekar Kathiresan4,5, Benjamin F. Voight2,5,,. the GIANT Consortium6, Arun J. Sanyal7, Joel N. Hirschhorn2,3 1Gastroenterology, Massachusetts General Hospital, Boston, MA, USA. 2Population Genetics and Metabolism Initiative, Broad Institute, Cambridge, MA, USA. 3Genetics, Children’s Hospital, Boston, MA, USA. 4Cardiology, Massachusetts General Hospital, Boston, MA, USA. 5Center of Human Genetics Research, Massachusetts General Hospital, Boston, MA, USA. 6Genetic Investigation of Anthropometric Traits Consortium, Cambridge, MA, USA. 7Gastroeterology, Virginia Commonwealth University, Richmond, VA, USA

#1885 BETAINE ALLEVIATES FATTY LIVER AND LIVER INJURY IN MICE FED HIGH-FAT DIET VIA IMPROVING ADIPOSE TISSUE FUNCTION Tong Yao, Zhenyuan Song Human Nutrition, University of Illinois at Chicago, Chicago, IL, USA

#1886 DIVERGENT INDUCTION OF KLF6 SPLICE FORMS BY ANGIOTENSIN II IN HEPG2 AND LX2 CELLS Gillian Patman, Helen Reeves Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom

#1887 DAILY EXERCISE ATTENUATES THE DEVELOPMENT OF HEPATIC STEATOSIS IN MICE HETEROZYGOUS FOR A MITOCHONDRIAL TRIFUNCTIONAL PROTEIN DEFECT R. S. Rector1,3, Grace Uptergrove1,3, Raad Gitan1, Jamal A. Ibdah1,2 1Gastroenterology, University of Missouri School of Medicine, Columbia, MO, USA. 2Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, USA. 3Harry S. Truman Memorial Veterans Medical Center, Columbia, MO, USA


Kazuyoshi Kon, Kenichi Ikejima, Tomonori Aoyama, Sachiko Ishikawa, Satoko Hosoya, Kumiko Arai, Shunhei Yamashina, Sumio Watanabe Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan

297A

298A

POSTER SESSIONS

#1888

#1894

METFORMIN TREATMENT IMPROVES VASCULAR INSULIN RESISTANCE AT THE LIVER MICROCIRCULATION IN RATS WITH NAFLD

INCREASED INSULIN SENSITIVITY IN MICE WITH HOMOZYGOUS DISRUPTION OF THIOESTERASE SUPERFAMILY MEMBER (THEM) 2: EVIDENCE FOR REGULATION OF HEPATIC GLUCOSE METABOLISM BY INTERACTIONS BETWEEN THEM2 AND PHOSPHATIDYLCHOLINE TRANSFER PROTEIN (PCTP)

Marcos Pasarín, Aina Rodriguez-Vilarrupla, Jorge Gracia-Sancho, Vincenzo La Mura, Juan Carlos Garcia-Pagán, Jaime Bosch, Juan G Abraldes Liver Unit. Hospital Clinic, Barcelona, Spain

#1889 PIGMENT EPITHELIUM-DERIVED FACTOR DEFICIENCY RESULTS IN INCREASED FAT MASS, HEPATIC STEATOSIS, AND INSULIN RESISTANCE Andreas L. Birkenfeld1, Chuhan Chung1, Christine Shugrue1, Michael J. Jurczak1, David W. Frederick1, Susan E. Crawford2, Gerald I. Shulman1, Varman Samuel1 1Medicine, Yale University, New Haven, CT, USA. 2Pathology, Research Institute of NorthShore University HealthSystem, Evanston, IL, USA

#1890 INCREASED STAT3 EXPRESSION AND IL-6 SECRETION BY ORAL ADMINISTRATION OF HOODIA PARVIFLORA ALLEVIATES INSULIN RESISTANCE AND NON ALCOHOLIC STEATOHEPATITIS Meir Mizrahi, Ami Ben-Ya’acov, Tomer Adar, Gadi Lalazar, Miriam S. Levi, Rafael Aharon, Yaron Ilan internal medicin liver unit, Hadassah medical center, Jerusalem, Israel

#1891 PIOGLITAZONE PREVENTS APOPTOSIS OF HEPATIC NKT CELLS IN OBESE AND DIABETIC KKAY MICE Hisafumi Yamagata1, Kenichi Ikejima1, Kazuyoshi Takeda2, Kazuyoshi Kon1, Tomonori Aoyama1, Shunhei Yamashina1, Sumio Watanabe1 1Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan. 2Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan

#1892 BROAD-SPECTRUM MATRIX METALLOPROTEINASE INHIBITION REVERSES HEPATIC STEATOSIS AND INSULIN RESISTANCE IN MURINE MODELS OF DIET-INDUCED OBESITY AND LEPTIN DEFICIENCY Vincent E. de Meijer, Hau D. Le, Jonathan A. Meisel, Mark Puder Surgery, Children’s Hospital Boston, Boston, MA, USA

#1893 CHEMICAL SYMPATHECTOMY AGGRAVATES STEATOSIS BUT ATTENUATES PROINFLAMMATORY AND –FIBROGENIC SIGNALLING IN A MURINE MODEL OF NON-ALCOHOLIC STEATOHEPATITIS T U E S D AY NOVEMBER 3


Reiner Wiest, Erwin Gäbele, Roland Buettner, Lukas Moleda, Juergen Schoelmerich, Rainer H. Straub, Claus Hellerbrand Department of Internal Medicine I, University Hospital, Regensburg, Germany Denotes AASLD Presidential Poster of Distinction

Hye Won Kang, Michele W. Niepel, David E. Cohen Department of Medicine, Brigham & Women’s Hospital, Boston, MA, USA

#1895 KUPFFER CELL ACTIVATION PARTICIPATES IN THE INITIATION OF HIGH FAT DIET-INDUCED HEPATIC INSULIN RESISTANCE Nicolas Lanthier1, Olivier Molendi-Coste1, Valérie Lebrun1, Martine Petit1, Yves J. Horsmans1, Patrice D. Cani2, Isabelle A. Leclercq1 1Laboratory of Gastroenterology, Université catholique de Louvain, Brussels, Belgium. 2Unit of Pharmacokinetics, Metabolism, Nutrition and Toxicology, Université catholique de Louvain, Brussels, Belgium

#1896 INCREASED UPTAKE & DE NOVO SYNTHESIS OF LONG CHAIN FATTY ACIDS AND INCREASED ESTERIFICATION TO TRIGLYCERIDES ARE THE MAJOR PROCESSES CONTRIBUTING TO HEPATIC STEATOSIS IN MICE Fengxia Ge, Chunguang Hu, Shengli Zhou, Paul D. Berk Medicine, Columbia University Medical Center, New York, NY, USA

#1897 GENETIC COVARIANCE BETWEEN GAMMAGLUTAMYL TRANSPEPTIDASE (GGT) AND FATTY LIVER RISK FACTORS, AS WELL AS THE NOVEL EFFECT OF β2-ADRENERGIC RECEPTOR (ADRB2) GENETIC VARIATION: A TWIN STUDY Rohit Loomba1, Fangwen Rao2,3, Lian Zhang2,3, David A. Brenner1, Daniel T. O’Connor2,3 1Division of Gastroenterology, University of California at San Diego, La Jolla, CA, USA. 2Division of Nephrology and Hypertension, University of California at San Diego and VASDHS, La Jolla, CA, USA. 3Center for Human Genetics and Genomics, University of California at San Diego, La Jolla, CA, USA

#1898 ADIPONECTIN DEFICIENCY DIMINISHES THE ANTIINFLAMMATORY ACTIVITIES OF ROSIGLITAZONE IN LIVER Mingyan Zhou1, Aimin Xu1,2, Paul K. H. Tam3, Karen S. L. Lam1,2, Yu Wang1 1Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong, China. 2Department of Medicine, University of Hong Kong, Hong Kong, China. 3Department of Surgery, University of Hong Kong, Hong Kong, China


POSTER SESSIONS

299A

#1899

#1904

CLAUDIN 10 (CLDN10) – A CANDIDATE SUSCEPTIBILITY GENE FOR NAFLD PROGRESSION

ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS ARE CAPABLE TO MODULATE LIVER INFLAMMATION IN MOUSE MODELS OF NONALCOHOLIC STEATOHEPATITIS

Gary Beale1, Ahmad Al-Serri2, Luca Miele4,1, Gillian Patman1, Maria Lorena Abate3, Ann K. Daly2, Elisabetta Bugianesi3, Christopher P. Day2, Helen Reeves1 1Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom. 2Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, United Kingdom. 3Department of Gastroenterology, University of Turin, Turin, Italy. 4Department of Internal Medicine, Policlinico Gemelli Hospital and Catholic University of the Sacred Heart, Rome, Italy

#1900 FATTY HEPATOCYTES ARE NOT MORE SUSCEPTIBLE TO BILE ACID-INDUCED APOPTOSIS: INVOLVEMENT OF PPAR-ALPHA ACTIVATION Golnar Karimian1, Manon Buist-Homan1, Uwe J. Tietge2, Klaas Nico Faber1, Han Moshage1 1Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Netherlands. 2Pediatrics, University Medical Center Groningen, Groningen, Netherlands

#1901 ADIPONECTIN PREVENTS PROGRESSION OF NONALCOHOLIC STEATOHEPATITIS IN MICE BY REGULATING OXIDATIVE STRESS AND KUPFFER CELL PHENOTYPE POLARIZATION Fukushima1,

Kamada1,

Matsumoto1,

Juichi Yoshihiro Hitoshi Yuichi Yoshida1, Hisao Ezaki1, Takayo Takemura1, Mina Hamano1, Shinichi Kiso1, Norikazu Maeda2, Shinji Kihara2, Tohru Funahashi2, Iichiro Shimomura2, Norio Hayashi2 1Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. 2Metabolic Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

#1902 A HIGH-FRUCTOSE DIET IMPAIRS LIVER REGENERATION MORE THAN A HIGH-FAT DIET AFTER PARTIAL HEPATECTOMY IN A RAT FATTY LIVER MODEL Shirou Tanoue, Hirofumi Uto, Ryo Kumamoto, Shinichi Hashimoto, Yuichiro Nasu, Fumisato Sasaki, Keita Funakawa, Akihiro Moriuchi, Toshio Sakiyama, Makoto Oketani, Akio Ido, Hirohito Tsubouchi Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

#1903 THE NRF2-KEAP1 SIGNALING PATHWAY IS ACTIVATED IN MICE DURING THE DEVELOPMENT OF NONALCOHOLIC STEATOHEPATITIS

Akihiro Seki1,3, Yoshio Sakai1,2, Isamu Tatsumi1, Takuya Komura1,3, Haruo Fujinaga1,3, Masao Honda1,3, Toshinari Takamura1, Takahiro Ochiya4, Shuichi Kaneko1,3 1Department of Disease Control and Homeostasis, Kanazawa University, Kanazawa, Japan. 2Department of Laboratory Medicine, Kanazawa University, Kanazawa, Japan. 3Department of Gastroenterology,, Kanazawa University, Kanazawa, Japan. 4National Cancer Institute, Tokyo, Japan

#1905 THE EFFECT OF 5-HYDROXYEICOSATETRAENOIC ACID ON CHOLESTEROL METABOLISM IN MACROPHAGES – A BIOLOGIC LINK BETWEEN ATHEROSCLEROSIS AND NON-ALCOHOLIC FATTY LIVER DISEASE Yu-Cheng Lin1, Haeki Min2, Ashwani Kapoor2, Faridoddin Mirshahi2, Arun J. Sanyal2 1Department of Pediatrics, Far Eastern Memorial Hospital, Taipei, Taiwan. 2Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, VA, USA

#1906 INT-747: A POTENT AND SELECTIVE FXR AGONIST REGULATING GLUCOSE METABOLISM AND ENHANCING INSULIN SECRETION Giovanni Rizzo1, Daniela Passeri1, Francesca De franco1, Gianmario Ciaccioli1, Loredana Donadio1, Salvatore Modica2, Antonio Moschetta2, Roberto Pellicciari3, Mark Pruzanski4, Luciano Adorini1,4 1Intercept Pharmaceuticals, Corciano (PG), Italy. 2Translational Pharmacology, Consorzio Mario Negri Sud, Santa Maria Imbaro (CH), Italy. 3Pharmaceutical Chemistry, University of Perugia, Perugia, Italy. 4Intercept Pharmaceuticals, New York, NY, USA

#1907 DIFFERENTIAL EXPRESSION OF MIRNA IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS David Armistead1,2, Michael Estep1, Maria Stepanova1,3, Nila Rafiq1,3, Ganiraju Manyam1,2, Ancha Baranova1,2, Hazem Elariny1,3, Zachary D. Goodman4, Zobair M. Younossi1,3 1Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA. 2Center for the Study of Genomics in Liver Diseases, Molecular and Microbiology Department, George Mason University, Fairfax, VA, USA. 3Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA. 4Armed Forces Institutes of Pathology, Washington, DC, USA

Yu-Kun J. Zhang, Ronnie L. Yeager, Yuji Tanaka, Curtis D. Klaassen Pharmacology, University of Kansas Medical Center, Kansas City, KS, USA T U E S D AY NOVEMBER 3

300A

POSTER SESSIONS


#1908

#1913

URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE: A NOVEL PHOSPHOLIPID-BASED APPROACH FOR THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)

EFFECT OF HEPATOCELLULAR STEATOSIS ON HEPATITIS C VIRUS REPLICATION AND ANTIVIRAL RESPONSE

Anita Pathil1, Arne Warth2, Walee Chamulitrat1, Wolfgang Stremmel1 1Internal Medicine, Gastroenterology and Hepatology, University Clinic of Heidelberg, Heidelberg, Germany. 2Institute for Pathology, University Clinic of Heidelberg, Heidelberg, Germany

#1909 PREVENTION OF STEROIDS MEDIATED HEPATIC INJURY AND INSULIN RESISTANCE BY PROMOTION OF CD4+CD25+FOXP3+ CELLS AND SUPPRESSION OF CD4+IL17+ LYMPHOCYTES Tomer Adar, Ami Ben-Ya’acov, Gadi Lalazar, Lidia Zolotaryova, Yehudit Shabat, Meir Mizrahi, Yoav Lichtenstein, Yaron Ilan Liver Unit, Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel

#1910 REDISTRIBUTION OF ADIPOSE TISSUE DERIVED REGULATORY T LYMPHOCYTES IS ASSOCIATED WITH JNK2 PHOSPHORYLATION AND ALLEVIATION OF HEPATIC INJURY AND INSULIN RESISTANCE Tomer Adar, Gadi Lalazar, Ami Ben-Ya’acov, Dimitri Kanovich, Elizabeth Axelrod, Meir Mizrahi, Yoav Lichtenstein, Lidia Zolotaryova, Arie Dagan, Yaron Ilan Liver Unit, Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel

#1911 THE MICRORNA MIR-923 IS HIGHLY ABUNDANT AND DIFFERENTIALLY EXPRESSED BETWEEN NORMAL AND FATTY LIVERS Clovis S. Palmer1, Xiao Zhang3, Harriet Feilotter3, Andrew R. Lloyd1, Amany Zekry1,2 1School of Medical Sciences, Pathology, University of New South Wales, Sydney, NSW, Australia. 2St George Hospital Clinical School of Medicine, University of New South Wales, Sydney, NSW, Australia. 3Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada

#1912 FETAL STRESS IN UTERO PREDISPOSES TO HEPATIC FIBROSIS IN ADULT MALE B6C3F1 MICE


Jorge Allina1,2, M. Isabel Fiel1, Shannon Doherty-Lyons2, Jacquelin Grabowski2, Judy T. Zelikoff2, Joseph A. Odin1,2 1Mount Sinai School of Medicine, New York, NY, USA. 2Enviromental Health, NYU, Tuxedo, NY, USA


Feyza Gunduz1,2, Sidhartha Hazari1, Partha K. Chandra1, Sibnarayan Datta1, Maria Samara1, Fredric G. Regenstein2, Srikanta Dash1, Luis A. Balart2 1Pathology and Lab Medicine, Tulane University Medical School, New Orleans, LA, USA. 2Medicine, Tulane University School of Medicine, New Orleans, LA, USA

#1914 BETAINE IMPROVES INSULIN RESISTANCE IN VITRO BY REVERSING INHIBITION OF IRS1 ACTIVATION Elango Kathirvel2,3, Kengathevy Morgan2,3, Timothy R. Morgan1,3 1VA Medical Center, Long Beach, CA, USA. 2Research Service, VA Medical Center, Long Beach, CA, USA. 3Department of Medicine, University of California, Irvine, CA, USA

#1915 DIET INDUCED OBESITY ALTERS PHASE II HEPATIC XENOBIOTIC METABOLISM: IMPLICATIONS FOR NONALCOHOLIC FATTY LIVER DISEASE Irina Kirpich1, Daniel J. Conklin3, Craig J. McClain1,2, Matthew C. Cave1,2 1Medicine/Gastroenterology, University of Louisville, Louisville, KY, USA. 2Louisville VAMC, Louisville, KY, USA. 3Medicine/Cardiology, University of Louisville, Louisville, KY, USA

#1916 ITRAQ TECHNOLOGY FOR THE DISCOVERY OF BIOMARKERS IN HUMAN NAFLD Michael Miller1, Michael Ferguson2, John F. Dillon1 Research Institute, University of Dundee, Dundee, United Kingdom. 2College of Life Sciences, University of Dundee, Dundee, United Kingdom

1Biomedical

#1917 INFLAMMATORY AND FIBROGENIC RESPONSE OF IN VITRO HEPATOCYTES EXPOSED TO FATTY ACIDS Norberto C. Chavez-Tapia, Natalia Rosso, Claudio Tiribelli Centro Studi Fegato, Trieste, Italy

#1918 A PHYSIOLOGICALLY RELEVANT NOVEL MURINE MODEL OF NONALCOHOLIC STEATOHEPATITIS Rohit Kohli1, Michelle Kirby1, Stavra Xanthakos1, Lili Miles3, William F. Balistreri1, Stephen C. Woods2, Randy J. Seeley2 1Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. 2Psychiatry, University of Cincinnati, Cincinnati, OH, USA. 3Pathology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA


POSTER SESSIONS

301A

#1919

#1924

IMPACT OF HIGH FAT DIET WITH TRANS-FATTY ACID ON NONALCOHOLIC FATTY LIVER DISEASE

FXR AND TGR5 ACTIVATION IMPROVES NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND INCREASES INTRAHEPATIC MYELOID SUPPRESSOR CELLS

Noriyuki Obara, Koji Fukushima, Yoshiyuki Ueno, Yuta Wakui, Takayuki Kogure, Keiichi Tamai, Eiji Kakazu, Jun Inoue, Yasuteru Kondo, Tooru Shimosegawa Division of Gastroenterology, Tohoku University Hospital, Sendai, Japan

#1920 THERAPEUTIC EFFECT OF A NOR-UDCA BASED DIET ON NASH PROGRESSION IN THE CHRONIC DISEASE MODEL OF HEPATOCYTE-SPECIFIC NEMO DELETION

Rachel McMahan1, Tibor Krisko1, Tao Jiang2, Xiaoxin Wang2, Russell Nash3, Mark Pruzanski4, Luciano Adorini5, Lucy GoldenMason1, Moshe Levi2, Hugo R. Rosen1 1GI/Hepatology, University of Colorado HSC, Aurora, CO, USA. 2Nephrology & Hypertension, University of Colorado HSC, Aurora, CO, USA. 3Colorado GI Pathology, Centennial, CO, USA. 4Intercept Pharmaceuticals, New York, NY, USA. 5Intercept Pharmaceuticals, Corciano, Italy

Naiara Beraza1,2, Lisa Ofner-Ziegenfuss3, Haksier Ehedego1, Mark V. Boekschoten4, Michael Muller4, Michael Trauner3, Christian Trautwein1 1Internal medicine, University Klinikum Aachen, Aachen, Germany. 2Metabolomics, CICbioGUNE, Derio, Spain. 3Laboratory of Experimental and Molecular Hepatology, Department of Gastroenterology and Hepatology, University Clinic of Internal Medicine, Medical University of Graz, Graz, Austria. 4Nutrition, Metabolism, and Genomics Group, Division of Human Nutrition, Wageningen University, Wageningen, Netherlands

#1921 EFFECT OF ALTERING GUT FLORA ON HEPATIC NKT CELLS AND STEATOSIS IN MICE WITH NONALCOHOLIC FATTY LIVER DISEASE Shuwen Liang, Zhiping Li Division of Gastroenterology, Johns Hopkins University, Baltimore, MD, USA

#1922 NOVEL COMPREHENSIVE ANIMAL MODELS OF NASH TREATED WITH GOLD-THIOGLUCOSE Masafumi Ono, Mitsunari Ogasawara, Akira Hirose, Tsunehiro Ochi, Kensuke Munekage, Yasuko Nozaki, Masaya Takahashi, Shinji Iwasaki, Toshiji Saibara, Saburo Onishi Gastroenterology and Hepatology, Kochi Medical School, Nankoku, Japan

#1923 BLOCKADE OF INTERLEUKIN 6 TRANSSIGNALING ENHANCED HEPATIC STEATOSIS BUT IMPROVED LIVER INJURY IN METHIONINE CHOLINE DEFICIENCY DIET-FED MICE Kanji Yamaguchi, Yoshito Itoh, Takeshi Okanoue, Toshikazu Yoshikawa Gastroenterology, Kyoto Prefectural University of Medicine, Kyoto, Japan
